"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02266147","Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma",,"Completed","No Results Available","B-cell Lymphoma","Drug: SD-101|Radiation: Radiation therapy","Number of participants experiencing dose-limiting toxicities (DLTs), injection-site reactions (ISRs), adverse events (AEs), and serious adverse events (SAEs).|Changes in interferon (IFN)-inducible genes|Response rate of treated tumor according to Cheson criteria|Response rate of untreated tumor according to Cheson criteria","Dynavax Technologies Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","29","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DV3-LYM-01","October 2014","April 2017","April 2017","October 16, 2014","null","March 1, 2018","Stanford University School of Medicine, Stanford, California, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Rochester Medical Center, Rochester, New York, United States","","https://ClinicalTrials.gov/show/NCT02266147"
2,"NCT02055924","Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas","BIBLOS","Recruiting","No Results Available","B-cell Lymphoma","Drug: Ibrutinib and immunochemotherapies","The primary endpoint is the incidence rate of DLTs at each dose level on cycle 1|Secondary safety endpoints|Response Rate|Duration of response (DoR)|Progression-Free Survival (PFS)|Time to Next Anti-Lymphoma Treatment (TTNLT)|Overall Survival (OS)|Pharmacokinetics profile of ibrutinib in Groups A bis and B bis","The Lymphoma Academic Research Organisation|Janssen Pharmaceutica N.V., Belgium","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","86","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIBLOS","May 2014","October 2018","November 2019","February 5, 2014","null","March 7, 2018","Universite Catholique de Louvain Saint Luc, Bruxelles, Belgium|CHU de Liège, Liège, Belgium|CHU UCL Namur asbl, Yvoir, Belgium|Centre François Baclesse, Caen, France|Hôpital Henri Mondor, Créteil, France|CHU de Dijon - Hôpital le Bocage, Dijon, France|CHRU de Lille - Hôpital Claude Huriez, Lille, France|Centre Léon Bérard, Lyon, France|CHU Montpellier, Montpellier, France|CHU de Nantes, Nantes, France|Hôpital Saint Louis, Paris, France|Centre François Magendie - Hôpital du Haut Lévêque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|CHU Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France","","https://ClinicalTrials.gov/show/NCT02055924"
3,"NCT02395601","A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas",,"Active, not recruiting","No Results Available","B-Cell Lymphoma","Drug: CPI-1205","Frequency of Dose-limiting toxicities (DLTs)|Frequency of adverse events|Pharmacokinetic parameters of CPI-1205: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F|Pharmacodynamic effects of CPI-1205 in lymphoma tissue: changes in levels of the trimethylated form of lysine residue 27 on histone 3; changes in the expression of genes whose transcription may be altered by EZH2 inhibition|Pharmacodynamic effects of CPI-1205 in bone marrow and in skin: changes in global levels of the trimethylated form of lysine residue 27 on histone 3 (H3K27me3)|Disease response assessment will be performed using the 2014 Lugano Response Criteria for Hodgkin and Non-Hodgkin Lymphoma","Constellation Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1205-01","March 2015","October 2018","January 2019","March 23, 2015","null","March 5, 2018","Horizon Oncology Center, Lafayette, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|The Ohio State University James Cancer Hospital, Columbus, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02395601"
4,"NCT00162656","Treatment of Mature B-cell Lymphoma/Leukaemia",,"Completed","No Results Available","B-Cell Lymphoma","Drug: half cyclophosphamide|Drug: without COPADM3|Drug: mini CYVE, without 3 maintenance courses|Drug: LMB B|Drug: LMB C","Event free survival|Survival|long term toxicity","Gustave Roussy, Cancer Campus, Grand Paris","All","6 Months to 20 Years   (Child, Adult)","Phase 3","848","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FAB LMB96","May 1996","May 2004","May 2011","September 13, 2005","null","March 28, 2012","Morgan Stanley Childrens Hospital of New York Presbyterian, New York, New York, United States|Institut Gustave Roussy, Villejuif, France|Sheffield Children's Hospital, Sheffield, United Kingdom","","https://ClinicalTrials.gov/show/NCT00162656"
5,"NCT03424122","INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",,"Recruiting","No Results Available","B-cell Lymphoma","Drug: INCB050465|Drug: Rituximab|Drug: Bendamustine|Drug: Ibrutinib","Number of treatment-emergent adverse events (TEAEs)|Apparent clearance of INCB050465 in combination with rituximab, bendamustine and rituximab, or ibrutinib|Apparent volume of distribution of INCB050465 in combination with rituximab, bendamustine and rituximab, or ibrutinib","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","81","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 50465-112 (CITADEL-112)","June 7, 2018","December 13, 2019","December 13, 2020","February 6, 2018","null","August 23, 2018","Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-San Antonio Northeast, San Antonio, Texas, United States|Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03424122"
6,"NCT02247609","Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas","4SCAR19273","Unknown status","No Results Available","B-cell Lymphomas","Genetic: Anti-CD19 CAR T cells","Number of patients with adverse events.|Survival time of Anti-CD19 CAR T cells in vivo.|Response rates to the 4th generation CAR T cells.|Survival time of the patients.","Peking University|University of Florida","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19273-4SCAR","January 2014","October 2016","October 2017","September 25, 2014","null","October 20, 2014","Peking University Cancer Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02247609"
7,"NCT01478269","Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen","ProDLBCL","Completed","No Results Available","B-Cell Lymphomas","","","Fondazione Italiana Linfomi ONLUS","All","18 Years and older   (Adult, Older Adult)","","1927","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","IIL_ProDLBCL","May 2009","May 2011","May 2011","November 23, 2011","null","November 23, 2011","Hemocentro-Unicamp, Campinas, Brazil|Centro Medico, Santa Isabel, Brazil|Centro Paulista de Oncologia, Sao Paolo, Brazil|Santa Casa Medical School, Sao Paolo, Brazil|A.O.SS. Biagio, Antonio e Cesare Arrigo, Alessandria, Italy|Centro di riferimento Oncologico Oncologia Medica A, Aviano (Pordenone), Italy|USC Ematologia e Trapianto di Midollo Osseo Ospedali Riuniti di Bergamo, Bergamo, Italy|Presidio Ospedaliero A.Perrino - Divisione di Ematologia, Brindisi, Italy|U.O. di Oncologia Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Italy|Ospedale Civile, Camposanpiero (PD), Italy|A.O.Pugliese Ciaccio Diviisone di Ematologia, Catanzaro, Italy|Presidio Ospedaliero Annunziata U.O.C. di Ematologia, Cosenza, Italy|Clinica Ematologica Policlinico Carreggi, Firenze, Italy|Ematologia 1 Ospedale S. Martino, Genova, Italy|Oncologia Medica B e C IST Genova, Genova, Italy|Ospedale Felettino, La Spezia, Italy|Ospedale Madonna delle grazie U.O. Ematologia, Matera, Italy|A O Papardo, Messina, Italy|Azienda Ospedaliero Universitaria Policlinico Gaetano Martino, Messina, Italy|Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori, Milano, Italy|Oncologia Medica 3 Istituto Nazionale dei Tumori di Milano, Milano, Italy|Osp. San Carlo Borromeo Divisione di Oncologia Medica, Milano, Italy|Ospedale Maggiore IRCCS-Dipartimento di Ematologia, Milano, Italy|Centro Oncologico Modenese, Modena, Italy|A.O. Maggiore della Carità S.C.D.U. Ematologia, Novara, Italy|A.O. di Padova Divisione di Oncologia Medica, Padova, Italy|Casa di cura La Maddalena Unita' di Ematologia, Palermo, Italy|Div. di Ematologia e TMO AOU Policlinico Giaccone di Palermo, Palermo, Italy|A O Universitaria di Parma, Parma, Italy|Ospedale Civile G.da Saliceto - UOA Ematologia, Piacenza, Italy|Azienda Ospedaliero Universitaria Pisana U.O. Ematologia, Pisa, Italy|AO Bianchi Melacrino Morelli UO Ematologia, Reggio Calabria, Italy|AO Arcispedale S.Maria Nuova Ematologia, Reggio Emilia, Italy|Ospedale Oncologico regionale CROB, Rionero in Vulture (PZ), Italy|Dipartimento di biotecnologie cellulari ed ematologia Ospedale Umberto I - La Sapienza, Roma, Italy|Policlinico A. Gemelli Università Cattolica del Sacro Cuore, Roma, Italy|Clinica Humanitas, Rozzano (MI), Italy|A.O.San Giovanni Battista, Torino, Italy|U.O. Oncologia Azienda ULSS7 P.O. di Vittorio Veneto, Vittorio Veneto, Italy","","https://ClinicalTrials.gov/show/NCT01478269"
8,"NCT03664336","Refractory Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma","","Outcome according to pattern of refractoriness","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","","104","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","refractory DLBCL","November 2016","July 2017","January 2018","September 10, 2018","null","September 10, 2018","Centre Hospitalier Lyon Sud, Pierre-Bénite, France","","https://ClinicalTrials.gov/show/NCT03664336"
9,"NCT02433795","Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)",,"Active, not recruiting","No Results Available","Marginal Zone B-cell Lymphoma","Drug: bendamustine plus rituximab","Overall response rate based on Revised Response Criteria for Malignant Lymphoma|Complete remission rate|Safety based on NCI CTCAE version 4.0","Seoul National University Hospital|Gyeongsang National University Hospital|Korea Cancer Center Hospital|Seoul National University Boramae Hospital|Hallym University Medical Center|Inje University|Gangnam Severance Hospital|Chonbuk National University Hospital|Chungnam National University|The Catholic University of Korea|Wonju Severance Christian Hospital|Gachon University Gil Medical Center|Seoul National University Bundang Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY14-09","May 2015","October 2018","December 2018","May 5, 2015","null","June 21, 2018","Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of|Hallym University Medical Center, Anyang-si, Korea, Republic of|Chungnam National University, Daejeon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Inje Universit, Seoul, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Seoul National University Boramae Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02433795"
10,"NCT03258047","Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma",,"Recruiting","No Results Available","B Cell Lymphoma","Combination Product: CAR-T","complete remission rate|progression free survival|overall survival|adverse events|duration of the modified T cells by CAR-T in the patients","First Affiliated Hospital of Zhejiang University","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","lymphoma center Q002","September 15, 2017","May 31, 2019","July 30, 2019","August 22, 2017","null","February 8, 2018","The first affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03258047"
11,"NCT02547948","CD19-targeting CAR T Cells for B Cell Lymphoma",,"Completed","No Results Available","B Cell Lymphoma","Biological: CD19-targeting CAR T Cells infusion","CAR T cell persistence|Tumor load","Fuda Cancer Hospital, Guangzhou","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD19-targeting CAR T","September 2015","August 15, 2017","August 15, 2017","September 14, 2015","null","August 16, 2017","Central laboratory in Fuda cancer hospital, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02547948"
12,"NCT03146533","CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.",,"Recruiting","No Results Available","B Cell Lymphoma","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CD19 CART","safety as assessed by the occurence of study related adverse events|observe the maximum tolerated dose (MTD)|objective response rate|disease control rate|overall survival|Progression-Free Survival|Determine duration of in vivo survival of CD19 CART cells|Peripheral blood cytokines|subgroup of T cell","Shenzhen Second People's Hospital|The Beijing Pregene Science and Technology Company, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FirstShenzhen01","May 2017","April 2019","October 2019","May 10, 2017","null","May 17, 2017","The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03146533"
13,"NCT03189524","A Study to Investigate BGB-3111 in Chinese Patients With B-cell Lymphoma",,"Recruiting","No Results Available","B-cell Lymphoma","Drug: BGB-3111","The safety and tolerability of BGB-3111 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE4.03 grading criteria in Part I|The efficacy measured by overall response rate (ORR) in Part II|The efficacy measured by complete response rate (CRR) in Part II|The efficacy measured by partial response rate (PRR) in Part II|The efficacy measured by progression free survival (PFS) in Part II","BeiGene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BGB-3111-1002","July 5, 2016","January 31, 2021","June 30, 2021","June 16, 2017","null","June 16, 2017","Beijing Cancer Hospital, Beijing, Beijing, China|Tongji Hospital, Tongji Medical College Huazhong Univ of Sci and Tch, Wuhan, Hubei, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Tianjin Hematonosis Hospital, Tianjin, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03189524"
14,"NCT03101709","The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma",,"Recruiting","No Results Available","B Cell Lymphoma","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CART-19","safety as assessed by the occurence of study related adverse events|efficacy assessed by anti-tumor activity of CART-19 cells|duration of CART-19","Henan Cancer Hospital|The Beijing Pregene Science and Technology Company, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HenanCH109","August 2016","July 2018","July 2019","April 5, 2017","null","April 5, 2017","Henan Cancer Hospital, Zhengzhou, Henan, China","","https://ClinicalTrials.gov/show/NCT03101709"
15,"NCT03670888","A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients",,"Not yet recruiting","No Results Available","B Cell Lymphoma","Biological: JHL1101|Biological: Rituximab","AUC0~t|AUC0-∞|Cmax","JHL Biotech, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","128","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","JHL-CLIN-1101-02","November 30, 2018","December 31, 2020","April 30, 2021","September 14, 2018","null","September 14, 2018","First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03670888"
16,"NCT02842138","Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma",,"Recruiting","No Results Available","B-cell Lymphoma","Biological: autologous anti-CD19 CAR T cells","Number of patients with adverse events|Treatment response rate of anti-CD19 CAR T cell infusion|overall survival rate of patients treated with anti-CD19 CAR T cells|progression-free survival of patients treated with anti-CD19 CAR T cells","Peking University|Marino Biotechnology Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016YJZ12","June 2016","June 2018","June 2019","July 22, 2016","null","February 27, 2017","Peking University Cancer Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT02842138"
17,"NCT03218072","A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas",,"Completed","No Results Available","B-cell Lymphomas","Drug: HLX01","AEs|SAEs|AUC0-inf|Cmax|t1/2|CD19 positive B cells|CD20 positive B cells|Antidrug antibodies of HLX01","Shanghai Henlius Biotech","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HLX01-NHL01","May 4, 2014","January 31, 2015","January 31, 2015","July 14, 2017","null","July 19, 2017","","","https://ClinicalTrials.gov/show/NCT03218072"
18,"NCT02741388","A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP","SELINDA","Recruiting","No Results Available","B-cell Lymphoma","Drug: selinexor|Drug: Rituximab|Drug: Dexamethasone|Drug: Oxaliplatin|Drug: Cisplatin|Drug: Cytarabine|Drug: Gemcitabine","Incidence rate of dose-limiting toxicities (DLTs) observed during the DLT assessment period (cycle 1) at each dose level examined|Response rates|Duration of response|Progression-free survival (PFS)|Time to next anti-lymphoma treatment (TTNLT)|Overall survival (OS)|Incidence of grade ≥ 2 renal toxicities, grade ≥ 2 neuropathy, and grade ≥ 3 toxicities","The Lymphoma Academic Research Organisation|Karyopharm Therapeutics Inc","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SELINDA","October 2016","September 2018","June 2020","April 18, 2016","null","March 7, 2018","Institut Jules Bordet, Bruxelles, Belgium|CHU Dijon, Dijon, France|CHRU de Lille - Hôpital Claude Huriez, Lille, France|CHU Montpellier - Hôpital Saint Eloi, Montpellier, France|CHU Nancy - Hôpital de Brabois, Nancy, France|Hôpital Saint-Louis, Paris, France|CHU Bordeaux - Centre François Magendie, Pessac, France|Centre Henri Becquerel, Rouen, France","","https://ClinicalTrials.gov/show/NCT02741388"
19,"NCT02060435","Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma","Other: EBER","overall survival","Samsung Medical Center","All","17 Years to 90 Years   (Child, Adult, Older Adult)","","571","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","2013-07-101-001","January 2013","December 2013","February 2014","February 12, 2014","null","February 12, 2014","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02060435"
20,"NCT02060656","Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)","LEGEND","Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Gemcitabine|Drug: Methylprednisolone|Drug: Rituximab|Drug: Cisplatin|Drug: Lenalidomide","Complete response rate (CRR)|Overall Response Rate|Event-free Survival|Overall Survival|Rates of successful stem cell harvest","Royal Marsden NHS Foundation Trust|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","92","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMH CCR: 3862|2012-002620-32","September 2013","February 2016","null","February 12, 2014","null","February 12, 2014","Royal Marsden NHS Foundation Trust - London and Surrey, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02060656"
21,"NCT01068392","Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)",,"Completed","No Results Available","B-cell Lymphomas","Drug: Oxaliplatin, Prednisolone","Response rate by International Working Group Response Criteria|progression free survival|overall survival","Dong-A University Hospital|Samsung Medical Center|Asan Medical Center|Chung-Ang University|Kyungpook National University|Chonnam National University Hospital|Korea Cancer Center Hospital|Korea University","All","20 Years and older   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CISL-MZL-10-3","October 2009","September 2013","September 2014","February 12, 2010","null","November 4, 2014","Dong-A University Hospital, Busan, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01068392"
22,"NCT00944567","A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma",,"Completed","No Results Available","Primary Mediastinal B-Cell Lymphoma","","response rate on PET scanning following initial chemo-immunotherapy","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","","125","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IELSG26|EudraCT number 2006-005794-22","January 2007","May 2011","February 27, 2017","July 23, 2009","null","August 15, 2017","A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|IRCCS Ospedale Oncologico, Bari, Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|Ospedale Oncologico, Cagliari, Italy|Policlinico Careggi, Firenze, Italy|A.O.Papardo, Messina, Italy|Ospedale Niguarda Ca' Granda, Milano, Italy|Ospedale San Raffaele, Milano, Italy|Università di Modena, Policlinico, Modena, Italy|Policlinico S. Matteo, Pavia, Italy|A.O. Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Università di Roma ""La Sapienza"" - DAI Ematologia, Rome, Italy|Humanitas, Rozzano, Italy|Ospedale Maggiore San Giovanni Battista, Torino, Italy|Ospedale di Circolo Fondazione Macchi, Varese, Italy|Clinic Hospital Universitari, Barcelona, Spain|IOSI, Bellinzona, Switzerland|Barts & the London NHS Trust, London, United Kingdom|Royal Marsden NHS Foundation Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00944567"
23,"NCT02531308","Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)","DLBCL","Terminated","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Metformin|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: pegfilgrastim","Progression Free Survival","Rush University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LYM2014-MET-R-CHOP","July 2015","July 2016","July 2016","August 24, 2015","January 27, 2017","January 27, 2017","Rush University Medical Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02531308"
24,"NCT00097929","An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)",,"Completed","No Results Available","B-cell Lymphoma","Drug: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months","Objective response rate based on FDG-PET and CT scan findings.|Response duration, Progression-free survival, Time to progression, Time to response, 3-Month and 6-month progression free survival.","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0683-013|MK0683-013|2004_029","May 1, 2005","July 31, 2006","July 31, 2006","December 2, 2004","null","April 7, 2017","","","https://ClinicalTrials.gov/show/NCT00097929"
25,"NCT02945215","A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients",,"Recruiting","No Results Available","B-Cell Lymphoma","Drug: IBI301|Drug: Rituximab","AUC0-inf of IBI301 and rituximab|Peak Plasma Concentration (Cmax)|Percentage and absolute value of CD19+|Percentage and absolute value of CD20+ B-cell|Positive rate of ADA|Positive rate of NAb|Safety profiles|Area under the plasma concentration versus time curve (AUC)","Innovent Biologics (Suzhou) Co. Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIBI301A201","November 2016","April 2018","April 2018","October 26, 2016","null","April 11, 2017","Beijing cancer hospital, Beijing, Beijing, China|Peking University third hospital, Beijing, Beijing, China|The 307th Hospital of Military Medical Sciences, Beijing, Beijing, China|Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Xiangya Hospital of Central South University, Changsha, Hunan, China|Jiangsu province people's hospital, Nanjing, Jiangsu, China|West China Hospital,Sichuan University, Chengdu, Sichuan, China|Tianjin People's Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT02945215"
26,"NCT03692767","Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma",,"Not yet recruiting","No Results Available","Refractory B-Cell Lymphoma","Biological: Anti-CD22 CAR NK Cells","Occurrence of treatment related adverse events as assessed by CTCAE v4.0","Allife Medical Science and Technology Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD22 CAR NK-BJZL-01","November 2018","November 2020","November 2021","October 2, 2018","null","October 2, 2018","","","https://ClinicalTrials.gov/show/NCT03692767"
27,"NCT03690310","Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma",,"Not yet recruiting","No Results Available","Refractory B-Cell Lymphoma","Biological: Anti-CD19 CAR NK Cells","Occurrence of treatment related adverse events as assessed by CTCAE v4.0","Allife Medical Science and Technology Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD19 CAR NK-BJZL-01","November 2018","November 2020","November 2021","October 1, 2018","null","October 1, 2018","","","https://ClinicalTrials.gov/show/NCT03690310"
28,"NCT01226849","Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma","SGH652","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: bortezomib, rituximab, ifosphamide, etoposide, carboplatin","To evaluate number of participants with adverse events with R-ICE plus bortezomib (VR-ICE)|Response rate","Singapore General Hospital|Janssen-Cilag Ltd.","All","21 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGH652","November 2010","November 2014","November 2014","October 22, 2010","null","April 27, 2017","Singapore General Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT01226849"
29,"NCT00801216","High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement","SCNSL1","Unknown status","No Results Available","B-Cell Lymphomas","Drug: High-dose sequential chemotherapy and autologous transplant","Event-free survival|Response duration|Overall survival|Tolerability|Neurotoxicity","IRCCS San Raffaele|Mundipharma K.K.","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 2","38","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCNSL1|IIL-SCNSL-1","January 2007","January 2010","January 2012","December 3, 2008","null","December 3, 2008","San Raffaele Scientific Institute, Milan, Italy|San Raffaele Scientific Institute, Milan, Italy","","https://ClinicalTrials.gov/show/NCT00801216"
30,"NCT02767674","Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Rituximab|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","2-year overall survival rate|2-year progression free survival rate|overall response rate","The First Affiliated Hospital with Nanjing Medical University","All","70 Years to 90 Years   (Older Adult)","Phase 3","258","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JSPH-002","May 2016","December 2018","July 2019","May 10, 2016","null","April 11, 2018","Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02767674"
31,"NCT00761384","High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma","HITT","Completed","No Results Available","B-cell Lymphoma","Drug: 90Y-ibritumomab","Maximal tolerable dose (MTD) absorbed dose to the liver, safety and time to treatment failure (TTF)|Overall response (OR), complete response (CR), their duration, absorbed dose to normal organ and tumours, relapse pattern, the effect of radioimmunotherapy (RIT) in its own right as assessed by positron emission tomography (PET)","Lund University Hospital|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6th radioimmunotherapy prot.|EudraCT number: 2007-002762-35","April 2008","January 2016","January 2016","September 29, 2008","null","February 19, 2016","Lund University Hospital, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT00761384"
32,"NCT00965289","High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma",,"Completed","No Results Available","B-Cell Lymphoma","Drug: Rituximab","CR rate after 3 high dose chemotherapy courses|CR and PR rate at the end of the study treatment|PFS,EFS and OS|Tolerance of Rituximab combined with chemotherapy","Nantes University Hospital|French Innovative Leukemia Organisation|Hoffmann-La Roche","All","18 Years to 60 Years   (Adult)","Phase 2","42","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GOELAMS 074","April 2002","May 2003","June 2009","August 25, 2009","null","August 26, 2009","University Hospital, Nantes, France","","https://ClinicalTrials.gov/show/NCT00965289"
33,"NCT01369784","Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma","PRO-R-IPI","Completed","Has Results","Diffuse Large B-cell Lymphoma","","R-IPI Index (Revised International Prognostic Index)|Predictive Value of R-IPI at Diagnosis|Bcl-2 Expression|Bcl-6 Expression|p-53 Expression|p53 Expression|Multiple Myeloma Oncogene 1 (MUM-1) Expression|MUM-1 Expression|Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status|Ann Arbor Staging|Response to First Line of Treatment|Response to Second Line of Treatment|Relationship Between Global Response Rate to 2nd (Second) Line of Treatment and Bcl-2 Expression at Diagnosis|Relationship Between Global Response Rate to 2nd Line of Treatment and Bcl-6 Expression at Diagnosis|Relationship Between Global Response Rate to 2nd Line of Treatment and p53 Expression at Diagnosis|Relationship Between Global Response Rate to 2nd Line of Treatment and Multiple Myeloma Oncogene 1 (MUM1) Expression at Diagnosis","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","All","18 Years and older   (Adult, Older Adult)","","158","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","PRO-R-IPI","February 2009","March 2011","March 2011","June 9, 2011","April 18, 2016","April 18, 2016","Hospital de Elda, Elda, Alicante, Spain|Hospital de Cabueñes, Gijón, Asturias, Spain|H. U. Central de Asturias, Oviedo, Asturias, Spain|H. U. Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|ICO-DYR, Hospitalet de Llobregat, Barcelona, Spain|Althaia, Manresa, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|Hospital Parc Taulí, Sabadell, Barcelona, Spain|H. Sierrallana, Torrelavega, Cantabria, Spain|Hospital General del SAS de Jerez, Jerez de la Frontera, Cádiz, Spain|Hospital Galdakao, San Sebastián, Guipuzcoa, Spain|H. Clínico U. Santiago de Compostela, Santiago de Compostela, La Coruña, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|H.U. Fundación Alcorcón, Alcorcón, Madrid, Spain|H.U.de Getafe, Getafe, Madrid, Spain|H. Severo Ochoa, Leganés, Madrid, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|H. Universitario de Canarias, La Laguna, Tenerife, Spain|H. Nuestra Señora del Prado, Talavera de la Reina, Toledo, Spain|H. Basurto, Bilbao, Vizcaya, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall D'Hebrón, Barcelona, Spain|Institut Catalá d'Oncologia de Girona, Gerona, Spain|H.U. Virgen de las Nieves, Granada, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|C.H.U. A Coruña, La Coruña, Spain|Hospital de León, León, Spain|Hospital Xeral, Lugo, Spain|Hospital Universitario Arnau de Vilanova, Lérida, Spain|H. Ramón y Cajal, Madrid, Spain|H. U. La Princesa, Madrid, Spain|H.G.U. Gregorio Marañón, Madrid, Spain|H.U. La Paz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|MD Anderson, Madrid, Spain|Hospital Son Llatzer, Mallorca, Spain|H.U. Virgen de la Arrixaca, Murcia, Spain|Hospital Morales Messeguer, Murcia, Spain|H. Carlos Haya, Málaga, Spain|Complexo Hospitalario de Ourense, Orense, Spain|Hospital Universitario Son Dureta, Palma de Mallorca, Spain|H. Universitario de Salamanca, Salamanca, Spain|H. General de Segovia, Segovia, Spain|H.U. Nuestra Señora de Valme, Sevilla, Spain|H. Arnau de Vilanova, Valencia, Spain|H. Clínico de Valencia, Valencia, Spain|H. Dr. Peset, Valencia, Spain|H. Río Hortega, Valladolid, Spain|Hospital Clínico Universitario Valladolid, Valladolid, Spain|H. Virgen de La Concha, Zamora, Spain|H. Nuestra Señora de Sonsoles, Ávila, Spain|H. Txagorritxu, Vitoria, Álava, Spain","","https://ClinicalTrials.gov/show/NCT01369784"
34,"NCT01793844","A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","","disease free survival|5-year overall survival|response rate|Number of participants with SAE|quality of life","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","","732","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","CSWOG0001","January 2008","June 2017","December 2017","February 18, 2013","null","December 11, 2015","Tumor center, Sun Yat-sen University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT01793844"
35,"NCT02733380","Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Chidamide|Drug: Vinorelbine|Drug: Liposomal Doxorubicin or mitoxantrone|Drug: Dexamethasone|Drug: Thalidomide","objective response rate|adverse events|abnormal laboratory examinations|incidence and relationship with study drugs of grade 3-4 adverse events and abnormal laboratory examinations|progression-free survival|duration of response","Henan Cancer Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HNSZLYYML-01","May 2016","May 2019","May 2020","April 11, 2016","null","August 14, 2018","Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China","","https://ClinicalTrials.gov/show/NCT02733380"
36,"NCT03630159","Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients","PORTIA","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Biological: Tisagenlecleucel|Drug: Pembrolizumab","Percent of participants recieving pembrolizumab per protocol schedule|Dose Timing part: Incidence of dose limiting toxicities (DLTs)|Expansion part: Overall response rate (ORR)|Duration of Response (DOR)|Progression Free Survival (PFS)|Overall Survival (OS)|In vivo cellular kinetics of tisagenlecleucel in blood, bone marrow, lymph nodes and other tissues by qPCR and flow cytometry|Impact of pembrolizumab dosing strategy on the cellular kinetics of tisagenlecleucel by qPCR and flow cytometry|Immunogenicity measured by antibody titres specific to tisagenlecleucel molecule and by the presence of T lymphocytes activated by the tisagenlecleucel protein","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCTL019J2101","September 4, 2018","October 28, 2019","February 27, 2023","August 14, 2018","null","August 31, 2018","University of Chicago Medical Center, Hematology & Oncology, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03630159"
37,"NCT03188198","Risk Adapted Therapy in Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Large B Cell Lymphoma","Drug: rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim","Response rate|Event-free survival","Mansoura University","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","mans lymphoma1","June 1, 2016","June 1, 2018","June 1, 2019","June 15, 2017","null","July 6, 2017","Oncology center, Mansoura, Egypt","","https://ClinicalTrials.gov/show/NCT03188198"
38,"NCT03391726","CART-19 Cells for R/R B-cell Lymphoma","CCFRRBL","Recruiting","No Results Available","Relapsed or Refractory B-cell Lymphoma","Other: CART-19 cells","Disease-free survival|Adverse events that are related to treatment","Fujian Medical University","All","1 Year to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CART-19-01","January 1, 2016","December 2019","December 2020","January 5, 2018","null","January 5, 2018","Fujian Medical University Union Hospital, Fuzhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT03391726"
39,"NCT02777736","CNS Prophylaxis in Diffuse Large B-cell Lymphoma","CLSG-CNS-001","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Methotrexate","Cumulative incidence of CNS relapse in patients treated either with methotrexate i.v. or methotrexate i.t. or without CNS prophylaxis|Complete remission rate|Overall response rate|Overall survival|Progression-free survival","Czech Lymphoma Study Group","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CLSG-CNS-001|2015-000591-97","July 2015","December 2018","December 2019","May 19, 2016","null","June 6, 2016","University Hospital Brno-Bohunice, Brno, Czech Republic|University Hospital Hradec Králové, Hradec Králové, Czech Republic|University Hospital Ostrava, Ostrava, Czech Republic|University Hospital Pilsen, Pilsen, Czech Republic|University Hospital Kralovske Vinohrady, Prague, Czech Republic|General University Hospital Prague, Prague, Czech Republic","","https://ClinicalTrials.gov/show/NCT02777736"
40,"NCT00906841","Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","B-cell Lymphoma","Drug: 90Y-DOTA-hLL2","Event free survival (EFS)|Objective disease response (CR, CRu and PR), SD and disease progression|Duration of response|Time to disease progression","French Innovative Leukemia Organisation","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","75","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIT90Y-DOTA-hLL2","October 2007","March 2016","April 2018","May 21, 2009","null","April 27, 2018","Chu/Clcc Nantes, Nantes, France","","https://ClinicalTrials.gov/show/NCT00906841"
41,"NCT00846157","Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients","NKCell","Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Biological: NKM injection","Event Free survival|Progression free survival","NKBio Co.Ltd.","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 3","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NKMGI 4-06","September 2007","September 2011","September 2014","February 18, 2009","null","June 28, 2011","The Catholic University of korea, Banpo-Dong 505, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT00846157"
42,"NCT01626352","Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy",,"Completed","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Bendamustine|Drug: Ofatumumab","Number of Patients With a Complete Response|Duration of Response|Time to Progression (TTP)|Overall Survival (OS)|Overall Response (OR)|Number of Patients With Treatment-Related Adverse Events (AEs) as a Measure of Safety|Progression-free Survival","SCRI Development Innovations, LLC|Novartis|GlaxoSmithKline|Cephalon","All","70 Years and older   (Older Adult)","Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LYM 75","October 2012","September 2016","April 2017","June 22, 2012","October 18, 2017","November 22, 2017","Florida Cancer Specialists-South, Fort Myers, Florida, United States|Woodlands Medical Specialists, Pensacola, Florida, United States|Florida Cancer Specialists North, Saint Petersburg, Florida, United States|Space Coast Cancer Center, Titusville, Florida, United States|Providence Medical Group, Terre Haute, Indiana, United States|RHHP/Hope Cancer Center, Terre Haute, Indiana, United States|Grand Rapids Oncology Program, Grand Rapids, Michigan, United States|Cancer Centers of Southwest Oklahoma, Lawton, Oklahoma, United States|Oklahoma University, Oklahoma City, Oklahoma, United States|Tennessee Oncology-Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01626352"
43,"NCT00754117","Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma","","evaluating the predictive value of a positive PET scan early in the course of standard chemotherapy","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","","8","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0801009588","May 2008","December 2010","December 8, 2012","September 17, 2008","null","May 28, 2018","Weill Cornell Medical College, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00754117"
44,"NCT01854606","Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma","COEB071X2103","Completed","No Results Available","CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma","Drug: AEB071|Drug: Everolimus","Phase Ib- Incidence of dose limiting toxicities (DLT) during the first cycle|Phase II- Overall response rate (ORR) = complete response (CR) + partial response (PR) according to the non-Hodgkin's Lymphoma International Working Group criteria|Occurrence of Adverse Events (AEs), Serious Adverse Events (SAEs) assessments of clinical laboratory values and vital sign measurements.|Best Overall Response (BOR)|Duration of Response (DOR)|Progression Free survival (PFS)|Overall Survival (OS)|Concentration-time profiles of Pharmacokinetics (PK) parameters - Phase Ib","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COEB071X2103","December 5, 2013","June 1, 2016","June 1, 2016","May 15, 2013","null","May 30, 2017","Washington University School of Medicine Dept of Oncology., Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center Onc. Dept., New York, New York, United States|Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, United States|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, New Territories, Hong Kong|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT01854606"
45,"NCT01402440","Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: AEB071","Frequency of Dose Limiting Toxicity (DLT) during cycle 1 (Dose Escalation phase)|Number of Pparticipants reporting Serious Adverse Events and Adverse Events (Dose Expansion phase)|Overall Response Rate, using NHLIWG criteria|Number of Participants reporting Serious Adverse Events and Adverse Events|AEB071 PK parameters including Cmax, tmax, AUCt, Ctrough, CL/F and RA|Pre and post-dose gene and protein expression of cytokines and any correlations with exposure to AEB071","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COEB071X2101|2010-024367-41","November 2011","April 2014","April 2014","July 26, 2011","null","January 7, 2015","City of Hope National Medical Center, Duarte, California, United States|Washington University School of Medicine Div. of Medical Oncology, St. Louis, Missouri, United States|Hackensack University Medical Center Hackensack (SC), Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center MSK 2, New York, New York, United States|Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State, Columbus, Ohio, United States|University of Texas/MD Anderson Cancer Center SC Location, Houston, Texas, United States|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Pierre-Benite Cédex, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT01402440"
46,"NCT01202448","Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma","PROCESS","Completed","No Results Available","Diffuse Large B-cell Lymphoma","Procedure: CSF analysis","CNS relapse/involvement|survival","Samsung Medical Center|Asan Medical Center|Yonsei University|National Cancer Center, Korea|Korea Cancer Center Hospital|Korea University","All","20 Years and older   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2010-04-091","August 2010","February 2015","February 2015","September 15, 2010","null","March 3, 2015","Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01202448"
47,"NCT02715843","Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma",,"Available","No Results Available","Non-Hodgkin's B-cell Lymphoma","Drug: MT-3724","","Molecular Templates, Inc.","All","18 Years and older   (Adult, Older Adult)","","null","Industry","Expanded Access","","MT-3724_NHL_001_EXT_US","null","null","null","March 22, 2016","null","September 18, 2018","University of Arizona, Tucson, Arizona, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02715843"
48,"NCT00895661","High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas",,"Completed","Has Results","B-cell Lymphoma|Indolent B-cell Lymphoma","Drug: rituximab","Determine Complete Response Rate (CRR) of Increased Dose Rituximab in Indolent B-cell Lymphomas|Overall Response Rate (ORR)|Progression-free Survival (PFS)|Incidence of Severity of Infusion Reactions, Infections and Neutropenia","Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-054","July 2009","October 2010","August 2015","May 8, 2009","May 9, 2017","June 9, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00895661"
49,"NCT02227251","A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Selinexor","Objective Response","Karyopharm Therapeutics Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KCP-330-009","November 2014","November 2018","August 2019","August 28, 2014","null","August 31, 2018","UACC Arizona, Tucson, Arizona, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Boca Raton Cancer Research Medical Center, Plantation, Florida, United States|University of Chicago, Chicago, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center/Northwestern University, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|New York Presbyterian Hospital/ Cornell Medical College, New York, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Greenville Hospital System, Greenville, South Carolina, United States|MD Anderson, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Virginia Mason Hospital & Medical Center, Seattle, Washington, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Liverpool Hospital, Ingham Institute of Medical Research, Liverpool, New South Wales, Australia|Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia|Icon Cancer Care, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ashford Cancer Centre, Kurralta Park, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Epworth Hospital, East Melbourne, Victoria, Australia|St. Vincent's Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Medical University of Graz, Graz, Austria|Medizinische Universität Innsbruck für Innere Medizin, Innsbruck, Austria|LKH Leoben Department for Haemato-Oncology, Leoben, Austria|Akh Linz Innere Med III - Zentrum für Hämatologie und med. Onkologie, Linz, Austria|Krankenhaus Barmherzigen Schwestern Linz, Linz, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|Uni. Klinik für Innere Medizin III Universitätsklinikum der PMU LKH Salzburg, Salzburg, Austria|Medical University of Vienna (MUW) Department of Medicine I, Vienna, Austria|Univ. General Hospital Hietzing, Vienna, Austria|Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium|AZ Sint-Jan, Bruges, Belgium|Institut Jules Bordet, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|UZ Gent, Gent, Belgium|CH Jolimont, La Louviere, Belgium|H-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|University Hospital for Active Treatment Dr. Georgi Stranski, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Haematological Diseases EAD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sir Mortimer B Davis Jewish General Hospital/McGill University, Montreal, Quebec, Canada|CHU Lyon Sud, Pierre-Bénite, Lyon, France|Centre Hospitalier Universitaire Henri Mondor, Créteil, France|CHU Dijon, Dijon, France|CHU Grenoble, Hôpital Michallon, Grenoble, France|Hospital St Louis, La Rochelle, France|CHRU de Lille - Hopital Claude-Huriez, Lille, France|Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France|CHU Montpellier, Montpellier, France|CHU Nantes, CHU Hôtel-Dieu, Nantes Cedex 1, France|Institut de Cancérologie du Gard, Nimes, France|Hostpial Saint Louis - CIRCO (Centre d'Investigations et de Recherche Clinique en Oncologie), Paris, France|Hopital Pitié Salpêtrière, Paris, France|Hôpital Necker Service d'Hématologie Adult, Paris, France|Centre Henri Becquerel, Rouen, France|Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France|Uniklinik Aachen Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen, Germany|HELIOS Klinikum Bad Saarow, Bad Saarow, Germany|Berlin School of Integrative Oncology, Berlin, Germany|CharitéCentrum (CC) für Tumormedizin, Berlin, Germany|Ev. Diakonie-Krankenhaus gGmbH, Bremen, Germany|Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany|Martin-Luther-University Halle-Wittenberg Department of Oncology, Halle, Germany|Medizinische Hochschule, Hannover, Germany|Universität Heidelberg Medizinische Klinik V Hämatologie, Onkologie und Rheumatologie, Heidelberg, Germany|UKS Homburg - Klinik für Innere Medizin, Homburg, Germany|Klinikum Kempten Klinik für Innere Medizin III - Hämatologie, Onkologie und Palliativmedizin, Kempten, Germany|Klinikum Leverkusen, Leverkusen, Germany|Klinikum Ludwigshafen, Ludwigshafen, Germany|Rotkreuzklinikum München, Muenchen, Germany|Klinikum Nürnberg Nord, Nuernberg, Germany|Universitatsklinikum Ulm - Klinik Fur Innere Medizin III, Ulm, Germany|General Hospital of Athens ""Evangelismos"", Athens, Greece|National & Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece|National & Kapodistrian University of Athens, Attiko University Hospital, Chaidari, Greece|University of Patras Medical School, Patras, Greece|Semmelweis Egyetem Általános Orvosi Kar, Budapest, Hungary|Országos Onkológiai Intézet ""A"" Belgyógyászati Onkológiai Osztály, Budapest, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Pécsi Tudományegyetem, ÁOK, I. számú Belgyógyászati Klinika, Pécs, Hungary|Veszprém Megyei Csolnoky Ferenc Kórház, Veszprém, Hungary|Regional Cancer Centre, IGIMS, Patna, Bihar, India|Rajiv Gandhi Cancer Hospital, New Delhi, Delhi, India|Regional Cancer Centre, Thiruvananthapuram, Kerala, India|Prince Aly Khan Hospital, Mumbai, Maharashtra, India|Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, India|Institute of Medical Sciences & SUM Hospital, Bhubaneswar, Odisha, India|Dayanand Medical College and Hospital, Ludhiāna, Punjab, India|Cancer Institute (WIA), Chennai, Tamil Nadu, India|Saveetha Medical College Hospital, Chennai, Tamil Nadu, India|G. Kuppu Swamy Naidu Hospital, Coimbatore, Tamil Nadu, India|Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India|King George's Medical University (KGMU), Lucknow, Uttar Pradesh, India|NRS Medical College, Kolkata, West Bengal, India|TATA Memorial Centre, Kolkata, West Bengal, India|Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India|Dr. B.R.A. Institute Rotary Cancer Hospital All India Institute of Medical Sciences, New Delhi, India|Hematology-Soroka, Beer Sheva, Israel|Rambam Healthcare Campus, Haifa, Israel|Wolfson MC, Holon, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Assuta Medical Center, Tel Aviv, Israel|TLV Sorasky Medical Center, Tel Aviv, Israel|Sheba Medical Center, Tel Hashomer, Israel|National Cancer Institute, Aviano, Pordenone, Italy|AZ Osp Santi Antonio e Biagio e Cesare Arrigo Divisione di Ematologia (III piano) Padiglione Fiandesio, Alessandria, Italy|Azienda Ospedaliero-Universitaria ""Ospedali Riuniti"" Università Politecnica delle Marche, Ancona, Italy|Instituto di Ematologia Seragnoli Pad 8 Universita di Bologna, Bologna, Italy|Inst Per La Ricerca La Cura Del Cancro, Candiolo, Italy|Azicnda Ospedalicra Universitaria San Martino, Genova, Italy|Istituto Tumori Romagna - IRST, Meldola, Italy|Ospedale San Raffaele, Milano, Italy|Policlinico di Modena (COM), Dipar. di medicina diagnostica, clinica e di sanità pubblica, Università degli studi di Modena e Reggio Emilia, Modena, Italy|SCDU Ematologia, Division of Hematology, Dept. of Translational Medicine, Universita del Piemonte Orientale, Novara, Italy|Az. Ospedaliera Univ. Senese, Siena, Italy|Città della Salute e della Scienza di Torino, Torino, Italy|VUMc (Vrije Universiteit Amsterdam), Amsterdam, Netherlands|LUMC (leidse universitair medisch centrum), Leiden, Netherlands|EMC (erasmus medisch centrum rotterdam), Rotterdam, Netherlands|North Shore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Szpitale Wojewódzkie w Gdyni, Gdyńskie Centrum onkologii, Gdynia, Poland|MCM (Małopolskie Centrum Medyczne), Krakow, Poland|Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli, Lublin, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa, Olsztyn, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Centrum Onkologii- Insytut Im. Marii Skłodowskiej-Curie Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Wromedica S. C., Wroclaw, Poland|Memorial Provincial Specialist Hospital in Lodz, Łódź, Poland|Institut za onkologiju i radiologiju Srbije, Belgrade, Serbia|Klinicko Bolnick Centar Zemun Odeljenje hematologije, Belgrade, Serbia|Klinički centar Srbije Klinika za hematologiju, Belgrade, Serbia|Kliničko bolnički centar Zvezdara, Belgrade, Serbia|Vojnomedicinska akademija, Belgrade, Serbia|Klinički centar Niš Klinika za hematologiju, Nis, Serbia|Institut za onkologiju Vojvodine, Sremska Kamenica, Serbia|Hospitla Universitari Germans Trias i Pujol - ICO, Badalona, Spain|Hospital University Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre Servicio de hematología, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital de Son Llàtzer, Palma de Mallorca, Spain|Clínica Universidad De Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|QuirónSalud Zaragoza, Zaragoza, Spain|Southampton University Hospital, Southampton, Hampshire, United Kingdom|Northwick Park Hospital, Harrow, Middlesex, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, Yorkshire, United Kingdom|Addenbrooke's Hospital Cambridge, Cambridge, United Kingdom|Cheltenham General Hospital, Cheltenham, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|King's College Hospital, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Trust Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom","","https://ClinicalTrials.gov/show/NCT02227251"
50,"NCT03513601","Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: (R)-CHOP regimen|Drug: (R)-CVP regimen","Progression-free survival|overall survival|disease control rate|objective remission rate","Mingzhi Zhang|Zhengzhou University","All","70 Years to 85 Years   (Older Adult)","Phase 4","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","hnslblzlzx2017-10","July 1, 2017","May 2019","May 2019","May 1, 2018","null","May 1, 2018","Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China","","https://ClinicalTrials.gov/show/NCT03513601"
51,"NCT00169468","Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma",,"Completed","No Results Available","B Cell Lymphoma","Drug: Rituximab -CHOP plus Velcade","Rate of complete remission|Number of SAE|Duration of response|Progression free survival|Overall survival","Lymphoma Study Association|Association pour le Développement de la Recherche Clinique et Informatique en Onco-Hématologie","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R-CHOP VELCADE","January 2005","January 2006","January 2006","September 15, 2005","null","August 23, 2018","Hôpital Saint-Louis, Paris, Paris 10, France|Institut Gustave Roussy, Villejuif, Villejuif Cedex, France|Hôpital Henri Mondor, Créteil, France|Hôpital Lyon Sud, Pierre Bénite, France","","https://ClinicalTrials.gov/show/NCT00169468"
52,"NCT01046825","Mature B-Cell Lymphoma And Leukemia Study III",,"Recruiting","No Results Available","Mature B-Cell Lymphoma","Drug: COPAD|Drug: COP, COPD M3, CYM|Drug: COP, COPADM8, CYVE","Gene differential profiling of Burkitts Lymphoma (BL) vs. non-BL|Catalog and estimate frequencies of copy number variations in childhood lymphomas|Integrated analysis of CNVs and gene expressions|Pattern and frequency of XLP gene mutations presenting with B-cell lymphomas in the United States and selected geographic regions|Pattern of EBV protein expression (e.g., EBNA 3) in EBV-positive lymphomas and to compare patterns of EBV protein expression with clinical, laboratory and outcome data|Complete response rate|Event-free survival|Overall Survival|Percentage of participants who complete therapy with the use of rituximab|Number of possible rituximab-related toxicities","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2|Phase 3","122","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SJBC3|NCI-2011-01251","September 9, 2010","October 31, 2022","October 31, 2022","January 12, 2010","null","July 10, 2018","Rady Children's Hospital San Diego, San Diego, California, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Children's Cancer Hospital, Cairo, Egypt|National University Health System, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT01046825"
53,"NCT03208556","Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma",,"Recruiting","No Results Available","Relapsed or Refractory B-cell Lymphoma","Biological: iPD1 CD19 eCAR T cells|Drug: Fludarabine and cyclophosphamide","safety of infusion of iPD1 CD19 eCAR T cells as assessed by the incidents of treatment related adverse events per NCI CTCAE V4.0|treatment response|overall survival|progression-free survival","Peking University|Marino Biotechnology Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017YJZ13","June 21, 2017","June 1, 2019","June 1, 2020","July 5, 2017","null","September 14, 2017","Beijing Cancer Hosptical, Beijing, China","","https://ClinicalTrials.gov/show/NCT03208556"
54,"NCT01799083","Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas","CIK","Unknown status","No Results Available","Solid Tumors|B Cell Lymphoma","Drug: Decitabine|Biological: cytokine-induced killer cell","Response confirmed by non-investigational CT or MRI, or confirmed by biopsy|tumor marker","Han weidong|Chinese PLA General Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-002","December 2012","December 2016","December 2017","February 26, 2013","null","January 28, 2016","Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01799083"
55,"NCT03576443","Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma","ILIAD","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Idelalisib","Overall response rate for GCB DLBCL","Nordic Lymphoma Group","All","19 Years and older   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG-LBC-07","July 7, 2017","July 1, 2022","July 1, 2022","July 3, 2018","null","July 3, 2018","Aarhus University Hospital, Aarhus C, Denmark|Halmstad County Hospital, Halmstad, Sweden|Linkoping University Hospital, Linköping, Sweden|Skane University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT03576443"
56,"NCT03650933","A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients",,"Not yet recruiting","No Results Available","Diffuse Large B-Cell Lymphoma, Unspecified Site","Biological: G-CHOP|Biological: R-CHOP","Objective response rate (ORR)","Nanjing Yoko Biomedical Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GB241NHL3","October 2018","October 2020","October 2021","August 29, 2018","null","August 29, 2018","","","https://ClinicalTrials.gov/show/NCT03650933"
57,"NCT03579082","A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Decitabine","ORR|TTP|OS|PFS","Mingzhi Zhang|Zhengzhou University","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","hnslblzlzx20171211","June 1, 2018","June 1, 2019","December 1, 2019","July 6, 2018","null","September 14, 2018","Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China","","https://ClinicalTrials.gov/show/NCT03579082"
58,"NCT03415399","Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma, B-Cell","Biological: ET190L1 ARTEMIS™ T cells","Maximum Tolerated Dose|Toxicity profile of ET190L1 ARTEMIS™ T-cell treatment|Tmax of serum cytokine levels|Time to baseline for serum cytokine levels|AUC of serum cytokine levels|Duration of in vivo engraftment of ET190L1 ARTEMIS™ T cells|Rate of disease response|Anti-tumor responses|B cell depletion","Eureka Therapeutics Inc.|Peking University","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Industry|Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ETCH17CD19AR103","September 9, 2017","September 21, 2019","September 21, 2019","January 30, 2018","null","August 7, 2018","Peking University Cancer Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT03415399"
59,"NCT03681535","Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma","DLBCL","Not yet recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Radiation: Radiation Therapy","Local control rate|Disease-free survival|Overall Survival|Patterns of failure","Duke University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00100510","November 2018","November 2027","November 2032","September 24, 2018","null","September 26, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03681535"
60,"NCT01805557","Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.","FIL_VERAL12","Unknown status","No Results Available","Diffuse Large B-cell Lymphoma Refractory|Diffuse Large B-cell Lymphoma Recurrent","Drug: R-DHAP|Drug: BR-DHAP","Complete Response (CR) Rate|Overall Response Rate (ORR)|Overall Survival (OS|Toxicity|Mobilizing potential|Feasibility","Fondazione Italiana Linfomi ONLUS|Janssen Pharmaceutica|Janssen-Cilag Ltd.|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","108","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_VERAL12","February 2013","September 2017","February 2018","March 6, 2013","null","March 1, 2016","AOU Careggi, Firenze, FI, Italy|A.O. Niguarda, Milano, MI, Italy|Osp. San Gerardo, Monza, MI, Italy|Ospedale Civile Guglielmo da Saliceto, Piacenza, PC, Italy|CRO Aviano, Aviano, Pordenone, Italy|Osp. Umberto I, Nocera Inferiore, SA, Italy|Medicina Interna 2 ad indirizzo Ematologico AOU San Luigi Gonzaga, Orbassano, Torino, Italy|AOU San Giovanni Battista-Ematologia 1, Torino, TO, Italy|Azienda Ospedaliero - Universitaria di Udine, Udine, UD, Italy|Osp. S. Antonio Abate Gallarate, Gallarate, Varese, Italy|Ospedale di Circolo e Fondazione Macchi - Ematologia, Varese, VA, Italy|A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy|Clinica di ematologia AOU Umberto I Ospedali Riuniti, Ancona, Italy|Divisione di Ematologia Spedali Civili, Brescia, Italy|Presidio Ospedaliero A.Perrino - Divisione di Ematologia, Brindisi, Italy|Divisione di Ematologia Osp. Businco, Cagliari, Italy|Ospedale Roberto Binaghi, Cagliari, Italy|Università Cattolica Campobasso, Campobasso, Italy|A.O. Universitaria Ospedali Riuniti di Foggia, Foggia, Italy|Ematologia 1 Ospedale S. Martino, Genova, Italy|Azienda Universitaria San Martino, Genova, Italy|Ospedale Santa Maria Goretti, Latina, Italy|Ospedale Vito Fazzi, Lecce, Italy|SC Ematologia ‐ Trapianto di midollo osseo Fond. IRCCS Istituto Nazionale Tumori, Milano, Italy|Ospedale Maggiore IRCCS-Dipartimento di Ematologia, Milano, Italy|AORN Cardarelli U.O.Ematologia, Napoli, Italy|SCDU Ematologia ‐ Università del Piemonte Orientale, Novara, Italy|Ematologia e Immunologia Clinica, Dipartimento di Medicina Università di Padova, Padova, Italy|Ospedale S. Antonio, Padova, Italy|Oncoematologia Dipartimento oncologico La Maddalena, Palermo, Italy|U.O. Complessa di Ematologia Ospedale di Parma, Parma, Italy|Fond. Maugeri - Centro medico, Pavia, Italy|Osp. S. Maria delle Croci, Ravenna, Italy|AO Bianchi Melacrino Morelli UO Ematologia, Reggio Calabria, Italy|AO Arcispedale S.Maria Nuova Ematologia, Reggio Emilia, Italy|Osp. degli Infermi Divisione di Oncologia, Rimini, Italy|Ospedale Oncologico regionale CROB, Rionero in Vulture (PZ), Italy|Ematologia Ospedale S.Camillo Forlanini, Roma, Italy|A.O. Universitaria S. Andrea, Roma, Italy|Osp.Sant'Eugenio Divisione di Ematologia, Roma, Italy|Policlinico Universitario Tor Vergata, Roma, Italy|Universita' La Sapienza, Roma, Italy|Clinica Humanitas, Rozzano (MI), Italy|Policlinico Le Scotte Clinica Ematologica, Siena, Italy|SC Oncoematologia con autotrapianto AO Santa Maria, Terni, Italy|Osp. San Giovanni Battista_Molinette Ematologia 2, Torino, Italy|Divisione di Ematologia Ospedale S. Nicola, Trani, Italy","","https://ClinicalTrials.gov/show/NCT01805557"
61,"NCT01499303","Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer",,"Completed","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Fostamatinib","Objective Response Rate","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","101","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4302C00001","December 2011","October 2013","October 2013","December 26, 2011","August 22, 2014","August 22, 2014","Research Site, Huntsville, Alabama, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Sarasota, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Iowa City, Iowa, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Hackensack, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, London, United Kingdom|Research Site, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01499303"
62,"NCT02708732","Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","No Results Available","Diffuse Large B-Cell Lymphoma","","Health-Related Quality of Life According to European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Score","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","","91","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ML29956","May 31, 2016","October 31, 2016","October 31, 2016","March 15, 2016","null","April 20, 2017","PH Associates - an OPen Health Company, Marlow, United Kingdom","","https://ClinicalTrials.gov/show/NCT02708732"
63,"NCT02951728","Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma","DR-CHOP","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Decitabine","maximum tolerated dose|complete response rate|Overall response rate|Event-free survival|Overall survival|Progression-free survival|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0","Ruijin Hospital","All","15 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","58","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DR-CHOP","October 2016","October 2018","October 2019","November 1, 2016","null","November 14, 2017","Shanghai Ruijin Hospital, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02951728"
64,"NCT03104478","Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)","RT3","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Procedure: Biological samples collection","Real time report of molecular characterization","The Lymphoma Academic Research Organisation","All","18 Years and older   (Adult, Older Adult)","","194","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RT3","May 9, 2017","February 2019","December 2020","April 7, 2017","null","July 19, 2018","CHU Caen, Caen, France|Hopital Henri Mondor, Creteil, France|CHU Le Bocage, Dijon, France|CH Départemental, La Roche sur Yon, France|CHU Claude Hurriez, Lille, France|CHU Montpellier, MONTPELLIER Cedex 5, France|CHU de Nantes, Nantes, France|Centre Francois Magendie, Pessac, France|CHU Lyon Sud, Pierre Bénite cedex, France|CHU de Poitiers - Hôpital de la Miletrie, Poitiers, France|Ch Annecy Genevois, Pringy, France|Centre Henri Becquerel, Rouen, France|IUCT Oncopôle - CHU de Toulouse, Toulouse, France|CHU Nancy Brabois, Vandoeuvre Les Nancy, France|Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT03104478"
65,"NCT03688152","A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma",,"Not yet recruiting","No Results Available","Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: INCB053914|Drug: INCB050465","Number of treatment-emergent adverse events (TEAEs)|Cmax of INCB053914 in combination with INCB050465|Tmax of INCB053914 in combination with INCB050465|Cmin of INCB053914 in combination with INCB050465|AUC0-t of INCB053914 in combination with INCB050465|Cl/F of INCB053914 in combination with INCB050465|Overall response rate|Duration of response|Progression-free survival","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 53914-102","November 2018","September 2020","September 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688152"
66,"NCT01622439","Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma","VALFRID","Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Valproate|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Establishment of maximum tolerable dose of valproate.","Lund University Hospital|Valcuria","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Version1.1","June 2012","March 2018","March 2018","June 19, 2012","null","March 12, 2018","Skåne University Hospital, Dept. of Oncology, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT01622439"
67,"NCT01278602","R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: R-ESHAP","Overall response rate|3-year progression-free survival rate|3-y overall survival rate","Fudan University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LMTG 11-01","December 2010","December 2013","February 2014","January 19, 2011","null","March 5, 2013","Fudan University Shanghai Cancer Center, Shanghai, China","","https://ClinicalTrials.gov/show/NCT01278602"
68,"NCT00138086","Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma",,"Completed","No Results Available","B-Cell Lymphoma","Drug: Zevalin plus BEAM","EFS (event free survival)|Overall response rate (ORR)|Toxicities, transplant related mortality at 1 and 2 years|Hematological reconstitution after ASCT and 1 year|Time to progression or relapse, disease free survival for complete responders after ASCT, overall survival","Lymphoma Study Association","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Z-BEAM","March 2005","null","March 2009","August 30, 2005","null","September 8, 2006","Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium|Hôpital Henri Mondor, Créteil, France|Hématologie CHU de Lille, Lille, France|Institut Curie, Paris, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland","","https://ClinicalTrials.gov/show/NCT00138086"
69,"NCT02763319","A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","B-MIND","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Rituximab (RTX)|Drug: MOR208|Drug: Bendamustine (BEN)","Progression-free survival (PFS)|Objective response rate (ORR)|Duration of response (DoR)|overall survival (OS)|disease control rate (DCR)|time to progression (TTP)|time to next treatment (TTNT)|Number of patients with adverse events|quality of life (QoL)|Number of patients developing MOR208 antibodies|Maximum Plasma Concentration of MOR208 (Cmax)|Apparent trough concentration (Cpd) of MOR00208","MorphoSys AG|ICON Clinical Research","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MOR208C204|2014-004689-11","June 2016","March 2020","March 2022","May 5, 2016","null","September 5, 2018","MorphoSys Research Site, Anaheim, California, United States|MorphoSys Research Site, Bakersfield, California, United States|MorphoSys Research Site, Los Angeles, California, United States|MorphoSys Research Site, Whittier, California, United States|MorphoSys Research Site, Plainville, Connecticut, United States|MorphoSys Research Site, Skokie, Illinois, United States|MorphoSys Research Site, Detroit, Michigan, United States|MorphoSys Research Site, Rochester, Minnesota, United States|MorphoSys Research Site, Hattiesburg, Mississippi, United States|MorphoSys Research Site, New York, New York, United States|MorphoSys Research Site, Stony Brook, New York, United States|MorphoSys Research Site, Oklahoma City, Oklahoma, United States|MorphoSys Research Site, Knoxville, Tennessee, United States|MorphoSys Research Site, Adelaide, Australia|MorphoSys Research Site, Albury, Australia|MorphoSys Research Site, Bedford Park, Australia|MorphoSys Research Site, Box Hill, Australia|MorphoSys Research Site, Concord, Australia|MorphoSys Research Site, Frankston, Australia|MorphoSys Research SIte, Garran, Australia|MorphoSys Research Site, Geelong, Australia|MorphoSys Research Site, Gosford, Australia|MorphoSys Research Site, Nedlands, Australia|MorphoSys Research Site, South Brisbane, Australia|MorphoSys Research Site, St. Albans, Australia|MorphoSys Research Site, Innsbruck, Austria|MorphoSys Research Site, Salzburg, Austria|MorphoSys Research Site, Winnipeg, Manitoba, Canada|MorphoSys Research Site, Saint John, New Brunswick, Canada|MorphoSys Research Site, Kingston, Ontario, Canada|MorphoSys Research Site, Greenfield Park, Quebec, Canada|MorphoSys Research Site, Saskatoon, Canada|MorphoSys Research Site, Zadar, Croatia|MorphoSys Research Site, Zagreb, Croatia|MorphoSys Research Site, Hradec Kralove, Czechia|MorphoSys Research Site, Prague, Czechia|MorphoSys Research Site, Oulu, Finland|MorphoSys Research Site, Tampere, Finland|MorphoSys Research Site, Chalon sur Saône, France|MorphoSys Research Site, Grenoble, France|MorphoSys Research Site, Le Mans, France|MorphoSys Research Site, Perigueux, France|MorphoSys Research Site, Aachen, Germany|MorphoSys Research Site, Berlin, Germany|MorphoSys Research Site, Berlin, Germany|MorphoSys Research Site, Düsseldorf, Germany|MorphoSys Research Site, Giessen, Germany|MorphoSys Research Site, Leipzig, Germany|MorphoSys Research Site, Mainz, Germany|MorphoSys Research Site, Munich, Germany|MorphoSys Research Site, Mutlangen, Germany|MorphoSys Research Site, Rostock, Germany|MorphoSys Research Site, Stuttgart, Germany|MorphoSys Research Site, Stuttgart, Germany|MorphoSys, Traunstein, Germany|MorphoSys, Budapest, Hungary|MorphoSys Research Site, Debrecen, Hungary|MorphoSys Research Site, Győr, Hungary|MorphoSys, Szeged, Hungary|MorphoSys Research Site, Haifa, Israel|MorphoSys Research Site, Jerusalem, Israel|MorphoSys Research Site, Jerusalem, Israel|MorphoSys Research Site, Kfar Saba, Israel|MorphoSys Research Site, Nahariya, Israel|MorphoSys Research Site, Petaẖ Tiqwa, Israel|MorphoSys Research Site, Reẖovot, Israel|MorphoSys Research Site, Tel Aviv, Israel|MorphoSys Research Site, Alessandria, Italy|MorphoSys Research Site, Bologna, Italy|MorphoSys Research Site, Campobasso, Italy|MorphoSys Research Site, Cona, Italy|MorphoSys Research Site, Genova, Italy|MorphoSys Research Site, Lecce, Italy|MorphoSys Research Site, Meldola, Italy|MorphoSys Research Site, Monza, Italy|MorphoSys Research Site, Napoli, Italy|Morphosys Research Site, Novara, Italy|MorphoSys Research Site, Orbassano, Italy|MorphoSys Research Site, Parma, Italy|MorphoSys Research Site, Pavia, Italy|MorphoSys Research Site, Pisa, Italy|MorphoSys Research Site, Ravenna, Italy|MorphoSys Research Site, Reggio Emilia, Italy|MorphoSys Research Site, Rimini, Italy|MorphoSys Research Site, Rome, Italy|MorphoSys Research Site, Rome, Italy|MorphoSys Research Site, Turin, Italy|MorphoSys Research Site, Busan, Korea, Republic of|MorphoSys Research Site, Goyang-si, Korea, Republic of|MorphoSys Research Site, Incheon, Korea, Republic of|MorphoSys Research Site, Jeonju, Korea, Republic of|MorphoSys Research Site, Seongnam, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Ulsan, Korea, Republic of|MorphoSys Research Site, Addington, New Zealand|MorphoSys Research Site, Auckland, New Zealand|MorphoSys Research Site, Grafton, New Zealand|Morphosys Research Site, Bydgoszcz, Poland|MorphoSys Research Site, Gdansk, Poland|MorphoSys Research Site, Gdynia, Poland|MorphoSys Research Site, Kraków, Poland|MorphoSys Research Site, Legnica, Poland|MorphoSys Research Site, Lodz, Poland|MorphoSys Research Site, Lublin, Poland|MorphoSys Research Site, Warsaw, Poland|MorphoSys Research Site, Wrocław, Poland|MorphoSys Research Site, Braga, Portugal|MorphoSys Research Site, Coimbra, Portugal|MorphoSys Research Site, Coimbra, Portugal|MorphoSys Research Site, Matosinhos, Portugal|MorphoSys Research Site, Porto, Portugal|MorphoSys Research Site, Porto, Portugal|MorphoSys Research Site, Bucharest, Romania|MorphoSys Research Site, Bucharest, Romania|MorphoSys Research Site, Iaşi, Romania|MorphoSys Research Site, Belgrade, Serbia|MorphoSys Research Site, Kragujevac, Serbia|MorphoSys Research Site, Sremska Kamenica, Serbia|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Cadiz, Spain|MorphoSys Research Site, Girona, Spain|MorphoSys Research Site, L'Hospitalet De Llobregat, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Palma de Mallorca, Spain|MorphoSys Research Site, Pamplona, Spain|MorphoSys Research Site, Pozuelo De Alarcón, Spain|MorphoSys, Sabadell, Spain|MorphoSys Research Site, Salamanca, Spain|MorphoSys Research Site, Valencia, Spain|MorphoSys Research Site, Adana, Turkey|MorphoSys Research Site, Ankara, Turkey|MorphoSys Research Site, Ankara, Turkey|MorphoSys Research Site, Ankara, Turkey|MorphoSys Research Site, Bornova, Turkey|MorphoSys Research Site, Gaziantep, Turkey|MorphoSys Research Site, İzmir, Turkey|MorphoSys Research Site, Manisa, Turkey|MorphoSys Research Site, Samsun, Turkey|MorphoSys Research Site, Leeds, United Kingdom|MorphoSys Research Site, Southend on Sea, United Kingdom","","https://ClinicalTrials.gov/show/NCT02763319"
70,"NCT03399513","Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma","R-CHOEP-brut","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Ibrutinib Oral Capsule [Imbruvica]|Drug: R-CHOEP chemotherapy","2-year progression-free survival|Overall survival|Event-free survival|Rate of complete remission|Rate of partial remission|Overall response rate|Progression rate|Relapse rate|Duration of response|Adverse events and serious adverse events|Rate of treatment-related deaths|Therapy cycles (number)|Therapy cycles (duration)|Used drugs|Outcome according to lymphoma biology","University Hospital Muenster|Janssen-Cilag G.m.b.H","All","18 Years to 60 Years   (Adult)","Phase 2","75","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UKM17_0017","May 2018","February 2022","February 2022","January 16, 2018","null","May 14, 2018","Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany","","https://ClinicalTrials.gov/show/NCT03399513"
71,"NCT03036904","Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas","V+DA-EPOCH-R","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma","Drug: Venetoclax|Drug: Rituximab|Drug: Etoposide|Drug: Vincristine Sulfate|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Doxorubicin Hydrochloride","Determination of the maximal tolerated dose (MTD)|Determination of dose limiting toxicity (DLT)|Define incidence and severity of adverse events, defined according to CTCAE v 4.0.|Overall response rate|Complete response rate|Event-free survival|Progression Free Survival|Overall survival","Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1607017413","February 6, 2017","February 2019","August 2020","January 30, 2017","null","May 21, 2018","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medicine, New York, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03036904"
72,"NCT03123393","TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: TAK-659","ORR as Assessed by IRC Based on Modified 2007 International Working Group (IWG) Criteria (Stage 2)|CR Rate as Assessed by IRC Based on Modified 2007 IWG Criteria (Stage 2)|ORR as Assessed by IRC Based on 2014 IWG-Lugano Criteria (Stage 2)|CR Rate as Assessed by IRC Based on 2014 IWG-Lugano Criteria (Stage 2)|Duration of Response (DOR) (Stage 2)|Duration of CR (Stage 2)|ORR as Assessed by IRC in Participants with Germinal Center B-cell (GCB) DLBCL (Stage 2)|ORR as Assessed by IRC in Participants with DLBCL Transformed from Indolent non-Hodgkin Lymphoma (NHL) (Stage 2)|Progression Free Survival (PFS) as Assessed by IRC (Stage 2)|Overall Survival (OS) (Stage 2)|ORR as Assessed by IRC to Select the Dose Regimen of TAK-659 from the Lead-in Dose Exploration Phase (Stage 2)|ORR as Assessed by IRC at 3, 6, and 9 cycles in Participants with DLBCL (Stage 2)","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","122","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C34004|U1111-1187-6208|2016-003716-12|17/YH/0181","October 10, 2017","January 31, 2020","August 31, 2021","April 21, 2017","null","September 7, 2018","University of Kansas Medical Center, Westwood, Kansas, United States|University of Michigan, Ann Arbor, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University Langone Medical Center, New York, New York, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Swedish Medical Oncology - Edmonds, Edmonds, Washington, United States|Swedish Cancer Institute - Issaquah, Issaquah, Washington, United States|Swedish Health Services, Seattle, Washington, United States|University of Washington, Hutchinson Cancer Research Center, Seattle, Washington, United States|Swedish First Hill Campus, Seattle, Washington, United States|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Centre Hospitalier Regional de Rimouski, Rimouski, Quebec, Canada|CHU de Quebec -Universite Laval-Hopital de L'Enfant Jesus, Quebec, Canada|Hopital Haut-Leveque, Pessac Cedex, Aquitaine, France|CHRU Clermont- Ferrand CHU Estaing, Clermont-Ferrand, Auvergne, France|Centre Henri-Becquerel, Rouen Cedex 1, Haute-normandie, France|Hopital Saint Louis, Paris Cedex 10, Ile-de-france, France|Groupe Hospitalier - Hopitaux Universitaires Pitie-Salpetriere - Charles-Foix - Pitie-Salpetriere, Paris Cedex 13, Ile-de-france, France|Hopital Necker-Enfants Malades, Paris, Ile-de-france, France|Institut Gustave Roussy, Villejuif Cedex, Ile-de-france, France|Hopital Dupuytren, Limoges Cedex, Limousin, Lorraine, France|Institut Paoli Calmettes Departement de Recherche Clinique et de l'Innovation, Marseille, Provence Alpes COTE D'azur, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, Rhone-alpes, France|Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy|Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Italy|Azienda Ospedaliero-Universitaria ""Maggiore della Carita"", Novara, Italy|Azienda Ospedaliero Universitaria Santa Maria della Misericordia di Udine, Udine, Italy|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario La Fe, Valencia, Spain|University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, England, United Kingdom|London North West Healthcare NHS Trust, Imperial College London, Harrow, England, United Kingdom|University College London Hospitals NHS Foundation Trust, London, England, United Kingdom|The Christie NHS Foundation Trust, Manchester, England, United Kingdom|Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT03123393"
73,"NCT03064867","Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Diffuse Large B-cell-lymphoma","Drug: Venetoclax|Drug: RICE","Recommended Phase II Dose|Overall Response Rate|Proportion of Patients Proceeding to Autologous Stem Cell Transplant|Progression Free Survival|Overall Survival|Number of Peripheral Blood Stem Cells Collected|Median Number of cluster of differentiation 34 (CD34+) Cells/kg","Paolo Caimi, MD|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE2415","June 26, 2017","September 21, 2018","March 15, 2020","February 27, 2017","null","July 18, 2018","University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03064867"
74,"NCT03200015","Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma",,"Active, not recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Metformin","Incidence of treatment-emergent adverse events|Response rates|Progression-free survival|Overall survival|Event-free survival|Time to progression or relapse","Hospital Universitario Dr. Jose E. Gonzalez","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HE16-00019","October 1, 2017","August 27, 2018","January 27, 2019","June 27, 2017","null","September 21, 2018","Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo Leon, Mexico","","https://ClinicalTrials.gov/show/NCT03200015"
75,"NCT01289210","VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas",,"Terminated","Has Results","Low Grade B Cell Lymphoma","Drug: VTX-2337 plus radiotherapy","Number of Participants Whose Tumors Responded to Treatment With Intratumoral Injection of VTX-2337 in Combination With Low-Dose Local Radiation.|Assess the Safety and Feasibility of the Combination Regimen.","VentiRx Pharmaceuticals Inc.|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","2","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VRXP-A104","July 2011","November 2011","October 2012","February 3, 2011","October 6, 2014","October 6, 2014","Stanford Cancer Center, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT01289210"
76,"NCT03485118","RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma","Hi-CHOP","Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: HS006+CHOP|Drug: Rituximab+CHOP","ORR","Zhejiang Hisun Pharmaceutical Co. Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HISUN-CD20-2016L01","May 12, 2016","August 12, 2016","January 14, 2018","April 2, 2018","null","April 2, 2018","","","https://ClinicalTrials.gov/show/NCT03485118"
77,"NCT03383406","A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma","IVAM","Enrolling by invitation","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy","Response|Assess response rate","Asan Medical Center","All","19 Years to 60 Years   (Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AsanMC_LMP2017-001","December 1, 2016","December 31, 2025","December 31, 2025","December 26, 2017","null","December 26, 2017","","","https://ClinicalTrials.gov/show/NCT03383406"
78,"NCT03121456","18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma","LYMPHODTECT","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Other: 18F-FDG PET SCAN|Other: MRI DIFFUSION","measurement of the correlation between the Delta SUVmax in PET-TDM (or between the Deauville criteria if the Delta SUVmax is not applicable) and the Delta ADCmax in diffusion MRI.|progression free-survival at 2 years|diagnostic performance of MRI scattering|- The degree of inter- and intra-observer association (concordance) of the ADCmax","Centre Antoine Lacassagne","All","19 Years and older   (Adult, Older Adult)","Not Applicable","74","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016/12","October 13, 2017","October 13, 2021","October 30, 2021","April 20, 2017","null","June 26, 2018","Centre antoine-LACASSAGNE, Nice, France","","https://ClinicalTrials.gov/show/NCT03121456"
79,"NCT03022123","The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: PL-doxorubicin and epirubicin","overall response rate","Hebei Medical University Fourth Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSPC-DMS- DLBCL -02","November 2016","November 2017","March 2018","January 16, 2017","null","January 16, 2017","Fourth Hospital of Hebei Medical University, Shi Jiazhuang, Hebei, China","","https://ClinicalTrials.gov/show/NCT03022123"
80,"NCT03670901","A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)",,"Not yet recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Biological: JHL1101|Biological: MabThera","Overall response rate (ORR)","JHL Biotech, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JHL-CLIN-1101-03","November 30, 2018","December 14, 2020","April 18, 2021","September 14, 2018","null","September 14, 2018","Beijing Cancer Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03670901"
81,"NCT03145064","Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: BGB-3111","Rate of objective response|Progression free survival (PFS)|Duration of response (DOR)|Time to response (TTR)","BeiGene","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BGB-3111-207","June 12, 2017","October 15, 2018","April 30, 2019","May 9, 2017","null","October 2, 2017","Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Peking University Cancer Hospital, Beijing, Beijing, China|West China Hospital, Sichuan University, Chengdu, Chengdu, China|Zhengjiang Cancer hospital, Hangzhou, Hangzhou, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|The first affiliated hospital of Soochow University, Suzhou, Suzhou, China|Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China|Tianjin Medical University Cancer Institute&Hospital, Tianjin, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03145064"
82,"NCT01238692","A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)",,"Active, not recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: LBH589|Drug: Rituximab","Efficacy of LBH589 alone and when given in combination with rituximab|Safety and tolerability of single agent LBH589 therapy and combination therapy of LBH589 with rituximab|Identify potential biological factors that might correlate with efficacy","Sarit Assouline|Quebec Clinical Research Organization in Cancer|Novartis|Hoffmann-La Roche|Jewish General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Q-CROC-02","November 2010","January 2016","December 2016","November 11, 2010","null","December 6, 2016","Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Sacré-Cœur Hospital, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT01238692"
83,"NCT00001271","A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma",,"Completed","No Results Available","B Cell Lymphoma","Drug: IgG-RFB4-SMPT-dgA","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 1","24","NIH","Interventional","Primary Purpose: Treatment","910176|91-C-0176","July 1991","null","April 2001","December 10, 2002","null","March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001271"
84,"NCT01466868","Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma","AKTIL","Terminated","No Results Available","Diffuse Large B Cell Lymphoma","Drug: MK2206","evaluation of the antitumor activity of MK-2206 in terms of objective response rate (ORR).|safety profile|overall survival|progression-free survival|duration of response","Centre Leon Berard|National Cancer Institute, France","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AKTIL","November 2011","September 2013","June 2014","November 8, 2011","null","July 10, 2014","Institut Bergonié, Bordeaux, France|Centre Henri Mondor, Créteil, France|CHRU, Lille, France|Centre Leon Berard, Lyon, France|Institut Paoli Calmettes, Marseille, France|CHU St Eloi, Montpellier, France|CHU, Nancy, France|CHU de Nantes, Nantes, France|Hôpital Saint-Louis, Paris, France|Hôpital Necker, Paris, France|Centre Hospitalier LYON SUD, Pierre Bénite, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT01466868"
85,"NCT00645359","Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma","dMRI","Terminated","Has Results","Diffuse Large B Cell Lymphoma","Procedure: diffusion MRI","Mean Difference in Apparent Diffusion Coefficient|The Odds Ratio (OR) Between Tumor Response (Based on Changes in MR Imaging) and Duration of Response","University of Michigan Cancer Center","All","18 Years and older   (Adult, Older Adult)","","9","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UMCC 2006.063|HUM 6946","November 2006","July 2011","April 2014","March 27, 2008","October 8, 2014","April 14, 2017","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00645359"
86,"NCT02595242","Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma",,"Withdrawn","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone","ORR(Objective response rate)","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSPC-HE1505/PRO/Ⅰ","June 2015","December 2016","June 2017","November 3, 2015","null","May 23, 2017","Tianjin people's Hospital, Tianjin, China","","https://ClinicalTrials.gov/show/NCT02595242"
87,"NCT01676558","A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)",,"Unknown status","No Results Available","Relapsed or Refractory Diffuse Large B Cell Lymphoma","Drug: 131I-rituximab","overall response rate|Response duration|progression free survival|Overall survival|Number of Adverse event","Korea Cancer Center Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DLBCL_131I-rituximab RIT","June 2012","June 2016","June 2017","August 31, 2012","null","November 14, 2012","Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of|Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01676558"
88,"NCT01949818","Treatment of Diffuse Large B Cell Lymphoma",,"Unknown status","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Yangzhengxiaoji capsule combined with CHOP regimen|Drug: CHOP regimen","Progression-free survival|overall survival","Mingzhi Zhang|Zhengzhou University","All","14 Years to 70 Years   (Child, Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","hnslblzlzx2011-4","September 2012","September 2016","September 2018","September 25, 2013","null","December 30, 2015","Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China","","https://ClinicalTrials.gov/show/NCT01949818"
89,"NCT02752204","An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma","TORCH","Active, not recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: AZD 2014|Drug: Rituximab","Best overall response rate (PR plus CR) (using the Revised Response Criteria for Malignant Lymphoma ) during the first 6 cycles|Tolerability rate (based on toxicity assessments using CTCAE v 4.0 criteria) of single agent AZD2014|Tolerability rate of additional toxicities when rituximab is combined with AZD2014 at its standard dose (stage 2 only)|Best overall response rate post 6 cycles until the end of the trial, assessed using Revised Response Criteria|Overall survival (OS) at 1 year|Progression free survival (PFS) at 1 year|Duration of response|Maximum % decrease in the radiological sum of the product of the diameters (SPD) from baseline by CT NCAP","University of Birmingham|Bloodwise|AstraZeneca|Cancer Research UK","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG_14-212","October 2015","September 7, 2017","April 2019","April 26, 2016","null","May 10, 2018","Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|University College London Hospitals, London, United Kingdom|Guys Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Norfolk & Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom|The Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02752204"
90,"NCT03677154","A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy",,"Not yet recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Mosunetuzumab|Drug: Tocilizumab","Percentage of Participants with Adverse Events|Positron Emission Tomography-Computed Tomography (PET-CT) Complete Response (CR) Rate at Time of Primary Response Assessment (PRA) According to Lugano 2014 Response Criteria|Maximum Serum Concentration (Cmax) of Mosunetuzumab|Minimum Serum Concentration (Cmin) of Mosunetuzumab|Area Under the Curve (AUC) of Mosunetuzumab|Clearance (CL) of Mosunetuzumab|Volume of Distribution at Steady State (Vss) of Mosunetuzumab|Objective Response Rate (ORR), Defined as Complete Response (CR) or Partial Response (PR) at Time of PRA Based on PET-CT as Assessed According to Lugano 2014 Response Criteria|Best ORR (CR or PR at any time) on Study Based on PET-CT and/or CT scans as Assessed According to Lugano 2014 Response Criteria|Duration of Response (DOR)|Progression-Free Survival (PFS)|Event-Free Survival (EFS)|Anti-Drug Antibodies (ADAs) to Mosunetuzumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO40554","October 8, 2018","October 3, 2023","October 3, 2023","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677154"
91,"NCT01282476","Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma",,"Terminated","Has Results","Diffuse Large B Cell Lymphoma","Drug: Panobinostat with Rituximab","Overall Response Rate|Progression-free Survival Rate|Toxicities","Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-441","June 2011","August 2013","August 2014","January 25, 2011","March 31, 2017","May 9, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01282476"
92,"NCT03399747","Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma",,"Enrolling by invitation","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Abb-R-CHOP","Response|Assess response rate","Asan Medical Center","All","19 Years and older   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Asan_LMP2017-002","December 7, 2016","December 31, 2024","December 31, 2024","January 16, 2018","null","January 16, 2018","","","https://ClinicalTrials.gov/show/NCT03399747"
93,"NCT01556035","Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma","REV-LEG","Completed","No Results Available","Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)","Drug: Lenalidomide","Overall response rate (complete response CR and partial response PR) at 6 months|Overall response rate (complete response CR and partial response PR) at 12 months|Duration of response|Progression-free survival|Overall survival and disease specific survival|Safety : description of adverse events occured including grade based on CTCAE v4.0|Quality of life","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUBX 2011/28","July 2012","March 2015","August 2015","March 16, 2012","null","September 23, 2016","CHU Amiens, Hôpital Sud, Amiens, France|CHU Besançon, Hôpital Saint-Jacques, Besançon, France|AP-HP Hôpital Avicenne, Bobigny, France|AP-HP Hôpital Ambroise Paré, Boulogne-billancourt, France|CHU de Clermont-Ferrand, Estaing, Clermont-ferrand, France|AP-HP Hôpital Henri Mondor, Creteil, France|CHU de Dijon, Le Bocage, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille Hôpital Claude Huriez, Lille, France|Centre Léon Bérard, Lyon, France|AP-HM Hôpital Nord, Marseille, France|CHRU de Montpellier Hôpital Saint-Eloi, Montpellier, France|CHU de Nantes, Hôtel Dieu, Nantes, France|CHU de Nice Groupe hospitalier l'Archet, Nice, France|AP-HP- Hôpital Saint Louis, Paris, France|AP-HP Groupe hospitalier Cochin, Paris, France|AP-HP Groupe hospitalier Bichat - Claude Bernard, Paris, France|AP-HP Hôpital Tenon, Paris, France|CHU de Bordeaux Hôpital du Haut Lévèque, Pessac, France|CHU Lyon Sud, Pierre Benite, France|CHU de Reims, Hôpital Robert Debré, Reims, France|CHU de Rouen, Hôpital Charles Nicolle, Rouen, France|CHU de Toulouse Hôpital Larrey, Toulouse, France|CHU de Tours- Hôpital Trousseau, Tours, France","","https://ClinicalTrials.gov/show/NCT01556035"
94,"NCT01766583","A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma","CLEAR","Completed","No Results Available","Relapsed/Refractory B-cell Lymphoma","Drug: CC-292 + lenalidomide","Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma|preliminary efficacy signals of the CC-292 + Lenalidomide combination|Observed maximum plasma concentration|time to reach maximum observed plasma concentration (Tmax)|Terminal phase rate constant (λz)|plasma decay half-life (t1/2)|Area under the curve from time zero to the last quantifiable concentration [AUC(0-t)]|Area under the curve from time zero to extrapolated infinity [AUC(0-∞)]|BTk receptor occupancy","The Lymphoma Academic Research Organisation|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLEAR","February 2013","November 2014","January 2018","January 11, 2013","null","March 7, 2018","Hopital henri mondor, Créteil, France|CHU de Lille, Lille, France|Institut Paoli Calmette, Marseille, France|CHU de Nantes, Nantes, France|CHU Lyon Sud, Pierre Bénite, France|CHU de Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT01766583"
95,"NCT01054781","Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma (DLBCL)","Drug: Rituximab","To evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL and|To evaluate the overall response rate of R+R-CHOP|To evaluate the duration of overall response|To evaluate the safety and tolerability of the R+R-CHOP combination treatment.|To evaluate the progression free survival.|To estimate the overall survival.|To explore prognostic or predictive biomarkers","Samsung Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","91","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-12-005","January 2009","November 2010","null","January 22, 2010","null","September 27, 2012","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01054781"
96,"NCT00530179","FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma","PET Chop","Unknown status","No Results Available","Diffuse Large B Cell Lymphoma","Procedure: Autologous Blood Stem Transplantation|Drug: R-CHOP (Rituximab, Cyclphosphamide, Etoposide, Cisplatin, Mesna, G-CSF","","Alberta Health Services|Hoffmann-La Roche|AHS Cancer Control Alberta","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0307003","July 2007","August 2011","null","September 17, 2007","null","December 7, 2011","Tom Baker Cancer Centre, Calgary, Alberta, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada","","https://ClinicalTrials.gov/show/NCT00530179"
97,"NCT03274492","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","POLARIX","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Polatuzumab Vedotin|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Vincristine Placebo|Drug: Prednisone|Drug: Polatuzumab vedotin Placebo","Progression-Free Survival (PFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma|Percentage of Participants With Complete Response (CR) as Assessed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) by Blinded Independent Central Review (BICR)|Event-Free Survival-Efficacy (EFSeff) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma|Percentage of Participants Who are Progression Free as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma|Overall Survival|Percentage of Participants With CR as Assessed by FDG-PET by Investigator|Disease-Free Survival (DFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma|Duration of Response as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma|Event-Free Survival-All Causes (EFSall) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma|Time to Deterioration in European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) Physical Functioning and Fatigue|Time to Deterioration in Functional Assessment of Cancer Therapy-Lymphoma Lymphoma Subscale (FACT-Lym LymS)|Percentage of Participants Achieving Meaningful Improvement in EORTC QLQ-C30 Physical Functioning and Fatigue|Percentage of Participants Achieving Meaningful Improvement in FACT-Lym LymS|EORTC QLQ-C30 Treatment-Related Symptoms Score|Functional Assessment of Cancer Treatment/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) Peripheral Neuropathy Score|Percentage of Participants With adverse Events (AEs)|Serum Concentration of Total Polatuzumab Vedotin|Plasma Concentration of Polatuzumab Vedotin Conjugate (Antibody-Conjugated Mono-Methyl Auristatin E [acMMAE])|Plasma Concentration of Polatuzumab Vedotin Unconjugated MMAE|Percentage of Participants With Anti-Drug Antibody (ADA) to Polatuzumab Vedotin","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","875","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GO39942|2017-002023-21","November 16, 2017","December 17, 2019","April 15, 2023","September 7, 2017","null","July 16, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Southern Cancer Center, Daphne, Alabama, United States|City of Hope, Duarte, California, United States|Ronald Reagan UCLA Medical Center; Drug Information Center, Los Angeles, California, United States|University of Colorado Cancer Center Department of Hematology, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Florida Cancer Specialists - Fort Myers (New Hampshire Ct), Fort Myers, Florida, United States|Florida Cancer Specialists & Research Institute, Saint Petersburg, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Emory University; Investigational Drug Service, Atlanta, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|University of Louisville Hospital; The James Graham Brown Cancer Center, Louisville, Kentucky, United States|Oscher Clinic, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute; Lymphoma Program, Boston, Massachusetts, United States|University of Michigan Health System; UMH Internal Medicine/Hematology-Oncology, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|HCA Midwest Division, Kansas City, Missouri, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States|Roswell Park Cancer Institute; Grace Cancer Drug Center, Buffalo, New York, United States|New York University Cancer Cen, New York, New York, United States|Columbia University Medical Center; Center for Lymphoid Malignancies, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Levine Cancer Institute - Clincal Trials Administration, Charlotte, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio State University; B406 Starling-Loving Hall, Columbus, Ohio, United States|Oncology/Hematology Care Clinical Trials LLC, Fairfield, Ohio, United States|Oncology Associates of Oregon, P.C, Eugene, Oregon, United States|Northwest Cancer Specialists - Portland (SW Barnes Rd), Portland, Oregon, United States|Oregon HSU; Bld-Brain Barr/Neuro-Onc, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center; Hematology/Oncology, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Cancer Center; Pharmacy, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina Hospital, Charleston, South Carolina, United States|Greenville Health System (GHS) Cancer Institute, Greenville, South Carolina, United States|Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Rocky Mountain Cancer Centers, LLP, Irving, Texas, United States|Texas Oncology-Tyler, Irving, Texas, United States|Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States|University of Utah; Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Oncology Associates of Southwest Virginia, Inc., Blacksburg, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Shenandoah Oncology Associates, Winchester, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|North Star Lodge, Yakima, Washington, United States|West Virginia Uni Med. Center - Robert Byrd Health Science, Morgantown, West Virginia, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital; Outpatient Pharmacy University Clinic, Westmead, New South Wales, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|The University of Adelaide - The Queen Elizabeth Hospital (TQEH), Woodville South, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Hospital; Cancer Clinical Trials Centre, Melbourne, Victoria, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie, Innsbruck, Austria|Landesklinikum Krems, Krems, Austria|Salzburger Landeskliniken LKH, Salzburg, Austria|Medizinische Universität Wien, Wien, Austria|Wilhelminenspital der Stadt Wien, Wien, Austria|CHU UCL Mont-Godinne, Mont-godinne, Belgium|Hospital Erasto Gaertner, Curitiba, PR, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, RS, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Hospital das Clinicas - UNICAMP, Campinas, SP, Brazil|Hospital Das Clinicas, Sao Paulo, SP, SP, Brazil|University of Alberta Hospital, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|CancerCare Manitoba, Investigational Drug Services, Pharmacy, Winnipeg, Manitoba, Canada|McMaster Univ Medical Center; Hamilton Reg Canc Ctr, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal - Pavillon E (PEA), Montreal, Quebec, Canada|CHU de Quebec-Universite Laval, Quebec, Canada|Peking Union Medical College Hospital, Beijing City, China|Beijing Cancer Hospital, Beijing, China|Fujian Provincial Cancer Hospital, Fuzhou City, China|Sun Yet-sen University Cancer Center, Guangzhou, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China|Jiangsu Cancer Hospital, Nanjing, China|Jiangsu Province Hospital, Nanjing, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai City, China|Shanghai East Hospital, Tongji University, Shanghai City, China|Fudan University Shanghai Cancer Center, Shanghai, China|Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin City, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Henan Cancer Hospital, Zhengzhou, China|Fakultni Nemocnice Hradec Kralove; Nephrology, Hradec Kralove, Czechia|3. Interni Klinika Fakultni Nemocnice Olomouc, Olomouc, Czechia|Fakultni Nemocnice Ostrava; Neurologicka Klinika, Ostrava, Czechia|Univerzita Karlova v Praze a Vseobecna fakultni nemocnice v Praze - 1; Lekarska Fakulta - I, Prague 2, Czechia|Fakultni Nemocnice V Motole, S.P,Pharmacy, Prague 5, Czechia|CHU Angers, Angers, France|Institut d'Hématologie de Basse Normandie, Caen, France|Ch Sud Francilien; Hematologie Oncologie, Corbeil Essonnes, France|Hopital Henri Mondor; Hematologie Clinique, Creteil, France|CHU de Dijon - Hopital le Bocage, Dijon, France|Hôpital Saint Vincent de Paul, Lille, France|CHU Montpellier - Saint ELOI, Montpellier, France|CHU de Nantes - Hotel Dieu, Nantes, France|Hôpital Saint-Louis; Service d'Hématologie, Paris, France|Gh Necker Enfants Malades; Hematologie Clinique, Paris, France|CHU Lyon Sud - Service Hématologie, Pierre Benite, France|Hopital Pontchaillou; Hematologie Clinique, Rennes, France|Centre Henri Becquerel; Hematologie, Rouen, France|CHU de Brabois, Vandoeuvre Les Nancy, France|CH Bretagne Atlantique; Médecine interne, Vannes Cedex, France|Vivantes Klinikum Am Urban, Berlin, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|HELIOS Klinikum Erfurt - Innere Medizin - 4. Medizinische Klinik, Hämatologie, Erfurt, Germany|Universitätsklinikum Essen, Essen, Germany|Universitaetsklinikum Halle (Saale), Halle, Germany|Apotheke des Universitätsklinikums Heidelberg, Heidelberg, Germany|Institut für Versorgungsforschung in der Onkologie GbR Koblenz, Koblenz, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Urologische Klinik u. Poliklinik, Mainz, Germany|Klinikum rechts der Isar der TU München; Institut für Röntgendiagnostik, München, Germany|Universitätsklinikum Münster, Münster, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Kowloon, Hong Kong|Palmerston North Hospital, Roslyn Palmerston North, Israel|Az.Osp.Univ.Sen.Poli.Le Scotte, Siena, Abruzzo, Italy|Servizio Farmacia Ospedaliera; Santa Maria Nuova, Reggio Emilia, Emilia-Romagna, Italy|Azienda Policlinico Umberto I, Roma, Lazio, Italy|IRCCS AOU San Martino - IST, Genova, Liguria, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|A.O. Spedali Civili Di Brescia-P.O. Spedali Civili; U.O. Radioterapia, Brescia, Lombardia, Italy|Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica, Milano, Lombardia, Italy|Istituto Nazionale dei Tumori, Monza, Lombardia, Italy|A.O.U. Maggiore della Carità, Novara, Piemonte, Italy|Ospedale Molinette - Universita' Di Torino; Cliniche Universitarie Ematologia I, Torino, Piemonte, Italy|National Hospital Organization Nagoya Medical Center, Aichi, Japan|Aichi Cancer Center, Aichi, Japan|Chiba University Hospital, Chiba, Japan|Chiba Cancer Center, Chiba, Japan|National Cancer Center Hospital East, Chiba, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto University Hospital, Kumamoto, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan|Tohoku University Hospital, Miyagi, Japan|Osaka City University Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Kindai University Hospital, Osaka, Japan|Jichi Medical University Hospital, Tochigi, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital; Hematology Medical Oncology, Gyeonggi-do, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital; hemato-oncology, Yangsan, Korea, Republic of|Auckland City Hospital; Renal Unit, Level 15, Auckland, New Zealand|Canterbury Health Laboratories; Immunology/Rheumatology, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Samodzielny Publiczny Psychiatryczny ZOZ; Oddzial Ogolnopsychiatryczny V Klinika Psychiatrii UM, Choroszcz, Poland|Malopolskie Centrum Medyczne, Krakow, Poland|Wojewódzki Szpital Specjalistyczny im.Kopernika ; Oddział Chemioterapii i Nowotworów, Lodz, Poland|SPZOZ MSW w Poznaniu im. Prof. L .Bierkowskiego; Oddzial Hematologii i Chorob Wewnetrznych, Poznan, Poland|Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie; Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Katedra i Klinika Hematologii; Nowotworów Krwi i Transplantacji Szpiku, Wrocław, Poland|Leningrad Regional Clinical Hospital; Hematology Department, Sankt-peterburg, Adygeja, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic, Kazan, Russian Federation|Penza Regional Oncology Dispensary, Penza, Russian Federation|Hospital Quirón de Madrid, Servicio de dermatología, Pozuelo de Alarcón, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Clinic de Barcelona; Consultas Externas Oftalmologia, Barcelona, Spain|Hospital San Pedro De Alcantara; Servicio de Nefrologia, Caceres, Spain|Institut Catala de Serveis Medics, Girona, Spain|Fundacion Jimenez Diaz, Clinica Nuestra Señora de la Concepcion; Servicio de Reumatologia, Madrid, Spain|Hospital Universitario la Paz; Servicio de Alergologia, Madrid, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Madrid, Spain|Hospital Regional Universitario Carlos Haya, Malaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hirslanden Medical Center, Tumorzentrum, Aarau, Switzerland|Universitätsspital Basel; Dermatologische Klinik Allergologische Poliklinik, Basel, Switzerland|Hopital Cantonal Universitaire De Geneve, Genève, Switzerland|Kaohsiung Medical University Hospital, Cancer Center, Kaohsiung, Taiwan|China Medical University Hospital; Clinical Research Center Clinical Pharmacy, Taichung, Taiwan|Chi-Mei Hospital, Liouying, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital; Diabetes, Taipei, Taiwan|Hemotoloji ve Hematolik Onkoloji Tani ve Tedavi Merkezi, Ankara, Turkey|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey|Dokuz Eylul University Medicine Faculty; Uroloji Departmani, Izmir, Turkey|Vehbi Koc Vakfi (VKV) - Amerikan Hastanesi, Teşvi̇ki̇ye, Turkey|Lvov City Clinical Hospital 5', Lviv, Chernihiv Governorate, Ukraine|Feofaniya Clinical hospital of the Ukrainian State Administration of President Affairs, Kyiv, Volhynian Governorate, Ukraine|Cherkassy Regional Oncology Hospital Dispensary, Cherkassy, Ukraine|Khmelnytsky Regional Clin Hosp, Khmelnitskyy, Ukraine|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom|University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary, Leicester, United Kingdom|Barts Health NHS Trust; Bartholomew's H., King George V Building, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom|Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom|University of Southampton; Southampton General Hospital; Cancer Sciences Unit, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT03274492"
98,"NCT02449265","Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Radiation: Consolidation involved-site radiotherapy (ISRT)|Radiation: Consolidation involved-field radiotherapy (IFRT)|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Progression-free survival - PFS|Adverse events with grade 3 or 4 - AEs|Overall survival - OS|Rate of in-field progression|Rate of out-field progression|Rate of regional failure","Wuhan University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WUCC-NHL03 Trial","October 2015","October 2019","October 2025","May 20, 2015","null","December 14, 2015","DiDeng, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT02449265"
99,"NCT02449278","The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Radiation: Consolidation involved-site radiotherapy (ISRT)|Radiation: Consolidation involved-field radiotherapy (IFRT)|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Progression-free survival - PFS|Adverse events with grade 3 or 4 - AEs|Overall survival - OS|Rate of in-field progression|Rate of out-field progression|Rate of regional failure","Wuhan University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WUCC-NHL04 Trial","October 2015","October 2019","October 2025","May 20, 2015","null","December 14, 2015","DiDeng, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT02449278"
100,"NCT01197560","Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","Has Results","Diffuse Large B-cell Lymphoma","Drug: Lenalidomide|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Rituximab|Drug: Etoposide","Stage 1: Percentage of Participants With an Overall Response Rate (ORR) According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999.|Stage 2: Progression-free Survival for Diffuse Large B-Cell Lymphoma (DLBCL) Participants|Stage 2: Complete Response Rate for Diffuse Large B-Cell Lymphoma (DLBCL) Participants|Stage 2: Overall Response Rate for Diffuse Large B-Cell Lymphoma (DLBCL) Participants|Stage 2: Duration of Overall Response for Diffuse Large B-Cell Lymphoma (DLBCL) Participants|Stage 2: Overall Survival (OS) for Diffuse Large B-Cell Lymphoma (DLBCL) Participants|Stage 2: Duration of Complete Response for Diffuse Large B-Cell Lymphoma (DLBCL) Participants|Stage 2: Overall Response Rate for Diffuse Large B-Cell Lymphoma (DLBCL) Patients With a Duration of Response Lasting ≥ 16 Weeks|Stage 2: Time to Progression for Diffuse Large B-Cell Lymphoma (DLBCL) Participants|Stage 2: Health Related Quality of Life for Diffuse Large B-Cell Lymphoma (DLBCL) Patients","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-DLC-001","September 1, 2010","July 4, 2013","April 5, 2018","September 9, 2010","August 20, 2014","September 10, 2018","Providence St Joseph Medical Center/Cancer Center, Burbank, California, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Washington University Siteman Cancer Center, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson Houston, Houston, Texas, United States|Royal Adelaide Hospital, Adelaide, Australia|Royal Brisbaine and Womens Hospital, Herston, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Innsbruck University Hospital, Innsbruck, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|Medical University of Vienna, Vienna, Austria|University Hospital Hradec Kralove, Hradec Kralove 5, Czechia|Charles University, Praha, Czechia|ICH CHU Brest- C.H.U. MORAVAN, Brest Cedex 2, France|CHU de Grenoble-Hopital Albert Michallon, Grenoble, France|Chd -Vendee, La Roche Sur Yon, France|Centre Hospitalier Lyon Sud, Lyon, France|Institute Paoli-Calmette, Marsielle, France|Hotel Dieu, Nantes Cedex 1, France|Hôpital Saint Jean, Perpignan, France|CHRU-Hopital du Haut -Leveque, Pessac, France|CHU de Rennes Hopital de Pontchaillou, Rennes, France|University Hospital OF Toulouse Purpan, Toulouse, France|Hopital de Brabois Adultes, Vandoeuvre-les Nancy cedex, France|Istituto di Ematologica Istituto di Ematologica "" L.e. A. Seragnoli' Azienda Ospedaliera Universitaria Policlinico, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Clinica Ematologica, A.O.U. San Martino di Genova, Genova, Italy|IEO istituto Europeo di Oncologia, Miano, Italy|Universita Federico II di Napoli Nuovo Policlinico, Napoli, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Irccs/Crob, Rionero In Vulture (PZ), Italy|Policlinico Tor Vergata (Universta Tor Vergata), Roma, Italy|Azienda Ospedaliera di Perugai Ospedale S. Maria della Miseri, Terni, Italy|Hospital Universitari Vll D' Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Costa Del Sol, Marbella, Spain|CH de Orense, Ourense, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hosptial Clinico Universitario de Salamanca, Salamanca, Spain|Onkologiska kliniken, Umea, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Royal Bournemouth Hospital Haematology, Bournemouth, United Kingdom|Royal Devon and Exeter Hospital Haematology Department, Exeter, United Kingdom|St. James Institute of Oncology, Leeds, United Kingdom|Royal Mardsen Hospital - Fulham (Satellite Site), London, United Kingdom|The Christie Foundation Trust, I'st Floor, Haemotology Oncology Outpatients, Lymphoma Team, Manchester, United Kingdom|Derrford Hospital, Plymouth, United Kingdom|Southhampton University Hospital NHS Trust, Southhampton, United Kingdom|Royal Mardsen NHS Foundation Trust, Sutton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01197560"
101,"NCT02412267","Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)","DLBL","Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)","Response rate as measured by the new international criteria proposed by Cheason for response in non Hodgkin's lymphoma at the end of cycle 2 ofatumomab|Progression free survival as measured from time of treatment start to time of disease progression|Safety and tolerability of Ofatumomab in combination with ICE chemotherapy as measured by CTCAE","National Cancer Centre, Singapore|GlaxoSmithKline","All","21 Years and older   (Adult, Older Adult)","Phase 2","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCC1001","April 2011","December 2015","March 2016","April 9, 2015","null","March 23, 2016","National Cancer Centre, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT02412267"
102,"NCT02692248","Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Ibrutinib|Drug: Rituximab|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Dexamethasone","Overall Response (OR) rate (complete remission + partial response) measured by PET(Positron Emission Tomography)/CT imagen scan|CR rate during induction and maintenance phases.|Conversion rate from SD (Stable Disease) or PR to PR or CR by PET/CT imagen scan|Response duration|Progression free survival|Event-free survival|Overall survival|Safety and tolerability of ibrutinib in combination rituximab, gemcitabine, oxaliplatin and dexamethasone","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","62","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBDCL-GELTAMO-2015","April 7, 2016","September 2020","September 2020","February 26, 2016","null","June 27, 2018","Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Especialidades, Jerez de la Frontera, Cádiz, Spain|Hospital Universitario Donostia, Donostia San Sebastian, Guipúzcoa, Spain|Hospital Universitario Son Espases, Palma, Islas Baleares, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Clínic Universitari de València, Valencia, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain","","https://ClinicalTrials.gov/show/NCT02692248"
103,"NCT02142049","Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma",,"Unknown status","No Results Available","Diffuse Large B Cell Lymphoma Relapsed|Diffuse Large B Cell Lymphoma Refractory","Drug: Ibrutinib|Drug: Part 1: Dose Level 1","Number of Dose-Limiting Toxicities as a Measure of Safety and Tolerability|Number of Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy|Number of Patients with Adverse Events as a Measure of Safety and Tolerability|Duration of Response (DOR), Progression Free Survival (PRF) and Overall Survival (OS) as a Measure of Efficacy","Pharmacyclics LLC.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-1124-CA","May 2014","August 2017","November 2017","May 20, 2014","null","October 30, 2017","SITE-1, Duarte, California, United States|SITE-2, Los Angeles, California, United States|SITE-10, Orange, California, United States|SITE-3, Chicago, Illinois, United States|SITE-5, Baltimore, Maryland, United States|SITE-6, Bethesda, Maryland, United States|SITE-4, Ann Arbor, Michigan, United States|SITE-8, Albuquerque, New Mexico, United States|SITE-9, Stony Brook, New York, United States|SITE-7, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02142049"
104,"NCT02951156","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","Javelin DLBCL","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Biological: Avelumab|Biological: Utomilumab|Biological: Rituximab|Other: Azacitidine|Drug: Bendamustine|Drug: Gemcitabine|Drug: Oxaliplatin","Phase 1b: Dose Limiting Toxicity (DLT)|Phase 1b: Objective Response (OR)|Phase 3: Progression Free Survival (PFS)|Phase 1b: Duration of Response (DR)|Phase 1b: Time to Tumor Response (TTR)|Phase 1b: Disease Control (DC)|Phase 1b: Progression-Free Survival (PFS)|Phase 1b: Overall Survival (OS)|Phase 1b: Minimal Residual Disease (MRD) burden|Phase 3: Overall Survival (OS)|Phase 3: Objective Response (OR)|Phase 3: Time to Tumor Response (TTR)|Phase 3: Duration of Response (DR)|Phase 3: Disease Control (DC).|Phase 3:Change from baseline in Brief Fatigue Inventory (BFI) questionnaire|Phase 3: Minimal residual disease (MRD) burden|Phase 1b: Phase 1b: AUC(0-τ) [Area under the serum concentration time profile from time zero to the next dose (after single dose)]|Phase 1b: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against avelumab|Phase 1b: PD L1 expression levels in tumor cells and cells of the tumor microenvironment at baseline|Phase 3: Change from baseline in the NCCN-FACT FLymSI-18 questionnaire|Phase 3: Change from baseline in the EQ-5D-5L questionnaire|Phase 3: AUC(0-τ) [Area under the serum concentration time profile from time zero to the next dose (after single dose)|Phase 3: Cmax [(Maximum observed serum concentration (after single dose)]|Phase 3: PD-L1 expression levels in tumor cells and cells of the tumor microenvironment at baseline|Phase 1b: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against rituximab|Phase 1b: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against utomilumab|Phase 3: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against avelumab|Phase 3: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against rituximab|Phase 3: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against utomilumab|Phase 1b: AUC(0-t) [Area under the serum concentration time profile from time zero to the time of the last quantifiable concentration (C last) (after single dose)|Phase 1b: AUC(0-t) Area under the serum concentration time profile from time zero to the time of the last quantifiable concentration (C last) [after single dose]|Phase 1b: AUC(0-t) Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration (C last) [after single dose and steady state]|Phase 1b: AUC(0-t) Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration (C last) [after single dose]|Phase 1b: Maximum observed serum concentration (after single dose)|Phase 1b: Maximum observed plasma concentration (after single dose and at steady state)","Pfizer|EMD Serono","All","18 Years and older   (Adult, Older Adult)","Phase 3","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B9991011|2016-002904-15","December 16, 2016","March 20, 2020","May 29, 2021","November 1, 2016","null","September 28, 2018","City of Hope Investigational Drug Services, Duarte, California, United States|City of Hope, Duarte, California, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Norton Diagnostic Center - Dupont, Louisville, Kentucky, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Tulane Medial Center, New Orleans, Louisiana, United States|Tulane Medical Center, New Orleans, Louisiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Nuclear Medicine Department, Kogarah, New South Wales, Australia|Pharmacy Department, Kogarah, New South Wales, Australia|Radiology Department, Kogarah, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Clinical Trials Pharmacy Monash Health, Clayton, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Monash Imaging, Clayton, Victoria, Australia|Cancer Clinical Trials Centre, Austin Health, Level 4, Heidelberg, Victoria, Australia|Department of Pharmacy, Heidelberg, Victoria, Australia|Nuclear Medicine, Heidelberg, Victoria, Australia|Radiology Department, Heidelberg, Victoria, Australia|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Region Hovedstadens Apotek, København Ø, Denmark|Rigshospitalet, København Ø, Denmark|CHRU Brest - Hôpital Morvan, Brest Cedex, France|CHRU Brest - Hôpital Morvan, Brest, France|CHD Vendée, La Roche-Sur-Yon, France|CHU Nantes - Hôtel Dieu, Nantes, France|Centre Hospitalier Lyon Sud, Pierre-Bénite Cedex, France|IRCCS Istituto Scientifico Romagnolo per Studio e Cura di Tumori (IRST), Meldola, FC, Italy|IRST, Meldola, FC, Italy|IRCCS Instituto Europeo di Oncologia, Milano, MI, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Farmacia Studi Clinici, Rozzano, MI, Italy|Istituto Clinico Humanitas, Rozzano, MI, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center Clinical Reseach Pharmacy, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center Clinical Trial Pharmacy, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Erasmus Medical Center, Hematology, Rotterdam, Netherlands|Radiologie & Nucleaire Geneeskunde, Rotterdam, Netherlands|Apotheek Erasmus Medical Center, Rotterdam, Netherlands|Centrum Onkologii Ziemi Lubelskiej im Sw. Jana z Dukli, Lublin, Lubelskie, Poland|Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli, Lublin, Lubelskie, Poland|Malopolskie Centrum Medyczne S.C., Krakow, Malopolskie, Poland|Nzoz McD Voxel Osrodek Pet-Tk-Nmr, Krakow, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|NU-MED Centrum Diagnostyki i Terapii Onkologicznej Zamosc Sp. z o.o., Zamosc, Poland|IDI-Unitat PET - Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Institut Català d'Oncologia de l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital del Mar, Barcelona, Spain|Hospital Quiron salud Barcelona - Diagnostico Imagen, Barcelona, Spain|CETIR, Centre Medic S.L, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital San Pedro de Alcantara, Caceres, Spain|Hospital San Pedro de Alcantara, Cáceres, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Centro de Investigación Medicina Especializada Sanitaria (CIMES), Málaga, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|APL, Stockholm, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Norrlands Universitetssjukhus, Umeå, Sweden|Sjukhusapoteket, Umea, Umeå, Sweden|The Christie NHS Foundation Trust, Manchester, United Kingdom|The Christie Pathology Partnership, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT02951156"
105,"NCT00776802","GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","GCS-100LE","Withdrawn","No Results Available","Diffuse Large B-cell Lymphoma","Drug: GCS-100|Drug: Etoposide; Dexamethasone","To determine the maximum tolerated dose of GCS-100 in combination with etoposide and dexamethasone by comprehensive lab, pharmacokinetics, physical assessments, and PET-CT imaging.|Overall response rate; correlate response to GCS-100 with the expression of galectin-3 in tumors; correlate serum galectin-3 levels with the administration of GCS-100","La Jolla Pharmaceutical Company","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PR-CS010","July 2008","April 2009","April 2009","October 21, 2008","null","June 25, 2013","UCLA Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00776802"
106,"NCT03589469","Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma Refractory|Diffuse Large B-cell Lymphoma Recurrent","Drug: Loncastuximab tesirine","Overall response rate (ORR)|Duration of Response (DOR)|CR rate|Relapse-free survival (RFS)|Progression Free Survival (PFS)|Overall Survival (OS)|Frequency and severity of adverse events (AEs) and serious AEs (SAEs)|Maximum concentration (Cmax) of Loncastuximab Tesirine , pyrrolobenzodiazepine (PBD) conjugated and warhead SG3199|Time to maximum concentration (Tmax) of Loncastuximab Tesirine, pyrrolobenzodiazepine (PBD) conjugated and warhead SG3199|Area under the curve (AUC0-last) of Loncastuximab Tesirine, pyrrolobenzodiazepine (PBD) conjugated and warhead SG3199|Area under the curve (AUC0-τ) of Loncastuximab Tesirine, pyrrolobenzodiazepine (PBD) conjugated and warhead SG3199|Area under the curve (AUC0-∞) of Loncastuximab Tesirine, pyrrolobenzodiazepine (PBD) conjugated and warhead SG3199|Accumulation index (AI) of Loncastuximab Tesirine, pyrrolobenzodiazepine (PBD) conjugated and warhead SG3199|Clearance (CL) of Loncastuximab Tesirine, pyrrolobenzodiazepine (PBD) conjugated and warhead SG3199|Measurement of Anti-drug antibodies to Loncastuximab Tesirine|Change from baseline in HRQoL as measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)|Change from baseline in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)|Changes from baseline of ECOG performance status|Changes from baseline of 12-lead electrocardiograms (ECGs)","ADC Therapeutics S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADCT-402-201","August 1, 2018","February 22, 2020","February 22, 2020","July 18, 2018","null","September 25, 2018","Northside Hospital, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|U.O. Oncologia ed Ematologia, Rozzano, Milano, Italy|Anastasios Stathis, Bellinzona, Canton Ticino, Switzerland|The Christie NHS Foundation Trust, Manchester, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT03589469"
107,"NCT01164267","Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)",,"Completed","No Results Available","Marginal Zone B-cell Lymphoma","Drug: Everolimus","Total Body CT-Scan","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG 34|2009-011725-14","March 2010","December 2012","null","July 16, 2010","null","November 25, 2013","General Hospital AKH, Vienna, Austria|Policlinico S. Orsola Malpighi, Bologna, Italy|IEO, Milano, Italy|INT, Milano, Italy|Humanitas, Milan, Italy|San Raffaele Hospital, Milan, Italy|AOU Maggiore della Carità, Novara, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy|AOU S. Giovanni Battista, Torino, Italy|IOSI, Bellinzona, Switzerland","","https://ClinicalTrials.gov/show/NCT01164267"
108,"NCT01865058","The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma.",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","","Progression free survival|Overall survival","Odense University Hospital|University of Southern Denmark","All","18 Years and older   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DLG-PET 10.06","June 2011","February 2014","August 2014","May 30, 2013","null","May 30, 2013","Hematology Rearch Unit, Odense University Hospital, Odense, Fyn, Denmark","","https://ClinicalTrials.gov/show/NCT01865058"
109,"NCT02329080","New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Methotrexate|Drug: Rituximab|Drug: Cytarabine|Drug: Thiotepa|Drug: liposomial cytarabine|Drug: Etoposide|Drug: Ifosfamide|Drug: Carmustine|Radiation: whole brain radiotherapy","progression free survival|Complete remission rate|response duration|overall survival|number of participants with adverse events","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","76","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG42","December 2014","December 2018","December 2023","December 31, 2014","null","March 27, 2018","Facultni nemocnice, Brno, Czechia|FNKV (Facultni Nemocnice Kralovske Vinohrady), Praha, Czechia|Vseobecna facultni nemocnice v Praze, Praha, Czechia|Spedali Civili, Brescia, Italy|UO Ematologia e CTMO, PO Businco, Cagliari, Italy|IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|UO Ematoliga Ospedale dell'Angelo, Mestre, Italy|Istituto Nazionale Tumori, Milano, Italy|Ospedale Maggiore Policlinico, Milano, Italy|San Raffaele H Scientific Institute, Milan, Italy|AOU Policlinico di Modena, Modena, Italy|SCDU Ematologia, Novara, Italy|Ematologia ed Immunologia Clinica - AO di Padova, Padova, Italy|UO Oncoematologia Ospedale Tortora, Pagani, Italy|Villa Sofia - Cervello, Palermo, Italy|Ematologia AOU, Parma, Italy|Ematologia Ospedale S.Maria delle Croci, Ravenna, Italy|A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia, Reggio Calabria, Italy|Arcispedale Santa Maria Nuova, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy|Ematologia Università La Sapienza, Roma, Italy|IRCCS Istituto Regina Elena (IFO), Roma, Italy|Policlinico Universitario Campus Bio-Medico, Rome, Italy|IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy|AOU Senese, Siena, Italy|AO S.Maria di Terni, Terni, Italy|SC Ematologia AO Città della Salute e della Scienza, Torino, Italy|UO Ematologia Ospedale Panico, Tricase, Italy|AOU Santa Maria della Misericordia, Udine, Italy|UOC Ematologia Policlinico Rossi, Verona, Italy|Ematologia Ospedale S. Bortolo, Vicenza, Italy|Erasmus MC, Rotterdam, Netherlands|Beatson Cancer Center, Glasgow, United Kingdom|Liverpool Aintree, Liverpool, United Kingdom|UCLH University College London Hospitals NHS foundation trust, London, United Kingdom|The Christie Hospital, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02329080"
110,"NCT02340936","Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: LR-ESHAP (lenalidomide 5 mg)|Drug: LR-ESHAP (lenalidomide 10 mg)|Drug: LR-ESHAP (lenalidomide 15 mg)|Drug: LR-ESHAP (lenalidomide 20 mg)","Phase I of the study: to evaluate the safety and the maximum-tolerated dose (MTD) of the combination R-ESHAP with lenalidomide as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (determine maximum tolerated dose)|Phase II of the study: Phase II: to evaluate ORR of LR-ESHAP in patients with relapsed or refractory DLBCL candidates to HDT and ASCT (determine the overall response rate)|Phase I of the study: to analyze the adverse events of LR-ESHAP (frequency and severity of the adverse events)|Phase I of the study: preliminarily analyze effectiveness (response rates (CR and PR), duration of response and survival (DFS and OS)|Phase I of the study: evaluate haematopoietic progenitor cells mobilization after treatment with LR-ESHAP (Evaluate CD34+ cell count)|Phase I of the study: evaluate hematologic recovery after HSCT (recovery of blood parameters)|Phase II of the study: analyze effectiveness (Complete remission (CR) rate (determined by positron emission tomography [PET]/CT), event-free survival (EFS) and overall survival (OS)|Phase II of the study: rate of transplanted patients (number of patients that undergo HSCT)|Phase II of the study: to analyze the adverse events of LR-ESHAP and ASCT. (frequency and severity of the adverse events)|Phase II of the study: evaluate mobilization after treatment with LR-ESHAP (number of stem cells (2 x 106/Kg Hematopoietic progenitor cell antigen (CD34)+ cells) collected after the salvage therapy.)|Phase II of the study: influence of clinical and biological prognostic factors on response rates and survival (influence of clinical and biological (such as cell of origin) prognostic factors on response rates and survival.)","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Celgene Corporation|Dynamic Science S.L.|Thermo Fisher Scientific","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","53","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LR-ESHAP","January 2011","September 2016","September 2019","January 19, 2015","null","February 8, 2018","ICO- Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO- Hospital Duran i Reynals, L´Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Alejandro Martín, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT02340936"
111,"NCT00486759","A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma",,"Terminated","Has Results","B-cell Lymphoma","Drug: Bevacizumab|Drug: Rituximab|Drug: CHOP|Drug: Placebo","Progression-free Survival (PFS)|Overall Survival|Overall Response (OR) Assessed According to the Revised Response Criteria for Malignant Lymphoma","Hoffmann-La Roche|Genentech, Inc.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 3","787","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BO20603","July 26, 2007","November 30, 2011","November 30, 2011","June 15, 2007","December 31, 2012","July 25, 2017","Uni of California - San Diego; Cancer Center & Dept of Medicine, La Jolla, California, United States|Kenmar Research Inst., Whittier, California, United States|University of Colorado Cancer Center Department of Hematology, Aurora, Colorado, United States|Uni Medical Center; Division Of Hemotology/Oncology, Jacksonville, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|University of Kansas Medical Center; Department of Hematology, Kansas City, Kansas, United States|St. Joseph Mercy Hospital; Department of Oncology, Ann Arbor, Michigan, United States|Northeast Oncology Associates, Concord, North Carolina, United States|Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates, Winston-Salem, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Charleston Cancer Center, Charleston, South Carolina, United States|Uni of Texas Southwestern Medical Center, Dallas, Texas, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States|Northwest Medical Specialties B, Federal Way, Washington, United States|Rainier Physicians, Puyallup, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Hospital Italiano; Haemathology, Buenos Aires, Argentina|Fundaleu; Haematology, Buenos Aires, Argentina|Hospital Britanico; Haematology, Buenos Aires, Argentina|HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología, Córdoba, Argentina|Greenslopes Private Hospital; Gallipoli Research Centre, Greenslopes, Queensland, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital; Haematology, Institute of Medical Veterinary Science, Adelaide, South Australia, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Frankston Hospital; Oncology/Haematology, Frankston, Victoria, Australia|Peter Maccallum Cancer Institute; Medical Oncology, Melbourne, Victoria, Australia|Alfred Hospital; Bone Marrow Transplant Unit, Melbourne, Victoria, Australia|Border Medical Oncology; Murray Valley Private Hospital, Wodonga, Victoria, Australia|Fremantle Hospital; Haematology, Fremantle, Western Australia, Australia|Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie, Wien, Austria|Centro Goiano de Oncologia - CGO, Goiania, GO, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital das Clinicas - UFRGS; Hematologia, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital das Clinicas - UNICAMP, Campinas, SP, Brazil|Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia, Santo Andre, SP, Brazil|Santa Casa de Misericordia de Sao Paulo; Hematologia e Hemoterapia, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP; Hematologia, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Moncton Hospital, Moncton, New Brunswick, Canada|Health Science Centre, St. John's, Newfoundland and Labrador, Canada|QEII HSC; Oncology, Halifax, Nova Scotia, Canada|Cancer Centre of Southeastern Ontario; Kingston General Hospital, Kingston, Ontario, Canada|Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre, Mississauga, Ontario, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, Canada|Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie, Greenfield Park, Quebec, Canada|Mcgill University - Royal Victoria Hospital; Oncology, Montreal, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hopital de L'Enfant-Jesus; Hematology, Quebec City, Quebec, Canada|Chuq - Hopital Hotel Dieu de Quebec; Oncology, Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Beijing Cancer Hospital, Beijing, China|Beijing Union Hospital, Beijing, China|General Hospital of Chinese PLA; Department of Hematology, Beijing, China|Fujian Cancer Hospital, Fuzhou, China|Fudan University Shanghai Cancer Center, Shanghai, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|Changhai Hospital of Shanghai, Shanghai, China|The Second Affiliated Hospital of Soochow University, Suzhou, China|First Affiliated Hospital of Soochow University, Suzhou, China|Tianjin Institute of Hematology & Blood Diseases Hospital, Tianjin, China|The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital), Xi'an, China|Organizacion Sanitas Internacional, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Instituto Cancerologia Medellin; Clinica Las Americas, Medellin, Colombia|Oncólogos de Occidente, Pereira, Colombia|Fakultni nemocnice Brno; Interni hematoonkologicka klinika, Brno, Czechia|Fn Hr. Kralove; IV. Interni Hematologicka Klinika, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Hemato-onkologicka klinika, Olomouc, Czechia|Fakultni Nemocnice Plzen, Hematologicko-Onkologicke Oddeleni, Plzen - Lochotin, Czechia|VshEOBECNÁ FAKULTNÍ NEMOCNICE; I. INTERNI KLINIKA, Praha 2, Czechia|Fakultní Nemocnice Královské Vinohrady; Hematologická Klinika, Praha, Czechia|Teodoro Maldonado Carbo Hospital; Oncology Service, Guayaquil, Ecuador|Hospital Carlos Andrade Marin; Servicio de Oncología, Quito, Ecuador|Hospital Solca Quito; Oncologia, Quito, Ecuador|Clinique Claude Bernard; Onco Hematologie, Albi, France|Centre Hospitalier Uni Ire; Service de Medecine D, Angers, France|Institut Bergonie; Hematologie Oncologie, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie, Bordeaux, France|Centre Francois Baclesse; Comite 2, Caen, France|Chu Estaing; Cons Hemato Medecine Interne, Clermont Ferrand, France|Chu Site Du Bocage;Hematologie Clinique, Dijon, France|CH Dptal Les Oudairies; Hematologie Oncologie, La Roche Sur Yon, France|Hopital Albert Michallon; Oncologie, La Tronche, France|Clinique Victor Hugo; Chimiotherapie, Le Mans, France|Hopital Claude Huriez; Hematologie, Lille, France|Hopital Uni Ire Dupuytren; Hematologie, Limoges, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut J Paolii Calmettes; Onco Hematologie 1, Marseille, France|Clinique Pont de Chaume; Oncologie Et Radiotherapie, Montauban, France|Hopital Saint Eloi; Hematologie Oncologie Medicale, Montpellier, France|Hopital de L'Archet; Hematologie Clinique, Nice, France|Polyclinique Kenval ; Radiotherapie Oncologie, Nimes, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, France|Hopital Pitie Salpetriere; Hematologie Clinique, Paris, France|Hopital Saint Jean; Hematologie, Perpignan, France|Hopital De Haut Leveque; Hematologie Clinique, Pessac, France|Ch Lyon Sud; Hemato Secteur Jules Courmont, Pierre Benite, France|Hopital De La Miletrie; Hematologie Et Oncologie Medicale, Poitiers, France|Ch Jacques Puel;Oncologie Medicale, Rodez, France|ICL; Hematologie, Saint-Priest en Jarez, France|Hopital Sud; Hematologie Clinique, Salouel, France|Hopital Purpan; Hematologie Clinique, Toulouse, France|Clinique Pasteur; Oncologie Medicale, Toulouse, France|Hopital Bretonneau; Hematologie Therapie Cellulaire, Tours, France|Hopitaux De Brabois; Hematologie Medecine Interne, Vandoeuvre Les Nancy, France|Institut Gustave Roussy; Unite D'Hematologie, Villejuif, France|Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie, Amberg, Germany|Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo., Berlin, Germany|Charité; Onkologie & Hämatologie, Berlin, Germany|DIAKO Ev. Diakonie-Krankenhaus Bremen GmbH; Med. Klinik II; Hämatologie und internistische Onkologie, Bremen, Germany|Carl-Thiem-Klinik Cottbus; Medizinische Klinik, Cottbus, Germany|Klinikzentrum Mitte; Medizinische Klinik Gastroenterologie Haematologie / Onkologie, Dortmund, Germany|St. Johannes Hospital; Abt. Innere Medizin, Dortmund, Germany|St Antonius Hospital; Haematologie/Onkologie, Eschweiler, Germany|Krankenhaus Nordwest Medizinische Klinik, Frankfurt, Germany|Klinik Fulda; Abt. Itz, Fulda, Germany|Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik, Greifswald, Germany|Georg-August-Uniklinik ; Zentrum Innere Medizin Abt. Hämatologie & Onkologie, Göttingen, Germany|Kath.Krankenhaus Hagen gem.GmbH St.-Marien-Hospital, Hagen, Germany|Asklepios Klinik St. Georg; Allgemeine Innere Medizin, Hamburg, Germany|Facharztzentrum Eppendorf, Studien GbR, Hamburg, Germany|Evang.Krankenhaus Abt. Hämatologie und Onkologie, Hamm, Germany|St.-Marien-Hospital Klinik Knappenstraße; Klinik für Hämatologie und Onkologie, Hamm, Germany|KRH Klinikum Siloah Medizinische Klinik III, Hannover, Germany|St. Bernward-Krankenhaus, Hildesheim, Germany|Universitaetsklinikum des Saarlandes; medizinische Klinik und Poliklinik; Innere Medizin I, Homburg/Saar, Germany|Städtisches Klinikum Karlsruhe gGmbH, II. Medizinische Klinik, Karlsruhe, Germany|St. Vincentius Kliniken Ag; Medizinische Klinik Abt. 2, Karlsruhe, Germany|Tagesklinik Landshut; Hämatologie/Onkologie, Landshut, Germany|Universitätsklinikum Leipzig Medizinische Klinik II Gastroenterolog. u. Hepatolog., Leipzig, Germany|Klinikum St.Georg gGmbH Klinik für Internistische Onkologie und Hämotologie, Leipzig, Germany|Klinikum der Stadt Ludwigshafen; Medizinische Klinik A, Ludwigshafen, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck, Med. Klinik I, Hämatologie/Onkologie, Lübeck, Germany|Märkische Kliniken GmbH, Klinikum Lüdenscheid; Hämatologie / Onkologie, Lüdenscheid, Germany|Otto von Guericke Uni Magdeburg Uniklinik; Hämatologie/Onkologie, Magdeburg, Germany|Klinikum Magdeburg gemeinnützige GmbH; Klinik Haematologie und Onkologie, Magdeburg, Germany|Klinikum Mannheim III. Medizinische Klinik, Mannheim, Germany|Klinikum der Universitaet Muenchen; Campus Großhadern; Medizinische Klinik III und Poliklinik, Muenchen, Germany|Westfälische Wilhelms-Universität Münster, Medizinische Klinik und Poliklinik A, Münster, Germany|Klinikum Oldenburg gGmbH; Klinik für Onkologie und Hämatologie, Oldenburg, Germany|Prosper-Hospital, Medizinische Klinik I, Recklinghausen, Germany|St Marien Krankenhaus; Medizinische Klinik Iii, Siegen, Germany|Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier, Germany|Krankenhaus der Barmherzigen Brüder Trier; Innere Medizin I, Hämatologie / Internistische Onkologie, Trier, Germany|Eberhard-Karls-Universität Tübingen; Medizinische Klinik I, Tübingen, Germany|Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany|HSK Dr.-Horst-Schmidt-Kliniken; Innere Medizin I Kardiologie; Angiologie und Intensivmedizin, Wiesbaden, Germany|Helios Klinik Wuppertal; Medizinische Klinik I, Wuppertal, Germany|Kliniken St. Antonius; Zentrum Für Innere Medizin, Haematologie/Onkologie, Wuppertal, Germany|Georgios Papanikolaou Hospital; Hematology Department, Thessaloniki, Greece|Queen Elizabeth Hospital; Clinical Oncology, Hong Kong, Hong Kong|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Fov. Onk. Egyesitett Szent Istvan es Szent Laszlo Korhaz; Dept Of Bone Marrow Transplant, Budapest, Hungary|National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary|University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology, Debrecen, Hungary|A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy|Ospedale Regionale Di Parma; Divisione Di Oncologia Medica, Parma, Emilia-Romagna, Italy|Az. Osp. Arcispedale S. Maria Nuova; U.O. Di Ematologia, Reggio Emilia, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica, Udine, Friuli-Venezia Giulia, Italy|Univ. Cattolica La Sapienza; Cattedra Di Ematologia, Roma, Lazio, Italy|ASST DI MONZA; Ematologia, Monza, Lombardia, Italy|Irccs Policlinico San Matteo; Divisione Di Ematologia, Pavia, Lombardia, Italy|Ospedale Gen.Le Prov.Le 'C.G.Mazzoni'; Ematologia, Ascoli Piceno, Marche, Italy|Università Cattolica Del Sacro Cuore S.S. Giovanni Paolo Ii; Uoc Di Onco-Ematologia, Campobasso, Molise, Italy|Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico, Orbassano, Piemonte, Italy|A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1, Torino, Piemonte, Italy|Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica, Bari, Puglia, Italy|Ospedale Ferrarotto; Divisione Di Ematologia, Via S. Sofia 78, Sicilia, Italy|Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy|Samsung Medical Centre; Oncology, Seoul, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, Korea, Republic of|Korean Cancer Center Hospital; Oncology, Seoul, Korea, Republic of|Severance Hospital - Yonsei University; Medicine Dept., Seoul, Korea, Republic of|Seamen' Hospital' Dept. of haematology, Klaipeda, Lithuania|Uni Hospital Santariskiu Clinic; Haematology, Vilnius, Lithuania|Hospital Pulau Pinang, Penang, Malaysia|Instituto Biomedico De Investigacion A.C., Aguascalientes, Mexico|Hospital Español; Hematología Sala 19, Mexico City, Mexico|Col Instituto Tecnologico Y Estudios Superiores de Monterrey, Monterrey, Mexico|Hospital Universitario Dr. Jose E. Gonzalez; Haematology, Monterrey, Mexico|North Shore Hospital; Haematolgy, Auckland, New Zealand|Uni of Auckland; Dept of Molecular Medicine & Haematology, Auckland, New Zealand|Christchurch Hospital; Canterbury Health Laboratories, Christchurch, New Zealand|Centro Hemato Oncologico Paitilla, Panama City, Panama|Hospital Nacional Almanzor Aguinaga Asenjo; Unidad De Investigacion Del Servicio De Oncologia Medica, Chiclayo, Peru|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen; Oncology, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Hospital Nacional LNS dela Policia Nacional del Perú. Unidad Onco; Deapartamento de Oncología, Lima, Peru|Cebu Cancer Institute; Perpetual Succour Hospital, Cebu, Philippines|National Kidney and Transplant Institute; Chemotherapy Unit, Diliman, Quezon City, Philippines|St Luke'S Medical Centre; Oncology, Quezon City, Philippines|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Szpital Uniwersytecki W Krakowie; Klinika Hematologii, Krakow, Poland|Medical University School; Dept. of Haematology, Lodz, Poland|Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie, Lublin, Poland|Zaklad Opieki Zdrowotnej Mswia; Oddzial Chemioterapii, Olsztyn, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny; Haematology Dept., Warszawa, Poland|Centralny Szpital Kliniczny Mswia; Klinika onkologii, hematologii i chorob wewnetrznych, Warszawa, Poland|Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Lymphoma Dept., Warszawa, Poland|HUC; Servico de Hematologia, Coimbra, Portugal|IPO de Lisboa; Servico de Hematologia, Lisboa, Portugal|Hospital de Sao Joao; Servico de Hematologia Clinica, Porto, Portugal|Republican Clinical Oncologic Dispensary of Republic Of Tatarstan, Kazan, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|Haematology Research Center; Haematology, Moscow, Russian Federation|Semashko Central Clinical Hospital Moscow; Hematology, Moscow, Russian Federation|Research Inst. of Hematology & Blood Transfusion ; Hematology, St Petersburg, Russian Federation|National Cancer Inst. ; Dept. of Chemotherapy, Bratislava, Slovakia|Hospital Mutua de Terrassa; Servicio de Hematologia, Terrassa, Barcelona, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Hematologia, Santander, Cantabria, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Hematologia, La Coruna, La Coruña, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Hospital de Basurto; Servicio de Hematologia, Bilbao, Vizcaya, Spain|Hospital de Galdakano, Galdakano, Vizcaya, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital Duran i Reynals; Servicio de Hematologia, Barcelona, Spain|Complejo Hospitalario de Jaen- Hospital Universitario Medico Quirurgico; Servicio de Hematologia, Jaen, Spain|Hospital Universitario Clínico San Carlos; Servicio de Hematología, Madrid, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Sevilla, Spain|Hospital Universitario la Fe; Servicio de Medicina Intena, Valencia, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Hematologia, Zaragoza, Spain|Skånes University Hospital, Skånes Department of Onclology, Lund, Sweden|Skånes Universitetssjukhus; Kliniska Forskningsenheten Onkologimottagning medicinsk behandling, Malmö, Sweden|Länssjukhuset; Medicinkliniken, Sundsvall, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Universitätsspital Zürich; Klinik für Onkologie, Zürich, Switzerland|Veterans General Hospital; Division of Oncology, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, Taiwan|Chang Gung Medical Foundation-Taipei, Taoyuan, Taiwan|King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|National Cancer Inst., Bangkok, Thailand|Rajavithi Hospital; Medicine, Bangkok, Thailand|Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Chiang Mai Uni Hospital; Division of Hematology,Dept of Medicine,Faculty of Medicine, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand|Birmingham Heartlands Hospital; Department of Haematology, Birmingham, United Kingdom|Bradford Royal Infirmary; Haematology Department, Bradford, United Kingdom|North Hampshire Hospital; Dept. of Haematology, Hampshire, United Kingdom|Princess Alexandra Hospital; Department of Haematology, Harlow, United Kingdom|Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, United Kingdom|Royal Liverpool Uni Hospital; Haematology, Liverpool, United Kingdom|St. George'S Hospital; Haematology, London, United Kingdom|Hillingdon Hospital, Middx, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, United Kingdom|Royal Hallamshire Hospital; Haematology Dept, Sheffield, United Kingdom|Weston Park Hospital; Cancer Clinical Trials Centre, Sheffield, United Kingdom|The Royal Wolverhampton Hospitals NHS Trust; Department of Haematology, Wolverhampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT00486759"
112,"NCT02780830","AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","INHIBITOR","Withdrawn","No Results Available","Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Module 1: Non-GCB Diffuse Large B-Cell Lymphoma","Drug: AZD2014|Drug: Ibrutinib","The incidence of adverse events (including adverse events detected via laboratory assessment, vital signs and ECG) (Part A).|Overall Response Rate (ORR) in patients with relapsed or refractory DLBCL receiving the combination of AZD2014 and ibrutinib (Part B only) by assessment of the proportion of patients with tumour response.|Maximum Tolerated Dose (MTD)|The incidence of adverse events (including adverse events detected via laboratory assessment, vital signs and ECG) (Part B).|Cmax of AZD2014 and ibrutinib following single (Cycle 1 Day 1 Part A, Cycle 0 Day 3 Part B1) and multiple dose.|AUC for AZD2014 and ibrutinib following single (Cycle 1 Day 1 Part A, Cycle 0 Day 3 Part B1) and multiple dose.|Overall Response Rate (ORR) in patients with relapsed or refractory DLBCL receiving the combination of AZD2014 and ibrutinib (Part A only) by assessment of the proportion of patients with tumour response.|The anti-tumour activity of the combination of AZD2014 and ibrutinib will be determined in Part A and Part B patients by evaluating duration of response (DoR) by assessment of the amount of time tumour response is maintained.|The anti-tumour activity of the combination of AZD2014 and ibrutinib will be determined in patients in both Parts A and B by evaluating disease control rate (DCR) at 24 weeks as the percentage of patients who achieve stable disease or a tumour response.|The anti-tumour activity of the combination of AZD2014 and ibrutinib will be determined in Part A and Part B patients by evaluating progression-free survival (PFS).","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D2276C00001|LYM 103","June 2016","April 2019","April 2019","May 24, 2016","null","September 15, 2016","","","https://ClinicalTrials.gov/show/NCT02780830"
113,"NCT01606605","Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma","","Number of patients who relapse or progress after 1st line chemotherapy|Number and type of genes and microRNA which are significantly related with relapse or progression (P < 0.05)","Samsung Medical Center","All","15 Years to 90 Years   (Child, Adult, Older Adult)","","350","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2010-05-025","January 2011","December 2012","December 2012","May 25, 2012","null","January 15, 2013","Samsung Cancer Research Institute, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01606605"
114,"NCT01481129","Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Diffuse Large B Cell Lymphoma","Drug: Akt Inhibitor MK2206|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007)|Duration of Response|Overall Survival|Progression-free Survival (PFS)|Toxicity as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-00081|LEONB-ET-2011-041|2011-001970-25|CDR0000716384|ET-2011-041|9022","December 2011","June 2013","June 2014","November 29, 2011","April 7, 2017","September 28, 2017","Hopitaux de Paris, Vellefaux, Paris, France|Institut Bergonie Cancer Center, Bordeaux, France|Henri Mondor University-Hospital Center, Creteil, France|Hospital Claude Huriez Chru, Lille, France|Centre Leon Berard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon-Sud, Pierre Benite, France|Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT01481129"
115,"NCT02926833","A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","ZUMA-6","Recruiting","No Results Available","Refractory Diffuse Large B Cell Lymphoma","Biological: axicabtagene ciloleucel|Drug: atezolizumab (anti-PD-L1)","Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT))|Phase 2: Complete Response Rate|Objective response rate (complete response [CR] + partial response [PR])|Duration of Response|Progression Free Survival|Overall Survival|Safety (Incidence of adverse events and clinically significant changes in safety lab values.)","Kite, A Gilead Company|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KTE-C19-106","September 2016","June 2018","June 2023","October 6, 2016","null","April 10, 2018","City of Hope, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02926833"
116,"NCT01599559","Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma",,"Recruiting","No Results Available","Primary Mediastinal B-cell Lymphoma","Other: observation|Radiation: 3D-Conformal Radiotherapy (3D-CRT)","Progression free survival (PFS)|Overall survival (OS)","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","540","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG37","November 2011","May 2017","May 2025","May 16, 2012","null","August 27, 2018","Norton Cancer Institute, Louisville, Kentucky, United States|Mayo Clinil Rocheser, Rochester, Minnesota, United States|Centro de Hematologia y Oncologia Pavlovsky, Buenos Aires, Argentina|Princess Margaret Hospital, Toronto, Canada|University of Duisburg-Essen, Campus Essen, Essen, Germany|A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Clinica di Ematologia Ospedali Riuniti ""Umberto I"", Ancona, Italy|Centro di Riferimento Oncologico - Aviano, Aviano, Italy|A.O.U Policlinico Consorziale di Bari, Bari, Italy|Bari IRCCS Istituto Tumori, Bari, Italy|Ospedale Papa Giovanni Xxiii, Bergamo, Italy|Sant'Orsola Malpighi, Bologna, Italy|Comprensorio Sanitario di Bolzano, Bolzano, Italy|Spedali Civili, Brescia, Italy|Asl Uoc Ematologia A Perrino, Brindisi, Italy|Ospedale Businco, Cagliari, Italy|AO Garibaldi Nesima Catalia, Catania, Italy|Unità Funzionale di Ematologia AOU Careggi, Firenze, Italy|U.O. Ematologia Vito Fazzi, Lecce, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|SC Ematologia Azienda Ospedali Riuniti Papardo Piemonte, Messina, Italy|Istituto Scientifico San Raffaele, Milano, Italy|Milano Ieo, Milano, Italy|SC Ematologia AO Niguarda, Milano, Italy|AOU Policlinico di Modena, Modena, Italy|Ematologia Università degli Studi di Federico II, Napoli, Italy|Ospedale Umberto I, Nocera, Italy|Azienda Ospedaliera Universitaria, Padova, Italy|Ospedali Riuniti Villa Sofia, Palermo, Italy|AOU di Parma, Parma, Italy|Fondazione IRCCS S. Matteo, Pavia, Italy|S.C. Ematologia Ospedale S. Marid Della Misericordia, Perugia, Italy|Ospedale Civico Guglielmo di Saliceto, Piacenza, Italy|U.O. Oncologia Ematologia Ospedale S. Maria Delle Croci, Ravenna, Italy|A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia, Reggio Calabria, Italy|ICCRS Azienda Ospedaliera Arcipedale ""Santa Maria Nuova"", Reggio Emilia, Italy|Ospedale Degli Infermi, Rimini, Italy|AO San Camillo Forlanini, Roma, Italy|AOU S. Andrea Roma, Roma, Italy|Ospedale S. Eugenio, Roma, Italy|Roma Regina Elena IFO, Roma, Italy|Roma San Giovanni, Roma, Italy|Università degli Studi La Sapienza, Roma, Italy|Rozzano Humanitas, Rozzano, Italy|Siena, Siena, Italy|AOS Maria di Terni, Terni, Italy|AOS S. Giovanni Battista ""Molinette"", Torino, Italy|Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino, Torino, Italy|Ospedale Cardinale Panico, Tricase, Italy|Azienda Ospedaliera Univesritaria, Udine, Italy|Asst Settelaghi Ospedale Macchi, Varese, Italy|Ospedale dell'Angelo, Venezia Mestre, Italy|Samsung Cancer Center, Seoul, Korea, Republic of|Oslo University Hospital, Oslo, Norway|St Olavs Hospital, Trondheim, Norway|Warsaw Centrum Onkologi Instytucie, Warsaw, Poland|Istituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Lund Universitet, Lund, Sweden|IOSI, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Olten, Olten, Switzerland|Kantonsspital, St Gallen, Switzerland|Kyiv National Cancer Institute, Kiev, Ukraine|National Cancer Institute, Kyiv, Ukraine|Basingstoke & North Hamptshire Hospital, Basingstoke, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Royal Cornwall Hospital, Cornwell, United Kingdom|University Hospital Coventry & Warwickshire NHS Trust, Coventry, United Kingdom|Derriford Hospital, Derriford, United Kingdom|Glasgow Beatson Cancer Center, Glasgow, United Kingdom|Leeds St. James's Hospital, Leeds, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Guy's & St. Thomas London, London, United Kingdom|UCLH St. Thomas, London, United Kingdom|Manchester The Christie NHS Foundation Trust, Manchester, United Kingdom|Newcastle Freeman Hospital, Newcastle, United Kingdom|Norfolk & Norwich University Hospital, Norfolk, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom|General Hospital, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01599559"
117,"NCT01741792","Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Completed","Has Results","Diffuse Large B-cell Lymphoma","Drug: Blinatumomab","Overall Objective Response Rate During Treatment Cycle 1|Percentage of Participants With a Best Overall Response of Complete Response|Percentage of Participants With a Best Overall Response of Partial Response|Duration of Objective Response|Duration of Complete Response|Duration of Partial Response|Progression-free Survival (PFS)|Overall Survival (OS)|Number of Participants With Adverse Events|Blinatumomab Steady State Serum Concentration|Leukocyte Counts|Lymphocyte Counts|Monocyte Counts|Granulocyte Count|CD19+ B-Cell Count|CD19+ B-Cells as a Percentage of All Lymphocytes|CD3+ T-Cell Count|CD3+ T-Cells as a Percentage of All Lymphocytes|CD4+ T-Cell Count|CD4+ T-Cells as a Percentage of All Lymphocytes|CD8+ T-Cell Count|CD8+ T-Cells as a Percentage of All Lymphocytes|CD19+ B-Cell to CD3+ T-Cell Ratio|CD4+ T-Cell to CD8+ T-Cell Ratio|CD4+ Naive T Cell Count|CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells|CD4+ Central Memory T-Cell (TCM) Count|CD4+ TCM Cells as a Percentage of All CD4+ T-Cells|CD4+ Effector Memory T-Cell (TEM) Count|CD4+ TEM Cells as a Percentage of All CD4+ T-Cells|CD8+ Naive T-Cell Count|CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells|CD8+ TCM Cell Counts|CD8+ TCM Cells as a Percentage of All CD8+ T-Cells|CD8+ Effector Memory T-Cell (TEM) Count|CD8+ TEM Cells as a Percentage of All CD8+ T-Cells|CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count|CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells","Amgen Research (Munich) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT103-208|2011-005781-38","July 2012","July 2014","September 2015","December 5, 2012","July 27, 2015","January 6, 2017","Universitätsmedizin, Göttingen, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Schleswig Holstein, Kiel, Germany|Klinikum der Johannes-Gutenberg Universität, Mainz, Germany|Universitätsklinikum, Ulm, Germany|Universititätsklinikum, Würzburg, Germany","","https://ClinicalTrials.gov/show/NCT01741792"
118,"NCT01186978","Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma","DLBCL","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Radiation: Radiation Therapy","To determine if high rates of local control can be maintained after a reduction in the RT dose and volume after 4 to 6 cycles of rituximab containing chemotherapy.|Progression-free survival|Overall Survival|To examine patterns of failure","Duke University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","62","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00025164","October 2010","May 2021","May 2022","August 23, 2010","null","January 23, 2018","Durham Regional Hospital, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01186978"
119,"NCT02471911","KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma","KPT-330+RICE","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: KPT-330|Drug: Rituximab|Drug: Etoposide|Drug: Carboplatin|Drug: Ifosfamide|Drug: Dexamethasone","Maximum Tolerated Dosage (MTD) of Selinexor/KPT-330 when combined with RICE chemo in a relapsed/refractory aggressive b-cell lymphoma setting.|Survival of subjects treated with KPT-330 + RICE|Progression-Free Survival of subjects treated with KPT-330 + RICE|Number of patients who demonstrate a Response to KPT-330+RICE|Number of patients who undergo stem cell collection after induction therapy with KPT-330 + RICE","Weill Medical College of Cornell University|Karyopharm Therapeutics Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1502015891","November 2015","June 2019","June 2020","June 15, 2015","null","January 30, 2018","Weill Cornell Medical College, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02471911"
120,"NCT02874404","TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Drug: PI3K-delta Inhibitor TGR-1202","Incidence of adverse events assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03|Duration of response|Overall response rate defined as the percentage of patients achieving a best response of complete response/complete response, partial response at any disease assessment time point|Progression-free survival|Time to response","Matthew Lunning, DO|National Cancer Institute (NCI)|University of Nebraska","All","19 Years and older   (Adult, Older Adult)","Phase 2","15","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","345-16|NCI-2016-01082|P30CA036727","October 2016","August 2020","August 30, 2021","August 22, 2016","null","July 30, 2018","University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT02874404"
121,"NCT02753062","Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma","PTLD","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: bendamustine, rituximab","complete response rate|Assess response rate|Assess event-free survival|Assess overall survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Assess health-related quality of life by EORTC QLQ-C30 (3rd edition)","Asan Medical Center|Cheolwon Suh","All","19 Years and older   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BR_PTLD","August 2015","August 2018","August 2023","April 27, 2016","null","April 27, 2016","Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02753062"
122,"NCT01481272","Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients","PLRG8","Completed","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Ofatumumab|Drug: Etoposide|Drug: Ifosfamid|Drug: Mesna|Drug: Cytarabine|Drug: Methotrexate|Drug: Leukovorin|Drug: Granulocyte-Colony Stimulating Factor","Response rate|Progression-free survival|Event-free survival|Overall survival|Number of participants with adverse events as a measure of safety and tolerability","Polish Lymphoma Research Group","All","18 Years and older   (Adult, Older Adult)","Phase 2","77","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PLRG8 (OMB114361)|2010-023568-42","November 2011","July 2017","null","November 29, 2011","null","July 17, 2017","Dolnośląskie Centrum Transplantacji Komórkowych, Wrocław, Dolnośląskie, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland|Centrum Onkologii - Istytut im. M.Sklodowskiej-Curie, Warszawa, Mazowieckie, Poland|Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. ks. Bronisława Markiewicza, Brzozów, Podkarpackie, Poland|Uniwersyteckie Cenrum Medyczne, Gdańsk, Pomorskie, Poland|Szpital Morski im. PCK Oddz. Onkologii i Radioterapii, Gdynia, Pomorskie, Poland|Klinika Transplantacji Szpiku i Onkohematologii; Centrum Onkologii Instytut im. M.Sklodowskiej-Curie, Oddz. w Gliwicach, Gliwice, Slaskie, Poland|Oddz. Hematologii, Samodzielny Publiczny ZOZ MSW z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn, Warminsko-Mazurskie, Poland","","https://ClinicalTrials.gov/show/NCT01481272"
123,"NCT00169169","Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","CD20-Positive Large B-Cell Lymphoma","Drug: ACVBP|Drug: ACE|Drug: rituximab|Procedure: Autologous stem cell transplant","- To compare event-free survival of patients randomized to receive Rituximab or no further therapy after HDT|- To compare response rate to induction treatments (ACVBP vs AC/ACE).|- To evaluate response rate at the end of treatment.|- To compare overall survival (ACVBP vs AC/ACE; Rituximab / nothing)|- To evaluate the safety and tolerability of Rituximab","Lymphoma Study Association","All","18 Years to 59 Years   (Adult)","Phase 3","430","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH-98.3","October 1999","null","August 2005","September 15, 2005","null","September 15, 2005","Hôpital Henri Mondor, Créteil, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Henri Becquerel, Rouen, France|CHRU de Nancy Brabois, Vandoeuvre-les-Nancy, France","","https://ClinicalTrials.gov/show/NCT00169169"
124,"NCT01470456","Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: SAR3419|Drug: rituximab","Number of participants achieving an Objective Response Rate|Number of participants with Adverse Events|Response Duration -Time|Progression Free Survival -Time|Overall survival -Time","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD12333|2011-002865-39|U1111-1120-0315","November 2011","July 2013","September 2014","November 11, 2011","null","November 13, 2014","Investigational Site Number 040002, Graz, Austria|Investigational Site Number 250004, Creteil Cedex, France|Investigational Site Number 250009, Dijon, France|Investigational Site Number 250006, Lille Cedex, France|Investigational Site Number 250011, Marseille Cedex 9, France|Investigational Site Number 250010, Montpellier, France|Investigational Site Number 250008, Nantes Cedex 01, France|Investigational Site Number 250007, Paris Cedex 10, France|Investigational Site Number 250001, Pierre Benite Cedex, France|Investigational Site Number 250005, Rennes, France|Investigational Site Number 250003, Rouen Cedex, France|Investigational Site Number 250002, Villejuif Cedex, France|Investigational Site Number 578001, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT01470456"
125,"NCT01004991","Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma",,"Completed","Has Results","Diffuse Large B Cell Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: vincristine|Drug: doxorubicin|Drug: prednisone|Drug: azacytidine","Complete Response","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0907010513","January 2010","September 2013","February 2016","October 30, 2009","April 10, 2017","April 10, 2017","Weill Cornell Medical College, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01004991"
126,"NCT00790036","Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy","PILLAR2","Completed","Has Results","Diffuse Large B-cell Lymphoma","Drug: Everolimus|Drug: Everolimus Placebo","Disease-free Survival (DFS)|Overall Survival (OS)|Lymphoma-specific Survival (LSS)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","742","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CRAD001N2301|2008-000498-40","July 24, 2009","June 15, 2016","June 15, 2016","November 13, 2008","July 12, 2017","July 12, 2017","Ironwood Cancer and Research Centers SC, Chandler, Arizona, United States|Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (3), La Jolla, California, United States|USC/Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisMedicalCenter(4), Los Angeles, California, United States|University of Colorado Health, Colorado Springs, Colorado, United States|Denver Health & Hospital Authority CACZ885M2301, Denver, Colorado, United States|Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States|University Cancer Institute, Boynton Beach, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Columbus Regional, Columbus, Georgia, United States|Rush University Medical Center Div. of Hematology & Oncology, Chicago, Illinois, United States|Indiana University Hospital IU Cancer Center, Indianapolis, Indiana, United States|Tulane University Health Sciences Center Office of Clinical Research, New Orleans, Louisiana, United States|Lahey Clinic Dept of Lahey Clinic (3), Burlington, Massachusetts, United States|Mayo Clinic - Rochester Dept. of MayoClinic-Rochester, Rochester, Minnesota, United States|Washington University School of Medicine Div. of Medical Oncology, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center Dartmouth, Lebanon, New Hampshire, United States|Levine Cancer Institute Oncology, Charlotte, North Carolina, United States|Wake Forest University Baptist Medical Center Dept. of WFUHS, Winston-Salem, North Carolina, United States|University of Pittsburgh Medical Center SC-3, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston, South Carolina, United States|Cancer Centers of the Carolinas Cancer Centers of Carolinas (3, Greenville, South Carolina, United States|University of Tennessee Cancer Institute SC-2, Memphis, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD, Fort Worth, Texas, United States|University of Texas/MD Anderson Cancer Center Dept of MD Anderson (18), Houston, Texas, United States|Baylor College of Medicine Dept.of Baylor College of Med., Houston, Texas, United States|South Texas Oncology and Hematology, PA South Texas Oncology (2), San Antonio, Texas, United States|Texas A&M HealthSciencesCtr-Scott & White Memorial Hospital CenterForCancerPrevention&Care, Temple, Texas, United States|University of Vermont Office of Clinical Trials Res., Burlington, Vermont, United States|University of Virginia Health Systems SC-2, Charlottesville, Virginia, United States|Blue Ridge Research Center at Roanoke Neurological Center SC, Roanoke, Virginia, United States|Dean Health System, Madison, Wisconsin, United States|Waukesha Memorial Hospital Cancer Center Dept.ofWaukeshaMemorialHosp., Waukesha, Wisconsin, United States|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Douglas, Queensland, Australia|Novartis Investigative Site, Greenslopes, Queensland, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Mississauga, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Québec, Quebec, Canada|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Bucaramanga, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Brno - Bohunice, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, Czechia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Mansoura, Egypt|Novartis Investigative Site, Amiens cedex1, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, La Roche sur Yon cedex 9, France|Novartis Investigative Site, Limoges cedex, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Saint Priest en Jarez Cedex, France|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Bad Saarow, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Piacenza, PC, Italy|Novartis Investigative Site, Pescara, PE, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Potenza, PZ, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Venezia, VE, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Matsuyama-city, Ehime, Japan|Novartis Investigative Site, Kure, Hiroshima, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Sunto-gun, Shizuoka, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Shinjuku-ku, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Grafton, Auckland, New Zealand|Novartis Investigative Site, Wellington, New Zealand|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Lublin, Lubelskie, Poland|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Warsaw, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N. Novgorod, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Dammam, Saudi Arabia|Novartis Investigative Site, Jeddah, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Cadiz, Andalucía, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zürich, CH, Switzerland|Novartis Investigative Site, Bellinzona, Switzerland|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela","","https://ClinicalTrials.gov/show/NCT00790036"
127,"NCT01472887","SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients","STARLYTE","Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: SAR3419","Number of participants achieving an Objective Response Rate|Number of participants with Adverse Events|Response duration - Time|Progression Free Survival - Time|Overall Survival - Time","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD10248|2011-003657-26|U1111-1115-3349","January 2012","September 2016","September 2016","November 17, 2011","null","January 25, 2018","Investigational Site Number 840001, Denver, Colorado, United States|Investigational Site Number 840003, Augusta, Georgia, United States|Investigational Site Number 840005, Boise, Idaho, United States|Investigational Site Number 056002, Gent, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 203002, Brno, Czechia|Investigational Site Number 203003, Praha 10, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 376003, Jerusalem, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380002, Bergamo, Italy|Investigational Site Number 380004, Bologna, Italy|Investigational Site Number 380008, Mestre, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380007, Modena, Italy|Investigational Site Number 380003, Palermo, Italy|Investigational Site Number 380006, Pavia, Italy|Investigational Site Number 616003, Brzozow, Poland|Investigational Site Number 616002, Kielce, Poland|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724004, Barcelona, Spain|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 724003, Valencia, Spain|Investigational Site Number 792003, Izmir, Turkey|Investigational Site Number 792001, Izmir, Turkey|Investigational Site Number 826001, Leicester, United Kingdom|Investigational Site Number 826002, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT01472887"
128,"NCT03376958","Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Relapsed /Refractory Diffuse Large B Cell Lymphoma","Drug: Apatinib","Progression-free Survival|Response Rate|Overall Survival|Median Survival Time","Zhengzhou University","All","14 Years to 70 Years   (Child, Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","hnslblzlzx2017-7","July 1, 2018","February 1, 2019","February 1, 2019","December 19, 2017","null","May 8, 2018","Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China","","https://ClinicalTrials.gov/show/NCT03376958"
129,"NCT01423539","A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)",,"Withdrawn","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: bendamustine|Drug: navitoclax|Drug: rituximab","Progression-free survival (time from randomization to progression, relapse or death of any cause)|Clinical response rates (complete response/partial response/stable disease)|Duration of response|Overall survival|Safety: Incidence of adverse events","Genentech, Inc.|AbbVie (prior sponsor, Abbott)","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GP27814","October 2011","February 2014","February 2014","August 26, 2011","null","November 2, 2016","Fountain Valley, California, United States|Hudson, Florida, United States|Lawrenceville, Georgia, United States|Centralia, Illinois, United States|Harvey, Illinois, United States|Terre Haute, Indiana, United States|Hazard, Kentucky, United States|Paducah, Kentucky, United States|Rockville, Maryland, United States|Jefferson City, Missouri, United States|Great Falls, Montana, United States|Newark, Ohio, United States|Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01423539"
130,"NCT03023878","Safety and Efficacy of Blinatumomab in Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","High-risk Diffuse Large B-Cell Lymphoma","Drug: Blinatumomab|Drug: Investigator's Choice Chemotherapy","Overall incidence and severity of treatment-emergent adverse events|Tumor response based on objective response rate.|Duration of response|Complete response rate|Progression free survival|Hematopoietic stem cell transplantation rate|Overall survival|Blinatumomab pharmacokinetic parameters","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","47","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150288|2016-002190-35","March 13, 2017","April 4, 2019","November 15, 2019","January 18, 2017","null","August 3, 2018","Research Site, Chicago, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Greenville, South Carolina, United States|Research Site, Edmonton, Alberta, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Créteil Cedex, France|Research Site, Paris Cedex 10, France|Research Site, Dresden, Germany|Research Site, Ulm, Germany|Research Site, Sevilla, Andalucía, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A coruña, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Bristol, United Kingdom|Research Site, Sheffield, United Kingdom","","https://ClinicalTrials.gov/show/NCT03023878"
131,"NCT00836173","Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Withdrawn","No Results Available","Diffuse Large B-cell Lymphoma","Drug: RICE|Drug: GaRD Treatment","To determine CR rates of standard salvage chemotherapy with rituximab, ifosfamide, carboplatin and etoposide (RICE) for relapsed/refractory diffuse aggressive NHL followed by a novel regimen of gallium nitrate, rituximab, and dexamethasone (GARD)|To determine progression-free survival and overall survival following an autologous stem cell transplant performed after the completion of the above regimen, as well as assessment of stem cell collection.|To determine the toxicities of the regimen|To investigate in vitro assays that may predict response to gallium based salvage chemotherapy","Loyola University|Genta Incorporated","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200119","July 2008","May 2012","May 2012","February 4, 2009","null","March 16, 2016","Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00836173"
132,"NCT01678404","131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma",,"Unknown status","No Results Available","Relapsed or Refractory Marginal Zone B-cell Lymphoma","Drug: 131I-rituximab","Overall response rate|Response duration|Progression free survival|Overall survival|Number of Adverse Events","Korea Cancer Center Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 2","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MZL 131I-rituximab RIT","October 2011","September 2014","September 2016","September 5, 2012","null","September 5, 2012","Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01678404"
133,"NCT02112526","ACP-196, a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma",,"Unknown status","No Results Available","Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)","Drug: ACP-196","To characterize the safety profile of ACP-196 in subjects with relapsed or refractory ABC DLBCL","Acerta Pharma BV","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-LY-002","July 2014","January 2017","April 2017","April 14, 2014","null","February 25, 2016","Los Angeles, California, United States|Washington, District of Columbia, United States|Atlanta, Georgia, United States|New York, New York, United States|Columbus, Ohio, United States|Houston, Texas, United States|Leicester, United Kingdom","","https://ClinicalTrials.gov/show/NCT02112526"
134,"NCT02957019","A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma (DLBCL)","Drug: L19-IL2 - Ph I|Drug: L19-IL2 at RD - Ph II|Drug: Rituximab","Number of patients with adverse events that are related to treatment and classified as DLTs for each administered dosage - phase I study|The rate of patients with complete response CR after 2 cycles of treatment - phase II study|The overall response rate (ORR) - phase I study|Median progression free survival (PFS) - phase I study|Median overall survival (OS) - phase I study|Pharmacokinetics assessment of L19-IL2 through blood sampling - phase I study|Human anti-fusion protein antibodies (HAFA) levels - phase I study|Percentage of Participants With On-Study Adverse Events (AEs) and Serious Adverse Events (SAEs) - phase II study|Percentage of Participants With Worst On-Study Hematological and Chemistry Abnormalities - phase II study|Number of Patients With Abnormal Physical Examinations - phase II study|Relative percentage difference in vital signs from baseline - phase II study|The overall response rate (ORR) - phase II study|Median progression free survival (PFS) - phase II study|Median overall survival (OS) - phase II study|Human anti-fusion protein antibodies (HAFA) levels - phase II study","Philogen S.p.A.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PH-L19IL2RTX-01/14","July 31, 2013","December 2018","December 2018","November 7, 2016","null","May 25, 2018","Münster University Hospital, Münster, Germany","","https://ClinicalTrials.gov/show/NCT02957019"
135,"NCT02530125","Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission",,"Terminated","Has Results","Stage III Diffuse Large B-Cell Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma","Other: Laboratory Biomarker Analysis|Biological: Pidilizumab","Response to Pidilizumab|The Frequency and Severity of Toxicity - Number of Grade 1, 2, 3, 4, and 5, Adverse Events Experienced During Treatment of Pidilizumab Defined by NCI CTCAE v 4.03.|Overall Survival (OS)|Progression Free Survival (PFS)|Relapsed Disease|Time to Second Line Chemotherapy (TSLC)","Northwestern University|Gateway for Cancer Research|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 15H08|NCI-2015-01415|STU00200695|P30CA060553","September 2015","January 2017","January 2017","August 20, 2015","March 19, 2018","March 19, 2018","Georgia Regents University Medical Center, Augusta, Georgia, United States|Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02530125"
136,"NCT00869999","Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma",,"Completed","Has Results","Diffuse Large B-cell Lymphoma","Drug: Everolimus|Drug: rituximab","Overall Response Rate|Duration of Overall Response|Progression-free Survival","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-002","May 2009","November 2011","November 2011","March 26, 2009","October 27, 2014","October 27, 2014","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconsess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00869999"
137,"NCT00978432","Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Terminated","Has Results","Diffuse Large B-cell Lymphoma","Drug: RAD001|Drug: LBH589|Drug: Doublet (RAD001 and LBH589)","Overall Response Rate|Assessment of Association Between Observed Response to RAD001 and LBH589 and the Response Predicted by Molecular Signatures Developed in Our Pre-clinical Model|Summary of Adverse Events (AEs)|Distribution of Change Across Time of mTOR and HDAC-I Inhibition From Baseline Until After the 1st 2 Cycles of Study Drug in Patients Who Received LBH and RAD.|Evaluate the Association of Observed Response to the Doublet With the Response Predicted by Molecular Signatures for Activated B Cell Like (ABC) DLBCL and for Germinal Center B Cell Like (GCB) DLBCL.","Anne Beaven, MD|Novartis|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00012947","February 2012","April 2015","March 2016","September 17, 2009","June 7, 2016","November 25, 2016","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00978432"
138,"NCT03255096","A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma (DLBCL)","Drug: RO6870810|Drug: Venetoclax|Drug: Rituximab","Percentage of Participants With Dose-Limiting Toxiciities (DLT)- Part 1|Percentage of Participants With Adverse Events (AEs) - Part 1|Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 1|Complete Response (CR) Rate as Determined by Independent Radiological Central Review (ICR) Using Modified Lugano Response Criteria- Recommended Dose (RD) Expansion - Part 2|Percentage of Participants With Adverse Events (AEs) - Part 2|Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 2|Maximum Concentration (Cmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Trough Serum Concentration (Cmin) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Time of Maximum Concentration (tmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Clearance (CL) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Volume of Distribution (Vd) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Area Under the Curve (AUC) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Complete Response (CR) Rate as Determined by the Investigator Based on the Modified Lugano Response Criteria- Part 1 and Part 2|Complete Response (CR) Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2|Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of Modified Lugano Response Criteria- Part 1 and Part 2|Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2|Duration of Response (DoR)- Part 1 and Part 2|Progression-Free Survival (PFS)- Part 1 and Part 2|Event-Free Survival (EFS)- Part 1 and Part 2|Disease-Free Survival (DFS)- Part 1 and Part 2|Overall Survival (OS)- Part 1 and Part 2|Half-Life (t1/2) of RO6870810 and its Potential Metabolites- Part 1 and Part 2|Percentage of Ant-Drug Antibodies (ADA) Against Rituximab - Part 1 and Part 2","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","94","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP39461|2017-000357-39","August 28, 2017","July 15, 2020","July 15, 2020","August 21, 2017","null","September 24, 2018","City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Dana Farber Cancer Inst. ; Dept. of Medical Oncology, Boston, Massachusetts, United States|Columbia University Medical Center; Center for Lymphoid Malignancies, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute - Blythe, Charlotte, North Carolina, United States|MD Anderson Cancer Center Department of Lymphoma & Myeloma, Houston, Texas, United States|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia|Rigshospitalet; Hæmatologisk Klinik, København Ø, Denmark|Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia, Barcelona, Spain|Hospital Duran i Reynals; Servicio de Hematologia, Barcelona, Spain|START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT03255096"
139,"NCT01562990","Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse",,"Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab, CMC544, Gemcitabine and Oxaliplatine","Determination of the Recommended Dose of R-CMC544|OVERALL RESPONSE RATE|PROGRESSION-FREE SURVIVAL|EVENT FREE SURVIVAL|OVERALL SURVIVAL|COMPLETE RESPONSE RATE","The Lymphoma Academic Research Organisation|Pfizer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMC-R-GEMOX|2011-003849-18","December 2012","August 2014","March 2016","March 26, 2012","null","May 23, 2016","AZ Sint Jan, Bruges, Belgium|University Hospital Gent, Gent, Belgium|CHU Mont-Godinne, Yvoir, Belgium|Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CHRU de Lille, Lille, France|CHU Lyon - Sud, Lyon, France|CHU Hôtel Dieu, Nantes, France|CHU Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|CHU Brabois, Vandoeuvre les nancy, France","","https://ClinicalTrials.gov/show/NCT01562990"
140,"NCT01066429","DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma",,"Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma (DLBCL)","Drug: Dexamethasone and dose-dense immunochemoterapy","efficacy of the EDOCH14-R scheme at an adjusted dose|hematological and extra-hematological toxicity of the EDOCH14-R scheme","Hospital Universitario Principe de Asturias","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DA-EDOCH14-R/07","December 2009","December 2010","December 2012","February 10, 2010","null","February 12, 2010","Principe de Asturias University Hospital, Alcala de Henares, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT01066429"
141,"NCT00831597","Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","904","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: bendamustine|Drug: rituximab","Best Overall Response Rate (ORR) of bendamustine in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma|Duration of Response (DOR)|Time to Progression (TTP)|Progression-Free Survival (PFS)|Safety Profile of Study Treatment|Overall Survival (OS)","Pharmatech|Cephalon","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PI-08904|IND Exemption Number 103985","November 2008","August 2013","September 2013","January 29, 2009","null","April 19, 2016","Pharmatech Oncology Study Site, Beverly Hills, California, United States|Pharmatech Oncology Study Site, Fountain Valley, California, United States|Pharmatech Oncology Study Site, Oxnard, California, United States|Pharmatech Oncology Study Site, Washington, District of Columbia, United States|Pharmatech Oncology Study Site, Washington, District of Columbia, United States|Pharmatech Oncology Study Site, Boynton Beach, Florida, United States|Pharmatech Oncology Study Site, Brooksville, Florida, United States|Pharmatech Oncology Study Site, Gainesville, Florida, United States|Pharmatech Oncology Study Site, Titusville, Florida, United States|Pharmatech Oncology Study Site, Joliet, Illinois, United States|Pharmatech Oncology Study Site, Lafayette, Indiana, United States|Pharmatech Oncology Study Site, Muncie, Indiana, United States|Pharmatech Oncology Study Site, Dubuque, Iowa, United States|Pharmatech Oncology Study Site, Paducah, Kentucky, United States|Pharmatech Oncology Study Site, York, Maine, United States|Pharmatech Oncology Study Site, Jackson, Mississippi, United States|Pharmatech Oncology Study Site, Chesterfield, Missouri, United States|Pharmatech Oncology Study Site, Cherry Hill, New Jersey, United States|Pharmatech Oncology Study Site, Phillipsburg, New Jersey, United States|Pharmatech Oncology Study Site, Bay Shore, New York, United States|Pharmatech Oncology Study Site, Bronx, New York, United States|Pharmatech Oncology Study Site, East Setauket, New York, United States|Pharmatech Oncology Study Site, Akron, Ohio, United States|Pharmatech Oncology Study Site, Columbus, Ohio, United States|Pharmatech Oncology Study Site, Bethlehem, Pennsylvania, United States|Pharmatech Oncology Study Site, Gettysburg, Pennsylvania, United States|Pharmatech Oncology Study Site, Hilton Head, South Carolina, United States|Pharmatech Oncology Study Site, Germantown, Tennessee, United States|Pharmatech Oncology Study Site, Austin, Texas, United States|Pharmatech Oncology Study Site, Corpus Christi, Texas, United States|Pharmatech Oncology Study Site, Fort Worth, Texas, United States|Pharmatech Oncology Study Site, Lubbock, Texas, United States|Pharmatech Oncology Study Site, Richardson, Texas, United States","","https://ClinicalTrials.gov/show/NCT00831597"
142,"NCT01502982","Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)","CRY-04","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: R-CHOEP14x6+HD-AraC+HD-Mtx","Time to treatment failure|Number of participants with adverse events|Clinical response rate|Time to progression|Overall survival|Incidence of CNS relapse|Molecular factors important for clinical outcome","Nordic Lymphoma Group|Amgen","All","18 Years to 64 Years   (Adult)","Phase 2","160","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG-LBC-04|2004-003075-37","November 2004","December 2013","May 2014","January 2, 2012","null","September 30, 2014","Odense University Hospital, Odense, Denmark|Helsinki University central Hospital, Helsinki, Finland|Oslo University Hospital, Oslo, Norway|Lund University Hospital, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT01502982"
143,"NCT00474188","A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Terminated","Has Results","Diffuse Large B-cell Lymphoma","Drug: CC-5013 (lenalidomide)|Drug: dexamethasone","Tumor Response Rate|Tumor Control Rate|Duration of Response|Time to Progression|Progression-free Survival","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-5013-NHL-005","May 2007","December 2008","December 2008","May 16, 2007","August 13, 2009","September 2, 2009","Palo Verde Hematology/Oncology, Ltd., Glendale, Arizona, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Advanced Medical Specialties, Miami, Florida, United States|Hematology/Oncology Associates of Treasure Coast, Port St. Lucie, Florida, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Cancer Care & Hematology Specialists of Chicagoland, Arlington Heights, Illinois, United States|Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|Southwest Oncology Associates, Lafayette, Louisiana, United States|Washington County Hospital, The Center for Clinical Research, Hagerstown, Maryland, United States|Kalamazoo Hematology & Oncology, Kalamazoo, Michigan, United States|Oncology & Hematology Specialists, PA, Denville, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Northwestern Carolina, Oncology and Hematology PA, Hickory, North Carolina, United States|New Bern Cancer Care, New Bern, North Carolina, United States|James Cancer Hospital, Columbus, Ohio, United States|SouthWest Regional Cancer Center, Austin, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|The Alfred Hospital, Melbourne, Victoria, Australia|Frankston Hospital, Frankston, Australia|HOCA, South Brisbane, Australia|Border Medical Oncology, Wodonga, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT00474188"
144,"NCT00169143","Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Untreated CD20-positive Large B-cell Lymphoma","Drug: Rituximab + ACVBP regimen plus Pegfilgrastim|Procedure: Autologous stem cell transplant","To evaluate the optimal combined dose intensity of the drug regimen|Specific dose intensities, incidence of neutropenia and neutropenic fever, duration of severe neutropenia, complete response rate, event-free and overall survival","Lymphoma Study Association|Amgen","All","18 Years to 61 Years   (Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH 03-39B","May 2004","January 2007","January 2007","September 15, 2005","null","August 23, 2018","Hôpital Henri Mondor, Créteil, France|Service d'Hématologie Clinique - CHU Le Bocage, Dijon, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Henri Becquerel, Rouen, France|CHRU de Nancy Brabois, Vandoeuvre-les-Nancy, France","","https://ClinicalTrials.gov/show/NCT00169143"
145,"NCT00788606","R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma",,"Terminated","No Results Available","Non-Hodgkin's Lymphoma|B-cell Lymphoma","Drug: bevacizumab, Rituximab","The primary endpoint of this study is cardiac and bevacizumab-specific toxicity. Toxicities will be evaluated according to the NCI Common Toxicity Criteria for Adverse Events v3.0|Response rates, failure free survival, and overall survival will be evaluated and are secondary endpoints","Royal Marsden NHS Foundation Trust|Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCR 2719","May 2008","June 2010","June 2010","November 11, 2008","null","October 14, 2016","David Cunningham, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","","https://ClinicalTrials.gov/show/NCT00788606"
146,"NCT01287741","A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)",,"Completed","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Rituximab|Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Progression-Free Survival (PFS), Investigator-Assessed|Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed|Overall Survival (OS)|Overall Response Rate (ORR), Investigator-Assessed|Overall Response Rate (ORR), IRC-Assessed|Complete Response (CR) at the End of Treatment, Investigator-Assessed|Complete Response (CR) at the End of Treatment, IRC-Assessed|Event-Free Survival (EFS), Investigator-Assessed|Disease-Free Survival (DFS), Investigator-Assessed|Duration of Response (DOR), Investigator-Assessed|Time to Next Anti-Lymphoma Treatment (TTNALT)|Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab|Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores|Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)","Hoffmann-La Roche|Fondazione Italiana Linfomi ONLUS","All","18 Years and older   (Adult, Older Adult)","Phase 3","1418","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO21005|2010-024194-39","July 31, 2011","April 29, 2016","January 31, 2018","February 1, 2011","August 17, 2017","August 1, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Ironwood Cancer TX & Rsch Ctrs, Chandler, Arizona, United States|Arizona Oncology, Tucson, Arizona, United States|California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States|cCare, Encinitas, California, United States|UCLA - School of Medicine; Division of Hematology/Oncology, Los Angeles, California, United States|Rocky Mountain Cancer Center - Aurora, Aurora, Colorado, United States|Florida Cancer Specialists; Department of Oncology, Fort Myers, Florida, United States|Florida Cancer Specialists; Saint Petersburg, Saint Petersburg, Florida, United States|Central Georgia Cancer Care PC, Macon, Georgia, United States|Illinois Cancer Care, P.C. - Galesburg, Galesburg, Illinois, United States|Joliet Oncology-Hematology; Associates, Ltd., Joliet, Illinois, United States|Cancer Care & Hematology; Specialists of Chicagoland, Niles, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Mercy Oncology / Hematology Center; Oncology, Portland, Maine, United States|Park Nicollet Clin-Cancer Ctr, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology Woodbury, Woodbury, Minnesota, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Mecklenburg Medical Group Charlotte, Charlotte, North Carolina, United States|Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates, Winston-Salem, North Carolina, United States|Signal Point Clinical; Research Center, LLC, Middletown, Ohio, United States|Cleveland CL N Coast Cancer Cr, Sandusky, Ohio, United States|Willamette Valley Cancer Insitute and Research Center, Springfield, Oregon, United States|Medical University of SC (MUSC), Charleston, South Carolina, United States|South Carolina Oncology Associates - SCRI, Columbia, South Carolina, United States|Chattanooga Oncology and Hematology Associates, PC, Chattanooga, Tennessee, United States|Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States|Texas Oncology, Pa - Amarillo, Amarillo, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|MD Anderson Cancer Center Department of Lymphoma & Myeloma, Houston, Texas, United States|Cancer Care Centers of South Texas-HOAST - San Antonio, New Braunfels, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Virginia Cancer Specialists - Winchester, Winchester, Virginia, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|Instituto Damic, Cordoba, Argentina|Sanatorio Britanico: Hematologia, Rosario, Argentina|Sanatorio Parque de Rosario, Rosario, Argentina|Cairns Base Hospital; Cancer Care Centre, Cairns, Queensland, Australia|Frankston Hospital; Oncology/Haematology, Frankston, Victoria, Australia|Monash Medical Centre; Haematology, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie, Innsbruck, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie, Wien, Austria|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Instituto de Ensino e Pesquisa Sao Lucas - IEP, Sao Paulo, SP, Brazil|Hospital Santa Marcelina;Oncologia, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, Canada|Chum Hopital Notre Dame; Centre D'Oncologie, Montreal, Quebec, Canada|Mcgill University - Royal Victoria Hospital; Oncology, Montreal, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hopital de L'Enfant-Jesus; Hematology, Quebec City, Quebec, Canada|Centre de sante et de services sociaux Rimouski Neigette, Rimouski, Quebec, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Peking University First Hospital, Beijing, China|The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, China|Beijing Cancer Hospital, Beijing, China|Beijing Hospital of Ministry of Health; Hematology, Beijing, China|General Hospital of Chinese PLA; Department of Hematology, Beijing, China|the First Hospital of Jilin University, Changchun, China|Hu Nan Provincial Cancer Hospital, Changsha, China|Fujian Medical University Union Hospital, Fujian, China|Fujian Cancer Hospital, Fuzhou, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|The Second Affiliated Hospital to Nanchang University, Nanchang, China|Jiangsu Cancer Hospital, Nanjing, China|Jiangsu Province Hospital, Nanjing, China|The First Affiliate Hospital of Guangxi Medical University, Nanning, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Changhai Hospital of Shanghai, Shanghai, China|First Hospital of China Medical University, Shenyang, China|The Second Affiliated Hospital of Soochow University, Suzhou, China|First Affiliated Hospital of Soochow University, Suzhou, China|Tianjin Cancer Hospital, Tianjin, China|Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan, China|Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center, Wuhan, China|The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital), Xi'an, China|Fundacion Cardioinfantil, Bogota, Colombia|Organizacion Sanitas Internacional, Bogota, Colombia|FOSCAL, Floridablanca, Colombia|Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia|Fn Hr. Kralove; IV. Interni Hematologicka Klinika, Hradec Kralove, Czechia|Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK, Praha 2, Czechia|Righospitalet, Haematologisk Klinik, Kobenhavn, Denmark|Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium, Roskilde, Denmark|Aarhus Universitetshospital, Hæmatologisk Afdeling R, Århus, Denmark|Uniklinik RWTH Aachen; Med. Klinik IV; Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammz, Aachen, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Universitätsklinikum ""Carl Gustav Carus""; Medizinische Klinik und Poliklinik I, Dresden, Germany|Friedrich-Alexander-Universität Erlangen-Nürnberg; Medizinische Klinik V, Erlangen, Germany|Klinik der Justus-Liebig-Universität; Innere Medizin, Gießen, Germany|Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V, Heidelberg, Germany|Universitätsklinikum Würzburg; Medizinische Klinik und Poliklinik II; Hämatologie / Onkologie, Würzburg, Germany|Pamela Youde Nethersole Eastern Hospital; Department of Medicine, Hong Kong, Hong Kong|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Semmelweis University, First Dept of Medicine, Budapest, Hungary|National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary|University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B, Debrecen, Hungary|Petz Aladar Megyei Korhaz; Hematologia, Gyor, Hungary|Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology, Kaposvar, Hungary|University of Pecs, I st Dept of Internal Medicine, Pecs, Hungary|University of Szeged, II Dept of Internal Medicine, Szeged, Hungary|Ospedale Riuniti; Divisione Di Ematologia, Reggio Calabria, Calabria, Italy|Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica, Napoli, Campania, Italy|Nuovo Policlinico, Ii Facolta; Divisione Di Ematologia, Napoli, Campania, Italy|Ospedale ""A.Tortora"" - Ematologia; Dipartimento Di Ematologia, Pagani (Sa), Campania, Italy|A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy|AUSL - IRCCS Santa Maria Nuova; U.O. Day Hospital di Oncologia, Reggio Emilia, Emilia-Romagna, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica, Udine, Friuli-Venezia Giulia, Italy|Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol, Roma, Lazio, Italy|A.O. Universitaria S. Martino Di Genova; Ematologia 1, Genova, Liguria, Italy|A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia, Brescia, Lombardia, Italy|Hospital San Raffaele, Milano, Lombardia, Italy|Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia, Milano, Lombardia, Italy|Irccs Policlinico San Matteo; Divisione Di Ematologia, Pavia, Lombardia, Italy|Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia, Alessandria, Piemonte, Italy|Ospedali Riuniti del Canavese, Ivrea, Piemonte, Italy|Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad, Novara, Piemonte, Italy|Az. Osp. S. Luigi Gonzaga; S.C.D.U. Medicina Interna Ii, Orbassano, Piemonte, Italy|A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1, Torino, Piemonte, Italy|A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia, Torino, Piemonte, Italy|Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica, Bari, Puglia, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; Ematologia E Trapianto Di Midollo Osseo, San Giovanni Rotondo, Puglia, Italy|Az. Osp. C. Panico; Rep. Ematologia E Trapianto, Tricase - LE, Puglia, Italy|Azienda Ospedaliero Univ, Catania, Sicilia, Italy|Az. Osp. Papardo; Struttura Complessa Di Ematologia, Messina, Sicilia, Italy|Azienda Ospedaliera Univ, Firenze, Toscana, Italy|Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy|Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy|Ospedale Ca Foncello; Ematologia, Treviso, Veneto, Italy|Uni Di Verona Policlinico G.B. Rossi; Divisione E Cattedra Di Ematologia, Verona, Veneto, Italy|Ospedale Di Vicenza; Nefrologia, Ematologia, Vicenza, Veneto, Italy|Nagoya Daini Red Cross Hospital; Hematology & Oncology, Aichi, Japan|Chiba University Hospital; Hematology, Chiba, Japan|Kyushu University Hospital; Hematology, Oncology & Cardiovascular medicine, Fukuoka, Japan|Kurume University Hospital; Hematology and Oncology, Fukuoka, Japan|Gifu University Hospital; First Department of Internal Medicine, Gifu, Japan|Hokkaido University Hospital; Hematology, Hokkaido, Japan|Kobe City Medical Center General Hospital; Hematology, Hyogo, Japan|Iwate Medical University Hospital;Hematology and Oncology, Iwate, Japan|Yokohama City University Hospital; Hematology, Rheumatology, Infectious Disease, Kanagawa, Japan|Kyoto University Hospital; Department of Hematology/Oncology, Kyoto, Japan|Niigata Cancer Center Hospital; Internal Medicine, Niigata, Japan|Kurashiki Central Hospital; Hematology, Okayama, Japan|Osaka City University Hospital; Hematology, Osaka, Japan|Osaka University Hospital; Hematology and Oncology, Osaka, Japan|Kindai University Hospital; Hematology and Rheumatology, Osaka, Japan|Shimane University Hospital;Hematology, Shimane, Japan|Jichi Medical University Hospital; Hematology, Tochigi, Japan|National Cancer Center Hospital; Hematology, Tokyo, Japan|Toranomon Hospital; Hematology, Tokyo, Japan|Nippon Medical School Hospital; Hematology, Tokyo, Japan|The Cancer Institute Hospital of JFCR; Hematology Oncology, Tokyo, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, Korea, Republic of|St. Mary'S Hospital, the Catholic University School of Medicine; Internal Medicine, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre, Chihuahua, Mexico|Hospital Universitario Dr. Jose E. Gonzalez; Haematology, Monterrey, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Centro de Estudios Clinicos de Queretaro, SC, Queretaro, Mexico|Centro Hemato Oncologico Panama, Panama, Panama|Instituto;Oncologico Miraflores, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica de Especialidades Medicas, Lima, Peru|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland|Medical University of Lodz; Hematology, Lodz, Poland|Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie, Lublin, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Medical Uni of Wroclaw; Hematology, Wroclaw, Poland|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Blokhin Cancer Research Center; Clinical Oncology, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko; Hematology, Nizhny Novgorod, Russian Federation|Penza Regional Oncology Dispensary, Penza, Russian Federation|Republican Clinical Hospital n.a. Baranov; Haematology, Petrozavodsk, Russian Federation|Research Inst. of Hematology & Blood Transfusion ; Hematology, St Petersburg, Russian Federation|Institute of Hematology, Belgrade, Serbia|Clinical Center Vojvodine; Clinic for Hematology, Novi Sad, Serbia|National Oncology Inst. ; Dept. of Haematology, Bratislava, Slovakia|Constantiaberg Medical Clinic; Dept. of Haematology & Bone Marrow Translant, Cape Town, South Africa|Mary Potter Oncology Centre, Groenkloof, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, South Africa|Drs Thomson, Brittain an Partners Inc, Pretoria, South Africa|Hospital de Navarra, Servicio de Hematología, Pamplona, Navarra, Spain|Hospital Universitari Sant Joan de Reus; Servicio de Oncologia, Reus, Tarragona, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital Duran i Reynals; Servicio de Hematologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Hematologia, Madrid, Spain|Complejo Hospitalario de Pontevedra; Servicio de Oncologia, Pontevedra, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia, Toledo, Spain|Kantonsspital Aarau; Zentrum Für Onkologie, Hämatologie & Transfusionsmedizin, Aarau, Switzerland|Ospedale San Giovanni; Oncologia, Bellinzona, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland|Veterans General Hospital; Division of Oncology, Taipei, Taiwan|National Taiwan Universtiy Hospital; Division of Hematology, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology, Taoyuan, Taiwan|King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|National Cancer Inst., Bangkok, Thailand|Rajavithi Hospital; Medicine, Bangkok, Thailand|Ramathibodi Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand|Aberdeen Royal Infirmary; Haematology - Ward 16, Aberdeen, United Kingdom|Birmingham Heartlands Hospital; Department of Haematology, Birmingham, United Kingdom|Addenbrookes Hospital; Haematology, Cambridge, United Kingdom|The HOPE Clinical Trials Unit, Leicester, United Kingdom|New Cross Hospital; Dept. Of Haematology, Wolverhampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01287741"
147,"NCT02898259","Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma",,"Recruiting","No Results Available","B Cell Lymphoma|Lymphoma","Drug: Ixazomib|Drug: Lenalidomide|Drug: Rituximab","maximum tolerated dose of oral ixazomib|Overall response rate|Duration of response|Time to progression|Progression free survival|Time to treatment failure|Overall survival","Case Comprehensive Cancer Center|The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1414","February 20, 2017","June 2019","June 2024","September 13, 2016","null","May 18, 2018","University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02898259"
148,"NCT02077166","Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: Ibrutinib|Drug: Lenalidomide|Drug: Rituximab","Phase 1: Determine the maximally tolerated dose (MTD) and /or the recommended Phase 2 (RP2) dose of lenalidomide in combination with fixed doses of ibrutinib and rituximab in subjects with relapsed or refractory DLBCL.|Phase 2: Overall response rate (ORR)|Phase 1: Overall response rate(ORR)|Phase 2: Duration of response (DOR)|Phase 2: Progression free survival (PFS)|Phase 2: Overall survival (OS)|Phase 2: Complete response (CR)|Phase 2: Safety and tolerability of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed or refractory non-GCB DLBCL.","Pharmacyclics LLC.|Janssen Research & Development, LLC|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","129","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-1123-CA","February 2014","March 2019","December 2019","March 4, 2014","null","June 7, 2018","University of Alabama, Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Cedar Sinai Medical Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Summit Medical Group, Morristown, New Jersey, United States|Weill Cornell Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Cincinnati Health Barrett Center, Cincinnati, Ohio, United States|Mid-Ohio Oncology/ Hematology, Columbus, Ohio, United States|University of TN Medical Center, Knoxville, Tennessee, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|Baylor Charles Sammons Cancer Center, Dallas, Texas, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|Northwest Medical Specialities, PLLC, Tacoma, Washington, United States|Ziekenhuis Netwerk Antwerpen - Campus Stuivenberg, Antwerpen, Belgium|CHU Brugmann, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Universiaetsklinikum Ulm, Ulm, Baden-Wuerttemberg, Germany|Klinikum der Universitaet Muenchen - Campus Grosshadern, Muenchen, Bayern, Germany|Klinikum rechts der Isar - Technische Universitaet Muenchen, III. Medizinische Klinik und Polyklinik, Muenchen, Bayern, Germany|Universitaetsklinikum Wuerzburg, Medizinische Klinik und Poliklinik II, Wuerzburg, Bayern, Germany|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Northwick Park Hospital, Harrow, United Kingdom|The Leeds Teaching Hospitals, Leeds, United Kingdom|Kings College Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02077166"
149,"NCT00918463","A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Terminated","Has Results","Diffuse Large B-cell Lymphoma","Drug: dasatinib","Response Rate|To Evaluate the Safety of Dasatinib Monotherapy as Treatment for Subjects With Relapsed or Refractory Aggressive DLBCL.|To Determine Potential Correlatives of Response.","Weill Medical College of Cornell University|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0809009979","June 2009","December 2010","May 23, 2011","June 11, 2009","August 31, 2018","August 31, 2018","Weill Cornell Medical College, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00918463"
150,"NCT02271945","Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas",,"Completed","Has Results","Relapsed/Refractory Aggressive B-cell Lymphomas","Drug: MEDI-551 12 mg/kg|Drug: MEDI0680 2.5 mg/kg|Drug: MEDI0680 10 mg/kg","Maximum Tolerated Dose (MTD) of MEDI-551|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Treatment-Emergent Serious Adverse Events (TESAEs)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Related to Clinical Laboratory Abnormalities|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Related to Vital Signs, Physical Findings Abnormalities|Number of Participants With Best Overall Response|Mean Peak and Trough Concentrations of MEDI551|Mean Peak and Trough Concentrations of MEDI0680|Terminal Half-Life (t1/2) of MEDI551|Terminal Half-Life (t1/2) of MEDI0680|Number of Participants With Positive Anti-Drug Antibodies (ADA) for MEDI-551 and MEDI0680|Duration of Complete Response|Number of Participants With Disease Control|Duration of Disease Control|Progression-free Survival (PFS)|Overall Survival (OS)|Time to Response (TTR)","MedImmune LLC","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D2852C00004","December 1, 2014","May 24, 2016","May 24, 2016","October 22, 2014","March 12, 2018","March 12, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Baltimore, Maryland, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02271945"
151,"NCT03391466","A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma","ZUMA-7","Recruiting","No Results Available","Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","Drug: Axicabtagene Ciloleucel|Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.","Event Free Survival|Objective Response Rate|Overall Survival","Kite, A Gilead Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KTE-C19-107","December 14, 2017","January 15, 2022","January 15, 2035","January 5, 2018","null","September 19, 2018","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|UC San Diego Moores Cancer Center, San Diego, California, United States|Stanford University, Stanford, California, United States|University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Maryland, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan Kettering, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Cliniques Universiaires Saint-Luc, Brussels, Belgium|UZ Leuven Gasthuisbert, Leuven, Belgium|Vancouver General Hospital, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Academic Medical Center Amsterdam, Amsterdam, Netherlands|Universitair Mendisch Centrum Utrecht, Utrecht, Netherlands|Institut Catala d'Oncologia de l'Hospitalet, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT03391466"
152,"NCT00440583","The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: chemotherapy followed by Zevalin","- Determine the 2-years progression-free survival of consolidation therapy with Yt90-Zevalin.|Determine the response duration(time to progression)after therapy.|Determine safety and tolerability of Yt90-Zevalin consolidation therapy.","Mahidol University|Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH011101","September 2006","September 2011","May 2012","February 27, 2007","null","January 30, 2015","Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT00440583"
153,"NCT01040871","Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Diffuse Large B-Cell Lymphoma","Drug: VELCADE|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine","Complete Response (CR) Rate|Overall Response Rate|Rate of Durable Response|Rate of Durable Complete Response|Subsequent Anti-lymphoma Therapy Rate at 1-year|Progression-free Survival (PFS)Rate at 1-year|Overall Survival Rate at 1-year|Change in Fatigue and Patient Utility Scores","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 2","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","26866138-LYM-2034","January 2010","June 2012","August 2012","December 30, 2009","November 27, 2013","January 13, 2014","Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie, Gent, Belgium","","https://ClinicalTrials.gov/show/NCT01040871"
154,"NCT02670616","Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma","Drug: Ibrutinib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: vincristine|Drug: Prednisolone","complete response rate|Progression-free survival|Overall survival (OS)|Toxicity Profile","Samsung Medical Center","All","19 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-04-027","May 1, 2016","June 2020","June 2022","February 2, 2016","null","April 20, 2018","Samsung Medical Center, Seoul, Seoul, Gangnam-gu, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02670616"
155,"NCT03681938","Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?",,"Active, not recruiting","No Results Available","Lymphoma, B-Cell","Procedure: Autograft","Compare the survival without progress of transplanted patients versus not transplanted patients|Cumulative Relapse Incidence|Overall survival","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","","183","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","ALERT-IPC 2017-015","July 3, 2017","July 28, 2019","July 28, 2019","September 24, 2018","null","September 24, 2018","Institut Paoli-Calmettes, Marseille, France","","https://ClinicalTrials.gov/show/NCT03681938"
156,"NCT02420210","Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma",,"Terminated","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Bendamustine Hydrochloride|Biological: Obinutuzumab|Drug: Dexamethasone|Other: Quality-of-Life Assessment|Other: Laboratory Biomarker Analysis","ORR (PR + CR) Using the Cheson et al Parameters|Feasibility, Defined as Completing All Required Geriatric Assessments Where Applicable Per the Protocol in 80% or More of the Enrolled Eligible Patients|Overall Survival|Overall Survival (OS)|Progression Free Survival|Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0","University of Chicago|National Cancer Institute (NCI)","All","70 Years and older   (Older Adult)","Phase 2","2","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB14-1120|NCI-2015-00355|P30CA014599","November 2015","August 2016","August 2016","April 17, 2015","March 14, 2018","June 6, 2018","University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02420210"
157,"NCT00209014","Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease",,"Terminated","No Results Available","B-Cell Lymphoma|Hodgkin's Disease","Drug: Thalidomide","","Emory University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0544-2003","July 2003","null","June 2006","September 21, 2005","null","May 7, 2009","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209014"
158,"NCT00118209","Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Large B Cell Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone|Drug: etoposide|Drug: filgrastim|Drug: pegfilgrastim","Event-free survival|Response rate|Overall survival|Whether the gene expression signatures that were previously associated with survival following CHOP therapy are associated with survival in either of the treatment arms of the prospective trial","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","523","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CALGB-50303|CDR0000433265|NCI-2009-00480|U10CA031946|U10CA180821","May 2005","October 2017","null","July 11, 2005","null","July 10, 2018","Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Camino Medical Group - Treatment Center, Mountain View, California, United States|Palo Alto Medical Foundation, Palo Alto, California, United States|Saint Helena Hospital, Saint Helena, California, United States|Naval Medical Center - San Diego, San Diego, California, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Creticos Cancer Center at Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|National Naval Medical Center, Bethesda, Maryland, United States|NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States|Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|Christian Hospital Northeast-Northwest, Saint Louis, Missouri, United States|New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord, New Hampshire, United States|New Hampshire Oncology - Hematology, PA - Hooksett, Hooksett, New Hampshire, United States|Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States|New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Mercy Cancer Center at Mercy Medical Center, Canton, Ohio, United States|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Easton Regional Cancer Center at Easton Hospital, Easton, Pennsylvania, United States|Geisinger Hazleton Cancer Center, Hazleton, Pennsylvania, United States|Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|Mountainview Medical, Berlin, Vermont, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States|Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown, West Virginia, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Saint Joseph's Hospital, Marshfield, Wisconsin, United States|Marshfield Clinic - Lakeland Center, Minocqua, Wisconsin, United States|Ministry Medical Group at Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Marshfield Clinic - Indianhead Center, Rice Lake, Wisconsin, United States|Marshfield Clinic at Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Saint Michael's Hospital Cancer Center, Stevens Point, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00118209"
159,"NCT03569696","Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy","NivoM","Not yet recruiting","No Results Available","Lymphoma, B-Cell","Biological: nivolumab","disease progression","Meirav Kedmi MD|Sheba Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-18-4728-MK-CTIL","July 2018","July 2023","September 2023","June 26, 2018","null","June 26, 2018","Sheba medical organization, Ramat Gan, Israel","","https://ClinicalTrials.gov/show/NCT03569696"
160,"NCT02992834","Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma",,"Not yet recruiting","No Results Available","Lymphoma, B Cell","Biological: IL-2 pre-treated CD19 cells|Biological: IL-7/IL-15 pre-treated CD19 cells","overall survival|progression-free survival|Objective Response Rate","jiangjingting|The First People's Hospital of Changzhou","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAAA","December 2016","August 2020","January 2022","December 14, 2016","null","December 14, 2016","First People's Hospital of Changzhou, Changzhou, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT02992834"
161,"NCT02904577","Indolent Non Follicular Lymphomas Prognostic Project",,"Recruiting","No Results Available","Indolent B-Cell Lymphomas","Other: Any treatment, watch and wait policy included","Progression-free survival for the treated cohort|Progression-free survival for the untreated cohort|Overall survival|Event-free survival|Remission rate with initial therapy|Epidemiology|Time dependent analysis for patients in Watch & Wait policy.|Remission rates with second and subsequent lines of therapy","Fondazione Italiana Linfomi ONLUS","All","18 Years and older   (Adult, Older Adult)","","370","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NF2010","September 2011","September 2022","September 2022","September 19, 2016","null","April 25, 2018","Vienna Univ Med Int I, Vienna, Austria|Center of Hematology and Hemotherapy, UNICAMP, University of Campinas, Campinas, Brazil|Hospital das Clínicas Universidade Federal de Goiás, Goiania, Brazil|Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil|São Paulo-Santa Casa Medical School, São Paulo, Brazil|Hospital Saint-Louis, Paris, France|SC Ematologia AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy|Oncologia Medica A - Centro di Riferimento Oncologico, Aviano (PN), Italy|UO Ematologia con Trapianto Policlinico Consorziale, Bari, Italy|USC Ematologia Ospedali Riuniti di Bergamo, Bergamo, Italy|Divisione di Ematologia e TMO Comprensorio Sanitario Bolzano, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy|SC. Ematologia, Spedali Civili, Brescia, Italy|Ematologia e CTMO Ospedale Businco, Cagliari, Italy|UOC Ematologia, Azienda Ospedaliera Garibaldi P.O. Nesima, Catania, Italy|US Oncoematologia- Ospedale Valduce, Como, Italy|Unità Operativa Complessa di Ematologia - AO di Cosenza, Cosenza, Italy|SC Ematologia, AO S. Croce e Carle, Cuneo, Italy|DIMI - Clinica Ematologica AOU San Martino IRCCS - IST, Genova, Italy|UOC di Ematologia con trapianto, Ospedale S. Maria Goretti, Latina, Italy|UO Ematologia, PO Vito Fazzi, Lecce, Italy|Ematologia Ospedale di Livorno, Livorno, Italy|Ematologia Ospedale Madonna delle Grazie, Matera, Italy|SC. Ematologia. Osp. Riuniti Papardo Piemonte, Messina, Italy|UO Ematologia - Policlinico Universitario Messina, Messina, Italy|Dipartimento di Oncoematologia Ospedale San Raffaele, Milano, Italy|SC Ematologia AO Niguarda Ca' Granda, Milano, Italy|UO Ematologia, AO San Carlo Borromeo, Milano, Italy|UO Oncologia Medica, Ospedale San Paolo, Milano, Italy|UOC Ematologia 1/CTMO, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Dipartimento di Oncologia ed Ematologia Università di Modena e Reggio Emilia, Modena, Italy|Clinica Ematologica AO San Gerardo di Monza, Monza, Italy|Unità Operativa Complessa Ematologia - Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Napoli, Italy|SCDU Ematologia - AOU Ospedale Maggiore, Novara, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|UO Oncoematologia Ospedale Umberto I, Pagani (SA), Italy|Divisione di Ematologia AOU Policlinico Paolo Giaccone., Palermo, Italy|Ematologia e CTMO Ospedale Maggiore di Parma, Parma, Italy|Ematologia IRCCS Policlinico S. Matteo di Pavia, Pavia, Italy|Dipartimento di Medicina Clinica e Sperimentale - Sez. Ematologia e Immunologia Clinica - Università di Perugia, Perugia, Italy|Dipartimento di Ematologia Ospedale Civile Spirito Santo Pescara, Pescara, Italy|UO Ematologia Ospedale Civile G. Da Saliceto, Piacenza, Italy|UO Ematologia AOU S. Chiara Pisa, Pisa, Italy|Divisione di Ematologia - Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy|SC Ematologia Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|UO Ematologia e Trapianto Cellule Staminali, IRCCS, Centro di riferimento Oncologico di Basilicata, Rionero in Vulture, Italy|Ematologia e Unità BMT Ospedale San Camillo, Roma, Italy|Ematologia Università Campus Biomedico, Roma, Italy|Ematologia Università Roma La Sapienza, Roma, Italy|Struttura Complessa di Ematologia - Roma IFO, Roma, Italy|UOSD DH Ematologia Ospedale San Eugenio, Roma, Italy|Dipartimento di Oncologia Medica ed Ematologia Istituto Humanitas, Rozzano (MI), Italy|UOC Medicina Interna MO DH Oncologico, Sassuolo, Italy|UOC Ematologia, AOU Senese, Siena, Italy|Ematologia PO SG Moscati, Taranto, Italy|SC Oncoematologia con autotrapianto AO S. Maria Terni, Terni, Italy|SC Ematologia Universitaria, AO Città della Salute e della Scienza, Torino, Italy|SC Ematologia, AO Città della Salute e della Scienza, Torino, Italy|Unità operativa Complessa Ematologia - Azienda Ospedaliera Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Divisione di Ematologia, Ospedale San Bortolo, Vicenza, Italy|LISBOA-IPO ""Francisco Gentil"", Lisboa, Portugal|National Cancer Institute of Health Ukraine, Kiev, Ukraine","","https://ClinicalTrials.gov/show/NCT02904577"
162,"NCT02679196","The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma, B Cell","Drug: KA2237","The occurrence of dose limiting toxicity (DLT);|Concentration (mg/ml) of KA2237 in serum/plasma over time (hours)|Concentration (mg/ml) of KA2237 in urine over time (hours)|Concentration (ng/ml) of key cytokine and intracellular signalling markers in immune cell subsets|Frequency of KA2237 related adverse events and laboratory abnormalities","Karus Therapeutics Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","53","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KTP-002","July 2016","October 2018","May 2019","February 10, 2016","null","August 27, 2018","MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02679196"
163,"NCT02594163","Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma Refractory|Follicular B-cell Non-Hodgkin's Lymphoma","Drug: Brentuximab Vedotin|Drug: Rituximab|Drug: Bendamustine","The objective response rate (ORR)|Progression-free survival (PFS)|Complete remission (CR) rate|Duration of response (DOR)|Overall survival (OS)|Number and severity of adverse events","Seattle Genetics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN35-023","October 2015","September 2017","September 2017","November 2, 2015","null","November 1, 2017","City of Hope, Duarte, California, United States|Sansum Clinic - West Pueblo, Santa Barbara, California, United States|Good Samaritan Hospital, Torrance, California, United States|The Oncology Institute of Hope and Innovation, Whittier, California, United States|Rocky Mountain Cancer Center, Aurora, Colorado, United States|Kaiser Permanente Oncology, Lonetree, Colorado, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, United States|Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Hematology and Oncology Associates of Northern New Jersey, P.A., Morristown, New Jersey, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Bon Secours Saint Francis Hospital, Greenville, South Carolina, United States|Greenville Health System Institutional Review Board, Greenville, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Oncology - Flower Mound, Denton, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, United States|Virginia Mason Clinical Research, Seattle, Washington, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|FN Brno, Brno, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Králové, Czechia|Fakultní nemocnice Královské Vinohrady, Praha, Czechia|Centre Hospitalier Regional Universitaire (CHRU) Brest - Hopital Morvan, Brest, France|CHU Côte de Nacre - Caen, Caen, France|Centre Hospitalier des Oudairies, La Roche-sur-Yon, France|Centre Hospitalier du Mans, Le Rocher, France|CHR Metz, Metz, France|Centre Hospitalier Universitaire de Nantes (CHU Nantes) - Hotel Dieu, Nantes, France|Centre Hospitalier de Perpignan, Perpignan, France|Centre Hospitalier Universitaire (CHU) de Poitier- Hopital de la Miletrie - Hopital Jean Bernard, Poitiers, France|Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes, France|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|IRCSS Policlinico San Matteo, Pavia, Italy|Azienda Policlinico Umberto I di Roma, Roma, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|A.O Ospadale Di Circolo E Fondazione Macchi, Varese, Italy|Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|Wojewódzki Szpital Specjalistyczny, Łódź, Poland|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa de Zaragoza, Zaragoza, Spain|University Hospital's Birmingham NHS Foundation trust-Queen Elizabeth Hospital, Birmingham, United Kingdom|Liverpool and Broadgreen Hospital, Liverpool, United Kingdom|Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT02594163"
164,"NCT00575406","Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma","NHL-14","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: liposomal Doxorubicin|Drug: Vincristin|Drug: Prednisolone","Reduction of cardiotoxicity in the R-COMP arm versus R-CHOP|Significance of serial NT-proBNP measurements for determination of anthracycline-dependent cardiotoxicity|Feasibility of evaluation with Haematopoietic Cell Transplantation Comorbidity Index (HCT-CI)|Rate of Complete Responses|Difference in Overall Survival at 3 and 5 yrs|Difference in Event-free Survival at 3 and 5 yrs|Difference in Progression-free Survival at 3 and 5 yrs|Difference in cause-specific death","Arbeitsgemeinschaft medikamentoese Tumortherapie","All","18 Years and older   (Adult, Older Adult)","Phase 2","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NHL-14|EudraCT 2007-004970-24","December 2007","January 2012","January 2012","December 18, 2007","null","August 30, 2013","Landeskrankenhaus Feldkirch, Feldkirch, Austria|Universitaetsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck, Austria|A.ö. Landeskrankenhaus Leoben, Leoben, Austria|Krankenhaus d. Barmherzigen Schwestern Linz, Linz, Austria|Krankenhaus der Elisabethinen Linz, Linz, Austria|Krankenhaus der Stadt Linz, Linz, Austria|Universitaetsklinik f. Innere Medizin III, Salzburg, Austria|AKH Wien / Haematologie u. Haemostaseologie, Vienna, Austria|Hanusch Krankenhaus, Vienna, Austria|Klinikum Kreuzschwestern Wels GmbH, Wels, Austria","","https://ClinicalTrials.gov/show/NCT00575406"
165,"NCT02596971","A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)",,"Active, not recruiting","No Results Available","Diffuse Large B-Cell Lymphoma, Lymphoma Follicular","Drug: Atezolizumab|Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Obinutuzumab|Drug: Prednisone|Drug: Vincristine|Drug: Rituximab","Percentage of Participants With CR at EOI, as Determined by the Independent Review Committee (IRC) Using Lugano 2014 Criteria|Percentage of Participants With Adverse Events|Percentage of Participants With CR at EOI, as Determined by the Investigator Using Lugano 2014 Criteria|Percentage of Participants With CR at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria|Percentage of Participants With CR at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Lugano 2014 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Lugano 2014 Criteria|Percentage of Participants With Best Response of CR or PR During Study, as Determined by Investigator Using Modified Cheson 2007 Criteria|Observed Serum Obinutuzumab Concentration|Observed Serum Atezolizumab Concentration|Observed Serum Rituximab Concentration|Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab|Percentage of Participants With Human Anti-Chimeric Antibodies (HACAs) to Rituximab|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","91","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO29563|2015-001364-19","December 22, 2015","April 11, 2018","March 27, 2020","November 4, 2015","null","August 1, 2018","LAC-USC/Norris Cancer Center, Los Angeles, California, United States|Rocky Mountain Cancer Center - Aurora, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Miami, Miami, Florida, United States|New York Uni Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology-Tyler, Irving, Texas, United States|Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Royal Brisbane Hospital, Brisbane, Queensland, Australia|The Queen Elizabeth Hospital; Haematology/Oncology, Woodville South, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Emilia-Romagna, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Emilia-Romagna, Italy|Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi di Rimini, Rimini, Emilia-Romagna, Italy|AOU Città della Salute e della Scienza di Torino - Presidio Le Molinette, Torino, Lazio, Italy|Asst Papa Giovanni XXIII, Bergamo, Lombardia, Italy|Azienda Ospedaliera Univ, Firenze, Toscana, Italy","","https://ClinicalTrials.gov/show/NCT02596971"
166,"NCT01195714","Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years",,"Completed","No Results Available","Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma","Drug: Ofatumumab","Overall Survival","The Lymphoma Academic Research Organisation","All","81 Years and older   (Older Adult)","Phase 2","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH09-7B","May 2010","April 2014","April 2014","September 6, 2010","null","March 7, 2018","Zna Stuivenberg, Antwerpen, Belgium|RHMS, Baudour, Belgium|Az Sint Jan Av, Bruges, Belgium|Institut Jules Bordet, Bruxelles, Belgium|Universite Libre de Bruxelles - Hopital Erasme, Bruxelles, Belgium|Ucl de Louvain St Luc, Bruxelles, Belgium|Chu de Liege, Bruxelles, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Clinique Notre Dame de Grace, Gosselies, Belgium|Hopital Jolimont, Haine Saint Paul, Belgium|Ch Hutois, Huy, Belgium|Az Groeninge - Campus Maria'S Voorzienigheid, Kortrijk, Belgium|Chu Tivoli, La Louvière, Belgium|Chr de La Citadelle, Liège, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Universite Catholique de Louvain Mont Godinne, Yvoir, Belgium|Ch Du Pays D'Aix, Aix En Provence, France|Ch Antibes, Antibes, France|Ch Henri Duffaut, Avignon, France|Hopital de Bayonne, Bayonne, France|Hopital Avicenne, Bobigny, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Ch Du Dr Duchenne, Boulogne sur Mer, France|Ch de Bour En Bresse, Bourg en Bresse, France|Chu de Brive, Brive la Gaillarde, France|Chu Cote de Nacre, Caen, France|Centre Henri Baclesse, Caen, France|Ch de Cannes, Cannes, France|Hopital de Chalon, Chalon sur Saone, France|Ch Chambery, Chambery, France|Ch de Chartres - Hopital Louis Pasteur, Chartres, France|Hopital Antoine Beclere, Clamart, France|Hopital D'Instruction Des Armees Percy, Clamart, France|Hopital Pasteur, Colmar, France|Ch Compiege, Compiegne, France|Ch Sud Francilien, Corbeil-Essonnes, France|Hopital Henri Mondor, Creteil, France|Chu Le Bocage, Dijon, France|Ch de Dunkerque, Dunkerque, France|Ch Dunkerque, Dunkerque, France|Ch Frejus St Raphael, Frejus, France|CH GERET, Gueret, France|Hopital Saint Louis, La Rochelle, France|Hopital Andre Mignot, Le Chesnay, France|Hopital Bicetre, Le Kremlin-Bicêtre, France|Ch de Meulan, Les Mureaux, France|Hopital St Vincent de Paul, Lille, France|Chu Claude Hurriez, Lille, France|Chu Dupuytren, Limoges, France|Centre Leon Berard, Lyon, France|Hopital Des Chanaux, Macon, France|Chu Hopital Nord, Marseille, France|Institut Paoli Calmette, Marseille, France|Chu de Meaux, Meaux, France|Chu Marc Jacquet, Melun, France|Hopital Bon Secours, Metz, France|Crlc Val D'Aurelle - Paul Lamarque, Montpellier, France|Centre Azureen de Cancerologie, Mougins, France|Hopital Americain de Paris, Neuilly sur Seine, France|Centre Antoine Lacassagne, Nice, France|Hopital St Antoine, Paris, France|Hotel Dieu, Paris, France|Hopital St Louis, Paris, France|Hopital de La Pitie Salpetriere, Paris, France|Institut Curie, Paris, France|Hopital Necker, Paris, France|Ch Marechal Joffre, Perpignan, France|Chu Lyon Sud, Pierre Bénite, France|Chu de Poitiers - Hopital de Miletrie, Poitiers, France|Ch Rene Dubos, Pontoise, France|Ch Annecy, Pringy, France|Chu Robert Debre, Reims, France|Ch de Roubaix - Hopital Victor Provo, Roubaix, France|Clinique Mathilde, Rouen, France|Centre Henri Becquerel, Rouen, France|Centre Rene Hugenin, Saint Cloud, France|Ch de Saint Germain, Saint Germain en Laye, France|Hopital Font Pre, Toulon, France|Chu de Toulouse, Toulouse, France|Ch de Troyes, Troyes, France|Hopital de Valence, Valence, France|Chu Brabois, Vandoeuvre Les Nancy, France|Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT01195714"
167,"NCT02474550","Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma|Neutropenia, Febrile","","incidence of febrile neutropenia|incidence of chemotherapy-related adverse events other than febrile neutropenia|Overall survival","Ajou University School of Medicine","All","19 Years and older   (Adult, Older Adult)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AJIRB-MED-OBS-14-254","April 2015","December 2018","December 2020","June 17, 2015","null","January 26, 2017","Ajou Universtiy School of Medicine, Suwon, Kyeonggi, Korea, Republic of|Soon Chun Yang University Hospital Bucheon, Bucheon, Korea, Republic of|Busan Paik Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Keimyung Univerisity Dongsan Medical Center, Daegu, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Inje University Ilsan Paik Hospital, Ilsan, Korea, Republic of|Gachon University Gill Hospital, Incheon, Korea, Republic of|Chonbuk Nationa University Hospital, Jeonju, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Choong Ang University Hopspital, Seoul, Korea, Republic of|Hallym University Sacred Heart Hospital, Seoul, Korea, Republic of|Hanyang University Hospital, Seoul, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Korea Institute of Radiological & Medical Science, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02474550"
168,"NCT01852435","R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B",,"Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma|Follicular Lymphoma Grade 3B","Drug: R-CEOP-70|Drug: R-CEOP-90|Drug: R-CHOP-50","progression free survival|overall survival|Response rate|Safety as assessed using the CTCAE","Ruijin Hospital","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","648","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NHL-001","May 2013","December 2017","February 2018","May 13, 2013","null","November 14, 2017","Southwest Hospital, Chongqing, Chongqing, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Tongji Hospital, Wuhan, Hubei, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The first hospital of China medical university, Shenyang, Liaoning, China|Shanxi Provincial Tumor Hospital, Taiyuan, Shanxi, China|West China Hospital, Chengdu, Sichuan, China|Institute of Hematology and Blood Diseases Hospital, Tianjin, Tianjin, China|Shandong Provincal Hospital, Jinan, China|Shanghai Ruijin Hospital, Shanghai, China","","https://ClinicalTrials.gov/show/NCT01852435"
169,"NCT00394693","Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma",,"Completed","No Results Available","Lymphoma, B-Cell","Genetic: Adenovirus Interferon gamma","Regression and disappearance of lesions|Safety|Quality of Life","Transgene","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TG1042.06","November 2006","January 2010","April 2010","November 1, 2006","null","July 16, 2014","Stanford University School of Medicine, Stanford, California, United States|Northwestern University Medical School, Chicago, Illinois, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Hopital Lapeyronie, Montpellier, France|Hopital de l'Hotel-Dieu, Nantes, France|University Hospital of Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT00394693"
170,"NCT03458546","Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Lymphoma, B-Cell","Drug: Roflumilast","To evaluate adverse drug reactions and toxicities as evaluated by NCI CTCAE using the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03","Adolfo Enrique Diaz Duque|The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTMS# 17-0087|18-073H","May 21, 2018","November 30, 2019","January 30, 2020","March 8, 2018","null","June 29, 2018","Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03458546"
171,"NCT03283202","Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors",,"Recruiting","No Results Available","Diffuse B-Cell Lymphoma","Drug: Avadomide (CC-122)|Drug: Rituximab|Drug: Cyclophosphamide 750mg/m2 by IV infusion|Drug: Vincristine|Drug: Prednisone","Maximum Tolerated Dose/Maximum Administered Dose (MTD/MAD) (Phase 1)|Complete Response Rate (CRR); Percentage of participants experiencing positron emission tomography (PET)-negative complete response (CR) (Phase 2)|Overall Response Rate (ORR); Percentage of participants who achieve a PR or CR according to the Lugano criteria.|ORR by Predictive Gene Signature|Progression-free Survival (PFS)|Event-free Survival (EFS)|Overall Survival (OS)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","82","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-DLBCL-002|U1111-1201-1994|2016-003778-42","October 4, 2017","February 28, 2020","May 28, 2022","September 14, 2017","null","August 22, 2018","Ronald Reagan UCLA Medical Center, Santa Monica, California, United States|George Washington University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Washington University, Saint Louis, Missouri, United States|UZ Gent, Gent, Belgium|University Hospital Gasthuisberg, Lueven, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hospital Germans Trias I Pujol, Badalona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de San Pedro de Alcantara, Caceres, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain","","https://ClinicalTrials.gov/show/NCT03283202"
172,"NCT03003039","A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","B-Cell Lymphoma","Biological: GB241|Biological: Rituximab","Area under the curve (AUC) for GB241 and rituximab concentrations|AUC for GB241 and rituximab concentrations|Maximum observed concentration of the GB241 and rituximab|Degree of clearance from baseline of CD19+ , CD20+ B-cells between the two study arms|Comparison of AEs between the two study arms|Comparison of the incidence rate of HACA（host anti-chimeric antibody） between the two study arms","Nanjing Yoko Biomedical Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GB241NHL1","October 2016","March 2018","null","December 26, 2016","null","December 26, 2016","Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03003039"
173,"NCT00931918","Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients",,"Completed","Has Results","Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)","Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL)|Progression-Free Survival Rate|Overall Survival|Overall Response Rate (ORR)|Complete Response Rate|Duration of Response|Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Negative Rate|Time to Progression (TTP)|Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) by Category|Percentage of Participants With Chemistry and Hematology Laboratory Values Grade 3 or Higher","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","206","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C05013|U1111-1183-0186","October 2009","August 2015","August 2015","July 2, 2009","January 11, 2017","January 11, 2017","Tower Cancer Research Foundation, Beverly Hills, California, United States|Fountain Valley Regional Hospital, Fountain Valley, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|Moores Cancer Center- UCSD, La Jolla, California, United States|Antelope Valley Cancer Center, Lancaster, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|University of Southern California, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|TORI- Central Pharmacy, Los Angeles, California, United States|TORI- Central Regulatory, Los Angeles, California, United States|Oncology Care Medical Associates, Montebello, California, United States|Bay Area Cancer Research Group, Pleasant Hill, California, United States|Wilshire Oncology Medical Group, Rancho Cucamonga, California, United States|Sharp Healthcare, San Diego, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists & Research Institute, Gainsville, Florida, United States|Alves/ Domenech Oncology-Hematology Clinic, Hollywood, Florida, United States|Florida Cancer Institute ATI, New Port Richey, Florida, United States|MD Anderson Cancer Center of Orlando, Orlando, Florida, United States|Coastal Oncology, PL, Ormond Beach, Florida, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Dublin Hematology and Oncology, Dublin, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Central Indiana Cancer Centers, Fishers, Indiana, United States|Cancer Care Center Inc. P.C., New Albany, Indiana, United States|Iowa Blood and Cancer Care, Cedar Rapids, Iowa, United States|Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology and Oncology Associates LLP, Sioux City, Iowa, United States|Kansas City Cancer Center, LLC, Overland Park, Kansas, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|St. Agnes Hospital of Baltimore, Baltimore, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Berkshie Hematology Oncology, Pittsfield, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mid Michigan Physicians, Lansing, Michigan, United States|Duluth Clinic, Duluth, Minnesota, United States|St. Luke's Hospital Cancer Care Center, Duluth, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Hematology/Oncology Associates of Northern New Jersey, P.A., Morristown, New Jersey, United States|Hematology Oncology Associates of South Jersey, Mount Holly, New Jersey, United States|St. Luke's- Roosevelt Medical Center, New York, New York, United States|Cornell, New York, New York, United States|Raleigh Hematology Oncology Associates P.C., Raleigh, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Kaiser Group Health, Portland, Oregon, United States|Hematology and Oncology Associates of NEPA, Dunmore, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Sayre, Pennsylvania, United States|Berks Hematology Oncology Associates, W Reading, Pennsylvania, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Chattanooga Oncology and Hematology Associates, PC, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology Cancer Center, Austin, Texas, United States|US Oncology- Central Drug, Fort Worth, Texas, United States|US Oncology- Central Laboratory, Fort Worth, Texas, United States|Oncology Consultants P.A., Houston, Texas, United States|Oncology Consultants, Houston, Texas, United States|US Oncology- Central Regulatory, The Woodlands, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Texoma Cancer Center, Wichita Falls, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Puget Sound Cancer Centers, Edmonds, Washington, United States|Northwest Cancer Specialists PC, Vancover, Washington, United States","","https://ClinicalTrials.gov/show/NCT00931918"
174,"NCT03307746","A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma","RiVa","Recruiting","No Results Available","B Cell Lymphoma","Drug: Varlilumab","Causality and severity of each adverse event|Activity - Lugano response criteria|Overall Survival|Progression-Free Survival","University Hospital Southampton NHS Foundation Trust|University Hospital Plymouth NHS Trust|The Christie NHS Foundation Trust|Oxford University Hospitals NHS Trust|Celldex Therapeutics|Cancer Research UK","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RHMCAN1278","November 23, 2017","March 1, 2019","October 1, 2020","October 12, 2017","null","September 7, 2018","The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|Plymouth Hospitals NHS Trust, Plymouth, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT03307746"
175,"NCT00316511","Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma",,"Completed","No Results Available","Malignancies|B-Cell Lymphoma","Drug: Aroplatin","Determine the maximum tolerated dose and dose-limiting toxicity of L-NDDP|Assess safety of L-NDDP|Determine the pharmacokinetic profile of L-NDDP|Assess clinical activity","Agenus Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-726-05","March 2006","June 2008","null","April 21, 2006","null","October 27, 2008","Boston, Massachusetts, United States|Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00316511"
176,"NCT02486952","MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma",,"Completed","Has Results","Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma","Drug: Cyclophosphamide|Drug: Hydroxydaunorubicin|Drug: Oncovin|Drug: Prednisone|Drug: Rituximab","Probability of Event Free Survival (EFS)|Percentage of Participants Who Were Alive","Hoffmann-La Roche|Serbian Lymphoma Group","All","18 Years and older   (Adult, Older Adult)","","154","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ML20390","August 2005","January 2011","January 2011","July 1, 2015","February 22, 2016","February 22, 2016","Belgrade, Serbia|Belgrade, Serbia|Kragujevac, Serbia|NIS, Serbia|Sremska Kamenica, Serbia","","https://ClinicalTrials.gov/show/NCT02486952"
177,"NCT00147121","Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)",,"Completed","No Results Available","Lymphoma, B-Cell","Drug: Rituximab + Standard CHOP|Drug: Rituximab + Bi-weekly CHOP","CR rate (phase II)|PFS (phase III)|ORR, PFS, OS, Safety (phase II)|OS, Safety (phase III)","Haruhiko Fukuda|Ministry of Health, Labour and Welfare, Japan|Japan Clinical Oncology Group","All","20 Years to 69 Years   (Adult, Older Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JCOG0203|C000000033","September 2002","February 2010","February 2010","September 7, 2005","null","September 22, 2016","Aichi Medical University, Aichi-gun,Nagakute,Yazako,Karimata,21, Aichi, Japan|Aichi Cancer Center Hospital, Nagoya,Chikusa-ku,Kanokoden,1-1, Aichi, Japan|Nagoya City University Hospital, Nagoya,Mizuho-ku,Mizuho-cho,Kawasumi,1, Aichi, Japan|Nagoya University School of Medicine, Nagoya,Showa-ku, Tsurumai-cho,65, Aichi, Japan|Nagoya Daini Red Cross Hospital, Nagoya,Showa-ku,Myoken-cho,2-9, Aichi, Japan|Nagoya Medical Center, Nagoya,Naka-ku,Sannomaru,4-1-1, Aich, Japan|Akita University School of Medicine, Akita,Hondo,1-1-1, Akita, Japan|Chiba Cancer Center Hospital, Chiba,Chuo-ku,Nitona-cho,666-2, Chiba, Japan|National Cancer Center Hospital East, Kashiwa,Kashiwanoha,6-5-1, Chiba, Japan|Ehime University Hospital, Shitsukawa,Toon, Ehime, Japan|University of Fukui Hospital, Yoshida-gun,Matsuoka,Shimoaizuki,23-3, Fukui, Japan|School of Medicine,Fukuoka University, Fukuoka,Jonan-ku,Nanakuma,7-45-1, Fukuoka, Japan|National Kyushu Cancer Center, Fukuoka,Minami-ku,Notame,3-1-1, Fukuoka, Japan|National Hospital Organization Kyusyu Medical Center, FukuokaChuo-ku,Jigyohama,1-8-1, Fukuoka, Japan|University of Occupational and Environmental Health, Kitakyushu,Yahatanishi-ku,Iseigaoka,1-1, Fukuoka, Japan|Ohta Nishinouchi Hospital, Kohriyama,Nishinouchi,2-5-20, Fukushima, Japan|Gunma University, Maebashi,Showa,3-39-15, Gunma, Japan|Sapporo Hokuyu Hospital, Sapporo,Shiroishi-ku,Higashi-sapporo,6-5-1, Hokkaido, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo,Shiroishi-ku,Kikusui,4-2-3-54, Hokkaido, Japan|Kanazawa Medical University, Kahoku-gun,Uchinada-machi,Daigaku,1-1, Ishikawa, Japan|Imamura Bun-in Hospital, Kagoshima,Kamoikeshinmachi,11-23, Kagoshima, Japan|Kagoshima University,Faculty of Medicine, Kagoshima,Sakuragaoka,8-35-1, Kagoshima, Japan|Tokai University School of Medicine, Isehara,Shimokasuya,143, Kanagawa, Japan|St.Marianna University School of Medicine,Yokohama City Seibu Hospital, Yokohama,Asahi-ku,Yasashi-cho,1197-1, Kanagawa, Japan|Kumamoto University Medical School, Kumamoto,Honjo,1-1-1, Kumamoto, Japan|NHO Kumamoto Medical Center, Kumamoto,Ninomaru,1-5, Kumamoto, Japan|Kyoto Prefectural University of Medicine, Kyoto,Kamigyo-ku,Kawaramachi-Hirokoji,465, Kyoto, Japan|Mie University School of Medicine, Tsu,Edobashi,2-174, Mie, Japan|Tohoku University Hospital, Sendai,Aoba-ku,Seiryo-machi,1-1, Miyagi, Japan|Nagasaki University Hospital, Nagasaki,Sakamoto,1-7-1, Nagasaki, Japan|Nagasaki Medical Center, Oomura,Kubara,2-1001-1, Nagasaki, Japan|Sasebo City General Hospital, Sasebo,Hirasemachi,9-3, Nagasaki, Japan|Niigata Cancer Center Hospital, Niigata,Kawagishi-cho,2-15-3, Niigata, Japan|Oita Prefectural Hospital, Oita,Bunyo,476, Oita, Japan|Faculty of Medicine,University of Ryukyus, Nakagami,Nishihara,Uehara,207, Okinawa, Japan|Faculty of Medicine, Saga University, Saga,Nabeshima,5-1-1, Saga, Japan|Saitama Cancer Center, Kita-adachi,Ina,Komuro,818, Saitama, Japan|Shiga Medical Center for Adults, Moriyama,Moriyama,5-4-30, Shiga, Japan|Hamamatsu University School of Medicine, Hamamatsu,Handayama,1-20-1, Shizuoka, Japan|Tokyo Metropolitan Komagome Hospital, Bunkyo-ku,Honkomagome,3-18-22, Tokyo, Japan|National Cancer Center Hospital, Chuo-kum,Tsukiji, 5-1-1, Tokyo, Japan|Jikei University,Daisan Hospital, Komae,Izumihoncho,4-11-1, Tokyo, Japan|Jikei University Hospital, Minato-ku,Nishishinbashi,3-25-8, Tokyo, Japan|Kyorin University School of Medicine, Mitaka,Shinkawa,6-20-2, Tokyo, Japan|Tokyo Medical University, Shinjuku-ku,Nishi-shinjuku,6-7-1, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT00147121"
178,"NCT01786018","Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas","TBF","Unknown status","No Results Available","B-cell Lymphoma Refractory","Drug: Thiotepa|Drug: Busulfan|Drug: Fludarabin|Procedure: transplant (HCT)|Radiation: Cytoreduction|Drug: Immunosuppression|Drug: Cyclosporine|Drug: Methotrexate|Drug: ATG|Procedure: Collection and infusions of Donor PBSC","Progression free survival|Transplant-related morbidity (TRM) at day +100 and at +365|Overall survival|Incidence of acute and chronic GVHD","Azienda Ospedaliera San Giovanni Battista","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBF2012","February 2013","February 2015","February 2015","February 7, 2013","null","July 8, 2014","Città della Salute e della Scienza di Torino, Torino, Italy","","https://ClinicalTrials.gov/show/NCT01786018"
179,"NCT02891590","Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia|B-cell Lymphomas","Drug: DTRMWXHS-12","Number of participants with adverse events|Plasma concentrations of DTRMWXHS-12","Zhejiang DTRM Biopharma","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DTRM_DTRMWXHS-12_001","September 2016","December 2018","null","September 7, 2016","null","February 2, 2018","Peking University Cancer Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT02891590"
180,"NCT02600897","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma","Drug: Lenalidomide|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Rituximab","Percentage of Participants with CR, Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans|Percentage of Participants with Adverse Events|Percentage of participants with dose-limiting toxicities (DLTs)|Percentage of participants with CR, determined by the investigator on the basis of PET and CT scans|Percentage of Participants with CR, Determined by the Independent Review Committee (IRC) and Investigator on the Basis of CT Scans Alone|Percentage of Participants with Objective Response, Determined by the IRC and Investigator on the Basis of PET and CT Scans|Percentage of Participants with Objective Response, Determined by the IRC and Investigator on the Basis of CT Scans Alone|Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants With Best Response of Clinical Response (CR) or Partial Response (PR), Determined by the Investigator on the Basis of CT Scans Alone|Observed Serum Obinutuzumab Concentration|Observed Serum Rituximab Concentration|Observed Serum and Plasma Polatuzumab Vedotin Concentration|Observed Plasma Lenalidomide Concentration|Percentage of Participants with Human Anti-human Antibodies (HAHAs) to Obinutuzumab|Percentage of Participants with Human Anti-chimeric Antibodies (HACAs) to Rituximab|Percentage of Participants with Anti-therapeutic Antibodies (ATAs) to Polatuzumab Vedotin","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","128","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO29834|2015-001999-22","March 23, 2016","February 23, 2022","February 23, 2022","November 9, 2015","null","July 17, 2018","Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Missouri/Ellis Fischel, Columbia, Missouri, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States|NYU School of Medicine, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Rocky Mountain Cancer Centers, LLP, Irving, Texas, United States|Texas Oncology-Tyler, Irving, Texas, United States|Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Hospital Clínico Málaga, Málaga, Malaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic. Barcelona, Barcelona, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Sevilla, Spain|Hospital La Fe, Valencia, Spain|St James University Hospital, Leeds, United Kingdom|University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary, Leicester, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Barts Hospital; Institute of Cancer, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Maidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|Barking, Havering and Redbridge University Hospitals NHS Trust - Queen's Hospital, Romford, United Kingdom|The Royal Wolverhampton Hospitals NHS Trust; Department of Haematology, Wolverhampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02600897"
181,"NCT00434629","Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant",,"Completed","No Results Available","B-cell Lymphoma|Non-Hodgkin's Lymphoma","Drug: Bexxar","dose-limiting toxicity|maximum tolerated dose|overall response rate|progression-free survival|time to treatment failure","University of Pennsylvania|GlaxoSmithKline","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 18406|UPenn IRB#805353|GSK 106665","February 2007","May 2015","May 2015","February 13, 2007","null","August 17, 2016","Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00434629"
182,"NCT00499018","Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma","DLCL04","Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma|IPI≥2","Drug: Rituximab|Drug: Ciclofosfamide|Drug: Doxorubicina|Drug: Vincristina|Drug: Prednisone|Drug: Pegfilgrastim|Drug: Mitoxantrone|Drug: ARA-C|Drug: Lenograstim|Drug: BCNU|Drug: VP-16|Procedure: ASCT","To evaluate the activity of arms ""R-MegaCHOP14/R-CHOP14 + R-MAD+BEAM and ASCT"" and ""R-MegaCHOP14/R-CHOP14"" in terms of 2-years Failure Free Survival (FFS).|To evaluate the activity of arms ""R-MegaCHOP14/R-CHOP14 + R-MAD+BEAM and ASCT"" and ""R-MegaCHOP14/R-CHOP14"" in terms of 3-years Overall Survival (OS).|To evaluate the efficacy of two different dose-dense + Rituximab chemotherapy regimens in term of 2-years Failure Free Survival (FFS).|To evaluate the activity of the first four courses of two different dose dense + Rituximab chemotherapy regimens (standard dose R-CHOP14 or intensified dose R-MegaCHOP14) in terms of Overall Response Rate (ORR) and Complete Remission (RC).|To evaluate the efficacy of the four different induction arms in terms of 2-years FFS (exploratory analysis).","Fondazione Italiana Linfomi ONLUS|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte","All","18 Years to 60 Years   (Adult)","Phase 3","399","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIL-DLCL04|EudraCT number 2007-000275-42","January 2006","June 2011","September 2013","July 11, 2007","null","February 15, 2011","Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy|Ospedale Civile Umberto I, Mestre, Venezia, Italy|Osp. Calvi, Noale, Mirano, Venezia, Italy|Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Ospedale Cardinal Massaia, Asti, Italy|Centro di Riferimento Oncologico, Aviano - PN, Italy|Azienda Ospedale Policlinico Consorziale, Bari, Italy|IRCC Istituto tumori Ematologia, Bari, Italy|Osp. Degli Infermi, Biella, Italy|Ospedale Policlinico S. Orsola Malpighi, Bologna, Italy|Spedali Civili, Brescia, Italy|UTMO Ematologia Università Spedali Civili, Brescia, Italy|Stabilimento ""Perrino"", Brindisi, Italy|Ospedale di Circolo, Busto Arsizio - VA, Italy|Ospedale Armando Businco, Cagliari, Italy|Università Cattolica del Sacro Cuore, Campobasso, Italy|IRCC, Candiolo (TO), Italy|Ospedale Pugliese, Catanzaro, Italy|Ospedale Bufalini, Cesena - FC, Italy|Stabilimento Ospedaliero, Ciriè - TO, Italy|Ospedale Generale di Zona, Civitanova Marche (MC), Italy|Presidio Ospedaliero Annunziata, Cosenza, Italy|Istituti Ospitalieri, Cremona, Italy|Az. Ospedaliero Universitaria Careggi, Firenze, Italy|Stabilimento Forlì, Forlì, Italy|Azienda Universitaria San Martino, Genova, Italy|A.S.L. 9, Ivrea, Italy|Ospedale Felettino, La Spezia, Italy|Istituto Vito Fazzi, Lecce, Italy|Azienda Ospedaliera Papardo, Messina, Italy|Azienda Ospedaliero Universitaria Policlinico Gaetano Martino, Messina, Italy|Istituto Europeo di Oncologia, Milano, Italy|Osp. San Carlo Borromeo, Milano, Italy|Ospedale Cà Grande - Niguarda, Milano, Italy|Ospedale Fatebenefratelli, Milano, Italy|Presidio Osp. Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Policlinico, Modena, Italy|Ospedale S. Gerardo, Monza, Italy|Università degli Studi Federico II, Napoli, Italy|Osp. Maggiore Della Carità, Novara, Italy|Ospedale S. Francesco, Nuoro, Italy|Ospedale San Luigi, Orbassano (TO), Italy|Azienda Ospedaliera, Padova, Italy|Università degli Studi, Parma, Italy|Fond. Maugeri - Centro medico, Pavia, Italy|Ospedale Policlinico San Matteo, Pavia, Italy|Ospedale di Piacenza, Piacenza, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Azienda Ospedaliera Ospedale San Carlo, Potenza, Italy|Ospedale Santa Maria delle Croci, Ravenna, Italy|Ospedale Bianchi Melacrino Morelli, Reggio Calabria, Italy|Ospedale Santa Maria Nuova, Reggio Emilia, Italy|Ospedale Oncologico Regionale, Rionero in Vulture (PZ), Italy|Istituto Regina Elena, Roma, Italy|Ospedale S. Eugenio, Roma, Italy|Policlinico Universitario A. Gemelli, Roma, Italy|Policlinico Universitario Campus Biomedico, Roma, Italy|Università degli Studi di Roma ""La Sapienza"", Roma, Italy|Università degli Studi di Roma 'Tor Vergata', Roma, Italy|Ospedale di Ronciglione, Ronciglione (VT), Italy|Istituto Clinico Humanitas, Rozzano - MI, Italy|Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy|Ospedale SS.Annunziata, Sassari, Italy|Spedali Riuniti, Siena, Italy|Ospedale Morelli, Sondalo, Italy|Stabilimento SS. Annunziata, Taranto, Italy|Azienda Ospedaliera di Perugia, Terni, Italy|Osp. S. Giovanni Battista ""Molinette"", Torino, Italy|Ospedale Ca Focello, Treviso, Italy|Presidio Ospedaliero di Vittorio Veneto, Treviso, Italy|Ospedale Generale Prov. Cardinale G. Panico, Tricase (LE), Italy|Policlinico Universitario, Udine, Italy|Osp. di Circolo e Fondazione Macchi, Varese, Italy|Stabilimento Ospedaliero, Verbania, Italy|Osp. Sant'Andrea Divisioen di Onco-Ematologia, Vercelli, Italy","","https://ClinicalTrials.gov/show/NCT00499018"
183,"NCT01044004","Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue",,"Withdrawn","No Results Available","B-cell Lymphoma|Fatigue","Drug: Armodafinil|Drug: placebo","To determine whether armodafinil is more effective than placebo in reducing fatigue as measured by the change in scores from the FACT-Fatigue reported at study entry, week 7 of study treatment, and study completion (week 13).|To determine whether armodafinil is more effective than placebo in improving work quality as measured by the change in scores from the WLQ© reported at study entry (week 1) and study completion (week 13).|To determine whether armodafinil is more effective than placebo in reducing fatigue as measured by standard actigraphy summary statistics will be done at week 1 of screening, week 7 of study treatment, and study completion (week 13).|To determine whether armodafinil is more effective than placebo in reducing fatigue as measured by actigraphy using applied functional data analysis during week 1 of screening, week 7 of study treatment, and study completion (week 13).|To evaluate whether measured cytokines (IL-2, IL-6, IL-10, TNF-α, and TGF-α) are elevated at baseline.|To evaluate whether measured cytokines (IL-2, IL-6, IL-10, TNF-α, and TGF-α) change from the time of study entry to study completion.|To assess whether cytokine levels (IL-2, IL-6, IL-10, TNF-α, and TGF-α) correlate with circadian patterns in wrist actigraphy and self-described reports of fatigue as measured by the FACT-Fatigue at baseline and study completion.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","09-1896","March 2010","June 2012","June 2012","January 7, 2010","null","July 23, 2013","","","https://ClinicalTrials.gov/show/NCT01044004"
184,"NCT02542111","A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Bortezomib|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin","Response rate|Progression free survival|Overall survival|Safety as assessed using the CTCAE","Ruijin Hospital","All","16 Years to 75 Years   (Child, Adult, Older Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","V-GDP","May 2015","May 2018","May 2018","September 4, 2015","null","November 14, 2017","Ruijin Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02542111"
185,"NCT01724021","A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a",,"Completed","Has Results","Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma","Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Drug: Bendamustine|Drug: Rituximab","Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6|Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8|Number of Participants With Treatment Emergent Adverse Events (AEs)|Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])|Cancer Therapy Satisfaction Questionnaire (CTSQ) Score|Rituximab Administration Satisfaction Questionnaire (RASQ) Score|Complete Response (CR) Rate|Event-free Survival (EFS)|Disease-free Survival (DFS)|Progression-free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With Anti-Rituximab Antibodies Over Time|Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time|Summary of Observed Serum Rituximab Concentration","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","743","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO28457|2012-003230-17","December 2012","January 2015","January 2015","November 9, 2012","August 29, 2016","January 23, 2018","Buenos Aires, Argentina|Corrientes, Argentina|Santa Fé, Argentina|Canberra, Australian Capital Territory, Australia|Camperdown, New South Wales, Australia|Liverpool, New South Wales, Australia|Randwick, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Hobart, Tasmania, Australia|Geelong, Victoria, Australia|Malvern, Victoria, Australia|Melbourne, Victoria, Australia|Wodonga, Victoria, Australia|Nedlands, Western Australia, Australia|Perth, Western Australia, Australia|Krems, Austria|Linz, Austria|Salzburg, Austria|Steyr, Austria|Wien, Austria|Belo Horizonte, MG, Brazil|Juiz de Fora, MG, Brazil|Varginha, MG, Brazil|Recife, PE, Brazil|Curitiba, PR, Brazil|Londrina, PR, Brazil|Caxias do Sul, RS, Brazil|Novo Hamburgo, RS, Brazil|Santa Maria, RS, Brazil|Santo Andre, SP, Brazil|Sao Jose do Rio Preto, SP, Brazil|Burnaby, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Hamilton, Ontario, Canada|Montreal, Quebec, Canada|Santiago, Chile|Santiago, Chile|Viña del Mar, Chile|Monteria, Colombia|Osijek, Croatia|Aalborg, Denmark|Holstebro, Denmark|Santiago de los Caballeros, Dominican Republic|Alexandria, Egypt|Cairo, Egypt|San Salvador, El Salvador|Aschaffenburg, Germany|Augsburg, Germany|Bamberg, Germany|Bayreuth, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bielefeld, Germany|Bielefeld, Germany|Bochum, Germany|Bochum, Germany|Bonn, Germany|Bottrop, Germany|Brandenburg, Germany|Bremen, Germany|Bremerhaven, Germany|Coesfeld, Germany|Darmstadt, Germany|Darmstadt, Germany|Dresden, Germany|Dresden, Germany|Düsseldorf, Germany|Eisenach, Germany|Essen, Germany|Essen, Germany|Frankfurt an der Oder, Germany|Frankfurt, Germany|Frankfurt, Germany|Frankfurt, Germany|Freiburg, Germany|Fürth, Germany|Georgsmarienhütte, Germany|Giessen, Germany|Giessen, Germany|Goslar, Germany|Gütersloh, Germany|Halle, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamm, Germany|Hamm, Germany|Hanau, Germany|Hannover, Germany|Hannover, Germany|Herford, Germany|Jena, Germany|Kaiserslautern, Germany|Kassel, Germany|Köln, Germany|Leer, Germany|Leipzig, Germany|Limburg, Germany|Lübeck, Germany|Magdeburg, Germany|Mainz, Germany|Mannheim, Germany|Marburg, Germany|Mayen, Germany|Moers, Germany|Mutlangen, Germany|Mönchengladbach, Germany|Mülheim, Germany|München, Germany|Münster, Germany|Neunkirchen/Saar, Germany|Nürnberg, Germany|Oldenburg, Germany|Osnabrueck, Germany|Paderborn, Germany|Pforzheim, Germany|Pinneberg, Germany|Pirna, Germany|Porta Westfalica, Germany|Pößneck, Germany|Ravensburg, Germany|Recklinghausen, Germany|Regensburg, Germany|Rostock, Germany|Rostock, Germany|Rostock, Germany|Rostock, Germany|Rötha, Germany|Schweinfurt, Germany|Schwäbisch-Hall, Germany|Siegburg, Germany|Stade, Germany|Stendal, Germany|Stuttgart, Germany|Traunstein, Germany|Trier, Germany|Velbert, Germany|Villingen-Schwenningen, Germany|Weilheim, Germany|Wiesbaden, Germany|Wilhelmshaven, Germany|Witten, Germany|Wuerselen, Germany|Zittau, Germany|Zwickau, Germany|Guatemala, Guatemala|Guatemala, Guatemala|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Budapest, Hungary|Gyor, Hungary|Gyula, Hungary|Kaposvar, Hungary|Nyíregyháza, Hungary|Szeged, Hungary|Szolnok, Hungary|Bandung, Indonesia|Jakarta, Indonesia|Jogjakarta, Indonesia|Surabaya, Indonesia|Catanzaro, Calabria, Italy|Ferrara, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Piacenza, Emilia-Romagna, Italy|Roma, Lazio, Italy|Candiolo, Piemonte, Italy|Cuneo, Piemonte, Italy|Brindisi, Puglia, Italy|Lecce, Puglia, Italy|Palermo, Sicilia, Italy|Lido Di Camaiore, Toscana, Italy|Livorno, Toscana, Italy|Busan, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Ampang, Malaysia|Kuala Lumpur, Malaysia|Kuching, Malaysia|Sabah, Malaysia|Amstelveen, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Beverwijk, Netherlands|Capelle Aan De Yssel, Netherlands|Delftzijl, Netherlands|Den Haag, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Goes, Netherlands|Leidschendam, Netherlands|Rotterdam, Netherlands|Tilburg, Netherlands|Utrecht, Netherlands|Auckland, New Zealand|Panama City, Panama|Panama, Panama|Panama, Panama|Arequipa, Peru|Cusco, Peru|La Victoria, Lima, Peru|Cebu City, Philippines|Manila, Philippines|Manila, Philippines|Quezon City, Philippines|Lisboa, Portugal|Matosinhos, Portugal|Ponta Delgada, Portugal|Setubal, Portugal|Viseu, Portugal|Baia Mare, Romania|Brasov, Romania|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Craiova, Romania|Iasi, Romania|Sibiu, Romania|Timisoara, Romania|Falun, Sweden|Göteborg, Sweden|Jönköping, Sweden|Karlstad, Sweden|Sundsvall, Sweden|Västerås, Sweden|Kaohsung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Khon Kaen, Thailand|Ankara, Turkey|Ankara, Turkey|Denizli, Turkey|Erzurum, Turkey|Malatya, Turkey|Ha Noi, Vietnam|Hochiminh city, Vietnam","","https://ClinicalTrials.gov/show/NCT01724021"
186,"NCT00038571","Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy",,"Completed","No Results Available","Lymphoma, B-Cell","Drug: PS341 (Bortezomib)","Number of Patients with Response to PS-341","M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.","All","17 Years and older   (Child, Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID01-596","May 2002","March 2005","March 2005","June 3, 2002","null","July 31, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00038571"
187,"NCT01788189","Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas","LeMLAR","Recruiting","No Results Available","B-cell Lymphoma","Drug: Lenalidomide","Dose-limiting toxicity|Progression-free survival","University Hospital, Essen|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","44","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT No. 2012-001891-13","January 2013","December 2018","June 2019","February 11, 2013","null","May 8, 2018","Klinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany","","https://ClinicalTrials.gov/show/NCT01788189"
188,"NCT01453205","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","Has Results","Diffuse Large B-Cell Lymphoma","Drug: MEDI-551 2 mg/kg|Drug: Rituximab|Drug: ICE|Drug: DHAP|Procedure: Autologous Stem Cell Transplant (ASCT)|Drug: MEDI-551 4 mg/kg","Objective Response Rate (ORR)|Progression-Free Survival (PFS)|Event-Free Survival (EFS)|Overall Survival (OS)|Time to Progression (TTP)|Time to Response (TTR)|Duration of Response (DR)|Number of Participants With Best Overall Response Assessed by Blinded Independent Central Review (BICR)|Acceptable Dose of MEDI-551|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Hematology/Coagulation Laboratory Results|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Chemistry Laboratory Results (Include Urinalysis)|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Signs and ECG Abnormalities|Number of Participants Who Developed Detectable MEDI-551 Anti-drug Antibodies (ADA)|Mean Serum Concentration of MEDI-551|Half-life (T1/2) of MEDI-551","MedImmune LLC","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","187","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD-ON-MEDI-551-1088","February 27, 2012","July 11, 2016","July 11, 2016","October 17, 2011","March 12, 2018","March 12, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Burbank, California, United States|Research Site, Palm Springs, California, United States|Research Site, Sylmar, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Westwood, Kansas, United States|Research Site, Hazard, Kentucky, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Rochester, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Fargo, North Dakota, United States|Research Site, Dayton, Ohio, United States|Research Site, Newark, Ohio, United States|Research Site, Sylvania, Ohio, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, St. John, New Brunswick, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha, Czechia|Research Site, Bordeaux, France|Research Site, Le Mans, France|Research Site, Libourne Cedex, France|Research Site, Marseille, France|Research Site, Marseille, France|Research Site, Pessac, France|Research Site, Rouen, France|Research Site, Tours, France|Research Site, Berlin, Germany|Research Site, Frankfurt, Germany|Research Site, Mainz, Germany|Research Site, Muenchen, Germany|Research Site, Tuebingen, Germany|Research Site, Wuerzburg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Aviv, Israel|Research Site, Gdynia, Poland|Research Site, Lublin, Poland|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Barcelona, Spain|Research Site, Cadiz, Spain|Research Site, Girona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Malaga, Spain|Research Site, Pamplona, Spain|Research Site, Salamanca, Spain|Research Site, San Sebastian de los Reyes, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kurupelit, Turkey|Research Site, Malatya, Turkey|Research Site, Talas, Turkey","","https://ClinicalTrials.gov/show/NCT01453205"
189,"NCT02660710","Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma|HIV","Drug: R-CHOP","Number of DLBCL patients receiving R-CHOP who experience NCI grade 3 or 4 non-hematologic toxicities|Number of patients who experience treatment-related death over a course of six cycles|Number of DLBCL patients by HIV status receiving R-CHOP who experience grade 3 or 4 non-hematologic toxicities over a course of six cycles|Number of patients receiving ≥ 90% of the prescribed doses of doxorubicin and cyclophosphamide, respectively among DLBCL patients in Malawi with HIV infection|Number of patients receiving ≥ 90% of the prescribed doses of doxorubicin and cyclophosphamide, respectively among DLBCL patients in Malawi without HIV infection|Number of patients with progression free survival with R-CHOP administered|Number of patients with overall survival with R-CHOP administered|Number of patients with complete response rates with R-CHOP administered|Number of years from treatment initiation until disease progression or death.|Number of years gained after rituximab plus CHOP chemotherapy administered","UNC Lineberger Comprehensive Cancer Center|John E. Fogarty International Center (FIC)|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1335|K01TW009488|R21CA180815","March 2016","March 2021","December 2022","January 21, 2016","null","May 24, 2018","UNC Project, Lighthouse Trust, Lilongwe, Malawi","","https://ClinicalTrials.gov/show/NCT02660710"
190,"NCT02354846","An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)",,"Recruiting","No Results Available","B-cell Lymphoma","","Percentage number of patients with hepatitis due to HBV reactivation|Percentage number of patients with hepatitis due to Safety assessment|Chemotherapy disruption due to hepatitis","Yonsei University","All","19 Years and older   (Adult, Older Adult)","","112","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","4-2014-0928","February 2015","March 2021","March 2021","February 3, 2015","null","July 17, 2018","Severance Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02354846"
191,"NCT00849654","Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma","PCYC-04753","Completed","No Results Available","B-Cell Lymphoma|B-Cell Leukemia","Drug: PCI-32765","Dose limiting toxicity assessment for each patient.|Adverse events|Pharmacokinetic/ Pharmacodynamic assessments|Tumor response","Pharmacyclics LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-04753","February 2009","July 2012","July 2012","February 24, 2009","null","May 22, 2013","Stanford University School of Medicine, Palo Alto, California, United States|University of Chicago, Chicago, Illinois, United States|National Cancer Institute, Bethesda, Maryland, United States|New York Prebyterian Hospital Cornell Medical Center, New York, New York, United States|Willamette Valley Cancer Institute/Research Ctr, Eugene, Oregon, United States|University of Texas, MD Anderson, Houston, Texas, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Northwest Cancer Specialists, Vancouver Cancer Center, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge Cancer Ctr, Yakima, Washington, United States","","https://ClinicalTrials.gov/show/NCT00849654"
192,"NCT03206671","Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","B-NHL 2013","Recruiting","No Results Available","Mature B-cell Non-Hodgkin Lymphoma","Drug: Rituximab window|Drug: Additional doses of Rituximab|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin hydrochloride|Drug: Vindesine Sulfate|Drug: Etoposide|Drug: Ifosfamide|Drug: Methotrexate|Drug: Prednisolone|Drug: Vincristine","Event-free survival (EFS)|Immune reconstitution rate (only in R3/R4 patients)|Overall survival (OS)|Relapse-free survival (RFS)|Response rate (RR)|Adverse event rate|Rate of patients achieving normal immunoglobulin level 12 months after start of treatment|Time interval to normal immunoglobulin level|Time interval from start of treatment to normal CD19 positive B-cells in the peripheral blood.|Rate of patients with normal lymphocyte subpopulations in the peripheral blood 12 months after start of treatment|Interval to normal lymphocyte subpopulations in the peripheral blood.|Rate of infections (defined by CTCAE V4) in the time interval from start of treatment until 24 months after start of treatment|Rate of infections (defined by CTCAE V4) in the time interval from start of treatment until immune reconstitution (achievement of age adjusted normal B-cell counts)|Rate of patients with sufficient titers after vaccination one year after start of treatment|Immune reconstitution rate (only in R1/R2 patients)","University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany)","All","up to 18 Years   (Child, Adult)","Phase 3","650","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UKM12_0020|2013-003253-21","August 3, 2017","August 2024","August 2024","July 2, 2017","null","August 10, 2018","Univ.Klinik für Kinder- und Jugendheilkunde Graz, Klin. Abteilung für pädiatrische Hämato-Onkologie, Graz, Austria|Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck, Universitätsklinik für Pädiatrie I, Innsbruck, Austria|Klinikum Klagenfurt am Wörthersee, Abteilung für Kinder- und Jugendheilkunde, Klagenfurt, Austria|LKH Leoben, Abteilung für Kinder- und Jugendheilkunde, Leoben, Austria|Kepler Universitätsklinikum, Med Campus IV / Onkologie, Linz, Austria|LKH Salzburg, Universitätsklinik für Kinder- und Jugendheilkunde, Kinderonkologie, Salzburg, Austria|St. Anna Kinderspital, Wien, Austria|Department of Pediatric Oncology, University Hospital Brno, Brno, Czechia|Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czechia|Børneonkologisk afsnit 303B, Børneafdelingen, Aalborg Universitetshospital Nord, Aalborg, Denmark|Børn og Unge afsnit 4, Børneafdelingen, Aarhus Universitetshospital Skejby, Aarhus, Denmark|Børneonkologisk afsnit 5054, BørneUngeKlinikken, Juliane Marie Centret, Rigshospitalet, Kobenhavn, Denmark|Børneonkologisk afsnit H2, H. C. Andersen Børnehospital, Odense Universitetshospital, Odense, Denmark|Helsinki University Hospital, Children´s Hospital, Dept of Pediatric Hematology and Oncology, Helsinki, Finland|Kuopio University Hospital, Paediatric Haematology and Oncology, Kuopio, Finland|University Hospital of Oulu, Paediatric Haematology and Oncology, Oulu, Finland|Tampere University Hospital, Paediatric Haematology and Oncology, Tampere, Finland|Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland|Universitätsklinikum Aachen, Klinik für Kinder - und Jugendmedizin, Hämatologie / Onkologie, Aachen, Germany|Klinikum Augsburg, Schwäbisches Kinderkrebszentrum, I. Klinik für Kinder und Jugendliche, Hämatologie / Onkologie, Augsburg, Germany|Charité Campus Virchow-Klinikum, Zentrum für Kinder- und Jugendmedizin, Abt. Hämatologie / Onkologie, Berg, Germany|HELIOS Klinikum Berlin-Buch, Kinderklinik, Pädiatrische Hämatologie und Onkologie, Berlin, Germany|Evangelisches Krankenhaus Bielefeld GmbH, Klinik für Kinder- und Jugendmedizin, Hämatologie und Onkologie, Bielefeld, Germany|Zentrum für Kinderheilkunde der Universität Bonn, Abt. Päd. Hämatologie / Onkologie, Bonn, Germany|Städtisches Klinikum Braunschweig gGmbH, Klinik für Kinder- und Jugendmedizin, Station K5 / Päd. Hämato- und Onkologie, Braunschweig, Germany|Klinikum Bremen-Mitte gGmbH, Prof.-Hess-Kinderklinik,Pädiatrische Onkologie und Hämatologie, Bremen, Germany|Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Päd. Hämatologie und Onkologie, Chemnitz, Germany|Vestische Kinderklinik, Universität Witten / Herdecke, Datteln, Germany|Klinikum Dortmund gGmbH, Klinik für Kinder- und Jugendmedizin, Station K1, Abt. Päd. Onkologie / Hämatologie, Dortmund, Germany|Universitätsklinik Carl Gustav Carus der TU Dresden, Klinik für Kinder- und Jugendmedizin, Dresden, Germany|Universitätsklinikum Düsseldorf, Zentrum für Kinder- und Jugendmedizin, Klinik für Päd. Hämatologie und Onkologie, Düsseldorf, Germany|HELIOS Klinikum Erfurt GmbH, Klinik für Kinder- und Jugendmedizin, Päd. Onkologie / Hämatologie, Erfurt, Germany|Universitätsklinikum Erlangen, Klinik für Kinder- und Jugendmedizin, Pädiatrische Onkologie / Hämatologie, Erlangen, Germany|Universitätsklinikum Essen, Zentrum für Kinder- und Jugendmedizin, Hämatologie / Onkologie, Essen, Germany|Universitätsklinikum Frankfurt, Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Frankfurt am Main, Germany|Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin, Klinik IV: Päd. Hämatologie und Onkologie, Freiburg, Germany|Universitätsklinikum Gießen und Marburg, Standort Gießen, Zentrum für Kinderhämatologie und -onkologie, Gießen, Germany|Universitätsklinikum Greifswald KdöR, Klinik und Poliklinik für Kinder- und Jugendmedizin, Abt. Pädiatrische Onkologie und Hämatologie, Greifswald, Germany|Georg-August-Universität Universitäts-Kinderklinik, Pädiatrie I, Göttingen, Germany|Universitätsklinikum Halle (Saale), Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie / Onkologie, Halle (Saale), Germany|Universitätsklinikum Hamburg Eppendorf, Zentrum für Kinder- und Jugendmedizin, Abt. Pädiatrische Hämatologie und Onkologie, Hamburg, Germany|Medizinische Hochschule Hannover, Kinderheilkunde, Päd. Hämatologie / Onkologie, Hannover, Germany|Universitäts-Kinderklinik Heidelberg, Abt. Hämatologie / Onkologie, Heidelberg, Germany|Gemeinschaftskrankenhaus Herdecke, Kinder- und Jugendmedizin, Päd. Hämatologie / Onkologie, Herdecke, Germany|Universitätskliniken für Kinder- und Jugendmedizin, Päd. Hämatologie und Onkologie, Geb. 9, Homburg, Germany|Universitätsklinikum Jena, Klinik für Kinder- und Jugendmedizin, Jena, Germany|Städtisches Klinikum Karlsruhe gGmbH, Kinderklinik, Station S 24, Karlsruhe, Germany|Klinikum Kassel Gesundheit Nordhessen Holding AG, Klinik für pädiatrische Hämatologie und Onkologie, Kassel, Germany|Universitätsklinikum Schleswig Holstein Campus Kiel, Klinik für Allgemeine Pädiatrie, Päd. Onkologie / Hämatologie, Kiel, Germany|HELIOS Klinikum Krefeld, Zentrum für Kinder- und Jugendmedizin, Päd. Hämatologie/Onkologie, Krefeld, Germany|Klinikum der Universität zu Köln, Klinik für Kinder- und Jugendmedizin, Abt. Kinderonkologie und -hämatologie, Köln, Germany|Universitätsklinikum Leipzig, Klinik für Kinder und Jugendliche, Abt. Päd. Hämatologie / Onkologie, Leipzig, Germany|Universitätsklinikum Schleswig Holstein Campus Lübeck, Klinik für Kinder- und Jugendmedizin, Hämatologie und Onkologie, Lübeck, Germany|Universitätsklinikum Magdeburg A. ö. R., Kinderklinik, Päd. Hämatologie / Onkologie, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kinder- und Jugendmedizin, Pädiatrische Hämatologie / Onkologie, Mainz, Germany|Klinikum Mannheim gGmbH, Universitäts-Kinderklinik, Päd. Onkologie /Hämatologie, Mannheim, Germany|Johannes Wesling Klinikum Minden, Klinik für Kinder- und Jugendmedizin, Päd. Hämatologie / Onkologie, Station E 22, Minden, Germany|Klinikum der LMU, Dr. von Haunersches Kinderspital, Pädiatrische Hämatologie / Onkologie, München, Germany|Klinikum Schwabing, Kinderklinik der TU Päd. Hämatologie / Onkologie, Station 24d, München, Germany|Universitätsklinikum Münster, Klinik für Kinder- und Jugendmedizin, Abt. Pädiatrische Hämatologie und Onkologie, Münster, Germany|Diakonie Neuendettelsau, Kliniken Hallerwiese / Cnopf'sche Kinderklinik, Pädiatrische Hämatologie /Onkologie, Nürnberg, Germany|Klinikum Oldenburg AöR, Zentrum für Kinder- und Jugendmedizin, Abt. Hämatologie / Onkologie, Oldenburg, Germany|Universitätsklinikum Regensburg, Klinik für Kinder- und Jugendmedizin, Abt. Päd. Hämatologie, Onkologie, SZT, Regensburg, Germany|Universitätsklinikum Rostock, Kinder- und Jugendklinik, Päd. Hämatologie und Onkologie, Rostock, Germany|Asklepios Klinik St. Augustin GmbH, Kinder- und Jugendmedizin, Kinder-Hämatologie und Onkologie, Sankt Augustin, Germany|HELIOS Kliniken Schwerin GmbH, Klinik für Kinder- und Jugendmedizin, Station A1, Schwerin, Germany|Klinikum Stuttgart, Olgahospital Zentrum für Kinder- und Jugendmedizin Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart, Germany|Klinikum Mutterhaus der Borromäerinnen gGmbH, Pädiatrische Abteilung, Trier, Germany|Universitätsklinik Tübingen Klinik für Kinderheilkunde und Jugendmedizin, Päd. Hämatologie / Onkologie, Tübingen, Germany|Universitätsklinikum Ulm, Klinik für Kinder- und Jugendmedizin, Päd. Hämatologie und Onkologie, Ulm, Germany|Universitätskinderklinik Würzburg, Päd. Onkologie und Hämatologie, Würzburg, Germany|Haukeland University Hospital, National Study Center Norway, Bergen, Norway|Oslo University Hospital, Rikshospitalet, Oslo, Norway|University Hospital Northern Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway|Sahlgrenska Universitetssjukhuset, Drottning Silvias Barn och Ungdomssjukhus, Barncancercentrum, Göteborg, Sweden|Universitetssjukhuset i Linköping, Barn och Ungdomsmedicinska kliniken, Barnonkologiska enheten, Linköping, Sweden|Skåne Universitetssjukhus, Barnonkologi, Lund, Sweden|Karolinska Universitetssjukhuset, Astrid Lindgrens Barnsjukhus, Barnonkologen, Stockholm, Sweden|Universitetssjukhus Umeå, Barnonkologiska avdelningen, Barn 3 Norrlands, Umeå, Sweden|Akademiska sjukhuset, Barnavdelningen för blod- och tumörsjukdomar, Uppsala, Sweden|Kantonsspital Aarau, Kinderklinik, Aarau, Switzerland|Universitäts - Kinderspital beider Basel, Basel, Switzerland|Ospedale San Giovanni, Reparto die Pediatria, Bellinzona, Switzerland|Universitätsklinik für Kinderheilkunde, Pädiatrische Hämatologie/ Onkologie, Inselspital, Bern, Switzerland|Hôpital des Enfants, Unité d'Oncologie Hématologie, Geneva, Switzerland|Centre hospitalier universitaire vaudois, Unité d'hémato-oncologie pédiatrique, Lausanne, Switzerland|Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland|Ostschweizer Kinderspital, Hämatologie/ Onkologie, Saint Gallen, Switzerland|Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT03206671"
193,"NCT02900716","Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia|B-Cell Lymphoma","Drug: DTRMWXHS-12|Drug: DTRM-505|Drug: DTRM-555","Number of patients with adverse events|Plasma concentration over time","Zhejiang DTRM Biopharma","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D15-11094","September 2016","December 2020","null","September 14, 2016","null","August 14, 2018","Yale Cancer Center, New Haven, Connecticut, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02900716"
194,"NCT02576990","Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)",,"Active, not recruiting","No Results Available","Mediastinal Large B-cell Lymphoma|Richter Syndrome","Biological: Pembrolizumab","Objective Response Rate (ORR) by Independent Central Review|ORR by Investigator Assessment|Progression Free Survival (PFS) by Independent Central Review and Investigator Assessment|Duration of Response (DOR) by Independent Central Review and Investigator Assessment|Disease Control Rate (DCR) by Independent Central Review and Investigator Assessment|Overall Survival (OS)|Number of Participants Who Experience an AE|Number of Participants Who Discontinue Study Drug Due to an AE","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3475-170|2015-002406-37|MK-3475-170","December 2, 2015","September 14, 2019","September 14, 2020","October 15, 2015","null","May 14, 2018","","","https://ClinicalTrials.gov/show/NCT02576990"
195,"NCT03060850","A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL",,"Recruiting","No Results Available","B-cell Lymphoma","Drug: AC0010MA","Recommended phase II dose|24 hours occupancy of AC0010|Tolerability as measured by adverse events using CTCAE and clinical laboratory parameters|Tolerability as measured by number of subjects with dose limiting toxicities|Maximum tolerated dose (MTD)|Occupancy of AC0010 after continued treatment|Objective Response Rate (ORR)|Cmax|Tmax|t1/2|AUC(0-t)|AUC(0-∞)","Hangzhou ACEA Pharmaceutical Research Co.,Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","184","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC201602AVTN05","March 17, 2017","February 14, 2019","February 14, 2020","February 23, 2017","null","October 3, 2017","Peking Union Medical College Hospital, Beijing, Beijing, China|The First Affiliated Hospital,Zhejiang University, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03060850"
196,"NCT03281551","Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma",,"Recruiting","No Results Available","B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma","Drug: PZ01 CAR-T cells","Incidence of Treatment Related Adverse Events|Overall response rate (ORR)|Overall survival (OS)|Minimal residual disease negative remission rate(MRD)","Pinze Lifetechnology Co. Ltd.|Chinese Academy of Sciences|Navy General Hospital, Beijing","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","50","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PZ01","October 1, 2017","September 1, 2020","November 1, 2020","September 13, 2017","null","September 15, 2017","Department of Hematology, Navy General Hospital of PLA, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03281551"
197,"NCT02570542","Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma (DLBCL)|Relapsed Diffuse Large B-cell Lymphoma (DLBCL)|Refractory Diffuse Large B-cell Lymphoma (DLBCL)","Procedure: leukapheresis|Drug: Plerixafor|Drug: carmustine, etoposide, cytarabine, melphalan|Procedure: Autologous Stem Cell Transplantation","progression-free survival (PFS)","Memorial Sloan Kettering Cancer Center|Columbia University|NorthShore University HealthSystem|University of Rochester|Medical College of Wisconsin|University of Nebraska|Sanofi|University Hospitals Seidman Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-193","October 2015","October 2019","October 2019","October 7, 2015","null","July 19, 2018","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Northwell Health, Manhasset, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Tennessee Oncology, Nashville, Tennessee, United States|Texas Transplant Institute, San Antonio, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02570542"
198,"NCT01414855","A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)",,"Completed","Has Results","Lymphoma, B-Cell","Drug: obinutuzumab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: prednisone|Drug: vincristine","Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment|Overall Response Rate (ORR) as Assessed by the Investigator at the End of Treatment|Complete Response (CR) Rate as Assessed by the Independent Review Facility (IRF) at the End of Treatment|Overall Response Rate (ORR) as Assessed by the IRF at the End of Treatment|Progression-Free Survival (PFS) as Assessed by the Investigator|Duration of Response (DOR)|Percentage of Participants With Adverse Events as a Measure of Safety|Number of Participants With Grade 3 to 4 Infusion-Related (IRR) Adverse Events (AE) in Participants Receiving Shorter Duration Infusion (SDI)|Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) for Obinutuzumab|Pharmacokinetics: Terminal Half-Life (t1/2) for Obinutuzumab|Pharmacokinetics: Clearance (Cl) for Obinutuzumab|Pharmacokinetics: Volume of Distribution (V) for Obinutuzumab|Pharmacokinetics: Area Under the Concentration-Time Curve 7 Day (AUC7day)|Pharmacodynamics: Peripheral Blood CD19-positive B-cell Count","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GAO4915g","August 31, 2011","December 31, 2013","December 23, 2016","August 11, 2011","March 19, 2015","April 25, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|cCare, Encinitas, California, United States|University of Colorado Cancer Center Department of Hematology, Aurora, Colorado, United States|Rocky Mountain Cancer Ctr - Denver (Williams), Denver, Colorado, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Florida Cancer Specialists; Department of Oncology, Fort Myers, Florida, United States|Florida Cancer Specialists; Saint Petersburg, Saint Petersburg, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Northwestern University; Robert H. Lurie Comp Can Ctr, Chicago, Illinois, United States|Onc Hem Assoc of Central IL, Peoria, Illinois, United States|McFarland Clinic, Ames, Iowa, United States|Jewish Cancer Care, Louisville, Kentucky, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|MT Cancer Inst Fndtn; MT Can Spec, Missoula, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Memorial Sloan-Kettering; Cancer Center, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MSKCC at Mercy Med Ctr, Rockville Centre, New York, United States|MSKCC at Sleepy Hollow, Sleepy Hollow, New York, United States|Emerywood Hematology and Onc, High Point, North Carolina, United States|Willamette Valley Cancer Insitute and Research Center, Springfield, Oregon, United States|Medical University of SC (MUSC), Charleston, South Carolina, United States|SCRI-Tennessee Oncology, Nashville, Tennessee, United States|Onc & Hem Assoc; USO Cent Pharm, Fort Worth, Texas, United States|MD Anderson Cancer Center Department of Lymphoma & Myeloma, Houston, Texas, United States|Methodist Hospital Research Institute, Houston, Texas, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States|USO - Tyler Cancer Ctr, Tyler, Texas, United States|Blue Ridge Cancer Care - Roanoke, Roanoke, Virginia, United States|Medical Oncology Associates, Spokane, Washington, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Aurora Bay Care Medical Center, Green Bay, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01414855"
199,"NCT02229981","Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma","ABC-102","Withdrawn","No Results Available","Diffuse Large B Cell Lymphoma|Kaposi Sarcoma","Drug: ABC294640","Determine Maximum tolerated dose (MTD) of ABC294640 in patients with refractory/relapsed DLBCL or KS and determine tolerability at MTD.|Evaluate safety of ABC294640 in patients with refractory/relapsed DLBCL or KS|Measure plasma levels of ABC294640 (pharmacokinetics) in patients with DLBCL or KS|Measure plasma levels of sphingosine-1-phosphate in response to ABC294640 in patients with DLBCL or KS|Measure levels of circulating CD4+ T cell count, KSHV/EBV viral loads, and HIV viral load (if applicable) in response to ABC294640 in patients with DLBCL or KS|Evaluate antitumor activity of ABC294640 in virus-associated DLBCL or KS patients by objective radiographic assessment using PET (DLBCL) or CT (KS) criteria, or measurement of clinically evident skin lesions (KS)","RedHill Biopharma Limited|Louisiana State University Health Sciences Center in New Orleans|Apogee Biotechnology Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABC-102","July 2014","June 2019","December 2019","September 3, 2014","null","December 7, 2017","Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT02229981"
200,"NCT00867087","Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma, B-Cell","Drug: inotuzumab ozogamicin (CMC-544)|Drug: rituximab","Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy|Kaplan-Meier Estimate of Progression Free Survival (PFS) 6 Months After Inotuzumab Ozogamicin Plus Rituximab Therapy|Kaplan-Meier Estimate of PFS 2 Years After Inotuzumab Ozogamicin Plus Rituximab Therapy|Percentage of Participants With a Response of CR or PR and Who Had Successful Granulocyte Colony Stimulating Factor (G-CSF) Mobilization of Peripheral Blood Stem Cells (PBSCs) Overall and After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy|Percentage of Participants With Successful G-CSF Mobilization of PBSC|Percentage of Participants Who Underwent Autologous Stem Cell Transplant (aSCT)|Event-Free Survival (EFS) After aSCT|Percentage of Participants With a CR After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy|Overall Survival (OS)|Percentage of Participants With Any Grade 3/4 Laboratory Abnormality During Therapy|Percentage of Participants With Treatment-Emergent Adverse Events (AEs) During Inotuzumab Ozogamicin Plus Rituximab Treatment","Pfizer|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","3129K5-2005|B1931001|2008-007802-12","June 8, 2009","October 31, 2012","October 31, 2012","March 23, 2009","August 22, 2017","December 5, 2017","Loyola University Medical Center, Foster G. McGraw Hospital and Satellites, Maywood, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center, Saint Peters, Missouri, United States|John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC), Hackensack, New Jersey, United States|John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC), Hackensack, New Jersey, United States|Hackensack University Medical CenteR, Hackensack, New Jersey, United States|John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC), Hackensack, New Jersey, United States|John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|UT Southwestern University Hospital - St. Paul, Dallas, Texas, United States|Zale Lipshy University Hospital, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Methodist Healthcare System of, San Antonio, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Pharmaceutical Research Center, Madison, Wisconsin, United States|CHRU de Lille Hopital Claude Huriez, Lille, France|Institut Paoli Calmettes, Marseille, France|CHU Saint-Eloi, Montpellier Cedex 5, France|Hopital Saint Louis, Paris, France|Hopital Haut-Leveque, Pessac, France|CH Lyon Sud, Pierre-Benite cedex 114, France|CH Lyon Sud, Pierre-benite Cedex, France|Departement d'Hematologie et d'Oncologie-, Strasbourg, France|Charite Campus Virchow-Kilinikum-, Berlin, Germany|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Asan Medical Center, Seoul, Seoul/korea, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Singapore General Hospital, Singapore, Singapore|Christie Hospital, Manchester, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT00867087"
201,"NCT01087424","Mini-CHOP and Rituximab in Patients Aged Over 80 Years",,"Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: R mini CHOP","Evaluating efficacy of R-miniCHOP by overall survival|Evaluating R-miniCHOP efficacy by Event free survival","Lymphoma Study Association","All","80 Years and older   (Older Adult)","Phase 2","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH03-7B","April 2006","June 2010","June 2010","March 16, 2010","null","August 23, 2018","","","https://ClinicalTrials.gov/show/NCT01087424"
202,"NCT01965119","Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma","JAK2","Completed","No Results Available","Relapsed or Refractory Hodgkin Lymphoma|Primary Mediastinal Large B-cell Lymphoma","Drug: Ruxolitinib","To assess the efficacy of disease control including complete response (CR), partial response (PR) and stable disease (SD)|Toxicity profile|Overal Survival","Samsung Medical Center","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMC 2013-06-039","November 1, 2013","June 30, 2017","September 30, 2017","October 18, 2013","null","October 27, 2017","Busan University Hospital, Busan, Korea, Republic of|Dong-A University, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korean Cancer Center Hospital, Seoul, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01965119"
203,"NCT00338494","Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma",,"Completed","No Results Available","B-Cell Lymphoma","Drug: Clofarabine","tolerated dose (MTD) of clofarabine|characterize and quantify the toxicity profile associated with clofarabine|determine the overall response rate, plus partial response of clofarabine","Yale University|Genzyme, a Sanofi Company","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0506000158","October 2005","March 2010","April 2011","June 20, 2006","null","January 29, 2015","Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00338494"
204,"NCT00216164","Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","Lymphoma, B-Cell","Drug: Rituximab|Drug: Gemcitabine","· Evaluate response rates to the rituximab plus gemcitabine treatment combination in patients with relapsed or refractory DLBCL.|· Evaluate toxicity, time to progression and overall survival.","Hoosier Cancer Research Network|Eli Lilly and Company|Walther Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOG LYM03-64","April 2005","March 2007","March 2007","September 22, 2005","null","May 2, 2011","Elkhart Clinic, Elkhart, Indiana, United States|Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States|Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Quality Cancer Center (MCGOP), Indianapolis, Indiana, United States|Center for Cancer Care, Inc., P.C., New Albany, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Providence Medical Group, Terre Haute, Indiana, United States|AP&S Clinic, Terre Haute, Indiana, United States","","https://ClinicalTrials.gov/show/NCT00216164"
205,"NCT01325701","Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Completed","Has Results","Diffuse Large Cell B-lymphoma","Drug: ibrutinib","Percentage of Patients With an Overall Response to Study Drug|Number of Patients With Adverse Events as a Measure of Safety and Tolerability|Ibrutinib and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765","Pharmacyclics LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 2","78","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-1106-CA|PCI-32765","May 2011","October 2014","October 2014","March 30, 2011","February 16, 2017","March 31, 2017","UCLA Medical Center, Los Angeles, California, United States|Stanford University School of Medicine, Stanford, California, United States|National Cancer Institute, Bethesda, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|New York University, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester School of Medicine and Dentistry, Rochester, New York, United States|The Ohio Sate university, Columbus, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Univerity of Washington, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01325701"
206,"NCT03129828","Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2","ImbruVeRCHOP","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Ibrutinib and Bortezomib + R-CHOP","2-year progression-free survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|1y- and 2y-PFS for patients based on cell-of-origin (COO, i.e. GCB vs. ABC subtype)|number of patients with complete remission in all patients and based on cell-of-origin|Predictive power of markers for Minimal Residual Disease (MRD) over time|Objective Response Rate (ORR) in all patients and based on cell-of-origin|Disease-Free Survival in all patients and based on cell-of-origin|Overall survival in all patients and based on cell-of-origin","Prof. Dr. Clemens Schmitt|Charite University, Berlin, Germany|Janssen-Cilag Ltd.","All","61 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT-Nr.: 2015-003429-32","March 17, 2017","March 31, 2022","March 31, 2022","April 26, 2017","null","July 18, 2018","Charité - Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, Campus Virchow Klinikum, Berlin, Germany","","https://ClinicalTrials.gov/show/NCT03129828"
207,"NCT00558220","R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas","R-MCEB","Completed","No Results Available","Diffuse Large B-Cell Lymphoma.|Primary Mediastinal B-Cell Lymphoma|Follicular Lymphoma Grade III","Procedure: immunotherapy|Procedure: Induction treatment part 1|Procedure: Induction treatment part 2 with PBPC collection|Procedure: Induction treatment part 3|Procedure: Consolidation treatment part 1: HD-chemotherapy with ASCT|Radiation: Consolidation treatment part 2: Radiotherapy","Progression-free survival|Complete remission and overall response rate|Overall survival","Czech Lymphoma Study Group|Ministry of Health, Czech Republic|Hoffmann-La Roche","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","106","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLSG 5_02|NR-8231/3","May 2002","null","October 2006","November 14, 2007","null","November 14, 2007","University Hospital Brno-Bohunice, Brno, Czech Republic|Hospital Chomutov, Chomutov, Czech Republic|University Hospital Hradec Králové, Hradec Králové, Czech Republic|University Hospital Královské Vinohrady, Prague, Czech Republic|General University Hospital, Prague, Czech Republic|University Hospital Motol, Prague, Czech Republic|Hospital Ústí nad Labem, Usti nad Labem, Czech Republic|Hospital České Budějovice, České Budějovice, Czech Republic","","https://ClinicalTrials.gov/show/NCT00558220"
208,"NCT02219737","Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","CD20 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: Carboplatin|Drug: Etoposide|Drug: Ibrutinib|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab","Maximum tolerated dose of the combination of ibrutinib with standard dosing R-ICE, graded using the Common Terminology Criteria for Adverse Events 4.0|Toxicity of the combination of ibrutinib with standard dosing R-ICE, graded using the CTCAE 4.0|Overall response rate, defined as the sum of partial and complete responses as determined by revised International Working Group Criteria for Malignant Lymphoma|PK parameters of ibrutinib in the presence of R-ICE as a measure of potential drug-drug interaction","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2014-00571|14-145|9588|P30CA008748","September 12, 2014","May 11, 2017","May 11, 2017","August 19, 2014","null","January 26, 2018","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02219737"
209,"NCT02976857","A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects","C-CAR011","Recruiting","No Results Available","Refractory Diffuse Large B-Cell Lymphoma","Biological: C-CAR-011","Dose-limiting toxicity (DLT)|Overall response rate|Disease control rate","Cellular Biomedicine Group Ltd.|The First Affiliated Hospital with Nanjing Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","15","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBMG2016002","December 2016","November 2017","January 2018","November 29, 2016","null","March 14, 2017","Hematological Department, People's Hospital of Jiangsu Province, Nanjing City, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT02976857"
210,"NCT01535989","Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma","IOSI-LND-001","Completed","No Results Available","B-cell Lymphoma Refractory","Drug: Inotuzumab Ozogamicin|Drug: Temsirolimus","number of participants with adverse events based on the CTCAE v.4|Antitumor activity based on Cheson criteria","Cristiana Sessa|Oncology Institute of Southern Switzerland","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IOSI-LND-001","December 2011","June 2016","June 2016","February 20, 2012","null","June 7, 2016","Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland|InselSpital, Universitätsspital Bern, Bern, Switzerland|Kantonsspital St.Gallen, San Gallen, Switzerland","","https://ClinicalTrials.gov/show/NCT01535989"
211,"NCT02268045","Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma",,"Completed","No Results Available","Diffuse Large B-cell Lymphoma","Biological: RTXM83","Response Rate|To evaluate Event Free Survival (EFS) in both treatment arms|To evaluate Safety in both arms|To demonstrate comparable pharmacokinetics of RTXM83 and Rituximab|To demonstrate comparable pharmacodynamics|To compare immunogenicity between both arms","mAbxience S.A|Pisa Farmacética|Laboratorios de Productos Éticos C.E.I.S.A.|Laboratorio Elea S.A.C.I.F. y A.|Tecnoquímicas S.A.|Innogene Kalbiotech Pte. Ltd|Libbs Farmacêutica LTDA|Key Oncologics (Pty) Ltd|Nanolek LLC|Actoverco","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","256","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RTXM83-AC-01-11","May 2013","May 2016","July 2017","October 20, 2014","null","September 21, 2017","Hosp. Interzonal ""R"" Carrillo, Ciudadela, Bariloche, Argentina|Clinica Radiologica del Sur, Cipolletti, Río Negro, Argentina|Clinica Viedma, Viedma, Río Negro, Argentina|Hospital Britanico, Buenos Aires, Argentina|Hospital Gral. de Agudos Donación Francisco Santojanni, Buenos Aires, Argentina|Insituto Roffo, Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), Cordoba, Argentina|Hospital Nacional de Clinicas, Cordoba, Argentina|Hospital Privado de Cordoba, Cordoba, Argentina|Sanatorio Allende, Cordoba, Argentina|Ctr. Oncologico de Rosario, Rosario, Argentina|Inst. Cardiovascular Rosario, Rosario, Argentina|Instituto de Hematología y Medicina Clínica Dr. Rubén Dávoli, Rosario, Argentina|Sanatorio Parque, Rosario, Argentina|Fundación ARS Médica, San Salvador de Jujuy, Argentina|Hospital J. B. Iturraspe, Santa Fe, Argentina|Hospital Angel Padilla, Tucumán, Argentina|Hospital Clinicas Porto Alegre, Pôrto Alegre, Rio Grande do Sul, Brazil|Hospital de Caridade de Ijuí, Ijuí, RS, Brazil|Hospital da Cidade de Passo Fundo, Passo Fundo, RS, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, RS, Brazil|Hospital Santa Marcelina, Itaquera, Sao Paulo, Brazil|Hospital Amaral Carvalho Jaú, Jaú, SP, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo-HCFMRP, Ribeirão Preto, SP, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia / Faculdade de Medicina do ABC, Santo André, SP, Brazil|Fundação Antônio Prudente - AC Camargo Câncer Center, Sao Paulo, SP, Brazil|Hospital das Clinicas-UFMG, Belo Horizonte, Brazil|UNICAMP-Univ Zeferino Vaz, Campinas, Brazil|Hospital Uniao Oeste Paranaense de Estudos e Comabte ao Cancer (UOPECCAN), Cascavel, Brazil|Hospital Erasto Gaertner CEPEP, Curitiba, Brazil|Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Brazil|Santa Casa de Porto Alegre, Porto Alegre, Brazil|Hospital Universitário Clemente Fraga Filho - UFRJ, Rio de Janeiro, Brazil|Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil|Instituto Est. de Hematologia Arthur de Siqueira Cavalcanti, Rio de Janeiro, Brazil|Monte Tabor - Hospital São Rafael, Salvador, Brazil|Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC, Sao Paulo, Brazil|Hospital Clinica Faculdade Medicina USP, Sao Paulo, Brazil|Hospital de Base de São José, São José do Rio Prêto, Brazil|Inst. Nacional de Cancerologia, Bogotá, Colombia|Fundación Valle de Lili, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Srinivasam Cancer Care Hospital, Bangalore, India|Cancer Institute, Chennai, India|Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India|Bibi General Hospital&Canc Ct, Hyderabad, India|Birla Cancer Center - SMS Hospital, Jaipur, India|Health Point Multi-specialty Hospital, Kolkata, India|Institute of Hematology and Transfusion Medicine, Kolkata, India|Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, India|Acharya Tulsi Regional Cancer Treatment and Research Institute, Madurai, India|Guru Hospital, Madurai, India|Meenakshi Mission Hospital, Madurai, India|Kailash Cancer Hospital and Research Centre, Vadodara, India|Dr. Hasan Sadikin Hospital, Bandung, Indonesia|Dharmais N. C. Center, Jakarta, Indonesia|Imam Khomeini Complex Hospital - Cancer Institute, Tehrān, Iran, Islamic Republic of|Hospital Sultanah Aminah, Johor Bahru, Malaysia|University Malaya Medical Centre - UMMC, Kuala Lumpur, Malaysia|Mount Miriam Cancer Hospital, Pulau Pinang, Malaysia|Hospital Pulau Pinang, Pulau Pinang, Malaysia|Insituto Nacional de Cancerología, Mexico City, Mexico|Instituto Privado de Hematologia e Investigaciona Clinica, Asunción, Paraguay|Cebu Doctors University Hospital, Cebu, Philippines|Perpetual Succour Hospital, Cebu, Philippines|Davao Doctors Hospital, Davao, Philippines|National Kidney and Transplant Institute, Quezon City, Philippines|Veterans Memorial Medical Center, Quezon City, Philippines|Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Kursk regional clinical oncology dispensary, Kursk, Russian Federation|N.N. Blokhin Russian Cancer Research Cente, Moscow, Russian Federation|National Medical Surgical Center n.a. N.I. Pirogov, Moscow, Russian Federation|Murmansk regional oncology dispensary, Murmansk, Russian Federation|State Budgetary Healthcare Institution of Stavropol region ""Pyatigorsk oncology center"", Pyatigorsk, Russian Federation|Rostov Scientific Research Oncology Institute, Rostov-na-Donu, Russian Federation|Russian Research Center for Radiology and Surgical Technologies, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Institution ""City Clinical Oncology Dispensary"", Saint-Petersburg, Russian Federation|Scientific Research Institute of Oncology n.a. N.N. Petrov, Saint-Petersburg, Russian Federation|Oncology Center # 2, Sochi, Russian Federation|Komi Republican Oncology Dispensary, Syktyvkar, Russian Federation|State Healthcare Institution of Tula region ""Tula regional clinical hospital"", Tula, Russian Federation|Republican Clinical Oncology Dispensary, Ufa, Russian Federation|Volgograd Regional Clinical Oncology Center, Volgograd, Russian Federation|Rainbow Oncology Centre, Amanzimtoti, South Africa|Tygerberg Academic Hosp, Cape Town, South Africa|GVI Oncology, Port Elizabeth, South Africa|Chris Hani Baragwanath Hospital, Soweto, South Africa","","https://ClinicalTrials.gov/show/NCT02268045"
212,"NCT00054665","PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma",,"Completed","Has Results","B-Cell Lymphoma","Drug: PS-341|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Filgrastim","Clinical Response Rate|Number of Participants With Adverse Events","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","030096|03-C-0096","February 2003","September 2008","July 2009","February 6, 2003","September 11, 2012","September 11, 2012","National Cancer Institute (NCI), Bethesda, Maryland, United States|Roswell Parck Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT00054665"
213,"NCT01854372","Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.",,"Withdrawn","No Results Available","Newly Diagnosed Diffuse Large B-Cell Lymphoma|Intermediate (Burkitt-Like) Lymphoma","Drug: R-HCVAD and R-MC","Progression free survival verified by PET scan.","The University of Texas Health Science Center at San Antonio","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTRC 11-53","June 2013","November 2013","November 2013","May 15, 2013","null","December 10, 2013","","","https://ClinicalTrials.gov/show/NCT01854372"
214,"NCT01510184","Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",,"Terminated","No Results Available","Diffuse Large B-cell Lymphoma|Follicle Center Lymphoma","Drug: Zevalin (ibritumomab tiuxetan)","Overall Survival|OS rate post randomization|Progression-free survival","Spectrum Pharmaceuticals, Inc","All","60 Years and older   (Adult, Older Adult)","Phase 3","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPI-ZEV-11-301","April 2012","February 2018","June 2018","January 13, 2012","null","October 18, 2017","Cancer Treatment Services Arizona, Casa Grande, Arizona, United States|Sutter East Bay Hospitals, Berkeley, California, United States|City of Hope, Duarte, California, United States|Halifax Health Medical Center, Daytona Beach, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Piedmont Hospital Cancer Center, Atlanta, Georgia, United States|St. Luke's Mountain States Tumor Institute (MSTI), Boise, Idaho, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, Suburban, Louisville, Kentucky, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Oncology Research-Park Nicollet Institute, Saint Louis Park, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Hackensack UMC / John Theurer Cancer Center, Hackensack, New Jersey, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Adams Cancer center, Gettysburg, Pennsylvania, United States|York Cancer Center / Cancer Care Associates of York, York, Pennsylvania, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Avera Hematology and Transplant, Sioux Falls, South Dakota, United States|Associates In Oncology and Hematology, Chattanooga, Tennessee, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Royal Hobart Hospital, Hobart, Tasmania, Australia|Royal Melbourne, Parkville, Victoria, Australia|Royal Adelaide Hospital, Adelaide, Australia|Barwon Health, Geelong, Australia|Western Hospital, Melbourne, Australia|Medizinische Universität Wien -AKH Wien, Vienna, Austria|Nuclear Medicine Physician, Jules Bordet Institute, Bruxelles, Belgium|University Hospital Gasthuisberg, Leuven, Belgium|Thunder Bay Regional Health Sciences Centre-Regional Cancer Care, Thunder Bay, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|CSSS Champlain Charles LeMoyne, Greenfield Park, Quebec, Canada|CHU A Michallon, Grenoble, Cedex 9, France|CHU Dupuytren, Limoges, Cedex, France|CHU Amiens, Hôpital Sud, Amiens, France|CH Avignon, Avignon, France|CH de la Côte Basque, Service d'Hématologie, Bayonne, France|Hématologie - CHU Jean Minjoz, Besancon, France|Institut Bergonié, Bordeaux, France|Hopital MORVAN - CHU Brest, Brest, France|Centre François Baclesse, Comite Hématologie, Caen, France|Hôpital Henri MONDOR, Creteil, France|CHD Vendée, La Roche-sur-Yon, France|CHRU Lille- Hospital Claude Huriez, Lille, France|Institut Paoli-Calmettes, Marseille, France|CHR Metz-Thionville, Metz, France|CH de Mulhouse - Hôpital Emile Muller, Mulhouse, France|Centre Antoine Lacassagne, Nice, France|CHR Orléans, Orleans, France|Institut Curie, Paris, France|Centre Hospitalier Saint Jean, Perpignan, France|Hôpital Haut-Levêque Centre F.Magendie, Pessac, France|Centre Hospitalier René Dubos,, Pontoise, France|Service d'Hématologie Centre Henri Becquerel, Rouen, France|CHU de Brabios, Vandoeuvre-les-nancy, France|St James 's Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Soroka Medical Centre, Beersheba, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Organization, Jerusalem, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel|Chaim Sheba Medical Center, Tel-Hashomer, Israel|Policlinico S Orsola Malpighi, Istituto di Ematologia ''L.e A. Seragnoli'', Bologna, Italy|New Ematologia dell'Ospedale ""Spedali Civili"" di Brescia, Brescia, Italy|Divisione di Ematoncologia, Milano, Italy|Azienda Ospedaliera Sant'Andrea, Roma, Italy|Azienda Ospedaliera San. Giovanni Battista di Torino, Dipartimento di Oncologia U.O.A Ematologia, Le Molinette,, Torino, Italy|Meander Medisch Centrum, Amersfoort, Netherlands|VU Medisch Centrum, Amsterdam, Netherlands|Haga Ziekenhuis, Den Haag, Netherlands|University Medical Centre Groningen (UMCG), Groningen, Netherlands|Spaarne Ziekenhuis, Internal Medicine/Ocology, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|St. Antonius Hospital, Nieuwegein, Netherlands|University Medical Center Radboud Nijmegen, Nijmegen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico|Clínica Universidad de Navarra (CUN), Pamplona, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Miguel Servet University Hospital, Zaragoza, Spain|Department of Haematology Bristol Royal Infirmary, Bristol, United Kingdom|Poole General Hospital, Dorset, United Kingdom|Beatson Cancer Centre, Glasgow, United Kingdom|King's College Hospital, London, United Kingdom|The Christie NHS Foundation Trust, The Christie Hospital,, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT01510184"
215,"NCT03287817","CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma","ALEXANDER","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|DLBCL","Biological: AUTO3","Phase I - Safety (incidence of Grade 3-5 toxicities) and confirmation of phase II dose and schedule.|Phase II - Overall response rate as per Lugano criteria|Feasibility of generating AUTO3: number of patients' cells successfully manufactured as a proportion of the number of patients undergoing leukapheresis.|Complete response rate, as per Lugano criteria.|Duration of response (DOR).|Progression-free survival (PFS).|Overall survival (OS).","Autolus Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AUTO3-DB1|2016-004682-11","September 5, 2017","March 2021","March 2021","September 19, 2017","null","August 10, 2018","University College London Hospitals NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom","","https://ClinicalTrials.gov/show/NCT03287817"
216,"NCT01991184","A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.",,"Active, not recruiting","No Results Available","Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma","Drug: GDC-0853","Safety: Incidence of dose-limiting toxicities (DLTs) of GDC-0853|Safety: Maximum tolerated dose (MTD) of GDC-0853|Safety: Incidence of adverse events|Pharmacokinetics: Area under the concentration-time curve (AUC) of GDC-0853|Pharmacokinetics: Maximum concentration (Cmax) of GDC-0853|Objective response to GDC-0853|Progression-free survival","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO29089","December 16, 2013","March 1, 2019","March 1, 2019","November 25, 2013","null","July 4, 2018","Stanford Cancer Center, Stanford, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Oregon Health Sciences Uni, Portland, Oregon, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|Peter MacCallum Cancer Centre; Department of Haematology, Melbourne, Victoria, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia","","https://ClinicalTrials.gov/show/NCT01991184"
217,"NCT01715961","Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma","SARCOPENIE","Completed","No Results Available","Diffuse Large B Cell Lymphoma|Grade IIIB Follicular Lymphoma","Procedure: anthropometric measurement","progression free survival|rate of over grade 2 toxicities|determination of both molecular subtypes GCB and ABC","Centre Henri Becquerel","All","70 Years and older   (Older Adult)","Not Applicable","98","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHB 11-02","January 2012","December 2015","August 2016","October 29, 2012","null","October 5, 2016","Centre Henri Becquerel, Rouen, France","","https://ClinicalTrials.gov/show/NCT01715961"
218,"NCT01976585","In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy",,"Recruiting","No Results Available","Low-Grade B-cell Lymphoma","Drug: rhuFlt3L/CDX-301|Drug: Poly-ICLC","response rate|safety profile|tumor-specific immune response","Joshua Brody|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 13-1347","December 2013","November 2018","November 2018","November 6, 2013","null","September 26, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01976585"
219,"NCT01582776","Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma",,"Active, not recruiting","No Results Available","Follicular Lymphoma Patients (Phase IB)|Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)","Drug: Lenalidomide and GA101","Phase I part: Determination of the recommended dose of lenalidomide in combination with fixed doses of GA101|Phase II part: Overall Response Rate (CR+CRu+PR) after 6 cycles|Overall survival (OS)|Event Free survival|Progression free survival|Response duration|Response rate at the end of maintenance treatment|Complete response rate after induction|Complete response rate after 3 cycles","The Lymphoma Academic Research Organisation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","317","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GALEN","October 3, 2012","July 11, 2018","March 2022","April 23, 2012","null","August 22, 2018","ZNA Stuivenberg, Antwerpen, Belgium|A.Z. Sint Jan AV, Bruges, Belgium|institut Jules Bordet, Bruxelles, Belgium|Université Catholique de Louvain Saint Luc, Bruxelles, Belgium|AZ Groeninge - Campus Maria's Voorzienigheid, Kortrijk, Belgium|CHU de Liège, Liège, Belgium|Université Catholique de Louvain Mont Godinne, Yvoir, Belgium|CHU d'Amiens, Amiens, France|Institut Bergonié, Bordeaux, France|Institut d'Hématologie de Basse Normandie, Caen, France|CHU d'Estaing, Clermont-Ferrand, France|Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHRU de Lille, Lille, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmette, Marseille, France|CHU St Eloi, Montpellier, France|CHU Brabois, Nancy, France|CHU Hôtel Dieu, Nantes, France|Hôpital St Louis, Paris, France|Centre François Magendie, Pessac, France|CH Lyon Sud, Pierre Bénite, France|CHU Pontchaillou, Rennes, France|Centre henri Becquerel, Rouen, France","","https://ClinicalTrials.gov/show/NCT01582776"
220,"NCT00553943","Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis",,"Completed","No Results Available","Lymphoma, Non-Hodgkin|Diffuse Large B-cell Lymphoma","Drug: Rituximab|Drug: Cytarabine","Response to treatment (CR/PR)|Toxicity, Overall survival, Time to progression","Lymphoma Study Association","All","18 Years to 60 Years   (Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R-C5R 2006","July 2007","June 2012","March 2017","November 6, 2007","null","August 23, 2018","ZNA Stuivenberg, Antwerpen, Belgium|Hôpital Saint Joseph, Arlon, Belgium|A. Z. Sint-Jan, Bruges, Belgium|UCL- Saint Luc, Bruxelles, Belgium|CH Notre Dame, Charleroi, Belgium|AZ VUB, Jette, Belgium|CHR de la Citadelle, Liège, Belgium|CHU Charleroi-Vésale, Montigny-Le-Tilleul, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Heilig Hart Ziekenhuis, Roeselare, Belgium|UCL - Mont-Godinne, Yvoir, Belgium|CH d'Annecy, Annecy, France|Centre Hospitalier d'Avignon, Avignon, France|Hôpital de Bayonne, Bayonne, France|Hôpital d'Avicenne, Bobigny, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|CH de Brive, Brive la Gaillarde, France|CHU Clemenceau, Caen, France|Centre Francois Baclesse, Caen, France|CH de Chambery, Chambery, France|CH de Chartres, Chartres, France|Hôpital Gilles de Corbeil, Corbeil-Essonnes, France|Hôpital Henri Mondor, Creteil, France|CHU Le Bocage, Dijon, France|Centre Hospitalier de Dunkerque, Dunkerque, France|Hôpital Saint Louis, La Rochelle, France|Hôpital Andre Mignot, Le Chesnay, France|Hôpital Bicêtre, Le Kremlin-Bicêtre, France|CHU de Lens, Lens, France|Hopital Saint Vincent de Paul, Lille, France|CHU Claude Huriez, Lille, France|Hôpital Dupuytren, Limoges, France|Centre Leon Berard, Lyon, France|Hôpital des Chanaux, Macon, France|CH de Meaux, Meaux, France|Hôpital Bon Secours, Metz, France|Hôpital Emile Muller, Mulhouse, France|Centre Antoine Lacassagne, Nice, France|Hôpital Saint Louis, Paris, France|Hôpital Necker, Paris, France|Centre Hospitalier de Perpigan, Perpignan, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Henri Becquerel, Rouen, France|CH de St Germain, St Germain en Laye, France|Hôpital Purpan, Toulouse, France|Hopital Brabois, Vandoeuvre les Nancy, France","","https://ClinicalTrials.gov/show/NCT00553943"
221,"NCT01846390","Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Peripheral T-Cell Lymphoma|Diffuse Large B-Cell Lymphoma","Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin|Drug: Romidepsin","Maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin.|Efficacy of romidepsin when combined with gemcitabine, dexamethasone and cisplatin|Number of patients with adverse events","Canadian Cancer Trials Group|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY15","April 30, 2013","July 6, 2016","September 19, 2018","May 3, 2013","null","September 20, 2018","Tom Baker Cancer Centre, Calgary, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01846390"
222,"NCT00799513","Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Lenalidomide","1-year progression-free survival|Median overall survival, response rate, response duration","IRCCS San Raffaele|Celgene Corporation","All","65 Years and older   (Older Adult)","Phase 2","47","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-003729-18","October 2009","October 2013","November 2013","December 1, 2008","null","March 22, 2012","San Raffaele Scientific Institute, Milan, Italy","","https://ClinicalTrials.gov/show/NCT00799513"
223,"NCT03151044","R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: High-dose Epirubicin Combined with CVP ± Rituximab|Drug: Standard-dose Epirubicin Combined with CVP ± Rituximab","Objective Response Rate (ORR)|Time to response (TRR)|Duration of response (DOR)|Progression-free survival (PFS)|Overall survival(OS)","FENG Ji-feng|Chinese Anti-Cancer Association|Jiangsu Cancer Institute & Hospital","All","18 Years to 60 Years   (Adult)","Phase 3","408","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015NL-078","July 2016","July 2017","July 2017","May 12, 2017","null","May 12, 2017","Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|Jiangyin People's hospital, Jiangyin, Jiangsu, China|Nanjing General Hospital, Nanjing, Jiangsu, China|Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China|Jiangsu Cancer Institute and Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Nantong Tumor Hospital, Nantong, Jiangsu, China|Wuxi People's hospital, Wuxi, Jiangsu, China|Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT03151044"
224,"NCT00386321","Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)","2-year progression-free survival and overall survival of patients|Response rate (partial response, complete unconfirmed response, and complete response)in patients|2-year progression-free survival, overall survival and response rate in BCL-2 positive patients","Chulalongkorn University|Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH011103","April 2006","July 2007","January 2010","October 11, 2006","null","November 18, 2010","King Chulalongkorn Memorial Hospital, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT00386321"
225,"NCT00400478","A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13",,"Completed","No Results Available","Diffuse Large B-Cell Lymphoma (DLBCL)|Follicular NHL Grade 3b","Drug: Rituximab","event free survival|progression free survival, overall survival and safety","Arbeitsgemeinschaft medikamentoese Tumortherapie|Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","683","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NHL-13 (ML18223)","January 2006","March 2013","March 2013","November 17, 2006","null","May 26, 2016","Border Medical Oncology, Wodonga, Victoria, Australia|Concord Repatriation General Hospital, Concord, Australia|Gosford Hospital, Gosford, Australia|Greenslopes Hospital, Greenslopes, Australia|Prince of Wales Hospital, Sidney, Australia|Krankenhaus Oberpullendorf, Oberpullendorf, Burgenland, Austria|Krankenhaus Oberwart, Oberwart, Burgenland, Austria|A.ö. Krankenhaus der Landeshauptstadt St. Pölten, St. Poelten, Niederoesterreich, Austria|A.ö. Krankenhaus der Statutarstadt Wr. Neustadt, Wr. Neustadt, Niederoesterreich, Austria|Krankenhaus d. Barmherzigen Schwestern Linz, Linz, Oberoesterreich, Austria|Krankenhaus der Elisabethinen Linz, Linz, Oberoesterreich, Austria|KH Barmherzige Schwestern Ried, Ried, Oberoesterreich, Austria|Klinikum Kreuzschwestern Wels GmbH, Wels, Oberösterreich, Austria|A.ö. Landeskrankenhaus Steyr, Steyr, Steiermark, Austria|Bezirkskrankenhaus Kufstein, Endach, Tirol, Austria|A.oe.Bezirkskrankenhaus Hall, Hall, Tirol, Austria|Universitätsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck, Tirol, Austria|Landeskrankenhaus Feldkirch, Feldkirch, Vorarlberg, Austria|LKH Bregenz, Bregenz, Austria|KH Dornbirn, Dornbirn, Austria|A.ö. Landeskrankenhaus Fürstenfeld, Fuerstenfeld, Austria|Universitätsklinikum Graz, Graz, Austria|LKH Hohenems, Hohenems, Austria|Universitaetsklinik Innsbruck, Innsbruck, Austria|Landeskrankenhaus Klagenfurt, Klagenfurt, Austria|A.ö. Landeskrankenhaus Leoben, Leoben, Austria|Krankenhaus der Stadt Linz, Linz, Austria|LKH Weinviertel Mistelbach, Mistelbach, Austria|St. Johanns LK, Salzburg, Austria|KH Barmherzige Brüder, Vienna, Austria|Krankenhaus der Stadt Wien Rudolfsstiftung, Vienna, Austria|AKH Wien / Hämatologie u. Hämostaseologie, Vienna, Austria|Kaiser-Franz-Josef-Spital, Vienna, Austria|Krankenhaus der Stadt Wien Lainz, Vienna, Austria|Hanusch-Krankenhaus, Vienna, Austria|Wilhelminenspital, Vienna, Austria|Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria|LKH Villach, Villach, Austria|LKH Vöcklabruck, Voecklabruck, Austria|KH Waidhofen/Thaya, Waidhofen, Austria|BKH Zams, Zams, Austria|Clinical Centre University Sarajevo, Sarajevo, Bosnia and Herzegovina|University Center Tuzla, Tuzla, Bosnia and Herzegovina|Centro Goiano de Oncologia, Goiania, Brazil|Hospital Santa Izabel, Salvador, Brazil|Hospital das Clinicas FMUSP, Sao Paolo, Brazil|Hospital deas Clinical FMUSP, Sao Paolo, Brazil|UMHAT ""St. George"" Plodviv, Plovdiv, Bulgaria|Nat. Centre of Hematology and Transfusiology Sofia, Sofia, Bulgaria|MHAT ""St. Marina"" Varna, Varna, Bulgaria|Chinese PLA General hospital, Bejing, China|West China Hospital of Sichuan University, Chengdu, China|Harbin Institue, Harbin, China|Jiangsu Cancer Hospital, Nanjing, China|Changhai Hospital, Shanghai, China|Shanghai Ruijin Hospital, Shanghai, China|Clinical Hopital Center Zagreb, Zagreb, Croatia|Clinical Hospital Dubrava, Zagreb, Croatia|Clinicall Hospital ""Merkur"", Zagreb, Croatia|Nemocnice Boskovice s.r.o., Boskovice, Czech Republic|Faculty Hospital Brno, Brno, Czech Republic|Univ. Hospital and Med. School Hradec Kralove, Kralove, Czech Republic|Onkologické Centrum J.G. Mendela, Novi Jicin, Czech Republic|Fakultni Nemocnice Olomouc, Olomouc, Czech Republic|Hospital Opava, Opava, Czech Republic|Fakultni nemocnice Ostrava, Ostrava-Poruba, Czech Republic|Faculty Hospital Binohrady FNKV, Prague, Czech Republic|Charles University Hospital, Praha, Czech Republic|University Hospital Motol, Praha, Czech Republic|RTO MN Usti n. Labem, Usti nad Labem, Czech Republic|North Estonian Regional Hospital, Tallin, Estonia|Tartu University Hospital, Tartu, Estonia|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Soroka Medical Centre, Beer Sheva, Israel|Rambam Medical Centre, Haifa, Israel|Rabin Medical Centre, Petah-Tikva, Israel|Kaplan Medical Centre, Rehovot, Israel|Riga Hematology Center, Riga, Latvia|Clinical Centre Skopje, Skopje, Macedonia, The Former Yugoslav Republic of|Hospital Ampang, Ampang, Malaysia|Hospital University Kebangsaan Malaysia, Kuala Lumpur, Malaysia|ISSSTE Hospital Regional de Leon, Leon, Mexico|Hospital Espanol de Mexico, Mexico City, Mexico|Hospital General de Mexico, Mexico City, Mexico|Instituto National de Cancerologia, Mexico City, Mexico|Hospital Regional Monterrey, ISSTE, Monterrey, Mexico|ISSSTEP Puebla, Puebla, Mexico|Hospital Carlso alberto seguin escobedo Arequipa, Arequipa, Peru|Hospital Alberto Sabogal sooguren Callao, Callao, Peru|Coltea Hospital, Bucharest, Romania|Coltea Hospital, Bucharest, Romania|University Emergency Center Bucharest, Bucharest, Romania|Clinic Judatean de Urgenta Brasov, Targu Mures, Romania|Emergency County Clinical Hospital, Targu Mures, Romania|Belgorod regional Clinical Hospital, Belgorod, Russian Federation|Moscow Regional Clinical Research Institute, Moscow, Russian Federation|Botkin City Clinical Hospital, Moscow, Russian Federation|Novgorod Regional Clinical Hospital, Novgorod, Russian Federation|Leningrad regional Cliniacal Hospital, St. Petersburg, Russian Federation|SPB Pavlov State Medical University, St. Petersburg, Russian Federation|Republican Clinic Oncology Dispensary, Ufa, Russian Federation|Clinical centre of Serbia, Belgrade, Serbia|Clinical Centre Nis, NIs, Serbia|Clinical Centre Novi Sad, Novisad, Serbia|Institute of Oncology Sremska Kamenica, Sremska Kamenica, Serbia|National Cancer Institut Bratislava, Bratislava, Slovakia|OUSA Bratislava, Bratislava, Slovakia|Východoslovenský onkolgický ústav, Kosice, Slovakia|Martinská fakultná nemocnima, Martin, Slovakia|Institut of Oncology Ljubljana, Ljubljana, Slovenia|Hopelands Cancer Centre, Pietremarizburg, South Africa|Wilgers Oncology Centre, Pretoria, South Africa|Falun Hospital, Falun, Sweden|Sunderby Hospital, Lulea, Sweden|Sundsvall Hospital, Sundsvall, Sweden|Uddevalla Hospital, Uddevalla, Sweden|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Taichung Veterans General Hospital, Taipei, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Phramongkutklao College of Medicine, Bangkok, Thailand|Ramathibodi Hospital, Bangkok, Thailand|Siriray Hospital, Bangkok, Thailand|Chiang Mai University, Chiang Mai, Thailand|Srinagarind Hospital, Khon kaen, Thailand|Songklanagrarind Hospital, Songkla, Thailand|Ankara University, School of Medicine, Ankara, Turkey|Osmangazi Univ. school of Medicine, Eskisehir, Turkey|Gaziantep University School of Medicine, Gaziantep, Turkey|Ericyes Univ. Med. School, Kayseri, Turkey","","https://ClinicalTrials.gov/show/NCT00400478"
226,"NCT03346642","Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs",,"Recruiting","No Results Available","Primary Mediastinal Large B-cell Lymphoma","Drug: Decitabine|Drug: GVD chemotherapy|Drug: SHR-1210","Number of Subjects with treatment-related adverse events (AEs)|Objective response rate (ORR)|Complete response (CR) rate|Median progression-free survival (PFS) time|Median overall survival (OS) time","Chinese PLA General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-025","June 1, 2017","June 1, 2018","October 1, 2018","November 17, 2017","null","November 20, 2017","Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China|Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03346642"
227,"NCT00717925","Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)",,"Completed","No Results Available","Lymphoma, B-Cell","Drug: Inotuzumab Ozogamicin (CMC-544)","Incidence and severity of adverse events, dose-limiting toxicities, and changes in laboratory test results.|Tumor response (according to the International Response Criteria for Non-Hodgkin's Lymphomas).","Wyeth is now a wholly owned subsidiary of Pfizer","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3129K1-103","March 2007","July 2008","July 2008","July 18, 2008","null","December 9, 2015","","","https://ClinicalTrials.gov/show/NCT00717925"
228,"NCT03029338","CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma",,"Recruiting","No Results Available","Lymphomas Non-Hodgkin's B-Cell|Relapse","Biological: CD19 CAR T cells","Number of patients with adverse events|Severity of the adverse events|Response rate|Progression-free survival(PFS)|Persistence of CAR T cells in vivo","Institute of Hematology & Blood Diseases Hospital|Union Stem cell & gene engineering Co.LTD","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XH-CD19CART-002","November 2016","November 2018","November 2019","January 24, 2017","null","January 24, 2017","Institute of Hematology & Blood Diseases Hospital, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03029338"
229,"NCT01523834","Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT","FIL_PanAL10","Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Panobinostat","Overall response rate (ORR) at the end of the induction phase|Complete Response (CR) Rate|Time to response (TTR)|Progression Free Survival (PFS)|Overall toxicity measured by CTCAE v.4|Overall Survival (OS)","Fondazione Italiana Linfomi ONLUS","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_PanAL10|2011-000175-13","February 2011","January 2014","January 2014","February 1, 2012","null","August 4, 2016","Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy|Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola, Bologna, Italy|Spedali Civili, Brescia, Italy|Ematologia I, A.O.U. San Martino, Genova, Italy|Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Italy|Divisione di Ematologia Università Avogadro, Novara, Italy|AO Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy|A.O. Città della Salute e della Scienza (Ematologia Univ), Torino, Italy|A.O. Città della salute e della scienza (S.C. Ematologia), Torino, Italy|AO Universitaria di Udine, Udine, Italy","","https://ClinicalTrials.gov/show/NCT01523834"
230,"NCT02054559","R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL","ASPIRE","Withdrawn","No Results Available","Diffuse Large B-cell Lymphoma","Drug: R-CHOP|Radiation: Radiotherapy","To compare 3-year event-free survival|To evaluate and compare OS between the two arms|To evaluate and compare the ORR and CR rate|To evaluate and compare disease-free survival (DFS)|To evaluate treatment-failure pattern|Number of Participants with Adverse Events in each arm|To assess patient-reported outcomes (PROs) in both arms|A role of interim PET after 3 cycles of R-CHOP chemotherapy: correlation with PFS and OS","Asan Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC_NHL02","null","January 2020","January 2020","February 4, 2014","null","February 23, 2016","Asan Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02054559"
231,"NCT01925612","Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)",,"Terminated","Has Results","Lymphoma, B-cell|Lymphoma, Large B-cell, Diffuse","Drug: brentuximab vedotin|Drug: rituximab|Drug: vincristine|Drug: cyclophosphamide|Drug: prednisone|Drug: doxorubicin","Complete Remission Rate|Incidence of Adverse Events|Incidence of Laboratory Abnormalities|Objective Response Rate|Progression-free Survival|Overall Survival","Seattle Genetics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN35-017","August 2013","May 1, 2017","May 1, 2017","August 20, 2013","June 21, 2018","June 21, 2018","Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|City of Hope National Medical Center, Duarte, California, United States|Sansum Clinic, Santa Barbara, California, United States|Stanford Cancer Center, Stanford, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|Augusta University, Augusta, Georgia, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|Illinois Cancer Specialists / Advocate Lutheran General Hospital, Niles, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins Medical Center, Baltimore, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Billings Clinic Cancer Research, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Summit Medical Group, Morristown, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Mid Ohio Oncology/Hematology Inc, Columbus, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Saint Francis Hospital / Bon Secours, Greenville, South Carolina, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States|US Oncology Investigational Products Center (IPC), Fort Worth, Texas, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|US Oncology Central Regulatory, The Woodlands, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Benaroya Research Institute/Virginia Mason Medical Center, Seattle, Washington, United States|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie, Hradec Kralove, Czechia|Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Centro di Riferimento Oncologico di Aviano, Aviano, Italy|Instituto di Ematologia ed Oncologia Medica, Bologna, Italy|Azienda Ospedaliero-Universitaria Pisana - Ospedale S. Chiara, Pisa, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|COPERNICUS Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, Poland|Malopolskie Centrum Medyczne S.C., Krakow, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim, Olsztyn, Poland|Hospital de la Santa Creu i Sant Paul, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Institut Català D'oncologia, L'Hospitalet de Llobregat, Spain|Complejo Hospitalano de Navarra Servicio Hematologia, Pamplona, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT01925612/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT01925612/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01925612"
232,"NCT03656835","Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma","Procedure: Molecular Nanotechnology","Treatment response|Early detection of relapse","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OSU-18154|NCI-2018-01536|P30CA016058","September 26, 2018","December 31, 2021","December 31, 2021","September 3, 2018","null","October 2, 2018","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03656835"
233,"NCT03259529","Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL","BeGeRN","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Bendamustine hydrochloride|Drug: Gemcitabine 500 mg|Drug: Gemcitabine 700 mg|Drug: Gemcitabine 1000 mg|Drug: Nivolumab|Drug: Rituximab","The recommended phase 2 dose (RP2D)|Overall Response Rate (ORR)|Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03|Duration of Response (DOR)|Progression-Free Survival (PFS)|Overall Survival (OS)","St. Petersburg State Pavlov Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DLBCL BeGeRN 1/2","March 27, 2017","December 27, 2019","December 27, 2020","August 23, 2017","null","September 6, 2018","First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation","","https://ClinicalTrials.gov/show/NCT03259529"
234,"NCT01679119","Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","INCA","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisolone|Drug: Rituximab|Drug: Inotuzumab Ozogamicin|Drug: Gemcitabine","Progression free survival|Overall response rate|Overall Survival|Treatment toxicity|Quality of life|Performance status post treatment|Co-morbidities of patients","University College, London|Pfizer|Cancer Research UK","All","18 Years and older   (Adult, Older Adult)","Phase 2","132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL 11/0475","October 2013","October 2018","April 2021","September 5, 2012","null","May 3, 2018","Stoke Mandeville Hospital (including Wycombe Hospital), Aylesbury, United Kingdom|North Hampshire Hospital, Basingstoke, United Kingdom|Royal United Hospital, Bath, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Bristol Oncology Centre, Bristol, United Kingdom|West Suffolk Hospital, Bury St Edmunds, United Kingdom|Castle Hill Hospital, Cottingham, United Kingdom|University Hospital, Coventry, Coventry, United Kingdom|Darent Valley Hospital, Dartford, United Kingdom|Royal Devon & Exeter Hospital, Exeter, United Kingdom|Medway Maritime Hospital, Gillingham, United Kingdom|Beatson West of Scotland Cancer Centre (including Gartnavel Royal Hospital), Glasgow, United Kingdom|James Paget University Hospital, Great Yarmouth, United Kingdom|Northwick Park Hospital, Harrow, United Kingdom|Kent and Canterbury Hospital, Kent, United Kingdom|Kettering General Hospital, Kettering, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Aintree University Hospital, Liverpool, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Guy's Hospital (including St Thomas's Hospital), London, United Kingdom|Royal Free Hospital, London, United Kingdom|University College London Hospital, London, United Kingdom|Luton and Dunstable Hospital, Luton, United Kingdom|Christie Hospital, Manchester, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|North Tyneside Hosptial (including Wansbeck Hospital and Hexham General Hospital), North Shields, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Princess Royal University Hospital, Orpington, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Queen's Hospital, Romford, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Kings Mill Hospital, Sutton-in-Ashfield, United Kingdom|Torbay Hospital, Torquay, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Royal Hampshire County Hospital, Winchester, United Kingdom|Worcester Royal Hospital (including Kidderminster Hospital and Alexandra Hospital), Worcester, United Kingdom|Wythenshawe Hospital (including Trafford General Hospital), Wythenshawe, United Kingdom","","https://ClinicalTrials.gov/show/NCT01679119"
235,"NCT03072771","Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Blinatumomab|Procedure: Autologous stem cell transplant|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Procedure: Peripheral blood draws","Feasibility and tolerability of blinatumomab consolidation post auto-SCT as measured by percentage of patients who can finish a full course of blinatumomab post-auto-SCT|Progression-free survival (PFS)|Overall survival|Complete remission rate in patients with residual disease after auto-SCT","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201704108","August 1, 2017","January 31, 2019","September 30, 2021","March 7, 2017","null","March 29, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03072771"
236,"NCT01670370","Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.",,"Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: R-GemOx","overall response rate|progression free survival|overall survival|The incidence and severity of adverse events","The First Affiliated Hospital with Nanjing Medical University","All","60 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JSPH-001","August 2012","December 2015","December 2018","August 22, 2012","null","April 11, 2018","","","https://ClinicalTrials.gov/show/NCT01670370"
237,"NCT01653067","STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma","STORM","Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab, Temsirolimus, DHAP, intravenous","Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)","Mathias Witzens-Harig|Johannes Gutenberg University Mainz|Technische Universität München|Ludwig-Maximilians - University of Munich|University Hospital Ulm|University Hospital Erlangen|Charite University, Berlin, Germany|University Hospital Freiburg|Johann Wolfgang Goethe University Hospital|University Hospital Heidelberg","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STORM-2011|2011-001491-20","September 2012","June 2018","July 2018","July 30, 2012","null","October 27, 2016","University Hospital Freiburg, Freiburg, Baden-Württemberg, Germany|University of Heidelberg Hospital, Heidelberg, Baden-Württemberg, Germany|University Hospital Ulm, Ulm, Baden-Württemberg, Germany|University Hospital Erlangen, Erlangen, Bayern, Germany|Ludwig-Maximilians-University of Munich, Munich, Bayern, Germany|Technische Universität München, Munich, Bayern, Germany|Johann Wolfgang Goethe University Hospitals, Frankfurt, Frankfurt, Hessen, Germany|Johannes Guttenberg University Mainz, Mainz, Rheinland-Pfalz, Germany|Charité University Berlin, Berlin, Germany","","https://ClinicalTrials.gov/show/NCT01653067"
238,"NCT03305445","Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL",,"Recruiting","No Results Available","Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: Ipilimumab|Drug: Nivolumab","Dose Limiting Toxicities (DLTs)|Completion Remission (CR) Rate|Progression Free Survival (PFS)|Overall Survival (OS)|IgVH level|Delayed CR|Overall Response Rate (ORR)","Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 17-2164","May 14, 2018","February 1, 2020","April 1, 2020","October 10, 2017","null","May 24, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03305445"
239,"NCT02734771","A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","BV mini CHP","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Brentuximab vedotin|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone","Percent of Subjects Completing Regimen|Overall Survival|Progression Free Survival|Overall Response Rate|Complete Response Rate","Patrick Reagan|Seattle Genetics, Inc.|University of Rochester","All","75 Years and older   (Older Adult)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ULYM15105|IST-2014-100578","June 2016","June 2019","June 2021","April 12, 2016","null","September 14, 2018","James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02734771"
240,"NCT01859819","Treatment for Advanced B-Cell Lymphoma","REBOOT","Recruiting","No Results Available","Diffuse Large Cell Lymphoma|Burkitt's Lymphoma|High Grade B-cell Lymphoma","Drug: Rituximab|Drug: IT Cytarabine","To determine if disease response rate will improve with this combination of therapy.|To determine if the combination of IT Depocyte®, Rituximab and FAB Chemotherapy is safe.","New York Medical College","All","3 Years to 31 Years   (Child, Adult)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NYMC-157|L 10,753","January 2013","December 2018","December 2019","May 22, 2013","null","March 29, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States|New York Medical College, Valhalla, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01859819"
241,"NCT00498914","Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects",,"Terminated","No Results Available","Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell Refractory","Drug: YM155","Overall response rate|Safety, efficacy, pharmacokinetics, and tolerability","Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","155-CL-009|Eudra CT 2006-002584-70","June 2007","April 2009","April 2009","July 11, 2007","null","September 4, 2015","Beverly Hills, California, United States|Palo Alto, California, United States|Aurora, Colorado, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Shreveport, Louisiana, United States|St Louis, Missouri, United States|Winston-Salem, North Carolina, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|San Antonio, Texas, United States|Ottawa, Ontario, Canada|Bordeaux, France|Montpellier, France|Nantes, France|Nice, France|Poitiers, France|Rouen, France|Tours, France|Barcelona, Spain|Madrid, Spain","","https://ClinicalTrials.gov/show/NCT00498914"
242,"NCT01516567","Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation",,"Active, not recruiting","No Results Available","Primary Mediastinal Large B Cell Lymphoma","Drug: Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab","Event free survival|Survival|Acute toxicity|Long term toxicity","Gustave Roussy, Cancer Campus, Grand Paris|Children's Oncology Group","All","6 Months to 17 Years   (Child)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Inter B-NHL Ritux 2010 Phase 2|2010-019224-31","December 1, 2011","April 2016","April 2019","January 25, 2012","null","August 2, 2017","University Hospitals Leuven, Leuven, Belgium|Children Oncology Group Operations centres, Monrovia, Canada|Gustave Roussy, Villejuif, France|2nd Dept. of Pediatrics Semmelweis Univ., Budapest, Hungary|Associazione Italiana di Ematologia ed Oncologia Pediatrica, Padova, Italy|Emma Children's Hospital, Amsterdam, Netherlands|Rectorat of Medical University, Wroclaw, Poland|Sociedad Española de Hematología y Oncología Pediátricas, Valencia, Spain|University of Birmingham, Birmingham, United Kingdom","","https://ClinicalTrials.gov/show/NCT01516567"
243,"NCT01279902","Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Rituximab plus CHOP Immunochemotherapy","Disease-free survival|Overall survival|any adverse events as a measure of safety and tolerability","Asan Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC_NHL01","August 2010","August 2016","January 2017","January 20, 2011","null","July 26, 2016","Asan Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01279902"
244,"NCT02252146","Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation",,"Completed","Has Results","Diffuse Large B Cell Lymphoma","Drug: IMO-8400","Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications","Idera Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8400-402","June 2014","December 2016","December 2016","September 30, 2014","November 14, 2017","December 12, 2017","UCLA Medical Center, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|Cancer Care Specialists of Illinois, Decatur, Illinois, United States|Horizon Bio Advance, Lafayette, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02252146/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02252146/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02252146"
245,"NCT03136497","A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: ABT-199|Drug: Ibrutinib|Drug: Rituximab","Maximum tolerated dose (MTD)|Incidence of treatment-emergent adverse events.|Efficacy as assessed by progression free survival (PFS)|Efficacy as assessed by overall survival (OS)","Hackensack Meridian Health|Janssen Scientific Affairs, LLC|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00005671|54179060LYM1004|ML30063","September 5, 2017","May 30, 2020","May 30, 2020","May 2, 2017","null","July 9, 2018","John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT03136497"
246,"NCT03456726","Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation",,"Recruiting","No Results Available","Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","Drug: Tazemetostat","Objective response rate (ORR)|Progression-free survival (PFS)|Duration of response (DOR)|Time to response (TTR)|Number of participants with any adverse event, as an assessment of safety","Eisai Co., Ltd.|Eisai Inc.","All","20 Years and older   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7438-J081-206","April 9, 2018","September 30, 2020","September 30, 2020","March 7, 2018","null","August 28, 2018","1004 Eisai Trial Site, Nagoya, Aichi, Japan|1029 Eisai Trial Site, Nagoya, Aichi, Japan|1020 Eisai Trial Site, Ota, Gunma, Japan|1007 Eisai Trial Site, Sapporo, Hokkaido, Japan|1019 Eisai Trial Site, Kobe, Hyogo, Japan|1005 Eisai Trial Site, Tsukuba, Ibaraki, Japan|1002 Eisai Trial Site, Isehara, Kanagawa, Japan|1028 Eisai Trial Site, Yokohama, Kanagawa, Japan|1021 Eisai Trial Site, Sendai, Miyagi, Japan|1013 Eisai Trial Site, Osakasayama, Osaka, Japan|1006 Eisai Trial Site, Suita, Osaka, Japan|1027 Eisai Trial Site, Suntou-gun, Shizuoka, Japan|1014 Eisai Trial Site, Shimotsuke, Tochigi, Japan|1026 Eisai Trial Site, Bunkyo-ku, Tokyo, Japan|1001 Eisai Trial Site, Chuo-ku, Tokyo, Japan|1025 Eisai Trial Site, Koto-ku, Tokyo, Japan|1017 Eisai Trial Site, Minato-ku, Tokyo, Japan|1022 Eisai Trial Site, Aomori, Japan|1010 Eisai Trial Site, Chiba, Japan|1012 Eisai Trial Site, Fukuoka, Japan|1016 Eisai Trial Site, Fukuoka, Japan|1011 Eisai Trial Site, Hiroshima, Japan|1024 Eisai Trial Site, Kumamoto, Japan|1003 Eisai Trial Site, Kyoto, Japan|1008 Eisai Trial Site, Kyoto, Japan|1023 Eisai Trial Site, Nagasaki, Japan|1009 Eisai Trial Site, Okayama, Japan|1015 Eisai Trial Site, Osaka, Japan|1018 Eisai Trial Site, Yamagata, Japan","","https://ClinicalTrials.gov/show/NCT03456726"
247,"NCT01724294","An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","Diffuse Large B-Cell Lymphoma","","Treatment patterns in clinical practice: Number of treatment cycles received|Event-free survival|Response rates|Safety: Incidence of adverse events","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","","113","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28497","December 2012","April 2016","April 2016","November 9, 2012","null","November 2, 2016","Bucuresti, Romania","","https://ClinicalTrials.gov/show/NCT01724294"
248,"NCT03009344","A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","Drug: tazemetostat","Dose-limiting toxicity (DLT) of tazemetostat during Cycles 0 and 1|Objective response rate (ORR) based on The Lugano Classification (CT-Based Response)|Mean maximum concentration (Cmax) of tazemetostat in blood|Mean time to reach maximum concentration (Tmax) of tazemetostat in blood|Mean area under the drug concentration-time curve (AUC) after first administration of tazemetostat in blood|Mean area under the drug concentration-time curve (AUC) after repeated administration of tazemetostat in blood|Mean maximum concentration (Cmax) of ER-897387 in blood|Mean time to reach maximum concentration (Tmax) of ER-897387 in blood|Mean area under the drug concentration-time curve (AUC) after first administration of ER-897387 in blood|Mean area under the drug concentration-time curve (AUC) after repeated administration of ER-897387 in blood|Number of participants with any serious adverse event and number of participants with any non-serious adverse event","Eisai Co., Ltd.|Eisai Inc.","All","20 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7438-J081-106","January 23, 2017","July 12, 2017","September 1, 2018","January 4, 2017","null","August 28, 2018","Eisai Trial Site, Isehara, Kanagawa, Japan|Eisai Trial Site, Chuo-ku, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT03009344"
249,"NCT03349346","Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma","Drug: Idelalisib|Drug: Rituximab|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide","Incidence Rate of Dose Limiting Toxicities (DLTs)|Proportion of Participants Experiencing Adverse Events (AEs)|Proportion of Participants Experiencing Serious Adverse Events (SAEs)|Proportion of Participants Experiencing Adverse Events (AEs) Leading to Idelalisib Interruption, Idelalisib Dose Reduction, Premature Discontinuation of Idelalisib, or Death|Rate of Grade ≥ 3 Transaminase Elevations Based on Laboratory Findings|Overall Response Rate (ORR)|Overall Survival (OS)|Progression-Free Survival (PFS)|Pharmacokinetic Parameter: Cmax of Idelalisib|Pharmacokinetic Parameter: Cmax of GS-563117|Pharmacokinetic Parameter: Ctrough of Idelalisib|Pharmacokinetic Parameter: Ctrough of GS-563117|Pharmacokinetic Parameter: Area Under the Concentration-Time Curve (AUC) of Idelalisib|Pharmacokinetic Parameter: Area Under the Concentration-Time Curve (AUC) of GS-563117|Levels of Optional Exploratory Biomarkers on Bone Marrow Samples (eg pAKT, pS6 ribosomal protein) and plasma cytokines|Acceptability and Palatability of Idelalisib 10-mg Dispersible Tablet","Gilead Sciences","All","1 Year to 18 Years   (Child, Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-313-1090|2017-001468-39","October 2018","February 2021","February 2026","November 21, 2017","null","September 11, 2018","Centre Hospitalier Régional Universitaire de Lille, Lille, France|Istituto Giannina Gaslini, Genova, Italy|Ospedale Pediatrico Bambino Gesu, Roma, Italy|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital Universitario HM Monteprincipe, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT03349346"
250,"NCT03610061","A Trial of Radiotherapy and Durvalumab in DLBCL","RaDD","Not yet recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Durvalumab|Radiation: Radiotherapy","Number of participants treated with radiotherapy and durvalumab with treatment-related adverse events as assessed using CTCAE v4.0. To determine the maximum tolerated dose (MTD).|Response rates (according to the Lugano classification for Response Criteria for Non-Hodgkin Lymphoma)|Progression free survival|Overall survival","Austin Health|Olivia Newton-John Cancer Research Institute|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONJ2017-003-DV-008259|TRP16-006","September 2018","February 2021","February 2023","August 1, 2018","null","August 1, 2018","","","https://ClinicalTrials.gov/show/NCT03610061"
251,"NCT03639181","Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)",,"Recruiting","No Results Available","B-cell Non-Hodgkin's Lymphoma","Biological: GB226","ORR|PFS|DOR|DCR|Assessment of safety parameters|Immunogenicity of Gxplore-003","Genor Biopharma Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","53","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Gxplore-003","June 15, 2018","September 30, 2018","December 30, 2020","August 21, 2018","null","August 21, 2018","Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03639181"
252,"NCT00204659","Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma",,"Completed","No Results Available","Primary Gastric Diffuse-Large B-Cell Lymphoma","Drug: Rituximab + CHOP chemotherapy","Complete remission rate|Progression-free survival|Overall survival|Toxicity","University Hospital Tuebingen|Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","64-03","March 2003","September 2008","September 2008","September 20, 2005","null","October 20, 2008","Zentralklinikum Augsburg, Augsburg, Germany|University of Giessen, Giessen, Germany|Klinikum Reutlingen, Reutlingen, Germany|University of Tubingen, Tuebingen, Germany|Schwarzwald-Baar Clinic, Villingen-Schwenningen, Germany","","https://ClinicalTrials.gov/show/NCT00204659"
253,"NCT03311958","Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Nivolumab, IV, 240 mg","Evaluation of the rate of conversion from positive to negative ctDNA in nivolumab treated patients|To evaluate adverse events in patients on nivolumab as maintenance drug in post-induction, post-salvage and post-autologous transplant setting|Relapse free survival (RFS-ctDNA) for nivolumab treated patients|Proportion of patients who are able to convert from ctDNA positive to ctDNA negative after nivolumab treatment|To compare the ctDNA results of Clonoseq and Neolabs platform","Fox Chase Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM-110","May 15, 2018","April 15, 2019","April 15, 2021","October 17, 2017","null","May 18, 2018","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03311958"
254,"NCT02423291","A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL","FIL_SGN01","Completed","Has Results","Primary Mediastinal Large B Cell Lymphoma","Drug: Brentuximab Vedotin","Overall Objective Response Rate in Patients With Relapsed or Refractory PMLBCL","Fondazione Italiana Linfomi ONLUS","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_SGN01","October 2013","July 2016","July 2016","April 22, 2015","June 26, 2017","June 26, 2017","S.C. Ematologia A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria, AL, Italy|Unità funzionale di Ematologia A.O.U. Careggi, Firenze, FI, Italy|Dip. Oncologia, Ematologia e Patologie dell'apparato respiratorio A.O.U. Policlinico di Modena, Modena, MO, Italy|Divisione di Ematologia Azienda Ospedaliera ""Bianchi Melacrino Morelli"", Reggio Calabria, RC, Italy|S. C. Ematologia IRCCS Azienda Ospedaliera Arcispedale ""S.Maria Nuova"", Reggio Emilia, RE, Italy|S.C.D.O. Ematologia 2 A.O. Città della Salute e della Scienza, Torino, TO, Italy|Istituto di Ematologia L. & A. Seragnoli, Bologna, Italy|Ematologia Ospedale Businco, Cagliari, Italy|Dipartimento di Biotecnologie Cellulari ed Ematologia Università ""La Sapienza"", Roma, Italy","","https://ClinicalTrials.gov/show/NCT02423291"
255,"NCT01340443","An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma",,"Completed","No Results Available","Diffuse Large B-Cell Lymphoma","","Safety: Incidence of adverse events|Overall Response Rate (complete response + partial response)|Progression-free survival, defined as time from first treatment to lymphoma progression or death|Overall Survival, defined as time from 1st treatment to death of any cause","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","","314","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25435","January 19, 2011","July 15, 2016","July 15, 2016","April 22, 2011","null","November 14, 2017","The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, China|the First Hospital of Jilin University, Changchun, China|Xiangya Hospital of Centre-South University, Changsha, China|Changzhou First People's Hospital, Changzhou, China|Daqing Oilfield General Hospital, Daqing, China|The First People's Hospital of Foshan, Foshan, China|Fuzhou General Hospital, PLA Nanjing Military Area Command, Fuzhou, China|Fujian Provincial Hospital, Fuzhou, China|Nanfang Hospital, Southern Medical University, Guangzhou, China|The affiliated Hospital of Guiyang Medical College, Guiyang, China|The Second Affiliated Hospital of Zhejiang University College, Hangzhou, China|Anhui Province Cancer Hospital, Hefei, China|Affiliated Hospital of Inner Mongolia Medical College, Hohhot, China|Shandong Cancer Hospital, Jinan, China|The First Affilliated Hospital of Kunming Medical College, Kunming, China|Lanzhou General Hospital, PLA Lanzhou Military Area Command, Lanzhou, China|Jiangsu Cancer Hospital, Nanjing, China|Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province), Shijiazhuang, China|Shanxi Province Cancer Hospital, Taiyuan, China|Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan, China|The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital), Xi'an, China|Henan Cancer Hospital, Zhengzhou, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China|Zhongshan General Hospital, Zhongshan, China","","https://ClinicalTrials.gov/show/NCT01340443"
256,"NCT03201471","Chidamide With R-CHOP Regimen for DLBCL Patients","DLBCL","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Chidamide + R-CHOP regimen","complete remission rate|progression free survival|overall survival|adverse events","First Affiliated Hospital of Zhejiang University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","lymphoma center Q001","August 20, 2017","December 30, 2019","February 5, 2020","June 28, 2017","null","August 2, 2018","The first affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03201471"
257,"NCT03105596","Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)",,"Not yet recruiting","No Results Available","B-cell Non-Hodgkin's Lymphoma","Drug: Chidamide plus DICE Regimen","objective response rate（ORR）|progression-free survival（PFS）|events-free survival（EFS）|overall survival（OS）","Peking University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Chidamide plus DICE","April 11, 2017","September 30, 2018","September 30, 2019","April 10, 2017","null","April 11, 2017","","","https://ClinicalTrials.gov/show/NCT03105596"
258,"NCT02890602","Erythropoietin for Management of Anemia Caused by Chemotherapy",,"Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Darbepoetin alfa|Drug: R-CHOP","Hematopoietic response|Quality of life as measured by Functional Assessment of Cancer Therapy Scales for anemia|Adverse events as measured by CTCAE v3.0|Proportion of patients requiring red blood cell transfusions|Mean time to response of hemoglobin","Kosin University Gospel Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","EPOMA","September 2012","December 31, 2018","December 31, 2018","September 7, 2016","null","August 8, 2018","","","https://ClinicalTrials.gov/show/NCT02890602"
259,"NCT03263026","Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Enzastaurin Hydrochloride|Other: R-CHOP + placebo","Overall survival in subjects who possess the DGM1™ biomarker|Overall survival in subjects who do not possess the DGM1™ biomarker|Safety of enzastaurin by assessing incidence of adverse events/serious adverse events, change of vital signs, ECG results, lab results, and physical exam findings from baseline","Denovo Biopharma LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","235","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DB102-02","March 20, 2018","October 2020","September 2021","August 28, 2017","null","October 2, 2018","Oncology Specialties: Clearview Cancer Institute, Huntsville, Alabama, United States|Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, United States|Christiana Care Health Services, Inc, Newark, Delaware, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare, Peoria, Illinois, United States|Orchard Healthcare Research, Skokie, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Norton Cancer Institute Oncology Practices - St. Matthews Location, Louisville, Kentucky, United States|Regional Cancer Care Associates, MD, Bethesda, Maryland, United States|Minnesota Oncology Hematology Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Summit Medical Group, Morristown, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|New York Medical College, Hawthorne, New York, United States|Laura & Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Hematology & Oncology Associates, Inc., Canton, Ohio, United States|Mid Ohio Oncology/Hematology Inc., Columbus, Ohio, United States|Tri-County Hematology & Oncology Associates, Inc., Massillon, Ohio, United States|Toledo Clinic Cancer Centers, Toledo, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center - Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Baylor Scott and White University Medical Center, Dallas, Texas, United States|Oncology Consultants: Memorial City, Houston, Texas, United States|Baylor College of Medicine (BCM) - Baylor Clinic, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Center Alliance, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Vince Lombardi Cancer Center (Aurora St. Luke's Medical Center), Milwaukee, Wisconsin, United States|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital (Hematology Dept), Beijing, China|JiLin Cancer Hospital（Lymphoma hematology Dept), Changchun, China|West China Hospital of Sichuan University (Hematology Dept), Chengdu, China|Second Affiliated Hospital of Dalian Medical University, Dalian, China|Fujian Medical University Union Hospital, Fuzhou, China|GuangDong General Hospital, Guangzhou, China|ZheJiang Cancer Hospital ( Lymphoma Dept), Hangzhou, China|Harbin Medical University Cancer Hospital (Oncology Internal), Harbin, China|Fudan University Shanghai Cancer Hospital, Shanghai, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|The First Affiliated Hospital of Medical School of Zhejiang University (Hematology Dept), Zhejiang, China|HeNan Cancer Hospital (Hematology Dept), Zhengzhou, China|The First Affiliated Hospital of ZhengZhou University (Oncology Dept), Zhengzhou, China","","https://ClinicalTrials.gov/show/NCT03263026"
260,"NCT00466258","LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)","LINFOTARGAM","Completed","No Results Available","HIV Infections|Diffuse Large B Cell Lymphoma","Drug: R-CHOP|Drug: Highly active antiretroviral therapy|Drug: Central nervous system (CNS) prophylaxis|Drug: Prophylaxis of opportunistic infections and support treatment","treatment toxicity according to the CTC criteria (version 3.0) of the National Cancer Institute (NCI)|opportunistic and non-opportunistic infections rate after 6 cycles of treatment with R-CHOP administered every 14 days and HAART in patients with DLBCL and HIV infection|adherence to the treatment with 6 cycles of R-CHOP considering the delays in the administration of the cycles and the reductions in the doses of chemotherapy (planned dose administered in predicted term)|efficacy of the treatment in patients with DLBCL and HIV infection after 6 cycles of treatment with R-CHOP administered every 14 days|global response and complete remission rate|duration of the response|event-free survival probability in 5 years|global survival probability in 5 years|predictive factors of the response after 6 cycles of treatment with R-CHOP administered every 14 days in patients with DLBCL and HIV infection|impact of the therapeutic combination of R-CHOP and HAART in the parameters of the HIV infection (HIV viral load and CD4+ lymphocyte count)","PETHEMA Foundation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-003750-23|LINFOTARGAM","October 2006","May 2009","November 2009","April 27, 2007","null","November 25, 2009","H. Son Llatzer, Palma de Mallorca, Baleares, Spain|Germans Trias i Pujol, Badalona, Barcelona, Spain|Consorci Sanitari de Mataró, Mataro, Barcelona, Spain|H. Parc Taulí, Sabadell, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|H. Clínic i Provincial, Barcelona, Barcelona, Spain|H. Vall d'Hebron, Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Sant Pau, Barcelona, Barcelona, Spain|ICO - Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain|ICO - Josep Trueta, Girona, Spain|H. Gregorio Marañón, Madrid, Spain|H. Joan XXIII, Tarragona, Spain|Hospital Universitario Dr. Peset, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT00466258"
261,"NCT01693614","Safety and Efficacy of BKM120 in Relapsed and Refractory NHL",,"Completed","Has Results","Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma","Drug: Buparlisib","Overall Response Rate (ORR) and Disease Control Rate (DCR) Per Investigator at 6 Months (FAS)|Progression- Free Survival (PFS) Based on Investigator Assessment (FAS)|Duration of Response for Diffuse Large B-cell Lymphoma (DLBCL), and Follicular Lymphoma (FL) Cohorts (FAS)|Overall Survival (OS) - Percentage of Participants With OS Events (FAS)|Percentage of Participants - Overall Survival- Kaplan Meier Estimates (FAS)|Overall Survival - Median (FAS)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBKM120Z2402|2012-002208-41","February 28, 2013","July 21, 2017","July 21, 2017","September 26, 2012","September 28, 2018","September 28, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center Univ Nebraska, Omaha, Nebraska, United States|Memorial Sloan Kettering Dept of Onc., New York, New York, United States|Medical University of South Carolina -Hollings Cancer Center Medical Univ of South Carolina, Charleston, South Carolina, United States|University of Texas MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston, Texas, United States|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Pierre-Benite Cedex, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Wurzburg, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Gyeonggi-do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Samsun, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT01693614/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT01693614/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01693614"
262,"NCT03671018","A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","B-cell Non-Hodgkin Lymphoma","Drug: Mosunetuzumab|Drug: Polatuzumab vedotin|Drug: Rituximab|Drug: Bendamustine|Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Tocilizumab","Complete Response (CR) Rate Based on Positron Emission Tomography-Computed Tomography (PET-CT), as Assessed Using Standard Criteria for non-Hodgkin Lymphoma (NHL)|Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab Vedotin|Recommended Phase II Dose of Mosunetuzumab in Combination with Ploatuzumab Vedotin|Percentage of Participants with Adverse Events (AE)|CR Rate Based on PET-CT, as Assessed Using Standard Criteria for NHL|CR Rate Based on CT Only, as Assessed Using Standard Criteria for NHL|Objective Response Rate (ORR), Defined as CR or PR, Based on PET-CT as Assessed Using Standard Criteria for NHL|Best ORR (CR or PR at any Time) Based on PET-CT or CT Only, as Assessed Using Standard Criteria for NHL|Duration of Response (DOR) as Assessed Using Standard Criteria for NHL|Progression-Free Survival (PFS) as Assessed Using Standard Criteria for NHL|Event-Free Survival (EFS) as Assessed Using Standard Criteria for NHL|Overall Survival (OS)|Time to Deterioration in Health Related Quality of Life|Anti-Drug Antibodies (ADAs) to Mosunetuzumab|ADAs to Polatuzumab Vedotin|Mosunetuzumab Serum Concentration","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO40516|2018-001141-13","September 25, 2018","April 30, 2023","September 28, 2023","September 14, 2018","null","October 1, 2018","City of Hope, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT03671018"
263,"NCT02857998","A Study of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms",,"Recruiting","No Results Available","Mature B-cell Neoplasms","Drug: HMPL-523","Dose limited toxicities evaluated with NCI CTCAE v4.03|Maximum plasma concentration calculated with Blood samples|Time to reach maximum concentration calculated with Blood samples|Objective response rate|Adverse events evaluated by NCI CTCAE v4.03","Hutchison Medipharma Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","92","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-523-00CH1","December 27, 2016","February 2020","February 2020","August 5, 2016","null","February 26, 2018","BeijingCancer Hospital, Beijing, Beijing, China|Fudan University Shanghai Cancer Hospital, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02857998"
264,"NCT03364439","R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients","FIL_DLCL10","Active, not recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Treatment plan","PFS Progression Free Survival|OS Overall Survival","Fondazione Italiana Linfomi ONLUS","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","112","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_DLCL10","January 2012","April 2018","June 2019","December 6, 2017","null","May 1, 2018","A.O. Niguarda, Milano, MI, Italy|Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, PZ, Italy|A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy|A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona, Ancona, Italy|Centro di riferimento Oncologico Oncologia Medica A, Aviano, Italy|Ospedale Degli Infermi - S.C. Oncologia, Biella, Italy|A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy|PO Perrino, Brindisi, Italy|Ospedale Businco, Cagliari, Italy|Ospedale di Castelfranco Veneto - Ematologia, Castelfranco Veneto, Italy|Osp.Generale Di Zona Valduce, Como, Italy|Ospedale Vito Fazzi - Ematologia, Lecce, Italy|Ospedali Riuniti Papardo, Messina, Italy|Osp. San Carlo Borromeo Divisione di Oncologia Medica, Milano, Italy|A.O. Universitaria Maggiore Della Carita' Di Novara, Novara, Italy|AOU di Parma - UO Ematologia e CTMO, Parma, Italy|Ausl Di Piacenza, Piacenza, Italy|AO Arcispedale S.Maria Nuova Ematologia, Reggio Emilia, Italy|Istituto Clinica Humanitas, Rozzano (MI), Italy|A.O.U. Citta della Salute e della Scienza di Torino - SC Ematologia, Torino, Italy|A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria, Torino, Italy","","https://ClinicalTrials.gov/show/NCT03364439"
265,"NCT01729806","Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma",,"Completed","No Results Available","CD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma","Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Rituximab","Incidence of toxicities according to the Common Terminology Criteria for Adverse Events version 4|Immune response as measured by the frequency of activated T-cells, absolute lymphocyte count, antibody dependent cell-mediated cytotoxicity, and kinetics and magnitude of B-cell depletion|Clinical anti-tumor response (complete response and partial response as per international workshop lymphoma response criteria [Cheson 2007])|Progression-free survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02213|PHI-69|CDR0000743246|NCI# 9197|9197|P30CA033572|U01CA062505|UM1CA186704|UM1CA186717","November 19, 2012","March 30, 2018","March 30, 2018","November 20, 2012","null","April 11, 2018","City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01729806"
266,"NCT02758925","CyBeR Association in Relapsed/Refractory DLBCL","CyBeR-Lymph","Not yet recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Rituximab|Drug: Bendamustine|Drug: Cytarabine","treatment response|overall survival|progression free survival","University Hospital, Caen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","78","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-005837-37","June 2016","November 2018","December 2018","May 3, 2016","null","May 4, 2016","","","https://ClinicalTrials.gov/show/NCT02758925"
267,"NCT00968331","Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Terminated","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Lenalidomide plus Rituximab","To assess the antitumour activity of Lenalidomide plus Rituximab (REVLIRIT) as salvage treatment in elderly patients with relapsed or refractory DLBCL, in terms of Overall Response Rate (CR and PR)|To assess the overall feasibility of the REVLIRIT regimen in terms of response To assess the duration of response, TTP and PFS, safety and tolerability of the REVLIRIT regimen in terms of AE and SAE frequency and severity","University of Bologna","All","65 Years and older   (Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REVLIRIT01","March 2009","December 2009","December 2011","August 31, 2009","null","August 27, 2012","Institute Of Hematology ""Seràgnoli"", Bologna, Italy","","https://ClinicalTrials.gov/show/NCT00968331"
268,"NCT02617485","MabionCD20® Compared to MabThera® in Lymphoma Patients",,"Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: prednisone","Area under the plasma concentration- time curve from time zero to final time point","Mabion SA","All","18 Years and older   (Adult, Older Adult)","Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MabionCD20-002NHL","December 2015","December 2016","June 2017","December 1, 2015","null","June 2, 2016","University Clinical Center Banja Luka, Banja Luka, Bosnia and Herzegovina|University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina|General Hospital Zenica, Zenica, Bosnia and Herzegovina|GH ""dr.Josip Bencevic"", Slavonski Brod, Croatia|CH Merkur, Zagreb, Croatia|CHC Zagreb, Zagreb, Croatia|S. Khechinashvili state University clinic, Tbilisi, Georgia|HEMA, Tibilisi, Georgia|Medulla - Chemotherapy and Immunotherapy Clinic, Tibilisi, Georgia|Institut of Oncology, Hematology Department, Chisinau, Moldova, Republic of|Wojewódzki Szpital Specjalistyczny w Legnicy, Oddział Hematologiczny, Legnica, Poland|Samodzielny Publiczny Szpital Kliniczny nr1, Klinika Hematologii i Transplantacji Szpiku, Lublin, Poland|Szpital Wojewódzki w Opolu, Oddział Hematologii i Onkologii Hematologicznej, Opole, Poland|MTZ Clinical Research Sp. Z o.o., Warsaw, Poland|Clinical Hospital Center Zemun, Belgrade, Serbia|Clinical Hospital Center Zvezdara, Belgrade, Serbia|Military Hospital Academy, Belgrade, Serbia|Public utility ""Chernivtsi regional clinical oncology dispensary"", Day patient department, Chernivtsi, Ukraine|Municipal Institution ""Dnipropetrovsk City multi-field Clinical Hospital #4"", Oncology and medical radiology department, Dnipropetrovsk, Ukraine|Regional Clinical Hospital of Ivano-Frankivsk, Hematology Department., Ivano-Frankivsk, Ukraine|Regional Clinical Oncology Dispensary, Chemotherapy Department, Ivano-Frankivsk, Ukraine|Kharkiv Regional Clinical Oncology Centre, Deartment of haematology, Kharkiv, Ukraine|National Institute of Cancer, Department of chemotherapy, Kiev, Ukraine|Kiev City Clinical Oncological Center, Department of chemotherapy #2, Kiev, Ukraine|Utility Enterprise ""Kirovograd regional oncology dispensary"", Kirovograd, Ukraine|Kryvyi Rih Oncology Dispensary, Dnipropetrovsk Highway, Krivoy Rog, Ukraine|Volyn' Regional clinical hospital, Haematology Department, Lutsk, Ukraine|State institution ""Institute for haemotopathology and haemotransfusion of National Academy of science of Ukraine, Lviv, Ukraine|Mykolayiv Region Clinical Hospital, Heamotology department, Mykolayiv, Ukraine|Poltava regional oncology hospital, heamotherapy department, Poltava, Ukraine|Regional clinical Hospital named after Novak, Hematology Department, Uzhgorod, Ukraine|Vinnitsya Regional Clinical Oncology Dispensary, Chemotherapy Department,, Vinnitsya, Ukraine|Regional Oncology dispensary, Zaporizhzhia, Ukraine|Zaporizhzhya Regional Clinical Hospital, Deartment of haematology and intensive therapy, Zaporizhzhia, Ukraine","","https://ClinicalTrials.gov/show/NCT02617485"
269,"NCT02753647","Chidamide Plus R-CHOP in Elderly DLBCL",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Chidamide","Complete response rate|Progression free survival rate|Overall survival rate|Overall response rate|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0","Ruijin Hospital","All","61 Years to 75 Years   (Adult, Older Adult)","Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-CHOP","April 2016","October 2018","April 2019","April 28, 2016","null","November 14, 2017","Shanghai Ruijin Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02753647"
270,"NCT03677141","A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma",,"Not yet recruiting","No Results Available","B-cell Non-Hodgkin Lymphoma","Drug: Mosunetuzumab|Drug: Polatuzumab Vedotin|Drug: Rituxumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Tocilizumab","Percentage of Participants with Adverse Events (AE)|Complete Response (CR) Rate at the Time of Primary Response Assessment Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Assessed According to Lugano 2014 Response Criteria|Maximum Serum Concentration (Cmax) of Mosunetuzumab|Minimum Serum Concentration (Cmin) of Mosunetuzumab|Area Under the Curve (AUC) of Mosunetuzumab|Clearance (CL) of Mosunetuzumab|Volume of Distribution at Steady State (Vss) of Mosunetuzumab|Maximum Plasma Concentration (Cmax) of Polatuzumab Vedotin|Minimum Plasma Concentration (Cmin) of Polatuzumab Vedotin|AUC of Polatuzumab Vedotin|CL of Polatuzumab Vedotin|Vss of Polatuzumab Vedotin|Best Objective Response Rate (ORR), Defined as Complete Response (CR) or Partial Response (PR) at any Time on Study Based on PET-CT and/or CT scan as Assessed According to Lugano 2014 Response Criteria|Duration of Response (DOR)|Anti-Drug Antibodies (ADAs) to Mosunetuzumab|ADAs to Polatuzumab Vedotin|Progression-Free Survival (PFS)|PFS at 1 Year|Event-Free Survival (EFS)|Time to Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30) Physical Functioning and Fatigue|Time to Deterioration in the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO40515|2018-001039-29","September 30, 2018","May 31, 2021","November 12, 2021","September 19, 2018","null","September 19, 2018","University of Alabama Birmingham, Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Cancer Center, Scottsdale, Arizona, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Michigan, Ann Arbor, Michigan, United States|Lifespan Cancer Institute, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03677141"
271,"NCT01659099","GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma","GAINED","Terminated","No Results Available","Diffuse Large B Cell Lymphoma CD20 Positive","Drug: GA101|Drug: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Bleomycin|Drug: Vindesin|Drug: Vincristine","2-year Event Free Survival|• Overall Response rate and Best overall response after 4 cycles and end of treatment according to Cheson 2007 criteria|• Overall Response Rate and Best overall response after 4 cycles and end of treatment according to Cheson 1999 criteria|• Duration of response (DoR)|• Progression-Free Survival (PFS)|• Overall survival (OS)|• Blood samples and on tumor tissue biopsy|• Focus on subpopulation|Number of stem cell collected after GA101 treatment|• Early metabolic response according to PET after 2 and 4 cycles","The Lymphoma Academic Research Organisation|Hoffmann-La Roche","All","18 Years to 60 Years   (Adult)","Phase 3","671","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GAINED","September 2012","August 2016","December 31, 2017","August 7, 2012","null","March 7, 2018","ZNA Stuivenberg, Antwerpen, Belgium|Hôpital Saint Joseph, Arlon, Belgium|RHMS Baudour, Baudour, Belgium|AZ St Jan Brugge Oostende AV, Brugge, Belgium|Institut Jules Bordet, Bruxelles, Belgium|CHU Brugmann, Bruxelles, Belgium|Hôpital Erasme, Bruxelles, Belgium|Clinique universitaire Saint LUC, Bruxelles, Belgium|CHU de Charleroi, Charleroi, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Ch Jolimont, Haine Saint Paul, Belgium|AZ GROENINGE - Oncology Centre - Campus Maria's Voorzienigheid, Kortrijk, Belgium|CHR de la Citadelle, Liège, Belgium|CHU de Liège - Clinique Saint Joseph, Liège, Belgium|CHU de Liège -Domaine Sart Tilman, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|Clinique Saint Joseph -Hôpital de Warquignies, Mons, Belgium|Clinique Sainte Elisabeth, Namur, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Heilig Hart Ziekenhuis, Roeselare, Belgium|Centre Hospitalier de Wallonie Picarde - CHwapi, Tournai, Belgium|CH de la Tourelle-Peltzer, Verviers, Belgium|Université Catholique de Louvain Mont Godinne, Yvoir, Belgium|CH d'Abbeville, Abbeville, France|CHU d'Amiens - Hôpital Sud, Amiens, France|CHU d'Angers, Angers, France|CH Victor Dupouy, Argenteuil, France|CH d'Arras, Arras, France|CH d'Avignon, Avignon, France|Hôpital de Bayonne - CHU de la Côte Basque, Bayonne, France|CH de Beauvais, Beauvais, France|CHU de Besançon - Hôpital Jean Minjoz, Besançon, France|CH de Blois, Blois, France|APHP - Hôpital Avicenne, Bobigny, France|Institut Bergonié, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|CH Dr Duchenne, Boulogne sur Mer, France|CH Fleyriat, Bourg en Bresse, France|CHU de Brest - Hôpital de Morvan, Brest, France|CH Brive la Gaillarde, Brive la Gaillarde, France|CHU de Caen, Caen, France|Centre François Baclesse, Caen, France|CH de Cannes, Cannes, France|Clinique Du Parc, Castelnau Le Lez, France|CH de Chambéry, Chambéry, France|CHU de Châlon sur Saône, Châlon sur Saône, France|APHP - Hôpital Antoine Béclère, Clamart, France|Hôpital d'Instruction des Armées Percy, Clamart, France|CHU d'Estaing, Clermont Ferrand, France|Pôle Santé Publique, Clermont Ferrand, France|CH de Compiègne, Compiègne, France|CH Sud Francilien, Corbeil Essonnes, France|APHP - Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CH de Dunkerque, Dunkerque, France|Institut Daniel Hollard, Grenoble, France|CHU de Grenoble, Grenoble, France|CHD Vendée, La Roche Sur Yon, France|CH La Rochelle, La Rochelle, France|APHP - Hôpital Bicêtre, Le Kremlin Bicêtre, France|CH du Mans, Le Mans, France|Clinique Victor Hugo, Le Mans, France|CH de Lens, Lens, France|CH Saint Vincent de Paul, Lille, France|CHRU Lille - Hôpital Claude Huriez, Lille, France|CHU Dupruytren - Limoges, Limoges, France|CH Bretagne Sud, Lorient, France|Centre Léon Bérard, Lyon, France|CH Mantes La Jolie, Mantes La Jolie, France|Hôpital de la Conception, Marseille, France|Institut Paoli Calmettes, Marseille, France|CH de Meaux, Meaux, France|CH Marc Jacquet, Melun, France|Hôpital Notre Dame Bon Secours, Metz, France|CHI de Meulan, Meulan en Yvelines, France|CHU de Montpellier - Saint Eloi, Montpellier, France|Centre Val d'Aurélie - Paul Lamarque, Montpellier, France|Centre Auréen de Cancérologie, Mougins, France|CH de Mulhouse - Hôpital Emile Muller, Mulhouse Cedex, France|CHU de Nantes - Hôtel Dieu, Nantes, France|Centre Catherine de Sienne, Nantes, France|Centre Antoine Lacassagne, Nice Cedex 2, France|CHU de Nice, Nice, France|CHU de Nîmes, Nîmes, France|Clinique Valdegour, Nîmes, France|CHR d'Orléans, Orléans, France|APHP - Hôpital Saint Louis, Paris Cedex 10, France|APHP - Hôpital Saint Antoine, Paris Cedex 12, France|Institut Curie, Paris, France|APHP - Hôpital de la Pitié Salpetrière, Paris, France|Hôpital Cochin, Paris, France|APHP - Hôpital Necker, Paris, France|CH Saint Jean, Perpignan, France|CHU de Haut Lévèque, Pessac, France|Hospices Civils de Lyon - CHU Lyon Sud, Pierre Bénite, France|CHU de Poitiers, Poitiers, France|CH René Dubos, Pontoise, France|CH d'Annecy, Pringy, France|CHU Robert Debré, Reims, France|Institut du Cancer de Courlancy, Reims, France|CHU de Rennes, Rennes, France|CH de Roubaix, Roubaix, France|Centre Henri Becquerel, Rouen, France|Clinique Mathilde, Rouen, France|CH Yves Le Foll - St Brieuc, Saint Brieuc, France|Centre René Huguenin, Saint Cloud, France|CHI de Poissy St Germain, Saint germain en laye, France|CHU de Saint Malo, Saint Malo, France|CH de Saint Quentin, Saint Quentin, France|Institut de Cancérologie, St Priest en Jarez, France|Strasbourg Oncologie Libérale, Strasbourg, France|CHU de Strasbourg, Strasbourg, France|Hopital Saint Husse, Toulon, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|CHU de Tours, Tours, France|CHU de Valence, Valence, France|CH de Valenciennes, Valenciennes, France|CHU de Brabois, Vandœuvre-lès-Nancy, France|CH Bretagne Atlantique, Vannes, France|CH de Versailles, Versailles, France|Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT01659099"
272,"NCT02752815","Reduced Chemotherapy in Low Risk DLBCL",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Epirubicin|Drug: Vincristine|Drug: Prednisone","Progression free survival|Overall survival|Complete Response rate|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0","Ruijin Hospital","All","14 Years to 75 Years   (Child, Adult, Older Adult)","Phase 4","290","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NHL-006","April 2016","April 2019","June 2019","April 27, 2016","null","May 4, 2018","Shanghai Ruijin Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02752815"
273,"NCT02653989","Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Withdrawn","No Results Available","Lymphoma, Large B-Cell, Diffuse|Primary Mediastinal Large B-cell Lymphoma|Transformed Indolent Lymphoma","Biological: MDV9300","Best overall response rate|Duration of response (for responders)|Progression-free survival|Time to response (for responders)|Overall survival|Composite of safety","Medivation, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDV9300-01","December 2016","June 2018","August 2018","January 13, 2016","null","November 25, 2016","Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02653989"
274,"NCT01914718","Dose-adjusted EPOCH-R in MYC Positive DLBCL",,"Terminated","No Results Available","Diffuse Large B-cell Lymphoma","Drug: DA-EPOCH-R","3-year progression-free survival|Objective response rate|3-year overall survival|Toxicity","Fudan University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LMTG 13-02","February 2013","December 2015","December 2017","August 2, 2013","null","August 20, 2014","Fudan University Cancer Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT01914718"
275,"NCT03484819","Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma",,"Not yet recruiting","No Results Available","Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Drug: Copanlisib|Other: Laboratory Biomarker Analysis|Biological: Nivolumab","Objective response rate|Incidence of adverse events|Progression free survival|Duration of response|Overall survival time","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","99","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2018-00478|MC1787|10193|UM1CA186686","September 28, 2018","August 31, 2020","August 31, 2020","April 2, 2018","null","September 12, 2018","","","https://ClinicalTrials.gov/show/NCT03484819"
276,"NCT02549651","MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: MEDI4736|Drug: tremelimumab|Drug: AZD9150","Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events|Number of subjects experiencing dose-limiting toxicities|Number of subjects who develop anti-drug antibodies (ADA)|Time to Response|Duration of Response|Progression Free survival|Time to progression|Event free survival|Overall survival|MEDI4736 Maximum Plasma Concentration (Cmax)|Tremelimumab Maximum Plasma Concentration (Cmax)|AZD9150 Maximum Plasma Concentration (Cmax)|MEDI4736 Minimum Plasma Concentration (Cmin)|Tremelimumab Minimum Plasma Concentration (Cmin)|AZD9150 Minimum Plasma Concentration (Cmin)|Individual MEDI4736 Concentrations|Individual tremelimumab Concentrations|Individual AZD9150 Concentrations|Change from baseline of STAT3 RNA (signal transducer and activator of transcription)|Baseline PD-L1 protein expression within the tumor","MedImmune LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4190C00023","July 13, 2016","November 7, 2023","November 7, 2023","September 15, 2015","null","August 31, 2018","Research Site, Duarte, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Durham, North Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Brest Cedex, France|Research Site, Marseille, France|Research Site, Montpellier Cedex 5, France|Research Site, Nantes, France|Research Site, Paris, France|Research Site, Pierre Benite Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Villejuif, France|Research Site, Berlin, Germany|Research Site, Jena, Germany|Research Site, Muenchen, Germany|Research Site, Muenchen, Germany|Research Site, Cork, Ireland|Research Site, Dublin 8, Ireland|Research Site, Galway, Ireland|Research Site, Aviano, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Roma, Italy|Research Site, Glasgow, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02549651"
277,"NCT00085696","VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma",,"Completed","No Results Available","B-Cell Lymphoma|Follicular Lymphoma|Marginal Lymphoma","Drug: VELCADE and rituximab","","Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M34103-061","May 2004","April 2006","null","June 15, 2004","null","February 11, 2008","UCLA School of Medicine, Los Angeles, California, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Emory University Cancer Institute, Winship Cancer Institute, Atlanta, Georgia, United States|Georgia Cancer Specialists, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Oncology/Henmatology Associates of Kansas City, Kansas City, Missouri, United States|Mid Ohio Oncology/Hematology Inc., Columbus, Ohio, United States|Charleston Cancer Center, Charleston, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|FNVHO - US Oncology, Fairfax, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00085696"
278,"NCT02456207","A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","B-cell Non Hodgkin's Lymphoma","Drug: SCT400|Drug: Rituximab","Area under the curve (AUC) for SCT400 and rituximab concentrations|AUC for SCT400 and rituximab concentrations|Maximum observed concentration of the SCT400 and rituximab|Change from baseline of CD19+ , CD20+ B-cells|Comparison of AEs between the two study arms|Comparison of HACA between the two study arms","Sinocelltech Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCT400NHL2","May 2015","December 2015","December 2015","May 28, 2015","null","May 28, 2015","Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02456207"
279,"NCT02323230","A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL",,"Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma","Biological: DPX-Survivac|Drug: Cyclophosphamide","Objective response rate|Immune response|Frequency of adverse events","ImmunoVaccine Technologies, Inc. (IMV Inc.)","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONC-DPX-Survivac-05","January 2015","June 2017","February 2018","December 23, 2014","null","July 18, 2017","Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02323230"
280,"NCT00850512","Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy","CHOP21+R-Z","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: CHOP21-R|Drug: Zevalin","Overall response rate and complete response rate will be the primary endpoints|overall survival (OS) and disease-free survival (DFS) will be the secondary endpoints","University of Bologna","All","60 Years and older   (Adult, Older Adult)","Phase 2","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHOP21+R-Z","null","null","null","February 25, 2009","null","February 25, 2009","Istituto di Ematologia e Oncologia Medica Seràgnoli, Bologna, BO, Italy","","https://ClinicalTrials.gov/show/NCT00850512"
281,"NCT02399085","A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL","L-MIND","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: MOR00208|Drug: Lenalidomide","Objective response rate (ORR = complete response [CR] + partial response [PR])|Disease control rate (DCR)|Duration of response (DoR)|Progression-free survival (PFS)|Overall survival (OS)|Safety of LEN combined with MOR00208 according to the frequency and severity of adverse events (AEs)|Potential immunogenicity of MOR00208|Pharmacokinetics (PK) of MOR00208","MorphoSys AG","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MOR208C203","December 2015","November 2018","November 2022","March 26, 2015","null","December 6, 2017","MorphoSys Research Site, Bakersfield, California, United States|MorphoSys Research Site, Redondo Beach, California, United States|MorphoSys Research Site, Santa Maria, California, United States|MorphoSys Research Site, Grand Junction, Colorado, United States|MorphoSys Research Site, Norwalk, Connecticut, United States|MorphoSys Research Site, Michigan Center, Michigan, United States|MorphoSys Research Site, Columbus, Ohio, United States|MorphoSys Research Site, Charleston, South Carolina, United States|MorphoSys Research Site, Tyler, Texas, United States|MorphoSys Research Site, Antwerp, Belgium|MorphoSys Research Site, Kortrijk, Belgium|MorphoSys Research Site, Liege, Belgium|MorphoSys Research Site, Yvoir, Belgium|MorphoSys Research Site, Olomouc, Czechia|MorphoSys Research Site, Clermont-Ferrand, France|MorphoSys Research Site, Limoges, France|MorphoSys Research Site, Lyon, France|MorphoSys Research Site, Paris, France|MorphoSys Research Site, Essen, Germany|MorphoSys Research Site, Frankfurt, Germany|MorphoSys Research Site, Munich, Germany|MorphoSys Research Site, Nürnberg, Germany|MorphoSys Research Site, Würzburg, Germany|MorphoSys Research Site, Budapest, Hungary|MorphoSys Research Site, Budapest, Hungary|MorphoSys Research Site, Debrecen, Hungary|MorphoSys Research Site, Bari, Italy|MorphoSys Research Site, Bologna, Italy|MorphoSys Research Site, Firenze, Italy|MorphoSys Research Site, Modena, Italy|MorphoSys Research Site, Novara, Italy|MorphoSys Research Site, Perugia, Italy|MorphoSys Research Site, Roma, Italy|MorphoSys Research Site, Terni, Italy|MorphoSys Research Site, Krakow, Poland|MorphoSys Research Site, Olsztyn, Poland|MorphoSys Research Site, Opole, Poland|MorphoSys Research Site, Poznan, Poland|MorphoSys Research Site, Rzeszow, Poland|MorphoSys Research Site, Warszawa, Poland|MorphoSys Research Site, Warszawa, Poland|MorphoSys Research Site, Barcelona, Spain|MorphoSys Research Site, Barcelona, Spain|MorphoSys Research Site, Barcelona, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Pamplona, Spain|MorphoSys Research Site, Sevilla, Spain|MorphoSys Research Site, Bournemouth, United Kingdom|MorphoSys Research Site, Liverpool, United Kingdom|MorphoSys Research Site, London, United Kingdom|MorphoSys Research Site, Newcastle, United Kingdom","","https://ClinicalTrials.gov/show/NCT02399085"
282,"NCT02670317","Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.","FIL-GALILEO","Terminated","No Results Available","Lymphoma, B-Cell","Drug: Obinutuzumab|Drug: Ibrutinib|Drug: CHOP","The efficacy of G-CHOP-21 in combination with Ibrutinib in terms of 2-yrs PFS (progression-free survival)|The safety of G-CHOP-21 in combination with Ibrutinib in terms of proportion of patients experiencing grade 3 or greater extra-hematologic toxicity or treatment interruption for safety reasons or any toxic death during the 6 cycles of treatment|Overall Survival (OS)|Complete Remission (CR) Rate|Overall Response Rate (ORR)|The Duration Of Response (DOR) after the end of treatment","Fondazione Italiana Linfomi ONLUS","All","18 Years to 60 Years   (Adult)","Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL-GALILEO|2015-005273-20","September 2016","February 2017","February 2017","February 1, 2016","null","March 20, 2017","IRCCS Candiolo - Fondazione del Piemonte per l'oncologia, Candiolo, TO, Italy|AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy|AOU Policlinico Consorziale, Bari, Italy|AO Papa Giovanni XXIII, Bergamo, Italy|Ospedale di Bolzano, Bolzano, Italy|Ospedale Businco, Cagliari, Italy|AO di Cosenza, Cosenza, Italy|AOU Careggi, Firenze, Italy|P.O. Vito Fazzi, Lecce, Italy|IRST Meldola, Meldola, Italy|Ospedale Papardo, Messina, Italy|Istituto Europeo Oncologico, Milano, Italy|AOU Policlinico di Modena, Modena, Italy|Ospedale San Gerardo, Monza, Italy|IRCCS Napoli Pascale, Napoli, Italy|Ospedale Maggiore della Carità, Novara, Italy|AOOR Villa Sofia Cervello, Palermo, Italy|AOU di Parma, Parma, Italy|Ospedale G. Da Saliceto, Piacenza, Italy|AOR San Carlo, Potenza, Italy|Ospedale Degli Infermi, Rimini, Italy|Policlinico Gemelli, Roma, Italy|Policlinico Umberto I, Roma, Italy|Humanitas, Rozzano, Italy|Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|AOU Città Della Salute e Della Scienza Ematologia Universitaria, Torino, Italy|AOU Città Della Salute e Della Scienza SC Ematologia, Torino, Italy|AOU di Udine, Udine, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, Italy","","https://ClinicalTrials.gov/show/NCT02670317"
283,"NCT01965977","Bortezomib Maintenance in High Risk DLBCL","Borma","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Bortezomib","3years relapse free survival|3years overall survival|3years event free survival|Toxicity profiles|Quality of life scale","Samsung Medical Center|Janssen, LP","All","19 Years and older   (Adult, Older Adult)","Phase 2","53","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SMC2013-04-124","April 8, 2015","October 30, 2018","October 30, 2018","October 18, 2013","null","September 6, 2018","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01965977"
284,"NCT02658968","Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)",,"Recruiting","No Results Available","Relapsed, Diffuse Large B-cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: Betalutin","Determine the Maximum Tolerated Dose|The best overall tumour response rate|Dosimetry","Nordic Nanovector","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT: 2015-001933-26","January 2016","December 2017","September 2019","January 20, 2016","null","April 10, 2017","San Diego, California, United States|San Francisco, California, United States|Miami, Florida, United States|Munich, Germany|Bologna, Italy|Torino, Italy|Verona, Italy|Valencia, Spain|Zaragoza, Spain|Bristol, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT02658968"
285,"NCT01933516","GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Indolent B-cell Non-Hodgkin's Lymphoma","Drug: GP2013","To evaluate safety of GP2013|Area under the curve calculated from start of dose to the end of the dosing interval (tau) of GP2013|Maximum observed concentration of GP2013|Time to reach maximum concentration of GP2013|Minimum (trough) observed concentration during each dosing interval of GP2013|Terminal elimination rate constant calculated as the slope of the linear regression of the terminal phase of the logarithmic concentration-time profile of GP2013|Elimination half-life associated with the terminal slope of GP2013|To evaluate efficacy of GP2013|To evaluate the incidence of immunogenicity (ADA formation) against GP2013|To evaluate peripheral CD19+ B-cell count","Sandoz|Novartis Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GP13-101","May 2013","August 2014","August 2014","September 2, 2013","null","July 26, 2018","Investigative Site, Tachikawa, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT01933516"
286,"NCT01804127","Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: R-CHOP","3-year progression-free survival|Objective response rate|3-year overall survival","Fudan University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","196","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LMTG 13-01","February 2013","December 2015","December 2017","March 5, 2013","null","March 5, 2013","Fudan University Cancer Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT01804127"
287,"NCT02815397","DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma","DLBCL","Terminated","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Metformin","Evaluation of Impact of Metformin on 18 Month Progression-free Survival|Effect of Metformin Overall Response Rate|Effect of Metformin Overall Survival|Safety Profile With Addition of Metformin Evaluated by Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v.4.0","Rush University Medical Center|Elsa U. Pardee Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LYM15 DA-EPOCH-RM","February 2016","July 2016","July 2016","June 28, 2016","November 17, 2017","November 17, 2017","Rush University Medical Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02815397"
288,"NCT03367143","Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma Refractory","Drug: Lenalidomide|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide","Complete response rate|Progression free survival rate|Overall survival rate|Overall response rate|Safety as assessed using CTCAE v4.0","Ruijin Hospital","All","16 Years to 75 Years   (Child, Adult, Older Adult)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","L-ICE","December 2016","December 2018","December 2019","December 8, 2017","null","December 8, 2017","Shanghai Ruijin Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03367143"
289,"NCT02955628","RICE-ibrutinib in Relapsed DLBCL",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma|Diffuse Large B-Cell Lymphoma Recurrent","Drug: Ibrutinib-RICE","Efficacy as measured by event free survival measured at 3-years follow up of patients who have received ibrutinib|Progression-free survival|Overall survival|Percentage of patients who have increased response from partial remission to complete remission ibrutinib before transplant","Singapore General Hospital|Janssen, LP","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGH-LYM-15-02","December 13, 2016","August 2023","August 2023","November 4, 2016","null","February 14, 2017","National University Hospital Singapore, Singapore City, Singapore|National Cancer Centre Singapore, Singapore City, Singapore|Raffles Hospital Singapore, Singapore City, Singapore|Singapore General Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT02955628"
290,"NCT02445248","Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients","JULIET","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma (DLBCL)","Biological: CTL019","Overall Response Rate (ORR)|Incidence and severity of adverse events (AEs)|Time to response (TTR)|Duration of overall response (DOR)|Event free survival (EFS)|Progression free survival (PFS)|Overall survival (OS)|In vivo cellular Pharmacokinetic (PK) profile of CTL019 transduced cells into target tissues|Incidence of immunogenicity to CTL019|Number of Participants with presence of exposure to replication-competent lentivirus (RCL) as Assessed by quantitative polymerase chain reaction (qPCR)|Prevalence of immunogenicity to CTL019","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","116","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCTL019C2201|2014-003060-20","July 29, 2015","February 20, 2023","February 20, 2023","May 15, 2015","null","July 24, 2018","Mayo Clinic - Arizona Mayo Clinic Building, Phoenix, Arizona, United States|University of California San Francisco SC-4, San Francisco, California, United States|Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia, United States|University of Chicago Medical Center, Hematology & Oncology, Chicago, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|The Sidney Kimmel Cancer Center at Johns Hopkins Hospital SC-2, Baltimore, Maryland, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Minnesota SC C2201, Minneapolis, Minnesota, United States|Weill Cornell Medical College, New York, New York, United States|Duke Unversity Medical Center, Durham, North Carolina, United States|The Ohio State University James Cancer Hospital &, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center SC, Houston, Texas, United States|Novartis Investigative Site, Camperdown, Australia|Novartis Investigative Site, Melbourne, Australia|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wurzburg, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT02445248"
291,"NCT03571568","A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Indolent B-Cell Non-Hodgkin Lymphoma","Biological: BI1206","Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or rituximab|Determining the MTD of BI-1206 at the same dose level experiencing a BI-1206 or Rituximab-related or possibly related dose-limiting toxicity (DLT)|Evaluation of PK parameters for BI-1206. Maximum observed plasma concentration (Cmax)|Evaluation of PK parameters for BI-1206. Area under the plasma concentration-time curve (AUC)|Evaluation of PK parameters for Rituximab. Maximum observed plasma concentration (Cmax)|Evaluation of PK parameters for Rituximab. Area under the plasma concentration-time curve (AUC)|Evaluation of ADA response to BI 1206|Measurement of B cell depletion|Assessment of overall response rate (response criteria for malignant lymphoma (Cheson, 2014). RR)","BioInvent International AB","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-BI1206-02","May 16, 2018","June 30, 2020","June 30, 2020","June 27, 2018","null","June 27, 2018","Department of Oncology, Skåne University Hospital, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT03571568"
292,"NCT02206308","Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.",,"Completed","No Results Available","B-cell Non Hodgkin's Lymphoma","Biological: Chimeric anti-CD20 monoclonal antibody","Number of participants with infusion-related reaction and with drug-related adverse events.|Area Under the plasma concentration versus time curve (AUC) of SCT400","Sinocelltech Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCT400NHLI","May 2012","July 2013","July 2013","August 1, 2014","null","August 1, 2014","","","https://ClinicalTrials.gov/show/NCT02206308"
293,"NCT01856192","Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma",,"Active, not recruiting","No Results Available","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|CD20 Positive","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","Progression free survival (PFS)|Overall response rate (RR) based on positron emission tomography (PET)-computed tomography (CT) scan|Complete remission (CR) rate based on PET-CT scan|Overall survival (OS)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","345","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2013-00959|E1412|S13-01316|ECOG-E1412|U10CA180820|U10CA021115|U24CA196172","August 27, 2013","August 31, 2019","null","May 17, 2013","null","September 13, 2018","Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Veteran's Administration Medical Center, Little Rock, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Memorial Medical Center, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Stanford Cancer Center South Bay, San Jose, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program NCORP, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Bayhealth Medical Center at Kent General, Dover, Delaware, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|The Watson Clinic, Lakeland, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Weiss Memorial Hospital, Chicago, Illinois, United States|Presence Saint Joseph Hospital-Chicago, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Heartland Cancer Research NCORP, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|AMITA Health Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Hinsdale Hematology Oncology Associates Incorporated, Hinsdale, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Trinity Medical Center, Moline, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|Swedish American Hospital, Rockford, Illinois, United States|SwedishAmerican Regional Cancer Center/ACT, Rockford, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Centers-East, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|IU Health Arnett Cancer Care, Lafayette, Indiana, United States|Premier Oncology Hematology Associates, Merrillville, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|IU Health Ball Memorial Hospital, Muncie, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Iowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Ottumwa Regional Health Center, Ottumwa, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Covenant Medical Center, Waterloo, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|University Health-Conway, Monroe, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Peninsula Regional Medical Center, Salisbury, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Saint Luke's Hospital of Duluth, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Saint Luke's Hospital, Chesterfield, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Hematology and Oncology, Lincoln, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Specialists-Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|Wentworth-Douglass Hospital, Dover, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|LRGHealthcare-Lakes Region General Hospital, Laconia, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|The Valley Hospital-Luckow Pavilion, Paramus, New Jersey, United States|Valley Hospital, Ridgewood, New Jersey, United States|Inspira Medical Center Vineland, Vineland, New Jersey, United States|Valley Health System-Hematology/Oncology, Westwood, New Jersey, United States|Inspira Medical Center Woodbury, Woodbury, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Christus Saint Vincent Regional Cancer Center, Santa Fe, New Mexico, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Kings County Hospital, Brooklyn, New York, United States|State University of New York Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Champlain Valley Physicians Hospital Medical Center, Plattsburgh, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Hendersonville Hematology and Oncology at Pardee, Hendersonville, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Vidant Oncology-Kinston, Kinston, North Carolina, United States|Annie Penn Memorial Hospital, Reidsville, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Marion L Shepard Cancer Center at Vidant Beaufort Hospital, Washington, North Carolina, United States|Southeastern Medical Oncology Center-Wilson, Wilson, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Summa Barberton Hospital, Barberton, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Saint Rita's Medical Center, Lima, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Ireland Cancer Center Landerbrook Health Center, Mayfield Heights, Ohio, United States|Lake University Ireland Cancer Center, Mentor, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Ireland Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|Ephrata Community Hospital, Ephrata, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Pottstown Hospital, Pottstown, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Hematology and Oncology Associates of North East Pennsylvania, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Grand View Hospital, Sellersville, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Seton Medical Center at The University of Texas, Austin, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Covenant Medical Center-Lakeside, Lubbock, Texas, United States|Texas Tech University Health Sciences Center-Lubbock, Lubbock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Augusta Health Cancer Center, Fishersville, Virginia, United States|Sovah Health Martinsville, Martinsville, Virginia, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|West Virginia University Charleston Division, Charleston, West Virginia, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Fox Valley Hematology and Oncology SC-Appleton, Appleton, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|HSHS Sacred Heart Hospital, Eau Claire, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|UW Cancer Center Johnson Creek, Johnson Creek, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Dean Hematology and Oncology Clinic, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Vince Lombardi Cancer Clinic-Marinette, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Marshfield Medical Center, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Ascension Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Lakeview Medical Center-Marshfield Clinic, Rice Lake, Wisconsin, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Ascension Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Aurora Cancer Care-Waukesha, Waukesha, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Diagnostic and Treatment Center, Weston, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01856192"
294,"NCT01704963","A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms",,"Completed","No Results Available","Recurrent Mature B-cell Neoplasms","Drug: PCI-32765","Number of patients with adverse events|Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast)|Area under the plasma concentration-time curve from time 0 to infinity time (AUC∞)|Maximum plasma concentration (Cmax)|Time to reach maximum plasma concentration (tmax)|Terminal elimination half-life (t1/2)|Pharmacodynamic evaluations|Tumor response","Janssen Pharmaceutical K.K.|Pharmacyclics LLC.","All","20 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100896|PCI-32765-JPN-101","September 12, 2012","November 20, 2015","February 1, 2017","October 12, 2012","null","February 2, 2018","Kyoto, Japan|Nagoya, Japan|Sendai, Japan|Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT01704963"
295,"NCT00998946","Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma, B-Cell","Drug: Pralatrexate Injection|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid","Objective Response Rate (ORR)|Duration of Response (DOR)|Progression Free Survival (PFS)|Overall Survival (OS)","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDX-015","September 2009","December 2014","December 2014","October 21, 2009","null","March 20, 2015","Tower Cancer Research Foundation, Beverly Hills, California, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|Owsley Brown Frazier Cancer Center, Louisville, Kentucky, United States|Overton Brooks VA Medical Center, Shreveport, Louisiana, United States|Frontier Cancer Center and Blood Institute, Billings, Montana, United States|New York University Hospital, New York, New York, United States|Providence Cancer Center, Portland, Oregon, United States|The West Clinic (ACORN), Memphis, Tennessee, United States|Gundersen Lutheran, LaCrosse, Wisconsin, United States|University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00998946"
296,"NCT00521638","Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Lymphoma, B-Cell","Biological: TRU-015","Safety: physical examinations, laboratory tests, adverse events. Maximum Tolerated Dose: dose-limiting toxicities. Efficacy: disease response and progression status per International Response Criteria for NHL.|Objective response rate in subjects with relapsed follicular NHL.","Wyeth is now a wholly owned subsidiary of Pfizer|Emergent Product Development Seattle LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3206K2-104","September 2007","April 2008","April 2008","August 28, 2007","null","January 14, 2013","Duarte, California, United States|San Diego, California, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Buffalo, New York, United States|Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00521638"
297,"NCT02128061","Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+",,"Active, not recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Lenalidomide|Drug: Rituximab","The overall survival (OS)|Progression-Free Survival (PFS)|Event-Free Survival (EFS)|Duration of Response (DoR)|Disease-Free Survival (DFS)|OS according to GCB/non-GCB phenotype|Response Rate at the end of treatment|Simplified Geriatric Scales|Health related Quality of Life (HRQOL)","The Lymphoma Academic Research Organisation|Centre Henri Becquerel","All","80 Years and older   (Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SENIOR","August 2014","February 2019","February 2019","May 1, 2014","null","December 11, 2017","ZNA Stuivenberg, Antwerpen, Belgium|A. Z. Sint-Jan, Bruges, Belgium|Hôpital Erasme, Brussel, Belgium|Institut Jules Bordet, Bruxelles, Belgium|Université Catholique de Louvain Saint Luc, Bruxelles, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|CHR Citadelle, Liege, Belgium|CHU de Liège, Liege, Belgium|Hôpital Sainte Elisabeth, Namur, Belgium|Clinique Saint Pierre, Ottignies, Belgium|CHR Peltzer La Tourelle, Verviers, Belgium|CHRU Mont Godinne, Yvoir, Belgium|CH d'Abbeville, Abbeville, France|CH du Pays d'Aix, Aix-en-Provence, France|CHU d'Amiens, Amiens, France|CHU d'Angers, Angers, France|CH Victor Dupouy, Argenteuil, France|CH d'Arras, Arras, France|CH d Avignon - Hopital Henri Duffaut, Avignon, France|CH Côte Basque, Bayonne, France|CHU Jean Minjoz, Besancon, France|CH de Blois, Blois, France|Institut Bergonié, Bordeaux, France|Polyclinique Bordeaux Nord, Bordeaux, France|CH de Boulogne-sur-Mer, Boulogne-sur-mer, France|CH de Bourg en Bresse, Bourg-en-bresse, France|CHU Morvan, Brest, France|CH de Brive, Brive, France|IHBN, Caen, France|CH de Cannes, Cannes, France|Clinique Du Parc, Castelnau-le-lez, France|Médipôle de Savoie, Challes-les-Eaux, France|CHU de Châlon sur Sâone, Chalon-sur-Sâone, France|CH Métropole Savoie, Chambery, France|Hôpital d'Instruction des Armées Percy, Clamart, France|CHU Estaing, Clermont-Ferrand, France|Pôle Santé République, Clermont-Ferrand, France|CH Sud Francilien de Corbeil, Corbeil-Essonnes, France|APHP - Hopital Henri Mondor, Creteil, France|CHU de Dijon - Hôpital le Bocage, Dijon, France|CH de Dunkerque, Dunkerque, France|CH Eure Seine, Evreux, France|CHU de Grenoble, Grenoble, France|Institut Daniel Hollard, Grenoble, France|CH Départemental de Vendée, La Roche sur Yon, France|Hôpital St Louis, La Rochelle, France|CH de Versailles - Hopital André Mignot, Le Chesnay, France|Hôpital Bicêtre, Le Kremlin Bicetre, France|CH du Mans, Le Mans, France|Clinique Victor Hugo, Le Mans, France|CHRU Lille - Hôpital Claude Huriez, Lille, France|Hôpital Saint Vincent de Paul, Lille, France|CHU de Limoges, Limoges, France|Centre Léon Bérard, Lyon, France|CH des Chanaux, Macon, France|Institut Paoli Calmette, Marseille, France|Hôpital de la conception, Marseille, France|CH de Meaux, Meaux, France|Centre Hospitalier Annecy Genevois, Metz-Tessy, France|Hôpital de Mercy, Metz, France|CHU de Montpellier, Montpellier, France|CHU de Mulhouse, Mulhouse, France|CHU de Nantes, Nantes, France|Centre Antoine Lacassagne, Nice, France|CHU de Nîmes, Nimes, France|CHR de la Source, Orleans, France|Hopital Saint Antoine, Paris, France|APHP - Hôpital Saint Louis, Paris, France|Hôpital de la Pitié Salpêtrière, Paris, France|APHP - Hôpital Necker, Paris, France|Clinique Francheville, Perigueux, France|CH Périgueux, Perigueux, France|CH de Perpigan, Perpignan, France|CHU du Haut Leveque, Pessac, France|Chu Lyon Sud, Pierre-Bénite, France|CHU de Poitiers, Poitiers, France|CH René Dubos, Pontoise, France|CH de Cornouaille, Quimper, France|CHU Robert Debre, Reims, France|CHU de Rennes, Rennes, France|CH de Roubaix, Roubaix, France|Centre Henri Becquerel, Rouen, France|CHU de Saint Malo, Saint Malo, France|Groupe Hospitalier Sud Réunion, Saint Pierre, France|CH Saint Quentin, Saint Quentin, France|CH de Saint Brieuc, Saint-Brieuc, France|Centre René Huguenin - Institut Curie, Saint-Cloud, France|Strasbourg Oncologie Libérale, Strasbourg, France|CHU de Strasbourg, Strasbourg, France|CHI Toulon La Seyne-sur-mer, Toulon, France|CHU Purpan - Toulouse, Toulouse, France|CHRU Bretonneau, Tours, France|Hôpital de Valence, Valence, France|CHU de Brabois, Vandoeuvre les Nancy, France|CH de Bretagne Atlantique, Vannes, France","","https://ClinicalTrials.gov/show/NCT02128061"
298,"NCT01534949","Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial","Triad-DLBCL","Terminated","No Results Available","Diffuse Large B-Cell Lymphoma","Biological: rituximab","safety","Celltrion","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 1","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-P10 1.2","February 2012","February 2013","February 2013","February 17, 2012","null","July 23, 2014","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01534949"
299,"NCT03520920","BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)",,"Recruiting","No Results Available","Marginal Zone Lymphoma|Follicular Lymphoma|Diffuse Large B-Cell Lymphoma","Drug: BGB-3111","overall response rate（ORR）|Progression free survival (PFS)|Duration of response (DOR)|Overall survival (OS)|Time to response (TTR)|Rate of complete response or complete metabolic response","BeiGene","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BGB-3111-213","January 4, 2018","November 2020","December 2020","May 10, 2018","null","May 10, 2018","Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|ongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China|Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Mdicine, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03520920"
300,"NCT00902525","Zevalin Twice in Aggressive Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: 90Y-Ibritumomab Tiuxetan","An interim analysis on all the available data after the enrolment of the 15th patient (completion of the 1st stage) will be conducted, both for safety and efficacy.|after the interim analysis, the writing committee of the study will evaluate to increase the second dose of Zevalin to 0.3 mCi/Kg. The same procedure will be applied to decide if the trial must be stopped after the enrolment of the 23rd patient.","Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZETAL07","January 2008","January 2009","September 2011","May 15, 2009","null","December 31, 2012","Divisione di Ematologia Ospedale SS Antonio e Biagio, Alessandria, AL, Italy|Istituto di Ematologia e Oncologia Medica L. Seragnoli Policlinco S. Orsola, Bologna, BO, Italy|Divisione di Ematologia, Spedali Civili, Brescia, BS, Italy|Divisione di Ematologia Ospedale Centrale di Bolzano, Bolzano, BZ, Italy|Divisione di Ematologia Ospedale Businco, Cagliari, CA, Italy|Divisione di Ematologia Ospedale Cardinale Panico, Tricase, LE, Italy|Divisione di Ematologia Ospedale Niguarda Cà Granda, Milano, MI, Italy|Divisione di Oncoematologia IRCC, Candiolo, TO, Italy|Divisione di Ematologia Istituto Nazionale Fondazione Pascale, Napoli, Italy|SC Ematologia Ospedale Maggiore Università Avogadro, Novara, Italy|Divisione di Oncoematologia Azienda Ospedalier S. Maria, Terni, Italy|SCDO Ematologia 2 AOU San Giovanni Battista, Turin, Italy","","https://ClinicalTrials.gov/show/NCT00902525"
301,"NCT02134262","Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",,"Unknown status","No Results Available","Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Drug: Cyclophosphamide or Bendamustine|Genetic: Dose Level -1|Genetic: Dose Level 1|Genetic: Dose Level 2|Genetic: Dose Level 3","Toxicity Profile|Quality test of CD19-CAR-T|Tumor shrinkage effect|Lymphocyte subset analysis of CD19-CAR-T|Human anti-mouse antibody (HAMA) test","Jichi Medical University|Takara Bio Inc.","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JMU-CD19CAR","May 2014","March 2017","March 2017","May 9, 2014","null","November 6, 2014","Jichi Medical University, Shimotsuke, Tochigi, Japan","","https://ClinicalTrials.gov/show/NCT02134262"
302,"NCT00577629","Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma",,"Completed","Has Results","Lymphoma, B-Cell","Drug: cyclophosphamide|Drug: etoposide|Drug: rituximab|Drug: cytarabine|Drug: doxorubicin|Drug: tositumomab","1 Year Progression-free Survival Rate|Disease-free Survival|Overall Survival|Overall Response|Secondary Malignancies","Duke University|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00007096|GSK-103421|5762","June 18, 2005","April 8, 2012","November 3, 2016","December 20, 2007","April 15, 2013","May 30, 2017","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00577629"
303,"NCT00924326","CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma",,"Active, not recruiting","No Results Available","Primary Mediastinal B-cell Lymphoma|Diffuse, Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma|Mantle Cell","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR PBL","Frequency and severity of treatment-related adverse events.|In vivo survival of anti-CD19- CAR-transduced T-cells|Regression of B-cell malignancies","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","43","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","090082|09-C-0082","February 17, 2009","September 30, 2015","December 31, 2020","June 18, 2009","null","September 25, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00924326"
304,"NCT02700022","A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas",,"Terminated","No Results Available","Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma","Drug: Alisertib","Maximum tolerated dose (MTD)|Toxicity|Rate of Response|Progression free survival","UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1503","October 2016","November 15, 2016","August 18, 2017","March 7, 2016","null","November 20, 2017","City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hills, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02700022"
305,"NCT02388581","First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL",,"Recruiting","No Results Available","Gastric Diffuse Large B-cell Lymphoma","Drug: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole","The pathologic complete remission rate (%) for antibiotics as 1st-line therapy for early-stage Hp-positive gastric pure (de novo) DLBCL|The median time to pathologic complete remission (months) after completion of antibiotics for Hp-dependent gastric pure (de novo) DLBCL (patients have pCR after Hp eradication therapy [antibiotics])|The relapse-free survival of early-stage Hp-positive gastric pure (de novo) DLBCL who received antibiotics as 1st-line therapy|The overall survival of early-stage Hp-positive gastric pure (de novo) DLBCL who received antibiotics as 1st-line therapy|The Hp eradication rate (%)","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Mackay Memorial Hospital|China Medical University Hospital|Taichung Veterans General Hospital|Changhua Christian Hospital|National Cheng-Kung University Hospital|Chang Gung Memorial Hospital|Kaohsiung Medical University","All","Child, Adult, Older Adult","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T2214","December 2014","December 2017","December 2024","March 17, 2015","null","March 25, 2016","National Health Research Institutes, Zhunan, Miaoli County, Taiwan","","https://ClinicalTrials.gov/show/NCT02388581"
306,"NCT03401853","Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Biological: Rituximab","Overall response rate|Incidence of serious or drug-related adverse events|Progression-free survival (PFS)|Overall survival (OS)","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","37","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9469|NCI-2017-02361|P30CA015704","May 29, 2018","February 15, 2021","February 15, 2021","January 17, 2018","null","April 9, 2018","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03401853"
307,"NCT00211276","A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma, B-Cell","Drug: ONTAK (denileukin diftitox)","Disease Response will be evaluated by CT or MRI scans at baseline, every 8 weeks while on therapy, and every 3 months after therapy, using standard response criteria defined by Cheson et al.|Safety data will include laboratory, history and physical, and adverse events reports for both local and systemic signs or symptoms of study patients. Survival at one year post-therapy will also be assessed.","Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#123","March 2005","January 2007","February 2007","September 21, 2005","null","March 14, 2012","Tower Cancer Research Foundation, Beverly Hills, California, United States|Pacific Coast Hematology/Oncology, Fountain Valley, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|Washington University Siteman Cancer Center, St. Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|St. Vincent's Comprehensive Cancer Center, New York, New York, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00211276"
308,"NCT00073749","Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma, B-Cell","Drug: Inotuzumab ozogamicin [CMC-544]","Safety profile|Progression-free survival|Overall survival|Response|Best overall response after 5 years","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3129K1-100|B1931002","August 2003","December 2010","December 2010","December 5, 2003","null","February 15, 2013","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmington, Alabama, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Pierre Benite Cedex, France|Pfizer Investigational Site, Bonn, NRW, Germany|Pfizer Investigational Site, Mainz, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Lausanne, Switzerland|Pfizer Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00073749"
309,"NCT03298412","Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCT",,"Recruiting","No Results Available","High-risk Diffuse Large B-cell Lymphoma","Drug: Blinatumomab","Minimal residual disease|Progression-free survival|Duration of MRD-negative status|Overall Survival|Adverse Events","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150291|2016-003255-30","May 23, 2018","September 4, 2020","May 31, 2021","October 2, 2017","null","September 14, 2018","Research Site, Atlanta, Georgia, United States|Research Site, Maywood, Illinois, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dallas, Texas, United States|Research Site, St Leonards, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Charleroi, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Créteil Cedex, France|Research Site, Lille, France|Research Site, Marseille, France|Research Site, Montpellier cedex 5, France|Research Site, Paris Cedex 10, France|Research Site, Pessac Cedex, France|Research Site, Pierre Benite Cedex, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Bergamo, Italy|Research Site, Brescia, Italy|Research Site, Firenze, Italy|Research Site, Palermo, Italy|Research Site, Bellinzona, Switzerland|Research Site, Bern, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Zuerich, Switzerland","","https://ClinicalTrials.gov/show/NCT03298412"
310,"NCT00299494","Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)",,"Completed","Has Results","B-Cell Lymphoma","Drug: inotuzumab ozogamicin|Drug: Rituximab","Maximum Tolerated Dose (MTD) of Inotuzumab Ozogamicin in Combination With Rituximab (375 mg/m^2 )|Percentage of Participants With a Treatment Emergent Adverse Event (TEAE) (Safety Population)|Percentage of Participants With Complete Response (CR), Unconfirmed CR (CRu), or Partial Response (PR)|Kaplan-Meier Estimates of Progression Free Survival (PFS)|Kaplan-Meier Estimates of the Probability of Being Progression Free at 6 Months|Kaplan-Meier Estimates of Overall Survival (OS)|Kaplan-Meier Estimates of the Probability of Survival at 6 Months|Kaplan-Meier Estimates of Time to Tumor Progression (TTP)|Kaplan-Meier Estimates of the Probability of Being Event Free at 6 Months|Duration of Response (CR+CRu+PR)|Area Under the Serum Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|AUClast of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of the Last Quantifiable Serum Concentration in a Dosing Interval (Tlast) of Inotuzumab Ozogamicin in Participants Receving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Area Under the Steady-state Serum Concentration-time Curve (AUCtau) of Inotuzumab Ozogamicin in Participants Receving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Peak Serum Concentration (Cmax) of Inotuzumab Ozogamicin in Participants Receving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time to Reach Maximum Concentration (Tmax) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Average Serum Concentration at Steady State (Cav) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Minimum Observed Serum Trough Concentration (Cmin) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab+Rituximab on Dosing Day 30 and Day 58|Clearance (CL) of Serum Inotuzumab Ozogamicin in Participants Receiving Inotuzumab+Rituximab on Dosing Day 30 and Day 58|Steady-state Volume of Distribution (Vss) of Inotuzumab Ozogamicin in Serum in Participants Receiving Inotuzumab MTD+Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|MRT of Inotuzumab Ozogamicin in Serum in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Serum Decay Half-Life (t1/2) of Inotuzumab Ozogamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|AUCinf of Total Calicheamicin (Conjugated + Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|AUClast of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of the Last Quantifiable Concentration in a Dosing Interval (Tlast) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Area Under the Steady-state Serum Concentration-time Curve (AUCtau) for Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30, and Day 58|Peak Serum Concentration (Cmax) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of Observed Maximum Concentration (Tmax) of Total Calicheamicin (Conjugated+Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Average Serum Concentration (Cav) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Minimum Observed Serum Trough Concentration (Cmin) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Clearance (CL) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Steady-state Volume (Vss) of Total Calicheamicin (Conjugated Plus Unconjugated) Distribution in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Mean Residence Time (MRT) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Serum Decay Half-Life (t1/2) of Total Calicheamicin (Conjugated Plus Unconjugated) in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Area Under the Steady-state Serum Concentration-time Curve (AUClast) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of the Last Quantifiable Concentration in a Dosing Interval (Tlast) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Peak Serum Concentration (Cmax) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of Observed Maximum Concentration (Tmax) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin + Rituximab on Dosing Day 1, Day 30 and Day 58|Minimum Observed Serum Trough Concentration (Cmin) of Unconjugated Calicheamicin in Participants Receiving Inotuzumab Ozogamicin+Rituximab on Dosing Day 30 and Day 58|Area Under the Serum Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m2 on Dosing Day 30 and Day 58|Area Under the Steady-state Concentration-time Curve (AUClast) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time of the Last Quantifiable Concentration in a Dosing Interval (Tlast) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Serum Decay Half-Life (t1/2) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab on Dosing Day 30 and Day 58|Area Under the Steady-state Serum Concentration-time Curve (AUCtau) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD+ Rituximab 375 mg/m^2 on Dosing Day 1, Day 30, and Day 58|Peak Concentration (Cmax) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Time to Reach Maximum Concentration (Tmax) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 1, Day 30 and Day 58|Average Serum Concentration (Cav) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Minimum Observed Serum Trough Concentration (Cmin) of Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Clearance (CL) of Serum Inotuzumab Ozogamicin Antibody in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58|Steady-state Volume (Vss) of Inotuzumab Ozogamicin Antibody Distribution in Participants Receiving Inotuzumab Ozogamicin MTD + Rituximab 375 mg/m^2 on Dosing Day 30 and Day 58","Pfizer|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","119","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3129K3-101|B1931004|2005-005436-27","May 4, 2006","May 19, 2014","June 2, 2014","March 6, 2006","March 8, 2018","March 8, 2018","University of Alabama at Birmingham-, Birmingham, Alabama, United States|IDS Pharmacy, Birmingham, Alabama, United States|University of Alabama at Birmingham-, Birmingham, Alabama, United States|California Cancer Care, Inc., Greenbrae, California, United States|University of California Medical Center, San Francisco, California, United States|California Cancer Care, San Mateo, California, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Emory University Investigational Drug Service, Atlanta, Georgia, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Nevada Cancer Institute-, Las Vegas, Nevada, United States|Rosewell Park Cancer Institute, Buffalo, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Gabrail Cancer Center, Dover, Ohio, United States|UHHS - Westlake, Westlake, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Royal Brisbane and Women's Hospital, Herston, Brisbane, QLD, Australia|Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Vlaams-brabant, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|University Hospital Gent - Department of Hematology, Gent, Belgium|Hôpital André MIGNOT, Le Chesnay, France|Hôpital Saint-Louis, Paris, France|CH Lyon Sud, Pierre Benite, France|Universitaetsklinik Bonn, Medizinische Klinik und Poliklinik III, Bonn, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet, III. medizinische klinik und Poliklinik, Mainz, Germany|Prince Of Wales Hospital, Shatin N.T., Hong Kong|Universita La Sapienza Cattedra di Ematologia, Roma, Italy|Asan Medical Center, Seoul, Korea, Republic of|Erasmus Medisch Centrum--, Rotterdam, Zuid-holland, Netherlands|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|University Hospital Zurich, Zurich, Switzerland|Derriford Hospital - Plymouth, Plymouth, Devon, United Kingdom|Somers Cancer Science Building MP824, Southampton, Hampshire, United Kingdom|Bart's Cancer Institute; Queen Mary University of London, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00299494"
311,"NCT03321643","Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Drug: Atezolizumab|Drug: Gemcitabine|Other: Laboratory Biomarker Analysis|Drug: Oxaliplatin|Biological: Rituximab","Incidence of adverse events|Complete response rate|Best overall response rate (complete response + partial response)|Biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2017-01957|PHI-96|10126|UM1CA186717","March 7, 2018","March 31, 2020","March 31, 2020","October 26, 2017","null","August 10, 2018","City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT03321643"
312,"NCT01569750","A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",,"Completed","No Results Available","CD20-positive B-cell Non-Hodgkin Lymphoma","Drug: Part 1, Cohort 1|Drug: Part 1, Cohort 2|Drug: Part 1, Cohort 3|Drug: Part 2, Cohort 1|Drug: Part 2, Cohort 2","Part 1 maximum tolerated dose of ibrutinib|The number of participants affected by a dose-limiting toxicity|Number of participants with potential drug-drug interactions between ibrutinib and vincristine|Overall response rate|Duration of response|Progression-free survival|Mean plasma concentrations of ibrutinib|Maximum observed plasma concentration of ibrutinib|Time to reach the maximum plasma concentration of ibrutinib|Area under the plasma concentration-time curve from time 0 to 24 hours of ibrutinib|Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of ibrutinib|Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of vincristine|Partial area under the plasma concentration versus time curve of vincristine|The number of participants with pharmacodynamic markers of ibrutinib in peripheral blood mononuclear cells|The number of participants with biomarkers predictive of clinical response|The number of participants affected by an adverse event","Janssen Research & Development, LLC|Pharmacyclics LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100844|PCI-32765DBL1002|2012-000546-35","June 14, 2012","September 4, 2014","September 4, 2014","April 3, 2012","null","August 22, 2017","New York, New York, United States|Rochester, New York, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Lille Cedex, France|Paris, France|Vandoeuvre Les Nancy, France","","https://ClinicalTrials.gov/show/NCT01569750"
313,"NCT00271050","External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma, B-Cell","Other: external beam radiotherapy plus 90-Y ibritumomab tiuxetan","PET and CT (w/oral and IV contrast)","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 7883|CCF IRB 7883|Case 1405","December 2005","December 2007","June 2010","December 29, 2005","null","December 21, 2010","Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00271050"
314,"NCT00515138","A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant",,"Terminated","No Results Available","Lymphoma, B-Cell","Drug: Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib","-Determine the maximum tolerated dose of bortezomib in combination with rituximab, ifosfamide, carboplatin, and etoposide for patients with relapsed or primary refractory aggressive B-cell NHL","University of California, San Francisco","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UC-CC06253","May 2007","November 2011","November 2011","August 13, 2007","null","April 12, 2012","University of California San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT00515138"
315,"NCT03558750","Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma",,"Recruiting","No Results Available","Recurrent Central Nervous System Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Central Nervous System Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Biological: Nivolumab|Biological: Rituximab|Drug: Lenalidomide","Dose limiting toxicity (DLT) (Phase I)|Overall response rate (complete response, partial response, or stable disease) (Phase II)|Time to progression (complete response, partial response, or stable disease)|Progression free survival|Overall survival|Incidence of adverse events per national Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03|Difference in overall response rate between those with and without programmed cell death ligand 1 (PD-L1) protein expression in tumor (subgroup analysis)|Difference in overall response rate between those with and without MYD88 mutation in tumor (subgroup analysis)","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC PCL 1758|NCI-2018-01092","June 14, 2018","May 31, 2022","May 31, 2023","June 15, 2018","null","June 18, 2018","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03558750"
316,"NCT03488251","PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_002)",,"Recruiting","No Results Available","Non-hodgkin Lymphoma,B Cell|Refractory Diffuse Large B-Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma","Drug: MT-3724","Tolerability as measured by number of subjects with dose limiting toxicities|Safety measured by number of subjects with Adverse Events using CTCAE|PK as measured by concentrations of free MT-3724 (Maximum Plasma Concentration [Cmax])|PK as measured by concentrations of free MT-3724 (Area Under the Curve [AUC])|PK as measured by concentrations of free MT-3724 (Time to reach maximum concentration after drug administration [Tmax])|PD as measured by tumor response|PD as measured by MT-3724 [anti-drug antibody (ADA) titer and neutralizing antibody (NA)]|PD as measured by B-cell count in peripheral blood as determined by flow cytometry measured against MT-3724 serum concentrations at pre-specified time points|PD as measured by by immunophenotype in peripheral blood, as determined by flow cytometry measured against MT-3724 serum concentrations at pre-specified time points|Tumor Response as measured by PET or CT scan","Molecular Templates, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT-3724_NHL_002","August 20, 2018","July 31, 2020","February 15, 2022","April 4, 2018","null","September 18, 2018","Good Samaritan Hospital, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03488251"
317,"NCT02361346","PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia","MT-3724NHL001","Recruiting","No Results Available","Non-Hodgkin's B-cell Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell|Small Lymphocytic Leukemia","Drug: MT-3724","Tolerability as measured by number of subjects with dose limiting toxicities|Safety as measured by number of subjects with Adverse Events using CTCAE|Tolerability as measured by adverse events using CTCAE and clinical laboratory parameters|PK as measured by concentrations of free MT-3724 (Cmax, AUC, tmax, Cinf)|PD as measured by clinical symptoms, tumor response, immunogenicity|Tumor Response as measured by PET or CT scan","Molecular Templates, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT-3724_NHL_001","February 2015","September 2019","September 2019","February 11, 2015","null","September 18, 2018","University of Arizona, Tucson, Arizona, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York University Langone Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada|LLC ARENSIA Exploratory Medicine, Tbilisi, Georgia|ARENSIA Exploratory Medicine,, Chisinau, Moldova, Republic of","","https://ClinicalTrials.gov/show/NCT02361346"
318,"NCT01148108","Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma",,"Completed","No Results Available","Mantle Cell Lymphoma|B Cell Lymphoma|Multiple Myeloma","Drug: Canfosfamide HCl for injection","Objective Response Rate|Duration of Response|Safety Assessments","Telik","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TLK286.2030","June 2010","September 2012","September 2012","June 22, 2010","null","March 15, 2013","Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01148108"
319,"NCT03571828","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma",,"Not yet recruiting","No Results Available","Diffuse Large B-cell Lymphoma(DLBCL)|Mantle Cell Lymphoma (MCL)|Follicular Lymphoma (FL)","Drug: AMG 562","Incidence of dose limiting toxicities (DLTs)|Incidence of treatment-emergent adverse events|Incidence of treatment-related adverse events|Incidence of disease-related events|Incidence of clinically-significant changes in vital signs|Incidence of clinically-significant changes in physical examinations|Incidence of clinically-significant changes in electrocardiograms (ECG)s|Maximum observed concentration (Cmax) of AMG 562|minimum concentration (Cmin)|time of maximum concentration (Tmax)|area under the concentration-time curve (AUC)","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170533","September 24, 2018","November 4, 2020","November 4, 2020","June 28, 2018","null","September 11, 2018","Research Site, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT03571828"
320,"NCT02282358","Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma|Relapsed and Refractory|Diffuse Large B-Cell Lymphoma and Follicular Lymphoma","Drug: Mocetinostat","efficacy as defined by overall response|event free survival|duration of response|toxicity according to the (NCI CTCAE) Version 4.0.","Memorial Sloan Kettering Cancer Center|MethylGene Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-106","October 2014","October 2019","October 2019","November 4, 2014","null","April 6, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02282358"
321,"NCT00556127","Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma","DLBCL","Completed","No Results Available","Diffuse Large B-Cell Lymphoma|POOR PROGNOSIS","Drug: Rituximab|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone|Drug: Granulocyte-colony-stimulating factor|Drug: Mitoxantrone|Drug: Cytarabine ARA-C|Drug: Dexamethasone|Drug: Carmustine BCNU|Drug: Etoposide|Drug: Melphalan|Radiation: Radiotherapy|Procedure: PBSC reinfusion","Failure-free survival","Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie","All","18 Years to 60 Years   (Adult)","Phase 2","94","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMURELL-DLBCL|Eudract Number 2004-000543-19","June 2002","null","September 2006","November 9, 2007","null","November 9, 2007","Az. Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Ospedale Regionale, Divisione di Oncologia,, Aosta, Italy|Azienda Ospedaliera Ospedale Policlinico Consorziale, Bari, Italy|Osp. degli Infermi, Biella, Italy|Spedali Civili, Brescia, Italy|Centro Trapianti Midollo Osseo, P.O. Businco, Cagliari, Italy|Ospedale S. Gerardo, Monza, Italy|Osp. maggiore della Carità, Novara, Italy|Università degli Studi Policlinico Monteluce, Perugia, Italy|Divisione di Medicina, Ospedale Generale E. Agnelli, Pinerolo, Torino, Italy|Istituto per la Ricerca e la Cura del Cancro, Candiolo, Torino, Italy|Osp. S. Giovanni Battista ""Molinette"", Torino, Italy|Ospedale di Chivasso e Ivrea, Torino, Italy|Stabilimento Ospedaliero Ciriè -, Torino, Italy","","https://ClinicalTrials.gov/show/NCT00556127"
322,"NCT03340766","Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)",,"Recruiting","No Results Available","Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)","Drug: Blinatumomab|Drug: Pembrolizumab","Incidence of dose limiting toxicities (DLTs)|Objective Response Rate|Progression Free Survival|Overall Survival|Complete Response rate|Duration of response|Blinatumomab Steady state concentration|Blinatumomab Clearance rate|Pembrolizumab Peak Plasma Concentration|Pembrolizumab Minimum plasma concentration|Pembrolizumab PK Parameter - AUC","Amgen|Merck Sharp & Dohme Corp.","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150290|2016-002191-27","March 16, 2018","March 22, 2021","January 24, 2025","November 14, 2017","null","April 27, 2018","Research Site, Charleston, South Carolina, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia","","https://ClinicalTrials.gov/show/NCT03340766"
323,"NCT01478542","OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine","OPTIMAL>60","Recruiting","No Results Available","CD20+ Aggressive B-Cell Lymphoma","Drug: Conventional Vincristine|Drug: Liposomal Vincristine|Drug: Ricover-scheme rituximab|Drug: optimised rituximab-schedule","Progression-free survival|for efficacy: CR-rate, PR-rate, rate of primary progressions, relapse rate, EFS and OS; rate and CTC grades of PNP. Prognostic value of the FDG-PET derived imaging biomarkers for lymphoma load: SUV, MTV, TLG.","University Hospital, Saarland|German High-Grade Non-Hodgkin's Lymphoma Study Group|Spectrum Pharmaceuticals, Inc","All","61 Years to 80 Years   (Adult, Older Adult)","Phase 3","1152","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSHNHL 2009-1","November 2011","October 2019","October 2019","November 23, 2011","null","July 16, 2018","Saarland University Hospital, Homburg, Saarland, Germany|Klinikum St. Marien Amberg, MVZ, Amberg, Germany|Klinikum Augsburg, Medizinische Klinik II, Augsburg, Germany|Praxis Dres. med. Brudler, Heinrich, Bangerter, Augsburg, Germany|Gemeinschaftspraxis Dres. Reichert, Janssen, Aurich, Germany|Helios Klinikum Bad Saarow, Klinik für Innere Medizin III, Bad Saarow, Germany|Sozialstiftung Bamberg, Med. Klinik V, Bamberg, Germany|Klinikum Bayreuth, Medizinische Klinik IV, Bayreuth, Germany|Charité- Universitätsmedizin Berlin, Campus Benjamin Franklin, Med. Klinik III, Berlin, Germany|Knappschaftskrankenhaus Bochum, Bochum, Germany|Johanniter Krankenhaus Bonn, Abteilung für Innere Medizin I, Bonn, Germany|Universitätsklinikum Bonn, Med. Klinik III, Bonn, Germany|Städt. Klinikum Brandenburg, Med. Klinik II, Brandenburg, Germany|Evangelisches Diakonie-Krankenhaus Bremen, Bremen, Germany|Praxis Dr. Obst, Burgwedel, Germany|Praxis Dr. Marquard, Celle, Germany|Klinikum Chemnitz, Innere Medizin III, Chemnitz, Germany|Klinikum Coburg, V. Med. Klinik, Coburg, Germany|Schwerpunktpraxis Dres. Glados/Retzlaff/Zühlsdorf/Deuticke, Coesfeld, Germany|St. Johannes Hospital Dortmund, Med. Klinik II, Dortmund, Germany|BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Germany|Gemeinschaftspraxis Dres. Mohm, Prange-Krex, Dresden, Germany|Universitätsklinikum Erlangen, Med. Klinik 5, Erlangen, Germany|St.-Antonius-Hospital Eschweiler, Hämatologie und Onkologie, Eschweiler, Germany|Klinikum Esslingen, Klinik für Gastroenterologie, Onkologie und Innere Medizin, Esslingen, Germany|Klinikum Frankfurt (Oder), Abteilung f. Innere Medizin, Frankfurt (Oder), Germany|Klinikum der J.W. Goethe-Universität Frankfurt, Hämatologie/Onkologie, Frankfurt, Germany|Krankenhaus Nordwest Frankfurt, II. Med. Klinik, Frankfurt, Germany|Praxis Dr. med. Reiber, Freiburg, Germany|Universitätsklinikum Freiburg, Innere Medizin I, Freiburg, Germany|Klinikum Fulda, Med. Klinik III, Fulda, Germany|St. Josef-Hospital Gelsenkirchen, Onkologie und Hämatologie, Gelsenkirchen, Germany|Praxis Dr. med. Schliesser, Gießen, Germany|Wilhelm-Anton-Hospital Goch, Innere Medizin, Goch, Germany|Onkologische Kooperation Harz, Onkologische Schwerpunktpraxis, Goslar, Germany|Universitätsmedizin Greifswald, Medizinische Universitätsklinik C, Hämatologie und Onkologie, Greifswald, Germany|Kreiskrankenhaus Gummersbach, Gummersbach, Germany|Universitätsmedizin Göttingen, Hämatologie und Onkologie, Göttingen, Germany|Klinikum Gütersloh, Gütersloh, Germany|Kath. Krankenhaus Hagen, St.-Marien-Hospital, Hagen, Germany|Gemeinschaftspraxis Rohrberg, Hurtz, Schmidt, Frank-Gleich, Halle (Saale), Germany|Asklepios Klinik St. Georg, Hämatologie/Onkologie, Hamburg, Germany|Hämatolog.-onkolog. Praxis Dres. Müller-Hagen, Bertram, Albertinen-Krankenhaus, Hamburg, Germany|Hämatologisch-onkologische Praxis Altona (HOPA), Hamburg, Germany|Universitätsklinikum Hamburg-Eppendorf (UKE), II. Med. Klinik und Poliklinik, Onkologie und Hämatologie, Hamburg, Germany|Klinikum Hannover-Siloah, Med. Klinik III, Hannover, Germany|Medizinische Hochschule Hannover (MHH), Zentrum für Innere Medizin, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Hannover, Germany|Praxis MediProjekt, Hannover, Germany|Universitätsklinikum Heidelberg, Innere Medizin V, Heidelberg, Germany|Klinikum Kreis Herford, Med. Klinik II, Herford, Germany|Onkologische Schwerpunktpraxis Dres. Freier, Sievers, Hildesheim, Germany|St. Bernward Krankenhaus Hildesheim, Med. Klinik II, Hildesheim, Germany|KMT Klinik Idar-Oberstein, Idar-Oberstein, Germany|Universitätsklinikum Jena, Klinik für Innere Medizin II, Jena, Germany|Praxis Dres Hansen, Reeb, Kaiserslautern, Germany|St. Vincentius Kliniken Karlsruhe, Med. Klinik Abt. 2, Karlsruhe, Germany|Städtisches Klinikum Karlsruhe, II. Med. Klinik, Hämatologie/Onkologie/Infektionskrankheiten, Karlsruhe, Germany|GMP Dres Siehl, Söling, Kassel, Germany|Rotes Kreuz Krankenhaus Kassel, Klinik für Interdisziplinäre Onkologie, Kassel, Germany|Klinikum Kempten-Oberallgäu, Hämatologie, Onkologie und Palliativmedizin, Kempten, Germany|Gemeinschaftsklinikum Mittelrhein, Ev. Stift St. Martin, Innere Medizin, Koblenz, Germany|Gemeinschaftspraxis Dres. Neise, Lollert, Krefeld, Germany|Praxis Dr. Strauch, Kronach, Germany|Gemeinschaftspraxis Dres. Schmitz, Steinmetz, Severin, Köln, Germany|Klinikum der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany|Krankenhaus Holweide, Köln, Germany|Klinikum Landshut, Med. Klinik I, Landshut, Germany|Caritas Krankenhaus Lebach, Lebach, Germany|Onkologische Schwerpunktpraxis, Leer, Germany|Klinikum St. Georg Leipzig, Abteilung für internistische Onkologie/Hämatologie, Leipzig, Germany|Klinikum Lippe-Lemgo, Med. Klinik II, Lemgo, Germany|Evangelisches Krankenhaus Paul Gerhardt Stift, Klinik für Innere Medizin II, Lutherstadt Wittenberg, Germany|Onkologische Schwerpunktpraxis Lörrach, Lörrach, Germany|Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany|Klinikum Magdeburg, Hämatologie/Onkologie, Magdeburg, Germany|Universitätsmedizin Mainz, III. Med. Klinik und Poliklinik, Mainz, Germany|Mannheimer Onkologie Praxis, Dres. Brust, Plöger, Schuster, Hensel, Mannheim, Germany|Universitätsklinikum Gießen und Marburg, Marburg, Germany|Johannes Wesling Klinikum, Klinik für Hämatologie, Onkologie und Palliativmedizin, Minden, Germany|Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin, Mutlangen, Germany|Kliniken Maria-Hilf Mönchengladbach, Innere Medizin I, Mönchengladbach, Germany|GMP Dres Schröder/Sieg, Mülheim an der Ruhr, Germany|Klinikum Großhadern, Med. Klinik 3, München, Germany|Klinikum rechts der Isar der Technischen Universität München, III. Med.Klinik, München, Germany|Praxis Dres. Schick, Schmidt, Fromm, Wiesmeier, Schick, Galler, Klapthor, München, Germany|Städtisches Klinikum München Harlaching, München, Germany|GMP Dres Kriebel-Schmitt, Pelz, Münster, Germany|Onkologische Praxis Dr. Ladda, Neumarkt, Germany|Lukaskrankenhaus Neuss, Med. Klinik II, Neuss, Germany|Kreiskliniken Esslingen, Klinikum Kirchheim-Nürtingen, Hämatologie, Internist. Onkologie und Palliativmedizin, Nürtingen, Germany|Gemeinschaftspraxis Dres. Balló, Böck, Offenbach, Germany|Ortenau Klinikum Offenburg-Gegenbach, Medizinische Klinik II, Offenburg, Germany|Klinikum Oldenburg, Hämatologie/Onkologie, Oldenburg, Germany|Onkologische Schwerpunktpraxis Dr. Hübner, Oldenburg, Germany|Pius Hospital Oldenburg, Klinik für Strahlentherapie und Internistische Onkologie, Oldenburg, Germany|Onkologische Schwerpunktpraxis im MVZ 2 GmbH, Dr. H. Eimermacher, Olpe, Germany|Klinikum Osnabrück, Med. Klinik III, Osnabrück, Germany|Paracelsus Krankenhaus Ruit, Kreiskliniken Esslingen gGmbH, Zentrum für Allgemeine Innere Medizin, Ostfildern, Germany|Brüderkrankenhaus St. Josef Paderborn, Klinik für Hämatologie und Onkologie, Paderborn, Germany|Gemeinschaftspraxis Dres. Baake, Leonhardt, Moegling, am Regio Klinikum Pinneberg, Pinneberg, Germany|Klinikum Ernst von Bergmann, Klinik für Hämatologie, Onkologie und Palliativmedizin, Potsdam, Germany|Gemeinschaftspraxis Dres. Decker, Nonnenbroich, Herbrik-Zipp, Ravensburg, Germany|Prosper-Hospital Recklinghausen, Med. Klinik I, Recklinghausen, Germany|Krankenhaus Barmherzige Brüder Regensburg, Klinik für Onkologie und Hämatologie, Regensburg, Germany|Klinikum am Steinenberg, Kreiskliniken Reutlingen GmbH, Reutlingen, Germany|Elblandklinikum Riesa, Klinik für Innere Medizin II, Riesa, Germany|Klinikum Südstadt Rostock, Innere Medizin, Rostock, Germany|Universitätsklinikum Rostock, Abteilung Hämatologie/Onkologie, Klinik u. Poliklinik für Innere Medizin, Rostock, Germany|GMP Dres Jacobs, Daus, Schmits, Saarbrücken, Germany|ZAHO-Siegburg, Zentrum für ambulante Hämatologie und Onkologie Siegburg, Siegburg, Germany|Diakonie-Klinikum Stuttgart, Med. Klinik II, Stuttgart, Germany|Klinikum Traunstein, Hämatologie/Onkologie, Traunstein, Germany|Klinikum Mutterhaus der Borromäerinnen, Med. Abteilung I, Trier, Germany|Krankenhaus der Barmherzigen Brüder Trier, I. Med. Abteilung, Trier, Germany|Universitätsklinikum Tübingen, Medizinische Klinik und Poliklinik, Onkologie, Hämatologie, Immunologie und Rheumatologie, Tübingen, Germany|Universitätsklinikum Ulm, Innere Medizin III, Ulm, Germany|Katharinen Hospital Unna, Unna, Germany|Med. Versorgungszentrum Weiden, Abteilung für Onkologie, Weiden, Germany|Praxis Dres med. Perker, Sandherr, Weilheim, Germany|HSK Wiesbaden, Innere Medizin III, Wiesbaden, Germany|Helios Klinkum Wuppertal, Med. Klinik I, Wuppertal, Germany|Hämatologisch-Onkologische Praxis Würselen, Würselen, Germany","","https://ClinicalTrials.gov/show/NCT01478542"
324,"NCT00768339","A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas",,"Terminated","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, B-Cell","Drug: AEG35156 antisense IV infusion","Objective tumor response according to CLL NCI-WG criteria","Aegera Therapeutics|The Leukemia and Lymphoma Society","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AEG35156-204","September 2008","June 2011","September 2011","October 8, 2008","null","July 13, 2011","Providence Saint-Joseph Medical Center, Burbank, California, United States|New York Medical College, Valhalla, New York, United States|The Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital - Sir Mortimer B. Davis, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT00768339"
325,"NCT02564744","Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|B-cell Non-Hodgkin's Lymphoma","Drug: Debio 1562|Drug: Rituximab","Number of Participants with Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Objective Response Rate (ORR)|Maximum plasma drug concentration (Cmax) of Debio 1562 and Rituximab|Area under the time-concentration curve from time 0 to t (AUC0-t) of Debio 1562 and Rituximab|Area under the time-concentration curve from time 0 to infinity (AUC0-inf) of Debio 1562 and Rituximab|Terminal half-life (t1/2) of Debio 1562 and Rituximab|Clearance (CL) of Debio 1562 and Rituximab|Volume of Distribution at Steady State (Vss) of Debio 1562 and Rituximab|Time to Maximum Plasma Concentration (Tmax) of Debio 1562 and Rituximab|Progression-free survival (PFS)|Time to response|Duration of response (DOR)|Overall survival (OS)|Number of participants with presence of human anti-drug antibody (ADA) for Debio 1562","Debiopharm International SA","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Debio 1562-201|2015-004061-87","May 2016","July 2019","July 2019","October 1, 2015","null","September 28, 2018","Alabama Oncology, Birmingham, Alabama, United States|VA Central California Health Care System, Fresno, California, United States|Smilow Cancer Center at Yale New Haven Hospital, New Haven, Connecticut, United States|Loyola University Medical Center, Maywood, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University of Michigan Medical Center, Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|Novant Health Oncology, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|CHU UCL Namur asbl - Site Godinne, Yvoir, Namur, Belgium|Jan Yperman Ziekenhuis, Ieper, West-Vlaanderen, Belgium|University Hospitals Leuven, Campus Gasthuisberg, Department of Medical Oncology, Leuven, Belgium|St. Augustinus Hospital, Department of Hematology, Wilrijk, Belgium|University Hospital Brno, Brno, Czechia|University Hospital Hradec Kralove, Hradec Králové, Czechia|University Hospital Kralovske Vinohrady, Prague, Czechia|General University Hospital in Prague, Prague, Czechia|Semmelweis University, Budapest, Hungary|National Institute of Oncology, Budapest, Hungary|University of Debrecen Clinical Center, Debrecen, Hungary|Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Nyíregyháza, Hungary|Medical Center of the University of Pecs, Pécs, Hungary|Civil Hospital of Brescia, Brescia, Italy|Oncology Institute of Southern Switzerland - Ospedale Regionale Bellinzona e Valli, Bellinzona, Ticino, Switzerland|Inselspital, University Hospital Bern, Department of Medical Oncology, Bern, Switzerland|Canton Hospital Winterthur, Winterthur, Switzerland","","https://ClinicalTrials.gov/show/NCT02564744"
326,"NCT02495454","GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma","FIL_GAEL","Suspended","No Results Available","CD20 Positive Diffuse Large B-cell Lymphoma|Elderly Unfit Patients","Drug: Ga101","Complete Response Rate (CRR)|Adverse Events (AEs)|PRR|ORR|OS|PFS|Activities of daily living (ADL)|Instrumental Activities of Daily Living (IADL)|Cumulative Illness Rating Scale (CIRS)|Questionnaire for quality of life (EORTC QLQ C30)","Fondazione Italiana Linfomi ONLUS","All","65 Years and older   (Older Adult)","Phase 2","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_GAEL|2014-005697-10","May 2015","June 2018","June 2020","July 13, 2015","null","May 22, 2018","A.O. Spedali Civili, Brescia, BS, Italy|AUSL di Ravenna, Ravenna, RA, Italy|Asmn-Irccs, Reggio Emilia, RE, Italy|Ematologia 1U - AO Città della Salute e della Scienza, Torino, TO, Italy|A.O. S. Maria di Terni, Terni, TR, Italy|A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy|A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona, Ancona, Italy|A.O. Ospedale Degli Infermi, Biella, Italy|Area Vasta Romagna e IRST, Meldola (FC), Italy|IRCCS, Istituto Nazionale dei Tumori, Milano, Italy|A.O. Universitaria Policlinico Di Modena, Modena, Italy|SCDU Ematologia - Università del Piemonte Orientale, Novara, Italy|Oncoematologia e TMO Dopartimento Oncologia La Maddalena, Palermo, Italy|Ausl Di Piacenza, Piacenza, Italy|Ausl Di Rimini, Rimini, Italy|UOC Ematologia - A.O. Sant'Andrea, Roma, Italy|A.O. Universitaria Senese, Siena, Italy|Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI, Varese, Italy","","https://ClinicalTrials.gov/show/NCT02495454"
327,"NCT02674750","Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations",,"Recruiting","No Results Available","Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations","Drug: CUDC-907","The efficacy of CUDC-907 in terms of objective response rate (ORR)|The efficacy of CUDC-907 in terms of progression-free survival (PFS)|To evaluate in terms of progression-free survival at 6 months (PFS6)|To evaluate overall survival (OS)|To evaluate the disease control rate (DCR)|To evaluate the duration of response (DOR)|To evaluate the incidence and severity of adverse events (AEs), serious adverse events (SAEs), and other safety parameters in subjects receiving CUDC-907","Curis, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CUDC-907-201","January 2016","January 2018","null","February 4, 2016","null","April 4, 2017","University of California San Francisco-Fresno, Fresno, California, United States|University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Rochester, Rochester, New York, United States|University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Penn State Hershey Cancer Institute-Clinical Trials Office, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Tennessee Cancer Center, Knoxville, Tennessee, United States|Tennessee Oncology Sarah Cannon, Nashville, Tennessee, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Durán i Reynals, Servicio de Oncología, Barcelona, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain","","https://ClinicalTrials.gov/show/NCT02674750"
328,"NCT01092182","Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Burkitt Lymphoma|Diffuse Large B-cell Lymphoma, c-MYC Positive|Plasmablastic Lymphoma","Drug: EPOCH-R|Drug: EPOCH-RR","PFS, EFS and OS","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","194","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100052|10-C-0052","February 24, 2010","February 28, 2021","February 28, 2023","March 24, 2010","null","August 9, 2018","Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Siouxland Hematology Oncology Associates LLP, Sioux City, Iowa, United States|Providence Medical Center, Kansas City, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Kansas City CCOP, Prairie Village, Kansas, United States|Shawnee Mission Medical Center-KCCC, Shawnee Mission, Kansas, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Massachusetts General Dana Farber and Beth Israel Cancer Centers, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Liberty Radiation Oncology Clinic, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cleveland Clinic Beachwood, Beachwood, Ohio, United States|Cleveland Clinic Transplantation Clinic, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Independence, Independence, Ohio, United States|Hillcrest Hospital, Mayfield Heights, Ohio, United States|Parma Community General Hospital, Parma, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Cleveland Clinic Strongsville, Strongsville, Ohio, United States|Cleveland Clinic Wooster, Wooster, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01092182"
329,"NCT01990144","Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Bendamustine+Rituximab","To evaluate the activity of R-B combination in terms of complete response rate (CRR).|To evaluate the safety and tolerability of R-B combination in terms of rate of adverse events occurrence.|To evaluate progression free survival (PFS)|To evaluate overall survival (OS)","Fondazione Italiana Linfomi ONLUS","All","70 Years and older   (Older Adult)","Phase 2","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_R-BENDA FRAIL","November 2011","February 2014","February 2016","November 21, 2013","null","November 21, 2013","Ente Eccl.Osp.Gen.Reg.'Miulli', Acquaviva Delle Fonti, Bari, Italy|Ospedale S. Nicola Pellegrino Di Trani, Trani, Barletta, Italy|Irccs Ospedale Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Foggia, Italy|Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, Forlì-Cesena, Italy|Ospedale Generale Di Zona, Civitanova Marche, Macerata, Italy|Nuovo Ospedale Di Sassuolo S.P.A., Sassuolo, Modena, Italy|Irccs Centro Di Riferimento Oncologico (Cro), Aviano, Pordenone, Italy|Irccs Centro Di Riferimento Oncologico Di Basilicata (Crob), Rionero in Vulture, Potenza, Italy|Ospedale Bianchi - Melacrino - Morelli, Reggio Di Calabria, Reggio Calabria, Italy|P.O. Umberto I, Nocera Inferiore, Salerno, Italy|Ospedale Civile Di Ivrea, Ivrea, Torino, Italy|Ospedale Civile Ss. Antonio E Biagio Di Alessandria, Alessandria, Italy|Asp Di Bolzano - Comprensorio Sanitario Di Bolzano, Bolzano, Italy|Pres.Ospedal.Spedali Civili Brescia, Brescia, Italy|Stabilimento ""Perrino"", Brindisi, Italy|Ospedale Armando Businco -, Cagliari, Italy|A.O. Universitaria Ospedale Vittorio Emanuele E Ferrarotto Di Catania, Catania, Italy|Nuovo Ospedale Garibaldi - Nesima, Catania, Italy|Osp.Generale Di Zona Valduce, Como, Italy|Presidio Ospedaliero Annunziata, Cosenza, Italy|A.O. Universitaria S. Martino Di Genova, Genova, Italy|Presidio Ospedaliero Matera, Matera, Italy|A.O. Universitaria Policlinico Martino Di Messina, Messina, Italy|Azienda Ospedaliera Papardo, Messina, Italy|Irccs Istituto Nazionale Dei Tumori (Int), Milano, Italy|Ospedale S. Carlo Borromeo, Milano, Italy|Ospedale Ca` Granda-Niguarda, Milano, Italy|A.O. Universitaria Policlinico Di Modena, Modena, Italy|Azienda Ospedaliera S. Gerardo Di Monza, Monza, Italy|Irccs Istituto Oncologico Veneto (Iov), Padova, Italy|A.O. Universitaria Policlinico Giaccone Di Palermo, Palermo, Italy|A.O. ""V. Cervello"", Palermo, Italy|Casa Di Cura La Maddalena Di Palermo, Palermo, Italy|A.O. Universitaria Di Parma, Parma, Italy|Ospedale Civile Spirito Santo, Pescara, Italy|Ausl Di Piacenza, Piacenza, Italy|A.O. Universitaria Pisana, Pisa, Italy|Ospedale S. Maria Delle Croci Di Di Ravenna, Ravenna, Italy|Ospedale Di S. Maria Nuova, Reggio Emilia, Italy|Ospedale Di Rimini, Rimini, Italy|Irccs Istituto Regina Elena (Ifo), Roma, Italy|Ospedale S. Eugenio, Roma, Italy|Azienda Osp. S.Giovanni/Addolorata Roma, Roma, Italy|A.O.Oo.Rr.S.Giovanni Di Dio E Ruggi D`Ar, Salerno, Italy|A.O. Universitaria Policlinico Di Sassari, Sassari, Italy|A.O. Universitaria Senese, Siena, Italy|Stabilimento Ss. Annunziata, Taranto, Italy|Azienda Ospedaliera ""S. Maria"", Terni, Italy|Ematologia 1 - A.O. UNIVERSITARIA S. GIOVANNI BATTISTA-MOLINETTE DI TORINO, Torino, Italy|Ematologia 2 - A.O. UNIVERSITARIA S. GIOVANNI BATTISTA-MOLINETTE DI TORINO, Torino, Italy|Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI, Varese, Italy|Oncologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI, Varese, Italy","","https://ClinicalTrials.gov/show/NCT01990144"
330,"NCT03645395","PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)",,"Not yet recruiting","No Results Available","Non-hodgkin Lymphoma|B Cell Refractory Diffuse Large B-Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma","Drug: MT-3724","Tolerability as measured by number of subjects with dose limiting toxicities|Safety measured by number of subjects with Adverse Events using CTCAE|PK as measured by concentrations of free MT-3724 (Maximum Plasma Concentration [Cmax])|PK as measured by concentrations of free MT-3724 (Area Under the Curve [AUC])|PK as measured by concentrations of free MT-3724 (Time to reach maximum concentration after drug administration [Tmax])|PD as measured by tumor response|Immunogenicity as measured by MT-3724 [anti-drug antibody (ADA) titer and neutralizing antibody (NA)]|PD as measured by B-cell count in peripheral blood as determined by flow cytometry measured against MT-3724 serum concentrations at pre-specified time points|PD as measured by by immunophenotype in peripheral blood, as determined by flow cytometry measured against MT-3724 serum concentrations at pre-specified time points|Tumor Response as measured by PET or CT scan","Molecular Templates, Inc.","All","18 Years to 101 Years   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT-3724_NHL_003","December 3, 2018","December 17, 2020","July 30, 2022","August 24, 2018","null","September 18, 2018","","","https://ClinicalTrials.gov/show/NCT03645395"
331,"NCT01241734","Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL","RICER","Unknown status","No Results Available","Diffuse Large B-cell Lymphoma.","Drug: Revlimid","Stage 1 - Safety (type, frequency, severity and relationship of adverse events to study treatment) and tolerability|Stage 1 - Overall response rate (CR, PR, SD)|Stage 2 - Proportion of patients with a stem cell collection of at least 3x106 CD34+ cells prior to ASCT|Stage 3 - Overall response rate (CR, PR, SD) and complete response rate, and conversion to higher quality of response during maintenance (e.g. from PR to CR)|Stage 2 • Incidence of DLT for determination of MTD to be used in Stage II conversion to higher quality of response during maintenance (e.g. from PR to CR)|Time to Response|Stage 2 - 1 and 2 year Overall Survival (OS)","Hackensack Meridian Health|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","67","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00001132 - RV-DLBCL-PI-0463","June 2010","December 2014","December 2014","November 16, 2010","null","February 4, 2014","John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01241734"
332,"NCT01691898","A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","ROMULUS","Active, not recruiting","Has Results","Follicular Lymphoma|Diffuse Large B-Cell Lymphoma","Drug: Obinutuzumab|Drug: Pinatuzumab Vedotin|Drug: Polatuzumab Vedotin|Drug: Rituximab","Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)|Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)|Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H|Number of Participants With Anti-Drug Antibodies (ADA) to Pinatuzumab Vedotin|Number of Participants With ADA to Polatuzumab Vedotin|Number of Participants With ADA to Obinutuzumab|Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C)|Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)|Percentage of Participants Who Died Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C)|Overall Survival (OS): Rituximab Containing Regimens (Arms A and B, Cohort C)|Percentage of Participants With CR at EOT Based on PET/CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)|Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)|Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by the Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)|Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)|Percentage of Participants With Best OR Based on PET/CT or CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)|Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|Maximum Observed Concentration (Cmax) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|Systemic Clearance (CL) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|Half-Life (t1/2) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|Volume of Distribution at Steady State (Vss) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)|AUCinf of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUCinf of Antibody Conjugated Monomethyl Auristatin E (acMMAE) for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Area Under the Concentration-Time Curve From Time Zero To Last Measurable Concentration (AUClast) of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of acMMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab|AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab|AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab|Cmax of Obinutuzumab: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO27834|2011-004377-84","September 27, 2012","March 8, 2017","February 12, 2019","September 25, 2012","April 19, 2018","August 14, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Florida Cancer Specialists - Fort Myers (Colonial Center Dr), Fort Myers, Florida, United States|Florida Cancer Specialists; Sarasota, Sarasota, Florida, United States|Univ of Michigan Med School; Hematology Oncology, Ann Arbor, Michigan, United States|Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States|Hematology Oncology Associates; Carol G. Simon Ctr, Morristown, New Jersey, United States|Regional Cancer Care Associates LLC - Morristown, Morristown, New Jersey, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|New York University Cancer Cen, New York, New York, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Oregon Health Sciences Uni, Portland, Oregon, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Texas Transplant Inst., San Antonio, Texas, United States|Texas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler, Texas, United States|Fairfax N Virginia Hem/Onc PC, Fairfax, Virginia, United States|Oncology & Hematolgy Associates of SW Va Inc. - Roanoke, Roanoke, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Univ of Wisconsin-Madison, Madison, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hopital Claude Huriez - CHU Lille, Lille, France|CHU Montpellier - Saint ELOI, Montpellier, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Henri Becquerel; Hematologie, Rouen, France|Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V, Heidelberg, Germany|Universitätsmedizin Johannes Gutenberg Universität; Klinik u. Poliklinik f. Neurologie, Mainz, Germany|Klinikum d.Universität München Campus Großhadern, München, Germany|A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Azienda Ospedale San Giovanni, Torino, Piemonte, Italy|Academisch Medisch Centrum; Hematologie, Amsterdam, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT01691898/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01691898"
333,"NCT02840110","Long-Term Follow-Up Study of Clinical Study Subjects Treated With ACTR087",,"Enrolling by invitation","No Results Available","B Cell Lymphomas","Other: ACTR087","Long-term safety of ACTR087 as assessed by overall survival|Long-term safety of ACTR087 as assessed by SAEs related to ACTR087/antibody combination|Long-term safety of ACTR087 as assessed by Gr3-4 AEs related to ACTR087/antibody combination|Long-term safety of ACTR087 as assessed by any grade adverse event of special interest (AESI) related to ACTR087/antibody combination","Unum Therapeutics Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","","50","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UT-201502","October 2016","December 2035","December 2035","July 21, 2016","null","September 25, 2017","Indiana Bone and Marrow Transplantation, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02840110"
334,"NCT01234467","Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma",,"Completed","Has Results","Diffuse Large B-Cell Lymphoma|Lymphoma, Diffuse Large-Cell|Diffuse Large-Cell Lymphoma|Lymphoma","Drug: Bendamustine|Drug: Rituximab","Complete Response (CR) Rate as Defined by The International Harmonization Project for Response Criteria|Overall Response Rate (ORR)|Partial Response Rate|Estimate of Progression-Free Survival|Overall Survival|Evaluate the Toxicity and Tolerability of Bendamustine in Combination With Rituximab","UNC Lineberger Comprehensive Cancer Center|Cephalon","All","65 Years and older   (Older Adult)","Phase 2","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1011|10-1405","March 2011","December 2013","August 2016","November 4, 2010","April 26, 2017","May 24, 2017","Seby B. Jones Cancer Center, Boone, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Northeast Medical Center, Concord, North Carolina, United States|Moses Cone Regional Cancer Center, Greensboro, North Carolina, United States|Leo Jenkins Cancer Center, East Carolina University Medical Center, Greenville, North Carolina, United States|Rex Healthcare, Raleigh, North Carolina, United States|Marion L. Shepard Cancer Center, Washington, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01234467"
335,"NCT02836925","Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection",,"Recruiting","No Results Available","Indolent B-cell Lymphoma|Hepatitis C","Drug: Ledipasvir+Sofosbuvir|Drug: Sofosbuvir+Velpatasvir","SVR12|ORR|PFS|EFS|OS|ORR for lymphoma|Rapid virological response|Extended rapid virological response|Early virological response|Toxicity - Incidence of Adverse Events","Fondazione Italiana Linfomi ONLUS","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_BArT","March 2016","October 2018","October 2020","July 19, 2016","null","March 29, 2018","A.O. Spedali Civili, Brescia, BS, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, MI, Italy|Irccs Centro Di Riferimento Oncologico (Cro), Aviano, Pordenone, Italy|Ospedale San Bortolo, Vicenza, VI, Italy|Ospedale Policlinico G.B. Rossi (Borgo Roma) Di Verona, Verona, VR, Italy|A.O. Universitaria Careggi Di Firenze, Firenze, Italy|Sc Ematologia Ao Niguarda Ca' Granda, Milano, Italy|Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori, Milano, Italy|Ospedale San Raffaele Ematologia, Milano, Italy|IRCCS Fondazione Pascale, Napoli, Italy|U.O. Ematologia AO di Padova, Padova, Italy|Policlinico P.Giaccone, Palermo, Italy|A.O. Universitaria Di Parma, Parma, Italy|Ematologia Policlinico San Matteo, Pavia, Italy|Ematologia - Policlinico Umberto I Università Sapienza, Roma, Italy|Dipartimento di Oncologia Medica ed Ematologia, Istituto Humanitas, Rozzano, Italy|AOU Città della Salute e della Scienza di Torino, Torino, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine, Udine, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, Italy","","https://ClinicalTrials.gov/show/NCT02836925"
336,"NCT00724971","Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab",,"Completed","No Results Available","Lymphoma, B-Cell","Drug: Inotuzumab Ozogamicin (CMC-544)|Drug: Rituximab (Rituxan)","Safety: physical examinations (with vital signs) and laboratory test measurements.|Efficacy: tumor response, best overall response and progression status (according to the International Response Criteria for Non-Hodgkin's Lymphomas).|Pharmacokinetics: serum concentration of Inotuzumab Ozogamicin (CMC-544), G544, total and free (unconjugated) calicheamicin, anti-Inotuzumab Ozogamicin (CMC-544) antibody and anti-Rituximab antibody.","Pfizer","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3129K3-1104|B1931005","July 2008","March 2010","March 2010","July 30, 2008","null","February 15, 2013","Pfizer Investigational Site, Aichi, Japan|Pfizer Investigational Site, Kanagawa, Japan|Pfizer Investigational Site, Tokyo, Japan|Pfizer Investigational Site","","https://ClinicalTrials.gov/show/NCT00724971"
337,"NCT03244176","Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study","AvR-CHOP","Recruiting","No Results Available","Lymphomas Non-Hodgkin's B-Cell","Drug: Avelumab","Immune-related toxicity|Response Rate|Failure Free Survival|Overall Survival|Overall Toxicity of Treatment","Austin Health|Merck KGaA","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS100070-0068","July 21, 2017","February 2021","July 2025","August 9, 2017","null","August 10, 2017","Austin Health, Heidelberg, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT03244176"
338,"NCT01471210","Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma","Drug: Urelumab (BMS-663513)","Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests|Dose-limiting toxicity and maximum tolerated dose of Urelumab (BMS-663513) as determined by the incidence of dose-limiting toxicities|Maximum observed serum concentrations (Cmax) of Urelumab (BMS-663513)|Minimum observed serum concentrations (Cmin) of Urelumab (BMS-663513)|Time of maximum observed serum concentration (Tmax) of Urelumab (BMS-663513)|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of Urelumab (BMS-663513)|Plasma half-life (T-HALF) of Urelumab (BMS-663513)|Total body clearance (CLT) of Urelumab (BMS-663513)|Volume of distribution at steady-state (Vss) of Urelumab (BMS-663513)|Human Anti-human Antibodies|Tumor response and progression as determined by proportion of patients with best overall response (BOR), progression-free survival (PFS), objective response rate (ORR), time to response, and duration of response","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","124","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA186-011|2012-000170-28","February 2012","April 2016","April 2016","November 15, 2011","null","April 19, 2017","Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|University Of Chicago, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Local Institution, Creteil Cedex, France|Local Institution, Lille Cedex, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Villejuif Cedex, France|Local Institution, Essen, Germany|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Local Institution, Pamplona, Spain","","https://ClinicalTrials.gov/show/NCT01471210"
339,"NCT01415765","MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma",,"Withdrawn","No Results Available","Lymphoma, Diffuse Large-Cell B-cell|Diffuse, Large B-cell Lymphoma|Lymphoma, Diffuse Large-Cell|Large-Cell Lymphoma, Diffuse","Drug: MLN4924|Drug: Etoposide|Drug: Prednisone|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Rituximab|Drug: Filgrastim","Assess response of MLN4924 in relapsed/refractory DLBCL|Assess toxicity and safe tolerated dose of MLN4924 and DA-EPOCH-R|Assess ORR (CR/PR) and PFS of MLN4924 and DA-EPOCH-R in relapsed/refractory DLBCL|Analyze molecular subtype (ABC and GCB)|Assess difference in response between ABC and GCB subtypes of relapsed/refractory DLBCL/MLN 4924 alone and w/MLN4924 and DA-EPOCH-R|Analyze mutations of the ITAM motifs, CARD11 and A20 in DLBCL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110216|11-C-0216","July 15, 2011","January 7, 2014","January 7, 2014","August 12, 2011","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT01415765"
340,"NCT02584920","A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma",,"Completed","No Results Available","B-cell Non Hodgkin's Lymphoma","Drug: HLX01|Drug: Rituximab","Area under the curve (AUC) for HLX01 and rituximab concentrations|The Maximum Concentration (Cmax) of the HLX01 and rituximab|Presence of Anti-Drug Antibodies against HLX01|Change from baseline of CD19+ B-cells","Shanghai Henlius Biotech","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HLX01-NHL02","October 2014","August 2015","August 2015","October 23, 2015","null","November 24, 2017","","","https://ClinicalTrials.gov/show/NCT02584920"
341,"NCT03664297","Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor",,"Recruiting","No Results Available","Mature B Cell Neoplasms","Drug: SHR1459","Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability])|Recommended phase 2 dose (RP2D)|Objective response rate (ORR)|Duration of Response (DoR)|Progression-free survival (PFS)|Time to Response (TTR)|Time to peak (Tmax)|Maximum plasma concentration (Cmax)|Halflife (T1/2)|Clearance/ bioavailability (CL/F)|apparent volume of distribution/bioavailability (Vd/F)|Area under curve (AUC)|Area under curve, steady state (AUCss)|Maximum plasma concentration, steady state (Cmax,ss)|Time to peak, steady state (Tmax,ss)|Apparent volume of distribution, steady state/bioavailability (Vss/F)|Accumulation index (Rac)","Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","90","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHR1459-I-101","February 6, 2018","December 31, 2018","December 31, 2020","September 10, 2018","null","September 10, 2018","Blood disease hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03664297"
342,"NCT01944943","Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia","VISMOLY","Terminated","No Results Available","Diffuse Large B-cell Lymphoma|Indolent Non-hodgkin Lymphoma|Primary Central Nervous System Lymphoma|Chronic Lymphocytic Leukemia","Drug: Vismodegib","The best overall response rate(ORR)|Overall Response rate|Progression Free Survival (PFS)|Response Duration|Overall survival|Correlation between Hedgehog (Hh) signaling in the tumor and the efficacy of Vismodegib|Safety endpoints","The Lymphoma Academic Research Organisation|Roche Pharma AG","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VISMOLY","February 2013","August 2014","October 2014","September 18, 2013","null","March 13, 2017","Hôpital Henri MONDOR, Creteil, France|CHU Dijon _ Hôpital d'Enfants, Dijon, France|CHRU de Lille _ Hôpital Huriez, Lille, France|CHU de Nantes _ Hôtel Dieu, Nantes, France|Hôpital Saint-Louis, Paris, France|CHU Haut Lévèque, Pessac, France|CH Lyon Sud, Pierre-Bénite, France|CHU Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|Hôpital René Huguenin _ Institut Curie, Saint-Cloud, France","","https://ClinicalTrials.gov/show/NCT01944943"
343,"NCT02205333","A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies","MEDI6469","Terminated","Has Results","Advanced Solid Tumors|Aggressive B-cell Lymphomas","Biological: MEDI6469 Monotherapy|Biological: MEDI6469 Plus Tremelimumab|Biological: MEDI6469 Plus Durvalumab|Biological: MEDI6469 plus Rituximab","Maximum Tolerated Dose (MTD) of MEDI6469|Number of Participants With DLTs|Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Treatment-emergent Serious Adverse Events|Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs|Number of Participants With Vital Signs and Physical Examination Abnormalities Reported as TEAEs|Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as TEAEs|Best Overall Response (BOR)|Objective Response Rate (ORR)|Disease Control Rate|Duration of Response (DOR)|Progression-free Survival (PFS)|Overall Survival (OS)|Maximum Observed Serum Concentration (Cmax)|Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUC0-inf)|Systemic Clearance (CL)|Terminal Phase Elimination Half-Life (T1/2)|Number of Participants Positive for Human Anti-mouse Antibodies (HAMA)","MedImmune LLC","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4981C00001","August 13, 2014","April 8, 2016","April 8, 2016","July 31, 2014","May 8, 2017","June 28, 2017","Research Site, Scottsdale, Arizona, United States|Research Site, Sacramento, California, United States|Research Site, Santa Monica, California, United States|Research Site, Washington, D.C., District of Columbia, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Detroit, Michigan, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Portland, Oregon, United States|Research Site, Memphis, Tennessee, United States|Research Site, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02205333"
344,"NCT01361191","Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma","R-MEGACHOP","Completed","No Results Available","Diffuse Large B-cell Lymphoma|Follicular Grade 3B Lymphoma","Drug: R-MEGACHOP","Event free survival at 3y in pat with DLBCL with a-IPI>1 or a-IPI=1 and ß2 µglobulin>=3mg/dl in pat PET+ after 3cycles of R-MegaCHOP and early rescue with R-IFE+TAPH or in pat PET- after 3cycles R-MegaCHOP followed by 3cycles of R-MegaCHOP without TAPH|To evaluate the overall survival after three years. Further secondary outcomes as described in study summary.","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","71","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEL/TAMO-2006|EudraCT number 2006-005254-68","June 2007","September 2012","September 2012","May 26, 2011","null","October 30, 2013","ICO- Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain|Hospital Clínico Univ. de Santiago, Santiago de Compostela, Galicia, Spain|Hospital Univ. Son Dureta, Palma de Mallorca, Mallorca, Spain|Hospital Son Llàtzer, Palma de Mallorca, Mallorca, Spain|Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Univ. Morales Meseguer, Murcia, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Universitario Río Hortega, Valladolid, Spain|Hospital Universitario Virgen de la Concha, Zamora, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain","","https://ClinicalTrials.gov/show/NCT01361191"
345,"NCT03223610","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",,"Recruiting","No Results Available","Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma","Drug: Venetoclax|Drug: Ibrutinib|Drug: Prednisone|Drug: Obinutuzumab|Drug: Revlimid (lenalidomide)","Number and grade of adverse events|Overall response rate (ORR)|Progressive-free survival (PFS)|Overall survival (OS)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","45","NIH","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170127|17-C-0127","February 9, 2018","March 1, 2019","September 1, 2022","July 21, 2017","null","September 7, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03223610"
346,"NCT03422523","Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy","ARGO","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: Atezolizumab|Drug: Rituximab|Drug: Gemcitabine 1000 mg|Drug: Oxaliplatin 100 MG","Progression free survival|AE's reported and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) for R-GemOx-Atezo|Lugano classification lymphoma response criteria (LYRIC) to PET/CT|Overall survival","University Hospital Southampton NHS Foundation Trust|Hoffmann-La Roche","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","112","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RHM CAN1219|2016-002654-21","May 9, 2018","November 2020","June 2023","February 5, 2018","null","July 19, 2018","The Christie NHS Foundation Trust, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT03422523"
347,"NCT02207062","Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis","Overall response rate (combined complete response + partial response)|Complete response rate|Disease control rate|Overall survival|Progression-free survival|Response rate relative to the underlying B-cell histology|Tolerability of chronic ibrutinib therapy","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9107|NCI-2014-01573|P30CA015704","October 2014","October 2018","null","August 1, 2014","null","March 6, 2018","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02207062"
348,"NCT02049541","Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Drug: PI3K inhibitor BKM120|Biological: rituximab|Other: Pharmacodynamics|Other: Correlative studies","MTD defined as the dose level at which no more than one of 6 patients experiences a DLT summarized using the National Cancer Institute (NCI) CTCAE version 4.0|Incidence of grade 3 or greater adverse events summarized using the NCI CTCAE version 4.0|Overall response rate (ORR) evaluated by computed tomography (CT) or positron emission tomography (PET)/CT|Change in correlative markers in blood, bone marrow and tumor tissue","Kami Maddocks|Novartis|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-13027|NCI-2014-00110","July 2014","December 31, 2018","December 31, 2018","January 30, 2014","null","September 12, 2018","Emory University, Atlanta, Georgia, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02049541"
349,"NCT02592876","Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","Lymphoma, B-cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular, Grade 3b|Follicular Lymphoma, Grade 3b","Drug: denintuzumab mafodotin|Drug: rituximab|Drug: ifosfamide|Drug: carboplatin|Drug: etoposide","Complete remission rate|Incidence of adverse events and laboratory abnormalities|Objective response rate|Duration of response|Progression-free survival|Overall survival|Proportion of patients achieving peripheral blood stem cell mobilization|Proportion of patients receiving autologous stem cell transplant","Seattle Genetics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN19A-003","October 2015","April 20, 2018","April 20, 2018","October 30, 2015","null","July 9, 2018","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|Scripps Mercy Cancer Center, San Diego, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Shands Cancer Center / University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|San Antonio Military Medical Center, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States|Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin (Milwaukee), Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02592876"
350,"NCT00946023","Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab",,"Terminated","Has Results","Lymphoma|B-cell Lymphoma|Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: Rituximab|Biological: Allogeneic Bone Marrow Transplant (BMT)","Progression-free Survival|Overall Survival|Relapse|Non-relapse Mortality|Incidence of Grades II-IV Acute Graft-versus-Host-Disease (GVHD)|Incidence of Grades III-IV Acute GVHD|Incidence of Chronic GVHD|Engraftment|Graft Failure","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","1 Year to 75 Years   (Child, Adult, Older Adult)","Phase 2","135","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J0941|NA_00025589","July 2009","July 2013","July 17, 2013","July 24, 2009","July 24, 2018","August 27, 2018","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00946023"
351,"NCT03483688","A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects",,"Not yet recruiting","No Results Available","B-cell Non-Hodgkin Lymphoma","Biological: CD19-directed CAR-T cells","Safety|Overall response rate (ORR)|Duration of remission (DOR)|Progression free survival (PFS)|Overall survival rate（OSR）","Peking Union Medical College Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBMG-C2017007","March 31, 2018","September 30, 2019","December 31, 2019","March 30, 2018","null","March 30, 2018","","","https://ClinicalTrials.gov/show/NCT03483688"
352,"NCT02732236","Marginal Zone Lymphoma Cohort in Korea",,"Recruiting","No Results Available","Lymphoma, B-Cell, Marginal Zone","Other: Rituximab","Hepatitis B virus reactivation in patients with marginal zone B-cell lymphoma after rituximab containing treatment","Dong-A University Hospital","All","20 Years and older   (Adult, Older Adult)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CISL-12-07","March 2013","February 2020","February 2022","April 8, 2016","null","April 18, 2018","Sung Yong Oh, Busan, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02732236"
353,"NCT03372837","Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL","Drug: Rituximab","Overall Response Rate|Complete Response (CR) Rate|Progression Free Survival (PFS)|Duration of Response (DOR)|Overall Survival (OS)","SymBio Pharmaceuticals","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017002","January 15, 2018","December 2019","December 2019","December 14, 2017","null","January 23, 2018","Research Site, Kakamigahara, Gifu, Japan|Research Site, Isehara, Kanagawa, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Yamagata, Japan","","https://ClinicalTrials.gov/show/NCT03372837"
354,"NCT02044276","A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia","AVOID","Completed","No Results Available","Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia","Drug: lipegfilgrastim|Drug: pegfilgrastim","Duration of severe neutropenia (DSN) ANC <0.5 * 10^9/L|Incidence of febrile neutropenia (FN) (strict definition)|Incidence of FN|Incidence of very severe neutropenia|Incidence of infections|Time to ANC recovery|Summary of participants with adverse events","Merckle GmbH|Teva Pharmaceutical Industries","All","65 Years to 85 Years   (Older Adult)","Phase 3","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XM22-ONC-305|2013-001284-23","March 31, 2014","August 29, 2017","April 24, 2018","January 23, 2014","null","May 25, 2018","Teva Investigational Site 32284, Aurich, Germany|Teva Investigational Site 32314, Bad Soden Am Taunus, Germany|Teva Investigational Site 32267, Berlin, Germany|Teva Investigational Site 32277, Berlin, Germany|Teva Investigational Site 32292, Bochum, Germany|Teva Investigational Site 32282, Dresden, Germany|Teva Investigational Site 32269, Dresden, Germany|Teva Investigational Site 32303, Dresden, Germany|Teva Investigational Site 32302, Frankfurt-Hochst, Germany|Teva Investigational Site 32276, Frechen, Germany|Teva Investigational Site 32293, Freiburg, Germany|Teva Investigational Site 32290, Freiburg, Germany|Teva Investigational Site 32322, Fulda, Germany|Teva Investigational Site 32320, Furth, Germany|Teva Investigational Site 32273, Goslar, Germany|Teva Investigational Site 32296, Gutersloh, Germany|Teva Investigational Site 32272, Hamburg, Germany|Teva Investigational Site 32295, Heilbronn, Germany|Teva Investigational Site 32270, Herne, Germany|Teva Investigational Site 32401, Herne, Germany|Teva Investigational Site 32279, Hof, Germany|Teva Investigational Site 32297, Kaiserslautern, Germany|Teva Investigational Site 32310, Kassel, Germany|Teva Investigational Site 32280, Kiel, Germany|Teva Investigational Site 32275, Koeln, Germany|Teva Investigational Site 32309, Krefeld, Germany|Teva Investigational Site 32287, Lahr, Germany|Teva Investigational Site 32289, Langen, Germany|Teva Investigational Site 32313, Lebach, Germany|Teva Investigational Site 32311, Leer, Germany|Teva Investigational Site 32278, Leipzig, Germany|Teva Investigational Site 32301, Munchen, Germany|Teva Investigational Site 32274, Oldenburg, Germany|Teva Investigational Site 32306, Poessneck, Germany|Teva Investigational Site 32291, Rotenburg, Germany|Teva Investigational Site 32300, Stade, Germany|Teva Investigational Site 32268, Stuttgart, Germany|Teva Investigational Site 32321, Stuttgart, Germany|Teva Investigational Site 32317, Villingen-Schwenningen, Germany|Teva Investigational Site 30061, Campobasso, Italy|Teva Investigational Site 31074, Barcelona, Spain|Teva Investigational Site 31071, Madrid, Spain|Teva Investigational Site 31070, Madrid, Spain|Teva Investigational Site 31073, Valencia, Spain|Teva Investigational Site 31072, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT02044276"
355,"NCT01009970","Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone|Drug: Doxorubicin","Feasibility of R-COMP in cardiopathic patients|Response rates|Progression free survival|Overall Survival","Fondazione Italiana Linfomi ONLUS","All","18 Months and older   (Child, Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIL-HEART01|2009-012143-42","May 2010","May 2011","May 2012","November 9, 2009","null","October 13, 2011","Ospedale SS Antonio Biagio e Cesare Arrigo, Alessandria, Italy|Università di Bari, Bari, Italy|Ospedale degli Infermi, Biella, Italy|Spedali Civili, Brescia, Italy|Ospedale Civitanova Marche, Civitanova Marche, Italy|AO Annunziata, Cosenza, Italy|Ospedale San Carlo, Cosenza, Italy|Ospedale Vito Fazzi, Lecce, Italy|Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST), Meldola (FC), Italy|A O Papardo, Messina, Italy|Ospedale Niguarda Cà Granda, Milano, Italy|Ospedale San Raffaele, Milano, Italy|Centro oncologico modenese, Modena, Italy|AO Universitaria Paolo Giaccone, Palermo, Italy|Ospedale La Maddalena, Palermo, Italy|A O Universitaria di Parma, Parma, Italy|Ospedale Santa Maria della Misericordia, Perugia, Italy|Ausl Ravenna, Ravenna, Italy|Ospedale Bianchi Melacrino Morelli, Reggio Calabria, Italy|AO Santa Maria Nuova, Reggio Emilia, Italy|Ausl Rimini, Rimini, Italy|Istituto Regina Elena, Roma, Italy|Ospedale Sant'Eugenio, Roma, Italy|Università La Sapienza, Roma, Italy|Clinica Humanitas, Rozzano (MI), Italy|Casa sollievo della sofferenza, San giovanni Rotondo, Italy|Università di Sassari, Sassari, Italy|Azienda Ospedaliera senese, Siena, Italy|Ospedale San Giovanni Battista Molinette, Torino, Italy|Ospedale Riuniti, Trieste, Italy|Santa Maria della Misericordia, Udine, Italy|Ospedale di circolo e Fondazione Macchi, Varese, Italy","","https://ClinicalTrials.gov/show/NCT01009970"
356,"NCT00842595","Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas",,"Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: rituximab|Drug: vinorelbine|Drug: ifosfamide|Drug: Mitoxantrone|Drug: Prednisone","Complete remission rate|overall remission rate|Toxicity|Pharmacoeconomy","French Innovative Leukemia Organisation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R NIMP","December 2003","November 2009","May 2010","February 12, 2009","null","July 24, 2013","Hôpital COCHIN, Paris, France","","https://ClinicalTrials.gov/show/NCT00842595"
357,"NCT00841945","Treatment of Aggressive Localized Lymphoma",,"Terminated","No Results Available","B Cell Lymphoma","Drug: rituximab|Drug: doxorubicin|Drug: vincristine|Drug: prednisone|Procedure: radiotherapy","Event Free Survival (EFS) and Progression Free Survival (PFS)|Pet-scan|radiotherapy","French Innovative Leukemia Organisation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","334","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GOELAMS 02 03","April 2005","January 2016","February 2017","February 12, 2009","null","February 23, 2017","Regional university hospital, Rennes, France","","https://ClinicalTrials.gov/show/NCT00841945"
358,"NCT01809600","Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults","RBL","Completed","No Results Available","Burkitt's Lymphoma|High-grade B-cell Lymphoma","Other: No intervention (observational study)","Event-free survival|complete response rate|overall survival|Grade 4 hematologic toxicities","Gachon University Gil Medical Center","All","20 Years and older   (Adult, Older Adult)","","43","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CISL-1203","February 2013","March 2014","March 2014","March 13, 2013","null","February 24, 2017","Gachon University Gil Medical Center, Incheon, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01809600"
359,"NCT03684694","Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",,"Not yet recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma","Drug: Loncastuximab Tesirine and Ibrutinib","Safety and tolerability of loncastuximab tesirine in combination with ibrutinib by measuring frequency and severity of adverse events (AEs)|Safety and tolerability of loncastuximab tesirine in combination with ibrutinib by measuring frequency and severity of serious adverse events (SAEs)|Safety and tolerability of loncastuximab tesirine in combination with ibrutinib by measuring incidence of dose limiting toxicities (DLTs) (dose escalation only)|Overall response rate (ORR)|Complete Response Rate (CR)|Duration of Response (DOR): time from first tumor response to disease progression or death|Overall survival (time between the start of treatment and death from any cause)","ADC Therapeutics S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADCT-402-103","December 2018","July 2022","September 2022","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03684694"
360,"NCT00586391","CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL","CRETI-NH","Active, not recruiting","No Results Available","B Cell Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia","Genetic: CD19CAR-28-zeta T cells|Drug: Ipilimumab","Adverse Event Data per Patient|Survival and function of CD19CAR T cells|Number of patients with tumor response|Correlation of additional doses and cumulative rise in the percentage of circulating gene modified cells","Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine","All","Child, Adult, Older Adult","Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19384-CRETI-NH","February 2009","July 2014","July 2029","January 4, 2008","null","January 23, 2018","Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00586391"
361,"NCT00599170","Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Diffuse, Large B-Cell, Lymphoma","Drug: Rituximab","The primary endpoint in this trial will be tumor complete response (CR, CRu) to R-CHOP + GM-CSF, given every 14 days|Response duration","University of Southern California","All","Child, Adult, Older Adult","Phase 2","52","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13nhl-07-3","January 10, 2008","January 10, 2019","January 10, 2020","January 23, 2008","null","April 2, 2018","USC Norris Comprehensive Cancer Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00599170"
362,"NCT01959698","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","CD20 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma","Drug: Carboplatin|Drug: Carfilzomib|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab","Best overall response rate (PR + CR) (Phase II)|MTD defined as the dose of carfilzomib added to standard R-ICE chemotherapy which, if exceeded, would put the patient at an undesirable risk of medically unacceptable dose-limiting toxicities (Phase I)|Complete response rate according to the International Working Group Response criteria as reported by the revised Cheson criteria|Overall survival|Pharmacokinetics (PK)/pharmacodynamics (PD) of carfilzomib and standard R-ICE combination therapy in adult patients with relapsed/refractory diffuse large B-cell lymphoma|Progression-free survival|Toxicity of the addition of carfilzomib to R-ICE at the MTD, assessed by the CTEP version 4.0 of the NCI CTCAE","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","73","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 240813|NCI-2013-01784|P30CA016056|R01CA136907","April 17, 2014","July 15, 2023","July 15, 2023","October 10, 2013","null","March 29, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT01959698"
363,"NCT02633111","DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","B-cell Non-Hodgkin Lymphoma|Aggressive","Other: collected at pre-treatment tumor biopsy|Other: Peripheral blood tests|Device: PET/CT","MRD assay to predict clinical relapse","Memorial Sloan Kettering Cancer Center|Mayo Clinic|M.D. Anderson Cancer Center|University of Pennsylvania|University of Miami","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","15-180","October 2015","October 2019","October 2019","December 17, 2015","null","April 25, 2018","University of Miami, Miami, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Md Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02633111"
364,"NCT02843061","Combination of Rituximab and NK Immunotherapy for B Lymphoma",,"Recruiting","No Results Available","B-cell Lymphoma Recurrent","Drug: Rituximab|Biological: NK immunotherapy","Relief degree evaluated by the RECIST|Progress free survival (PFS)|Overall survival (OS)","Fuda Cancer Hospital, Guangzhou|Shenzhen Hank Bioengineering Institute","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NK-Rituximab","July 2016","July 2017","July 2019","July 25, 2016","null","July 25, 2016","Cancer Institute in Fuda cancer hospital, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02843061"
365,"NCT01397825","MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine",,"Completed","Has Results","Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma|Mantle Cell Lymphoma|Burkitt's Lymphoma","Drug: Alisertib (MLN8237)|Drug: Rituximab|Drug: Vincristine","Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1]|Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1]|Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1]|Number of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1]|Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 1]|Number of Participants With Treatment-Emergent Adverse Events [Phase 1]|Overall Response Rate [Phase 2]|Overall Response Rate as Assessed by the Investigator [Phase 1]|Complete Response Rate [Phase 2]|Duration of Response (DOR) [Phase 2]|Progression Free Survival (PFS) [Phase 2]|Number of Participants With Treatment-Emergent Adverse Events [Phase 2]|Number of Participants With Clinically Significant Vital Signs Findings [Phase 2]|Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 2]|Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 2]|Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 2]|Cmax: Maximum Plasma Concentration for Alisertib|Tmax: Time to First Occurrence of Cmax fo Alisertib|AUCt: Area Under the Concentration Time Curve Over the Dosing Interval From Time 0 to Time t for Alisertib|Cmax: Maximum Plasma Concentration for Vincristine|AUCt: Area Under the Concentration-time Time Curve Over the Dosing Interval From Time 0 to Time t for Vincristine|AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine|T1/2: Terminal Disposition Phase Half-life for Vincristine","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C14011|2011-000609-32|U1111-1181-0333|12/NE/0268","August 9, 2011","February 5, 2015","October 5, 2016","July 20, 2011","March 27, 2018","March 27, 2018","Tucson, Arizona, United States|Beverly Hills, California, United States|Burbank, California, United States|Miami, Florida, United States|Lexington, Kentucky, United States|Worcester, Massachusetts, United States|New York, New York, United States|Rochester, New York, United States|Chapel Hill, North Carolina, United States|Philadelphia, Pennsylvania, United States|Germantown, Tennessee, United States|Memphis, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Burlington, Vermont, United States|Orbassano, Torino, Italy|Genova, Italy|Palermo, Italy|Roma, Italy|Madrid, Spain|Sevilla, Spain|Aberdeen, Grampian Region, United Kingdom|London, Greater London, United Kingdom|Southampton, Hampshire, United Kingdom|Birmingham, West Midlands, United Kingdom","","https://ClinicalTrials.gov/show/NCT01397825"
366,"NCT02955823","A Phase II Study of the FIL on Elderly Frail Patients With DLBCL",,"Recruiting","No Results Available","Diffuse Large B-cells Non-Hodgkin Lymphoma","Drug: Rituximab-Dexamethasone-Lenalidomide","ORR|Safety: clinical relevant toxicity|CR|OS|PFS|EFS|Quality of life","Fondazione Italiana Linfomi ONLUS","All","70 Years and older   (Older Adult)","Phase 2","68","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_ReRi","September 2016","September 2020","March 2021","November 4, 2016","null","April 25, 2018","Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia, Meldola, Forlì-Cesena, Italy|A.O. C. Panico - U.O.C Ematologia e Trapianto, Tricase, Lecce, Italy|Ospedale della Versilia USL12 - UOC Medicina - Sezione Ematologia, Camaiore, Lucca, Italy|ASUR 8 - Medicina Interna e Ematologia, Civitanova Marche, Macerata, Italy|Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS - Ematologia, Reggio nell'Emilia, Reggio Emilia, Italy|Ospedali Riuniti del Canavese - S.C. Medicina trasfusionale ed Ematologia, Ivrea, Torino, Italy|Ospedale Dell'Angelo - U.O. Ematologia, Mestre, Venezia, Italy|A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia, Alessandria, Italy|Clinica di Ematologia A.O.Universitaria Ospedali Riuniti, Ancona, Ancona, Italy|A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy|Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. Oncoematologia, Catania, Italy|IRCCS AOU S. Martino - IST - Clinica Ematologica, Genova, Italy|Ospedale Vito Fazzi - Ematologia, Lecce, Italy|Ospedale Madonna delle Grazie - Ematologia, Matera, Italy|Azienda Ospedali Riuniti Papardo-Piemonte - S.C. Ematologia, Messina, Italy|Istituto Scientifico San Raffaele - Unità Linfomi - Dipartimento Oncoematologia, Milano, Italy|Ospedale Maggiore - Policlinico - Fondazione IRCCS Ca' Granda - Ematologia, Milano, Italy|Ospedale Niguarda Ca' Granda - SC Ematologia, Milano, Italy|Azienda Ospedaliero - Universitaria Policlinico di Modena - Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Modena, Italy|I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1, Padova, Italy|AOU di Parma - U.O. Complessa di Ematologia, Parma, Italy|AO di Perugia - Ematologia, Perugia, Italy|A.O.R. San Carlo - U.O. Ematologia, Potenza, Italy|Ospedale delle Croci - Ematologia, Ravenna, Italy|Ospedale degli Infermi di Rimini - U.O. di Ematologia, Rimini, Italy|Azienda Ospedaliera S. Andrea - Ematologia, Roma, Italy|Policlinico Universitario Campus Bio-Medico - Area Ematologia Trapianto Cellule Staminali Medicina Trasfusionale e Terapia cellulare, Roma, Italy|AOU Senese - U.O.C. Ematologia, Siena, Italy|Univ. Perugia Sede Terni - Oncoematologia, Terni, Italy|A.O.U. Citta della Salute e della Scienza di Torino - S.C. Ematologia U, Torino, Italy|Ospedale ULSS 6 di Vicenza - Ematologia, Vicenza, Italy","","https://ClinicalTrials.gov/show/NCT02955823"
367,"NCT03255018","Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas",,"Recruiting","No Results Available","Non-Hodgkin Lymphoma|Lymphoma|Diffuse Large B-Cell Lymphoma|Gray Zone Lymphoma|Primary Central Nervious System Lymphoma","Drug: Pembrolizumab","Best overall response rate of pembrolizumab in patients with relapsed/refractory gray- zone lymphomas (GZL) and extra-nodal diffuse large B-cell lymphomas (DLBCL)|toxicity profile of pembrolizumab in patients with GZL and extra-nodal DLBCL|best overall response rate according to the 5-point Lugano classification for interpreting FOG-PET scans|duration of response for patients who respond to pembrolizumab|progression-free survival (PFS)|event-free survival (EFS)|overall survival (OS)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","14 Years to 99 Years   (Child, Adult, Older Adult)","Phase 2","52","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170149|17-C-0149","February 15, 2018","July 1, 2020","July 1, 2022","August 21, 2017","null","July 12, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03255018"
368,"NCT02737085","the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells","Adverse Events That Are Related to Treatment","Southwest Hospital, China","All","14 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Southwest Hospital, China","March 2016","December 2019","December 2019","April 13, 2016","null","September 7, 2016","Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China","","https://ClinicalTrials.gov/show/NCT02737085"
369,"NCT01718691","Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma",,"Completed","Has Results","Low-grade B Cell Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated","Drug: SyB L-0501|Drug: rituximab","Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)|Overall Response Rate (Antitumor Effect: PR or Better) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)|Complete Response Rate (CR) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)|Overall Response Rate (PR or Better) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)|Complete Response Rate Based on WHO Handbook for Reporting Results of Cancer Treatment (1979)|Overall Response Rate (PR or Better) Based on ""WHO Handbook for Reporting Results of Cancer Treatment (1979)""|Progression-Free Survival (PFS)|Duration of Response (DOR)|Overall Survival (OS)|Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Discontinuation Due to Adverse Event|Laboratory Test Abnormalities (Biochemical Tests)|Laboratory Test Abnormalities (Hematology Tests)","SymBio Pharmaceuticals","All","20 Years to 79 Years   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011002","November 2011","November 2013","November 2013","October 31, 2012","April 27, 2016","April 27, 2016","Research site, Nagoya, Aichi, Japan|Research site, Kashiwa, Chiba, Japan|Research site, Sapporo, Hokkaido, Japan|Research site, Isehara, Kanagawa, Japan|Research site, Sendai, Miyagi, Japan|Research site, Moriguchi, Osaka, Japan|Research site, Izumo, Shimane, Japan|Research site, Hamamatsu, Shizuoka, Japan|Research site, Utsunomiya, Tochigi, Japan|Research site, Fukuoka, Japan|Research site, Kagoshima, Japan|Research site, Kyoto, Japan|Research site, Nagasaki, Japan|Research site, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT01718691"
370,"NCT00487513","Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Procedure: Procurement of Follicular B Cell Lymphoma Cells","Tissue collection for vaccine generation","Dana-Farber Cancer Institute","All","35 Years and older   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","06-276","June 2007","January 2017","January 2017","June 18, 2007","null","March 9, 2017","Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00487513"
371,"NCT03207178","Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma",,"Recruiting","No Results Available","Recurrent or Refractory B Cell Malignancy","Biological: Mixed CD19/CD20 CAR-T Transfer","Overall complete remission rate|The initial effect time|The one-year survival rate|The safety and the tolerability(incidence of treatment-emergent adverse events defined as dose-limited toxicity)|The time to disease progression|The one-year recurrence|The life quality improvement","Shanghai Longyao Biotechnology Inc., Ltd.|Xuzhou Medical University|Shanghai Jiao Tong University School of Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LYCT-1701","March 1, 2017","February 28, 2019","February 28, 2020","July 2, 2017","null","July 2, 2017","Shanghai Longyao Biotechnology Inc., Ltd., Shanghai, Jingan, China","","https://ClinicalTrials.gov/show/NCT03207178"
372,"NCT00324467","Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","LYTPET","Active, not recruiting","No Results Available","Lymphoma, Non-Hodgkin|Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Ondansetron|Drug: Dexamethasone|Drug: Diphenhydramine|Drug: Acetaminophen|Drug: Ifosfamide|Drug: Mesna (IV)|Drug: Mesna (oral)|Drug: Carboplatin|Drug: Etoposide|Drug: Rituximab|Other: PET Scan","Progression-free survival (PFS) in participants with advanced stage DLBCL|Overall survival (OS) in participants with advanced stage DLBCL|The safety of R-ICE therapy in first-line therapy of DLBCL following four cycles of R-CHOP as assessed using the NCI Common Terminology Criteria for Adverse Events Version 3.0|Investigate clinical and biologic markers that characterize participant heterogeneity and may serve as predictors of response to therapy and overall outcome.|Efficacy of tailoring first-line therapy bases on a mid-treatment PET scan result for patients with advanced stage DLBCL","British Columbia Cancer Agency|Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H06-00017","August 2006","December 2018","December 2018","May 11, 2006","null","November 28, 2017","BC Cancer Agency, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT00324467"
373,"NCT00455897","CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lymphoma, Diffuse","Drug: GM-CSF|Drug: CHOP|Drug: Rituximab","To determine the safety of GM-CSF when administered in combination with CHOP-R to patients with previously untreated diffuse large B cell non-Hodgkin's lymphoma.|To assess the response rate, 2-year event-free survival and overall survival with CM-CSF and CHOP-R in this patient population|to analyze the biologic activity of GM-CSF at this dosing schedule and timing.","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-342","December 2006","November 2007","July 2011","April 4, 2007","null","January 18, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00455897"
374,"NCT03314922","A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)",,"Recruiting","No Results Available","Lymphoma","Drug: INCB050465","Number of participants with treatment-emergent adverse events (TEAEs)|Changes in pharmacodynamic (PD) markers of B-cell activation in plasma|Objective response rate|Duration of response|Progression-free survival","Incyte Corporation","All","20 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 50465-111/CITADEL-111","June 5, 2018","June 2019","December 2019","October 19, 2017","null","June 28, 2018","National Cancer Center, Chuo Ku, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT03314922"
375,"NCT02012088","Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb",,"Active, not recruiting","No Results Available","Lymphoma","Drug: RCOMP|Drug: RCHOP","Subclinical cardiac toxicity|Survival|Response rate|Cardiac/cardiovascular toxicity|Toxicity (except cardiac)|Cardiac biomarkers","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","All","60 Years and older   (Adult, Older Adult)","Phase 2","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEL-R-COMP-2013","October 2013","October 2016","August 2021","December 16, 2013","null","February 8, 2018","Hospital Universitario de Alava, Vitoria, Alava, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital de Cabueñes, GIjón, Asturas, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO- Hospital Duran i Reynals, L´Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario de Salamanca, Salamanca, Castilla Y Leon, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Castilla Y Leon, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain","","https://ClinicalTrials.gov/show/NCT02012088"
376,"NCT01613300","Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients",,"Active, not recruiting","No Results Available","B-Cell Lymphomas","Drug: Ofatumumab","Rate of acute grade II-IV graft-versus-host disease at 1 year|To analyze the complete response rate after treatment. Further secondary outcomes as described in study summary","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GELTAMO-O-CRT-2011|2011-004729-29","May 2012","June 2016","June 2020","June 7, 2012","null","October 30, 2017","Hospital Vall d'Hebron, Barcelona, Spain|Hospital Reina Sofia, Córdoba, Spain|H.U. 12 de Octubre,, Madrid, Spain|H.U. Gregorio Marañón,, Madrid, Spain|H.U. La Paz, Madrid, Spain|H. Morales Meseguer., Murcia, Spain|Complejo Hospitalario Carlos Haya, Málaga, Spain|H. Clinico de Salamanca, Salamanca, Spain|Hospital Virgen del Rocío, Sevilla, Spain|H. La Fe, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT01613300"
377,"NCT02443077","Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Procedure: Autologous Bone Marrow Transplantation|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Etoposide|Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Other: Pharmacogenomic Study|Other: Placebo","24-month progression-free survival (PFS), defined as the proportion of patients who are alive and progression-free 2 years from randomization|Overall survival (OS)|Time to hematopoietic engraftment|PFS|Response rate using the Lugano classification|Treatment-related mortality|Incidence of hematologic toxicity of ibrutinib therapy|Incidence of secondary malignancies","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","302","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NCI-2015-00668|BMT CTN 1201|A051301|U10CA180821","July 6, 2016","July 1, 2020","null","May 13, 2015","null","September 13, 2018","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Grand Valley Oncology, Grand Junction, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Yale University, New Haven, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States|Hematology/Oncology Clinic LLP, Baton Rouge, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Simonds-Sinon Regional Cancer Center, Fitchburg, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University Pointe, West Chester, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Laurens, Clinton, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt-Ingram Cancer Center Cool Springs, Franklin, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Farmington Health Center, Farmington, Utah, United States|Logan Regional Hospital, Logan, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Riverton Hospital, Riverton, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|South Jordan Health Center, South Jordan, Utah, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Rockwood North Cancer Treatment Center, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center - Eau Claire, Eau Claire, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Vince Lombardi Cancer Clinic-Marinette, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Marshfield Medical Center, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT02443077"
378,"NCT01516580","Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients",,"Active, not recruiting","No Results Available","B-cell Non Hodgkin Lymphoma|Mature B-cell Leukemia Burkitt-type","Drug: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|Drug: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C","Event free survival|Survival|Acute toxicity|Long term toxicity","Gustave Roussy, Cancer Campus, Grand Paris|Children's Oncology Group","All","6 Months to 17 Years   (Child)","Phase 3","482","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Inter B-NHL Ritux 2010 Phase 3|2010-019224-31","December 2011","June 13, 2017","December 2021","January 25, 2012","null","June 14, 2017","University Hospitals Leuven, Leuven, Belgium|Children Oncology Group Operations centres, Monrovia, Canada|The University of Hong Kong (Clinical Trials Centre), Hong-Kong, China|Institut de Cancérologie Gustave roussy, Villejuif, France|2nd Dept. of Pediatrics Semmelweis Univ., Budapest, Hungary|Associazione Italiana di Ematologia ed Oncologia Pediatrica, Padova, Italy|Emma Children's Hospital, Amsterdam, Netherlands|Rectorat of Medical University, Wroclaw, Poland|Sociedad Española de Hematología y Oncología Pediátricas, Valencia, Spain|University of Birmingham, Birmingham, United Kingdom","","https://ClinicalTrials.gov/show/NCT01516580"
379,"NCT02628405","R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","CD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma","Drug: Carboplatin|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Rituximab","Maximum tolerated dose defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients of the addition of lenalidomide to rituximab-ifosfamide-carboplatin-etoposide (Phase I)|Toxicity profile defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment as measured by Common Terminology Criteria for Adverse Events version 4.0 (Phase I)|Overall response rate defined as a complete metabolic response or partial metabolic response (Phase II)|Percentage of patients proceeding to stem cell transplant|Complete metabolic response rate|Overall survival|Incidence of adverse events","Academic and Community Cancer Research United|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RU051417I|NCI-2015-01990|P30CA015083","May 20, 2016","May 20, 2019","January 20, 2023","December 11, 2015","null","July 26, 2018","Mayo Clinic in Florida, Jacksonville, Florida, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Marshfield Clinic, Marshfield, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02628405"
380,"NCT02867553","Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions","RADIO-LYMPH","Active, not recruiting","No Results Available","Indolent Cutaneous B Cell Lymphomas","Drug: rituximab|Radiation: Multi-fields radiotherapy","Disease free survival","CHU de Reims","All","18 Years and older   (Adult, Older Adult)","Phase 3","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PN09001","October 2011","July 2018","January 2019","August 16, 2016","null","September 7, 2016","Chu de Reims, Reims, France","","https://ClinicalTrials.gov/show/NCT02867553"
381,"NCT01235793","The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma","DRBEAT","Recruiting","No Results Available","B-Cell Lymphoma Originating in the CNS","Drug: Temozolomide","Efficacy of the DRBEAT Regimen|Safest dose of temozolomide for the DRBEAT Regimen","Cedars-Sinai Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00019873","October 14, 2010","December 2018","December 2019","November 8, 2010","null","January 16, 2018","Cedars Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01235793"
382,"NCT03028103","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",,"Active, not recruiting","No Results Available","Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma","Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide","Part A: Effect of CYP3A inhibition by fluconazole on the PK of tazemetostat (AUC0-t, AUC0-8)|Part A: Cmax of tazemetostat during co-administration with fluconazole|Part B: The potential of tazemetostat to inhibit or induce CYP2C8 using repaglinide as a probe substrate (AUC0-t, AUC0-∞)|Part B: Cmax of repaglinide during co-administration with tazemetostat|Part B: The potential of tazemetostat to inhibit or induce CYP2C19 using omeprazole as probe a substrate (AUC0-t, AUC0-∞)|Part B: Cmax of omeprazole during co-administration with tazemetostat|Part B: Effect of increased gastric pH by omeprazole on the PK of tazemetostat (AUC0-t, AUC0-8)|Part B: Cmax of tazemetostat during co-administration with omeprazole|Incidence of treatment-emergent adverse events as a measure of safety|Part A: PK of tazemetostat and its metabolites after administration alone and with fluconazole (AUC0-t, AUC0-8)|Part A: Tmax of tazemetostat after administration alone with fluconazole|Part A: t1/2 of tazemetostat after administration alone with fluconazole|Part A: Cmax of tazemetostat metabolites after administration alone and with fluconazole|Part A: Tmax of tazemetostat metabolites after administration alone and with fluconazole|Part A: t1/2 of tazemetostat metabolites after administration alone and with fluconazole|Part A: Exposure of fluconazole after administration of 400 mg once daily for 4 days (AUC0-8)|Part A: Cmax of fluconazole after administration of 400mg once daily for 4 days|Part A: Tmax of fluconazole after administration of 400mg once daily for 4 days|Part A: The antitumor activity of Tazemetostat will be assessed in patients with diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL) or advanced solid tumors .|Part B: The antitumor activity of Tazemetostat will be assessed in patients with diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL) or advanced solid tumors..","Epizyme, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EZH-105","March 27, 2017","December 2018","January 2019","January 23, 2017","null","July 31, 2018","University of Arizona Cancer Center, Tucson, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03028103"
383,"NCT01148446","R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL","ANZINTER3","Completed","No Results Available","Elderly Patients (>65 Years)|Diffuse Large B Cell Lymphoma (DLBCL)","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Epirubicin|Drug: Vinblastine|Drug: Rituximab|Drug: G-CSF","Event Free Survival (EFS)|Complete Remission (CR) rate|Disease Free Survival (DFS)|Multidimensional Evaluation Scale for the definition of ""frail"" and ""non frail"" patients","Fondazione Italiana Linfomi ONLUS","All","66 Years to 80 Years   (Older Adult)","Phase 3","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIL ANZINTER3","January 2003","January 2006","null","June 22, 2010","null","June 22, 2010","Ospedale di Vigevano, Vigevano, Pavia, Italy|S.C. di Ematologia, Spedali Civili, Brescia, Italy|Ospedale Garibaldi-Nesima, Catania, Italy|Ospedale civile Divisione di Ematologia, Civitanova Marche (MC), Italy|Ospedale San Sebastiano, Correggio (RE), Italy|Presidio Ospedaliero Annunziata, Cosenza, Italy|Istituto Vito Fazzi, Lecce, Italy|Azienda Ospedaliera Policlinico, Modena, Italy|AO Arcispedale S.Maria Nuova Ematologia, Reggio Emilia, Italy|Ospedale civile DH oncologico, Sassuolo (MO), Italy|Ospedale San Giovanni Battista - Molinette, Torino, Italy","","https://ClinicalTrials.gov/show/NCT01148446"
384,"NCT01266668","The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)",,"Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse","","Overall Survival|Progression-free survival","Chonbuk National University Hospital","All","20 Years to 85 Years   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","Chonbuk 011","February 2010","May 2011","June 2011","December 24, 2010","null","November 29, 2011","Chonbuk National University Hospital, Jeonju, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01266668"
385,"NCT03318835","Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients",,"Recruiting","No Results Available","Thalidomide","Drug: Thalidomide combined with R-CHOP|Drug: R-CHOP","3 year PFS|ORR|OS|adverse event","Fudan University","All","18 Years and older   (Adult, Older Adult)","Phase 3","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FDSCC LYM2017-01","August 22, 2017","August 22, 2020","August 22, 2020","October 24, 2017","null","October 24, 2017","Fudan University Cancer Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03318835"
386,"NCT00561379","Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab",,"Completed","No Results Available","Lymphoma, Large-Cell, Diffuse","Drug: CHOP+RITUXIMAB|Drug: CEEP-RITUXIMAB","3 years Event-free survival ( Kaplan Meier method)|3 years overall survival|Prognostic impact of: Level of expression of protéine bcl2 protein in tumor cells; FCGR3A genotype; génomic profile (DNA microarray)on response, survival, and Event-Free-Survival|Cost","Nantes University Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRD 04/4-O","April 2005","May 2013","May 2013","November 21, 2007","null","June 13, 2013","Nantes University Hospital, Nantes, France","","https://ClinicalTrials.gov/show/NCT00561379"
387,"NCT01939730","Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: Rituximab|Drug: GM-CSF","Overall Response Rate of Rituximab plus GM-CSF of repeat doses (once weekly times four)","M.D. Anderson Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM98-304","August 1999","December 2006","September 2013","September 11, 2013","null","November 4, 2015","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01939730"
388,"NCT03465527","Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL",,"Active, not recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: PrednisoLONE 50 MG","(treatment-related mortality rate; TRM)|IMWG fragility score before and after pre-phase treatment|TRM and RR according to IMWG fragility score|response rate; RR|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Incidence of neutropenic fever","Kosin University Gospel Hospital","All","65 Years and older   (Older Adult)","Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Prephase","April 13, 2017","December 31, 2018","December 31, 2019","March 14, 2018","null","March 15, 2018","Kosin University Gospel Hospital, Busan, Sue-gu, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03465527"
389,"NCT03213977","R-DA-EDOCH Versus R-CEOP90, w/o Upfront Auto-HSCT in Young Patients With Intermediate/High-risk DLBCL",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: R-DA-EPOCH|Drug: R-DA-EPOCH + auto-HSCT|Drug: R-CEOP90|Drug: R-CEOP90 + auto-HSCT","disease-free survival|complete response|overall survival|Incidence of Treatment-Emergent Adverse Events","Fujian Medical University","All","16 Years to 60 Years   (Child, Adult)","Phase 3","475","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DLBCL-005","February 1, 2017","February 1, 2019","February 1, 2021","July 11, 2017","null","July 13, 2017","Fujian Medical University Union Hospital, Fuzhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT03213977"
390,"NCT02272686","Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma",,"Terminated","No Results Available","Lymphoma","Drug: Ibrutinib","Disease-Free Survival Rate","M.D. Anderson Cancer Center|Pharmacyclics LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0096|NCI-2015-00843","June 3, 2016","December 22, 2017","December 22, 2017","October 23, 2014","null","January 5, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02272686"
391,"NCT01458366","Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas",,"Active, not recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: Bendamustine|Drug: Ofatumumab|Drug: Carboplatin|Drug: Etoposide|Procedure: CT Scan|Procedure: PET Scan|Genetic: Stem Cell Transplant (STC)","Phase I: Maximum-Tolerated Dose of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE)|Phase II: Overall Frequency of Response with Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide|Phase I: Overall Frequency of Response|Phase II: Complete Response (CR) and Partial Response (PR) Rate|Phase II: Progression-Free Survival|Phase II: Overall Survival|Phase II: Proportion of Patients Who Are Able to Undergo Stem Cell Transplant (SCT)|Phase II: Safety and Tolerability of the Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide","Sidney Kimmel Cancer Center at Thomas Jefferson University|GlaxoSmithKline|Novartis|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11D.404|2011-61","November 9, 2011","November 2018","October 2021","October 24, 2011","null","June 6, 2018","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01458366"
392,"NCT01181999","Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma",,"Unknown status","No Results Available","Lymphoma, Large B-cell, Diffuse","Drug: rituximab","the overall response rate|Number of patients with adverse events|progression-free survival","Chonnam National University Hospital|Samsung Medical Center|Asan Medical Center|Severance Hospital","All","70 Years and older   (Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML25393","August 2010","March 2012","September 2014","August 16, 2010","null","September 22, 2011","Chonnam National University Hwasun Hosptial, Jeollanam-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01181999"
393,"NCT01897571","Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL",,"Recruiting","No Results Available","B-cell Lymphomas (Phase 1)|Advanced Solid Tumors (Phase 1)|Diffuse Large B-cell Lymphoma (Phase 2)|Follicular Lymphoma (Phase 2)|Transformed Follicular Lymphoma|Primary Mediastinal Large B-Cell Lymphoma","Drug: Tazemetostat","Maximum tolerated dose (MTD) (Phase 1 only)|Objective response rate (ORR; complete response + partial response [CR + PR]) (Phase 2)|The effect of a high fat meal on the bioavailability of tazemetostat (Phase 1)|The effect of tazemetostat on exposure of midazolam, a CYP3A4 substrate|To assess the preliminary activity of tazemetostat (Phase 1)|The effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on progression-free survival (PFS) (Phase 2)|The effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on duration of response (DOR) (Phase 2)|The safety and tolerability of tazemetostat monotherapy and tazemetostat in combination with prenisolone (Phase 1 and Phase 2)|The pharmacokinetic (PK) profile of tazemetostat monotherapy and tazemetostat in combination with prednisolone (Phase 1 and Phase 2)|The effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on overall survival (OS)","Epizyme, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","420","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7438-G000-101","June 2013","November 2019","January 2020","July 12, 2013","null","June 4, 2018","Birmingham, Alabama, United States|Duarte, California, United States|Santa Barbara, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Ocala, Florida, United States|Ann Arbor, Michigan, United States|New York, New York, United States|Houston, Texas, United States|San Antonio, Texas, United States|Arlington, Virginia, United States|Seattle, Washington, United States|Clayton, Australia|Geelong, Australia|Melbourne, Australia|Montreal, Canada|Toronto, Canada|Bordeaux, France|Caen, France|Creteil, France|Lille, France|Lyon, France|Marseille, France|Montpellier, France|Nantes, France|Paris, France|Pierre Benite, France|Rennes, France|Rouen, France|Villejuif Cedex, France|Gottingen, Germany|Muenster, Germany|Bologna, Italy|Napoli, Italy|Krakow, Poland|Lublin, Poland|Warsaw, Poland|Taipei City, Taiwan|Chernivtsi, Ukraine|Dnipro, Ukraine|Ivano-Frankivs'k, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Mykolayiv, Ukraine|Uzhgorod, Ukraine|Zaporizhzhya, Ukraine|Zhytomyr, Ukraine|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01897571"
394,"NCT03625037","GEN3013 (DuoBody®-CD3xCD20) Safety Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma","Biological: GEN3013 (DuoBody®-CD3xCD20)","Dose Limiting Toxicities (DLTs)|Adverse Events (AEs)|Cytokine measures|Area-under-the-concentration-time curve (AUC0-C last)|Maximum Plasma Concentration (Cmax) of GEN3013|Presence of neutralizing anti-drug antibodies (ADAs) in blood (positive/negative).|Reduction in tumor size","Genmab","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","110","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCT3013-01","June 26, 2018","January 30, 2022","December 30, 2025","August 10, 2018","null","September 28, 2018","VU University Medical Center, Amsterdam, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|The Christie NHS Foundation Trust, Manchester, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT03625037"
395,"NCT02900651","Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: MAK683","Incidence of dose limiting toxicities (DLTs)|Safety and tolerability|Overall Response Rate (ORR)|Duration of overall response (DOR)|Progression-free survival (PFS)|Best Overall Response (BOR)|Peak Plasma Concentration (Cmax) of MAK683|Area Under the Plasma Concentration (AUC) Time Curve of MAK683|Half-Life of MAK683|H3K27 tri methylation level in PBMC","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","113","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMAK683X2101|2016-001860-12","October 3, 2016","August 5, 2019","August 5, 2019","September 14, 2016","null","June 6, 2018","Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Sunto-gun, Shizuoka, Japan|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT02900651"
396,"NCT00168740","Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)",,"Completed","No Results Available","Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma","Drug: rituximab","overall response rate|time to disease progression|progressive disease-free interval","Biogen","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDEC-102-05","April 1995","null","null","September 15, 2005","null","September 15, 2005","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|City of Hope Natioal Medical Center, Duarte, California, United States|Scripps Memorial Hospital, La Jolla, California, United States|UCSD Stem Cell Laboratory, La Jolla, California, United States|Hoag Hospital, Newport Beach, California, United States|Sutter Cancer Center, Sacramento, California, United States|Sidney Kimmel Cancer Center, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, United States|University of Iowa General Hospital, Iowa City, Iowa, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Louisiana State University, Shreveport, Louisiana, United States|University of Maryland Cancer Center, Baltimore, Maryland, United States|Michigan State University, East Lansing, Michigan, United States|St. Louis University Medical Center, St. Louis, Missouri, United States|Roswell Park Cancer Center, Buffalo, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|The West Clinic, P.C., Memphis, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Sciences Center, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Ottawa General Hospital, Ottawa, Ontario, Canada|Toronto-Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00168740"
397,"NCT02792491","Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over",,"Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone","3 year progression free survival rate|Overall response rate|Overall survival|Toxicity profile","Pusan National University Hospital","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2","57","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Elderly RD_R-CHOP","August 2012","December 2017","December 2017","June 7, 2016","null","June 9, 2016","","","https://ClinicalTrials.gov/show/NCT02792491"
398,"NCT00333008","A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.",,"Unknown status","No Results Available","Diffuse Large B Cell Lymphoma|Lymphoma, Non-Hodgkin","Drug: Doxil|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab|Drug: Pegfilgrastim","Safety assessment: National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTACAE) v3.0|Efficacy: tumor evaluations every three (q 3) cycles","The Alvin and Lois Lapidus Cancer Institute|Ortho Biotech Products, L.P.","All","18 Years and older   (Adult, Older Adult)","Phase 2","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY-012006","May 2006","null","null","June 2, 2006","null","September 26, 2006","Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Northwest Hospital Center, Randallstown, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00333008"
399,"NCT02772822","A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients",,"Not yet recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: SCT400 plus CHOP|Drug: Rituximab plus CHOP","Overall response rate(ORR) after completion of treatment|Complete remission(CR) plus complete remission/unconfirmed(CRu) after completion of treatment|Progression-free survival(PFS)|Event-free survival(EFS) at 1 year and directly after an event, whichever comes first. The events are defined as progressive disease, relapse, death from any cause, or new anticancer treatment|Duration of remission(DOR) measured from prior achievement of complete remission or partial remission to occurrence of an event or at 1 year, whichever comes first. The events are defined as progressive disease, relapse of death from any cause|Overall survival(OS)|Comparison of adverse events(AEs) between the two study arms|Number of participants with seropositive for human anti-chimeric antibody(HACA) between the two study arms","Sinocelltech Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SCT400NHL3","June 2016","June 2019","December 2019","May 16, 2016","null","May 16, 2016","Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02772822"
400,"NCT02853370","Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma",,"Active, not recruiting","No Results Available","Marginal Zone B-cell Lymphoma","Drug: Bendamustine and Rituximab","CT-scan of organomegaly (spleen-liver-lymph nodes)","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","65","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG 36","July 2012","April 2020","April 2020","August 2, 2016","null","February 28, 2018","Créteil (Hôpital Henri Mondor), Creteil, France|Dijon (CHU de Dijon - Hôpital d'Enfants), Dijon, France|Grenoble cedex 9 (CHU Michallon), Grenoble, France|Le Kremlin Bicêtre (Hôpital Bicêtre), Le Kremlin Bicetre, France|Le Mans (C.H. Le Mans), Le Mans, France|Lille cedex (CHRU Lille - Hôpital Claude Huriez), Lille, France|Pierre Bénite, Lyon Sud, France|Vandoeuvre-les-Nancy cedex (CHU Brabois), Nancy, France|Nantes cedex 01 (CHU de Nantes - Hôtel Dieu), Nantes, France|Paris cedex 10 (Hôpital Saint-Louis), Paris, France|Pessac cedex (Centre François Magendie), Pessac, France|Rouen (Centre Henri Becquerel), Rouen, France|Ospedale Civile Ss. Antonio E Biagio, Alessandria, Italy|A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona, Ancona, Italy|Ospedale Armando Businco, Cagliari, Italy|A.O. Universitaria S. Martino Di Genova, Genova, Italy|Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Sede Di Meldola (Fc), Meldola, Italy|Irccs Fondazione Centro S. Raffaele Del Monte Tabor, Milano, Italy|A.O. Universitaria Policlinico Di Modena, Modena, Italy|A.O. ""V. Cervello"", Palermo, Italy|A.O. Universitaria Policlinico Giaccone, Palermo, Italy|A.O. Universitaria Di Parma, Parma, Italy|Ausl Di Piacenza, Piacenza, Italy|Ospedale S. Maria Delle Croci Di Di Ravenna, Ravenna, Italy|Ospedale Bianchi - Melacrino - Morelli, Reggio Calabria, Italy|Ospedale Di S. Maria Nuova-Irccs, Reggio Emilia, Italy|Irccs Centro Di Riferimento Oncologico Di Basilicata (Crob), Rionero, Italy|Irccs Istituto Dermatologico S. Gallicano (Ifo), Roma, Italy|Azienda Ospedaliera ""S. Maria"", Terni, Italy|Ospedale Di Circolo E Fondazione Macchi, Varese, Italy","","https://ClinicalTrials.gov/show/NCT02853370"
401,"NCT03373019","Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Chidamide|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Neoplasm by Histology|Neoplasms|Lymphoproliferative Disorders|Lymphatic Diseases|Immunoproliferative Disorders|Immune System Diseases|Lymphoma, Non-Hodgkin|Cyclophosphamide|Rituximab|Gemcitabine|Cisplatin|Dexamethasone|HDAC Inhibitor","Drug: Chidamide combined with R-GDP","ORR|CR|OS|3 year PFS|adverse event","Fudan University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-RD1","December 21, 2017","June 30, 2019","March 1, 2021","December 14, 2017","null","December 14, 2017","Kai Xue, Shanghai, Shanghai, China|Kai Xue, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03373019"
402,"NCT03576807","The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma",,"Recruiting","No Results Available","Relapsed or Refractory B-cell Lymphomas","Drug: CD20 CAR-T cells","Study related adverse events [ Time Frame: 4 weeks ]|Graft Activity Endpoint Detection","Xin Wang|Shanghai Longyao Biotechnology Inc., Ltd.","All","10 Years to 80 Years   (Child, Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHLY1701","April 4, 2018","April 3, 2019","April 3, 2020","July 3, 2018","null","July 3, 2018","The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT03576807"
403,"NCT03378947","EBV-associated Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","To Characterize and Compare Clinical, Pathological and Molecular Features","Other: clinical and pathological data EBV-related GZL and DLBCL","status at last follow up","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","","70","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","Hospices civils de lyon","June 1, 2017","January 15, 2018","June 1, 2018","December 20, 2017","null","December 22, 2017","HCL, Lyon, Pierre Bénite, France","","https://ClinicalTrials.gov/show/NCT03378947"
404,"NCT00379574","Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL",,"Completed","Has Results","Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell","Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisolone|Drug: Lenograstim","Number of Patients Who Achieved Complete Response|Number of Patients Who Experienced Adverse Events","Asan Medical Center|Janssen Korea, Ltd., Korea","All","15 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","49","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC 2006-276","September 2006","January 2011","January 2011","September 22, 2006","March 14, 2013","March 15, 2013","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of|Asan Medical Cener, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT00379574"
405,"NCT02431988","Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation","COBALT","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Procedure: Leukapheresis|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CAR19 T-Cells","Feasibility of adequate leucapheresis collection and generation of CAR19 T cells.|Toxicity evaluation following CAR19 T-cell administration.|Efficacy of CAR19 T-cells.|CAR19 T-cell engraftment|B cell compartment|Cytokine profile|Clinical complete response|Eligibility to allogeneic transplantation","University College, London","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL/14/0385|2015-000348-40","June 2016","December 2018","December 2020","May 1, 2015","null","May 2, 2018","University College London Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02431988"
406,"NCT02151903","Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL",,"Completed","No Results Available","B-cell Non-Hodgkin Lymphoma","Drug: DI-Leu16-IL2","Tumor response in patients|Safety assessment in patients monitoring adverse events|Safety assessment in patients monitoring clinical laboratory tests|Safety assessment in patients monitoring physical exams","Alopexx Oncology, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AO-101-EXT","November 2014","July 2016","July 2016","June 2, 2014","null","March 17, 2017","City of Hope, Duarte, California, United States|University of Minnesota, Minneapolis, Minnesota, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT02151903"
407,"NCT02541565","Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma",,"Recruiting","No Results Available","Composite Lymphoma|Grade 3b Follicular Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage I Follicular Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage II Follicular Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage III Follicular Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma|Stage IV Follicular Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","Incidence of toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Treatment-related mortality|Event-free survival|Overall survival|Response rate measured by tumor imaging","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9291|NCI-2015-01309|MK-3475|P30CA015704","November 24, 2015","November 24, 2020","November 24, 2020","September 4, 2015","null","October 26, 2017","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02541565"
408,"NCT03161054","Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas",,"Recruiting","No Results Available","Aggressive Non-Hodgkin Lymphoma","Drug: Prednisone|Drug: Vinorelbine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Rituximab","Complete Remission Rate (CRR)|Incidence of adverse events|Overall response rate (ORR)|Clinical Benefit|Progression Free Survival (PFS)|Event Free Survival (EFS)|Disease Free Survival (DFS)|Overall Survival (OS)|Patient-Reported Outcome (PRO)","Fondazione Italiana Linfomi ONLUS","All","65 Years and older   (Older Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_DEVEC","September 12, 2017","December 2019","May 2020","May 19, 2017","null","November 30, 2017","Università Politecnica delle Marche - Clinica di Ematologia, Ancona, Italy|AOU Policlinico Consorziale - U.O. Ematologia con Trapianto, Bari, Italy|IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia, Bari, Italy|A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy|Ospedale Antonio Perrino - U.O. Ematologia, Brindisi, Italy|Università Cattolica - Ematologia, Campobasso, Italy|Osp. civile di Carrara - Oncologia Medica, Carrara, Italy|Ospedale di Castelfranco Veneto - Ematologia, Castelfranco Veneto, Italy|Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. Ematologia, Catania, Italy|AO S.Antonio Abate - Oncologia, Gallarate, Italy|Ospedali Riuniti del Canavese - S.C.Medicina trasfusionale ed Ematologia, Ivrea, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia, Meldola, Italy|Ospedale Dell'Angelo - U.O. Ematologia, Mestre, Italy|ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milano, Italy|P.O. San Martino - Ematologia, Oristano, Italy|AOU di Parma - UO Ematologia e CTMO, Parma, Italy|Ospedale Guglielmo da Saliceto - U.O.Ematologia, Piacenza, Italy|A.O.R. ""San Carlo"" - U.O. Ematologia, Potenza, Italy|Ospedale delle Croci - Ematologia, Ravenna, Italy|A.O. Bianchi Melacrino Morelli - Ematologia, Reggio Calabria, Italy|Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS c/o CORE (II piano) - Ematologia, Reggio Emilia, Italy|Ospedale degli Infermi di Rimini - U.O. di Ematologia, Rimini, Italy|AO Sant'Andrea - Ematologia, Roma, Italy|Ospedale S. Camillo - Ematologia, Roma, Italy|Policlinico Tor Vergata - Ematologia, Roma, Italy|Università Cattolica S. Cuore - Ematologia, Roma, Italy|Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico, Sassuolo, Italy|AOU Senese - U.O.C. Ematologia, Siena, Italy|Azienda Ospedaliera della Valtellina e della Valchiavenna P.O. Sondrio - Medicina Interna - Centro Malattie del Sangue P.O. Sondrio, Sondrio, Italy|Ospedale SS. Annunziata ASL1 Abruzzo - U.O.S. Ematologia Universitaria, Sulmona, Italy|A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria, Torino, Italy|AO Ordine Mauriziano - SCDU Ematologia e Terapie Cellulari, Torino, Italy","","https://ClinicalTrials.gov/show/NCT03161054"
409,"NCT03440567","Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",,"Recruiting","No Results Available","CCND1 Positive|CD20 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Avelumab|Drug: Carboplatin|Drug: Etoposide Phosphate|Drug: Ibrutinib|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Biological: Rituximab|Biological: Utomilumab","Maximum tolerated dose determined by dose-limiting toxicities|Incidence of adverse events evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|CR rate defined as the proportion of response-evaluable participants that have a documented CR at any time|Duration of response defined as the duration from the time a patient first achieves CR or PR until the time that relapse or progressive disease is objectively documented|Overall response rate defined as the proportion of response-evaluable participants that have a documented complete response (CR) or partial response (PR) at any time|Progression-free survival","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","39","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17428|NCI-2018-00098","June 8, 2018","June 8, 2020","June 8, 2020","February 21, 2018","null","June 15, 2018","City of Hope Medical Center, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT03440567"
410,"NCT01874288","Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL","DI-Leu16-IL2","Completed","No Results Available","B-cell Non-Hodgkin Lymphoma","Drug: 0.5 mg/m2 DI-Leu16-IL2|Drug: 1.0 mg/m2 DI-Leu16-IL2|Drug: 2.0 mg/m2 DI-Leu16-IL2|Drug: 4.0 mg/m2 DI-Leu16-IL2|Drug: 6.0 mg/m2 DI-Leu16-IL2|Drug: 8.0 mg/m2 DI-Leu16-IL2|Drug: 10.0 mg/m2 DI-Leu16-IL2|Drug: 50mg/m2 Rituximab","Maximum tolerated dose of DI-Leu16-IL2|Evaluate immunogenicity","Alopexx Oncology, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AO-101","July 2013","September 2016","September 2016","June 11, 2013","null","January 17, 2018","City of Hope, Duarte, California, United States|St. Jude Hospital Yorba Linda, Fullerton, California, United States|University of Minnesota, Minneapolis, Minnesota, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Joe Arlington Cancer Research and Treatment Center, Lubbock, Texas, United States","","https://ClinicalTrials.gov/show/NCT01874288"
411,"NCT03505762","Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment",,"Recruiting","No Results Available","B-Cell Non-Hodgkin Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Biological: Rituximab|Drug: Vincristine Sulfate","Cumulative incidence of hyperglycemia of standard or tailored rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP)|Cumulative incidence of hyperglycemia of standard or tailored R-CHOP|Response rates of standard or tailored R-CHOP as measured by Cheson's criteria|Rates of grade III or higher adverse events using Common Terminology Criteria for Adverse Events (CTCAE) criteria from standard or tailored R-CHOP|Severity of prednisone related adverse events using the Patient Reported Outcome (PRO)-CTCAE|Health related quality of life (HRQOL) scores","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00050108|NCI-2018-00585|CCCWFU 98317|P30CA012197","July 19, 2018","June 2022","June 2024","April 23, 2018","null","July 27, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03505762"
412,"NCT00538096","A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma",,"Withdrawn","No Results Available","Lymphoma, B-Cell|Lymphoma, Non-Hodgkin","Drug: MEDI-538","All endpoints will be analyzed descriptively. AEs and SAEs will be summarized by dose cohort, body system, severity, and relationship to MEDI-538 through 30 days after discontinuation of MEDI-538.|The secondary endpoints of this study include measurement of the pharmacokinetics,immunogenicity, and antitumor activity of MEDI-538 in this patient population.","MedImmune LLC","All","18 Years to 60 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MI-CP137","September 2007","March 2010","May 2010","October 2, 2007","null","September 5, 2008","","","https://ClinicalTrials.gov/show/NCT00538096"
413,"NCT03211702","Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)",,"Recruiting","No Results Available","Lymphoma, Large B-cell, Diffuse","","Event-free survival|Overall survival|Progression-free survival|Cumulative incidence of grade 3/4 adverse events and premature treatment discontinuation","Chonbuk National University Hospital|The Catholic University of Korea|Kyungpook National University|Keimyung University Dongsan Medical Center|Korea University Anam Hospital|Korea University Guro Hospital|Kosin University Gospel Hospital|Pusan National University Hospital|Soonchunhyang University Hospital|Ajou University School of Medicine|Chonnam National University Hospital|Chungnam National University Hospital|Yeungnam University Hospital","All","65 Years and older   (Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GERIAD2","August 25, 2017","August 2019","August 2021","July 7, 2017","null","August 29, 2017","Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03211702"
414,"NCT02555267","Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Large B-cell, Diffuse","","Event-free survival|Overall survival|Progression-free survival|Cumulative incidence of grade 3/4 adverse events and premature treatment discontinuation","Chonbuk National University Hospital|The Catholic University of Korea|Kyungpook National University|Keimyung University Dongsan Medical Center|Korea University Anam Hospital|Korea University Guro Hospital|Kosin University Gospel Hospital|Pusan National University Hospital|Soonchunhyang University Hospital|Ajou University School of Medicine|Chonnam National University Hospital","All","65 Years and older   (Older Adult)","","148","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GERIAD","September 2015","August 2019","August 2019","September 21, 2015","null","August 29, 2017","Chonbuk National University Hospital, Jeonju, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02555267"
415,"NCT00927797","Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)","PERLL","Unknown status","No Results Available","Immunocytoma/Morbus Waldenström|B-Cell Non-Hodgkin's Lymphoma|B-Cell Chronic Lymphocytic Leukemia","Drug: Cyclophosphamide, Pentostatin, Rituximab","Efficacy: overall response rate|Toxicity according to WHO-Grading|Efficacy: complete remission rate|Efficacy: partial remission rate|Efficacy: progression-free survival","Heidelberg University|Diakonie Krankenhaus Schwäbisch Hall, Germany|Ludwig-Maximilians - University of Munich|Klinikum am Plattenwald, Bad Friedrichshall, Germany|Diakonieklinikum Stuttgart, Germany|Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany|Universitätsmedizin Mannheim","All","18 Years and older   (Adult, Older Adult)","Phase 2","185","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","L-278/2004|BfArM 4022892","February 2005","January 2009","January 2012","June 25, 2009","null","June 25, 2009","","","https://ClinicalTrials.gov/show/NCT00927797"
416,"NCT00561756","Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: plasmid DNA vaccine therapy|Other: flow cytometry|Other: immunoenzyme technique","Safety and immunogenicity|Antibody and T-cell responses against CD20|Antitumor response","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-100|MSKCC-07100","October 2007","November 2015","November 2015","November 21, 2007","null","November 17, 2015","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00561756"
417,"NCT02910063","Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL",,"Recruiting","No Results Available","B-Cell Non Hodgkin Lymphoma","Drug: Blinatumomab|Drug: Investigator's Choice Chemotherapy","Phase 2 and 3- Complete Metabolic Response|Phase 3- Complete Metabolic Response|Phase 3 - Overall Survival|Phase 2 Objective Response Rate|Phase 2 Progression-Free Survival|Phase 2 Duration of Response|Phase 2 Successful Mobilization Rate|Phase 2 Hematopoietic Stem Cell Transplant rates (both autologous and allogeneic)|Phase 2 100 Day non-relapse mortality after autologous HSCT|Phase 2 Blinatumomab concentration steady state|Phase 2 Incidence and severity of adverse events|Phase 3 Objective response rate|Phase 3 Progression-Free Survival|Phase 3 Duration of Response|Phase 3 Successful Mobilization Rate|Phase 3 Hematopoietic Stem Cell Transplant rates (both autologous and allogeneic)|Phase 3 Patient-reported clinical outcome assessments|Phase 3 Blinatumomab concentration steady state|Phase 3 Overall incidence and severity of treatment-emergent adverse events|Phase 2 Blinatumomab clearance|Phase 2 Blinatumomab half life|Phase 3 Blinatumomab clearance|Phase 3 Blinatumomab half life","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","332","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150292|2016-002044-16","January 23, 2017","May 4, 2021","March 5, 2022","September 21, 2016","null","August 17, 2018","Research Site, Duarte, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Greenville, South Carolina, United States|Research Site, St Leonards, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Montreal, Quebec, Canada|Research Site, Bergamo, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Udine, Italy|Research Site, San Juan, Puerto Rico|Research Site, Cordoba, Andalucía, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Murcia, Spain|Research Site, Bristol, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom","","https://ClinicalTrials.gov/show/NCT02910063"
418,"NCT03118180","CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Biological: CD19 targeted chimeric antigen receptor T cells","overall response rate","Zhejiang University|Innovative Cellular Therapeutics Co., Ltd.","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CART19-001","April 5, 2017","December 31, 2018","December 31, 2020","April 18, 2017","null","April 18, 2017","the First Affiliated Hospital,School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03118180"
419,"NCT03038672","Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas",,"Recruiting","No Results Available","ALK-Positive Large B-Cell Lymphoma|Atypical Burkitt/Burkitt-Like Lymphoma|Burkitt-Like Lymphoma With 11q Aberration|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Mucocutaneous Ulcer|High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Human Herpesvirus 8-Positive Neoplastic Cells Present|Intravascular Large B-Cell Lymphoma|Large B-Cell Lymphoma With IRF4 Rearrangement|Plasmablastic Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System|Primary Effusion Lymphoma|Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Lymphomatoid Granulomatosis|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study|Drug: Varlilumab","Overall response rate assessed by computed tomography (CT)-based criteria or positron emission tomography (PET)-CT based criteria|Duration of response|Survival time|Progression free survival (PFS)|Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","106","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2017-00120|MC168D|10089|UM1CA186686","November 30, 2017","December 31, 2019","December 31, 2019","February 1, 2017","null","August 23, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03038672"
420,"NCT02933320","BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia",,"Recruiting","No Results Available","B-cell Lymphoma|Chronic Lymphocytic Leukaemia|Waldenström Macroglobulinaemia","Biological: BI-1206 single agent dose escalation phase|Biological: BI-1206 single agent expansion phase|Biological: Combination of BI-1206 with Rituximab","Documenting Adverse Events (AEs), Serious Adverse Events (SAEs) (graded according to NCI-CTCAE Version 4.02) and laboratory parameters and determining their causality in relation to BI-1206.|Documenting AEs, SAEs (graded according to NCI-CTCAE Version 4.02) and laboratory parameters and determining their causality in relation to BI-1206 and, where appropriate, anti-CD20 antibody.|Measurement of PK parameter values for BI-1206 including AUC using ELISA|Measurement of PK parameter values for BI-1206 including Cmax using ELISA|Measurement of PK parameter values for BI-1206 including Tmax using ELISA|Measurement of PK parameter values for BI-1206 including half life T1/2 using ELISA|Measurement of anti-drug antibody (ADA) response to BI-1206 during the BI-1206 treatment period using ELISA|Measurement of peripheral blood B-lymphocyte depletion during the BI-1206 treatment period using flow cytometry.|Assessment of best disease response according to criteria for malignant lymphoma (Cheson, 2014) Waldenström macroglobulinaemia assessment criteria (Owen 2013, Kimby 2006) or NCI chronic lymphocytic leukaemia (CLL) criteria (Hallek, 2008).|Measure progression free survival at 1 year after the first BI-1206 administration on the study for all patients|Measure overall survival at 1 year after the first BI-1206 administration on the study for all patients","Cancer Research UK","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","81","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRUKD16001","October 4, 2016","January 2022","January 2022","October 14, 2016","null","February 2, 2018","Leicester Royal Infirmary, Leicester, England, United Kingdom|St Barts Hospital, London, England, United Kingdom|Christie Hospital, Manchester, England, United Kingdom|Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, England, United Kingdom|Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02933320"
421,"NCT00220285","Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma|Lymphoma, B-Cell|Lymphoma, Low-Grade","Drug: Zevalin (SH L 749 , BAY86-5128)","Best overall response rates (the percentage of patients who achieved PR or better response)|The incidence of critical toxicity|Safety evaluation|Complete response (CR or CRu) rates|Progression-free survival (PFS)","Bayer","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91102|305618","August 2004","null","October 2005","September 22, 2005","null","December 30, 2014","Nagoya-shi, Aichi, Japan|Kashiwa-shi, Chiba, Japan|Maebashi-shi, Gunma, Japan|Kanazawa-shi, Ishikawa, Japan|Isehara-shi, Kanagawa, Japan|Kyoto-shi, Kyoto, Japan|Sendai-shi, Miyagi, Japan|Chuo-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT00220285"
422,"NCT01157988","90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma",,"Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: ibritumomab tiuxetan (Zevalin)","Objective response|Safety and toxicity|Progression-free survival","Chonnam National University Hospital|Samsung Medical Center|Asan Medical Center|Chonbuk National University Hospital|Dong-A University Hospital|Pusan National University Hospital|Severance Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CISL-2007","January 2007","January 2009","null","July 8, 2010","null","July 8, 2010","Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01157988"
423,"NCT02494700","Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Radiation: Radiation Therapy","Local Orbital Control","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-1046|NCI-2015-01203","July 6, 2015","July 1, 2019","July 1, 2020","July 10, 2015","null","February 15, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02494700"
424,"NCT03150329","Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",,"Recruiting","No Results Available","Grade 3a Follicular Lymphoma|Grade 3b Follicular Lymphoma|Recurrent Classical Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Classical Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Vorinostat","Incidence of adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.03|Complete response rate|Duration of response|Overall response rate|Overall survival|Progression free survival|Time to response","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17080|NCI-2017-00800","September 1, 2017","July 2019","July 2019","May 12, 2017","null","July 30, 2018","City of Hope Medical Center, Duarte, California, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT03150329"
425,"NCT03332121","B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma",,"Recruiting","No Results Available","CD20 Positive B Cell Non-Hodgkin's Lymphoma","Biological: B001","Safety of B001 as assessed by adverse reactions and events|Concentration-time curve of B001|PD results of B001|Immunogenicity of B001|ORR of B001","Shanghai Pharmaceuticals Holding Co., Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B001-101","March 22, 2018","January 7, 2020","February 18, 2020","November 6, 2017","null","March 27, 2018","Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03332121"
426,"NCT01263418","Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas",,"Withdrawn","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, B-Cell, Marginal Zone|Lymphoma, Low-Grade|Lymphoma, Intermediate-Grade","Drug: Ofatumumab","To determine overall response rates (ORR) following ofatumumab treatment in older (≥ 70 years old) patients with previously untreated low or intermediate risk indolent NHL|To determine the complete response rate (CR) following ofatumumab treatment in older patients without prior systemic therapy for low or intermediate risk indolent NHL|To evaluate the toxicity and tolerability of ofatumumab treatment in the study population|Estimate progression free survival (PFS) at 2 years after ofatumumab treatment|Evaluate molecular response to ofatumumab therapy by performing PCR analysis for BCL2/IgH from the peripheral blood at baseline and 3 months from initiation of treatment","UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline","All","70 Years and older   (Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1018|IRB # 10-1910","June 2011","January 2016","January 2018","December 20, 2010","null","October 12, 2015","","","https://ClinicalTrials.gov/show/NCT01263418"
427,"NCT03189836","Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Biological: ACTR707|Biological: rituximab","Safety as assessed by dose limiting toxicities (DLTs)|Determination of maximum tolerated dose and proposed recommended Phase 2 dose|Anti-lymphoma activity as measured by overall response rate|Anti-lymphoma activity as measured by duration of response|Anti-lymphoma activity as measured by progression-free survival|Anti-lymphoma activity as measure by overall survival|Assessment of persistence of ACTR707 as measured by flow cytometry and qPCR|Assessment of ACTR707 phenotype and function as measured by flow cytometry|Assessment of inflammatory markers and cytokines/chemokines|Rituximab PK","Unum Therapeutics Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATTCK-20-03","October 4, 2017","January 2021","March 2021","June 16, 2017","null","March 20, 2018","Indiana Bone and Marrow Transplantation, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Tennessee Oncology - Nashville, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03189836"
428,"NCT02776813","Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Biological: ACTR087|Biological: rituximab","Safety as assessed by dose limiting toxicities (DLTs)|Safety as assessed by determination of the maximum tolerated dose (MTD)|Safety as assessed by determination of the recommended phase 2 dose (RP2D)|Safety as assessed by and adverse events, laboratory assessments and physical examinations|Safety as assessed by mini-mental state examination (MMSE)|Overall response rate|Duration of response|Progression free survival|Overall survival","Unum Therapeutics Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UT-201501|ATTCK-20-2","August 2016","January 2020","March 2020","May 18, 2016","null","March 20, 2018","Indiana Bone and Marrow Transplantation, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02776813"
429,"NCT03579927","CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",,"Not yet recruiting","No Results Available","CD19 Positive|Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Biological: Filgrastim|Drug: Melphalan|Biological: Rituximab|Biological: Umbilical Cord Blood-derived Natural Killer Cells","Incidence of adverse events defined as graft failure, grade 3, 4 graft versus host disease, grade 3,4 cytokine release syndrome, grade 3, 4, neuro-toxicity, or death from any cause|Complete response (CR) or partial response (PR)|Progression-free survival (PFS) time|Overall survival (OS) time|Response status|Number of chimeric antigen receptor (CAR) NK cells in blood by flow cytometry","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-0295|NCI-2018-01111|P30CA016672","September 21, 2018","March 21, 2019","March 21, 2019","July 9, 2018","null","August 6, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03579927"
430,"NCT02213913","Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas",,"Recruiting","No Results Available","Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia","Drug: lenalidomide|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: rituximab|Other: quality-of-life assessment|Other: laboratory biomarker analysis","PFS|MTD of adding lenalidomide to the DA-EPOCH-R regimen as a front-line therapy in patients with DHL lymphomas (using CTCAE v 4.0) (Phase I)|PFS (Phase II)|Add lenalidomide to the DA-EPOCH-R regimen as a front-line therapy in patients with DHL lymphomas (Phase I)|Overall response rate defined as the sum of partial response (PR) and complete response (CR) by computed tomography (CT) of positron emission tomography/CT and/or resolution of marrow-only involvement (if originally involved) (Phase I)|Anti-tumor activity, calculated as the sum of stable disease, PR, and CR according to the Revised Response Criteria for Malignant Lymphoma and Cheson et al (Phase I)|Duration of response, calculated as the duration from detecting any objective response until progression or death from any cause, according to the Revised Response Criteria for Malignant Lymphoma and Cheson et al (Phase I)|Incidence of adverse events, defined as the occurrence of all grades of toxicity (using CTCAE version 4.0)","University of Chicago|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-1406|NCI-2014-01581|IRB13-1406|P30CA014599","July 29, 2014","June 2018","June 2018","August 12, 2014","null","September 29, 2017","Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Maryland, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02213913"
431,"NCT00201422","Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma",,"Completed","No Results Available","MALT Lymphoma","Other: Omeprazole, Amoxicillin, Clarithromycin","evaluate the efficacy of Helicobacter pylori eradication therapy with respect to objective regression rate and time to disease progression of primary low-grade gastric MALToma.|objective regression rate and time to disease progression of primary low-grade gastric MALToma.","National Health Research Institutes, Taiwan","All","Child, Adult, Older Adult","Not Applicable","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T1296","June 1996","January 2004","January 2004","September 20, 2005","null","March 28, 2016","National Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT00201422"
432,"NCT02436707","Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Drug: Ibrutinib|Drug: Rituximab|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin|Drug: Mesna|Drug: Cyclophosphamide|Drug: Etoposide|Drug: G-CSF","Measure overall response rate|Number and severity of adverse events|Transplantation rate|Stem cell collection rate|Event free Survival Rate|Overall Survival","Canadian Cancer Trials Group|Janssen, LP|Roche Pharma AG","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","320","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY17","May 5, 2015","June 2019","December 2019","May 7, 2015","null","September 27, 2018","Tom Baker Cancer Centre, Calgary, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|The Vitalite Health Network - Dr. Leon Richard, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada","","https://ClinicalTrials.gov/show/NCT02436707"
433,"NCT02760485","A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Drug: itacitinib|Drug: ibrutinib","Phase 1: Safety and tolerability as assessed by adverse events and changes in clinical and laboratory assessments|Phase 2: Efficacy as assessed by objective response rate (ORR)|Efficacy as assessed by duration of response (DOR)|Efficacy as assessed by progression-free survival (PFS)|Efficacy as assessed by overall survival (OS)","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","78","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 39110-206","December 2016","September 2018","December 2018","May 3, 2016","null","June 21, 2018","Mayo Clinic Arizona, Scottsdale, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|LAC-USC Medical Center/Kenneth Norris Jr Cancer Hospital, Los Angeles, California, United States|Moores UC San Diego Cancer Center, San Diego, California, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Georgia Regents Research Institute, Augusta, Georgia, United States|University of Maryland Cancer Center, Baltimore, Maryland, United States|University of Michigan Cancer Center, Ann Arbor, Michigan, United States|Michigan State University Breslin Cancer Center, Lansing, Michigan, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States|Regional Cancer Center Associates, LLC, Little Silver, New Jersey, United States|Roswell Cancer Center, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Toledo Clinic Cancer Centers, Toledo, Ohio, United States|Tulsa Cancer Center, Tulsa, Oklahoma, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Northwest Medical Specialists & Research Institute, Puyallup, Washington, United States","","https://ClinicalTrials.gov/show/NCT02760485"
434,"NCT03352765","Rituximab, Bendamustine and Melphalan Chemo-immunotherapy Followed by Reinfusion of One's Own Stem Cell for Treatment of B-cell Lymphoma in Elderly Patients",,"Recruiting","No Results Available","Lymphoma","Drug: rituximab|Drug: bendamustine|Drug: melphalan|Procedure: Autologous Stem Cell Transplantation (ASCT)","Dose limiting toxicities (DLT)","Memorial Sloan Kettering Cancer Center","All","70 Years and older   (Older Adult)","Phase 1|Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-373","November 20, 2017","November 2020","November 2020","November 24, 2017","null","August 13, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03352765"
435,"NCT02529852","A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Drug: Lenalidomide|Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Maximum Tolerated Dose (MTD) of Lenalidomide, Obinutuzumab, and CHOP|Overall Response Rate","M.D. Anderson Cancer Center|Celgene|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","59","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0069|NCI-2015-01517","November 4, 2015","November 2021","November 2021","August 20, 2015","null","April 19, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02529852"
436,"NCT00689169","Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma","ZBEAM2","Completed","No Results Available","Lymphoma, Large Cell, Diffuse","Drug: ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Procedure: ASCT|Drug: Rituximab","Event free survival (EFS): events being death from any cause, relapse for complete responders and unconfirmed complete responders, progression during and after treatment and changes of therapy|Overall response rate (ORR) (Complete Response CR and Partial Response PR)","Lymphoma Study Association|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","75","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZBEAM2|2007-000270-23","August 2007","January 2011","January 2014","June 3, 2008","null","March 7, 2018","service d'onco hématologie adultes, hôpital Saint Louis, Paris, France","","https://ClinicalTrials.gov/show/NCT00689169"
437,"NCT02285062","Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","ROBUST","Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: lenalidomide|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: prednisone|Drug: vincristine","Progression Free Survival|Overall Survival|Complete Response Rate|Duration of Complete Response|Time to Next Lymphoma Treatment|Objective Response Rate|Health Related Quality of Life|Event Free Survival","Celgene","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","570","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CC-5013-DLC-002|2013-004054-21","January 21, 2015","August 15, 2018","August 3, 2022","November 6, 2014","null","April 26, 2018","Highlands Oncology Group, Fayetteville, Arkansas, United States|John Muir Health, Concord, California, United States|California Cancer Associates for Research and Excellence cCARE, Encinitas, California, United States|Moores UCSD Cancer Center MC-0987, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of Californai, Irvine, Orange, California, United States|UC Davis Cancer Center, Sacramento, California, United States|Memorial Hospital, Colorado Springs, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Memorial Healthcare System, Hollywood, Florida, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Cancer Treatment Centers of America - Southeastern Regional Medical Center, Newnan, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|McFarland Clinic, Ames, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Hematology-Oncology Clinic, Baton Rouge, Louisiana, United States|Cancer Center of Acadiana, Lafayette, Louisiana, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|Willis Knighton Medical Center, Shreveport, Louisiana, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Maryland Oncology Hematology PA, Columbia, Maryland, United States|Associates of Oncology/Hematology, P.C., Rockville, Maryland, United States|Saint Joseph Medical Center, Westminster, Maryland, United States|St. Joseph Mercy Hosp, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|St. Louis Cancer Care LLP, Bridgeton, Missouri, United States|Saint Louis Univ Hospital - Saint Louis, Saint Louis, Missouri, United States|Regional Cancer Care Associates/Cherry Hill Division, LLC., Cherry Hill, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Carol G Simon Cancer Center, Morristown, New Jersey, United States|Regional Cancer Care Associates - Somerset Division, Somerville, New Jersey, United States|Queens Medical Associates PC, Fresh Meadows, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Firsthealth of The Carolinas, Pinehurst, North Carolina, United States|St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Bon Secours Saint Francis Health System, Greenville, South Carolina, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Parkland Health and Hospital Systems, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Utah Cancer Specialist, Salt Lake City, Utah, United States|Virginia Cancer Institute, Richmond, Virginia, United States|VCU Massey Cancer Center, Richmond, Virginia, United States|Swedish Cancer Institute Edmonds Campus, Edmonds, Washington, United States|Swedish Medical Center, Issaquah, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Swedish Cancer Institute Ballard Campus, Seattle, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Albury Wodonga Regional Cancer Centre, Albury, New South Wales, Australia|Shoalhaven Cancer Care Centre, Nowra, New South Wales, Australia|Bendigo Hosp, Bendigo, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Geelong Hospital, Geelong, Victoria, Australia|St Vincents Hospital Melbourne, Fitzroy, Australia|Frankston Hospital, Frankston, Australia|Austin Hospital, Heidelberg, Australia|Royal Melbourne Hospital, Parkville, Australia|Wellington Hospital, Wellington, Australia|Westmead Hospital, Westmead, Australia|Wollongong Hospital, Wollongong, Australia|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|H. Hartziekenhuis Roeselare-Menen vzw campus Wilgenstraat, Roeselare, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|Regionaal Ziekenhuis Jan Yperman VZW, West-Vlaanderen, Belgium|GZA St. Augustinus, Wilrijk, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Fraser Health Authority, Surrey, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier Universitaire de Sherbrooke CHUS, Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Beijing Cancer Hospital, Beijing, PR, China|Peking University People's Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|West China Medical School West China Hospital Sichuan University, Chengdu, China|Xinqiao Hospital, Third Military Medical University, Chongqing, China|Fujian Medical University Union Hospital, Fuzhou, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, China|Nanfang Hospital of Southern medicine university in Guangzhou, Guangzhou, China|First Affiliated Hospital, Hangzhou, China|Harbin Medical University Tumor Hospital, Harbin, Heilongjiang, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|First Affiliated Hospital of Soochow University, Suzhu, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady, Interni hematologicka klinika, Prague 10, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha, Czechia|Centre Hospitalier de la cote basque, Bayonne, France|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|CHRU de Brest - Hopital Morvan, Brest Cedex, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier Departemental de Vendee, La Roche -Sur-Yon - Cedex 9, France|CHU Hopital Saint Eloi, Montepellier Cedex 5, France|Hotel Dieu, Nantes, France|Hopital Necker, Paris Cedex 15, France|Hopital Saint Louis, Paris, France|Hopital Haut Leveque, Pessac Cedex, France|Centre Hospitalier D'annecy, Pringy, France|CHRU Rennes, Rennes, France|Centre Hospitalier de Saint Brieuc Hopital Yves le Foll, ST-Brieuc cedex 1, France|Centre Hospitalier Universitaire de Toulouse, Toulose, France|CHU de Nancy-Hopital Brabois Adulte, Vandoeuvre les Nancy, France|Institut Gustave Roussy, Villejuif Cedex, France|Cork University Hospital, Wilton, Cork, Ireland|St Vincent's University Hospital, Dublin 4, Ireland|St James's Hospital, Dublin 8, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|University College Hospital Galway, Galway, Ireland|The Soroka University Medical Center, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Rabin Medical Center, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Assuta Medical Centers, Tel Aviv, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo, Allessandria, Italy|Azienda Ospedaliero Universitaria Ospedali, Ancona, Italy|Centro di Riferimento Oncologico, Aviano, Italy|Azienda Ospedaliera Poloclinico di Bari, Bari, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Italy|Spedali Civili Di Brescia, Brescia, Italy|Ospedale Ferrarotto, Catania, Italy|Azienda Sanitaria Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ospedale Civile di Ivrea, Ivrea, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Istituto Nazionale Dei Tumori, Milano, Italy|Azienda Ospedaliera Niguarda Ca Granda, Milano, Italy|Azienda Ospedaliero Universitaria Di Modena Policlinico, Modena, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|A.O.U. Maggiore della Carità, Novara, Italy|AOU San Luigi Gonzaga, Orbassano (TO), Italy|Azienda Ospedaliera Di Padova, Padova, Italy|Presidio Ospedaliero Andrea Tortora, Pagani, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Civile Spirito Santo, Pescara, Italy|Azienda Sanitaria Locale di Ravenna, Ravenna, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Ospedale degli Infermi di Rimini, Rimini, Italy|Policlinico Umberto I, Roma, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Azienda Ospedaliera S Maria di Terni, Terni, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Presidio Ospedaliero Di Treviso Ca' Foncello, Treviso, Italy|Azienda Ospedaliera Cardinale G Panico, Tricase, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Azienda ULSS 6 Vicenza, Vicenza, Italy|Akita University Hospital, Akita-shi, Japan|National Cancer Center Hospital, Chuo-ku, Japan|Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital, Fukuyama, Japan|Kyushu University Hospital, Higashi-ku, Fukuoka, Japan|Tokai University School of Medicine, Isehara City, Kanagawa, Japan|National Cancer Center Hospital East, Kashiwa, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-City, Japan|National Hospital Organization Kyushu Cancer Center, Minami-Ku, Fukuoka, Japan|Toranomon Hospital, Minato-ku, Japan|Aichi Cancer Center, Nagoya, Japan|Kochi Medical School Hospital, Nankoku-shi, Japan|Sendai Medical Center, Sendai-city, Japan|Ehime University Hospital, Toon, Japan|Yamagata University Hospital, Yamagata, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Marys Hospital College of Medicine The Catholic University of Korea, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis Molengracht, Breda, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|Jeroen Bosch Ziekenhuis, s-Hertogenbosch, Netherlands|Vlietland Ziekenhuis, Schiedam, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Auckland City Hospital, Auckland, New Zealand|Canterbury Health Laboratories, Christchurch, New Zealand|Palmerston North Hospital, Palmerston, New Zealand|Szpital Morski im. PCK, Gdynia, Poland|Malopolskie Centrum Medyczne S.C., Kraków, Poland|Zaklad Opieki Zdrowotnej MSW z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Samodz.Pub.Zaklad Opieki Zdrow-ej Min-wa Spraw Wewnetrznych w Poznaniu im Prof.Ludwika Bierkowskiego, Poznan, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, Portugal|Hospital Distrital Da Figueira Da Foz, Figueira da Foz, Portugal|Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal|Champalimaud Cancer Center, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, Portugal|Hospital Garcia de Orta, Pragal, Portugal|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico|Tatarstan Republican Oncology Center, Kazan, Russian Federation|Russian Cancer Research Center n.a. Blokhin, Chemotherapy Department, Moscow, Russian Federation|Research Oncology Institute of Rosmed Technologies n.a. prof. N.N. Petrov, St. Petersburg, Russian Federation|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|Hospital de San Pedro de Alcantara, Caceres, Spain|Hospital Universitario de Canarias, La Laguna, Spain|Hospital Universitario de la Princessa, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona/ Navarra, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Complejo Hospitalario Nuestra Senora de Valme, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Kantonsspital Aarau AG, Aarau, Switzerland|Ente Ospedaliero Cantonale, Bellinzona, Switzerland|Hopitaux Universitaire de Geneve, Geneva, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|Chang Gung Memorial Hospital - Chiayi, Puzi City Chiayi County, Taiwan|China Medical University Hospital, Taichung City, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan|Cukurova Universitesi Tip Fakultesi Balcali Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Ankara University Medical Faculty Cebeci Hospital, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Pamukkale University Medical Faculty, Denizli, Turkey|Dicle University Medical Faculty, Diyarbakir, Turkey|Trakya Universitesi Tip Fakultesi Hastanesi, Edirne, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, Istanbul, Turkey|Koc Universitesi Tip Fakultesi Amerikan Hastanesi, Istanbul, Turkey|Dokuz Eylul University Izmir, Izmir, Turkey|Erciyes University Kayseri, Kayseri, Turkey","","https://ClinicalTrials.gov/show/NCT02285062"
438,"NCT02531841","High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma","MATRix","Recruiting","No Results Available","Diffuse Large B-cell-lymphoma","Drug: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|Drug: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)","The primary outcome measure PFS will be measured by the number of events (PD, relapse or death from any cause) within the treatment arms|The secondary outcome measure CR will be assessed on day 60 after randomization using the IPCG response criteria|The secondary outcome measure Response duration will be measured by the time from CR, CRu or PR until relapse or PD using the IPCG response criteria|The secondary outcome OS is measured as time from randomization until death of any cause|Number of patients with (Serious) adverse events as assessed by CTCAE v4.0|Number of patients with treatment related toxicity as assessed by CTCAE v4.0|Number of patients with neurotoxicity assessed by MMSE, EORTC QLQ-BN20 and the neuro-psychological battery","University Hospital Freiburg|German Federal Ministry of Education and Research|International Extranodal Lymphoma Study Group (IELSG)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DRKS00005503","July 2014","November 2017","December 2019","August 25, 2015","null","August 25, 2015","University Hospital Freiburg - Department for Hematology, Oncology and Stem cell Transplantion, Freiburg, Baden-Wuerttemberg, Germany|Klinikum Stuttgart, Clinic of Hematology, Oncology and Palliative Care, Stuttgart Cancer Center / Tumor Center Eva Mayr-Stihl, Stuttgart, Baden-Wuerttemberg, Germany","","https://ClinicalTrials.gov/show/NCT02531841"
439,"NCT02998476","A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)",,"Active, not recruiting","No Results Available","Lymphoma","Drug: INCB050465","Objective response rate based on Lugano Classification criteria|Median duration of response|Median progression-free survival|Overall survival (OS)|Safety as assessed by percentage of subjects with adverse events","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 50465-202/CITADEL-202","December 2016","December 2018","July 2020","December 20, 2016","null","September 10, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States|Sutter Gould Medical Foundation, Modesto, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Asclepes Research Centers, Weeki Wachee, Florida, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Indiana BMT, Beech Grove, Indiana, United States|Parkview Research Center, Fort Wayne, Indiana, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|St. Agnes Hospital, Baltimore, Maryland, United States|St. John Hospital and Medical Center, Detroit, Michigan, United States|Karmanos Cancer Institute, Farmington Hills, Michigan, United States|CHI Health - St. Francis Medical Center, Grand Island, Nebraska, United States|Summit Medical Group, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Utah Cancer Specialists- Network, Salt Lake City, Utah, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|ZNA Stuivenberg, Antwerpen, Belgium|UZ Leuven, Leuven, Belgium|AZ Delta, Roeselare, Belgium|LHSC - Victoria Hospital, London, Ontario, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Centre Antoine Lacassagne, Nice cedex 02, Alpes Maritimes, France|Centre Francois Baclesse, Caen Cedex 05, Calvados, France|CHU Dijon - Hopital du Bocage, Dijon cedex, Cote dÝOr, France|Centre Hospitalier Libourne, Libourne Cedex, Gironde, France|CHU de Grenoble - Hôpital Albert Michallon, Grenoble, Isere, France|Centre Hospitalier d'Angers, Angers Cedex 01, Maine Et Loire, France|CHU de Nancy - Hôpital de Brabois Adultes, Vandoeuvre les Nancy, Meurthe Et Moselle, France|Hopital Claude Huriez - CHU Lille, Lille cedex, Nord, France|Hôpital Saint-Louis, Paris cedex 10, Paris, France|Centre Hospitalier Lyon Sud, Pierre Bénite, Rhone, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans Cedex 02, Sarthe, France|Hôpital Henri Mondor, Créteil Cedex, Val De Marne, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza, Brzozów, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|ICO l´Hospitalet - Hospital Duran i Reynals, L'Hospitalet de llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain|The Christie, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02998476"
440,"NCT02702141","A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Non-Hodgkin Lymphoma|DLBCL|Diffuse Large B-cell Lymphoma|Grade 3 Follicular Lymphoma","Drug: SGN-CD19B","Incidence of adverse events|Incidence of laboratory abnormalities|Blood concentrations of SGN-CD19B|Incidence of antitherapeutic antibodies|Objective response rate|Rate of response|Progression-free survival","Seattle Genetics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN19B-001","February 2016","July 10, 2018","July 10, 2018","March 8, 2016","null","August 13, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic Minnesota, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New York University (NYU) Cancer Institute, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, The, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States|Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02702141"
441,"NCT02842931","R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: R-DA-EPOCH-21|Drug: R-DA-EPOCH-21 + auto-SCT|Drug: R-mNHL-BFM-90|Drug: R-mNHL-BFM-90 + auto-SCT","complete response|overall survival|disease-free survival|event-free survival","National Research Center for Hematology, Russia|National Research Center for Hematology","All","18 Years to 60 Years   (Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DLBCL-2015","February 2015","February 2020","February 2023","July 25, 2016","null","July 25, 2016","National Research Center for Hematology, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT02842931"
442,"NCT01213095","Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)",,"Completed","No Results Available","Lymphoma","Drug: rituximab","3 year progression free survival|Overall survival|toxicity","Dong-A University Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CISL-MZL-10-4(ML25403)","September 2010","September 2013","September 2015","October 1, 2010","null","April 11, 2016","Sung Yong Oh, Busan, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01213095"
443,"NCT03356054","Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse","HOVON 136 NHL","Not yet recruiting","No Results Available","DLBCL","Combination Product: R-DHAP|Drug: Brentuximab Vedotin","The rate of patients with serious toxicity during cycle 1-2 of the combination brentuximab vedotin-R-DHAP|Metabolic CR rate (PET-diagnostic CT) after the third cycle of brentuximab vedotin-R-DHAP salvage therapy|Rate of CTCAE grade 3/4 non-hematological toxicity, including neurotoxicity after each cycle of brentuximab vedotin-R-DHAP","Stichting Hemato-Oncologie voor Volwassenen Nederland","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HO136|2016-001211-21","December 2017","June 2021","June 2025","November 29, 2017","null","November 29, 2017","ZNA, Antwerp, Belgium|AMC, Amsterdam, Netherlands|VUmc, Amsterdam, Netherlands|Haga hospital, Den Haag, Netherlands|UMCG, Groningen, Netherlands|MUMC, Maastricht, Netherlands|Antonius hospital, Nieuwegein, Netherlands|Radboudumc, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|UMCU, Utrecht, Netherlands|Isala, Zwolle, Netherlands|Hospital Clinic de Barcelona, Barcelona, Spain|Institute Català d'Oncologica - Hospital, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital La Fe, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT03356054"
444,"NCT01536561","Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma, Non-Hodgkin","Biological: Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)","Number of Participants (Par.) During Initial Treatment Exposed to the Indicated Dose Levels of the Therapeutic Dose (TD), Re-dose, and Total Dose (TD + Re-dose)|Number of Participants During Retreatment Exposed to the Indicated Dose Levels of the TD, Re-dose, and Total Dose (TD + Re-dose)|Maximum Tolerated Dose (MTD) of TST/I 131 TST Evaluated in the Study|Tumor/Organ Dosimetry of TST/I 131 TST for All Predoses (Initial Treatment)|Tumor/Organ Dosimetry at the Indicated Predoses of 475 mg, 95 mg, and 0 mg (Initial Treatment)|Number of Participants (Par.) With the Indicated Response as Assessed by the Investigator|Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator|Duration of Response for All Unconfirmed Responders (CR, CCR, or PR) as Assessed by the Investigator|Time to Progression of Disease or Death|Overall Survival|Half-life: Initial Half-life (t1/2 Alpha) and Terminal Half-life (t1/2 Beta) of I 131 TST for the Antibody Predose Levels of 0 mg, 95 mg, and 475 mg|Clearance (CL) of I 131 TST for the Indicated Antibody Predose Levels|Area Under the Concentration Time Curve (AUC) of I 131 TST for the Indicated Antibody Predose Levels|Maximum Blood Concentration (Cmax) of I 131 TST for the Indicated Antibody Predose Levels|Volume of Distribution at Steady State (Vss) of I 131 TST for the Indicated Antibody Predose Levels|Number of Participants Who Developed Human Anti-mouse Antibodies (HAMA Postivitiy) After Receiving Tositumomab|Time to HAMA Positivity From the First Dosimetric Dose (Time From Baseline [Dosimetric Dose] to the First Reported Presence of HAMA)|Number of Participants With the Indicated Type of Infection|Time to Nadir for the Indicated Hematologic Laboratory Parameters|Time to Recovery to Baseline for the Indicated Hematologic Laboratory Parameters|Nadir Values for the Hematologic Parameters ANC, Platelets, and WBC Count|Nadir Values for Hemoglobin, a Hematologic Parameter","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","59","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","104728","April 24, 1990","July 2, 1997","October 16, 2009","February 22, 2012","March 30, 2012","August 31, 2017","","","https://ClinicalTrials.gov/show/NCT01536561"
445,"NCT01109069","Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia",,"Enrolling by invitation","No Results Available","B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Diffuse Well-differentiated Lymphocytic Lymphoma|B Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Waldenstrom Macroglobulinemia|Burkitt Lymphoma|B-Cell Diffuse Lymphoma","Drug: PCI-32765","Adverse Events/ Safety Tolerability|Progression-free survival|Duration of Response|Overall Survival|Tolerability","Pharmacyclics LLC.|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-1103-CA|PCI-32765","June 2010","December 2018","December 2018","April 22, 2010","null","April 4, 2018","Stanford University, Stanford, California, United States|Stanford, California, United States|University of Chicago, Chicago, Illinois, United States|Boston, Massachusetts, United States|New Hyde Park, New York, United States|New York, New York, United States|Rochester, New York, United States|Columbus, Ohio, United States|Springfield, Oregon, United States|Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Houston, Texas, United States|Tyler, Texas, United States|Fletcher Allen Health Care and University of Vermont, Burlington, Vermont, United States|Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States","","https://ClinicalTrials.gov/show/NCT01109069"
446,"NCT03003520","A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Durvalumab|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Lenalidomide","Complete Response Rate|Treatment-Emergent Adverse Events (AEs)|Clinical response to study treatment in biomarker-defined subpopulations|Rate of subjects who continue into consolidation therapy","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEDI4736-DLBCL-001|2015-005173-20","February 28, 2017","August 2, 2018","March 13, 2023","December 28, 2016","null","September 11, 2018","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Mayo Clinic, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Mid Ohio Oncology Hematology Inc, Columbus, Ohio, United States|Swedish Cancer Institute, Seattle, Washington, United States|Innsbruck Medical University Department of Internal Medicine, Innsbruck, Austria|Landeskrankenhaus Salzburg, Salzburg, Austria|Medical University of Vienna Internalmedicine 1, Hematology, Vienna, Austria|Hanusch Krankenhaus, Wien, Austria|Aarhus Sygehus, Arhus C, Denmark|Rigshospitalet, Kobenhavns Universitet - Centre for Clinical Intervention Research - The Copenhagen, Copenhagen, Denmark|Odense Universitetshospital, Odense C, Denmark|(North Estonia Medical Centre) - Onkoloogia-ja Hematoloogiakliinik, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|University Hospital Birmingham, Birmingham, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford, United Kingdom","","https://ClinicalTrials.gov/show/NCT03003520"
447,"NCT00286832","Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV",,"Completed","No Results Available","Diffuse Large-Cell Lymphoma","Procedure: PET scan","","Copenhagen University Hospital at Herlev|Nordic Lymphoma Group","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NLG PET Study","August 2005","January 2011","January 2011","February 6, 2006","null","July 6, 2011","Department of Hematology, Odense University Hospital, Odense, Denmark","","https://ClinicalTrials.gov/show/NCT00286832"
448,"NCT01511562","Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: thiotepa|Procedure: stem cell transplant|Drug: G-CSF","progression free survival|event free survival|number of participants with treatment-related adverse events as assessed by CTCAE v4.0|overall survival","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","113","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CALGB-51101|CDR0000721927|NCI-2012-00110","September 2012","October 2026","null","January 18, 2012","null","May 4, 2017","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Reid Health, Richmond, Indiana, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Community Hospital, Niles, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Lakeland Hospital, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Weill Medical College of Cornell University, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|Oncology Hematology Care Inc - Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physicians LLC-Samaritan North, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton NCI Community Oncology Research Program, Dayton, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Dayton Physicians LLC-Signal Point, Middletown, Ohio, United States|Dayton Physicians LLC-Wilson, Sidney, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Surgical Associates Inc, Tulsa, Oklahoma, United States|Warren Clinic Oncology-Tulsa, Tulsa, Oklahoma, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin Corners, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|Swedish Cancer Institute-Eastside Oncology Hematology, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Group Health Cooperative-Seattle, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Compass Oncology Vancouver, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01511562"
449,"NCT03478514","Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma",,"Not yet recruiting","No Results Available","Mantle Cell Lymphoma|B Cell Lymphoma","Drug: Palbociclib|Drug: Ibrutinib","Progression free survival|Overall survival|Duration of response|Overall Response Rate|Complete Response|Toxicity: Incidence and severity of adverse events by summaries of toxicity data/contingency tables","Alliance Foundation Trials, LLC.|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFT-32","September 2018","June 2022","December 2022","March 27, 2018","null","September 5, 2018","","","https://ClinicalTrials.gov/show/NCT03478514"
450,"NCT00689845","Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma",,"Unknown status","No Results Available","Lymphoma","Biological: bleomycin sulfate|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: methotrexate|Drug: prednisolone|Drug: prednisone|Drug: vincristine sulfate|Drug: vindesine","Complete response rate on PET scanning at the completion of chemoimmunotherapy|Progression-free survival|Death|Survival time","University Hospital Southampton NHS Foundation Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000588011|USCTU-IELSG-26-RHM-CAN0546|EU-20818|EudraCT 2006-005794-22|USCTU-07/Q1704/68","June 2007","null","null","June 4, 2008","null","July 8, 2009","Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|St. George's Hospital, London, England, United Kingdom|Christie Hospital, Manchester, England, United Kingdom|Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom|Cancer Research Centre at Weston Park Hospital, Sheffield, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Royal Marsden - Surrey, Sutton, England, United Kingdom|Saint Bartholomew's Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00689845"
451,"NCT03010982","Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Advanced Solid Tumors","Drug: Tazemetostat and [14C] Tazemetostat","Plasma PK of [14C] tazemetostat, tazemetostat, and its metabolite EPZ-6930 after IV administration of approximately 12 µg of [14C] tazemetostat containing approximately 500 nCi of radioactivity and oral BID administration of 800 mg tazemetostat (AUC 0-7,|Total recovery and relative excretion of radioactivity in urine and feces after an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity oral 800 mg dose of [14C] tazemetostat|Estimate tazemetostat absolute bioavailability (F) after repeated oral administration of 800 mg BID (AUC 0-12 and AUC 0-~)|Compare the total radioactivity concentration-time profiles in blood and plasma after oral administration of [14C] tazemetostat (AUC 0-t, AUC 0-12, AUC 0-~)|Determine peak plasma concentration (Cmax) after oral administration of [14C] tazemetostat|Determine the plasma terminal half-life (t1/2) after oral administration of [14C] tazemetostat|Plasma PK of tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity (Plasma AUC 0-t, AUC 0-12)|Determine the peak plasma concentration (Cmax) of tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity|Determine the time to peak plasma concentration (Tmax) tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity","Epizyme, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EZH-103","January 2017","December 2018","December 2018","January 5, 2017","null","April 17, 2018","The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, United Kingdom","","https://ClinicalTrials.gov/show/NCT03010982"
452,"NCT01448096","Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Large B Cell Diffuse Lymphoma","Drug: Rituximab|Procedure: Prophylactic intrathecal chemotherapy","progression-free survival|overall survival|Number of patients with CNS recurrence|Number of patients with adverse events","Chonbuk National University Hospital|Consortium for Improving Survival of Lymphoma","Female","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Chonbuk058","August 2011","August 2019","August 2019","October 7, 2011","null","August 29, 2017","Chonbuk National University Hospital, Jeonju, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01448096"
453,"NCT02636322","Smart Start: Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Drug: Rituximab|Drug: Ibrutinib|Drug: Lenalidomide|Drug: Etoposide|Drug: Prednisone|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Doxorubicin","Overall Response Rate (ORR) of Rituximab, Lenalidomide, and Ibrutinib in Participants With High Risk Diffuse Large B-Cell Lymphoma|Complete Response Rate (CRR) of Rituximab, Lenalidomide, and Ibrutinib combined with CHOP or EPOCH in Participants With High Risk Diffuse Large B-Cell Lymphoma","M.D. Anderson Cancer Center|Celgene|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0147|NCI-2016-00017","March 2016","March 2023","March 2024","December 21, 2015","null","July 2, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02636322"
454,"NCT00634179","A Phase I/II Trial of VR-CHOP in Lymphoma Patients",,"Completed","Has Results","Lymphoma, B-Cell|Follicular Lymphoma","Drug: Bortezomib|Biological: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)|An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria","Emory University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00002996|X05215","February 2008","November 2015","November 2015","March 12, 2008","March 15, 2016","October 27, 2016","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00634179"
455,"NCT02825836","BTK Inhibitor in B Cell Malignancies",,"Active, not recruiting","No Results Available","Relapsed/Refractory B Cell Malignancies|Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma","Drug: M7583","Part 1 (does escalation): Number of subjects with at least one dose limiting toxicity (DLT) during Cycle 1|Part 2 (dose expansion): Best overall response (BOR)|Part 1: Best overall response|Duration of response|Progression- free survival time|Number of subjects With Adverse Events (AEs), Serious AEs, AEs Leading to Death and AEs Leading to Discontinuation|Number of subjects with abnormalities in laboratory measurements, electrocardiogram (ECG)s, vital signs, and ECOG performance status|Bruton's tyrosine kinase (BTK)occupancy in Peripheral blood mononuclear cell (PBMCs )|Area under the plasma concentration-time curve from time zero to 8 hours after administration (AUC0 8h)|Maximum observed plasma concentration (Cmax)|Time to reach maximum plasma concentration (tmax),|Dose normalized Area under the Curve from time 0 to 8 hours(AUC0-8h)|Dose normalized Cmax (Cmax/dose)|Accumulation ratio for Area under the curve AUC0-8h [Racc(AUC0-8h)]|Accumulation ratio for maximum plasma concentration Cmax [Racc(Cmax)]","EMD Serono Research & Development Institute, Inc.|Merck KGaA|EMD Serono","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS200662_0001|2016-000286-23","August 26, 2016","August 31, 2018","August 31, 2020","July 7, 2016","null","July 20, 2018","Azienda Ospedaliera Universitaria, Bologna, Italy|Malopolskie Centrum Medyczne, Krakow, Poland|Research site 1, London, United Kingdom|Research site 2, London, United Kingdom|Research site, Plymouth, United Kingdom","","https://ClinicalTrials.gov/show/NCT02825836"
456,"NCT01560117","Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma",,"Completed","No Results Available","Follicular T-NHL Lymphoma|Rituximab Maintenance","Drug: Rituximab","conversion rate of bcl-2 in blood and bone marrow defined by PCR|Number of patients with a response after 8 weeks","Arbeitsgemeinschaft medikamentoese Tumortherapie","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","AGMT_NHL 9","January 2004","July 2009","July 2010","March 22, 2012","null","January 9, 2018","","","https://ClinicalTrials.gov/show/NCT01560117"
457,"NCT00983944","Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma",,"Withdrawn","No Results Available","Lymphoma","Biological: bleomycin sulfate|Biological: rituximab|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate","Complete response rate|Two-year progression-free survival|Overall survival|Toxicity as assessed by NCI CTCAE v3.0|Immunohistochemical staining results|Correlation of soluble CD30 levels with disease activity in PMLCL","Ohio State University Comprehensive Cancer Center","All","10 Years and older   (Child, Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-08178|NCI-2011-03123","September 2009","April 25, 2011","April 25, 2011","September 24, 2009","null","November 30, 2017","","","https://ClinicalTrials.gov/show/NCT00983944"
458,"NCT00446095","Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma",,"Completed","Has Results","Lymphoma","Drug: fostamatinib","Overall Response Rate as Assessed According to the""Revised Response Criteria for Malignant Lymphoma"" (Cheson 2007).|Clinical Benefit Rate as Assessed According to the ""Revised Response Criteria for Malignant Lymphoma"" (Cheson 2007).|Progression Free Survival (PFS)|Overall Survival (OS)","Rigel Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","81","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4300C00023|C-935788-009","April 2007","April 2010","October 2010","March 12, 2007","December 18, 2014","September 19, 2016","Research Site, Los Angeles, California, United States|Research Site, Stanford, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, Omaha, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00446095"
459,"NCT02589145","Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype",,"Active, not recruiting","No Results Available","Lymphoma","Drug: Lenalidomide|Drug: Vorinostat|Drug: Gemcitabine|Drug: Busulfan|Drug: Melphalan|Drug: Rituximab|Drug: Dexamethasone|Drug: Caphosol|Drug: Glutamine|Drug: Pyridoxine|Drug: Enoxaparin|Procedure: Stem Cell Transplant|Drug: Palifermin","Maximum Tolerated Dose (MTD) of Lenalidomide with Vorinostat, Gemcitabine, Busulfan, Melphalan and Autologous Stem-Cell Transplant z(ASCT)|Event Free Survival of Lenalidomide with Vorinostat, Gemcitabine, Busulfan, Melphalan and Autologous Stem-Cell Transplant (ASCT)","M.D. Anderson Cancer Center|Celgene Corporation","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0558|NCI-2015-01938","June 22, 2016","June 2021","June 2021","October 28, 2015","null","May 23, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02589145"
460,"NCT02532192","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Withdrawn","No Results Available","Lymphoma","Drug: Belinostat|Drug: Rituximab|Drug: Cisplatin|Drug: Cytarabine|Drug: Dexamethasone|Drug: Ciprofloxacin|Drug: Fluconazole","Maximum Tolerated Dose (MTD) of Belinostat with RDHAP Chemotherapy in Participants with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|Overall response Rate (ORR)","M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-1068|NCI-2015-01521","December 2015","December 2019","null","August 25, 2015","null","January 6, 2016","","","https://ClinicalTrials.gov/show/NCT02532192"
461,"NCT01277172","TREatment of degeNerative and Neoplastic Diseases With Rituximab","TREND","Unknown status","No Results Available","Diffuse Large B Cell Lymphoma","Biological: Rituximab","Basal and final serum CD 20 levels comparison.|Comparison of safety of PBO-326 versus Mabthera","Probiomed S.A. de C.V.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO-1908|PRO1908TREND","October 2010","September 2011","October 2011","January 14, 2011","null","January 14, 2011","INCan, Mexico, D.f., Mexico","","https://ClinicalTrials.gov/show/NCT01277172"
462,"NCT02803840","Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma",,"Unknown status","No Results Available","Lymphoma","Radiation: Low-dose radiotherapy","Response rate|Quality of life according to the EORTC QLQ-C30 questionnaire","Centro di Riferimento Oncologico - Aviano","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRO-2011-14","July 2011","June 2016","June 2016","June 17, 2016","null","June 17, 2016","Centro di Riferimento Oncologico, Aviano, Pordenone, Italy","","https://ClinicalTrials.gov/show/NCT02803840"
463,"NCT02405078","Pilot Project for Creation of the Diffuse Large B-cell Lymphoma (DLBCL) Response Prediction Model",,"Recruiting","No Results Available","Lymphoma","Drug: 18F-fluorodeoxyglucose|Procedure: FDG PET/CT Imaging|Procedure: Blood Draws","Response to Standard Immunochemotherapy","M.D. Anderson Cancer Center|Sequenta","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2015-0022|NCI-2015-01946","October 2015","October 2019","October 2019","April 1, 2015","null","August 23, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02405078"
464,"NCT02366663","BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL","SPINOZA","Terminated","Has Results","Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Radiation: 90-Yttrium Ibritumomab tiuxetan|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Procedure: Autologous Hematopoietic Stem Cell Transplant|Biological: Rituximab","Overall Survival|Progression-free Survival|Time to Progression|Number of Patients With Complete or Partial Response at Day 30|Time to Neutrophil Engraftment|Incidence of Infection|Incidence of Non-relapse Mortality (NRM) Defined as Death Occurring in a Patient From Causes Other Than Relapse or Progression|Cumulative Incidence of Secondary Malignancies|Time to Platelet Engraftment|Number of Patients With Grade 3-5 Toxicities Graded by the NCI CTCAE Version 4.0|Cumulative Incidence of New, Abnormal Cytogenetics","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","3","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12338|NCI-2015-00185","January 2015","October 2016","October 2016","February 19, 2015","February 13, 2018","March 12, 2018","City of Hope Medical Center, Duarte, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02366663"
465,"NCT02141451","ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL",,"Recruiting","No Results Available","Diffuse Large B Cell Non-Hodgkin Lymphoma","Drug: Rituximab|Drug: INCB7839","Maximum Tolerated Dose of INCB7839|Rate of progression free survival|Incidence of Serious Adverse Events|Rate of disease free survival|Rate of overall survival|Mean time to progression","Masonic Cancer Center, University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013LS081|HM2013-24","May 2014","December 2018","May 2019","May 19, 2014","null","September 26, 2018","University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02141451"
466,"NCT02928861","18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Device: 18F-FDG PET/CT","2 year progression-free survival","Beijing Cancer Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","XW-DLBCL-002","October 2016","December 2017","December 2018","October 10, 2016","null","October 10, 2016","Peking University Cancer Hospital, Beijing, Beijing, China|Peking University Cancer Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT02928861"
467,"NCT03299738","A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL",,"Not yet recruiting","No Results Available","Refractory or Relapsed B-cell Non-Hodgkin Lymphoma","Biological: C-CAR011","Safety: Vital signs, physical examination, clinical laboratory tests, incidence of adverse events (AEs) and serious adverse events (SAEs)|Overall response rate (ORR)|Duration of remission (DOR)|Progression free survival (PFS)|Overall survival (OS)","Cellular Biomedicine Group Ltd.|Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBMG-C2017006","December 2017","December 2018","August 2019","October 3, 2017","null","December 19, 2017","Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03299738"
468,"NCT01459887","Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma",,"Completed","No Results Available","Diffuse Large B Cell Lymphoma","Drug: CHOP combined with CMAB304|Drug: CHOP, CMAB304","overall response rate|event-free survival","Shanghai CP Guojian Pharmaceutical Co.,Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","304NHL-050617","September 2006","December 2010","February 2011","October 26, 2011","null","October 26, 2011","SUN-YAT-SEN university cancer center, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT01459887"
469,"NCT00411086","Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma",,"Completed","Has Results","Lymphoma","Biological: Rituximab|Biological: Sargramostim (GM-CSF)","Complete Response Rate|Median Progression-Free Survival (PFS)|Overall Response (OR) Rate","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDA-2006-0260|P30CA016672|CDR0000521620|NCI-2009-00187","November 2006","November 2016","November 2016","December 13, 2006","December 5, 2017","December 5, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00411086"
470,"NCT00169195","Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma",,"Completed","No Results Available","Diffuse Large Cell Lymphoma","Drug: Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)","Overall response rate (ORR) (complete response, [CR]; unconfirmed complete response, [CRu] and partial response, [PR])|Event free survival (EFS)","Lymphoma Study Association|Hoffmann-La Roche|Sanofi-Synthelabo|Eli Lilly and Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","49","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R-GEMOX","April 2003","November 2012","November 2012","September 15, 2005","null","September 2, 2015","Hôpital Henri Mondor, Créteil, France|Service d'Hématologie Clinique - CHU Le Bocage, Dijon, France|Service des Maladies du Sang - CHRU de Lille, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital Saint Louis, Paris, France|Service D'Hématologie Adulte - Hôpital Necker, Paris, France|Centre Henri Becquerel, Rouen, France|CHRU de Nancy Brabois, Vandoeuvre les Nancy, France","","https://ClinicalTrials.gov/show/NCT00169195"
471,"NCT03540303","Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma",,"Recruiting","No Results Available","Relapsed Non Hodgkin Lymphoma","Drug: CAR19 T cells carrying cytoplasmic activated PD-1","safety: occurrence of study related adverse events|objective response rate","Henan Cancer Hospital|The Pregene (ShenZhen) Biotechnology Company, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","15","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HenanCH CAR 2-1","April 12, 2018","April 30, 2020","April 30, 2020","May 30, 2018","null","May 30, 2018","Henan Cancer Hospital, Zhengzhou, Henan, China","","https://ClinicalTrials.gov/show/NCT03540303"
472,"NCT00794638","A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma","Drug: SyB L-0501|Drug: Rituximab","Dose-limiting toxicity|CR rate and the overall response rate, determination by Independent Review Committee","SymBio Pharmaceuticals","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008002","November 2008","March 2010","May 2010","November 20, 2008","null","May 28, 2010","Nagoya-city, Aichi, Japan|Isehara-city, Kanagawa, Japan|Kyoto-city, Kyoto, Japan|Chuo-ku, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT00794638"
473,"NCT01354392","AZD1152 in Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: AZD1152","Overall response rate (ORR; Cheson 2007 criteria)|Progression free survival at 1 year|Percentage change in tumour size|Safety of AZD1152","Oxford University Hospitals NHS Trust|The Christie NHS Foundation Trust|University of Manchester|Early Phase Cancer Research Hub, Oxford","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ORH/PID/6265","September 2011","September 2013","September 2013","May 16, 2011","null","July 2, 2014","Christie NHS Foundation Trust (Christie Hospital), Machester, Lancashire, United Kingdom|Oxford Radcliffe NHS Trust (Cancer & Haematology Centre, Churchill Hospital), Oxford, Oxfordshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT01354392"
474,"NCT01357733","Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients",,"Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Other: Early interim FDG PET/CT after 1 cycle of R-CHOP","Change from baseline in summed peak standardized uptake value lean (SULpeak) after 3 cycles|Change from baseline in summed SULpeak after 1 cycle|2 year disease free survival|Qualitative response|Quantitative response","The Catholic University of Korea","All","19 Years and older   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","KC11EISI0293","March 2, 2012","December 31, 2018","December 31, 2020","May 23, 2011","null","April 3, 2018","The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01357733"
475,"NCT01434472","High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma",,"Recruiting","No Results Available","Post-Transplant Lymphoproliferative Disorder|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Radiation: Indium In-111 Ibritumomab Tiuxetan|Drug: Mycophenolate Mofetil|Other: Pharmacological Study|Biological: Rituximab|Radiation: Total-Body Irradiation|Radiation: Yttrium Y-90 Ibritumomab Tiuxetan","Progression-free survival|Engraftment and hematopoietic toxicity|Overall survival|Response rates|Treatment-related mortality","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2398.00|NCI-2011-01189|P01CA044991|P30CA015704","November 16, 2011","June 1, 2018","null","September 15, 2011","null","December 6, 2017","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01434472"
476,"NCT03349450","DPX-Survivac and Checkpoint Inhibitor in DLBCL","SPiReL","Recruiting","No Results Available","Adult Diffuse Large Cell Lymphoma|Recurrent|Adult Refractory Diffuse Large B-Cell Lymphoma","Biological: DPX-Survivac|Biological: Pembrolizumab|Drug: Cyclophosphamide 50mg","To document the objective response rate using modified Cheson criteria to treatment with DPX-Survivac and low dose cyclophosphamide administered together with Pembrolizumab in patients with recurrent, survivin-expressing B cell lymphomas|To document changes in tumour volume using waterfall analyses|To document the toxicity profile|To document duration of response using modified Cheson criteria.|To document duration of response using immune related response criteria","Sunnybrook Health Sciences Centre|ImmunoVaccine Technologies, Inc. (IMV Inc.)|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0891","March 13, 2018","May 2020","May 2021","November 21, 2017","null","August 22, 2018","Tom Baker Cancer Centre - Alberta Health Services, Calgary, Alberta, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03349450"
477,"NCT03571308","A Phase Ib/II Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)","ACCEPT","Recruiting","No Results Available","Non Hodgkin Lymphoma","Drug: acalabrutinib","Phase I: Dose limiting toxicity of acalabrutinib combined to R-CHOP|Phase II: Overall response rate of the combination acalabrutinib and R-CHOP|Safety of the combination acalabrutinib and R-CHOP as determined by treatment-related adverse events as assessed by CTCAE v4.03.|Pharmacokinetics of acalabrutinib using area under the plasma concentration versus time curve (AUC)|Maximum Plasma Concentration (Cmax) of acalabrutinib|Time after administration when maximum concentration of acalabrutinib in the plasma is reached (Tmax)|Time required for concentration of acalabrutinib to reach half original value (T1/2)|Overall response rate of the combination acalabrutinib and R-CHOP according to cell of origin.|Two years progression-free survival|Two years overall survival","University Hospital Southampton NHS Foundation Trust","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RHM CAN 1129","June 2, 2017","December 31, 2018","December 31, 2021","June 27, 2018","null","June 27, 2018","Southampton University Hospitals NHS Tust, Southampton, Hampshire, United Kingdom|St James's University Hospital, Leeds, United Kingdom|University College London Hospitals, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham City Hospital Campus, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom","","https://ClinicalTrials.gov/show/NCT03571308"
478,"NCT00987493","Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: bendamustine hydrochloride|Drug: lenalidomide","Dose-limiting toxicity (phase I)|Maximum-tolerated dose (phase I)|Objective response (complete and partial response) (phase II)|Adverse events according to NCI CTCAE v. 3.0|Event-free survival (phase II)|Response duration (phase II)|Time to progression (phase II)|Overall survival (phase II)|Quality of life|Usefulness and feasibility of the SAKK C-SGA|Association between WHO performance status, QOL indicators, and SAKK C-SGA scores|Progression Free Survival (PFS)","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAKK 38/08|SWS-SAKK-38/08|2009-012559-67|EU-20976|CDR0000652127","September 2009","April 2014","April 2016","October 1, 2009","null","August 12, 2016","Kantonsspital Baden, Baden, Switzerland|Universitaetsspital Basel, Basel, Switzerland|St. Claraspital AG, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Bruderholz, Bruderholz, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Hopital Fribourgeois, Fribourg, Switzerland|Hôpitaux Universitaires de Genève HUG, Geneva 14, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital Liestal, Liestal, Switzerland|Kantonsspital Olten, Olten, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Stadtspital Triemli, Zürich, Switzerland|Universitäts Spital Zürich, Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT00987493"
479,"NCT02086604","Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Brentuximab vedotin|Drug: Lenalidomide","Safety as measured by grade and frequency of adverse events|Maximum Tolerated Dose (MTD) as measured by the number of dose-limiting toxicities in each dose level (cohort)|Objective response rate as measured by CD30 expression|Overall response rate|Duration of response|Progression-free survival (PFS)","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201404056","September 18, 2014","June 9, 2017","November 30, 2019","March 13, 2014","null","June 1, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States|Ohio State University, James Cancer Hospital, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02086604"
480,"NCT03283137","Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL",,"Recruiting","No Results Available","CLL|B-cell Non Hodgkin Lymphoma","Drug: TGR-1202|Drug: Pembrolizumab","Number of patients with adverse events|proportion of patients with complete remission (CR)|duration of response (DOR)|progression free survival (PFS) rate|MRD negativity rate|nodal response rate|overall survival (OS) rate","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB17-0901","January 23, 2018","December 2020","December 2020","September 14, 2017","null","April 17, 2018","University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03283137"
481,"NCT01855750","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Drug: Ibrutinib|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone (or equivalent)","Event-free survival|Progression-free survival|Complete response rate|Overall survival|Time to worsening symptoms in the Lym subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)|Oral plasma clearance of ibrutinib|Oral volume of distribution at steady state of ibrutinib|Area under the plasma concentration-time curve of ibrutinib|Minimum observed plasma concentration of ibrutinib|Number of participants affected by an adverse event","Janssen Research & Development, LLC|Pharmacyclics LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 3","844","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CR102118|PCI-32765DBL3001|U1111-1139-6222|2013-000959-40","September 3, 2013","February 26, 2018","June 16, 2020","May 16, 2013","null","September 24, 2018","Tucson, Arizona, United States|Greenbrae, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Salinas, California, United States|Stanford, California, United States|Danbury, Connecticut, United States|Hartford, Connecticut, United States|Washington, District of Columbia, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Peoria, Illinois, United States|Fort Wayne, Indiana, United States|Goshen, Indiana, United States|Indianapolis, Indiana, United States|Topeka, Kansas, United States|Louisville, Kentucky, United States|Baton Rouge, Louisiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Hackensack, New Jersey, United States|New Brunswick, New Jersey, United States|Bronx, New York, United States|Fresh Meadows, New York, United States|Johnson City, New York, United States|Mineola, New York, United States|New York, New York, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|Hickory, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|North Charleston, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Temple, Texas, United States|Burlington, Vermont, United States|Seattle, Washington, United States|Buenos Aires, Argentina|Ciudad Autonoma De Buenos Aires, Argentina|Ciudad De Buenos Aires, Argentina|Adelaide, Australia|Concord, Australia|Darlinghurst, Australia|Hobart, Australia|Melbourne, Australia|Nedlands, Australia|Perth, Australia|Randwick, Australia|South Brisbane, Australia|Woolloongabba, Australia|Antwerpen, Belgium|Brugge, Belgium|Brussel, Belgium|Gent, Belgium|Haine-Saint-Paul, La Louviere, Belgium|Kortrijk, Belgium|Leuven, Belgium|Porto Alegre, Brazil|Rio De Janeiro, Brazil|Sao Paulo, Brazil|São Paulo, Brazil|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|Toronto, Ontario, Canada|Levis, Quebec, Canada|Montreal, Quebec, Canada|Beijing, China|Changchun, China|Chengdu, China|Guangzhou, China|Hangzhou, China|Harbin, China|Jinan, China|Nanjing, China|Shanghai, China|Tianjin, China|Brno, Czechia|Hradec Kralove, Czechia|Ostrava, Czechia|Praha 10, Czechia|Praha 2, Czechia|Aarhus C, Denmark|Copenhagen, Denmark|Roskilde, Denmark|Vejle, Denmark|Helsinki, Finland|Jyväskylä, Finland|Oulu, Finland|Turku, Finland|Grenoble Cedex 9, France|Limoges, France|Paris, France|Pessac, France|Pierre Benite, France|Rouen, France|Tours, France|Villejuif, France|Augsburg, Germany|Bamberg, Germany|Berlin, Germany|Dresden, Germany|Essen, Germany|Frankfurt, Germany|Jena, Germany|Muenchen, Germany|Münster, Germany|Villingen-Schwenningen, Germany|Budapest N/A, Hungary|Debrecen, Hungary|Gyula, Hungary|Szombathely, Hungary|Veszprém, Hungary|Beer-Sheva, Israel|Hadera, Israel|Haifa, Israel|Petah Tikva, Israel|Ramat-Gan, Israel|Tel Aviv, Israel|Fukuoka, Japan|Hiroshima, Japan|Isehara, Japan|Kobe, Japan|Kumamoto, Japan|Kyoto, Japan|Nagano, Japan|Nagoya, Japan|Narita, Japan|Osaka-Sayama, Japan|Osaka, Japan|Sapporo, Japan|Sendai, Japan|Suita, Japan|Tachikawa, Japan|Tokyo, Japan|Tsukuba, Japan|Busan, Korea, Republic of|Goyang-Si, Korea, Republic of|Seoul, Korea, Republic of|Mexico, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|Amsterdam Zuidoost, Netherlands|Arnhem, Netherlands|Dordrecht, Netherlands|Groningen, Netherlands|Leiden, Netherlands|Nieuwegein, Netherlands|Rotterdam, Netherlands|Oslo, Norway|Tromso, Norway|Brzozow, Poland|Chorzów, Poland|Krakow, Poland|Lodz, Poland|Olsztyn, Poland|Poznan, Poland|Warszawa, Poland|Wroclaw, Poland|Ekaterinburg, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Rostov-Na-Donu, Russian Federation|Saint-Petersburg, Russian Federation|Sochi, Russian Federation|St. Petersburg, Russian Federation|Volgograd, Russian Federation|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Sevilla, Spain|Linköping, Sweden|Luleå, Sweden|Lund, Sweden|Uppsala, Sweden|Taichung, Taiwan|Tainan, Taiwan|Taoyuan County, Taiwan|Adana, Turkey|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Samsun, Turkey|Cherkassy, Ukraine|Khmelnitskiy, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Makiivka, Ukraine|Glasgow, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom|Oxford, United Kingdom|Romford, United Kingdom|Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01855750"
482,"NCT02931201","Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Device: 18F-FDG PET/CT","Change from baseline in summed standardized uptake value (SUVmax) of lesion after 2 or 4 cycles|2 year progression-free survival","Beijing Cancer Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","XW-DLBCL-001","October 2016","December 2017","December 2018","October 12, 2016","null","October 12, 2016","Peking University Cancer Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02931201"
483,"NCT00290667","Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: pharmacological study|Radiation: radiation therapy","Pharmacokinetics (in first 20 patients of each cohort with a distinct variation of the rituximab schedule) assessed on days -4, -1, 10, 29, 57, 99, 155, 239, 267, 295, 407, and 491 of treatment|Safety and treatment related deaths at 3 months after study completion|Toxicity assessed by NCI criteria, adverse events, serious adverse events, protocol adherence, and treatment-related deaths at 3 months after study completion|Time to treatment failure assessed at 2 years within the study and periodically thereafter|Complete response rate assessed at 2 years within the study and periodically thereafter|Progression rate|Survival time|Progression-free survival","German High-Grade Non-Hodgkin's Lymphoma Study Group","All","61 Years to 80 Years   (Adult, Older Adult)","Phase 2","586","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000454505|DSHNHL-2004-1|EU-20536|DSHNHL-CHOP-R-ESC|EUDRACT-2005-00529-68","February 2004","December 2013","November 2015","February 13, 2006","null","November 26, 2015","University Hospital Brno, Brno, Czech Republic|Charles University Hospital, Prague 5, Czech Republic|Hopital Debrousse, Lyon, France|Haematologisch Onkologische Praxis, Aachen, Germany|Ostalb-Klinikum Aalen, Aalen, Germany|Klinikum St. Marien, Amberg, Germany|Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany|Specialist Practice for Oncology, Aschaffenburg, Germany|II. Medizinische Klinik, Aschaffenburg, Germany|Haematologische Praxis, Augsburg, Germany|Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg, Augsburg, Germany|Klinikum Augsburg, Augsburg, Germany|Kreiskrankenhaus Aurich, Aurich, Germany|Regional Hospital Am Plattenwald, Bad Friedrichshall, Germany|Regional Hospital Bad Hersfeld, Bad Hersfeld, Germany|HELIOS Klinikum Bad Saarow, Bad Saarow, Germany|Kreiskrankenhaus Bad Saeckingen, Bad Saeckingen, Germany|Internistische Praxis - Bad Salzuflen, Bad Salzuflen, Germany|Onkologische Schwerpunktpraxis und Tagesklinik Dres, Bad Soden, Germany|Ermstalklinik Bad Urach, Bad Urach, Germany|Klinikum am Bamberg, Bamberg, Germany|Krankenhaus Hohe Warte Mediziniche Klinik, Bayreuth, Germany|Klinikum Bayreuth, Bayreuth, Germany|Praxis Dr. med. Stefan Korsten, Bergisch Gladbach, Germany|Onkologisches Versorgungszentrum Friedrichshain, Berlin, Germany|DRK Kliniken Berlin - Koepenick, Berlin, Germany|Internistische Gemeinschaftspraxis - Berlin, Berlin, Germany|Haematologisch-Onkologische Schwerpunktpraxis, Berlin, Germany|Evang. Waldkrankenhaus Spandau, Berlin, Germany|Internistische Gemeinschaftspraxis - Berlin, Berlin, Germany|Charite - Campus Charite Mitte, Berlin, Germany|Onkolog - Haematolog Schwerpunktpraxis, Berlin, Germany|Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Vivantes Klinikum Neukoelln, Berlin, Germany|Robert Roessle Comprehensive Cancer Center - Charite Campus Buch, Berlin, Germany|Hospital Complex Bernburg, Bernburg, Germany|Franziskus Hospital, Bielefeld, Germany|Krankenhaus Bietigheim, Bietigheim, Germany|Saint Agnes Hospital, Bocholt, Germany|Augusta-Kranken-Anstalt gGmbH, Bochum, Germany|St. Josef-Hospital - Bochum, Bochum, Germany|Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany|Johanniter-Krankenhaus Bonn, Bonn, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Medizinische Poliklinik, Bonn, Germany|Praxis fuer Haematologie und Internistische Onkologie - Borken, Borken, Germany|Knappschaftskrankenhaus Bottrop, Bottrop, Germany|Hamatologische Sprechstunde, Brandenburg, Germany|Staedtisches Klinikum Braunschweig, Braunschweig, Germany|Praxis Dres. F.& G. Doering, Bremen, Germany|Klinikum Bremen-Mitte, Bremen, Germany|DIAKO Ev. Diakonie Krankenhaus gGmbH, Bremen, Germany|St. Joseph Hospital, Bremerhaven, Germany|Zentralkrankenhaus, Bremerhaven, Germany|Medizinische Klinik Am Lukas - Krankenhaus, Buende, Germany|Praxis fuer Haematologie und Onkologie - Burgwedel, Burgwedel, Germany|General Hospital, Celle, Germany|Onkologische Schwerpunktpraxis Celle, Celle, Germany|Hospital Kuchwald Chemnitz, Chemnitz, Germany|Klinikum Coburg, Coburg, Germany|Internistische Praxis - Coesfeld, Coesfeld, Germany|Lung Clinic Cologne-Merheim, Cologne-Merheim, Germany|Praxis Internistischer Onkologie und Haematologie - Koeln, Cologne, Germany|Kliniken der Stadt Koeln gGmbH - Krankenhaus Holweide, Cologne, Germany|Praxis fuer Onkologie - Kalk, Cologne, Germany|Praxis Fuer Haematologie Internistische Onkologie, Cologne, Germany|Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany|Carl - Thiem - Klinkum Cottbus, Cottbus, Germany|Praxis Dr. Rheinhold Siegmund - Dr. Matthias Penke, Damme, Germany|Klinikum Darmstadt, Darmstadt, Germany|Staedtisches Klinikum Dessau, Dessau, Germany|Internistische Praxis, Detmold, Germany|Saint Johannes Hospital Dortmund, Dortmund, Germany|Klinikum Dortmund, Dortmund, Germany|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Duesseldorf, Duesseldorf, Germany|Johanniter-Krankenhaus Rheinhausen GmbH, Duisburg, Germany|St. Johannes Hospital - Medical Klinik II, Duisburg, Germany|Franz Hospital Dulmen, Dulmen, Germany|Florence-Nightingale-Krankenhause, Deaconess Kaiserswerth, Dusseldorf, Germany|Klinikum Barnim GmbH, Werner Forssmann Krankenhaus, Eberswalde, Germany|Virngrund-Klinik Ellwangen, Ellwangen, Germany|Hans - Susemihl - Krankenhaus, Emden, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Medizinische Klinik III - Universitaetsklinikum Erlangen, Erlangen, Germany|St. Antonius Hospital, Eschweiler, Germany|Universitaetsklinikum Essen, Essen, Germany|Evangelisches Krankenhaus Essen Werden, Essen, Germany|Staedtische Kliniken Esslingen, Esslingen, Germany|Schwerpunktpraxis fuer Haematologie und Onkologie - Flensburg, Flensburg, Germany|Gemeinschaftspraxis fuer Internistische - Frankenthal, Frankenthal, Germany|Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany|St. Marienkrankenhaus - Frankfurt am Main, Frankfurt am Main, Germany|Onkologie Bethanien, Frankfurt, Germany|Krankenhaus Nordwest, Frankfurt, Germany|Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany|Praxis Internistischer Onkologie und Haematologie - Frechen, Frechen, Germany|Gemeinschaftspraxis - Freiburg, Freiburg, Germany|Evang. Deaconess Hospital Freiburg, Freiburg, Germany|Praxis fur Interdisziplinaere Onkologie, Freiburg, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Municipal Hospital Complex, Fulda, Germany|Klinikum Garmisch - Partenkirchen GmbH, Garmisch-Partenkirchen, Germany|Robert - Koch Hospital, Gehrden, Germany|Saint Josef Hospital, Gelsenkirchen, Germany|Internistische Praxisgemeinschaft, Germering, Germany|Centre for Internal Medicine Giessen, Giessen, Germany|Gemeinschaftspraxis Fuer Innere Medizin, Hematologie Und Onkologie, Giessen, Germany|Wilhelm-Anton-Hospital gGmbH, Goch, Goch, Germany|Staedtisches Klinikum Goerlitz GmbH, Goerlitz, Germany|Universitaetsklinikum Goettingen, Goettingen, Germany|DR Herbert - Nieper Krankenhaus Goslar, Goslar, Germany|Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Germany|Staedtisches Klinikum Guetersloh, Guetersloh, Germany|Kreiskrankenhaus Gummersbach GMBH, Gummersbach, Germany|Internistisch-Haematologische Gemeinschaftspraxis - Gustrow, Gustrow, Germany|Allgemeines Krankenhaus Hagen, Hagen, Germany|St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH, Hagen, Germany|St. Salvator Krankenhaus, Halberstadt, Germany|Internistische Gemeinschaftspraxis - Halle, Halle, Germany|Universitaetsklinikum Halle, Halle, Germany|Krankenhaus St. Elisabeth und St. Barbara, Halle, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle, Germany|St. Sixtus Hospital, Haltern, Germany|Praxis fuer Innere Medizin - Bergedorf, Hamburg, Germany|Marienkrankenhaus, Hamburg, Germany|Allgemeines Krankenhaus Altona, Hamburg, Germany|Onkologische Schwerpunktpraxis Dr. med. Verpoort, PD Dr. med. Zeller and Dr. med. Wierecky, Hamburg, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|University Medical Center Hamburg - Eppendorf, Hamburg, Germany|Asklepios Klinik Nord Heidberg, Hamburg, Germany|Haematologisch-Onkologische Praxis Altona, Hamburg, Germany|St. Marien Hospital, Hamm, Germany|Evangelische Krankenhaus Hamm, Hamm, Germany|Klinikum Stadt Hanau, Hanau, Germany|Schwerpunktpraxis Haematologie/Onkologie - Hannover, Hannover, Germany|Krankenhaus Siloah - Medizinische Klinik II, Hannover, Germany|Henriettenstiftung Frauenklinik, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Oncology Specialists Clinic, Harrislee, Germany|Ruprecht - Karls - Universitaet Heidelberg, Heidelberg, Germany|Thoraxklinik Heidelberg, Heidelberg, Germany|Regional Hospital Heidenheim, Heidenheim, Germany|Klinikum Herford, Herford, Germany|Marienhospital at Ruhr University Bochum, Herne, Germany|Privatklinik Dr. R. Schindlbeck GmbH & Co. KG, Herrsching, Germany|Onkologische Schwerpunktpraxis, Hildesheim, Germany|St. Bernward Krankenhaus, Hildesheim, Germany|Staedtisches Krankenhaus Hildesheim, Hildesheim, Germany|Evang. Hospital, Holzminden, Germany|Haematologie und Internistische Onkologie Praxis, Homberg, Germany|Universitaetsklinikum des Saarlandes, Homburg, Germany|Hospital Complex Hoyerswerda, Hoyerswerda, Germany|Clinic for Bone Marrow Transplantation and Hematology and Oncology, Idar-Oberstein, Germany|Internistische Gemeinschaftspraxis - Jena, Jena, Germany|Klinikum der Friedrich-Schiller Universitaet Jena, Jena, Germany|Onkologische Gemeinschaftspraxis - Kaiserslautern, Kaiserslautern, Germany|Westpfalz-Klinikum GmbH, Kaiserslautern, Germany|Staedtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany|St. Vincentius - Kliniken, Karlsruhe, Germany|Red Cross Hospital Kassel, Kassel, Germany|Internistische Gemeinschaftspraxis - Kassel, Kassel, Germany|Klinikum Kempten Oberallgaeu, Kempten, Germany|Staedtisches Krankenhaus Kiel, Kiel, Germany|Praxis fuer Haematologie und Onkologie, Koblenz, Germany|Stiftungsklinikum Mittelrhein - Gesundheitszentrum Evangelisches Stift Sankt Martin Koblenz gGmbH, Koblez, Germany|Leonardis Clinic, Kornwestheim, Germany|Haematologische / Onkologische Schwerpunktpraxis, Krefeld, Germany|Klinikum Krefeld GmbH, Krefeld, Germany|Internistische Onkologische Praxis - Kronach, Kronach, Germany|Frankenwald Klinik, Kronach, Germany|Internistische Praxis - Landshut, Landshut, Germany|Klinikum Landshut, Landshut, Germany|Caritas - Krakenhaus Lebach, Lebach, Germany|Onkologische Schwerpunktpraxis - Leer, Leer, Germany|Praxis fuer Onkologie am Diakonissenhaus, Leipzig, Germany|Forschungsgesellschaft mbH, Leipzig, Germany|Gemeinschaftspraxis fuer Dres. Aldaoud und Schwarzer, Leipzig, Germany|University Leipzig Clinic of Internal Medicine, Leipzig, Germany|Klinikum ""St. Georg"" Leipzig, Leipzig, Germany|Klinikum Lippe - Lemgo, Lemgo, Germany|St. Vincenz Hospital Limburg, Limburg, Germany|St. Bonifatius Hospital Lingen, Lingen, Germany|Dreifaltigkeits Hospital, Lippstadt, Germany|Kreiskrankenhaus Loerrach, Loerrach, Germany|Onkologische Schwerpunktpraxis, Loerrach, Germany|Klinikum Ludwigsburg, Ludwigsburg, Germany|Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen am Rhein, Germany|St. Marien Hospital Ludwighafen, Ludwigshafen, Germany|Schwerpunktpraxis fuer Haematologie und Onkologie - Luebeck, Luebeck, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany|Sana Kliniken Luebeck, Luebeck, Germany|Kreiskrankenhaus Luedenscheid, Luedenscheid, Germany|Evangelisches Krankenhaus - Lutherstadt Wittenberg, Lutherstadt Wittenberg, Germany|Universitatsklinikum der MA, Magdeburg, Germany|Staedtisches Klinikum Magdeburg - Altstadt, Magdeburg, Germany|Internistische Gemeinschaftspraxis - Magdeburg, Magdeburg, Germany|St. Vincenz und Elisabeth Hospital, Mainz, Germany|Johannes Gutenberg University, Mainz, Germany|Gemeinschaftspraxis, Mannheim, Germany|III Medizinische Klinik Mannheim, Mannheim, Germany|Schwerpunktpraxis Internist Onkologie - Marburg, Marburg, Germany|Universitaetsklinikum Giessen und Marburg GmbH - Marburg, Marburg, Germany|Regional Hospital Mayen, Mayen, Germany|Gemeinschaftspraxis Dres. med. Ellbrueck/Goeller/Kraenzle/Niedermeier/Jocham, Memmingen, Germany|Krankenhaus Ludmillenstift, Meppen, Germany|Gemeinschaftspraxis - Minden, Minden, Germany|Klinikum Minden, Minden, Germany|Krankenhaus Maria Hilf GmbH, Moenchengladbach, Germany|Haematologische Praxis - Moenchengladbach, Moenchengladbach, Germany|Ev. Hospital Bethesda, Monchengladbach, Germany|Evangelisches Krankenhaus - Muelheim, Muelheim an der Ruhr, Germany|St. Marien Hospital - Muelheim an der Ruhr, Muelheim An Der Ruhr, Germany|Kreiskrankenhaus Muenchberg, Muenchberg, Germany|Gemeinschaftspraxis - Muenster, Muenster, Germany|Haematologisch - Onkologische Gemeinschaftspraxis - Muenster, Muenster, Germany|Klinik und Poliklinik fuer Kinder und Jugendmedizin - Universitaetsklinikum Muenster, Muenster, Germany|Universitaets - Kinderpoliklinik, Munich, Germany|Krankenhaus Muenchen Schwabing, Munich, Germany|Munich Oncologic Practice at Elisenhof, Munich, Germany|Klinikum der Universitaet Muenchen - Grosshadern Campus, Munich, Germany|Staedtisches Krankenhaus Muenchen - Harlaching, Munich, Germany|Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany|Municipal Hospital Munich, Munich, Germany|Klinikum Schwaebisch Gmuend Stauferklinik, Mutlangen, Germany|Staedtisches Krankenhaus Nettetal GmbH, Nettetal, Germany|Klinikum Neubrandenburg, Neubrandenburg, Germany|Onkologische Schwerwpunktpraxis Dr. Ladda, Neumarkt, Germany|Regional Hospital Neumarkt, Neumarkt, Germany|Onkologische Schwerpunktpraxis Dr. Schmidt, Neunkirchen, Germany|Staedtisches Klinikum Neunkirchen gGmbH, Neunkirchen, Germany|Internistische Praxis - Neuss, Neuss, Germany|Lukaskrankenhaus Neuss, Neuss, Germany|DRK Krankenhaus Neuwied, Neuwied, Germany|Praxis fuer Haematologie und Interne Onkologie, Norderstedt, Germany|Gemeinschaftspraxis fuer Onkologie - Nordhorn, Nordhorn, Germany|Gemeinschaftspraxis fuer Haematologie - Northeim, Northeim, Germany|Praxisklinik fuer Innere Medizin - Nuernberg, Nuremberg, Germany|Klinikum Nuernberg - Klinikum Nord, Nuremberg, Germany|Schlossbergkliniken Oberstaufen, Oberstaufen, Germany|Internistische Gemeinschaftspraxis - Offenbach, Offenbach, Germany|Klinikum Offenburg, Offenburg, Germany|Pius Hospital - Oldenburg, Oldenburg, Germany|Internistische Gemeinschaftspraxis - Oldenburg, Oldenburg, Germany|Ev. Hospital Oldenburg, Oldenburg, Germany|Klinikum Oldenburg, Oldenburg, Germany|St. Martinus Hospital - Olpe, Olpe, Germany|Marien Hospital, Osnabrueck, Germany|Klinikum Osnabrueck GmbH, Osnabrueck, Germany|Paracelsus - Klinik Osnabrueck, Osnabrueck, Germany|Bruederkrankenhaus St. Josef Paderborn, Paderborn, Germany|Asklepios Klinik - Parchim, Parchim, Germany|Staedtisches Krankenhaus, Pforzheim, Germany|Krankenhaus Siloah - Pforzheim, Pforzheim, Germany|Praxis fuer Innere Medizin am Krankenhaus Siloah - Pforzheim, Pforzheim, Germany|Gemeinschaftspraxis - Pinneberg, Pinnebeg, Germany|Klinikum Ernst Von Bergmann, Potsdam, Germany|Kreiskrankenhaus Radebeul, Radebeul, Germany|Gemeinschaftspraxis - Ravensburg, Ravensburg, Germany|Krankenhaus St. Elisabeth - Ravensburg, Ravensburg, Germany|Elisabeth Krankenhaus, Recklinghausen, Germany|Prosper-Hospital Recklinghausen, Recklinghausen, Germany|Hematologische Onkologische Praxis, Regensburg, Germany|Klinikum der Universitaet Regensburg, Regensburg, Germany|Krankenhaus Barmherzige Brueder Regensburg, Regensburg, Germany|Internistische Praxis Dres. Hempel und Hochdorfer, Rehling, Germany|Klinikum Remscheid GmbH, Remscheid, Germany|Jakobi Krankenhaus, Rheine, Germany|Haematologische/Onkologische Schwerpunktpraxis - Rostock, Rostock, Germany|Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock, Rostock, Germany|Klinikum Suedstadt Rostock, Rostock, Germany|Diakonie - Krankenhaus, Rotenburg, Germany|Internistische Schwerpunktpraxis, Russelsheim, Germany|Caritasklinik St. Theresia, Saarbrucken, Germany|Gemeinschaftspraxis - Saarbruecken, Saarbruecken, Germany|St. Elizabeth-Klinik Saarlouis, Saarlouis, Germany|Martin - Luther Hospital, Schleswig, Germany|Praxis fur Innere Medizin - Schmiedeberg, Schmiedeberg, Germany|Deaconess Hospital, Schwabisch Hall, Germany|Gemeinschaftspraxis fuer Haematologie und Internist - Schweinfurt, Schweinfurt, Germany|HELIOS Klinikum - Schwelm, Schwelm, Germany|Klinikum Schwerin, Schwerin, Germany|Leopoldina - Krankenhaus, Schwienfurt, Germany|St. Marien - Krankenhaus Siegen GMBH, Siegen, Germany|Evang. Jung-Stilling Hospital, Siegen, Germany|St. Lukas - Clinic Solingen, Solingen, Germany|Krankenhaus Maria-Hilf - Stadtlohn, Stadtlohn, Germany|Onkologische Schwerpunktpraxis - Straubing, Straubing, Germany|Hospital Bad Cannstatt, Stuttgart, Germany|Haematologische Praxis, Stuttgart, Germany|Klinik fuer Onkologie - Katharinenhospital Stuttgart, Stuttgart, Germany|Diakonie Klinikum Stuttgart, Stuttgart, Germany|Gastroenterologische und Haematologisch-Onkologische Praxis E. M. Dr. Hoering von Ehr Respondek, Stuttgart, Germany|Klinikum Stuttgart - Buergerhospital, Stuttgart, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|St. Elisabeth Hospital Thuine, Thuine, Germany|Regional Hospital Traunstein, Traunstein, Germany|Onkologische Gemeinschaftspraxis - Trier, Trier, Germany|Krankenanstalt Mutterhaus der Borromaerinnen, Trier, Germany|Krankenhaus Der Barmherzigen Brueder, Trier, Germany|Praxis Fuer Internistische Haematologie / Onkologie, Troisdorf, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Hospital Tutzing, Tutzing, Germany|Praxis fuer Haematologie und Onkologie, Twistringen, Germany|Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm, Ulm, Germany|Ev. Hospital Unna, Unna, Germany|St. Marienhospital - Vechta, Vechta, Germany|Municipal Hospital Complex, Villingen-Schwenningen, Germany|Onkologische Schwerpunktpraxis - Villingen, Villingen, Germany|Regional Hospital Waldbrol, Waldbrol, Germany|Haematologische Praxis, Weiden, Germany|Gemeinschaftspraxis feur Haemotologie und Onkologie - Weilheim, Weilheim, Germany|Sophien - und Hufeland - Klinikum Weimar gGmbH, Weimar, Germany|Onkologische Schwerpunktpraxis, Wendlingen, Germany|Harz-Klinikum Wernigerode-Blankenburg GmbH, Wernigerode, Germany|Asklepios Nordseeklinik Westerland GmbH, Westerland, Germany|Ammerland-Klinik GmbH, Westerstede, Germany|Hospital Wetzler, Wetzlar, Germany|Deutsche Klinik fuer Diagnostik, Wiesbaden, Germany|Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany|Ev. Hospital Witten-Herdecke, Witten, Germany|Klinikum der Stadt Wolfsburg, Wolfsburg, Germany|Burkhard and Reimann Gemeinschaftspraxis, Worms, Germany|Medizinische Poliklinik, Universitaet Wuerzburg, Wuerzburg, Germany|Kliniken St. Antonius, Wuppertal 2, Germany|Helios Kliniken Wuppertal University Hospital, Wuppertal, Germany|Heinrich-Braun-Krankenhaus Zwickau, Zwickau, Germany|Azienda Ospedaliera di Padova, Padova, Italy|Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands|Akademia Medyczna im. Piastow Slaskich, Wroclaw, Poland|Goeteborg University, Goeteborg, Sweden|Kantonsspital Aarau, Aarau, Switzerland|Universitaets-Kinderspital beider Basel, Basel, Switzerland|Ospedale ""la Carita"", Locarno, Locarno, Switzerland|Kinderspital Luzern, Lucerne 16, Switzerland|Ostschweizer Kinderspital, St. Gallen, Switzerland|University Children's Hospital, Zurich, Switzerland|Royal Manchester Children's Hospital, Manchester, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT00290667"
484,"NCT02889523","Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients Treated by Chemiotherapy","Epi-RCHOP","Suspended","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Tazemetostat|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisolone","Phase I : Number of Dose Limiting Toxicities|Phase II : Number of Serious Adverse Events (SAE) et Adverse Events (AE)|Phase II : Complete Response Rate|Phase I : Serum concentration of CHOP components in presence/absence of Tazemetostat|Phase I : Serum concentration of Tazemetostat and its metabolite (EZH 6930) in presence of CHOP|Phase II : Overall response rate (ORR)|Phase II : progression free survival (PFS)|Phase II : serum concentration of R-CHOP components in the presence/absence of tazemetostat|Phase II : serum concentration of tazemetostat and its metabolite (EZH-6930) in the presence of R-CHOP","The Lymphoma Academic Research Organisation|Epizyme, Inc.","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","133","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Epi-RCHOP","October 2016","September 2020","May 2023","September 5, 2016","null","May 24, 2018","CHRU Lille - Hôpital Claude Huriez, Lille Cedex, France|CHU de Nantes - Hôtel Dieu, Nantes, France|CHU Lyon Sud, Pierre-Bénite Cedex, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT02889523"
485,"NCT02362997","Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL",,"Recruiting","No Results Available","Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Peripheral T-Cell Lymphoma","Drug: Pembrolizumab","Progression-free survival after ASCT|Overall Survival|Relapse|Safety and Tolerability assessed by Grade 2 and above toxicity related to study treatment|Response rate to pembrolizumab","Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-566","April 2015","September 2020","December 2022","February 13, 2015","null","September 19, 2018","City of Hope National Medical Center, Duarte, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02362997"
486,"NCT02871869","Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Diffuse, Large B-Cell, Lymphoma","Drug: vindesine|Drug: cyclophosphamide|Drug: Epirubicin|Drug: prednisone tablets|Drug: Cinobufacini Tablets|Drug: Rituximab","Progression-free survival (PFS)|Overall response rate (ORR)|overall survival rate (OS)|Safety and Tolerability|Relationship between synergistic effect of Cinobufacini Tablets and expression of Na+/K+-ATPase α3","Xinjiang Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","316","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XinjiangMU2016(015)V2.0","September 2016","September 2018","December 2021","August 18, 2016","null","July 17, 2017","Cancer Hospital Affiliated to Xinjiang Medical University, Ürümqi, Xinjiang, China","","https://ClinicalTrials.gov/show/NCT02871869"
487,"NCT02391116","Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Completed","Has Results","Diffuse, Large B-Cell, Lymphoma","Drug: Copanlisib (BAY80-6946)","Objective Response Rate (ORR) in Total Population Based on Investigator Assessment|ORR in Total Population Based on Investigator Assessment|ORR by CD79b Status Based on Investigator Assessment|ORR by DLBCL/COO Subtype Based on Investigator Assessment|Duration of Response (DOR) in Total Population|DOR by CD79b Status|DOR by DLBCL/COO Subtype|Progression-free Survival (PFS) in Total Population|PFS by CD79b Status|PFS by DLBCL/COO Subtype|Overall Survival (OS) in Total Population|OS by CD79b Status|OS by DLBCL/COO Subtype|Duration of Stable Disease (DOSD) in Total Population|Disease Control Rate (DCR) in Total Population|DCR by CD79b Status|DCR by DLBCL/COO Subtype|Number of Patients With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17119|2014-004848-36","May 8, 2015","July 5, 2016","January 19, 2018","March 18, 2015","January 8, 2018","March 9, 2018","Ballarat, Victoria, Australia|Prahran, Victoria, Australia|Box Hill, Australia|Kingswood, Australia|Wilrijk, Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Leuven, Belgium|St. John's, Newfoundland and Labrador, Canada|Brampton, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Aarhus C, Denmark|Odense C, Denmark|Caen Cedex, France|Creteil, France|Lille, France|PARIS cedex, France|Pierre Benite, France|Poitiers Cedex, France|Münster, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Milano, Lombardia, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Truro, Cornwall, United Kingdom|Southampton, Hampshire, United Kingdom|London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02391116"
488,"NCT00834951","Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Non Hodgkin's Lymphoma","Radiation: Low dose total body irradiation","","University of Aarhus|Aarhus University Hospital|Rigshospitalet, Denmark","All","60 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTBI-NHL-01","January 2003","December 2007","December 2008","February 3, 2009","null","February 3, 2009","","","https://ClinicalTrials.gov/show/NCT00834951"
489,"NCT03151876","Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Drug: Chidamide|Drug: Cladribine|Drug: gemcitabine|Drug: Busulfan|Procedure: Autologous hematopoietic stem cell transplantation","Event free survival|Overall survival|Complete remission|Adverse events","Sichuan University","All","18 Years to 60 Years   (Adult)","Phase 2","93","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ChiCGB-DLBCL","June 12, 2017","December 2020","December 2021","May 12, 2017","null","July 18, 2018","Beijing cancer hospital, Beijing, Beijing, China|Peking university third hospital, Beijing, Beijing, China|The first affiliated hospital of Chongqing medical university, Chongqing, Chongqing, China|Southwest Hospital, Chongqing, Chongqing, China|General Hospital of Lanzhou military command, Lanzhou, Gansu, China|Henan cancer hospital, Zhengzhou, Henan, China|The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan, China|Tongji Hospital, Wuhan, Hubei, China|Jiangsu province hospital, Nanjing, Jiangsu, China|Rui jin hospital Shanghai jiao tong University, Shanghai, Shanghai, China|Tong Ren Hospital, Shanghai, Shanghai, China|Shan Xi Da Yi Hospital, Taiyuan, Shanxi, China|Tangdu Hospital, Xi'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Affiliated Hospital of Southwest Medical University, Nanchong, Sichuan, China|Blood diseases hospital, Chinese academy of medica, Tianjin, Tianjing, China|The first affiliated hospital of Xinjiang medical Universtiy, Ürümqi, Xinjiang, China|Kunming General Hospital of Chengdu Military Area, Kunming, Yunnan, China","","https://ClinicalTrials.gov/show/NCT03151876"
490,"NCT00670358","Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: lenalidomide|Drug: prednisone|Drug: vincristine sulfate|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Toxicity as assessed by NCI CTCAE v3.0 (Phase I)|Event-free survival at 12 months (Phase II)|Overall response rate|Overall complete response rate|Event-free survival|Overall survival|Progression-free survival|Duration of response|Immune function before and after treatment as assessed by T-, B-, and NK-cell quantification|Correlation of immune function with clinical outcomes","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1|Phase 2","47","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC078E|P30CA015083|RV-NHL-PI-0325|07-007992|NCI-2009-01196","August 25, 2008","May 2019","May 2019","May 1, 2008","null","June 7, 2018","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00670358"
491,"NCT03682796","Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma",,"Not yet recruiting","No Results Available","Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Lymphoma, Mantle-Cell|Lymphoma, Marginal Zone|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular","Drug: TRPH-222","Maximum Tolerated Dose (MTD)|Evaluate incidence and severity of AEs, serious AEs, TRPH-222-related AEs, AEs leading to death or discontinuation from treatment|Tumor Activity|TRPH-222 Pharmacokinetics (PK)","Triphase Research and Development III Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRPH-222-100","October 15, 2018","January 31, 2022","August 30, 2022","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682796"
492,"NCT01848132","Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.",,"Completed","No Results Available","Diffuse, Large B-Cell, Lymphoma","Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine","Proportion of patients with Event-Free Survival at 2 years.|Event-Free survival at 2 years in the different subtypes of DLBCL|Overall survival at 2 years|Overall response rate and complete remissions|Toxicity according to the CTC criteria|To evaluate the predictive value for EFS of interim PET/CT evaluation|To identify clinical and biological prognostic factors for response and survival.","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","121","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRCAP-GELTAMO12|2012-005138-12","October 3, 2013","January 2018","August 2018","May 7, 2013","null","September 19, 2018","Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain|Hospital Son Llàtzer, Palma, Islas Baleares, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT01848132"
493,"NCT01324596","A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib","REMoDL-B","Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Intravenous|Drug: Bortezomib","Progression Free Survival|Overall survival|Event-free survival|Disease-free survival|Time to progression|Response duration|Complete and overall response rates|Evaluation of toxicity (according to CTCAE version 4.0)|Quality of life and assessment of peripheral neuropathy","University Hospital Southampton NHS Foundation Trust|Janssen-Cilag Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RHMCAN0749","April 2011","April 2015","June 2015","March 29, 2011","null","April 15, 2016","Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Liestal, Basel, Switzerland|Universitatsspital Basel, Basel, Switzerland|Ospedale Regionale Bellinzona e Valli (IOSI), Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|STSAG Thun, Bern, Switzerland|Spitalzenturm Oberwallis, Brig, Switzerland|Kantonsspital Graubunden, Chur, Switzerland|Luzerner Kantonsspital, Lucerne, Switzerland|Kantonsspital Olten, Olten, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Stadtspital Triemli, Zurich, Switzerland|UniversitatsSpital Zurich, Zurich, Switzerland|University Hospital Aintree, Aintree, United Kingdom|Monklands, Hairmyres and Whishaw Hospitals, Airdrie, United Kingdom|Antrim Area Hospital, Antrim, United Kingdom|Stoke Mandeville Hospital and Wycombe Hospital, Aylesbury, United Kingdom|Ysbyty Gwynedd Hospital, Bangor, United Kingdom|Basildon Hospital, Basildon, United Kingdom|North Hampshire & Basingstoke Hospital, Basingstoke, United Kingdom|Royal United Hospital, Bath, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Arrowe Park, Birkenhead, United Kingdom|Good Hope Hosptial, Birmingham, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Sandwell General Hospital Birmingham, Birmingham, United Kingdom|Victoria Hospital, Blackpool, United Kingdom|Royal Bournemouth, Bournemouth, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Queen's Hospital Burton, Burton upon Trent, United Kingdom|West Suffolk Hospital, Bury St. Edmunds, United Kingdom|Velindre Hospital, Cardiff, United Kingdom|Broomfield Hospital, Chelmsford, United Kingdom|Cheltenham General Hospital and Gloucestershire Royal Infirmary, Cheltenham, United Kingdom|Chesterfield Royal, Chesterfield, United Kingdom|St Richard's Hospital, Chichester, United Kingdom|Colchester General Hospital, Colchester, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darent Valley Hospital, Dartford, United Kingdom|Royal Derby Hospitals, Derby, United Kingdom|Doncaster Royal Infirmary, Doncaster, United Kingdom|Ulster Hospital, Dundonald, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Queen Elizabeth Hospital, Gateshead, Gateshead, United Kingdom|Medway Maritime Hospital, Gillingham, United Kingdom|Beatson West of Scotland Cancer centre, Glasgow, United Kingdom|Diana Princess of Wales, Grimsby, Grimsby, United Kingdom|Harrogate District Hospital, Harrogate, United Kingdom|Hemel Hempstead General and Watford General, Hemel Hempstead and Watford, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Kent and Canterbury Hospital, Kent, United Kingdom|Queen Elizabeth Hospital, King's Lynn, United Kingdom|St James University Hospital, Leeds, United Kingdom|Lincoln County Hospital, Pilgrim Hospital, Grantham and District Hospital, Lincoln, United Kingdom|Royal Liverpool, Liverpool, United Kingdom|Barnet General Hospital, London, United Kingdom|Ealing Hospital, London, United Kingdom|Guy's Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Hillingdon Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|Northwick Park Hospital, London, United Kingdom|Princess Royal University Hospital, London, United Kingdom|QE Woolwich, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St Bartholomews Hospital, London, United Kingdom|St George's Hospital, London, United Kingdom|St Helier Hospital, London, United Kingdom|The Royal Marsden, London, United Kingdom|University College Hospital London, London, United Kingdom|Luton and Dunstable Hospital, Luton, United Kingdom|Maidstone Hospital and The Tunbridge Wells Hospital, Maidstone, United Kingdom|Christie Hospital, Manchester, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes General Hospital, Milton Keynes, United Kingdom|Freeman Hospital, Newcastle, Newcastle, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Mount Vernon Hospital, Northwood, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|George Eliot Hospital, Nuneaton, United Kingdom|Royal Oldham, Oldham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Poole General Hospital, Poole, United Kingdom|Craigavon Area Hospital, Portadown, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|Glan Clwyd District General Hospital, Rhyl, United Kingdom|Queen's Hospital, Romford, United Kingdom|Salisbury District Hospital, Salisbury, United Kingdom|Scunthorpe General Hospital, Scunthorpe, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Wexham Park, Slough, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Southend Hospital, Southend, United Kingdom|County Hospital, Stafford, United Kingdom|Royal Stoke Hospital, Stoke, United Kingdom|Sunderland Royal Hospital, Sunderland, United Kingdom|Great Western Hospital, Swindon, United Kingdom|Torbay District General Hospital, Torbay, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Pinderfields Hospital, Dewsbury Hospital and Ponerfract Hospital, Wakefield, United Kingdom|Warwick Hospital, Warwick, United Kingdom|Worcestershire Royal Hospital, Worcester, United Kingdom|Worthing Hospital, Worthing, United Kingdom","","https://ClinicalTrials.gov/show/NCT01324596"
494,"NCT02544724","NM-IL-12 (rHuIL‐12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy",,"Unknown status","No Results Available","Lymphoma, Large B-Cell, Diffuse (DLBCL)","Biological: NM-IL-12","Safety and tolerability|Immunogenicity of NM-IL-12|Response rate (Complete Response or Partial Response) as assessed by PET/CT|Time to neutrophil recovery|Time to platelet count recovery|Incidence of systemic infections|Incidence and duration of neutropenic fever|Need for RBC and platelet transfusion|Peak Plasma Concentration (Cmax) of NM-IL-12|Area under the plasma concentration versus time curve (AUC) of NM-IL-12|Peak Plasma Concentration (Cmax) of IFN-g and IP-10","Neumedicines Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NM-ONC-002","November 2016","August 2017","December 2017","September 9, 2015","null","August 3, 2016","","","https://ClinicalTrials.gov/show/NCT02544724"
495,"NCT02428751","R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma",,"Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Pegylated liposomal doxorubicin|Drug: Doxorubicin|Drug: Rituximab|Drug: Cyclophophamide|Drug: Vincristine|Drug: Prednisone","event-free survival (EFS)|overall response rate (ORR)|complete remission (CR) rate|overall survival (OS)","Wenqi Jiang|Sun Yat-sen University","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 3","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","308-2015-005","September 2015","March 2020","May 2020","April 29, 2015","null","November 18, 2015","Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical Unversity, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|Wujing Zongdui Hospital of Guangdong Province, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT02428751"
496,"NCT03245905","Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL",,"Not yet recruiting","No Results Available","Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)","Drug: Chidamide","objective response rate（ORR）|progression-free survival（PFS）|overall survival（OS）","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSIIT-B09","August 20, 2017","December 31, 2018","September 30, 2019","August 10, 2017","null","August 10, 2017","Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03245905"
497,"NCT02728882","Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma","EECBL","Recruiting","No Results Available","Lymphoma","Biological: CD19-targeted CAR-T cells","Objective Reaction Rates","Sinobioway Cell Therapy Co., Ltd.|The First Affiliated Hospital of Anhui Medical University","All","3 Years to 75 Years   (Child, Adult, Older Adult)","Not Applicable","24","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACCO-2015-06-02","July 2, 2015","July 2019","July 2019","April 5, 2016","null","March 23, 2017","The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China","","https://ClinicalTrials.gov/show/NCT02728882"
498,"NCT00355199","Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.",,"Completed","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Rituximab-HDS|Drug: Rituximab-CHOP","Event Free Survival|Complete Remission|Disease Free Survival|Overall Survival|Toxicity|Efficacy of R-HDS Conditioning as Salvage Therapy in Patients Non-responders After Four Cycles of R-CHOP 14","Gruppo Italiano Terapie Innovative nei Linfomi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","246","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EUDRACT: 2005-00700-14","May 2005","March 2013","March 2013","July 21, 2006","August 10, 2017","August 10, 2017","Clinica di Ematologia - Nuovo Ospedale Torrette, Ancona, Italy|U.O. Ematologia - Ospedali Riuniti di Bergamo, Bergamo, Italy|Divisione di Ematologia - Ospedale Centrale di Bolzano, Bolzano, Italy|CTMO - Ematologia - Ospedale ""R. Binaghi"", Cagliari, Italy|Divisione di Ematologia - Ospedale Ferrarotto, Catania, Italy|S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Divisione Ematologia - Istituto S. Raffaele, Milano, Italy|Oncologia Medica - Istituto Nazionale dei Tumori, Milano, Italy|U.O. Ematologia - Istituto Nazionale dei Tumori, Milano, Italy|Divisione di Ematologia - Azienda Ospedaliera, Padova, Italy|Ematologia - Azienda Ospedaliera V. Cervello, Palermo, Italy|Ematologia Clinica - Ospedale Civile di Pescara, Pescara, Italy|Ematologia e TMO - Ospedale S. Camillo, Roma, Italy|Divisione Universitaria di Ematologia - Azienda Ospedaliera S. Giovanni Battista (Molinette), Torino, Italy|Dipartimento di Medicina Clinica e Sperimentale - Università di Verona, Verona, Italy|Divisione di Ematologia - Presidio Ospedaliero S. Bortolo, Vicenza, Italy","","https://ClinicalTrials.gov/show/NCT00355199"
499,"NCT03217253","Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction",,"Suspended","No Results Available","Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Liver Dysfunction|Metastatic Malignant Solid Neoplasm|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Tazemetostat","Incidence of adverse events of tazemetostat in patients with varying degrees of hepatic dysfunction assessed using Common Terminology Criteria for Adverse Events version 4.0|Recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction|Pharmacokinetic (PK) profiles of tazemetostat in patients with varying degrees of hepatic dysfunction|Antitumor activity of tazemetostat|Antitumor activity of tazemetostat in population with tumors with aberrations in EZH2 or SWI/SNF complex pathways|Objective confirmed response|Duration of response|Best response","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2017-01231|10130|UM1CA186644","March 16, 2018","September 1, 2020","September 1, 2020","July 14, 2017","null","July 18, 2018","University Health Network Princess Margaret Cancer Center LAO, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03217253"
500,"NCT00058422","Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Biological: darbepoetin alfa|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: yttrium Y 90 ibritumomab tiuxetan","Overall survival|Progression-free survival|Event-free survival|incidence of adverse experiences|Conversion rate to complete remission","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","60 Years to 120 Years   (Adult, Older Adult)","Phase 2","65","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02-090|MSKCC-02090","February 2003","February 2019","February 2019","April 9, 2003","null","March 2, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00058422"
501,"NCT02867566","A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients",,"Recruiting","No Results Available","Diffuse, Large B-Cell, Lymphoma","Drug: IBI301 plus CHOP|Drug: Rituximab plus CHOP","Overall response rate(ORR)|Complete remission(CR)|Progression-free survival(PFS)|Event-free survival(EFS)|Overall survival(OS)","Innovent Biologics (Suzhou) Co. Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CIBI301A301","August 2016","December 2018","December 2018","August 16, 2016","null","April 17, 2017","Institute of Hematology; Chinese Academy of Medical Sciences, Tianjin, China","","https://ClinicalTrials.gov/show/NCT02867566"
502,"NCT01156259","30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy",,"Unknown status","No Results Available","Lymphoma, Large B-Cell, Diffuse","Radiation: 3D-CRT based Involved Field Radiotherapy","disease free survival|overall survival|acute treatment toxicity|late treatment toxicity|treatment failure type","Chinese Academy of Medical Sciences|Sun Yat-sen University","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CH-LYM-004","April 2010","April 2015","May 2015","July 2, 2010","null","July 2, 2010","Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01156259"
503,"NCT02384954","QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab",,"Recruiting","No Results Available","Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma","Biological: Rituximab|Biological: ALT-803","Determination of MTD or MED, Phase II Dose Level Designation|Number of treatment related adverse events as a measure of safety|Overall Response Rate|Progression-free Survival|Overall Survival|Duration of Response|Blood Cell Counts|Levels of specific biomarkers as a predictive measure of efficacy|Immunogenicity|Pharmacokinetics as a measure of drug persistence|Polymorphism|Mutations|Lymph node biopsies","Altor BioScience","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","86","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA-ALT-803-02-14","April 2015","December 2018","June 2023","March 10, 2015","null","May 8, 2018","University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine Oncology, Saint Louis, Missouri, United States|The Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02384954"
504,"NCT03229616","BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT",,"Recruiting","No Results Available","Autologous Hematopoietic Stem Cell Transplantation|Diffuse Large B-cell Lymphoma|Conditioning","Drug: Busulfan (BU)|Drug: Cyclophosphamide (CY)|Drug: Etoposide (VP-16)","relapse rate|DFS|OS|TRM","Nanfang Hospital of Southern Medical University|Guangzhou First People's Hospital|Zhujiang Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Peking University People's Hospital","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BUCY+VP-16 vs BUCY-DLBCL-2017","July 5, 2017","June 2020","June 2020","July 25, 2017","null","October 12, 2017","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03229616"
505,"NCT02031419","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: CC-122|Drug: CC-223|Drug: Rituximab|Drug: CC-292","Safety|Efficacy|Pharmacokinetics - CC-223 and CC-292 interaction","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","174","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-DLBCL-001","December 18, 2013","December 15, 2019","November 30, 2020","January 9, 2014","null","September 11, 2018","Sansum Clinic, Santa Barbara, California, United States|Stanford Cancer Center, Stanford, California, United States|Rocky Mountain Cancer Centers, LLP [Boulder-COBO], Boulder, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Cencer and Research Institute, Tampa, Florida, United States|Northwestern University, Division of Hematology Oncology, Dept. of Medicine, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|West Cancer Center, Germantown, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Osteoporosis Clinical Center and Research Program, Madison, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|Centre Leon Berard, Lyon, France|Institut Gustave Roussy, Villejuif Cedex, France|Istituto Nazionale Dei Tumori, Milano, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Sanitaria Ospedaliera San Giovanni Battista Molinette, Turin, Italy","","https://ClinicalTrials.gov/show/NCT02031419"
506,"NCT02991638","Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia|Indolent B-cell Lymphomas|Chronic Hepatitis B|Lymphoma, Small Lymphocytic|Mantle-Cell Lymphoma|Waldenstrom's Macroglobulinaemia|Follicular Lymphoma","Drug: Ibrutinib","Overall response rate (ORR)|Duration of remission|Rates of HBV Reactivation while on Ibrutinib therapy|Adverse events and severe adverse events","The University of Hong Kong|Janssen, LP","All","18 Years and older   (Adult, Older Adult)","Phase 3","62","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HKUBTK01","November 1, 2016","December 2020","June 2021","December 13, 2016","null","April 12, 2018","The University of Hong Kong, Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT02991638"
507,"NCT03467373","A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Chemotherapy in Participants With Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","Follicular Lymphoma|B-Cell Lymphoma|Non-Hodgkin Lymphoma","Drug: RO7082859|Drug: Obinutuzumab (G)|Drug: Rituximab (R)|Drug: Tocilizumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Part I: Percentage of Participants with Dose Limiting Toxicities (DLTs)|Part I and II: Percentage of Participants with Adverse Events|Part II: Percentage of Participants with a Complete Response (CR) as Assessed by the Investigator using Modified Lugano 2014 Criteria|Part II: Percentage of Participants with Overall Response (Partial Response [PR] or Complete Response [CR])|Part II: Percentage of Participants with PR, CR or SD (Disease Control Rate [DCR])|Part II: Duration of Response (DOR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Part II: Area Under the Serum Concentration Versus Time Curve (AUC) of RO7082859|Part II: Time to Maximum Serum Concentration (tmax) of RO7082859|Par II: Maximum Serum Concentration (Cmax) of RO7082859|Part II: Minimum Serum Concentration (Cmin) of RO7082859|Change from Baseline in T-cell Activation Markers|Part II: Area Under the Serum Concentration Versus Time Curve (AUC) of Rituxiamb|Part II: Time to Maximum Serum Concentration (tmax) of Rituximab|Par II: Maximum Serum Concentration (Cmax) of Rituximab|Part II: Minimum Serum Concentration (Cmin) of Rituximab","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","172","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP40126|2017-003648-18","March 13, 2018","June 1, 2023","June 1, 2023","March 16, 2018","null","September 11, 2018","Ingalls Memorial Hospital, Harvey, Illinois, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania, United States|Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia|Cross Cancer Institute; Clinical Trials, Edmonton, Alberta, Canada|Princess Margaret Hospital, Medical Oncology & Haematology, Toronto, Ontario, Canada|Rigshospitalet; Hæmatologisk Klinik, København Ø, Denmark|Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany|Universitätsklinikum Würzburg; Studienzentrale Hämatologie/Onkologie, Würzburg, Germany|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|The HOPE Clinical Trials Unit, Leicester, United Kingdom|University College London Hospitals NHS Foundation Trust; NIHR UCLH Clinical Research Facility, London, United Kingdom|Derriford Hospital; Haematology, Plymouth, United Kingdom","","https://ClinicalTrials.gov/show/NCT03467373"
508,"NCT01359592","S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: R-CHOP regimen|Other: laboratory biomarker analysis|Radiation: fludeoxyglucose F 18|Radiation: selective external radiation therapy|Radiation: yttrium Y 90 ibritumomab tiuxetan","Five-year PFS rate of patients with DLBCL|PFS within the PET+ and PET- subgroups of patients with newly diagnosed limited-stage DLBCL|Toxicity of protocol treatments|Overall survival of patients with DLBCL|Association of germinal center B-cell subtype (GCB) vs stromal-1 vs stromal-2 gene expression signatures with PFS or overall survival","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","159","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000700624|S1001|U10CA032102","September 2011","June 2020","March 2024","May 25, 2011","null","October 5, 2017","Providence Cancer Center, Anchorage, Alaska, United States|Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States|Aurora Presbyterian Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States|St. Anthony Central Hospital, Denver, Colorado, United States|Kaiser Permanente - Denver, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|CCOP - Colorado Cancer Research Program, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Kaiser Permanente - Lafayette, Lafayette, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Yale Cancer Center, New Haven, Connecticut, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northside Hospital Cancer Center, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|WellStar Cobb Hospital, Austell, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Harbin Clinic Cancer Center - Medical Oncology, Rome, Georgia, United States|Kapiolani Medical Center at Pali Momi, 'Aiea, Hawaii, United States|Oncare Hawaii, Incorporated - Pali Momi, 'Aiea, Hawaii, United States|Leeward Radiation Oncology, 'Ewa Beach, Hawaii, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Lusitana, Honolulu, Hawaii, United States|Queen's Cancer Institute at Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Incorporated, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Kuakini, Honolulu, Hawaii, United States|Hawaii Medical Center - East, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Galesburg, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Kellogg Cancer Care Center, Highland Park, Illinois, United States|Provena St. Mary's Regional Cancer Center - Kankakee, Kankakee, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|North Shore Oncology and Hematology Associates, Limited - Libertyville, Libertyville, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|Cancer Care and Hematology Specialists of Chicagoland - Niles, Niles, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Hematology Oncology Associates - Skokie, Skokie, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's Hospital - South, Overland Park, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|CCOP - Kansas City, Prairie Village, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology - Woodbury, Woodbury, Minnesota, United States|Saint Luke's Cancer Institute at Saint Luke's Hospital, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology Oncology Associates, Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Parvin Radiation Oncology, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology, Incorporated, Saint Joseph, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Rex Cancer Center at Rex Hospital, Raleigh, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|MeritCare Broadway, Fargo, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Roger Maris Cancer Center at MeritCare Hospital, Fargo, North Dakota, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Cancer Centers of the Carolinas - Faris Road, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Grove Commons, Greenville, South Carolina, United States|Greenville Hospital Cancer Center, Greenville, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Greer Medical Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|University Hospital - San Antonio, San Antonio, Texas, United States|Island Hospital Cancer Care Center at Island Hospital, Anacortes, Washington, United States|St. Joseph Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|Highline Medical Center Cancer Center, Burien, Washington, United States|Columbia Basin Hematology, Kennewick, Washington, United States|Skagit Valley Hospital Cancer Care Center, Mount Vernon, Washington, United States|Harrison Poulsbo Hematology and Onocology, Poulsbo, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical, PLLC, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|Polyclinic First Hill, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|North Puget Oncology at United General Hospital, Sedro-Woolley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Evergreen Hematology and Oncology, PS, Spokane, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown, West Virginia, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States","","https://ClinicalTrials.gov/show/NCT01359592"
509,"NCT01563861","S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Genetic: RNA analysis|Genetic: gene expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Proportion of GCB phenotype among limited-stage vs advanced-stage patients|Differences in PFS between limited- and advanced-stage patients with the GCB and non-GCB phenotypes|Association between GCB markers and OS","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","","397","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000729157|S9704-S0014-S0313A|U10CA032102","February 2012","March 2012","March 2012","March 27, 2012","null","December 21, 2017","","","https://ClinicalTrials.gov/show/NCT01563861"
510,"NCT03379493","Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Lymphomas Non-Hodgkin's B-Cell","Biological: ET190L1 ARTEMIS™ T cells","Maximum Tolerated Dose|Toxicity profile of ET190L1 ARTEMIS™ T-cell treatment|Overall response rate (ORR)|Overall response rate (ORR) in histologic subtypes of CD19+ Non-Hodgkin's lymphoma|Duration of overall response (DOR)|Progression free survival (PFS)|Overall survival (OS)","Eureka Therapeutics Inc.|Duke University|Duke Clinical Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry|Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ETUS16CD19AR107","April 4, 2018","December 10, 2024","December 10, 2024","December 20, 2017","null","August 7, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03379493"
511,"NCT03003546","Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Not yet recruiting","No Results Available","Aggressive Non-Hodgkin Lymphoma|CD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma","Other: Laboratory Biomarker Analysis|Drug: Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Other: Pharmacological Study","MTD defined as the highest dose level patients develop a dose limiting toxicity assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|OS|PFS|Tumor response assessed using The Lugano Classification Response criteria","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LS1681|NCI-2016-01984|P30CA015083","November 2018","June 2022","June 2022","December 28, 2016","null","April 18, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03003546"
512,"NCT01279772","This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas","IELSG33","Terminated","No Results Available","Diffuse Large B-Cell Lymphoma of the Breast","","local and CNS relapse rate|progression free survival|overall survival|overall, complete and partial response rates following RCHOP","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","","1","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IELSG33","October 2011","null","null","January 19, 2011","null","March 13, 2017","","","https://ClinicalTrials.gov/show/NCT01279772"
513,"NCT02343536","A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular","Drug: Oral Azacitidine|Drug: Rituximab|Drug: cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Maximum Tolerated Dose (MTD)|Maximal Administered Dose (MAD)|Adverse Event (AE)|Pharmacokinetics- Cmax|Pharmacokinetics - AUC|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics CL/F|Pharmacokinetics - Vz/F|Overall response rate (ORR)|Complete response (CR) rate|Progression free survival (PFS)","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-DLBCL-001","April 29, 2015","April 30, 2018","March 1, 2020","January 22, 2015","null","December 2, 2017","Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medicine, New York, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT02343536"
514,"NCT03450343","Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma",,"Not yet recruiting","No Results Available","Large B-Cell Diffuse Lymphoma","Drug: Oral azacitidine|Drug: R-ICE","Presence or absence of a dose limiting toxicity in the combination of oral azacitadine and R-ICE|Response rate|progression free survival|Adequate peripheral stem cell collection","Medical University of South Carolina|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","102732|OA-CL-DLBCL-PI-13065","November 2018","March 2020","March 2021","March 1, 2018","null","July 16, 2018","","","https://ClinicalTrials.gov/show/NCT03450343"
515,"NCT03479918","R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)",,"Recruiting","No Results Available","Lymphoma, High-Grade","Drug: R-DA-EPOCH-21|Drug: R-BL-M-04|Drug: R-DA-EPOCH-21 + auto-SCT|Drug: R-BL-M-04 + auto-SCT","Overall survival|Relapse-free survival|Progression|Complete remission|Partial remission","Elena N.Parovichnikova|National Research Center for Hematology, Russia","All","18 Years to 60 Years   (Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HGBL DH and HGBL NOS","March 15, 2018","March 15, 2021","March 15, 2024","March 27, 2018","null","March 27, 2018","National Research Center for Hematology, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT03479918"
516,"NCT01334502","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: everolimus|Drug: prednisone|Drug: vincristine sulfate","MTD of everolimus in combination with R-CHOP|Adverse events profile|Toxicity profile|Proportion of patients who have a significant toxicity|Rate of EFS|Overall response rate, CR rate, overall survival, PFS, and duration of response","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCCTG-N1085|CDR0000698584|NCI-2011-02643","March 2012","February 2015","August 2017","April 13, 2011","null","August 10, 2017","Mayo Clinic Cancer Center, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01334502"
517,"NCT01278615","Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Terminated","Has Results","Recurrent Adult Diffuse Large Cell Lymphoma","Other: Laboratory Biomarker Analysis|Drug: Selumetinib","Response Rate (Complete Response [CR] and Partial Response [PR]) in Patients Treated With Selumetinib|Disease Control Rate (Complete Response [CR], Partial Response [PR], and Stable Disease [SD]) in Patients Treated With Selumetinib|Duration of Response|Incidence of Adverse Events Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Overall Survival|Progression-free Survival|Time to Treatment Failure","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2011-02558|NU-10H03|CDR0000690641|12-0110|8611|N01CM00071|N01CM62201|P30CA014599","December 2010","February 2014","May 2014","January 19, 2011","February 3, 2016","February 3, 2016","Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Weill Medical College of Cornell University, New York, New York, United States|M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01278615"
518,"NCT03280394","Liquid Biopsy in Mature B-cell Tumors",,"Recruiting","No Results Available","Mature B-Cell Neoplasm","Diagnostic Test: Liquid Biopsy","Accuracy of interim plasma cell free DNA genotyping for cHL patients|Accuracy of interim plasma cell free DNA genotyping for DLBCL patients|Accuracy of interim plasma cell free DNA genotyping for FL patients|Accuracy of interim plasma cell free DNA genotyping for MCL patients","Oncology Institute of Southern Switzerland","All","18 Years and older   (Adult, Older Adult)","","444","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IOSI-EMA003","September 1, 2017","December 31, 2027","December 31, 2027","September 12, 2017","null","September 12, 2017","Institute of Oncology Research, Bellinzona, Tessin, Switzerland","","https://ClinicalTrials.gov/show/NCT03280394"
519,"NCT00880581","A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas",,"Completed","Has Results","Lymphoma, Non-Hodgkin|Lymphoma|Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell|Lymphomas: Non-Hodgkin","Drug: PF-3512676|Radiation: Local radiotherapy","Overall ObjectiveResponse (ORR) Rate|Response Rate After Cycle 2","Ronald Levy|Pfizer|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-14820|SU-03272009-2038|LYMNHL0064","January 2009","September 2011","January 2015","April 14, 2009","March 14, 2017","March 14, 2017","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00880581"
520,"NCT01321541","Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant","PIX-R","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma|de Novo DLBCL|DLBCL Transformed From Indolent Lymphoma|Follicular Grade 3 Lymphoma","Drug: Pixantrone + Rituximab|Drug: Gemcitabine + Rituximab","Progression Free Survival (PFS)|Overall survival|Complete Response Rate|Overall Response Rate|Safety Evaluation","CTI BioPharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PIX306 (PIX-R Trial)","April 2011","August 2017","December 2017","March 23, 2011","null","August 3, 2017","Arizona Clinical Research Center, Tucson, Arizona, United States|Arizona Oncology Associates, Tucson, Arizona, United States|Highlands Oncology Group, Bentonville, Arkansas, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|George Washington University Department of Medicine, Washington, D.C., District of Columbia, United States|Integrated Community Oncology Network-St. Vincent's, Jacksonville, Florida, United States|Integrated Community Oncology Network-Southside, Jacksonville, Florida, United States|Integrated Community Oncology Network, Orange Park, Florida, United States|Carle Physician Group, Danville, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Carle Foundation Physician Services, Mattoon, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Baptist Hospital East, Louisville, Kentucky, United States|Harry and Jeanette Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, PC, Bethesda, Maryland, United States|Cancer & Hematology Center of Western Michigan, Grand Rapids, Michigan, United States|Metro Minnesota CCOP-Unity Hospital, Fridley, Minnesota, United States|Metro Minnesota CCOP-St. Johns, Maplewood, Minnesota, United States|Metro Minnesota Community Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Metro Minnesota Community Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Metro Minnesota CCOP-Regions Hospital, Saint Paul, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Nebraska Hematology-Oncology, PC, Lincoln, Nebraska, United States|Hematology-Oncology Associates of Northern New Jersey, Morristown, New Jersey, United States|North Shore Hematology/Oncology Associates, East Setauket, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Gabrail Cancer Center, Dover, Ohio, United States|Toledo Clinical Cancer Center, Toledo, Ohio, United States|Mercy Cancer Center at St. Anne's, Toledo, Ohio, United States|Toledo Clinic Cancer Center-Toledo, Toledo, Ohio, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Northwest Cancer Specialists, PC, Tualatin, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Upstate Oncology Associates, Greenville, South Carolina, United States|South Carolina Cancer Specialists, Hardeeville, South Carolina, United States|South Carolina Cancer Specialists, Hilton Head Island, South Carolina, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Cancer Care Centers of South Texas-HOAST, New Braunfels, Texas, United States|Cancer Care Centers of South Texas-HOAST, San Antonio, Texas, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Saint Vincent Hospital Green Bay Oncology, Green Bay, Wisconsin, United States|Green Bay Oncology-St. Mary's Hospital MC, Green Bay, Wisconsin, United States|Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology), Innsbruck, Austria|Hospital Elisabethinen Linz, Internal Department 1 - Hemato-Oncology, Linz, Austria|Hanusch Hospital, Department of Internal Medicine III, Vienna, Austria|Saint Luc University Hospital, Department of Hematology, Brussels, Belgium|General Hospital Delta, Hematology Department, Roeselare, Belgium|General Hospital Turnhout, Hematology Department, Turnhout, Belgium|UMHAT ""Sveti Georgi"", Plovdiv, Clinical Hematology Clinic, Plovdiv, Bulgaria|UMHAT ""Sveti Georgi"", Plovdiv, Department of Medical Oncology, Plovdiv, Bulgaria|MHAT ""Tokuda Hospital Sofia"", Hematology Clinic, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Ivan Rilski"", Department of Clinical Hematology, Sofia, Bulgaria|Specialized Hospital For Active Treatment Of Hematological Diseases, Sofia, Clinical Hematology Clinic, Sofia, Bulgaria|MHAT Hristo Botev, Vratsa, First Department of Internal Medicine, Vratsa, Bulgaria|University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno, Czechia|University Hospital Hradec Kralove, 4th Department of Internal Medicne, Clinical Hematology, Hradec Kralove, Czechia|University Hospital Ostrava, Institute of Clinical Hematology, Ostrava, Czechia|University Hospital Kralovske Vinohrady, Department of Clinical Hematology, Prague, Czechia|General University Hospital in Prague, 1st Department of Internal Medicine - Department of Hematology, Prague, Czechia|Aalborg University Hospital, Department of Hematology, Aalborg, Denmark|Service d'hématologie clinique, Avenue Laennec Salouel, Amiens, Cedex 1, France|Centre hopitalier de la cote basque, Bayonne, France|Centre hospitalier de Beziers, Beziers, France|Polyclinique de Bordeaux nord Acquitaine, Bordeaux, France|Centre hospitalier du Mans, Le Mans Cedex 03, France|Centre hospitalier Lyon Sud, Pierre Benite Cedex, France|Saint Quentin Hospital Center, Department of Oncology-Hematology, Saint-Quentin, France|Hautepierre Hospital, Department of Hematology and Oncology, Strasbourg Cedex, France|Gemeinschaftspraxis Drs. Klausmann, Aschaffenburg, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Klinik für Innere Medizin III, Frankfurt (a.M.), Germany|Universitaetsklinikum Halle, Halle (Saale), Germany|St. Marien Hospital Hamm, Hamm, Germany|Universitätsklinik Köln, Köln, Germany|Klinikum Nürnberg Nord, Nürnberg, Germany|Klinikum Mutterhaus der Borromäerinnen, Trier, Germany|St. Istvan and St. Laszlo Hospital of Budapest, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Moritz Kaposi General Hospital, Kaposvár, Hungary|University Hospital ""Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi"", Ancona, Italy|Bologna University Hospital Authority St. Orsola-Malpighi Polyclinic, Bologna, Italy|Scientific Institute of Romagna for the Study and Treatment of Cancer (I.R.S.T.) S.R.L., Meldola, Italy|""Ospedali Riuniti Villa Sofia-Cervello"" Hospital, Palermo, Italy|Romagna Local Health Authority (AUSL Romagna) - ""Santa Maria delle Croci"", Ravenna, Italy|Romagna Local Health Authority (AUSL Romagna) - ""Infermi"" Hospital, Rimini, Italy|Siena University Hospital Authority Santa Maria alle Scotte Polyclinic, Siena, Italy|Santa Maria Hospital, Terni, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy|Independent Public Healthcare Facility Municipal Hospital Group, Chorzów, Poland|Marine Hospital of Polish Red Cross, Department of Chemotheraphy, Gdynia, Poland|Silesia Medical University, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland|Malopolskie Medical Center S.C. , Department of Hematology, Krakow, Poland|Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz, Lodz, Poland|Oncology Center of Lublin Land, Department of Clinical Oncology, Lublin, Poland|Institute of Hematology and Transfusion Medicine, Clinic of Hematology, Warsaw, Poland|Wroclaw Medical University, Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw, Poland|Rapid Diagnosis Polyclinic SA, Brasov, Romania|Fundeni Clinical Institute Center for Hematology and Bone Marrow Transplantation, Bucharest, Romania|Bucharest University Emergency Hospital, Hematology Clinic, Bucharest, Romania|State Budget Healthcare Institution of Sverdlovsk region: Sverdlovsk Regional Clinical Hospital #1, Ekaterinburg, Russian Federation|Federal State Public Institution: Main Military Clinical Hospital n.a. N.N. Burdenko of the Russian Ministry of Defense, Moscow, Russian Federation|Moscow State Budget Medical Institution: City Clinical Hospital n.a. S.P.Botkin, Moscow, Russian Federation|State Medical Institution: Republican Hospital named after V.A. Baranov, Petrozavodsk, Russian Federation|St. Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care, St. Petersburg, Russian Federation|State Healthcare Institution: Republican Clinical Oncology Center, Ufa, Russian Federation|University Hospital with Outpatient Clinic F.D. Roosevelt Banska Bystrica, Department of Hematology, Banska Bystrica, Slovakia|National Cancer Institute, Department of Hematology and Transfusiology, Bratislava, Slovakia|University Hospital Martin, Department of Hematology and Transfusiology, Martin, Slovakia|J. A. Reiman University Hospital with Polyclinic in Presov, Presov, Slovakia|A Coruña University Hospital, A Coruña, Spain|Hospital Universitario Vall Hebrón, Barcelona, Spain|Hospital Iniversitario Puerta del Mar, Cadiz, Spain|Institut Català de Oncologia (ICO), Hospital Dr Trueta, Girona, Spain|Hospital Iniversitario La Paz, Madrid, Spain|Hospital Universitario Araba, Vitoria, Spain|Cherkasy Regional Oncology Center, Regional Treatment and Diagnostic Hematology Center, Cherkasy, Ukraine|Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine|National Institute of Cancer, Kyiv, Ukraine|State Institution: Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine|Beatson West of Scotland Cancer Center, Glasgow, United Kingdom|St. George's Healthcare NHS Trust, London, United Kingdom|Christie Hospital, Department of Medical Oncology, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT01321541"
521,"NCT01144403","A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.",,"Terminated","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mitoxantrone|Drug: Rituximab","Overall Response Rate (ORR)|Overall Survival (OS)|Progression-free Survival (PFS)|Number of Participant With Adverse Event (AE)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML22489|2009-011433-27","June 2010","August 2014","August 2014","June 15, 2010","August 29, 2016","October 18, 2016","Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Iasi, Romania|Targu-mures, Romania|Timisoara, Romania","","https://ClinicalTrials.gov/show/NCT01144403"
522,"NCT01649856","A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Lymphoma, Large B-Cell, Diffuse","Drug: CHOP|Drug: rituximab [MabThera/Rituxan]","Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu)|Cancer Treatment Satisfaction Questionnaire (CTSQ) Domain Scores|Rituximab Administration Satisfaction Questionnaire (RASQ) Domain Scores|Median Duration of Rituximab Administration for Each Treatment Cycle|Percentage of Participants by Time Spent in the Infusion Chair/Bed for Each Treatment Cycle|Percentage of Participants by Time Spent in the Hospital for Each Treatment Cycle|Number of Participants With an Event-Free Survival (EFS) Event|Duration of EFS|Number of Participants With Relapse or Death at the Time of Primary Analysis|Duration of Disease-Free Survival (DFS)|Number of Participants With Progression, Relapse, or Death|Duration of Progression-Free Survival (PFS)|Number of Deaths|Duration of Overall Survival (OS)","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","572","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO28107|2012-000669-19","August 24, 2012","October 21, 2014","September 16, 2016","July 25, 2012","February 12, 2016","October 11, 2017","EHS CAC Hospital FRANTZ FANON ZABANA BLIDA; Hematology ward, Blida, Algeria|Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie, Tizi Ouzou, Algeria|Cemic; Haematology, Buenos Aires, Argentina|Hospital Privado de Comunidad; Oncology, Mar Del Plata, Argentina|Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|CHU Brugmann (Victor Horta), Bruxelles, Belgium|Clin Univ de Bxl Hôpital Erasme, Bruxelles, Belgium|CHU Charleroi-ISPPC-Espace Santé, Charleroi, Belgium|CHU de Charleroi, Charleroi, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Gent, Gent, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|AZ Turnhout Sint Elisabeth, Turnhout, Belgium|CHR de Verviers - East Belgium, Verviers, Belgium|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CE, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Clinicas Oncologicas Integradas - COI, Rio De Janeiro, RJ, Brazil|Hospital Giovanni Battista - Mae de Deus Center; Instituto do Cancer, Porto Alegre, RS, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Hospital das Clinicas - FMUSP; Hematologia, Sao Paulo, SP, Brazil|University Hospital Sv.Georgi Clnic of Hematology; Hematology, Plovdiv, Bulgaria|Military Medical Academy; Hematology And Oncology, Sofia, Bulgaria|UMHAT Alexandrovska EAD; Hematology, Sofia, Bulgaria|Lion'S Gate Hospital, North Vancouver, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Regional health authority A vitalite health network, Moncton, New Brunswick, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, Canada|Southlake Regional Health Center; Community Care Clinic / Oncology, Newmarket, Ontario, Canada|Toronto East General Hospital; Haematology/Oncology, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, Canada|Clínica Imbanaco; Oncology, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Middle Finland Central Hospital, Jyväskylä, Finland|Oulu University Hospital; Oncology, Oulu, Finland|Tampere University Hospital; Dept of Oncology, Tampere, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, Finland|Ch Victor Dupouy; Hematologie, Argenteuil, France|Hopital Augustin Morvan; Hematologie, Brest, France|Ch Du Mans; Medecine Hematologie Oncologie, Le Mans, France|Centre ONCOGARD - Institut de Cancerologie du Gard, Nimes, France|Ch De Saint Quentin; Medecine B10, Saint Quentin, France|Hopital Sud; Hematologie Clinique, Salouel, France|Hopital Yves Le Foll; Hematologie Oncologie, St Brieuc, France|Clinique Ste Anne, Strasbourg, France|Hopital Hautepierre; Hematologie Oncologie, Strasbourg, France|Hia Sainte Anne; Medecine Interne Oncologie, Toulon, France|University General Hospital of Alexandroupolis; Haemotology, Alexandroupolis, Greece|General Hospital of Athens Evangelismos; Hematology, Athens, Greece|Laiko General Hospital; Hematology Clinic, Athens, Greece|Metropolitan Hospital; Hematology Dept, Athens, Greece|Periph. University General Hospital of Heraklion; Hematology, Heraklion, Greece|University Hospital of Ioannina; Hematology, Ioannina, Greece|University Hospital Of Patras; Dept. Of Internal Medicine-Hematology Division, Patras, Greece|Theagenio Anticancer Hospital; Dept. of Haematology, Thessaloniki, Greece|Georgios Papanikolaou Hospital; Hematology Department, Thessaloniki, Greece|Cork Uni Hospital; Oncology Dept, Cork, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Galway Uni Hospital; Oncology Dept, Galway, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Haemek Medical Center; Hematology Department, Afula, Israel|Rambam Medical Center; Heamatology & Bone Marrow Transplantation, Haifa, Israel|Wolfson Mc; Haematology, Holon, Israel|Shaare Zedek Medical Center; Hematology Dept., Jerusalem, Israel|Meir Medical Center; Heamatology Dept, Kfar Saba, Israel|Beilinson Medical Center; Haematology, Petach Tikva, Israel|Chaim Sheba Medical Center; Hematology BMT & CBB, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Ichilov Sourasky Medical Center; Heamatology, Tel Aviv, Israel|Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia, Pescara, Abruzzo, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia, Rimini, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|AOU Ospedali Riuniti; Ematologia, Trieste, Friuli-Venezia Giulia, Italy|Uni Cattolica; Divisione Di Ematologia, Roma, Lazio, Italy|Az. Osp. Sant'Andrea; U.O. C. Ematologia, Roma, Lazio, Italy|ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy|ASST DI CREMONA; U.O.S. di Ematologia, Cremona, Lombardia, Italy|Ospedale Di Circolo E Fondazione Macchi; Ematologia, Varese, Lombardia, Italy|Ospedale Civile; S.C. Ematologia, Pesaro, Marche, Italy|A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia, Torrette Di Ancona, Marche, Italy|Ospedale Mauriziano Umberto I, Torino, Piemonte, Italy|Az. Osp. G. Moscati; U.O. Do Ematologia, Taranto, Puglia, Italy|Ospedale Oncologico A Businco-Cagliari; Ematologia Sez., Cagliari, Sardegna, Italy|Azienda Ospedaliero Uni Ria Policlinico G. Martino; U.O. Di Oncologia Medica, Messina, Sicilia, Italy|Casa Di Cura La Maddalena; Oncoematologia E Trapianto Del Midollo Osseo, Palermo, Sicilia, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia, Padova, Veneto, Italy|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Meander Medisch Centrum; Locatie Lichtenberg, Amersfoort, Netherlands|Deventer Ziekenhuis; Interne Geneeskunde, Deventer, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Maxima Medisch Centrum; Inwendige Geneeskunde, Eindhoven, Netherlands|Groene Hart Ziekenhuis Bleulandlocatie; Inwendige Geneeskunde, Gouda, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Atrium Medisch Centrum, Heerlen, Netherlands|Spaarne Ziekenhuis; Inwendige Geneeskunde, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden; Interne, Leeuwarden, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus Mc - Locatie Centrum; Dept of Hematology, Rotterdam, Netherlands|Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed, Rotterdam, Netherlands|Maasstad ziekenhuis, Rotterdam, Netherlands|Zuyderland ziekenhuis locatie Geleen, Sittard-Geleen, Netherlands|Isala Klinieken, Locatie Sophia; Inwendige Geneeskunde, Zwolle, Netherlands|Hospital Nacional Almanzor Aguinaga Asenjo; Unidad De Investigacion Del Servicio De Oncologia Medica, Chiclayo, Peru|Instituto;Oncologico Miraflores, Lima, Peru|Oncosalud Sac; Oncología, Lima, Peru|Katedra i Klinika Hematologii i Transplantacji Szpiku SUM, Katowice, Poland|Swietokrzyskie Centrum Onkologii; Onkologia Ogolna, Kielce, Poland|Malopolskie Centrum Medyczne, Krakow, Poland|Szpital Wojewodzki w Opolu, Oddzial Hematologii i Onkologii Hematologicznej, Opole, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka; Oddział Chorób Wewnetrznych/Hematologiczny, Slupsk, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|HUC; Servico de Hematologia, Coimbra, Portugal|Hospital Santo Antonio dos Capuchos; Servico de Hemato-Oncologia, Lisboa, Portugal|Hospital de Santa Maria; Servico de Hematologia e Transplantacao de Medula, Lisboa, Portugal|IPO do Porto; Servico de Onco-Hematologia, Porto, Portugal|Hospital de Sao Joao; Servico de Hematologia Clinica, Porto, Portugal|Regional Oncology Center, Chelyabinsk, Russian Federation|Central City Hospital #7; Hematology, Ekaterinburg, Russian Federation|Republican Clinical Oncologic Dispensary of Republic Of Tatarstan, Kazan, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|Rus Med Academy for Postgraduate Education; Oncology Department, Moscow, Russian Federation|Vladimirskiy Regional Scientific Research Inst. ; Hematology, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko; Hematology, Nizhny Novgorod, Russian Federation|Clinical MSCh No1, Perm, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|Riyadh Military Hospital, Riyadh, Saudi Arabia|Clinical Center Kragujevac;Center for Hematology, Kragujevac, Serbia|Clinic of Haematology Cc Nis, NIS, Serbia|National Hospital; Oncotherapy Dept, Bloemfontein, South Africa|Tygerberg Hospital; Haematology Department, Cape Town, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, South Africa|Hospital de Cabueñes; Servicio de Hematología y Hemoterapia, Gijon, Asturias, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Hematologia, Sabadell, Barcelona, Spain|Hospital Punta Europa; Servicio de Hematologia, Algeciras, Cadiz, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Hematologia, Santander, Cantabria, Spain|Hospital de Donostia; Servicio de Hematologia, San Sebastian, Guipuzcoa, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Hematologia, Las Palmas de Gran Canarias, Las Palmas, Spain|Hospital de Gran Canaria Dr. Negrin; Servicio de Oncologia, Las Palmas de Gran Canaria, Las Palmas, Spain|Hospital de Cruces; Servicio de Hematologia, Barakaldo, Vizcaya, Spain|Hospital General Univ. de Alicante; Servicio de Oncologia, Alicante, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Hematologia, Girona, Spain|Hospital Lucus Augusti; Servicio de Hematologia, Lugo, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Hematología, Madrid, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Madrid, Spain|Hospital Costa del Sol; Servicio de Hematologia, Malaga, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Universitario Dr. Peset; Servicio de Hematologia, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa; Servicio de Hematologia, Zaragoza, Spain|Hospital Universitario Miguel Servet; Servicio Hematologia, Zaragoza, Spain|King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Ramathibodi Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand|Cukurova Uni ; Hematology, Adana, Turkey|Diskapi Research And Training Hospital; hematology, Ankara, Turkey|Hacettepe Uni Medical Faculty; Hematology, Ankara, Turkey|Ankara University; Hematology, Ankara, Turkey|Gaziantep Uni Medical School; Hematology, Gaziantep, Turkey|Istanbul University Cerrahpasa Medical Faculty; Hematology Department, Istanbul, Turkey|Dokuz Eylul Uni ; Hematology, Izmir, Turkey|Ege Uni Medical School; Hematology, Izmir, Turkey|Erciyes Uni ; Hematology, Kayseri, Turkey|Ondokuzmayis University Medical Faculty Heamatology Department, Samsun, Turkey|Cumhuriyet Uni. Med. Fac.; Hematology, Sivas, Turkey|Karadeniz Technical Uni School of Medicine; Hematology, Trabzon, Turkey|Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU; Chair of Oncology and Medical Radiology, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncological Center; Chemotherapy Department, Kiev, Ukraine|State Oncology Regional Treatment-Diagnostic Center; Chemotherapy Department, Lviv, Ukraine|SOUTHMEAD HOSPITAL; Richard Bright Dialysis Centre, Bristol, United Kingdom|Ipswich Hospital; Oncology Pharmacy, Ipswich, United Kingdom|Macclesfield District General Hospital, Macclesfield, United Kingdom|Kings Mill Hospital, Sutton in Ashfield, United Kingdom|Singleton Hospital: Pharmacy Department, Swansea, United Kingdom|Instituto de Oncologia y Hematologia UCV, Caracas, Venezuela|Banco Municipal de Sangre; Hematología, Caracas, Venezuela","","https://ClinicalTrials.gov/show/NCT01649856"
523,"NCT00981097","Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma",,"Completed","No Results Available","Lymphoma|Nonneoplastic Condition","Genetic: polymerase chain reaction|Other: laboratory biomarker analysis","Proportion of patients with diffuse large B-cell/immunoblastic and Burkitt histologies with elevated serum free light chains (FLC)|Proportion of patients with Hodgkin lymphoma clonal immunoglobulin (Ig) DNA detection in the plasma|Agreement between the detection of a monoclonal Ig DNA spike in plasma and the detection of a monoclonal DNA spike in tumor tissue|Agreement between the fragment length of a spike in tumor tissue and the fragment length of the spike in plasma|Detection rate of elevated FLC in each histology, including diffuse large B-cell/immunoblastic and Burkitt lymphoma|Detection rate of clonal Ig DNA in each histology, including diffuse large B-cell/immunoblastic, Burkitt lymphoma, and Hodgkin lymphoma|Analysis of the clinical and pathologic correlates of detection by the serum/plasma tests: disease subtype, stage of disease, disease bulk, lactate dehydrogenase, and Ki67 index|Detection rate of clonotypic B cells in peripheral blood mononuclear cells from patients with Hodgkin lymphoma","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation","All","18 Years and older   (Adult, Older Adult)","","52","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AMC-064|U01CA121947|CDR0000648183","August 2009","June 2013","June 2013","September 22, 2009","null","August 29, 2014","Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States|University of California at Davis Center for Aids Research and Education Services, Sacramento, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Miami, Miami, Florida, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Boston University Cancer Research Center, Boston, Massachusetts, United States|Mallinckrodt Institute of Radiology at Washington University Medical Center, St. Louis, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St. Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia, Philadelphia, Pennsylvania, United States|Thomas Street Health Center, Houston, Texas, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|Benaroya Research Institute at Virginia Mason Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00981097"
524,"NCT02257567","A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma","Drug: Bendamustine|Drug: Obinutuzumab|Drug: Polatuzumab vedotin (Liquid)|Drug: Rituximab|Drug: Polatuzumab vedotin (Lyophilized)","Phase Ib: Percentage of Participants with Adverse Events|Phase II: Percentage of Participants with Complete Response (CR) According to Modified Lugano Criteria as Measured by Positron Emission Tomography (PET)/Computed Tomography (CT) Scan and Determined by Independent Review Committee (IRC)|Pharmacokinetics: Area Under Concentration-Time Curve (AUC) of Polatuzumab (lyophilized), Bendamustine, and Rituximab in Arm G|Pharmacokinetics: Maximum Concentration (Cmax) of Polatuzumab (lyophilized), Bendamustine, and Rituximab in Arm G|Pharmacokinetics: Systemic Clearance (CL) of Polatuzumab (lyophilized), Bendamustine, and Rituximab in Arm G|Pharmacokinetics: Steady-State Volume of Distribution (Vss) of Polatuzumab (lyophilized), Bendamustine, and Rituximab in Arm G|Arm G (Phase II NF Cohort): Percentage of Participants with Adverse Events|Percentage of Participants with CR According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by the Investigator|Percentage of Participants with CR or Partial Response (PR) According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by IRC and Investigator|Percentage of Participants with CR According to Modified Lugano Criteria as Measured by CT Scan and Determined by IRC and Investigator|Percentage of Participants with CR or PR According to Modified Lugano Criteria as Measured by CT Scan and Determined by IRC and Investigator|Percentage of Participants by Best Objective Response (BOR) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan only and Determined by the Investigator|Phase II: Percentage of Participants with Adverse Events|Phase Ib: Percentage of Participants with Anti-Drug Antibodies (ADAs) to Polatuzumab in Cohort 1A|Phase Ib: Percentage of Participants with ADAs to Polatuzumab and Obinutuzumab in Cohort 1B|Phase II: Percentage of Participants with ADAs to Polatuzumab in Arms A and C|Phase II: Percentage of Participants with ADAs to Polatuzumab and Obinutuzumab in Arms E and F|Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Rituximab in Cohort 1A (milligrams per milliliter [mg/mL])|Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Obinutuzumab in Cohort 1B (mg/mL)|Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Rituximab in Cohort 1A (hour * milligrams per milliliter [h*mg/mL])|Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Obinutuzumab in Cohort 1B (h*mg/mL)|Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Rituximab in Arms A and C (mg/mL)|Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Rituximab in Arms A and C (h*mg/mL)|Pharmacokinetics: Cmax of Bendamustine and Rituximab in Arms B and D (mg/mL)|Pharmacokinetics: AUC of Bendamustine and Rituximab in Arms B and D (h*mg/mL)|Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Obinutuzumab in Arms E and F (mg/mL)|Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Obinutuzumab in Arms E and F (h*mg/mL)|Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS)|Duration of Response (DOR) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan and Determined by IRC|Progression Free Survival (PFS) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan and Determined by IRC|Phase II NF Cohort: Percentage of Participants with CR According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by the Investigator|Phase II NF Cohort: Percentage of Participants with CR or PR According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by the Investigator|Phase II NF Cohort: Percentage of Participants with CR According to Modified Lugano Criteria as Measured by CT Scan only and Determined by the Investigator|Phase II NF Cohort: Percentage of Participants with CR or PR According to Modified Lugano Criteria as Measured by CT Scan only and Determined by the Investigator|Phase II NF Cohort: Percentage of Participants by BOR According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan only and Determined by the Investigator|Phase II NF Cohort: Percentage of Participants with ADAs to Polatuzumab (lyophilized) in Arm G","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO29365|2014-001361-28","October 15, 2014","May 29, 2018","July 12, 2021","October 6, 2014","null","August 2, 2018","Birmingham Hem-Onc-Montclair, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Clearview Cancer Institute, Huntsville, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|Univ of Colorado Canc Ctr, Aurora, Colorado, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Joliet Oncology-Hematology; Associates, Ltd., Joliet, Illinois, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Weinberg CA Inst Franklin Sq, Baltimore, Maryland, United States|St. Louis Univ Care Center, Saint Louis, Missouri, United States|Regional Cancer Care Associates LLC - Morristown, Morristown, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|New York University Cancer Cen, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Signal Point Clinical; Research Center, LLC, Middletown, Ohio, United States|West Clinic, Germantown, Tennessee, United States|Swedish Cancer Inst., Seattle, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Aurora Cancer Care, Milwaukee, Wisconsin, United States|Prince of Wales Hospital; Oncology, Randwick, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Monash Medical Centre; Haematology Research, Clayton, Victoria, Australia|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultní nemocnice Ostrava Klinika hematoonkologie, Ostrava, Czechia|I Interni klinika; Vseobecna fakultni nemocnice, Prague 2, Czechia|Chu Site Du Bocage;Hematologie Clinique, Dijon, France|Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut J Paolii Calmettes; Onco Hematologie 1, Marseille, France|CHU Saint Eloi; Service d'Hématologie Clinique, Montpellier, France|CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique, Nantes, France|CHU Lyon Sud - Service Hématologie, Pierre Benite, France|Centre Henri Becquerel; Hematologie, Rouen, France|Charité Research Organisation GmbH, Berlin, Germany|Vivantes Klinikum Am Urban, Berlin, Germany|HELIOS Klinikum Erfurt - Innere Medizin - 4. Medizinische Klinik, Hämatologie, Erfurt, Germany|Universitätsmedizin Greifswald; Innere Medizin C, Hämatologie/Onkologie, Greifswald, Germany|Asklepios Klinik St. Georg, Abteilung Hämatologie,Onkologie & Stammzelltransplantation, Hamburg, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Abt. für Hämatologie und Onkologie, Mainz, Germany|Universitätsklinikum Marburg Zentrum f. Innere Medizin, Marburg, Germany|Mühlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik für Hämatologie, Onkologie und Pallia., Minden, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Münster, Germany|Klinik der Uni Regensburg; Hämatologie/Onkologie, Studienzentrale, Regensburg, Germany|Semmelweis University, First Dept of Medicine, Budapest, Hungary|National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary|University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B, Debrecen, Hungary|Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica, Napoli, Campania, Italy|A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica, Udine, Friuli-Venezia Giulia, Italy|Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol, Roma, Lazio, Italy|A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia, Brescia, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia, Milano, Lombardia, Italy|Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia, Alessandria, Piemonte, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|UMCG - Groningen; Hematology, Groningen, Netherlands|UMC St. Radboud; Hematology, Nijmegen, Netherlands|VUMC, NL -amsterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona; Hematology, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Sevilla, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Ankara University; Hematology, Ankara, Turkey|Osmangazi University Medical School; Hematology, Eskisehir, Turkey|Dokuz Eylul Uni ; Hematology, Izmir, Turkey|Ondokuzmayis University Medical Faculty Heamatology Department, Samsun, Turkey|Karadeniz Technical Uni School of Medicine; Hematology, Trabzon, Turkey|The HOPE Clinical Trials Unit, Leicester, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom|Southampton General Hospital; Somers Cancer Research Building, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT02257567"
525,"NCT02776891","A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse|Burkitt Lymphoma","Radiation: Gallium citrate","Uptake of radiotracer in tumor tissue|Comparing Gallium citrate uptake","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UCSF CC#16251","May 2016","December 2018","December 2019","May 18, 2016","null","January 23, 2018","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02776891"
526,"NCT02855359","Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma",,"Terminated","No Results Available","Diffuse, Large B-Cell, Lymphoma|Follicular Lymphoma, Grade 3b|Transformed Lymphoma / DLBCL","Drug: denintuzumab mafodotin|Drug: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Part B Outcome Measure: Complete Response Rate (CR)|Part A and Part B Outcome Measure: Incidence of adverse events|Part A and Part B Outcome Measure: Incidence of laboratory abnormalities|Event-free survival (EFS) between study arms in Part B.|Progression-free survival (PFS) between study arms in Part B.|Overall survival (OS) between study arms in Part B.|Objective response rate (ORR) at End Of Treatment (EOT) between study arms in Part B.|Duration of objective response and of complete response (CR) between study arms in Part B.","Seattle Genetics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN19A-004","August 2016","January 2018","May 15, 2018","August 4, 2016","null","July 9, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Saint Bernards Cancer Center, Jonesboro, Arkansas, United States|City of Hope, Duarte, California, United States|Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University of Colorado Health Memorial Hospital, Colorado Springs, Colorado, United States|Poudre Valley Hospital Harmony Campus, Fort Collins, Colorado, United States|Central Georgia Cancer Care, Macon, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Hattiesburg Clinic (Forrest General Hospital), Hattiesburg, Mississippi, United States|Research Medical Center, Kansas City, Missouri, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Montefiore Medical Center - Bronx, Bronx, New York, United States|Mount Sinai Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Regional Medical Oncology Center, Wilson, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Tennessee Oncology / Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor Health - Baylor University Medical Center, Dallas, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Scott and White Memorial Hospital - Temple, Temple, Texas, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Vista Oncology INC PS, Olympia, Washington, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Ponce Medical School Foundation, Ponce, Puerto Rico","","https://ClinicalTrials.gov/show/NCT02855359"
527,"NCT00851552","Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment",,"Terminated","Has Results","Lymphoma","Biological: rituximab|Drug: bortezomib|Drug: pegylated liposomal doxorubicin hydrochloride|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Genetic: proteomic profiling|Other: flow cytometry|Other: laboratory biomarker analysis","Antitumor Efficacy in Terms of Overall, Complete, and Partial Response Rates and Time to Progression at Weeks 9 and 21|Safety","Roswell Park Cancer Institute|Ortho Biotech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000635486|RPCI-I-136508","January 2009","September 2011","September 2011","February 26, 2009","July 21, 2014","July 21, 2014","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT00851552"
528,"NCT01131208","Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab",,"Completed","No Results Available","Lymphoma","Genetic: gene expression analysis|Other: laboratory biomarker analysis","Identification of genes predictive of clinical outcome|Identification of genes that change their prognostic profile with the addition of rituximab to CHOP chemotherapy","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","60 Years to 120 Years   (Adult, Older Adult)","","200","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000671515|ECOG-E4494T2","April 21, 2010","August 21, 2010","August 21, 2010","May 26, 2010","null","May 17, 2017","","","https://ClinicalTrials.gov/show/NCT01131208"
529,"NCT02964858","Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.","DOBL","Recruiting","No Results Available","NonHodgkin Lymphoma","Radiation: Standard Arm|Radiation: Experimental Arm","Event Free Survival|Local Control Rate|Overall Survival|Overall response rate|Late toxicity|Acute toxicity|Quality of Life scores","Tata Memorial Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","840","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Project No-1627","November 2016","November 2022","June 2023","November 16, 2016","null","February 23, 2017","Tata Memorial Center, Mumbai, Maharashtra, India","","https://ClinicalTrials.gov/show/NCT02964858"
530,"NCT01926665","Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","No Results Available","Lymphoma","Drug: Carfilzomib|Drug: Dexamethasone","Maximum Tolerated Dose (MTD) of Carfilzomib (CFZ) After Autologous Stem Cell Transplantation (ASCT)|Efficacy of Carfilzomib (CFZ) After Autologous Stem Cell Transplantation (ASCT)","M.D. Anderson Cancer Center|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-1070|NCI-2014-00994","June 17, 2014","September 17, 2017","September 17, 2017","August 21, 2013","null","September 19, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01926665"
531,"NCT01351935","Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia",,"Completed","No Results Available","B Cell Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia","Drug: AVL-292","Safety, tolerability,and dose limiting toxicities will be determined using AEs,PE,ophthalmologic examinations,clinical laboratory tests,vital signs, ECGs and echocardiograms/MUGA scans.|Establish recommended Phase 2 dose, after completing dose escalation in Part 1 and evaluating accumulated safety,PK,and PD data from the dose escalation phase (Part1)|Evaluate the Pharmacokinetic parameters of AVL-292|Evaluate the Pharmacodynamics of AVL-292 by measurement of free Btk|Characterize preliminary anti-tumor efficacy of AVL-292 in relapsed and/or refractory B-NHL, CLL and WM","Celgene Corporation|The Leukemia and Lymphoma Society|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","113","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVL-292-003","July 2011","June 2015","June 2015","May 11, 2011","null","August 27, 2015","Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama, United States|University of Arizona (SPORE), Tucson, Arizona, United States|University of California San Diego, LaJolla, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Horizon Oncology Center, LaFayette, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mount Sinai School of Medicine and Mount Sinai Graduate School of Biological Sciences, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Sciences Center, San Antonio, Texas, United States|US Oncology, The Woodlands, Texas, United States","","https://ClinicalTrials.gov/show/NCT01351935"
532,"NCT02920697","Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leukaemia (CLL)|B-Cell Non-Hodgkin Lymphoma (NHL)|Multiple Myeloma (MM)","Drug: S 55746","Maximum Tolerated Dose (MTD)|Incidence of Adverse Events (AEs)|Plasma concentration of S 55746|The pharmacokinetic (PK) profile of S 55746: Area Under the Curve [AUC]|The PK profile of S 55746: Maximal Concentration [Cmax]|Apoptotic activity from blood samples|Objective Response Rate (ORR)|Clinical Benefit Rate (CBR)|Duration of response|Progression Free Survival (PFS)","Institut de Recherches Internationales Servier|Servier","All","18 Years and older   (Adult, Older Adult)","Phase 1","65","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CL1-55746-001|2013-003779-36|ISRCTN04804337","March 2014","September 2018","September 2018","September 30, 2016","null","March 15, 2018","The Alfred Hospital Malignant Haematology & Stem Cell Transplantation Services, Melbourne, Australia|Hopital Claude Huriez, Lille, France|CHU de Nantes, Nantes, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|Gustave Roussy, Villejuif, France|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Städtisches Klinikum Schwabing, Munich, Germany|Universitätsklinikum Ulm, Ulm, Germany|National Oncology Institute, Budapest, Hungary|CRU Hungary Kft, Miskolc, Hungary|Severance Hospital, Seoul, Korea, Republic of|St. Mary's Hospital, Seoul, Korea, Republic of|Warsaw Institute of Oncology, Warsaw, Poland|Warsaw Medical University, Warsaw, Poland|National Cancer Center (NCC), Singapore, Singapore|National University Cancer Institute Singapore, Singapore, Singapore|University College London Hospitals, London, United Kingdom|Freeman Hospital, Newcastle, United Kingdom","","https://ClinicalTrials.gov/show/NCT02920697"
533,"NCT00156013","Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)",,"Completed","Has Results","Lymphoma, B-Cell|Lymphoma, Non-Hodgkin","Drug: CLOFARABINE","Phase I Maximum Tolerated Dose|Phase II Overall Response|Toxicity","Oncology Specialists, S.C.|Genzyme, a Sanofi Company","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1066306 (0408)","September 2005","April 2010","April 2010","September 12, 2005","July 9, 2012","November 29, 2017","Oncology Specialists, SC, Park Ridge, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00156013"
534,"NCT02038933","Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)",,"Active, not recruiting","Has Results","Lymphoma. Non-Hodgkin","Drug: Nivolumab","Objective Response Rate (ORR) Per Independent Radiologic Review Committee (IRRC) Assessment|Duration of Response (DOR)|Complete Remission Rate|Duration of Complete Remission|Rate of Partial Remission|Duration of Partial Remission|Progression Free Survival|Objective Response Rate (ORR) Per Investigator Assessment","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","161","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-139|2013-003621-28","February 10, 2014","April 8, 2016","September 1, 2018","January 17, 2014","May 30, 2017","May 7, 2018","Mayo Clinic Arizona, Phoenix, Arizona, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Center, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Woodville, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, B-leuven, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Creteil, France|Local Institution, Montpellier Cedex 05, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Homburg, Germany|Local Institution, Ulm, Germany|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Hospitalet Llobregat- Barcelona, Spain|Local Institution, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom","","https://ClinicalTrials.gov/show/NCT02038933"
535,"NCT00136591","A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma",,"Terminated","No Results Available","Follicular Lymphoma","Drug: Bortezomib","To determine the response rate to Velcade™ as a single agent|To determine the overall complete response (CR) rate (CR + complete response unconfirmed [CRu])|To determine time to progression (TTP)|To determine overall survival|To determine duration of response|To determine the time to best response|To evaluate the safety and tolerability of Velcade™|To evaluate the effects of Velcade™ given biweekly at 1.5 mg/m2 versus 1.6 mg/m2 weekly","Lymphoma Study Association|Janssen-Cilag International NV","All","18 Years and older   (Adult, Older Adult)","Phase 2","87","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FL05-1|Janssen: 28866138-LYM-2003|Eudrac: 2005-000734-21","September 2005","January 2010","January 2010","August 29, 2005","null","October 26, 2010","Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT00136591"
536,"NCT01014208","Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma","ORCHARRD","Completed","Has Results","Lymphoma, Large-Cell, Diffuse","Drug: OFATUMUMAB + DHAP|Drug: RITUXIMAB + DHAP","Progression-free Survival as Assessed by Independent Reviewers|Number of Participants With Overall Response (OR) and Complete Response (CR) After Salvage Chemoimmunotherapy|Number of Participants With Overall Response (OR) and Complete Response (CR) Three Months After Autologous Stem Cell Transplant|Event-free Survival|Overall Survival (OS)|Number of Participants With the Ability to Mobilize at Least 2 Million Cluster of Differentiation (CD)34+ Cells Per Kilogram From Peripheral Blood|Number of Participants Completing Autologous Stem Cell Transplant (ASCT)|Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) During Treatment|Change From Baseline in the Functional Assessment of Cancer Therapy Lymphoma Trial Outcome Index (FACT-Lym TOI) Total Score During Treatment|Time to Neutrophil and Platelet Recovery After Each Cycle of Salvage Chemotherapy|Time to Engraftment After High-dose Therapy (HDT)/ASCT","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","447","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110928","March 2010","February 2014","November 2014","November 16, 2009","October 16, 2014","August 7, 2015","GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Westwood, Kansas, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Chaple Hill, North Carolina, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Graz, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Wien, Austria|GSK Investigational Site, Wien, Austria|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Hasselt, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Yvoir, Belgium|GSK Investigational Site, Fuzhou, Fujian, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Nanjing, Jiangsu, China|GSK Investigational Site, Jianan, Shandong, China|GSK Investigational Site, Hangzhou, Zhejiang, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Chengdu, China|GSK Investigational Site, Jiang Su Province, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Brno, Czech Republic|GSK Investigational Site, Hradec Kralove, Czech Republic|GSK Investigational Site, Aarhus, Denmark|GSK Investigational Site, Koebenhavn, Denmark|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Oulu, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Kaposvár, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Szombathely, Hungary|GSK Investigational Site, Ludhiana, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Vellore, India|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Galway, Ireland|GSK Investigational Site, James Street, Ireland|GSK Investigational Site, Petach-Tikva, Israel|GSK Investigational Site, Ramat Gan, Israel|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Akita, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nagasaki, Japan|GSK Investigational Site, Okayama, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tochigi, Japan|GSK Investigational Site, Tokushima, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Jellanamdo, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Amersfoort, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Enschede, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Hoofddorp, Netherlands|GSK Investigational Site, Leiden, Netherlands|GSK Investigational Site, Maastricht, Netherlands|GSK Investigational Site, Nieuwegein, Netherlands|GSK Investigational Site, Nijmegen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Sittard-geleen, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Zwolle, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Chorzow, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, Pozuelo de Alarcón/Madrid, Spain|GSK Investigational Site, Salamanca, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Lund, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Blackpool, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Cheltenham, United Kingdom|GSK Investigational Site, Edinburgh, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Headington, Oxford, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Northwood, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Southampton, United Kingdom|GSK Investigational Site, Whitchurch, Cardiff, United Kingdom|GSK Investigational Site, Wolverhampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01014208"
537,"NCT00644124","Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma",,"Completed","No Results Available","Lymphoma, Non-Hodgkin","Drug: aflibercept","selected dose of aflibercept based on Dose Limiting Toxicities observed|Adverse events|Response rate|Progression free survival|Biomarkers","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD10173|EudraCT 2007-003737-16","March 2008","October 2011","October 2011","March 26, 2008","null","May 6, 2016","Sanofi-Aventis Administrative Office, Paris, France","","https://ClinicalTrials.gov/show/NCT00644124"
538,"NCT00445341","Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Lymphoma","Drug: Flavopiridol","Number of Participants With Adverse Events (e.g. Toxicity)|Response Rate (Complete Response (CR) and Partial Response (PR))","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","28","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","070081|07-C-0081","November 27, 2006","April 30, 2012","October 18, 2012","March 9, 2007","October 5, 2012","January 30, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT00445341/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT00445341/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00445341"
539,"NCT00135499","R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","Lymphoma, Large-Cell, Diffuse","Drug: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vindesine|Drug: Bleomycin|Drug: Prednisone|Drug: Vincristine","event free survival|complete response rate|progression rate|relapse rate|disease-free survival for complete responders|overall survival|neuromeningeal relapse rate|number of SAE","Lymphoma Study Association|Fondation ARC","All","60 Years to 65 Years   (Adult, Older Adult)","Phase 3","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH01-5B","October 16, 2001","April 27, 2010","April 27, 2010","August 26, 2005","null","August 23, 2018","Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium|Hôpital Henri Mondor, Créteil, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland","","https://ClinicalTrials.gov/show/NCT00135499"
540,"NCT01555541","Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Diffuse Large Cell Lymphoma Relapsed/Refractory","Drug: Ofatumumab|Drug: Etoposide|Drug: Cytarabine","Number of patients achieving complete response to the treatment upon successful stem cell mobilization|Time to neutrophil and platelet engraftment following successful stem cell mobilization|Progression free survival following treatment with Ofatumumab in combination with etoposide and high-dose ara-C (OVA) and subsequent autologous stem cell transplantation","C. Babis Andreadis|University of California, San Francisco|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","112525","June 2012","June 2018","June 2019","March 15, 2012","null","June 9, 2017","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT01555541"
541,"NCT00140660","ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","Diffuse Large Cell Lymphoma","Drug: rituximab","Event-free survival (EFS)|Response rate at the end of the treatment|Disease-free survival for complete responders|Overall survival|additionnal toxicities with R-ACVBP","Lymphoma Study Association|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","223","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH03-1B","December 2003","July 2008","April 2012","September 1, 2005","null","March 13, 2017","Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium|Hôpital Henri Mondor, Créteil, France|Hématologie CHU de Lille, Lille, France|Hôpital Saint Louis, Paris, France|Hématologie Adultes - Hôpital Necker, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Hématologie CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Centre Pluridisciplinaire d'Oncologie, CHUV, Lausanne, Switzerland","","https://ClinicalTrials.gov/show/NCT00140660"
542,"NCT00971763","Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: gemcitabine hydrochloride|Drug: prednisolone|Drug: vincristine sulfate","Overall response rate|Toxicity|Progression-free survival|Overall survival","University College, London","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000644293|UCL/05/154|2005-003888-23|EU-20951","March 2006","July 2011","July 2011","September 4, 2009","null","December 4, 2014","Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom|Leeds General Infirmary, Leeds, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Cancer Research UK and University College London Cancer Trials Centre, London, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT00971763"
543,"NCT00829205","Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment",,"Withdrawn","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Dietary Supplement: Se-methyl-seleno-L-cysteine|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Other: laboratory biomarker analysis|Other: pharmacological study","Dose-limiting toxicity and maximum tolerated dose of Se-methyl-seleno-L-cysteine (MSC) (Phase I)|Overall response rate (Phase II)|Toxicity as assessed by NCI CTCAE v 3.0|Serum and intracellular Se and Se species|Pharmacokinetics of MSC|Protein markers of selenium activity","Cancer Research UK|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000632722|CRUK-UCL-SelRICE|EUDRACT-2008-002678-36|EU-20902","January 2009","null","null","January 26, 2009","null","August 26, 2013","Barts and the London NHS Trust, London, England, United Kingdom|Saint Bartholomew's Hospital, London, England, United Kingdom|Christie Hospital, Manchester, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT00829205"
544,"NCT00144807","ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Diffuse Large Cell Lymphoma","Drug: rituximab|Drug: doxorubicin|Drug: cyclophosphamide|Procedure: autologous stem cell transplantation","Complete remission rate (CR + CRu)|Event-free survival and overall survival of patients submitted to autologous transplant and of the entire study population","Lymphoma Study Association","All","18 Years to 59 Years   (Adult)","Phase 2","128","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH03-3B","December 2003","September 2008","April 2012","September 5, 2005","null","September 2, 2015","Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium|Polyclinique Bordeaux Nord, Bordeaux, France|Hôpital Henri Mondor, Créteil, France|Hématologie CHU de Lille, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital Saint Louis, Paris, France|Hématologie Adultes - Hôpital Necker, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Hématologie CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland","","https://ClinicalTrials.gov/show/NCT00144807"
545,"NCT00950755","Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology",,"Completed","Has Results","Lymphoma, Non-Hodgkin","Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)","Number of Participants (Par.) With Response as Assessed by the Investigator|Number of Participants With Confirmed Response as Assessed by the Investigator|Number of Participants With Confirmed Complete Response (CR) as Assessed by the Investigator|Number of Participants With Confirmed Complete Response Plus Clinical Complete Response (CR + CCR) as Assessed by the Investigator|Number of Participants With Confirmed Partial Response (PR) as Assessed by the Investigator|Duration of Response for All Confirmed Responders (CR, CCR, or PR) as Assessed by the Investigator|Time to Progression of Disease or Death as Assessed by the Investigator|Time to Treatment Failure as Assessed by the Investigator|Overall Survival|Number of Participants With the Indicated Adverse Events (AE) Possibly or Probably Related to Study Drug and Experienced by at Least 5% of Participants|Number of Participants With the Indicated Serious Adverse Events (SAE) Related to Study Drug|Number of Participants With the Indicated Type of Infection|Number of Participants With an Infection for Which Anti-infectives Were Administered|Duration of the Indicated Grade 3 or Grade 4 Hematologic Toxicities|Time to Nadir and Time to Recovery to Baseline in Hematologic Laboratory Evaluations|Nadir Values for Hematologic Parameters ANC, Platelets, and WBC Count|Nadir Values for Hemoglobin, a Hematologic Parameter|Number of Participants Who Became Positive or Negative for Human Anti-murine Antibody (HAMA) After Study Treatment|Time to HAMA Positivity From First Dosimetric Dose|Number of Participants in the Indicated Categories of Thyroid Function Assessment|Number of Days Each Participant Took to Reach Hypothyroidism After the First Dosimetric Dose","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","104505","June 1998","April 2011","April 2011","August 3, 2009","August 29, 2012","January 18, 2017","","","https://ClinicalTrials.gov/show/NCT00950755"
546,"NCT00066508","Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy",,"Completed","No Results Available","Lymphoma","Drug: bortezomib","Overall response rate (combined complete response and partial response)|Safety|Tolerability|Time to disease progression|Possible mechanism of resistance","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000316254|UCLA-0301090","May 2003","July 2005","null","August 7, 2003","null","January 8, 2013","Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00066508"
547,"NCT00137995","R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Lymphoma, Large-Cell, Diffuse","Drug: Rituximab|Drug: Etoposide|Drug: Carboplatine|Drug: Ifosfamide + Mesna|Drug: Cisplatine|Drug: Cytosine Arabinoside|Drug: Dexamethasone|Procedure: Autologous Stem Cell Transplantation|Drug: BCNU|Drug: Cytarabine|Drug: Melphalan","MARR (mobilization adjusted response rate)|EFS (event free survival)|Progression rate|Overall survival|Duration of response","Lymphoma Study Association","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","481","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CORAL","June 2003","October 2008","October 2008","August 30, 2005","null","March 13, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States|Australian leukemia and lymphoma group, Sydney, Australia|Groupe d'atude des lymphome de l'adulte, Yvoir, Belgium|Czech Lymphoma study group, Praha, Czech Republic|Hospital district of south west Finland, Turku, Finland|German high grade non hodgkin's lymphoma group, Hamburg, Germany|Israel Society of Hematology, Tel-Hashomer, Israel|Nordic center, Uppsala, Sweden|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland|National cancer research institute, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00137995"
548,"NCT01410630","FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma",,"Suspended","No Results Available","Lymphoma|Lymphoma, Non-Hodgkin|Large B Cell Diffuse Lymphoma","Diagnostic Test: FLT-PET/CT|Diagnostic Test: FDG-PET/CT|Drug: FLT","Positive Predictive Value (PPV) of 3'-deoxy-3'-[F-18]-fluorothymidine (FLT) Positron emission tomography (PET/CT) versus Fluorodeoxyglucose (FDG)PET/CT|Overall survival after initiation of therapy","Jonsson Comprehensive Cancer Center|National Institutes of Health (NIH)","All","Child, Adult, Older Adult","Not Applicable","137","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LYMIMG0001|SU-07072011-8046|19997|17-001275|JCCCID811","September 1, 2018","October 1, 2023","October 1, 2024","August 5, 2011","null","August 14, 2018","University of California at Los Angeles, Los Angeles, California, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|MD Anderson Cancer Center - University of Texas, Houston, Texas, United States|Aachen University, Aachen, Germany","","https://ClinicalTrials.gov/show/NCT01410630"
549,"NCT00301821","Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Lymphoma","Biological: epratuzumab|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Event-free Survival After 12 Months|Overall Survival|Progression-free Survival (PFS)|Overall Response Rate (ORR)","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","107","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCCTG-N0489|NCI-2012-02685|CDR0000459932","January 2006","October 2008","April 2015","March 13, 2006","March 24, 2015","August 1, 2016","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Aurora Presbyterian Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|CCOP - Colorado Cancer Research Program, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center, Grand Junction, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States|St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Galesburg Clinic, Galesburg, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States|Kewanee Hospital, Kewanee, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Trinity Medical Center - East, Moline, Illinois, United States|Moline, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|St. Margaret's Hospital, Spring Valley, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Reid Hospital & Health Care Services, Incorporated, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Southwest Medical Center, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Haematology-Oncology Associates of Ohio and Michigan, PC, Lambertville, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|Alexandria, Minnesota, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Fergus Falls, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Meeker County Memorial Hospital, Lichfield, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Chippewa County - Montevideo Hospital and Medical Center, Montevideo, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|HealthEast Cancer Care at St. Joseph's Hospital, St Paul, Minnesota, United States|CentraCare Clinic - River Campus, St. Cloud, Minnesota, United States|Park Nicollet Cancer Center, St. Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, St. Paul, Minnesota, United States|United Hospital, St. Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|HealthEast Cancer Care at Woodwinds Health Campus, Woodbury, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Immanuel Medical Center, Omaha, Nebraska, United States|Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Fremont Memorial Hospital, Fremont, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|St. Luke's Hospital, Maumee, Ohio, United States|Middletown Regional Hospital, Middletown, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Firelands Regional Medical Center, Sandusky, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|AnMed Cancer Center, Anderson, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Hematology-Oncology Associates of Fredericksburg, Incorporated, Fredericksburg, Virginia, United States|Franciscan Skemp Healthcare - La Crosse Campus, La Crosse, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00301821"
550,"NCT00898157","Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494",,"Completed","No Results Available","Lymphoma","Other: laboratory biomarker analysis","Correlation of biomarkers with response and outcome","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","60 Years to 120 Years   (Adult, Older Adult)","","1600","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000571530|ECOG-E4494T1","September 24, 2007","September 24, 2008","September 24, 2008","May 12, 2009","null","May 19, 2017","","","https://ClinicalTrials.gov/show/NCT00898157"
551,"NCT00140595","ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1",,"Completed","No Results Available","Diffuse Large-Cell Lymphoma","Drug: rituximab|Drug: doxorubicin|Drug: cyclophosphamide","Event-free survival (EFS), events defined as death from any cause, relapse for complete responders (CR) and unconfirmed complete responders (CRu), progression during or after treatment, changes of therapy during allocated treatment.|Response rate at the end of the treatment, progression rate, relapse rate, disease-free survival for complete responders, overall survival, neuromeningeal relapse rate and additional toxicities with ACVBP+rituximab combination","Lymphoma Study Association|Amgen","All","18 Years to 59 Years   (Adult)","Phase 3","380","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH03-2B","December 2003","January 2009","January 2009","September 1, 2005","null","March 4, 2011","Groupe d'étude des lymphomes de l'adulte, Yvoir, Belgium|Hôpital Henri Mondor, Créteil, France|Centre Léon Bérard, Lyon, France|Hôpital Saint Louis, Paris, France|Hématologie Adultes - Hôpital Necker, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Hématologie CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT00140595"
552,"NCT02631044","Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",,"Recruiting","No Results Available","Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle-cell Lymphoma|Primary Mediastinal B-cell Lymphoma","Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule|Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule","Treatment-related adverse events (AEs) as assessed by CTCAE v4.03|Dose-limiting toxicities of JCAR017|Objective response rate (ORR)|Complete response (CR) rate|Duration of response|Progression-free survival (PFS)|Overall survival|Health-related quality of life|Maximum concentration of JCAR017 (Cmax) in the peripheral blood|Time to maximum concentration of JCAR017 (Tmax) in the peripheral blood|Area-under-the-concentration-vs-time-curve (AUC) in the peripheral blood","Juno Therapeutics, Inc.|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","274","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","017001","December 2015","December 2020","December 2020","December 15, 2015","null","June 8, 2018","University of Alabama-Birmingham, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Blood Marrow Transfer Group of Georgia - Northside Hospital, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02631044"
553,"NCT00169130","ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma, Large-Cell, Diffuse","Drug: doxorubicin|Drug: cyclophosphamide|Procedure: Autologous stem cell transplantation","Event free survival.|Complete response rate at the end of treatment.|Disease-free survival for complete responders.|Overall survival.","Lymphoma Study Association|Fondation ARC","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH98-B2","October 1999","null","null","September 15, 2005","null","July 13, 2007","Service d'Hematologie, Mont-Godinne, Belgium|Hôpital Henri Mondor, Creteil, France|Hôpital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Centre Henri Becquerel, Rouen, France","","https://ClinicalTrials.gov/show/NCT00169130"
554,"NCT02128945","Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies","FLUDATEP","Completed","No Results Available","Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients","Other: [18F] - Fludarabine PET/CT","Standardized measure of [18F]-Fludarabine uptake in tumor tissue.|Calculation of the equivalent dose to all organs and evaluation of effective dose to the whole body","University Hospital, Caen|CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2013-002796-18|13-090","April 2014","April 2016","May 2016","May 1, 2014","null","September 14, 2016","University Hospital, Caen, France","","https://ClinicalTrials.gov/show/NCT02128945"
555,"NCT01224821","Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies","RIT-II-001","Completed","Has Results","Lymphoma, Non-Hodgkin","Biological: Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab","Number of Participants Who Received the Therapeutic Dose at the Seven Clinical Research Sites|Number of Participants With the Indicated Therapeutic Doses (TD) (Total Body Dose)|Number of Participants (Par.) With Response (CR, CCR, or PR), as Assessed by the Investigator|Number of Participants With Confirmed Response (CR, CCR, or PR), as Assessed by the Investigator|Number of Participants With CR and CCR, as Assessed by the Investigator|Number of Participants With Confirmed CR and CCR, as Assessed by the Investigator|Duration of Response for All Confirmed Responders (CR, CCR, or PR), as Assessed by the Investigator|Duration of Response for All Unconfirmed Responders (CR, CCR, or PR), as Assessed by the Investigator|Duration of Response for All Confirmed Complete Responders, as Assessed by the Investigator|Duration of Response for All Unconfirmed Complete Responders, as Assessed by the Investigator|Duration of Response for All Confirmed Clinical Complete Responders, as Assessed by the Investigator|Duration of Response for All Unconfirmed Clinical Complete Responders, as Assessed by the Investigator|Median Time to Treatment Failure for All Participants|Overall Survival|Time to Disease Progression or Death for Responders, as Assessed by the Investigator|Time to Disease Progression or Death for All Participants, as Assessed by the Investigator","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","47","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","104731","December 1995","November 1997","May 2008","October 20, 2010","April 17, 2012","December 12, 2016","","","https://ClinicalTrials.gov/show/NCT01224821"
556,"NCT00308087","Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma","PREMIER","Terminated","Has Results","Lymphoma, Follicular","Drug: Sargramostim (Leukine)|Drug: Rituximab","Number of Participants With a Complete Response or Unconfirmed Complete Response at Week 8 With Confirmation at Week 12|Summary of Treatment-Emergent Adverse Events (TEAE)|Participant Summary of Best Response Across All Visits|Kaplan-Meier Estimates of Progression-Free Survival|Kaplan-Meier Estimates for Duration of Partial Response or Better to Treatment|Summary of Cost Effectiveness","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","310421|91499|PREMIER","May 2006","June 2009","June 2009","March 29, 2006","August 30, 2010","December 27, 2013","Birmingham, Alabama, United States|Huntsville, Alabama, United States|Los Angeles, California, United States|Montebello, California, United States|Pleasant Hill, California, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Ocala, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Springfield, Illinois, United States|Indianapolis, Indiana, United States|New Albany, Indiana, United States|Duluth, Minnesota, United States|Fresh Meadows, New York, United States|New York, New York, United States|Columbus, Ohio, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00308087"
557,"NCT00268853","A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin","RAPID","Completed","No Results Available","Diffuse Large-Cell Lymphoma","Drug: CPOP-R|Drug: CHOP-R","The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.|The secondary objective is to compare the overall survival, event free survival and cardiac safety of the 2 treatments. Other comparisons will include duration of response, overall objective response rate, and time to treatment failure (TTF).","CTI BioPharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PIX203","November 2005","May 2012","May 2012","December 23, 2005","null","January 19, 2015","Bay Medical Oncology & Hematology, Concord, California, United States|Hazel Hawkins Hospital, Dept. of Medical Oncology, Hollister, California, United States|UCSD Moore's Cancer Center-Blood & Marrow Transplantation Division, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Hematology/Oncology Group of Orange County, Orange, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|The Center of Hematology and Oncology, Boca Raton, Florida, United States|Broward Oncology Associates, Ft. Lauderdale, Florida, United States|Osceola Cancer Center, Kissimmee, Florida, United States|Watson Clinic for Cancer Care and Research, Lakeland, Florida, United States|Watson Clinic, Lakeland, Florida, United States|Memorial Cancer Institute, Pembroke Pines, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States|Oncology Hematology Associates of West Broward, Tamarac, Florida, United States|Hematology Oncology Specialists, Tampa, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Columbus Clinic, Columbus, Georgia, United States|Oncology Hematology of Northern Illinois, Gurnee, Illinois, United States|Mid-Illinois Hematology & Oncology Associates, Normal, Illinois, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Western Kentucky Hematology/Oncology Group, Paducah, Kentucky, United States|Our Lady of the Lake Regional Medial Center, Hematology Oncology, Baton Rouge, Louisiana, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Maryland Hematology/Oncology Associates, PA, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, P.C., Bethesda, Maryland, United States|Frederick Memorial Hospital Cancer Center, Frederick, Maryland, United States|Tufts-New England Medical Center-The Neely Ctr for Clinical Cancer Research, Boston, Massachusetts, United States|Hubert H Humphrey Cancer Center, Robbinsdale, Minnesota, United States|North Missssppi Hematology Oncology Associates, Tupelo, Mississippi, United States|Capital Comprehensive Cancer Care, Jefferson City, Missouri, United States|Southeast Nebraska Hematology and Oncology Consultants, P.C., Lincoln, Nebraska, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|New Mexico Hematology/Oncology Consultants, Albuquerque, New Mexico, United States|Jacobi Medical Center Phase I Oncology, Bronx, New York, United States|Our Lady of Mercy Medical Center, Bronx, New York, United States|Cancer Care Center, New Albany, New York, United States|St. Luke's Roosevelt Hospital, New York City, New York, United States|Interlake Foundation, Inc., Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Brody School of Medicine at East Carolina University - Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States|Cancer Treatment & Research Mid-Dakota Clinic, Bismark, North Dakota, United States|Summa Health Systems Hospitals, Akron, Ohio, United States|Barberton Citizen's Hospital, Barberton, Ohio, United States|Oncology Partners Network, Cincinnati, Ohio, United States|Dayton Clinical Oncology Program, Dayton, Ohio, United States|Northwest Kaiser Permanente, Portland, Oregon, United States|Berks Hematology-Oncology Associates Ltd., Reading, Pennsylvania, United States|Charleston Cancer Center, Charleston, South Carolina, United States|Low County Hematology & Oncology, Mount Pleasant, South Carolina, United States|The Family Cancer Center, Collierville, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Southwest Regional Cancer Center, Austin, Texas, United States|Texas Hematology Oncology Center, Dallas, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Northern Utah Hematology Oncology, P.C., Ogden, Utah, United States|Multicare Oncology Hematology Specialists, Tacoma, Washington, United States|London Health Science Center Regional Care Program, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Queen Elizabeth II HSC, Halifax, Canada|CHU Hotel Dieu, Nantes, France|Hopitaux Universitaires de Strabourg - Hopital Hautepierre, Strasbourg, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Duesseldorf, Duesseldorf, Germany|Klinikum der Universitaet zu Koeln, Koeln, Germany|Klinikum Nurnberg Nord - Medizinische, Nuernberg, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, Germany|Instituto di Ematologia ""Lorenzo e Ariosto"", Bologna, Italy|Azienda Ospedaliera Careggi, Firenze, Italy|Farmacia Osepdaliera, Odpedale Umberto I, Mestre, Italy|Ospedal V. Cervello, Palermo, Italy|Uiversita La Sapienza, Roma, Italy|Policlinico S. Maria alle Scotte, Siena, Italy|Ospedale Civile, Udine, Italy","","https://ClinicalTrials.gov/show/NCT00268853"
558,"NCT00144755","R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Diffuse Large Cell Lymphoma","Drug: Darbepoetin alfa","Efficacy of R-CHOP 14 vs R-CHOP 21 measured by event-free survival (EFS)|Efficacy of darbepoetin alfa in association with chemotherapy measured by the EFS.|Efficacy and toxicity of R-CHOP 14 vs R-CHOP 21|Efficacy and toxicity of Darbepoetin alfa in association with R-CHOP.","Lymphoma Study Association|Amgen","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 3","600","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH03-6B","December 2003","December 2012","December 2012","September 5, 2005","null","September 2, 2015","Université de Gent, Gent, Belgium|Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium|Polyclinique Bordeaux Nord, Bordeaux, France|Hôpital Henri Mondor, Créteil, France|Hématologie CHU de Lille, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital Saint Louis, Paris, France|Hématologie Adultes - Hôpital Necker, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Hématologie CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland","","https://ClinicalTrials.gov/show/NCT00144755"
559,"NCT00193505","Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma",,"Completed","No Results Available","Non-Hodgkins Lymphoma","Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide|Drug: Rituximab|Drug: 90Y Zevalin","complete response rate|progression-free survival|overall survival","SCRI Development Innovations, LLC|Biogen","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LYM 27|106-P092","October 2003","August 2005","August 2005","September 19, 2005","null","May 3, 2011","Tennessee Oncology, PLLC, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00193505"
560,"NCT00544219","PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Procedure: positron emission tomography","Event-free survival|Overall survival during follow-up|Objective response|Positron emission tomography (PET) results|Histological results of remaining PET-positive lesion(s) after treatment","Swiss Group for Clinical Cancer Research","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","156","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAKK 38/07|SWS-SAKK-38-07|EU-20763|EUDRACT-2007-001806-26|CDR0000569869","September 2007","September 2012","January 2016","October 16, 2007","null","June 15, 2016","European Institute of Oncology, Milan, Italy|Hirslanden Klinik Aarau, Aarau, Switzerland|Kantonspital Aarau, Aarau, Switzerland|Kantonsspital Baden, Baden, Switzerland|Praxis Dr. Streit, Baden, Switzerland|Saint Claraspital AG, Basel, Switzerland|Universitaetsspital-Basel, Basel, Switzerland|Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Bruderholz, Bruderholz, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland|Kantonsspital Liestal, Liestal, Switzerland|Kantonsspital Olten, Olten, Switzerland|Praxis Dr. Beretta, Rheinfelden, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland|Regionalspital, Thun, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT00544219"
561,"NCT03410004","Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma",,"Not yet recruiting","No Results Available","Experimental","Drug: Chidamide","objective response rate（ORR）|Disease Control Rate （DCR）|progression-free survival（PFS）|overall survival（OS）","Chinese Academy of Medical Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSIIT-B07","January 25, 2018","September 30, 2019","September 30, 2020","January 25, 2018","null","January 25, 2018","","","https://ClinicalTrials.gov/show/NCT03410004"
562,"NCT00435916","Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin","Drug: SGN-40","Objective response as assessed by CT and PET scans and revised response criteria for malignant lymphoma.|Progression-free survival, disease-free survival, and overall survival.|Adverse events, laboratory values, and anti-drug antibody immune responses.|PK profile.","Seattle Genetics, Inc.|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SG040-0004","December 2006","January 2009","January 2009","February 16, 2007","null","January 7, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic-Arizona, Scottsdale, Arizona, United States|University of California Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Sharp Healthcare, San Diego, California, United States|Georgetown University, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Mayo Clinic-Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Weill Medical College of Cornell University, New York, New York, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|Swedish Cancer Institute, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00435916"
563,"NCT00307177","Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma",,"Completed","No Results Available","Influenza","Biological: Trivalent inactivated influenza vaccine|Biological: Trivalent Baculovirus-expressed Influenza HA vaccine","","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","04-036","August 2004","April 2005","April 2005","March 27, 2006","null","December 5, 2014","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00307177"
564,"NCT00324831","GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Suspended","No Results Available","Lymphoma","Drug: autologous immunoglobulin idiotype-KLH conjugate vaccine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: rituximab|Drug: sargramostim|Drug: vincristine|Procedure: Intervention/procedure|Procedure: antibody therapy|Procedure: biological therapy|Procedure: chemotherapy|Procedure: colony-stimulating factor therapy|Procedure: cytokine therapy|Procedure: monoclonal antibody therapy|Procedure: non-specific immune-modulator therapy|Procedure: therapeutic procedure|Procedure: tumor cell derivative vaccine|Procedure: vaccine therapy","Disease-free survival as measured by the Kaplan-Meier method at 3 years|Disease-free survival as measured by the Kaplan-Meier method at 2 years|Duration of response (complete or partial response)|Overall disease-free survival","Favrille|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","480","Industry","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","CDR0000466677|FAV-ID-11|FAV-WIRB-20051774","null","null","null","May 11, 2006","null","December 18, 2013","Tower Cancer Research Foundation, Beverly Hills, California, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00324831"
565,"NCT03153462","Axicabtagene Ciloleucel Expanded Access Study","ZUMA-9","Available","No Results Available","Relapsed/Refractory Diffuse Large B Cell Lymphoma|Relapsed/Refractory Primary Mediastinal B Cell Lymphoma|Relapsed/Refractory Transformed Follicular Lymphoma|Relapsed/Refractory High-Grade B-Cell Lymphoma","Biological: Axicabtagene Ciloleucel","","Kite, A Gilead Company","All","18 Years and older   (Adult, Older Adult)","","null","Industry","Expanded Access":Treatment IND/Protocol","","KTE-C19-109","null","null","null","May 15, 2017","null","September 27, 2018","City of Hope, Duarte, California, United States|Stanford Cancer Institute, Stanford, California, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03153462"
566,"NCT03685344","Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",,"Not yet recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma","Drug: Loncastuximab Tesirine and Durvalumab","Safety and tolerability of loncastuximab tesirine in combination with durvalumab by frequency and severity of adverse events|Frequency and severity of serious adverse events (SAEs)|Incidence of dose limiting toxicities (DLTs) (dose escalation only)|Overall Response Rate (ORR)|Complete Response Rate CR|Duration of response (time from first tumor response to disease progression or death)|Overall survival (time between the start of treatment and death from any cause)","ADC Therapeutics S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADCT-402-104","November 30, 2018","July 8, 2020","July 6, 2022","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685344"
567,"NCT00457782","A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Multiple Myeloma|Chronic Lymphocytic Leukaemia|B-cell Non-Hodgkin's Lymphoma","Drug: KW-2478","To determine Safety & Tolerability by adverse event rates in order to determine recommended Phase II dose|Pharmacokinetics and Pharmacodynamics","Kyowa Hakko Kirin UK, Ltd.|Kyowa Kirin Pharmaceutical Development, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2478-EU-001","April 2007","August 2010","January 2011","April 6, 2007","null","February 1, 2011","St Bartholomew's Hospital, London, United Kingdom|UCLH, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Nottingham University NHS Trust, Nottingham, United Kingdom|Cancer Research UK Clinical Centre, Southampton, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom","","https://ClinicalTrials.gov/show/NCT00457782"
568,"NCT01239394","Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma",,"Completed","Has Results","Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma","Drug: ofatumumab","Efficacy: Complete Response Rate (CRR)|Overall Response Rate (ORR)|Progression-free Survival (PFS)|Toxicity: Infusion Reactions, Grade 3-4 Infections, and Neutropenia","Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-271","December 2010","March 2013","March 2015","November 11, 2010","March 17, 2017","October 18, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01239394"
569,"NCT00070083","Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: oblimersen sodium|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","","British Columbia Cancer Agency|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Older Adult)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000329985|BCCA-NCI-5818|NCI-5818","July 2003","null","null","October 7, 2003","null","April 7, 2009","Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States|British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada|Fraser Valley Cancer Centre at British Columbia Cancer Agency, Surrey, British Columbia, Canada|British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT00070083"
570,"NCT00588094","Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL",,"Completed","Has Results","Lymphoma|B-cell Non-Hodgkin's Lymphoma","Drug: Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant","Improve the Overall Response Rate","Memorial Sloan Kettering Cancer Center","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","03-075","October 2003","March 2010","March 2010","January 8, 2008","December 4, 2015","December 4, 2015","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00588094"
571,"NCT02073097","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Drug: carfilzomib|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis","Recommended Phase II dose (Phase I)|Progression Free Survival (Phase II)|Overall Survival (Phase II)|Complete Response Rate (Phase II)|Partial Response Rate (Phase II)","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE3413|NCI-2014-00249|P30CA043703","October 1, 2014","December 2018","December 2018","February 27, 2014","null","August 6, 2018","Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02073097"
572,"NCT02030834","Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas",,"Active, not recruiting","No Results Available","Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas","Biological: CART-19","Number of Adverse Events","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 13413, 818607","February 5, 2014","September 2018","August 2019","January 9, 2014","null","March 21, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02030834"
573,"NCT02281279","Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",,"Withdrawn","No Results Available","B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Biological: rituximab|Drug: lenalidomide|Drug: romidepsin|Other: laboratory biomarker analysis","MTD, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I)|Overall response rate (Phase II)|Adverse events profile, graded according to the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Toxicity profile, defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment (Phase I)|Response profile, defined to be a CR or PR noted as the objective status (Phase I)|CR rate (Phase II)|Survival time (Phase II)|PFS (Phase II)|Incidence of adverse events, graded according to the revised NCI CTCAE version 4.0 (Phase II)","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1288|NCI-2014-02186|RM-FOL-PI-0034|P30CA015083","October 2016","October 2020","null","November 3, 2014","null","August 11, 2016","","","https://ClinicalTrials.gov/show/NCT02281279"
574,"NCT00764517","Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma","Drug: Cladribine|Other: Laboratory Biomarker Analysis|Biological: Rituximab|Drug: Vorinostat","Objective Response Rate|Toxicities as Assessed Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Tolerability of Treatment|Progression-free Survival|Event-free Survival|Contribution (if Any) of DNA Methylation/Histone Deacetylation|Scientific Correlates","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","57","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00004180|NCI-2011-03737|4180|HEM-08002-L|CR00021415|P30CA069533","August 2008","January 2015","March 2017","October 2, 2008","November 13, 2017","December 11, 2017","OHSU Knight Cancer Institute, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00764517"
575,"NCT03135262","A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Follicular Lymphoma|Lymphoma, Large B-Cell, Diffuse","Drug: Idasanutlin|Drug: Obinutuzumab|Drug: Venetoclax|Drug: Rituximab","RP2D of Idasanutlin When Given in Combination With Obinutuzumab or Rituximab|RP2D of Venetoclax When Given in Combination With Obinutuzumab or Rituximab|Percentage of Participants With Dose-Limiting Toxicities (DLTs)|Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Complete Response (CR), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography-Computed Tomography (PET-CT) Scans Using Modified Lugano 2014 Criteria|Percentage of Participants With CR, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria|Percentage of Participants With CR, Determined by the IRC on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria|Percentage of Participants With CR, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria|Percentage of Participants With Objective Response, Determined by the IRC on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria|Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria|Percentage of Participants With Objective Response, Determined by the IRC on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria|Percentage of Participants With Objective Response at EOI, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria|Percentage of Participants With Objective Response During the Study, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria|Observed Serum Concentration of Obinutuzumab in Participants With FL|Observed Serum Concentration of Obinutuzumab in Participants With DLBCL|Observed Serum Concentration of Rituximab in Participants With FL|Observed Serum Concentration of Rituximab in Participants With DLBCL|Observed Plasma Concentration of Idasanutlin in Participants With FL|Observed Plasma Concentration of Idasanutlin in Participants With DLBCL|Observed Plasma Concentration of Venetoclax in Participants With FL|Observed Plasma Concentration of Venetoclax in Participants With DLBCL","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","140","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BH39147|2016-002480-34","June 15, 2017","October 27, 2022","October 27, 2022","May 1, 2017","null","September 17, 2018","University of Colorado, Aurora, Colorado, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Norton Cancer Institute - Dutchmans, Louisville, Kentucky, United States|Mount Sinai Medical Center, New York, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Sayre, Pennsylvania, United States|Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, United States|Swedish Cancer Inst., Seattle, Washington, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|Klinikum Augsburg, Augsburg, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Klinikum Kassel; Klinik für Onkologie und Hämatologie, Kassel, Germany|Universitätsklinikum Köln, Köln, Germany|Klinikum rechts der Isar der TU München, München, Germany|Universitätsklinikum Würzburg; Studienzentrale Hämatologie/Onkologie, Würzburg, Germany|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Christchurch Hospital, Christchurch, New Zealand|Auckland Clinical Studies Limited, Grafton, New Zealand","","https://ClinicalTrials.gov/show/NCT03135262"
576,"NCT00796731","SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma|Non-Hodgkin","Drug: SAR3419","Incidence of DLT(s) at each dose level|Cumulative DLT(s)|Incidence of Adverse Events and laboratory abnormalities|Tumor response (complete response, partial response) and duration of the response|Pharmacokinetics parameters","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED6829|EudraCT 2007-004868-41","October 2008","June 2012","June 2012","November 24, 2008","null","July 17, 2012","Sanofi-Aventis Investigational Site Number 250004, Creteil Cedex, France|Sanofi-Aventis Investigational Site Number 250006, Lille Cedex, France|Sanofi-Aventis Investigational Site Number 250001, Pierre Benite Cedex, France|Sanofi-Aventis Investigational Site Number 250005, Rennes, France|Sanofi-Aventis Investigational Site Number 250003, Rouen Cedex, France|Sanofi-Aventis Investigational Site Number 250002, Villejuif Cedex, France","","https://ClinicalTrials.gov/show/NCT00796731"
577,"NCT01812005","Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Terminated","Has Results","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Drug: alisertib|Biological: rituximab|Other: laboratory biomarker analysis","Best Overall Response Rate (ORR) to Alisertib Alone|Overall Response Rate (ORR)|Overall Response Rate(ORR)|Complete Response Rate (CR)|Complete Response Rate|Overall Survival|Progression-free Survival","Ohio State University Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-12106|NCI-2012-02794","May 21, 2013","October 14, 2015","April 20, 2017","March 15, 2013","June 5, 2018","June 5, 2018","Emory University, Atlanta, Georgia, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01812005"
578,"NCT01980628","Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma",,"Completed","Has Results","Marginal Zone Lymphoma|B-cell Lymphoma","Drug: ibrutinib","ORR (Overall Response Rate)|DOR (Duration of Response)","Pharmacyclics LLC.|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-1121-CA","December 2013","July 2016","October 2, 2017","November 11, 2013","February 10, 2017","January 18, 2018","Site Reference ID/Investigator# 837, Tucson, Arizona, United States|Site Reference ID/Investigator# 047, Duarte, California, United States|Site Reference ID/Investigator# 377, Santa Monica, California, United States|Site Reference ID/Investigator# 763, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 033, Atlanta, Georgia, United States|Site Reference ID/Investigator# 370, Chicago, Illinois, United States|Site Reference ID/Investigator# 195, Detroit, Michigan, United States|Site Reference ID/Investigator# 350, New Hyde Park, New York, United States|Site Reference ID/Investigator# 745, New York, New York, United States|Site Reference ID/Investigator # 200, New York, New York, United States|Site Reference ID/Investigator # 407, New York, New York, United States|Site Reference ID/Investigator# 220, Hershey, Pennsylvania, United States|Site Reference ID/Investigator# 348, Seattle, Washington, United States|Site Reference ID/Investigator# 560, Ghent, Oost-vlaanderen, Belgium|Site Reference ID/Investigator# 737, Rouen Cedex 1, Haute-normandie, France|Site Reference ID/Investigator# 735, Paris Cedex 10, Ile-de-france, France|Site Reference ID/Investigator# 750, Lille Cedex, NORD Pas-de-calais, France|Site Reference ID/Investigator# 749, La Roche-sur-Yon Cedex 9, PAYS DE LA Loire, France|Site Reference ID/Investigator# 736, Nantes cedex 1, PAYS DE LA Loire, France|Site Reference ID/Investigator# 142, Pierre Bénite Cedex, Rhone-alpes, France|Site Reference ID/Investigator# 742, Rennes cedex 9, France|Site Reference ID/Investigator# 669, Mainz, Rheinland-Pfalz, Germany|Site Reference ID/Investigator# 030, Manchester, England, United Kingdom|Site Reference ID/Investigator# 814, Oxford, England, United Kingdom|Site Reference ID/Investigator# 368, Plymouth, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT01980628"
579,"NCT01193842","Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas",,"Active, not recruiting","Has Results","AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|CD20 Positive|HIV Infection|Plasmablastic Lymphoma|Primary Effusion Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage II Grade 3 Contiguous Follicular Lymphoma|Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma|Stage IV Grade 3 Follicular Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate|Drug: Vorinostat","Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)|Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)|Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)|Change in CD8 Cell Counts (Phase I)|Changes in Absolute CD4 Cell Counts (Phase I)|Changes in Epstein-Barr Virus (EBV) Viral Load|Changes in Human Herpes Virus (HHV)-8 Viral Load|Changes in Human Immunodeficiency Virus (HIV) Viral Load|Event-free Survival (EFS) (Phase II)|Overall Survival (OS) (Phase II)|Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)|Pharmacokinetic Clearance (Phase I)|Tumor Response (Phase I)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","107","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2011-02508|AMC #75|CDR0000683379|AMC-075|UM1CA121947","October 6, 2010","November 12, 2016","October 14, 2021","September 2, 2010","June 12, 2018","June 12, 2018","Jackson Hospital and Clinic, Montgomery, Alabama, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Veterans Administration-San Diego Medical Center, San Diego, California, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Jackson Memorial Hospital-Holtz Children's Hospital, Miami, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Stroger Hospital of Cook County MBCCOP, Chicago, Illinois, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|AIDS Malignancy Consortium, Rockville, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Washington University - Jewish, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Memorial Sloan Kettering-Rockefeller Outpatient Pavilion, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Miriam Hospital, Providence, Rhode Island, United States|Thomas Street Clinic, Houston, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01193842"
580,"NCT00622388","Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant",,"Completed","Has Results","Lymphoma, Large-Cell, Diffuse","Drug: Ofatumumab","Number of Participants With Objective Response|Number of Participants Classified as Responders and Non-responders for Objective Response|Duration of Response|Progression-free Survival (PFS)|Time to Next Diffuse Large B-Cell Lymphoma (DLBCL) Therapy|Overall Survival (OS)|Number of Participants With Positive Human Anti-human Antibodies (HAHA) at Screening and at Visits 12, 13, 14, and 18|Median Percent Change From Baseline in CD45+CD19+ and CD45+CD20+ Cells in the Peripheral Blood at the Indicated Visits|Number of Participants Who Experienced at Least One Adverse Event (AE)|Percent Change From Screening in Complement (CH50) Levels|AUC(0-inf) and AUC(0-168) for Ofatumumab at the Eighth Infusion|Cmax and Ctrough for Ofatumumab at the First and Eighth Infusions|Half-life (T1/2) for Ofatumumab at the Eighth Infusion|Clearance (CL) of Ofatumumab at the Eighth Infusion|Volume of Distribution at Steady State (Vss) of Ofatumumab at the Eighth Infusion","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","111776|GEN415","December 2007","May 2010","August 2014","February 25, 2008","September 8, 2011","July 24, 2015","GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00622388"
581,"NCT01994850","A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas",,"Active, not recruiting","No Results Available","CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Positive Diffuse Large B-cell Lymphoma or CD30 Positive Grey Zone Lymphoma","Drug: brentuximab vedotin","Number of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","32","Other","Interventional","Primary Purpose: Treatment","UPCC 17413","November 2013","July 2017","null","November 26, 2013","null","July 6, 2017","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01994850"
582,"NCT00945724","Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis","IELSG30","Recruiting","No Results Available","Large B-cell Diffuse Lymphoma of Testis","Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate","Adverse events assessments|Activity of the drugs","International Extranodal Lymphoma Study Group (IELSG)","Male","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG30|EudraCT Number 2009-011789-26","April 2009","July 2017","December 2019","July 24, 2009","null","February 28, 2018","A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Spedali Civili, Brescia, Italy|Ematologia Ospedale Businco, Cagliari, Italy|S. Martino Hospital, Genova, Italy|European Institute of Oncology, Milan, Italy|San Raffaele H Scientific Institute, Milan, Italy|Policlinico, Modena, Italy|A.O. San Gerardo, Monza, Italy|AOU Maggiore della Carità, Novara, Italy|S. Matteo, Pavia, Italy|Ospedale Civile, Piacenza, Italy|U.O. Ematologia AUSL Ravenna, Ravenna, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|IFO Regina Elena, Roma, Italy|Policlinico Universitario Campus Biomedico, Roma, Italy|Università La Sapienza, Rome, Italy|Humanitas, Rozzano, Italy|Azienda Ospedaliero-Universitaria, Sassari, Italy|A.O. S. Maria, Terni, Italy|A.O.U. San Giovanni Battista-Molinette, S.C. Ematologia 2, Torino, Italy|Ospedale di Circolo Fondazione Macchi, Varese, Italy|IOSI, Bellinzona, Switzerland","","https://ClinicalTrials.gov/show/NCT00945724"
583,"NCT00783367","Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas",,"Active, not recruiting","No Results Available","Follicular Lymphoma|Marginal Zone B-Cell Lymphoma|MALT Lymphoma|Lymphoma of Mucosa-Associated Lymphoid Tissue|Lymphoma, Small Lymphocytic|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma","Drug: lenalidomide-low dose dexamethasone plus rituximab|Drug: Lenalidomide + Rituximab","Response rate to lenalidomide-dexamethasone + rituximab therapy in relapsed small B-cell lymphoma with rituximab resistance|Time until progression after lenalidomide-dexamethasone + rituximab therapy in relapsed small B-cell lymphomas with rituximab resistance|Compare the response rate for the previous rituximab-containing regimen to that obtained subsequently to lenalidomide-dexamethasone + rituximab therapy|Determine the toxicity profile of lenalidomide-dexamethasone + rituximab therapy in patients who have received a previous rituximab-containing combination regimen","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 02408|UPenn IRB#807684|RV-NHL-PI-0296","July 2008","December 2013","null","October 31, 2008","null","January 25, 2017","University of Pennsylvania; Abramson Cancer Center; Lymphoma Program, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00783367"
584,"NCT02220842","A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Drug: Atezolizumab|Drug: Obinutuzumab|Drug: Tazemetostat","Percentage of Participants With Dose Limiting Toxicities (DLTs)|Recommended Phase 2 Dose (RP2D) of Atezolizumab|Obinutuzumab Minimum Serum Concentration (Cmin)|Percentage of Participants With Adverse Events (AEs) Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)|Percentage of Participants With Anti-therapeutic Antibody Response to Atezolizumab and Obinutuzumab|Atezolizumab Maximum Serum Concentration (Cmax)|Atezolizumab Minimum Serum Concentration (Cmin)|Obinutuzumab Maximum Serum Concentration (Cmax)|Percentage of Participants With Best Overall Response According to Lugano Classification|Percentage of Participants With Objective Response (Complete Response or Partial Response) According to Lugano Classification|Progression Free Survival (PFS) According to Lugano Classification|Overall Survival (OS)|Duration of Objective Response (DOR) According to Lugano Classification|Tazemetostat Plasma Concentrations","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","92","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO29383|2014-001812-21","December 18, 2014","May 1, 2019","May 1, 2019","August 20, 2014","null","August 7, 2018","Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|UW- Fred Hutchinson Cancer Center, Seattle, Washington, United States|Hopital Claude Huriez - CHU Lille; Service des maladies du sang, Lille, France|Hopital Saint Eloi, Montpellier, France|Hôpital Saint-Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut Gustave Roussy, Villejuif, France|Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin; Hematology and Oncology, Berlin, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Barts Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02220842"
585,"NCT03132584","Cyclophosphamide and Alemtuzumab In Lymphoma",,"Recruiting","No Results Available","Non Hodgkin Lymphoma|High-grade B-cell Lymphoma|CD52 Positive Non-Hodgkin Lymphoma|DLBCL or High-grade B-cell Lymphoma NOS","Drug: Cyclophosphamide|Drug: Alemtuzumab","MTD of Cyclophosphamide and Alemtuzumab|Overall Response Rate|Complete Response Rate|Progression Free Survival|Overall Survival|Response Rate","Dana-Farber Cancer Institute|Genzyme, a Sanofi Company|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-034","July 30, 2017","September 1, 2020","May 1, 2023","April 28, 2017","null","September 18, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03132584"
586,"NCT00901615","Lenalidomide and R-CHOP in B-cell Lymphoma","R2CHOP-1","Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma","Drug: Lenalidomide and R-CHOP","Incidence of Dose Limiting Toxicities|Complete response rate and Overall response rate at the end of treatment|Complete and Overall response rates after induction|Progression-Free Survival and Overall survival|Duration of response|Collection of adverse events","Lymphoma Study Association","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","108","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2CHOP-1","January 6, 2009","November 19, 2010","November 23, 2015","May 14, 2009","null","August 23, 2018","CHU de Dijon, Dijon, France|CHRU Lille, Lille, France|CHU Lyon Sud, Pierre Benite, France|Centre Henri Becquerel, Rouen, France|CHU Brabois, Vandoeuvre les Nancy, France","","https://ClinicalTrials.gov/show/NCT00901615"
587,"NCT00290472","CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","Has Results","B-cell Chronic Lymphocytic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Malignant Neoplasm|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Drug: temsirolimus","Objective Overall Response Rate|Duration of Response|Overall Survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","89","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00047|CDR0000365314|NCI-6199|12983A|6199|N01CM62201|N01CM62202|P30CA014599","March 2004","April 2010","April 2010","February 13, 2006","February 11, 2014","May 23, 2014","University of Chicago, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Evanston Hospital CCOP, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Adventist La Grange Memorial Hospital, La Grange, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Oncology Care Associates PLLC, Saint Joseph, Michigan, United States|M D Anderson Cancer Center, Houston, Texas, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00290472"
588,"NCT01004718","Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)",,"Unknown status","No Results Available","Lymphoma","Radiation: Fludeoxyglucose F18|Procedure: Computed Tomography|Procedure: Positron emission tomography","Amount of lesional FDG uptake (assessed by qualitative assessment, standardized uptake value (SUV), and lesion to background uptake ratios)|Rate of change of lesional FDG uptake (measured by change in SUV)|Characteristics of lesional SUV frequency histograms (e.g., mean, standard deviation, full-width-half-maximum (FWHM), etc.) and/or lesional SUV heterogeneity maps, along with changes in these characteristics|Effect of lesion size (e.g., lesions = 3 cm) on primary outcome variables.|Effect of lesion location on primary outcome variables (e.g., nodal vs extranodal)|Effect of imaging delay time of PET image acquisition upon number of lymphomatous lesions detected","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UPCC 21408|NCI-2009-01348","May 2009","July 2013","null","October 30, 2009","null","September 20, 2016","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01004718"
589,"NCT01889069","A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)",,"Active, not recruiting","No Results Available","Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone|Drug: Bendamustine","Percentage of Participants with Administration-Associated Reactions (AAR)|Percentage of Participants with AEs|Event-Free Survival (EFS) According to International Working Group (IWG) Response Criteria|Progression-Free Survival (PFS) According to IWG Response Criteria|Overall Survival (OS)|Disease-Free Survival (DFS) According to IWG Response Criteria|Percentage of Participants with Complete Response (CR) According to IWG Response Criteria|FL: Plasma Concentration of Rituximab|DLBCL: Plasma Concentration of Rituximab|DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab|DLBCL: Maximum Plasma Concentration (Cmax) of Rituximab|DLBCL: Apparent Total Clearance (CL/F) of Rituximab|Percentage of Participants by Responses to Rituximab Administration Satisfaction Questionnaire (RASQ)","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","161","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML28881|2013-000647-12","July 31, 2013","June 15, 2019","June 15, 2019","June 28, 2013","null","September 11, 2018","Irccs Crob, Rionero in Vulture, Basilicata, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli; Unità Operativa di Ematologia, Reggio Calabria, Calabria, Italy|Azienda Ospedaliera S.G. Moscati; Divisione Ematologia, Avellino, Campania, Italy|Asl ce - p.o. Avers; Uoc ematologia, Aversa, Campania, Italy|A.O. San Sebastiano; U.O.C. Oncologia, Caserta, Campania, Italy|Seconda università degli studi di napoli; Medicina clinica e sperimentale magrassi - lanzara, Napoli, Campania, Italy|Osp. Santa Maria Goretti; Ematologia, Latina, Lazio, Italy|Ospedale S. Eugenio; Divisione Di Ematologia, Roma, Lazio, Italy|Regina Elena National Cancer Institute; Hematology, Roma, Lazio, Italy|Az. Osp. S. Camillo Forlanini; Uo Ematologia E Trapianti Di Midollo Osseo, Roma, Lazio, Italy|Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol, Roma, Lazio, Italy|Azienda Ospedaliera S. Giovanni Addolorata; UOC Ematologia, Roma, Lazio, Italy|ASL Viterbo; Presidio Ospedaliero di Ronciglione; UOC Ematologia, Ronciglione, Lazio, Italy|Ospedale Valduce;U.O.S. Oncologia Ed Ematologia, Como, Lombardia, Italy|ASST DI CREMA; U O Oncologia Medica, Crema, Lombardia, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|Az. Osp. Carlo Poma; Divisione Di Oncologia Medica, Mantova, Lombardia, Italy|Osp. San Raffaele; Dip. Di Oncoematologia, Milano, Lombardia, Italy|Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico, Milano, Lombardia, Italy|Irccs Policlinico San Matteo; Divisione Di Ematologia, Pavia, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Ospedale Gen.Le Prov.Le 'C.G.Mazzoni'; Ematologia, Ascoli Piceno, Marche, Italy|Ospedale di Civitanova Marche; Medicina Interna, Civitanova Marche, Marche, Italy|Ospedale di Macerata; Medicina Generale, Macerata, Marche, Italy|Università Cattolica Del Sacro Cuore S.S. Giovanni Paolo Ii; Uoc Di Onco-Ematologia, Campobasso, Molise, Italy|Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia, Alessandria, Piemonte, Italy|Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad, Novara, Piemonte, Italy|Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica, Bari, Puglia, Italy|Azienda ospedaliera oo rr di foggi; Hematology, Foggia, Puglia, Italy|Ospedale S.Nicola Pellegrino; Reparto Di Ematologia, Trani, Puglia, Italy|Ospedale Roberto Binaghi; Centro trapianti di midollo osseo, Cagliari, Sardegna, Italy|Osp. San Francesco; Ematologia e CTMO, Nuoro, Sardegna, Italy|ARNAS Garibaldi; Ematologia, Catania, Sicilia, Italy|Az. Osp. Papardo; Struttura Complessa Di Ematologia, Messina, Sicilia, Italy|ARNAS-Ospedale Civico Maurizio Ascoli; Unità Operativa di Oncologia Medica, Palermo, Sicilia, Italy|Azienda Uni Ria Policlinico P. Giaccone ; Divisione Di Ematologia E Trapianto, Palermo, Sicilia, Italy|Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy|USL 4 di Prato - Nuovo Ospeale di Prato, Prato, Toscana, Italy|A.O. Santa Maria Terni; S.C. Oncoematologia, Terni, Umbria, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy","","https://ClinicalTrials.gov/show/NCT01889069"
590,"NCT01063439","BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)",,"Unknown status","No Results Available","Non Hodgkin's Lymphoma","Drug: Busulfan, Etoposide, Cytarabine, Melphalan","progression-free survival|overall survival|Response rate according to the International Working Group criteria|Adverse events|•Pharmacogenetic study","Inje University","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BuEAM-DLBCL","January 2010","August 2014","February 2015","February 5, 2010","null","December 2, 2010","Inje University Busan Paik Hospital, Busan, Korea, Republic of|Asan Medical Center, University of Ulsan, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Yeonsei University Hospital, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01063439"
591,"NCT01539174","Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma",,"Withdrawn","No Results Available","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis|Other: pharmacological study","PFS following treatment with rituximab intense dosing and CHOP-21 in previously untreated patients with high risk DLBCL|CR in previously untreated patients with high risk DLBCL treated with rituximab intense dosing and CHOP-21","Fox Chase Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OER-HM-039|NCI-2011-03309","null","null","null","February 27, 2012","null","March 3, 2016","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01539174"
592,"NCT00288067","Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",,"Terminated","Has Results","Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Stage II Marginal Zone Lymphoma|Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenström Macroglobulinemia","Drug: fenretinide|Drug: rituximab","Safety, in Terms of Dose-limiting Toxicity (DLT) of 2 Daily Doses of Single Agent Fenretinide (Phase I)|Response Rates of B-Non-Hodgkin Lymphoma to the Combination of Rituximab and Fenretinide (Phase II)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","32","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00104|CDR0000456502|UWCC-UW-6071|UWCC-06-0644-H/A|UWCC-6071|FHCRC-6071|6071|6957|R21CA119519","October 2005","July 2013","July 2013","February 7, 2006","October 6, 2014","October 6, 2014","University of Washington Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00288067"
593,"NCT02729896","A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Active, not recruiting","No Results Available","Lymphoma","Drug: Atezolizumab [TECENTRIQ]|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Rituximab","Percentage of Participants with CR at EOI, as Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography and Computed Tomography (PET-CT) Scan|Percentage of Participants with CR at EOI, as Determined by Investigator on the Basis of PET-CT Scans|Percentage of Participants with CR at EOI, as Determined by IRC and Investigator on the Basis of CT Scans Alone|Percentage of Participants with Objective Response (CR + PR) at EOI, as Determined by the IRC and by the Investigator on the Basis of PET-CT Scans|Percentage of Participants with Objective Response (CR + PR) at EOI, as Determined by the IRC and by the Investigator on the Basis of CT Scans Alone|Percentage of Participants with Best Response of CR or PR during the Study, as Determined by the Investigator on the Basis of CT Scans Alone|RP2D of Pola in Combination with Fixed Doses of Obinutuzumab and Atezo|Percentage of Participants with Adverse Events and Serious Adverse Events|Percentage of Participants with Dose-Limiting Toxicities (DLT)|Serum Obinutuzumab Concentration|Serum Rituximab Concentration|Serum Atezo Concentration|Serum Pola Concentration|Plasma Pola Concentration|Serum Pola Analyte Concentration|Plasma Pola Analyte Concentration|Incidence of Human Anti-Human Antibodies (HAHAs) to Obinutuzumab|Incidence of Human Anti-Chimeric Antibodies (HACAs) to Rituximab|Incidence of Anti-Therapeutic Antibodies (ATAs) to Atezo|Incidence of ATAs to Pola","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO29561|2015-004845-25","November 9, 2016","September 3, 2018","April 17, 2020","April 6, 2016","null","September 24, 2018","UCLA, Los Angeles, California, United States|University Miami, Miami, Florida, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Columbia Basin Hem-Onc; Department Hematology Oncology, Kennewick, Washington, United States|Robert Byrd Health Science; Dept of Medicine, Section of Hematology/Oncology, Morgantown, West Virginia, United States|Städtisches Klinikum Dessau Klinik für Innere Medizin Abt. Intensivmedizin, Dessau-Roßlau, Germany|Uniklinik Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik, Greifswald, Germany|Medizinische Hochschule; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie, Hannover, Germany|Universitätsklinikum Jena Klinik f.Chirurgie Abt. Allgemein- und Viszeralchirurgie, Jena, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Universitätsklinikum Würzburg, Wuerzburg, Germany|Szpitale Wojewodzkie w Gdyni Sp. z o.o., Gdynia, Poland|Wojewódzki Szpital Specjalistyczny im.MikołajaKopernika;KlinikaHematologiiUniwersytetuMedycznego, Lodz, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej MSW z W-MCO w Olsztynie, Olsztyn, Poland|Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych, Warsaw, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Medical Uni of Wroclaw; Hematology, Wroclaw, Poland","","https://ClinicalTrials.gov/show/NCT02729896"
594,"NCT00312845","Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Non-Hodgkin's Lymphoma","Drug: Bortezomib + Rituximab|Drug: Rituximab","Progression Free Survival|Overall Response Rate","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 3","676","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","26866138-LYM-3001","March 2006","June 2010","July 2010","April 11, 2006","July 26, 2011","June 25, 2012","East Alabama Medical Center, Opelika,, Alabama, United States|Central Hematology Oncology Medical Group, Inc, Alhambra, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|St. Jude Heritage Medical Group, Fullerton, California, United States|Wilshire Oncology Medical Group, Inc., La Verne, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|North Valley Hematology Oncology, Mission Hills, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Norwalk Medical Group, Norwalk, Connecticut, United States|Hematology Oncology PC, Stamford, Connecticut, United States|Integrated Community Oncology Network, Jacksonville, Florida, United States|Innovative Clinical Research of South Florida, Miami, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Emory Univeersity ,Winship Cancer Institute, Atlanta, Georgia, United States|Suburban Hematology-Oncology Associates, Lawrenceville, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|North Idaho Cancer Center, Coeur D Alene, Idaho, United States|Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States|Siouxland Hematolgoy-Oncology Associates, Sioux City, Iowa, United States|Kansas City Cancer Center, LLC, Kansas City, Kansas, United States|Louisville Oncology, Louisville, Kentucky, United States|Hematology & Oncology Specialists, Metairie, Louisiana, United States|Sinai Hospital, Baltimore, Maryland, United States|Hattiesburg Clinic, Hattesburg, Missouri, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Lancaster Cancer Center, Ltd., Lancaster, Pennsylvania, United States|The Western Pennsylvania Hospital, Pittsburg, Pennsylvania, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Oncology Consultants, Houston, Texas, United States|South Texas Oncology and Hematology, San Antonio, Texas, United States|Medical College of Wisconsin Milwaukee, Milwaukee, Wisconsin, United States|Higa San Martin, La Plata - Buenos Aires, Argentina|Hospital Professor Rodolfo Rossi, La Plata - Buenos Aires, Argentina|Centro Oncologico Integracion Regional, Mendoza, Argentina|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|ULB Erasme, Anderlecht, Belgium|AZ Stuivenberg, Antwerpen, Belgium|AZ Sint Jan, Brugge, Belgium|Institute J. Bordet, Bruxelles, Belgium|Clinique Notre Dame, Charleroi, Belgium|UZ Antwerpen - Universitair Ziekenhuis Antwerpen, Edegem, Belgium|UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium|Virga Jesse Ziekenhuis, Dienst Hematologie, Hasselt, Belgium|CHR La Citadelle, Liege, Belgium|CHU Sart Tilman, Liege, Belgium|Heilig Hart Roeselare, Roeselare, Belgium|Servico de Oncologia do Hospital Sao Lucas da PUC do rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil|Instituto Nacional de Cancer, Rio de Janeiro, Brazil|Hospital Brigadeiro, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Sao Paulo, Brazil|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|University Health Network - Princess Margaret Hospital, Toronto, Ontario, Canada|Juravinski Cancer Centre, Hamilton, Canada|West China Hospital of Sichuan, Chengdu, Sichuan, China|Cancer Hospital (Institute), CAMS&PUMC, Beijing, China|Beijing Cancer Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China|Cancer Center, Sun Yat-Sen University, Guangzhou, China|Peking University Third Hospital, Haidian District Beijing, China|RuiJin Hospital, Shanghai, China|Cancer Hospital - FuDan University, Shanghai, China|Bank of Cyprus Oncology Centre, Nikosia, Cyprus|Fakultni nemocnice Brno, Brno, Czech Republic|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic|Fakultni nemocnice Olomouc, Olomouc, Czech Republic|Vseobecna Fakultni Nemocnice, Praha, Czech Republic|Paijat - Hameen Keskussairaala, Lahti, Finland|Satakunnan Keskussairaala, Pori, Finland|Institut Bergonie, Bordeaux, France|Clinique Victor Hugo, Le Mans, France|Hopital Claude Huriez, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Hotel Dieu, Nantes, France|Service des Maladies due sang - Hopital haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Onkologische Schwerpunktpraxis, Herrsching, Germany|Universitatsklinikum Munster - Klinik fur Innere Medizin, Munster, Germany|Praxis für Hämetologie und Oncologie, Würzburg, Germany|Laiko General Hospital of Athens - 1st Internist Clinic - Hematology Department, Athens, Greece|University General Hospital Attikon - 2nd Department of Internal Medicine - Propedeutic & Research Institute, Athens, Greece|University Hospital of Patras - Department of Internal Medicine - Hematology Division, Rio Patras, Greece|Debreceni Egyetem, Orvos- es Egeszsegtudomanyl Centrum, iii. Belgyogyaszati Klinika, Debrecen, Hungary|Petz Aladar County Hospital, Gyor, Hungary|SZEgedi Tudomanyegyetem, II Belgyaszati Klinika, Szeged, Hungary|Institution Manipal Hospital, Bangalore, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India|Apollo Speciality Hospital, Chennai, India|Nizam's Institute of Medical Sciences, Hyderabaad, India|SMS Medical College Hospital, Jaipur, India|Apollo Hospitals, Hyderabad Apollo Hospital Complex, Jubilee Hills, India|Shirdi Saibaba Cancer Hospital, Karnataka, India|Department of Medical Oncology - Regional Cancer Centre, Kerala, India|Regional Cancer Centre, Kerala, India|Tata Memorial Centre, Mumbai, India|Soroka Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Sorraski Tel Aviv Medical Center, Tel Aviv, Israel|Sheba Medical Center, Tel HaShomer, Israel|Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy|Universita degli Studi di Perugia, Perugia, Italy|Azienda Ospedallera Universitaria Policlinico Tor Vergata, Roma, Italy|Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista, Torino, Italy|Lung Cancer Center - National Cancer Center, Gyeonggi-Do, Korea, Republic of|Samsung Medical Center - Division of Hematology-Oncology, Department of Medicine, Ilmon-Dong, Kangnam-Ku, Seoul, Korea, Republic of|Hematology-Oncology Clinic, Center for Specific Organs Cancer - National Cancer Center, Ilsandong-Gu, Goyang-Si, and Gyeonggi-Do, Korea, Republic of|Samsung Medical Center - Department of Internal Medicine, Ilwon dong, Kangnam-Ku, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran, Delagacion Tlalpan, Mexico|Instituto Nacional De Cancerologia Incan, Delagacion Tlalpan, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez UANL, Monterrey, Nuevo leon, Mexico|Canterbury Health Laboratories, Christchurch, New Zealand|Klinika Hematologii Instytut Chorob Wewnetrznych, Gdansk, Poland|Klinika Hematologii CMUJ, Krakow, Poland|Klinika Hematologii - Uniwersytetu Medycznego, Lodz, Poland|Klinika Hematologii i Transplantologii Szpiku AM, Lublin, Poland|Wojskowy Instytut Medyczny - Klinika Hematologii, Warsawa, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Klinika Hematologii AM, Warszawa, Poland|Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Katedra i Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Wroclaw, Poland|Servico de Hematologia - Hospital de Dia - Hospital Da Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. - Departmento de Hematologia, Lisboa, Portugal|Hospital de Dia de Hematologia - Hospital de Santa Maria E.P.E., Lisboa, Portugal|Serviço de Onco-hematologia, Instituto Português de Oncologia do Porto Franscisco Gentil, EPE, Porto, Portugal|San Juan VA Medical Center, San Juan, Puerto Rico|Spitalul clinic de urgenta, Brasov, Romania|Institutul Clinic Fundeni Clinica de Hematologie, Bucuresti, Romania|Spitalul Universitar de Urgenta Hematologie, Bucuresti, Romania|Spitalul Clinic judetean de urgenta ""Sf. Spiridon, Clinica Hematologie, Iasi, Romania|Spitalul Clinic judetean de urgenta Mures, Targu Mures, Romania|Arkhangelsk Region Clinical Hospital, Arghangelsk, Russian Federation|Altay Regional Oncology Dispensary, Barnaul, Russian Federation|Belgorod Regional Oncology Center, Belgorod, Russian Federation|Cheliabinsk Regional Oncology Dispensary, Cheliabinsk, Russian Federation|Ekaterinburg City Clinical Hospital #7, Ekaterinburg, Russian Federation|1st Republican Clinical Hospital of Udmurtia, Izhevsk, Russian Federation|Cancer Research Center, Moscow, Russian Federation|S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation|Moscow Region Clinical Research Institute, Moscow, Russian Federation|Semashko Central Clinical Hospital #2, Moscow, Russian Federation|City Oncology Hospital #62, Moscow, Russian Federation|Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation|Novosibirsk State Regional Clinical Hospital, Novosibirsk, Russian Federation|Novosibirsk State Medical University, Novosibirsk, Russian Federation|Medical Scientifical Radiology Center, Obninsk, Russian Federation|Republikan Hospital named after V.A. Baranov, Petrozavodsk, Russian Federation|Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|St. Petersburg Clinical Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation|St. Petersburg City Hospital #31, St. Petersburg, Russian Federation|Tomsk Research Oncology Institute, Tomsk, Russian Federation|Republican Clinical Hospital of Bashkorkostan, Ufa, Russian Federation|FN F.D. Roosevelt - Oddelenie hematologie, Banska Bysterica, Slovakia|Fakultna nemocnica L. Pasteura - Klinika hematologie a onkohematologie, Kosice, Slovakia|Vychodoslovensky Onkologicky Ustave, a.s., Kosice, Slovakia|Martinska FN, Klinika hematologie a transfuziologie, Martin, Slovakia|GVI Oncology Clinical Trial Unit, Panorama, Cape Town, South Africa|Mary Potter Oncology Centre - Little Company of Mary Hospital, Groenkloof, Pretoria, South Africa|Chris Hani Baragwanath Hospital, Johannesburg, South Africa|East Cape Oncology Centre - St. Georges Hospital, Port Elizabeth, South Africa|Hospital Durans I Reynals - Institut Catala d'Oncologia, Barcelona, Spain|Hospital Germans Trias i Pujol Institut Catala d'Oncologia, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Onkologiska kliniken Universitetssjukhuset, Lund, Sweden|Centrum for Hematologi Karolinska University Hospital, Stockholm, Sweden|Hematologiska kliniken M54 Karolinska University Hospital, Stockholm, Sweden|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand|Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine|Dnepropetrovsk Regional Clinical Oncology Dispensary, Dnepropetrovsk, Ukraine|Institute for Emergency and Urgent Medical Assistance named after V.K. Gusak of AMS of Ukraine, Donetsk, Ukraine|Khmelnitskiy Regional Hopsital, Khmelnitsky, Ukraine|Kiev Center of Marrow Transplantaion, Kiev, Ukraine|Krivoy Rog Oncology Dispensary, Krivoy Rog, Ukraine|Institute of Blood Pathology and Transfusional Medicine of AMS of Ukraine, Lviv Clinical Hospital #5, Lviv, Ukraine|Ukrainian Medical Stomatological Academy, Poltava Regional Dispensary, Poltava, Ukraine|Crimean Republic Clinical Oncology Dispensary, Simferopol, Ukraine|Zhitomir Gerbachevsky Regional Clinical Hospital, Zhitomir, Ukraine|Aberdeen Royal Infirmary - Department of Haematology, Aberdeen, United Kingdom|Addenbrooke's Hospital - Department of Haematology, Cambridge, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Guy's & St. Thomas Hospital, London, United Kingdom|Derriford Hospital - Department of Haematology, Plymouth, United Kingdom|Taunton & Somerset Hospital, Taunton, United Kingdom","","https://ClinicalTrials.gov/show/NCT00312845"
595,"NCT02706405","JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","BCL2 Gene Rearrangement|BCL6 Gene Rearrangement|CD19 Positive|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|MYC Gene Rearrangement|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Drug: Cyclophosphamide|Biological: Durvalumab|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Incidence of toxicity graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03|Dose limiting toxicity (DLT) rates|Maximum tolerated dose of durvalumab in combination with JCAR014 determined as the dose level with the DLT estimate closest to the target toxicity level of 30%|Maximum JCAR014 concentration (Cmax) by flow cytometry|Area under the curve (AUC) of JCAR014 by flow cytometry|Maximum JCAR014 Cmax in blood by quantitative polymerase chain reaction (qPCR) analysis|AUC of JCAR014 cells by qPCR analysis|Time to loss of JCAR014 detection in blood by qPCR analysis|Rate of complete response (CR) by investigator assessment using Lugano criteria|Rate of partial response (PR) by investigator assessment using Lugano criteria|Objective response rate (ORR, defined as the proportion of patients with a best response of either complete response or partial response) by investigator assessment using Lugano criteria|Duration of response|Progression free survival|Overall survival|Cmax of durvalumab in serum|AUC of durvalumab in serum|Clearance of durvalumab in serum|Terminal half-life of durvalumab in serum|Antibodies and cellular immune responses to JCAR014|Anti-drug antibodies directed against durvalumab","Fred Hutchinson Cancer Research Center|AstraZeneca|Juno Therapeutics, Inc.|MedImmune LLC|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9457|NCI-2015-02286|P30CA015704|R01CA136551","November 15, 2016","December 1, 2019","December 1, 2033","March 11, 2016","null","April 4, 2018","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02706405"
596,"NCT01178645","Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma",,"Unknown status","No Results Available","Non-Hodgkin Lymphoma","Drug: Busulfan, etoposide, cytarabine, and melphalan","Progression-free survival|Overall survival|Response rate according to the International Working Group criteria|Adverse events|Pharmacogenetic study","Seoul National University Hospital|Inje University|Severance Hospital|Asan Medical Center|Ulsan University Hospital","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BuEAM-BCL except for DLBCL","July 2010","December 2014","null","August 10, 2010","null","August 25, 2014","Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea, Republic of|Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of|Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01178645"
597,"NCT02965157","Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma",,"Unknown status","No Results Available","Lymphoma, B-Cell","Biological: CART20","all cause mortality","Beijing Biohealthcare Biotechnology Co.,Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EY201605-19","August 2016","January 2018","null","November 16, 2016","null","November 16, 2016","Chinese Academy of Medical Sciences Tumor Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT02965157"
598,"NCT03586024","Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)",,"Recruiting","No Results Available","Lymphoma","Drug: Pembrolizumab","Number of adverse events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 54417","July 3, 2018","July 3, 2021","July 3, 2022","July 13, 2018","null","July 13, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03586024"
599,"NCT00972478","Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","Has Results","Stage II Contiguous Adult Diffuse Large Cell Lymphoma|Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate|Drug: Vorinostat","Safe Dose of Vorinostat to be Used in Combination With R-CHOP Assessed by CTCAE Version 4.0 (Phase I)|Progression-free Survival (Phase II)|Overall Survival (Phase II)|Response Rate (Complete Response [CR]+Partial Response [PR]) (Phase II)|Toxicity of Vorinostat-R-CHOP in Patients With Newly Diagnosed DLBCL","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","83","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2011-01964|CDR0000653803|S0806|U10CA032102","November 2010","December 2015","null","September 7, 2009","October 31, 2016","October 13, 2017","Providence Hospital, Mobile, Alabama, United States|The University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|NEA Baptist Memorial Hospital, Jonesboro, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Kaiser Permanente, Fresno, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Yale University, New Haven, Connecticut, United States|Memorial University Medical Center, Savannah, Georgia, United States|Oncare Hawaii Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Oncare Hawaii Inc-POB II, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|OnCare Hawaii-Liliha, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Oncare Hawaii Inc-Kuakini, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Franciscan St. Francis Health-Beech Grove, Beech Grove, Indiana, United States|Franciscan Saint Francis Health-Indianapolis, Indianapolis, Indiana, United States|Reid Hospital and Health Care Services, Richmond, Indiana, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Saint Rose Ambulatory and Surgery Center, Great Bend, Kansas, United States|Hays Medical Center, Hays, Kansas, United States|Hutchinson Regional Medical Center, Hutchinson, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Providence Medical Center, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Main Office, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wichita NCI Community Oncology Research Program, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Christus Saint Frances Cabrini Hospital, Alexandria, Louisiana, United States|DeSoto Regional Health System, Mansfield, Louisiana, United States|University Health-Conway, Monroe, Louisiana, United States|Overton Brooks Veteran's Administration Medical Center, Shreveport, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Highland Clinic, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|Cancer Research Consortium of West Michigan NCORP, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Saint John's Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Cancer Research for the Ozarks NCORP, Springfield, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Frontier Cancer Center and Blood Institute-Billings, Billings, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Arnot Ogden Medical Center/Falck Cancer Center, Elmira, New York, United States|Interlakes Foundation Inc-Rochester, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Park Ridge Hospital Breast Health Center, Hendersonville, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, North Carolina, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton NCI Community Oncology Research Program, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Saint Charles Medical Center-Bend, Bend, Oregon, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Cooperative of Puget Sound Oncology Consortium, Seattle, Washington, United States|Group Health Cooperative-Seattle, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|The Polyclinic, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|United General Hospital, Sedro-Woolley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States","","https://ClinicalTrials.gov/show/NCT00972478"
600,"NCT00042666","A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: LY317615","Estimate the clinical response rate in patients with relapsed or refractory DLBCL who have received LY317615|Estimate objective response rate|Measure progression free survival|Duration of overall response|Evaluate safety of LY317615 in this population|Evaluate population pharmacokinetics|Assess PKC beta expression by immunohistochemistry in readily assessable DLBCL tumors from patients","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4849|H6Q-MC-JCAI","June 2002","September 2008","September 2008","August 6, 2002","null","October 19, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Royal Oak, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00042666"
601,"NCT00736450","Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Terminated","Has Results","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Biological: oblimersen sodium|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Procedure: biopsy|Genetic: microarray analysis|Other: immunohistochemistry staining method|Genetic: gene expression analysis|Genetic: cytogenetic analysis","Time to Perform Microarray Study After Receipt of Tissue|Number of Participants With Microarray Testing Results Are Completed Within 7 Days.|Efficacy of Treatment, in Terms of Complete Response Rate (Anyone Achieving a CR or Cru)","University of Nebraska|National Cancer Institute (NCI)|Genta Incorporated","All","19 Years and older   (Adult, Older Adult)","Not Applicable","37","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","462-07|NCI-2009-01692|P30CA036727","July 2008","September 2012","October 2012","August 15, 2008","August 31, 2018","August 31, 2018","Saint Francis Medical Center, Grand Island, Nebraska, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00736450"
602,"NCT00392496","Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma",,"Completed","Has Results","Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Drug: sunitinib malate","Objective Tumor Response","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00692|CDR0000652059|NCIC-182","February 2007","January 2012","January 2012","October 26, 2006","December 12, 2013","May 15, 2014","National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00392496"
603,"NCT00712582","Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: Etoposide, carboplatin, ifosfamide|Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin|Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine","To determine the 2-year PFS and overall survival from the start of induction therapy conditional on attaining either a negative FDG-PET or a negative biopsy at the interim evaluation.|Obtain preliminary data on biodistribution, dosimetry and potential clinical usefulness of the proliferation marker [18F] fluorothymidine (FLT) in pts with diffuse large cell lymphoma, using combined (FDG-PET/CT).|To determine the role of CT volumetric analysis compared to standard unidimensional CT in this patient population.","Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Columbia University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","101","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-026","July 2008","July 2018","July 2018","July 10, 2008","null","July 19, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00712582"
604,"NCT00667615","Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","Has Results","Hodgkin's Disease|Lymphoma","Drug: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim","Maximum Tolerated Dose (MTD) of Vorinostat Given Orally for 10 Days in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma|Complete Response Rate to Rituximab and a Combination of Vorinostat With Cyclophosphamide, Etoposide, and Prednisone in Elderly Pts With Relapsed Diffuse Large B-cell Lymphoma Who Aren't Candidates for Autologous Stem Cell Transplantation.","Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.|Northwestern University|NorthShore University HealthSystem Research Institute|Weill Medical College of Cornell University","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-045","April 2008","February 2017","February 2017","April 28, 2008","November 7, 2017","January 5, 2018","Memorial Sloan Kettering Cancer Center @ BaskingRidge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center @ Phelps, Sleepy Hollow, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT00667615/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00667615"
605,"NCT00621452","Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",,"Completed","No Results Available","B-cell Chronic Lymphocytic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Biological: aldesleukin|Genetic: polymerase chain reaction|Genetic: gene rearrangement analysis|Procedure: lymph node biopsy|Biological: genetically engineered lymphocyte therapy|Procedure: bone marrow aspiration|Other: flow cytometry|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay","Feasibility of transfecting and expanding the necessary numbers of T cells and the types of problems and toxicities which might be encountered, graded according the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0|Comparison of the percentages of CD20-specific T cells and malignant B cells present in the blood before and after each T cell infusion|Immune response as assessed by ELISA and percent chromium release in cytotoxicity assays|Absolute numbers of T cells expressing the chimeric T Cell receptor (cTCR) per cubic uL of blood","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Phase 1","12","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2154.00|NCI-2010-00416","August 2007","January 2014","null","February 22, 2008","null","August 6, 2014","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00621452"
606,"NCT00532259","CT-011 MAb in DLBCL Patients Following ASCT",,"Completed","Has Results","Lymphoma, Large Cell, Diffuse|Lymphoma, Mixed Cell, Diffuse|Primary Mediastinal Large B-Cell Lymphoma","Drug: CT-011","Progression-free Survival|Overall Survival","CureTech Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-2007-01","October 2007","August 2011","August 2011","September 20, 2007","September 12, 2014","September 12, 2014","Moores UCSD Cancer Center, La Jolla,, California, United States|Scripps Cancer Center, San Diego, California, United States|Northside Hospital, Atlanta,, Georgia, United States|Emory University-Winship Cancer Institute, Atlanta, Georgia, United States|Northwestestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Colombus, Ohio, United States|Temple University, Philadelphia, Pennsylvania, United States|The University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor Sammons Cancer Center, Dallas,, Texas, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Gujarat Cancer and Research Institute, Ahmedabad, India|Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India|Rambam Medical Center, Haifa, Israel|Hadassah Medical Organization, Jerusalem, Israel|Chaim Sheba Medical Center, Tel Hashomaer, Ramat Gan, Israel","","https://ClinicalTrials.gov/show/NCT00532259"
607,"NCT02132624","CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.",,"Completed","No Results Available","B Cell Lymphoma|B Cell Leukemia","Biological: Autologous 3rd generation CD19-targeting CAR T cells","CAR T cell persistence|Tumor load","Uppsala University|Uppsala University Hospital|Karolinska University Hospital|AFA Försäkring AB, Sweden|Swedish Cancer Society","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","003:TCELL|2013-001393-19","April 2014","May 31, 2017","May 31, 2017","May 7, 2014","null","October 30, 2017","Uppsala University Hospital, Dept of Oncology, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT02132624"
608,"NCT03098355","Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies",,"Recruiting","No Results Available","B-Cell Leukemia|B-Cell Lymphoma","Biological: 4SCAR19/22 T cells|Drug: Interleukin-2","Evaluate the frequency and severity of adverse events including, but not limited to, cytokine release syndrome (CRS)","Zhujiang Hospital|Shenzhen Geno-Immune Medical Institute","All","1 Year to 14 Years   (Child)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","anti-CD19/22 CART Cells","December 30, 2017","December 15, 2019","December 31, 2019","March 31, 2017","null","December 29, 2017","Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03098355"
609,"NCT03068416","CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy",,"Recruiting","No Results Available","B-cell Leukemia|B-Cell Lymphoma","Biological: CAR T cells","Safety|Tumor response|B cell levels|CAR T cell persistence|Immunological profile","Uppsala University|Uppsala University Hospital|AFA försäkringar","All","up to 100 Years   (Child, Adult, Older Adult)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","004:TCELL|2016-004043-36","September 18, 2017","April 2019","April 2019","March 1, 2017","null","October 4, 2017","Uppsala University Hospital, Dept of Oncology, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT03068416"
610,"NCT01284192","Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)",,"Completed","No Results Available","Advanced Malignancies|Positive for Anaplastic Lymphoma Kinase|Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS|Solid Tumor|B-Cell Lymphoma","Drug: ASP3026","Safety and tolerability of ASP3026 assessed by recording of adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and clinical observations|Pharmacokinetic assessment through analysis of blood and urine samples|Objective response rate (ORR)","Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A3026-CL-0101","December 2010","February 2014","March 2016","January 26, 2011","null","June 28, 2016","Site US160, Orange, California, United States|Site US184, Sacramento, California, United States|Site US11, Chicago, Illinois, United States|Site US2688, Detroit, Michigan, United States|Site US2492, Houston, Texas, United States|Site US1905, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT01284192"
611,"NCT02963038","CAR T Cells for Refractory B Cell Malignancy",,"Recruiting","No Results Available","B-Cell Leukemia|B-Cell Lymphoma","Biological: Autologous CD19-targeting CAR T cells","Tumor load|CAR T cell persistence","Hebei Senlang Biotechnology Inc., Ltd.|The Second Hospital of Hebei Medical University","All","1 Year to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","10","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SenL_19","June 2016","June 2017","June 2021","November 15, 2016","null","April 28, 2017","No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China","","https://ClinicalTrials.gov/show/NCT02963038"
612,"NCT02911142","Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma",,"Recruiting","No Results Available","Primary Effusion Lymphoma|B-Cell Lymphoma","Drug: Lenalidomide|Drug: Rituximab|Drug: Prednisone|Drug: Etopside|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide","(Phase I) Maximum tolerated dose of DA-EPOCH_R2|(Phase II) Overall survival in treatment-naive patients with primary effusion lymphoma treated with DA-EPOCH-R2","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","36","NIH","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160171|16-C-0171","September 21, 2016","October 1, 2022","October 1, 2025","September 22, 2016","null","August 31, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02911142"
613,"NCT03366350","Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|B Cell Lymphoma","Genetic: Second generation CAR-T cells|Procedure: Hematological stem cell transplantation","Occurrence of study related adverse events|Number of participants with an MRD negative complete remission after CAR-T therapy and HSCT","Wuhan Sian Medical Technology Co., Ltd|Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|People's Hospital Of Yichang","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","30","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CART-CD19-02","January 1, 2018","January 1, 2021","June 1, 2021","December 8, 2017","null","January 23, 2018","Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT03366350"
614,"NCT03366324","Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|B Cell Lymphoma","Genetic: Second generation CAR-T cells|Procedure: Hematological stem cell transplantation","Occurrence of study related adverse events|Number of participants with an MRD negative complete remission after CAR-T therapy and HSCT","Wuhan Sian Medical Technology Co., Ltd|Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|People's Hospital Of Yichang","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CART-CD19-03","January 1, 2018","January 1, 2021","June 1, 2021","December 8, 2017","null","January 23, 2018","Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT03366324"
615,"NCT02413489","An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma",,"Terminated","Has Results","Lymphoma, Mantle-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular","Drug: Daratumumab","Overall Response Rate (ORR)|Duration of Response|Progression Free Survival (PFS)|Overall Survival (OS)|Time to Response","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR106660|54767414LYM2001|2014-005299-26","September 2, 2015","June 1, 2017","June 1, 2017","April 10, 2015","June 25, 2018","June 25, 2018","Duarte, California, United States|Fountain Valley, California, United States|Jacksonville, Florida, United States|Pembroke Pines, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Rochester, Minnesota, United States|Omaha, Nebraska, United States|New Brunswick, New Jersey, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States|Adelaide, Australia|Box Hill, Australia|Melbourne, Australia|Brugge, Belgium|Gent, Belgium|Lille, France|Limoges Cedex, France|Nantes Cedex 01, France|Paris Cedex 10, France|Pessac, France|Pierre Benite, France|Rouen Cedex, France|Goyang-Si, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Ankara, Turkey|Atakum, Turkey|Istanbul, Turkey|Kocaeli, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02413489/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02413489/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02413489"
616,"NCT02611323","A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: Obinutuzumab|Drug: Rituximab|Drug: Polatuzumab Vedotin|Drug: Venetoclax","Percentage of Participants with CR, Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans|Percentage of Participants with CR, Determined by the Investigator on the basis of PET and CT Scans|Percentage of Participants with CR, Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants with CR, Determined by the IRC on the Basis of CT Scans Alone|Percentage of Participants with Objective Response, Determined by an IRC on the Basis of PET and CT Scans|Percentage of Participants with Objective Response, Determined by the Investigator on the Basis of PET and CT Scans|Percentage of Participants with Objective Response, Determined by an IRC on the Basis of CT Scans Alone|Percentage of Participants with Objective Response, Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants with Best Response of CR or PR, Determined by the Investigator on the Basis of CT Scans Alone|Observed Serum Obinutuzumab Concentration|Observed Serum Rituximab Concentration|Observed Serum Polatuzumab Vedotin Concentration|Observed Plasma Polatuzumab Vedotin Concentration|Observed Serum Concentration of Total Antibody to Polatuzumab Vedotin|Observed Plasma Concentration of Polatuzumab Vedotin Antibody-Conjugated Mono-Methyl Auristatin E (MMAE) (acMMAE)|Observed Plasma Concentration of Polatuzumab Vedotin Unconjugated MMAE|Observed Plasma Venetoclax Concentration|Percentage of Participants with Human Anti-Human Antibodies (HAHAs) to Obinutuzumab|Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Polatuzumab Vedotin|Recommended Phase 2 Dose (RP2D) of Polatuzumab Vedotin|Recommended Phase 2 Dose (RP2D) of Venetoclax|Percentage of Participants with Dose-Limiting Toxicities (DLTs)|Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","134","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO29833|2015-001998-40","March 9, 2016","August 25, 2021","August 25, 2021","November 20, 2015","null","July 12, 2018","University of Arizona Cancer Center, Tucson, Arizona, United States|Yale Cancer Center, New Haven, Connecticut, United States|Memorial Healthcare System, Pembroke, Florida, United States|Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States|University of Louisville Hospital; The James Graham Brown Cancer Center, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Scott and White, Temple, Texas, United States|Royal North Shore Hospital; Haematology Department, St. Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|Papa Giovanni Hospital XXIII, Bergamo, Emilia-Romagna, Italy|UO Ematologia, Ospedale S.Maria delle Croci, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi U.O. Ematologia, Rimini, Emilia-Romagna, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia, Torino, Piemonte, Italy","","https://ClinicalTrials.gov/show/NCT02611323"
617,"NCT00703664","Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma","Drug: Bortezomib|Other: Laboratory Biomarker Analysis|Drug: Vorinostat","Overall Response Rate (ORR)|Best Response|Progression-free Survival (PFS)|Duration of Partial Response|Duration of Stable Disease","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","65","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00275|CDR0000598308|MCC-15428|8064|N01CM00071|N01CM00100|N01CM62201|N01CM62204|N01CM62208|P30CA076292","July 9, 2008","December 1, 2017","December 1, 2017","June 23, 2008","August 7, 2018","August 7, 2018","Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT00703664/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00703664"
618,"NCT02965092","CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|B Cell Lymphoma","Genetic: Second generation CAR-T cells","Number of Adverse Events|Clinical responses to CD19 CAR-T cells","Wuhan Sian Medical Technology Co., Ltd|Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|People's Hospital Of Yichang","All","up to 60 Years   (Child, Adult)","Phase 1","50","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CART-CD19-01","December 1, 2015","January 2021","December 2021","November 16, 2016","null","May 31, 2018","Affiliated Union Hospital to Huazhong University of Science and Technology, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT02965092"
619,"NCT00466531","Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19",,"Active, not recruiting","No Results Available","Leukemia","Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide","Safety (phase I)|efficacy of the two CD19-targeted T cell methods (phase II)|Antileukemic effect|Comparison of in vivo survival of patients receiving genetically modified anti-CD19 T cells after T-cell infusion with vs without lymphodepleting therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-138|MSKCC-06138","March 21, 2007","December 2019","December 2019","April 27, 2007","null","May 15, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00466531"
620,"NCT02624986","A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants",,"Active, not recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: Idasanutlin|Drug: Obinutuzumab|Drug: Rituximab","Percentage of Participants with Complete Response (CR), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans|Percentage of Participants with Dose-Limiting Toxicities (DLTs)|Recommended Phase 2 Dose (RP2D) for Idasanutlin in Combination with Obinutuzumab|RP2D of Idasanutlin in Combination with Rituximab|Percentage of Participants with CR, Determined by the Investigator on the Basis of PET and CT Scans|Percentage of Participants with CR, Determined by an IRC and the Investigator on the Basis of CT Scans Alone|Percentage of Participants with Objective Response, Determined by an IRC on the Basis of PET and CT Scans|Percentage of Participants with Objective Response, Determined by the Investigator on the Basis of PET and CT Scans|Percentage of Participants with Objective Response, Determined by an IRC on the Basis of CT Scans Alone|Percentage of Participants with Objective Response, Determined by the Investigator on the Basis of CT Scans Alone|Percentage of Participants with Best Response of CR or Partial Response (PR), Determined by the Investigator on the Basis of CT Scans Alone|Serum Obinutuzumab Concentration|Serum Rituximab Concentration in DLBCL Participants|Plasma Idasanutlin Concentration in DLBCL Participants|Plasma Idasanutlin Concentration in FL Participants|Percentage of Participants with Adverse Events","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BH29812|2015-002100-83","December 23, 2015","February 20, 2021","February 20, 2021","December 9, 2015","null","September 18, 2018","Mayo Clinic Arizona, Phoenix, Arizona, United States|University of Colorado, Aurora, Colorado, United States|Norton Medical Plaza II, Louisville, Kentucky, United States|Mayo Clinic, Rochester, Minnesota, United States|Swedish Cancer Institute, Cary, North Carolina, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Sayre, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|Zentralklinikum Augsburg, Augsburg, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Charité Research Organisation GmbH Campus-Virchow-Klinikum, Berlin, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Universitätsklinikum Köln, Köln, Germany|Universitätsklinikum Wurzburg, Würzburg, Germany|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System; Pharmacy, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|North Shore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Auckland Clinical Studies Limited, Grafton, New Zealand","","https://ClinicalTrials.gov/show/NCT02624986"
621,"NCT02300402","Detection and Characterization of Residual Masses in Lymphomas","ADAMANTIUS","Recruiting","No Results Available","Hodgkin Lymphoma|B-Cell Lymphoma","","apparent diffusion coefficient changes of post-treatment residual lymphoma masses and whether this MR-derived parameter helps in characterizing its viability in addition to PET|correlation between standardized uptake value and apparent diffusion coefficient changes; correlation with post-treatment histopathological findings if tissue proof|correlation between the PET and MR-derived functional parameters with clinical outcome (end-treatment response and survival)","The Lymphoma Academic Research Organisation","All","18 Years to 80 Years   (Adult, Older Adult)","","120","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ADAMANTIUS","October 2014","December 2018","December 2019","November 25, 2014","null","March 7, 2018","Hopital Henri Mondor, Créteil, France","","https://ClinicalTrials.gov/show/NCT02300402"
622,"NCT02086175","A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas","Drug: Imprime PGG|Drug: Rituximab","Overall Response Rate|Determine progression-free survival (PFS) and duration of response. Evaluate safety of this combination in relapsed/refractory indolent NHL patients|To perform correlative laboratory studies using on-treatment peripheral blood samples and post-treatment tumor samples to quantify the binding of Imprime PGG to neutrophils and correlate with treatment response","Dana-Farber Cancer Institute|Biothera","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-398","December 2014","December 2018","August 2021","March 13, 2014","null","May 9, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02086175"
623,"NCT02787239","Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL",,"Completed","No Results Available","B-cell Non Hodgkin's Lymphoma","Drug: HLX01|Drug: Rituximab|Drug: CHOP","Percentage of Participants With Objective Response Rate (ORR)","Shanghai Henlius Biotech","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HLX01-NHL03","October 2015","May 2018","May 2018","June 1, 2016","null","October 1, 2018","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China","","https://ClinicalTrials.gov/show/NCT02787239"
624,"NCT00294632","Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: Lenalidomide|Drug: Rituximab","Maximum Tolerated Dose (MTD) of Lenalidomide in Combination with Rituximab i|Objective Response Rate","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","112","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0461|NCI-2012-01356","February 2006","February 2016","February 2016","February 22, 2006","null","February 4, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00294632"
625,"NCT03410901","TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","B-Cell Non-Hodgkin Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma","Biological: Anti-OX40 Antibody BMS 986178|Other: Laboratory Biomarker Analysis|Radiation: Radiation Therapy|Drug: TLR9 Agonist SD-101","Number of participants experiencing Dose-limiting Toxicities (DLT) within 8 weeks of treatment initiation|Overall Response Rate (ORR)|Progression-Free Survival (PFS)","Ronald Levy|National Cancer Institute (NCI)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LYMNHL0144|NCI-2017-02452|IRB-44250|R35CA197353","April 9, 2018","October 9, 2020","October 9, 2020","January 25, 2018","null","July 19, 2018","Stanford University, School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03410901"
626,"NCT00880867","Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma",,"Terminated","No Results Available","B Cell Lymphoma|T Cell Lymphoma","Drug: Poly-ICLC","Toxicity (DLT)|Tumor Response","Nevada Cancer Institute|CLL Topics","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NVCI-0838","April 2009","May 2010","April 2011","April 14, 2009","null","July 20, 2011","Nevada Cancer Institute, Las Vegas, Nevada, United States","","https://ClinicalTrials.gov/show/NCT00880867"
627,"NCT00210366","Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma",,"Terminated","No Results Available","Lymphoma, B-Cell","Drug: Idarubicin","objective response to treatment|duration of response|overall survival|acute side effects of idarubicin","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG21","November 2004","July 2010","null","September 21, 2005","null","July 30, 2010","Servizio Radiochemioterapia - Ospedale San Raffaele, Milan, Italy","","https://ClinicalTrials.gov/show/NCT00210366"
628,"NCT00210314","Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma",,"Completed","No Results Available","Lymphoma, B Cell","Drug: high dose methotrexate|Drug: high dose cytarabine|Radiation: radiotherapy","The main endpoint is the complete remission (CR) rate after chemotherapy|Overall response rate|Response duration (time to relapse or progression) for responder patients|Overall survival|Event-free survival|Meningeal relapse rate|Early and late neurotoxicity","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","79","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG20","July 2003","September 2007","December 2007","September 21, 2005","null","March 30, 2015","Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland","","https://ClinicalTrials.gov/show/NCT00210314"
629,"NCT00329030","Rituxan vs Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (BMT CTN 0401)",,"Completed","Has Results","Lymphoma, B-Cell|Lymphoma, Large-Cell, Immunoblastic|Lymphoma, Non-Hodgkin","Drug: Autologous transplantation using rituxan/BEAM|Drug: Autologous transplantation using Bexxar/BEAM","Progression-free Survival (PFS)|Overall Survival|Incidence of Relapse/Progression|Complete Response (CR) and Partial Response (PR) Proportion|Platelet Recovery to 20,000 Cells/μL|Hematologic Function|Incidence of Infection|Mucositis Severity|Immune Reconstitution|Immune Reconstitution of Quantitative Immunoglobulins|Treatment-related Mortality (TRM)|Neutrophil Recovery","National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","224","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMTCTN0401|BMT CTN 0401|U01HL069294-05|384","December 2005","August 2013","August 2013","May 24, 2006","June 10, 2016","September 25, 2017","Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida College of Medicine (Shands), Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|St. Lukes Mountain States Tumor Institute, Boise, Idaho, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Maryland Medical Systems/Greenbaum Cancer Center, Baltimore, Maryland, United States|Johns Hopkins/SKCCC, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, The New York Presbyterian Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals of Cleveland/Case Western, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Columbia River Oncology Program, Portland, Oregon, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|University of Utah Medical School, BMT, Salt Lake City, Utah, United States|Intermountain BMT Program, Salt Lake City, Utah, United States|Virginia Commonwealth University/MCV Hospital, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00329030"
630,"NCT00907348","Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma","REAL07","Unknown status","No Results Available","Non Hodgkin Lymphoma|Follicular Lymphoma","Drug: LR-CHOP21","Evaluation of adverse events according with Common Terminology Criteria for Adverse events (CTCAE)|Overall Response Rate (ORR)","Fondazione Italiana Linfomi ONLUS|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIL_REAL07","October 2007","October 2009","January 2012","May 22, 2009","null","October 13, 2011","Divisione di Ematologia Osp. SS. Antonio e Biagio, Alessandria, Italy|Divisione di Oncologia Medica A Centro di Riferimento Oncologico, Aviano, Italy|Cattedra di Ematologia Università Policlinico, Bari, Italy|IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy|Istituto di Ematologia ""Seragnoli"" Polic.S.Orsola-Malpighi, Bologna, Italy|Divisione di Ematologia Spedali Civili, Brescia, Italy|Divisione di Ematologia Osp. Businco, Cagliari, Italy|Onco-Ematologia I.R.C.C., Candiolo (TO), Italy|Ematologia 1 Ospedale S. Martino, Genova, Italy|Divisione di Ematologia Ospedale Niguarda, Milano, Italy|UO Ematologia II Facoltà di Medicina e Chirurgia Università Federico II, Napoli, Italy|Divisione di Ematologia Università Avogadro, Novara, Italy|UO Ematologia Università - Policlinico San Matteo, Pavia, Italy|Dipartimento di biotecnologie cellulari ed ematologia Ospedale Umberto I - La Sapienza, Roma, Italy|Oncoematologia - Univ. Perugia Sede Terni,, Terni, Italy|S.C.Ematologia 1 AOU San Giovanni Battista, Torino, Italy|SC Ematologia 2 ASO San Giovanni Battista, Torino, Italy|UO Ematologia Osp. Cardinale Panico, Tricase (LE), Italy","","https://ClinicalTrials.gov/show/NCT00907348"
631,"NCT00256490","Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by PET/CT",,"Unknown status","No Results Available","Lymphoma, Large-Cell","Procedure: PET/CT 20 days after the first cycle of chemotherapy","Disease free survival at 2 years","Université de Sherbrooke","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CRC 05-020|CIMF 2005-01","November 2005","null","November 2009","November 21, 2005","null","November 21, 2005","Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT00256490"
632,"NCT01118845","Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Non-Hodgkin's Lymphoma|Lymphoma, Large Cell|Diffuse, Mantle Cell Lymphoma, Lymphoma|Follicular Lymphoma|Large B-Cell, Diffuse","Drug: SyB L-0501|Drug: Rituximab","The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma|The Complete Response (CR) Rate Determined on the Basis of Revised Response Criteria for Malignant Lymphoma|Progression Free Survival (PFS)|Number of Subjects With Adverse Event|Number of Adverse Events|Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values|Number of Subjects With Grade ≥3 Physical Examination Finding|Concomitant Medication Usage|The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Japan|The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Japan|The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Japan|The Half-life Period (t1/2) of Unchanged SyB L-0501 in Japan|The Maximum Concentration (Cmax) of Unchanged SyB L-0501 in Korea|The Maximum Drug Concentration Time (Tmax) of Unchanged SyB L-0501 in Korea|The Area Under the Curve (AUC) for Unchanged SyB L-0501 in Korea|The Half-life Period (t1/2) of Unchanged SyB L-0501 in Korea","SymBio Pharmaceuticals","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010001","April 2010","October 2011","October 2011","May 7, 2010","July 4, 2013","July 4, 2013","Nagoya, Aichi, Japan|Matsuyama, Ehime, Japan|Kurume, Fukuoka, Japan|Maebashi, Gunma, Japan|Sapporo, Hokkaido, Japan|Kanazawa, Ishikawa, Japan|Isehara, Kanagawa, Japan|Ninomaru, Kumamoto, Japan|Sendai, Miyagi, Japan|Kita-ku, Okayama, Japan|Kurashiki, Okayama, Japan|Hidaka, Saitama, Japan|Izumo, Shimane, Japan|Chuo-ku, Tokyo, Japan|Akita, Japan|Fukuoka, Japan|Kagoshima, Japan|Kyoto, Japan|Seo-gu, Busan, Korea, Republic of|Jung-gu, Daegu, Korea, Republic of|Goyang-si, Gyeonggi-do, Korea, Republic of|Hwasun-gun, Jeonnam, Korea, Republic of|Gangnam-gu, Seoul, Korea, Republic of|Seodaemun-gu, Seoul, Korea, Republic of|Songpa-gu, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01118845"
633,"NCT02623920","Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","S-BR","Withdrawn","No Results Available","Diffuse Large B Cell Lymphoma|Mediastinal Large B-cell Lymphoma|Grey Zone Lymphoma|High Grade B Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma","Drug: Brentuximab|Drug: Bendamustine|Drug: Rituximab","CR rate|Percentage of patients obtaining a CR + PR using Cheson criteria|Median time to progression|PFS|Complete response rate assessed by PET/CT|Frequency of adverse events (AEs) and serious AEs assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|CD34+ peripheral blood stem cells assessed by flow cytometry|Median time to engraftment|Soluble CD30 levels in blood by biochemical assay","University of Arizona","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1507953455","December 16, 2015","May 17, 2017","May 17, 2017","December 8, 2015","null","May 19, 2017","Arizona Cancer Center at UMC North, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02623920"
634,"NCT02082977","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma",,"Terminated","No Results Available","Cancer","Drug: GSK2816126","Part 1: Number of participants with serious adverse events (SAEs) and non-serious adverse events (Non-SAEs)|Part 1: Number of participants with dose limiting toxicities (DLT)|Part 1: Number of participants withdrawn due to AEs|Part 1: Number of participants with dose interruptions|Part 1: Number of participants with dose reductions|Part 1: Number of participants with worst case change from Baseline in clinical chemistry parameters|Part 2: Characterize the metabolic profile of GSK2816126 after repeat-dosing|Part 2: Number of subjects with Adverse Events (AES), and Serious Adverse Events (SAEs), withdrawals due to AES, dose interruptions and reductions|Part 2: Number of subjects with withdrawals due to AEs, dose interruptions and reductions|Part 2: Number of subjects with DLT|Part 2: Changes from Baseline in clinical laboratory parameters|Part 2: Changes from Baseline in vital signs|Part 2: Changes from Baseline in cardiac parameters|Part 2: Population PK parameters for GSK2816126|Part 2: Relationship between GSK2816126 exposure markers (dose, concentration, CMAX or AUC) and PD (pharmacodynamic) responses. PD responses assessed by change from baseline in tri-methylation of histone H3K27 (H3K7ME3)|Part 2: Samples to characterize the metabolites in blood, bile and/or urine|Part 2: Concentration of GSK2816126 in urine measured with an investigational bioanalytical method and extrapolated to total amount excreted in urine over time using urine volume|Part 2: Duration of response (DoR)|Part 2: Progression-free survival (PFS)|Part 2: To assess potential change in 4Beta-hydroxycholesterol to cholesterol ratio in plasma following repeat dosing of GSK2816126|Part 2: Relationship between GSK2816126 exposure markers (dose, concentration, CMAX or AUC) and safety/efficacy/ responses","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","117208","April 24, 2014","June 20, 2017","June 20, 2017","March 11, 2014","null","June 4, 2018","GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Villejuif cedex, France|GSK Investigational Site, Sutton, Surrey, United Kingdom|GSK Investigational Site, Southampton, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02082977/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02082977/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02082977"
635,"NCT01300793","Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide","V-RICE","Terminated","No Results Available","Non-Hodgkin's Lymphoma|B-cell Lymphoma","Drug: Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide","Determine the MTD of Velcade (bortezomib), Rituximab, Ifosfamide, Carboplatin, Etoposide (V-RICE) for patients with relapsed/primary refractory aggressive B-cell non-Hodgkin's lymphoma (NHL)|tolerability and safety, response rate, the amount of peripheral blood CD34+ progenitor cells collected and the rate of engraftment, assess the rate of autologous stem cell transplant","University of California, San Francisco|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06253","May 2007","July 2011","April 2012","February 23, 2011","null","September 26, 2012","Unviersity of California Medical Center, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT01300793"
636,"NCT03147885","Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Extranodal Marginal Zone Lymphoma|Recurrent Follicular Lymphoma|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Extranodal Marginal Zone Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Stage III Non-Hodgkin Lymphoma|Stage IV Non-Hodgkin Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma","Drug: Selinexor","Maximum tolerated dose of selinexor in combination with RCHOP chemotherapy defined as =< 1/6 patients experience a dose limiting toxicity (Phase Ib)|Progression-free survival (PFS) for patients with newly diagnosed DLBCL treated with RCHOP-selinexor combination (Phase II)|CR of patients with newly DLBCL treated with selinexor and RCHOP|PR of patients with newly diagnosed DLBCL treated with selinexor and RCHOP|SD of patients with newly diagnosed DLBCL treated with selinexor and RCHOP|ORR (CR and PR) of patients with newly diagnosed DLBCL treated with selinexor and RCHOP|OS of patients with newly diagnosed DLBCL treated with RCHOP-selinexor combination|Change in CRM1/XPO-1 activity expression assessed in tissue by polymerase chain reaction (PCR)|Change in CRM1/XPO-1 activity expression assessed in tissue by immunohistochemistry (IHC)","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","44","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-125","June 20, 2017","June 29, 2018","December 28, 2018","May 10, 2017","null","February 14, 2018","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03147885"
637,"NCT02992522","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma","Drug: Lenalidomide|Biological: Obinutuzumab|Drug: Venetoclax","MTD defined as the highest level at which no more than 6 patients experience a DLT assessed by National Cancer Institute Common Terminology Criteria of Adverse Events version 4|Objective response rate (ORR) defined as the proportion of patients achieving a complete or partial, response according to the Lugano Lymphoma Response Criteria|Progression-free survival","Beth Christian|Celgene|Genentech, Inc.|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-16187|NCI-2016-01723","February 21, 2017","January 31, 2020","January 31, 2021","December 14, 2016","null","October 19, 2017","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02992522"
638,"NCT02405676","BNHL-2015 for Children or Adolescents in China","BNHL-2015","Recruiting","No Results Available","Mature B-cell Non-Hodgkin Lymphoma","Drug: Prednisone,Vincristine, Cyclophosphamide|Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Drug: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Drug: Rituximab","Event free survival|Overall survival","Children's Cancer Group, China|Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China|Nanjing Children's Hospital|West China Second University Hospital|Xiangya Hospital of Central South University|Qilu Hospital of Shandong University|Children’s Hospital of Sochow University, China|Tianjin Medical University Cancer Institute and Hospital","All","up to 16 Years   (Child)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCCG-BNHL-2015","January 2015","June 2021","December 2024","April 1, 2015","null","February 9, 2018","West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT02405676"
639,"NCT00881920","Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL","CHARKALL","Recruiting","No Results Available","Lymphoma|Myeloma|Leukemia","Biological: Kappa CD28 T cells","Number of Patients with Dose-Limiting Toxicities (DLT)|To measure the anti-tumor effects of CAR-K+ T lymphocytes.","Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-23574-CHARKALL|CHARKALL","July 2009","July 2019","July 2034","April 15, 2009","null","February 28, 2018","Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00881920"
640,"NCT01078922","Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas",,"Terminated","Has Results","Non-Hodgkin Lymphomas","Drug: Ofatumumab","Overall Response (OR)|Overall Clinical Benefit (OCB)","Oncology Specialists, S.C.|University of Illinois at Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OFT113588 (0908)","February 2010","October 2013","October 2013","March 2, 2010","May 2, 2014","July 16, 2014","University of Illinois at Chicago, Chicago, Illinois, United States|Oncology Specialists, S.C, Niles, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01078922"
641,"NCT00968760","CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies",,"Active, not recruiting","No Results Available","Lymphoma|B-cell Lymphoma","Procedure: Leukapheresis|Procedure: Stem Cell Transplant|Procedure: CD19-specific T Cell Infusion|Drug: IL-2|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan","Maximum Tolerated Dose (MTD) of T-cells ± IL-2","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Ziopharm|Intrexon Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","60","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0635|5R01CA141303-03|NCI-2011-01129|RP120241","June 2011","June 2019","June 2019","August 31, 2009","null","January 10, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00968760"
642,"NCT03570892","Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","BELINDA","Not yet recruiting","No Results Available","Non-Hodgkin Lymphoma","Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and HSCT","Event-free survival (EFS)|EFS as assessed by local investigator|Overall Survival (OS)|Overall Response Rate (ORR)|Duration of Response (DOR)|SF-36v2|FACT-Lym|EQ-VAS|Tisagenlecleucel transgene concentrations|Tisagenlecleucel immunogenicity (humoral and cellular)|Presence of replication competent lentivirus (RCL)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","318","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CCTL019H2301|2016-002966-29","October 26, 2018","June 18, 2025","June 18, 2025","June 27, 2018","null","June 27, 2018","","","https://ClinicalTrials.gov/show/NCT03570892"
643,"NCT00225212","Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Non-Hodgkin's Lymphoma|Diffuse Large Cell Lymphoma|Mantle Cell Lymphoma|Transformed Lymphoma|Other Subtypes of B-cell Lymphoma|Lymphoma","Drug: Rituximab 375 mg/m2","Event-free Survival (EFS)|Overall Survival (OS)","Stanford University","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","protocol97|73750","November 1997","March 2003","March 2003","September 23, 2005","September 5, 2014","September 15, 2014","Stanford University Medical Center, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00225212"
644,"NCT00482053","Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT",,"Terminated","Has Results","Lymphoma, B-cell|Lymphoma, Non-Hodgkin|Diffuse Large B-cell Lymphoma (DLBCL)|Malignant Lymphoma, Non-Hodgkin","Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)|Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Procedure: Total lymphoid irradiation (TLI)|Drug: Rituximab|Drug: Carmustine|Drug: Etoposide|Drug: Filgrastim|Drug: Anti-thymocyte globulin (ATG)|Drug: Cyclosporine|Drug: Mycophenolate mofetil (MMF)|Drug: Cyclophosphamide|Drug: Acetaminophen|Drug: Diphenhydramine|Drug: Hydrocortisone|Drug: Methylprednisolone","Event-free Survival (EFS) Per Protocol|Median Time to Neutrophil Engraftment After Autologous Transplant|Median Time to Platelet Engraftment After Autologous Transplant|Median Time to Neutrophil Engraftment After Allogeneic Transplant|Median Time to Platelet Engraftment After Allogeneic Transplant|Incidence of Chronic Graft vs Host Disease (GvHD)|Overall Survival (OS)","Stanford University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-06703|97355|BMT186","October 2006","May 2010","May 2010","June 4, 2007","May 14, 2018","May 14, 2018","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00482053"
645,"NCT03277729","A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","CD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Indolent Non-Hodgkin Lymphoma","Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis","Dose-limiting toxicity|Complete remission|Progression-free survival|Overall survival|Incidence of adverse events","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9738|NCI-2017-01595|P30CA015704","December 5, 2017","November 16, 2022","November 16, 2037","September 11, 2017","null","April 13, 2018","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03277729"
646,"NCT03484702","Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: JCAR017","Overall Response Rate (ORR) of JCAR017 in subjects with Non-Hodgkin Lymphoma (NHL; including secondary central nervous system (CNS) involvement)|ORR of JCAR017 in subjects with relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL)|Adverse Events (AEs)|Overall Response Rate (ORR)on the underlying chronic lymphocytic leukemia (CLL) in subjects with Richter´s transformation|Complete response rate (CRR)|Event-free survival (EFS)|Progression-free survival (PFS)|Overall survival (OS)|Duration of response (DOR)|Pharmacokinetic - Cmax|Pharmacokinetic - Tmax|Pharmacokinetic - AUC|Patient-Reported Outcomes - EORTC QLQ-C30|Patient-Reported Outcomes - EQ-5D-5L|Patient-Reported Outcomes - FACT-Lym","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JCAR017-BCM-001|U1111-1209-4055|2017-000106-38","June 5, 2018","August 2, 2022","August 2, 2022","April 2, 2018","null","July 6, 2018","Universitair Ziekenhuis Gent, Gent, Belgium|Helsinki University, Helsinki, Finland|CHRU-Hopital Claude Huriez, Lille, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|Medizinische Kinik und Poliklinik I, Dresden, Germany|Universitat zu Koln, Köln, Germany|LMU Klinikum der Universität, München, Germany|Universitatsklinikum Ulm, Ulm, Germany|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Hospital Vall d'Hebron, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT03484702"
647,"NCT02747732","Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma|Primary Mediastinal (Thymic) Large B-cell Lymphoma|Transformed Indolent Lymphoma|Recurrent Disease|Refractory Cancer","Drug: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6","overall response rate (ORR) of the combination of ibrutinib, bendamustine and rituximab (IBR)|progression free survival (PFS)|overall survival (OS)|duration of response.","Meirav Kedmi MD|Johnson & Johnson|Sheba Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Bruton's Tyrosine_Meirav Kedmi","December 2016","June 2020","October 2021","April 22, 2016","null","March 8, 2017","Dr. Meirav Kedmi, Ramat Gan, Israel|Sheba medical organization, Ramat Gan, Israel","","https://ClinicalTrials.gov/show/NCT02747732"
648,"NCT02168907","CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Terminated","No Results Available","B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: 6,8-bis(benzylthio)octanoic acid|Drug: bendamustine hydrochloride|Biological: rituximab|Other: laboratory biomarker analysis","MTD of 6,8-bis(benzylthio)octanoic acid, when used in combination with bendamustine hydrochloride and rituximab determined by dose-limiting toxicities graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)|Response rate assessed by the modified IWG criteria|Disease control rate assessed by the modified IWG criteria|Overall survival assessed by the modified IWG criteria|Progression free survival assessed by the modified IWG criteria|Bone marrow biopsy analysis|Incidence of toxicities graded according to NCI CTCAE","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00027759|NCI-2014-01280|CCCWFU 28114|P30CA012197","December 2014","February 2015","February 2015","June 20, 2014","null","July 2, 2018","Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02168907"
649,"NCT03642626","MT2017-45 :CAR-T Cell Therapy for Heme Malignancies",,"Not yet recruiting","No Results Available","Acute Lymphoblastic Leukemia|Large B-cell Lymphoma","Drug: KYMRIAH|Drug: YESCARTA|Drug: Fludarabine|Drug: Cyclophosphamide","Arm A: Complete Remission (CR)|Arm A: CRi (complete remission without count recovery)|Arms B & C: Overall Response Rate (ORR)|Arm A: MRD-negative CR (or CRi)|Arm A: Proportion of patients who are alive but not in remission|Arm A: Treatment Related Mortality (TRM)|Arm A: Relapse-free Survival (RFS)|Arm A: Event-Free Survival (EFS)|Arm A: Overall Survival (OS)|Arm A: Toxicity|Arms B/C: Complete Remission (CR)|Arms B/C: Treatment Related Mortality (TRM)|Arms B/C: Relapse-free Survival (RFS)|Arms B/C: Event-free Survival (EFS)|Arms B/C: Overall Survival (OS)|Arms B/C: Toxicity","Masonic Cancer Center, University of Minnesota","All","Child, Adult, Older Adult","Phase 2","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017LS118|MT2017-45","November 2018","June 2028","June 2028","August 22, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03642626"
650,"NCT01030900","Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas",,"Active, not recruiting","No Results Available","Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma","Biological: campath|Biological: Rituximab|Drug: EPOCH","PFS and OS","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100011|10-C-0011","October 22, 2009","September 1, 2020","September 1, 2020","December 14, 2009","null","September 12, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01030900"
651,"NCT02367040","Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)","CHRONOS-3","Recruiting","No Results Available","Lymphoma,Non-Hodgkin","Drug: Copanlisib (BAY 80-6946)|Drug: Placebo|Drug: Rituximab","Progression free survival (PFS)|Objective tumor response|Duration of response (DOR)|Complete response|Time to progression (TTP)|Overall survival (OS)|Time to deterioration in DRS-P of at least 3 points as measured by the FLymSI-18 (Lymphoma Symptom Index -18)questionnaire|Number of participants with adverse Events as a measure of safety and tolerability|Time to improvement in DRS-P of at least 3 points, as measured by the FLymSI-18 questionnaire, will be evaluated for patients with a baseline DRS-P score of 30 points or less","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17067|2013-003893-29","August 3, 2015","May 31, 2020","August 28, 2020","February 20, 2015","null","September 13, 2018","Rogers, Arkansas, United States|Long Beach, California, United States|West Covina, California, United States|Whittier, California, United States|Denver, Colorado, United States|Hartford, Connecticut, United States|Miami, Florida, United States|Maywood, Illinois, United States|Louisville, Kentucky, United States|Farmington Hills, Michigan, United States|Las Vegas, Nevada, United States|Englewood, New Jersey, United States|Morristown, New Jersey, United States|MSK Basking Ridge, New Jersey, New Jersey, United States|MSK Bergen, New Jersey, New Jersey, United States|MSK Monmoth, New Jersey, New Jersey, United States|MSK Westchester, Harrison, New York, United States|MSK Commack, Long Island City, New York, United States|MSK Rockville Centre, Long Island City, New York, United States|New York, New York, United States|Goldsboro, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Bend, Oregon, United States|Allentown, Pennsylvania, United States|Danville, Pennsylvania, United States|Watertown, South Dakota, United States|Salt Lake City, Utah, United States|Spokane, Washington, United States|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Cordoba, Córdoba, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Córdoba, Argentina|Kingswood, New South Wales, Australia|Kogarah, New South Wales, Australia|Orange, New South Wales, Australia|Waratah, New South Wales, Australia|Ballarat, Victoria, Australia|Nedlands, Australia|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Leoben, Steiermark, Austria|Landeskrankenhaus Rankweil, Rankweil, Vorarlberg, Austria|Krems, Austria|Linz, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Lesnoy, Belarus|Minsk, Belarus|Bruxelles - Brussel, Belgium|Ottignies, Belgium|Turnhout, Belgium|Verviers, Belgium|Ijuí, Rio Grande Do Sul, Brazil|Passo Fundo, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Barretos, Sao Paulo, Brazil|Jaú, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Brazil, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Temuco, Araucanía, Chile|Santiago, Chile|Santiago, Chile|Hefei, Anhui, China|Fuzhou, Fujian, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Zhengzhou, Henan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Shengyang, Liaoning, China|Chengdu, Sichuan, China|Urumchi, Xinjiang, China|Urumqi, Xinjiang, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|China, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Tianjin, China|Medellín, Antioquia, Colombia|Barranquilla, Atlántico, Colombia|Bogotá, Cundinamarca, Colombia|Montería, Córdoba, Colombia|Floridablanca, Santander, Colombia|Cali, Valle Del Cauca, Colombia|Cali, Valle Del Cauca, Colombia|Bogota, Colombia|Aalborg, Denmark|Aarhus C, Denmark|Copenhagen, Denmark|Odense C, Denmark|Roskilde, Denmark|Bayonne, France|Brest, France|Limoges, France|Metz Cedex 03, France|Nantes, France|NICE Cedex 2, France|Perigueux, France|Pessac, France|Poitiers, France|Vandoeuvre-les-nancy, France|Aschaffenburg, Bayern, Germany|Landshut, Bayern, Germany|München, Bayern, Germany|Potsdam, Berlin, Germany|Recklinghausen, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Chemnitz, Sachsen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Athens, Greece|Athens, Greece|Chaidari, Greece|Larissa, Greece|Patras, Greece|Piraeus, Greece|Thessaloniki, Greece|Chai wan, Hong Kong|Hong Kong, Hong Kong|Kowloon, Hong Kong|New Territories, Hong Kong|Shatin, Hong Kong|Budapest, Hungary|Budapest, Hungary|Gyor, Hungary|Kaposvar, Hungary|Pecs, Hungary|Tatabanya, Hungary|Dublin 4, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Bologna, Emilia-Romagna, Italy|Pordenone, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Cagliari, Sardegna, Italy|Firenze, Toscana, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Maebashi, Gunma, Japan|Kobe, Hyogo, Japan|Nankoku, Kochi, Japan|Sendai, Miyagi, Japan|Matsumoto, Nagano, Japan|Omura, Nagasaki, Japan|Kurashiki, Okayama, Japan|Hirakata, Osaka, Japan|Izumo, Shimane, Japan|Chuo-ku, Tokyo, Japan|Shinagawa-ku, Tokyo, Japan|Aomori, Japan|Fukuoka, Japan|Kumamoto, Japan|Niigata, Japan|Okayama, Japan|Osaka, Japan|Yamagata, Japan|Busan, Korea, Republic of|Busan, Korea, Republic of|Jeollanam-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Kaunas, Lithuania|Esch-sur-alzette, Luxembourg|Luxembourg, Luxembourg|Ipoh, Malaysia|Kelantan, Malaysia|Kota Kinabalu, Malaysia|Kuala Lumpur, Malaysia|Kuala Lumpur, Malaysia|Pulau Pinang, Malaysia|Selangor, Malaysia|México, D.F., Distrito Federal, Mexico|Morelia, Michoacán, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Oaxaca, Mexico|Tauranga, New Zealand|Cebu City, Philippines|Manila, Philippines|Pasig City, Philippines|Quezon City, Philippines|Gdansk, Poland|Gdynia, Poland|Gliwice, Poland|Krakow, Poland|Lublin, Poland|Vila Nova de Gaia, Porto, Portugal|Almada, Portugal|Porto, Portugal|Porto, Portugal|Porto, Portugal|Baia Mare, Romania|Brasov, Romania|Bucharest, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Craiova, Romania|Iasi, Romania|Targu-Mures, Romania|Chelyabinsk, Russian Federation|Engels, Russian Federation|Irkutsk, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Penza, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tula, Russian Federation|Volgograd, Russian Federation|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Poprad, Slovakia|George, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Saxonwold, Gauteng, South Africa|L'Hospitalet de Llobregat, Barcelona, Spain|Majadahonda, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Salamanca, Spain|Falun, Sweden|Uddevalla, Sweden|Changhua, Taiwan|Kaohsiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Khon Kaen, Thailand|Pathumthani, Thailand|Ankara, Turkey|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Trabzon, Turkey|Cherkasy, Ukraine|Dnipro, Ukraine|Khmel'nytsky, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Zaporizhzhya, Ukraine|Ha Noi, Vietnam|Ho Chi Minh City, Vietnam","","https://ClinicalTrials.gov/show/NCT02367040"
652,"NCT03093831","Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma",,"Recruiting","No Results Available","Lymphoma, B-Cell, Marginal Zone","Drug: Ibrutinib","Overall Response Rates|Progression-Free Survival|Overall Survival|Frequency and severity of adverse events|Frequency of adverse events requiring discontinuation of study drug or dose reductions","National Cancer Centre, Singapore|Singapore General Hospital|Samsung Medical Center","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","54179060LYM2009","July 8, 2016","January 2020","January 2021","March 28, 2017","null","September 14, 2018","Samsung Medical Center, Seoul, Korea, Republic of|Singapore General Hospital, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT03093831"
653,"NCT01122472","Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP","REMARC","Active, not recruiting","No Results Available","Lymphoma|Diffuse Large B-cell Lymphoma","Drug: Lenalidomide|Drug: Placebo","Progression-Free-Survival (PFS)|Overall survival (OS)|Event-Free Survival (EFS)|Response rate at the end of maintenance treatment|Percentage of patients who convert from PR (partial response) to CR (complete response)|Safety of lenalidomide in maintenance|PFS2","The Lymphoma Academic Research Organisation","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 3","650","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REMARC","April 2009","June 2016","September 2019","May 13, 2010","null","March 12, 2018","Flinders Medical Centre - Repatriation General Hospital, Adelaïde South Australia, Australia|Bendigo Hospital, Bendigo, Australia|Concord Repatriation General Hospital, Concord - Nsw, Australia|St Vincent's Hospital, Melbourne, Fitzroy, Australia|Frankston Hospital Monash Medical Centre, Frankston, Australia|Fremantle Hospital, Fremantle - WA, Australia|Austin Hospital, Heidelberg, Australia|Royal Hobart Hospital, Hobart, Australia|Mater Misericordiae Hospital - Calvary Mater NewCastle, Hunter, Australia|St George Hospital, Kogarah, Australia|Sir Charles Gardiner Hospital, Nedlands - WA, Australia|Gold Coast Hospital, Southport, Australia|Canberra Hospital, Woden - ACT, Australia|Albury Base Hospital/Murray Valley Private Hospital, Wodonga, Australia|Queen Elizabeth Hospital, Woodville -sa, Australia|LKH Feldkirch, Feldkirch, Austria|Medizinische Universität Innsbruck für Innere Medizin, Innsbruck, Austria|LKH Leoben-Eisenerz Department für Hämato-Onkologie, Leoben, Austria|Krankenhaus Barmherzigen Schwestern Linz - Abteilung für Inner, Linz, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|AKh Linz - Innere Medizin 3 - Zentrum für Hämatologie un, Linz, Austria|Universitätklinik der PMU Salzburg - Für Innere Medizin III, Salzburg, Austria|Landeskrankenhaus Steyr - Innere Medizin II, Steyr, Austria|Uniersitätsklinik f. Innere Medizin I, Vienna, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|ZNA Middelheim, Antwerpen, Belgium|ZNA Stuivenberg, Antwerpen, Belgium|Hopital Saint Joseph, Arlon, Belgium|A.Z. Sint Jan AV, Bruges, Belgium|CHU Brugmann, Bruxelles, Belgium|Institut Jules BORDET, Bruxelles, Belgium|Universite Catholique de Louvain Saint Luc, Bruxelles, Belgium|CH Notre Dame, Charleroi, Belgium|CHU Charleroi-Vesale, Charleroi, Belgium|Centre de Sante des Fagnes, Chimay, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Clinique Notre Dame de Grace, Gosselies, Belgium|Hopital Jolimont, Haine saint paul, Belgium|CH Hutois, HUY, Belgium|AZ VUB, Jette, Belgium|AZ Groeninge - Campus Maria s Voorzienigheid, Kortrijk, Belgium|CHR de la Citadelle, Liege, Belgium|CHU de Liege, Liege, Belgium|CHU Ambroise Pare, Mons, Belgium|Clinique Saint Joseph, Mons, Belgium|Hopital Sainte Elisabeth, Namur, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Heilig Hart Ziekenhuis, Roeselare, Belgium|CH de la Tourelle-Peltzer, Verviers, Belgium|A.Z. Sint-Augustinus, Wilrijk, Belgium|Universite Catholique de Louvain Mont Godinne, Yvoir, Belgium|CHR de la Région d'Annecy, Annecy Cedex, France|CH Antibes-Juan les Pins, Antibes, France|CH d'Arras, Arras Cedex, France|Hopital Henri DUFFAUT, Avignon, France|Hopital de BAYONNE, Bayonne, France|CHG Mail Pierre Charlot, Blois, France|Hôpital d'Avicenne, Bobigny, France|Hopital Jean VERDIER, BONDY Cedex, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hopital DUCHENNE, Boulogne sur Mer, France|CH de Bourg-en-Bresse, Bourg-en-Bresse, France|Centre Hospitalier de Brive, Brive-La-Gaillarde, France|Centre François Baclesse, CAEN Cedex 05, France|CHU Clémenceau- Côte de Nacre, Caen Cedex, France|CH de Cannes, Cannes, France|Hôpital de Châlon, Chalon sur Saone, France|Centre Hospitalier, Chambery, France|CH Chartres, Chartres Cedex, France|Hopital Antoine Béclère, Clamart, France|Hôpital des instructions des Armées PERCY, Clamart, France|Hopital Louis Pasteur, Colmar Cedex, France|CH de Compiègne, Compiegne Cedex, France|Hopital Sud Francilien, Corbeil-Essonnes, France|CH Henri Mondor, Créteil, France|CHU le Bocage, Dijon, France|CH de Dunkerque, Dunkerque, France|CHI Evreux, Evreux, France|CHI Fréjus Saint Raphaêl, Frejus, France|Institut Daniel Hollard, Grenoble, France|Centre Hospitalier de Guéret, Gueret, France|Hopital Bicêtre, Kremlin Bicêtre Cedex, France|CHG La Rochelle, La Rochelle Cedex 01, France|Hopital André Mignot, Le Chesnay, France|Clinique Victor Hugo - Centre Jean Bernard, LE Mans, France|CHU de Lens, Lens, France|CHRU de Lille, Lille Cedex, France|Hôpital Saint Vincent de Paul, Lille, France|Hopital DUPUYTREN, LIMOGES Cedex, France|Centre Léon Bérard, LYON Cedex 08, France|Clinique de la Sauvegarde, Lyon, France|CH les CHANAUX, Macon Cedex, France|Institut Paoli Calmettes, Marseille Cedex, France|Hopital Nord, Marseille, France|CHG Meaux, Meaux, France|CH Marc JACQUET, MELUN Cedex, France|Hopital Notre Dame de Bon Secours, Metz Cedex, France|CRLC Val d'Aurelle, Montpellier Cedex, France|Centre Azuréen de Cancérologie, Mougins, France|Hopital Emile Muller- CHU Mulhouse, MULHOUSE Cedex, France|Hôpital Américain de Paris, Neuilly sur seine, France|Centre Antoine Lacassagne, Nice, France|CHU de Nice, Nice, France|Hôtel Dieu, Paris Cedex 04, France|Institut Curie, Paris Cedex 05, France|Hopital de la Pitié Salpetrière, Paris Cedex 13, France|Hopital Saint Antoine, Paris, France|Hopital St-Louis, Paris, France|Hopital NECKER, Paris, France|CH de Perpignan, Perpignan, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, France|CH René DUBOS, Pontoise, France|Hopital Robert DEBRE, REIMS Cedex, France|Centre Henri BECQUEREL, Rouen, France|Clinique Mathilde, Rouen, France|Centre René Huguenin, Saint Cloud Cedex, France|CHG Saint Germain, St Germain en Laye, France|CHI Toulon La Seyne-sur-mer, Toulon, France|CHU Purpan Pav. Dieulafoy, Toulouse Cedex 9, France|Hopital de Troyes, Troyes Cedex, France|CH Valence, Valence Cedex 9, France|CH de Valenciennes, Valenciennes, France|CHU Nancy Brabois, Vandoeuvre, France|Institut Gustave ROUSSY, VILLEJUIF Cedex, France|Haemek Medical Center, Afula, Israel|Barzilai Medical Center, Ashkelon, Israel|Soroka, Beer sheva, Israel|Bnai-Zion medical center, Haifa, Israel|Meir Medical Center, Kfar saba, Israel|Rabin Medical Center - Beilinson Hospital, Petah Tikwah, Israel|Kaplan Medical Center, Rehovot, Israel|SPZOZ Zespol Szpitali Miejskich w Chorzowie, Chorzow, Poland|Klinika Hematologii Collegium Medicum UJ, Krakow, Poland|Oddzial Chorob Rozrostowych Regionalny Osrodek Onkologiczny, Lodz, Poland|Medical University of Warsaw, Warsaw, Poland|Klinika Nowotworow Ukladu Chlonnego- Centrum Onkologii, Warszawa, Poland|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Português de Oncologia de Lisboa de Francisco Gentil, Lisboa, Portugal|Hospital de Santa Maria, Lisboa, Portugal|IPO - Francisco Gentil - Porto, Porto, Portugal|Complejo Hospitalario Universitario de A Coruna, A coruna, Spain|Hospital Universitario Fundacion Alcorcon, Alcorcon, Spain|Hospital Clinic Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hopital Universitario Virgen de la Arrixaca, El palmar, Spain|Hopital de Jerez (S.A.S), Jerez de la frontera, Spain|Hospital de Leon, Leon, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Général Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario - La Paz, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Hospital Central Asturias, Oviedo, Spain|Hospital Clinico Salamanca, Salamanca, Spain|Universitario Marques de Valdecilla, Santander, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mutua de Terrassa, Terrassa, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland","","https://ClinicalTrials.gov/show/NCT01122472"
654,"NCT02981745","Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia",,"Recruiting","No Results Available","Relapsed or Refractory B Cell Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Waldenstrom's Macroglobulinemia|Mantle Zone Lymphoma Refractory/Recurrent|Follicle Centre Lymphoma Diffuse|Diffuse Large B Cell Lymphoma","Drug: CT-1530","Incidence rate of dose limiting toxicities (DLTs) during the first cycle of treatment (Phase I)|Overall Response Rate (ORR) - Phase I|Progression free survival (PFS) per RECIST v1.1 - Phase I|Duration of response (DOR)","Centaurus Biopharma Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-1530-101","April 1, 2017","September 2018","December 2018","December 5, 2016","null","July 19, 2017","Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02981745"
655,"NCT01955499","Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma","Drug: Ibrutinib|Drug: Lenalidomide|Other: Pharmacological Study","Maximum tolerated dose (MTD)|Incidence of toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 criteria|Number of patients responding to treatment|Degree of response|Duration of overall response|Duration of stable disease|Progression free survival (PFS)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2013-01810|OSU 13022|9426|K24CA201524|P30CA016058|U01CA132123|U01CA076576|UM1CA186644|UM1CA186705|UM1CA186712","September 13, 2013","December 31, 2019","null","October 7, 2013","null","July 19, 2018","University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01955499"
656,"NCT03079947","Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma|Peripheral T Cell Lymphoma","","overall survival|relapse of the disease|progression free survival","Peking Union Medical College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PUMCH-1149","January 2017","January 2020","January 2020","March 15, 2017","null","March 27, 2017","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03079947"
657,"NCT01239875","Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Adult Diffuse Mixed Cell Lymphoma|Adult Diffuse Small Cleaved Cell Lymphoma|Adult Grade III Lymphomatoid Granulomatosis|Adult Immunoblastic Large Cell Lymphoma|Adult Lymphoblastic Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3 Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia With Nodal Disease","Biological: dendritic cell vaccine therapy|Procedure: cryotherapy|Biological: pneumococcal polyvalent vaccine|Other: laboratory biomarker analysis|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Biological: autologous dendritic cell-tumor fusion vaccine","Incidence of significant toxicity as assessed by the CTEP Active Version CTCAE|Overall response rate|Feasibility as estimated by the number of patients receiving at least one dose of tumor antigen loading and vaccine delivery divided by the number receiving leukapheresis|Clinical benefit rate as estimated by the number of patients with an objective status of stable disease (SD) or an objective status of CR or PR|Time to response|Duration of response|Percent change from baseline in index lesion measurements as a marker of distant immune and treatment response|Change in immunologic correlates before and after vaccination treatment|Correlation of immunologic markers with cancer and treatment-related outcomes (e.g., response, toxicities)","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","16","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LS1081|NCI-2010-02003|10-003023","November 2010","December 2015","December 2017","November 11, 2010","null","March 22, 2017","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01239875"
658,"NCT03103971","huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Adult B Acute Lymphoblastic Leukemia|BCL2 Gene Rearrangement|BCL6 Gene Rearrangement|CD19 Positive|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|MYC Gene Rearrangement|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma","Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Other: Pharmacological Study","Incidence of toxicity graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Dose-limiting toxicity (DLT) rates|Maximum concentration (Cmax) of autologous human anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (huJCAR014) cells in blood|Time to maximum concentration (Tmax), of huJCAR014 cells in blood|Area under the curve of huJCAR014 cells in blood|Presence of huJCAR014 cells in bone marrow|Complete response (CR) rate|Partial response (PR) rate|Objective response rate (ORR) defined as the proportion of patients with a best response of either CR or PR|Duration of response (DOR), defined as the time from date of first response to relapse/progression or death|Progression-free survival (PFS)|Event-free survival (EFS)|Overall survival (OS)","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9364|NCI-2017-00421|P30CA015704","November 3, 2017","July 17, 2019","July 17, 2033","April 7, 2017","null","May 30, 2018","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03103971"
659,"NCT03620578","DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL","HO152","Recruiting","No Results Available","Non Hodgkin Lymphoma|Lymphoma, B-Cell|High-grade B-cell Lymphoma|MYC Translocation|BCL-2 Translocation","Drug: DA-EPOCH-R followed by Nivolumab","12 months DFS from Nivolumab consolidation registration|Complete metabolic response (CMR) rate on 18F-FDG PET-CT after DA-EPOCH-R|18 months Progression-Free Survival (PFS)|18 months OS|12 months OSc|Rate of CTCAE grade >=2 toxicities|consolidation MRD conversion|predictive value of mid-treatment 18F-FDG PET-CT","Stichting Hemato-Oncologie voor Volwassenen Nederland","All","18 Years and older   (Adult, Older Adult)","Phase 2","102","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOVON 152 DLBCL|2017-003631-12","August 1, 2018","August 2022","August 2026","August 8, 2018","null","August 14, 2018","ZNA, Antwerp, Belgium|UZ Leuven, Leuven, Belgium|Flevoziekenhuis, Almere, Netherlands|Meander MC, Amersfoort, Netherlands|AMC, Amsterdam, Netherlands|VUmc, Amsterdam, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Maxima MC, Eindhoven, Netherlands|MST, Enschede, Netherlands|ADRZ, Goes, Netherlands|UMCG, Groningen, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|Westfries Gasthuis, Hoorn, Netherlands|MC Leeuwarden, Leeuwarden, Netherlands|LUMC, Leiden, Netherlands|MUMC, Maastricht, Netherlands|Radboud UMC, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Maasstadziekenhuis, Rotterdam, Netherlands|Zuyderland MC, Sittard, Netherlands|Sint Elisabeth Ziekenhuis, Tilburg, Netherlands|UMCU, Utrecht, Netherlands|Isala Klinieken, Zwolle, Netherlands","","https://ClinicalTrials.gov/show/NCT03620578"
660,"NCT00720135","Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",,"Completed","No Results Available","Anaplastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia","Biological: DI-Leu16-IL2 immunocytokine|Biological: rituximab|Other: flow cytometry|Other: immunohistochemistry staining method|Other: pharmacological study|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay|Genetic: reverse transcriptase-polymerase chain reaction","Maximum tolerated dose of DI-Leu16-IL2|Optimal biologic dose of DI-Leu16-IL2|Toxicities associated with the DI-Leu16-IL2 regimen|Immunogenicity as a result of DI-Leu16-IL2 administration|Pharmacokinetics of DI-Leu16-IL2 administration|Clinical responses and survival","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","03131|NCI-2010-01228|CDR0000598679|P50CA107399","January 2008","July 2014","July 2014","July 22, 2008","null","June 8, 2015","City of Hope, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT00720135"
661,"NCT01680991","A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease",,"Completed","Has Results","Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma","Drug: Obinutuzumab","Area Under the Serum Concentration Time Curve From Zero to Day 7 (AUC0-7) of Obinutuzumab on Day 1, Cycle 1|Maximum Observed Serum Concentration (Cmax) of Obinutuzumab on Day 1, Cycle 1|Area Under the Serum Concentration Versus Time Curve From 0 to Day 21 (AUC0-21) of Obinutuzumab at Cycle 8|Cmax of Obinutuzumab at Cycle 8|Time to Maximum Observed Serum Concentration (Tmax) of Obinutuzumab at Cycle 8|Apparent Terminal Half-life (t1/2)|Volume of Distribution at Steady State (Vss) of Obinutuzumab at Cycle 8|Total Systemic Clearance at Steady State (CLss) of Obinutuzumab at Cycle 8|Minimum Observed Serum Concentration of Obinutuzumab|Percentage of Participants With Complete Response (CR), CR Unconfirmed (CRu) at End of Treatment (1 Month After Cycle 8) in NHL Participants (DLBCL and FL Participants) Per Cheson 1999 Criteria|Percentage of Participants With Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD) at End of Treatment (1 Month After Cycle 8) in NHL Participants (DLBCL and FL Participants) Per Cheson 1999 Criteria|Percentage of Participants With Best Overall Response (BOR) of CR, CRu at Anytime During Study in NHL Participants (DLBCL and FL Participants) Per Cheson 1999 Criteria|Percentage of Participants With BOR of PR, SD, and PD at Anytime During Study in NHL Participants (DLBCL and FL Participants) Per Cheson 1999 Criteria|Percentage of Participants With Complete Remission (CRe), CRe With Incomplete BM Recovery (CRi) at End of Treatment (1 Month After Cycle 8) in CLL Participants According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Guidelines|Percentage of Participants With PR, SD, and PD at End of Treatment (1 Month After Cycle 8) in CLL Participants According to IWCLL 2008 Guidelines|Percentage of Participants With BOR of CRe, CRi at Anytime During the Study in CLL Participants According to IWCLL 2008 Guidelines|Percentage of Participants With BOR of PR, SD, and PD at Anytime During Study in CLL Participants According to IWCLL 2008 Guidelines|Number of Participants With Positive Human Anti-Human Antibodies (HAHA)|Number of Participants With Positive Human Anti-Chimeric Antibodies (HACA)|Number of Participants With B-cell Depletion or Recovery|Duration of Depletion of CD19+ B-cell|Time to Recovery of CD19+ B-cell","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YP25623","September 2012","December 2014","December 2014","September 7, 2012","April 25, 2016","April 25, 2016","Beijing, China|Beijing, China|Guangzhou, China|Shanghai, China","","https://ClinicalTrials.gov/show/NCT01680991"
662,"NCT01045928","Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Adult Non-Hodgkin Lymphoma|Adult Grade III Lymphomatoid Granulomatosis|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia","Drug: lenalidomide|Biological: rituximab|Genetic: polymerase chain reaction|Genetic: nucleic acid sequencing|Genetic: polymorphism analysis|Other: flow cytometry|Other: laboratory biomarker analysis","Maximum tolerated dose of lenalidomide (Phase I)|Proportion of subjects who are able to complete 12 cycles of maintenance therapy with lenalidomide and rituximab after autologous stem cell transplantation (ASCT)(PHASE II)|Progression-free survival after ASCT|Evaluation of potential differences in effects of lenalidomide and rituximab on progression-free survival after ASCT according to histologic subtypes of B-cell NHL|Overall response rate associated with treatment with lenalidomide and rituximab after ASCT, defined as the proportion of subjects with measurable disease at enrollment who achieve a partial response or complete response|Enumeration of peripheral blood lymphocyte subsets by flow cytometry, including T cells, B cells, and NK cells and analysis of potential associations between these levels with progression-free survival|Analysis of FCgammaRIIIa receptor sequences in enrolled subjects to determine the presence or absence of FCgammaRIIIa-158 polymorphisms (V/V, V/F, and F/F); determining potential associations of these polymorphisms with progression-free survival|Incidence of non-relapse mortality (NRM) defined as death from any cause other than B-cell NHL|Incidence of unacceptable toxicity during study treatment","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE2409|NCI-2009-01580","January 2010","March 2011","March 2012","January 11, 2010","null","November 26, 2015","Fairview Cancer Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01045928"
663,"NCT03019640","Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Indolent Adult Non-Hodgkin Lymphoma","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Drug: Cytarabine|Drug: Etoposide|Biological: Filgrastim|Drug: Lenalidomide|Drug: Melphalan|Biological: Rituximab","Treatment-related mortality within 30 days (TRM30)|Relapse-free survival (RFS)|Overall survival (OS)|Natural killer (NK) cell persistence","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","15 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0751|NCI-2018-01239|P30CA016672","October 10, 2017","March 31, 2020","March 31, 2020","January 12, 2017","null","September 19, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03019640"
664,"NCT01055496","Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma, B-Cell","Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone","To determine the tolerability, the initial safety profile, as evaluated by an analysis of laboratory results and adverse event (AE) reporting.|Determination of MTD or recommended dose of the immunochemotherapeutic regimens R-CVP or R-GDP given in combination with inotuzumab ozogamicin in subjects with CD22-positive NHL.|To obtain preliminary information on the antitumor activity of R-CVP or R-GDP in combination with inotuzumab ozogamicin as measured by ORR, progression-free survival, and overall survival data in MTD confirmation/expanded efficacy cohorts|To evaluate PK of 0.8 mg/m2 of inotuzumab ozogamicin when combined with R CVP or with R-GDP|To develop a molecular predictor of response to inotuzumab ozogamicin plus R-CVP or R-GDP.","Pfizer|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 1","104","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3129K2-1105|B1931003","March 2010","July 2013","March 2014","January 25, 2010","null","April 1, 2014","Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Federal Way, Washington, United States|Pfizer Investigational Site, Gig Harbor, Washington, United States|Pfizer Investigational Site, Lakewood, Washington, United States|Pfizer Investigational Site, Puyallup, Washington, United States|Pfizer Investigational Site, Tacoma, Washington, United States|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Ghent, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Paris Cedex 10, France|Pfizer Investigational Site, Pierre-Benite Cedex, France|Pfizer Investigational Site, Shatin NT, Hong Kong|Pfizer Investigational Site, Nagoya, Aichi, Japan|Pfizer Investigational Site, Chuo-ku, Tokyo, Japan|Pfizer Investigational Site, Tokyo, Japan|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Southampton, Hants, United Kingdom|Pfizer Investigational Site, Eastleigh, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01055496"
665,"NCT02253992","An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Advanced Solid Tumors|Advanced B-cell NHL","Biological: Urelumab|Biological: Nivolumab","Safety as measured by the rate of adverse events (AEs) and Serious Adverse Events (SAEs)|Best Overall Response (BOR)|Objective response rate (ORR)|Duration of Response (DOR)|Progression-free survival rate (PFSR)|Maximum observed serum concentration (Cmax) of Urelumab,(µg/mL)|Time of maximum observed serum concentration (Tmax) of Urelumab, (hr)|Area under the concentration-time curve in one dosing interval (AUCTAU) of Urelumab (µg.hr/mL)|Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of Urelumab (µg.hr/mL)|Total body clearance (CLT) of Urelumab (L/day)|Volume of distribution at steady state (Vss) of Urelumab|Half life (t1/2) of Urelumab|Trough concentration (Cmin) of Urelumab (µg/mL)|Occurrence of specific anti-drug antibodies (ADA) to Urelumab and Nivolumab|Anti-drug Antibody (ADA) status of the subject in response to Urelumab and Nivolumab|Nivolumab end of Infusion concentration (EOI)|Trough concentration (Cmin) of Nivolumab (µg/mL)","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA186-107|2014-002241-22","September 29, 2014","December 26, 2018","September 27, 2019","October 1, 2014","null","July 24, 2018","Stanford University School Of Medicine, Palo Alto, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Md Anderson, Houston, Texas, United States|Local Institution, Besancon, France|Local Institution, Marseille, France|Local Institution, Rennes Cedex 9, France|Local Institution, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Clinica Universitaria De Navarra, Pamplona, Spain","","https://ClinicalTrials.gov/show/NCT02253992"
666,"NCT02650414","CD22 Redirected Autologous T Cells for ALL",,"Recruiting","No Results Available","B Cell Leukemias|B Cell Lymphomas","Biological: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB","Frequency and severity of adverse events, including, but not limited to, cytokine release syndrome (CRS)|Evaluate Overall Complete Remission Rate (ORR)|Evaluate overall response rate including complete remission (CR) and complete remission with incomplete blood count recovery (CRi)|Evaluate duration of remission (DOR)","University of Pennsylvania|Children's Hospital of Philadelphia","All","1 Year to 24 Years   (Child, Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-012219, 823312|UPCC 15CT055","January 2016","December 2019","December 2020","January 8, 2016","null","August 1, 2018","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02650414"
667,"NCT00336843","Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: Zevalin-BuCyE","Event-free survival|Overall survival|Toxicity of the treatment combination","Asan Medical Center|Schering-Plough","All","up to 64 Years   (Child, Adult)","Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC 2005-276","November 2005","February 2009","May 2010","June 14, 2006","null","February 17, 2016","Asan Medical Center, Departement of Internal Medicine, Division of Oncology, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT00336843"
668,"NCT00061425","Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG",,"Completed","No Results Available","Non-Hodgkin's Lymphoma|Lymphoma, B-Cell","Drug: radiolabeled epratuzumab","","Immunomedics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","null","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IM-T-hLL2-06-EU","August 2000","November 2007","null","May 28, 2003","null","January 9, 2009","","","https://ClinicalTrials.gov/show/NCT00061425"
669,"NCT03383952","A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia",,"Recruiting","No Results Available","B Cell Leukemia|B Cell Lymphoma","Biological: ICAR19 CAR-T cells","Measure the safety of ICAR19 CAR-T cells|Measure the anti-tumor effect of ICAR19 CAR-T cells|Survival time of ICAR19 T cells in vivo.","Immune Cell, Inc.|Weifang People's Hospital","All","2 Years to 80 Years   (Child, Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD19 Targeted CAR-T","March 1, 2017","December 31, 2020","December 31, 2025","December 27, 2017","null","December 27, 2017","Weifang People's Hospital, Weifang, Shandong, China","","https://ClinicalTrials.gov/show/NCT03383952"
670,"NCT03398967","A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma",,"Recruiting","No Results Available","B Cell Leukemia|B Cell Lymphoma","Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells","Number of Participants with Severe/Adverse Events as a Measure of Safety and Tolerability|MTD of universal dual specificity CD19 and CD20 or CD22 CAR-T cells|Copies numbers of CAR in peripheral blood(PB), bone marrow(BM)and lymph nodes|Six-month Objective response rate of complete remission and partial remission|Six-month Overall survival|Six-month Progression free survival","Chinese PLA General Hospital","All","12 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-026","January 2, 2018","May 20, 2022","May 20, 2022","January 16, 2018","null","January 16, 2018","Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03398967"
671,"NCT03166878","A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma",,"Recruiting","No Results Available","B Cell Leukemia|B Cell Lymphoma","Biological: UCART019","Number of Participants with Severe/Adverse Events as a Measure of Safety and Tolerability|Highest dose of UCART019 that is estimated to result in defined DLT with the exception of allowable UCART019 infusion related 'expected' AEs, using CTCAE 4.0, in less than 1/3 patients|Copy numbers of UCAR019 in PB, BM and lymph nodes|Objective response rate of complete remission and partial remission.Descriptive statistics will be used|Overall survival.Descriptive statistics will be used|Progression free survival.Descriptive statistics will be used","Chinese PLA General Hospital","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-021","June 2017","May 2022","May 2022","May 25, 2017","null","June 23, 2017","Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03166878"
672,"NCT00210379","Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma, B Cell","Drug: rituximab|Drug: CHOP|Drug: intrathecal methotrexate|Procedure: radiotherapy","Disease-free survival|Progression-free survival|Event-free survival|Overall survival will be a secondary end-point because post-relapse therapy is not specified in this protocol and is expected to be highly variable","International Extranodal Lymphoma Study Group (IELSG)","Male","18 Years and older   (Adult, Older Adult)","Phase 2","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG10","November 2000","November 2004","March 2007","September 21, 2005","null","July 22, 2009","Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland","","https://ClinicalTrials.gov/show/NCT00210379"
673,"NCT02953509","Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Indolent Lymphoma","Drug: Hu5F9-G4|Drug: Rituximab","Dose-limiting toxicities (Number of participants with a DLT)|Objective response (defined by the Investigator according to the Lugano classification for lymphomas)","Forty Seven, Inc.|The Leukemia and Lymphoma Society","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5F9003","November 2016","March 2020","January 2023","November 2, 2016","null","August 1, 2018","University of Alabama At Birmingham (Uab) Comprehensive Cancer Center, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|Stanford University, Palo Alto, California, United States|University of Chicago, Chicago, Illinois, United States|NIH, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Carolinas Healthcare Systems- Levine Cancer Institute, Charlotte, North Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Oxford University Hospital, Oxford, Oxforshire, United Kingdom|Barts Cancer Institute, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02953509"
674,"NCT00542919","A Study for Patients With Non-Hodgkin's Lymphomas",,"Completed","No Results Available","T-Cell Lymphoma|B-Cell Lymphoma","Drug: enzastaurin","Tumor response rate|Progression-free survival|Time to progressive disease|Duration of response|Progression free survival|Safety","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","57","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11503|H6Q-MC-S057","November 2007","March 2010","February 27, 2018","October 12, 2007","null","April 11, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Anaheim, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Garran, Australian Capital Territory, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auchenflower, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prahran, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brasilia, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Curitiba, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jau, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chennai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Navrangpura, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Secunderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tepic, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tlalpan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lima, Peru","","https://ClinicalTrials.gov/show/NCT00542919"
675,"NCT02106091","Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL",,"Recruiting","No Results Available","Relapsed B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma","Drug: AFM11","Number of participants with serious and non-serious adverse events as a measure of safety and tolerability of AFM11.|Maximum Tolerated Dose (MTD) of AFM11.|Pharmacokinetic profile of AFM11 and immunological markers of AFM11 activity.|Tumor Response.","Affimed GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFM11-101|2013-001919-78","April 2014","August 2018","September 2018","April 8, 2014","null","February 6, 2018","Tufts Medical Center, Boston, Massachusetts, United States|Charles Hospital Prague, Prague, Czechia|University Hospital of the Saarland, Homburg/Saar, Germany|University Hospital, Kiel, Germany|University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany|University Hospital, Ulm, Germany|University Hospital, Wuerzburg, Germany|SP ZOZ University Hospital Krakow, Krakow, Poland|MTZ Clinical Research, Warsaw, Poland","","https://ClinicalTrials.gov/show/NCT02106091"
676,"NCT03019055","Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",,"Recruiting","No Results Available","CLL/SLL|Lymphomas Non-Hodgkin's B-Cell","Biological: CAR-20/19-T","Number of Adverse Events after CAR 20/19-T cell infusion","Medical College of Wisconsin|Children's Hospital and Health System Foundation, Wisconsin","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00028724","October 16, 2017","September 2020","September 2021","January 12, 2017","null","July 13, 2018","Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03019055"
677,"NCT02992223","Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT",,"Completed","No Results Available","Refractory B-Cell Non-Hodgkin Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma","","Overall Survival|Progression Free Survival","Azienda Ospedaliera Città della Salute e della Scienza di Torino","All","19 Years and older   (Adult, Older Adult)","","58","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Oss_Z-BEAM","July 2014","July 2015","July 2015","December 14, 2016","null","December 14, 2016","","","https://ClinicalTrials.gov/show/NCT02992223"
678,"NCT01647971","Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Non-Hodgkins Lymphoma|B-cell Lymphoma|Waldenstrom's Macroglobulinemia|Marginal Zone Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Primary Central Nervous System Lymphoma","Drug: Ublituximab","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Maximum Tolerated Dose acceptable for participants|Efficacy","TG Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TGTX 1101-101","August 2012","June 2018","December 2018","July 24, 2012","null","September 13, 2018","TG Therapeutics Investigational Trial Site, Huntsville, Alabama, United States|TG Therapeutics Investigational Trial Site, Jonesboro, Arkansas, United States|TG Therapeutics Investigational Trial Site, Athens, Georgia, United States|TG Therapeutics Investigational Trial Site, Macon, Georgia, United States|TG Therapeutics Investigational Trial Site, Bethesda, Maryland, United States|TG Therapeutics Investigational Trial Site, Morristown, New Jersey, United States|TG Therapeutics Investigational Trial Site, New York, New York, United States|TG Therapeutics Investigational Trial Site, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01647971"
679,"NCT01626495","Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma","Pedi CART19","Active, not recruiting","No Results Available","B Cell Leukemia|B Cell Lymphoma","Biological: CART-19","Number of Participants with Severe/Adverse Events as a Measure of Safety and Tolerability|Ability of two different types of CAR+ T cells to expand and persist in the patient|Impact of CAR+ T cell infusion on cancer","University of Pennsylvania","All","1 Year to 24 Years   (Child, Adult)","Phase 1","76","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-007706, 815870|CHP959","August 2011","September 2016","December 2018","June 22, 2012","null","April 5, 2018","CHOP - http://www.chop.edu/service/oncology/pediatric-cancer-research/cart-19-trial.html, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01626495"
680,"NCT03375619","Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells",,"Recruiting","No Results Available","CLL/SLL|Lymphomas Non-Hodgkin's B-Cell","Other: Long-Term Follow-Up of Patients who Received CAR-20/19-T cells","Proportion of patients with listed categories: new malignancies, new incidence or exacerbation of a prior rheumatologic or other autoimmune disorder, new incidence of a hematologic disorder.|Proportion of patients who relapse or progress among patients who had not relapsed or progressed at study entry from CAR-20/19 T cell treatment; Incidence of death.|Absolute B- and T-lymphocyte counts.|Proportion of patients with persistence of CAR-20/19-T cells as measured by integrated vector DNA by quantitative polymerase chain reaction.|Recovery of immunoglobulin production as measured by quantitative immunoglobulin levels (IgG, IgA, IgM).","Medical College of Wisconsin","All","18 Years to 70 Years   (Adult, Older Adult)","","24","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PRO30317","December 1, 2017","August 1, 2020","August 1, 2040","December 18, 2017","null","March 23, 2018","Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03375619"
681,"NCT03497533","Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19","Trident19-H","Recruiting","No Results Available","Non-hodgkin Lymphoma,B Cell","Biological: TriCAR-T-CD19","Safety (Incidence of treatment-related adverse events as assessed by CTCAE v4.0)|Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)|Partial response rate [PR] (Partial response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)|Duration of Response （The time from response to relapse or progression）|Progression Free Survival（The time from the first day of treatment to the date on which disease progresses.）|Overall Survival（The number of patient alive, with or without signs of cancer）","Timmune Biotech Inc.|Hunan Provincial People's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","6","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ChiCTR1800014528","August 3, 2018","December 31, 2020","December 31, 2020","April 13, 2018","null","August 29, 2018","Hunan Provincial People's Hospital, Changsha, Hunan, China","","https://ClinicalTrials.gov/show/NCT03497533"
682,"NCT00081861","Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma","Drug: Avastin|Drug: Rituximab","Number of Participants With Response (Complete Response or Progressive Disease)","M.D. Anderson Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2003-0520","March 2004","September 2007","September 2007","April 27, 2004","August 26, 2009","April 5, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00081861"
683,"NCT00989586","Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Completed","Has Results","Lymphoma","Biological: milatuzumab|Biological: veltuzumab|Procedure: Correlative/Special Studies|Procedure: Quantitative T-, B-, and NK cell subsets|Procedure: Pharmacokinetics|Procedure: Human Anti-Human Antibodies|Biological: veltuzumab and milatuzumab","Dose Limiting Toxicity (DLT) for Phase I Patients|Maximum Tolerated Dose (MTD)for Phase I Patients|Overall Objective Response Rate|Progression-free Survival (PFS)|Fcγ-receptor Polymorphism Response to Treatment|Quantitative T-, B-, and NK-cell Subsets Using Flow Cytometry|Access Pharmacokinetics Through AUC0-∞ (Area Under Curve)|Access Pharmacokinetics Through Cmax|Monitor Human Anti-veltuzumab Antibodies and Human Anti-milatuzumab (HAHA)","Beth Christian|Immunomedics, Inc.|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","35","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-09024|NCI-2011-03150","September 2009","April 2015","September 2015","October 5, 2009","February 6, 2017","February 6, 2017","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00989586"
684,"NCT01545544","Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)","Lympho C","Unknown status","No Results Available","Chronic Hepatitis C","","presentation of NHL and HCV infection, and treatments of NHL and HCV infection|Summary of intercurrents biological and clinical events|virological response|haematological response","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","All","18 Years and older   (Adult, Older Adult)","","138","Other","Observational","Observational Model: Case-Only","ANRS HC13 Lympho C","November 2006","November 2014","November 2014","March 6, 2012","null","February 7, 2014","Hôpital Necker, Paris, France","","https://ClinicalTrials.gov/show/NCT01545544"
685,"NCT01200589","Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy","HOMER","Terminated","Has Results","Non-Hodgkin's Lymphoma","Biological: Ofatumumab|Biological: Rituximab","Progression-free Survival (PFS) - Number of Participants With PFS Events|Number of Participants With Complete Response (CR)|Number of Participants With Overall Response (OR)|Number of Deaths|Number of Participants With Infection Related Adverse Events|Number of Participants With Infusion Related Adverse Events Due to Study Drug|Number of Participants With Myelosuppression Adverse Events|Duration of Response (DOR)|Time to Next Treatment|Pharmacokinetics","Novartis Pharmaceuticals|GlaxoSmithKline|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","438","Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","113676","October 11, 2010","December 19, 2016","December 19, 2016","September 13, 2010","May 16, 2018","May 16, 2018","Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Gilbert, Arizona, United States|Novartis Investigative Site, Hot Springs, Arkansas, United States|Novartis Investigative Site, Greenbrae, California, United States|Novartis Investigative Site, Monterey, California, United States|Novartis Investigative Site, Pleasant Hill, California, United States|Novartis Investigative Site, Rancho Mirage, California, United States|Novartis Investigative Site, Salinas, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Pablo, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, New Milford, Connecticut, United States|Novartis Investigative Site, Torrington, Connecticut, United States|Novartis Investigative Site, Lakeland, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Pembroke Pines, Florida, United States|Novartis Investigative Site, Port Saint Lucie, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Macon, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Evanston, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Quincy, Illinois, United States|Novartis Investigative Site, Skokie, Illinois, United States|Novartis Investigative Site, Anderson, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Ames, Iowa, United States|Novartis Investigative Site, Mount Sterling, Kentucky, United States|Novartis Investigative Site, Metairie, Louisiana, United States|Novartis Investigative Site, Shreveport, Louisiana, United States|Novartis Investigative Site, Waterville, Maine, United States|Novartis Investigative Site, Silver Spring, Maryland, United States|Novartis Investigative Site, Grand Rapids, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Columbia, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Saint Joseph, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Bozeman, Montana, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Lake Success, New York, United States|Novartis Investigative Site, Mount Kisco, New York, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Bismarck, North Dakota, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Danville, Pennsylvania, United States|Novartis Investigative Site, Ephrata, Pennsylvania, United States|Novartis Investigative Site, Lancaster, Pennsylvania, United States|Novartis Investigative Site, Willow Grove, Pennsylvania, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Germantown, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Fort Sam Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Ogden, Utah, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Fredericksburg, Virginia, United States|Novartis Investigative Site, Kennewick, Washington, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Mount Vernon, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Sequim, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Salvador, Bahía, Brazil|Novartis Investigative Site, Betim, Minas Gerais, Brazil|Novartis Investigative Site, Curitiba, Paraná, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Barretos, São Paulo, Brazil|Novartis Investigative Site, Jau, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Hradec Kralove, Czechia|Novartis Investigative Site, Ostrava, Czechia|Novartis Investigative Site, Praha 2, Czechia|Novartis Investigative Site, Boulogne sur Mer Cedex, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, France|Novartis Investigative Site, La Roche sur Yon Cedex 9, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Pessac cedex, France|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Kyoto, Japan|Novartis Investigative Site, Miyagi, Japan|Novartis Investigative Site, Nagasaki, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Tochigi, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Miraflores, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Parktown, Gauteng, South Africa|Novartis Investigative Site, Athlone Park, Amanzimtoti, South Africa|Novartis Investigative Site, Port Elizabeth, South Africa|Novartis Investigative Site, Saxonwold, Johannesburg, South Africa|Novartis Investigative Site, Donetsk, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Makiivka, Ukraine|Novartis Investigative Site, Simferopil, Ukraine","","https://ClinicalTrials.gov/show/NCT01200589"
686,"NCT00397800","Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: yttrium Y 90 ibritumomab tiuxetan","Dose-limiting toxicity|Response|Survival","Technische Universität München","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000515982|KRDI-TUM-R-F-015-V-0030-I|EU-20633","June 2005","May 2008","May 2013","November 10, 2006","null","August 28, 2012","Medizinische Klinik, Klinikum Augsburg, Augsburg, Germany|Medizinische Klinik III - Universitaetsklinikum Erlangen, Erlangen, Germany|Universitaetsklinikum Goettingen, Goettingen, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany|Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg, Germany|Universitatsklinik Mainz, Mainz, Germany|LMU-Klinikum Grosshadern, Munich, Germany|Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany|Klinikum der Universitaet Regensburg, Regensburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm, Ulm, Germany|Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg, Wuerzburg, Germany","","https://ClinicalTrials.gov/show/NCT00397800"
687,"NCT02756247","A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma","Drug: Buparlisib|Drug: Ibrutinib","Maximum tolerated dose (MTD)","Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-009","May 2016","May 2019","May 2019","April 29, 2016","null","June 25, 2018","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT02756247"
688,"NCT02401048","A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas",,"Active, not recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Follicular Lymphoma","Drug: Ibrutinib|Drug: MEDI4736","Phase 1b/2 (Number and type of adverse events)|Phase Ib/2 (Overall response rate)|Phase Ib/2 (Pharmacokinetics of ibrutinib) Cmax|Phase Ib/2 (Pharmacokinetics of ibrutinib) AUC0-24|Phase Ib/2 (Pharmacokinetics of MEDI4736) Cmax|Phase Ib/2 (Pharmacokinetics of MEDI4736) Ctrough|Phase Ib/2 (Pharmacodynamics of ibrutinib) Btk occupancy after ibrutinib administration","Pharmacyclics LLC.|AstraZeneca|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","109","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-1136-CA","May 2015","April 2018","July 2018","March 27, 2015","null","July 6, 2017","Site-0397, Birmingham, Alabama, United States|Site-0047, Duarte, California, United States|Site-0038, Stanford, California, United States|Site-0388, Miami, Florida, United States|Site-0126, Chicago, Illinois, United States|Site-0020/0173, Boston, Massachusetts, United States|Site-0729, Ann Arbor, Michigan, United States|Site-0130, Detroit, Michigan, United States|Site-0343, Hackensack, New Jersey, United States|Site-0402, Philadelphia, Pennsylvania, United States|Site-0114, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02401048"
689,"NCT03355859","Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Non Hodgkin Lymphoma","Biological: JWCAR029","Treatment-related adverse events (AEs)|Dose-limiting toxicities of JWCAR029|Objective response rate (ORR)|Maximum concentration (Cmax) of JWCAR029 in the peripheral blood and bone marrow|Time to maximum concentration (Tmax) of JWCAR029 in the peripheral blood and bone marrow|Area-under the concentration-vs-time-curve (AUC) of JWCAR029 in the peripheral blood and bone marrow|Complete response (CR) rate|Duration of response|Progression-free survival (PFS) and PFS ratio|Overall survival|Health-related quality of life (HRQoL)","Zhao Weili|MingJu Therapeutics (Shanghai) Co., Ltd|Ruijin Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JWCAR029-001","December 2017","October 2019","March 2022","November 28, 2017","null","November 28, 2017","Ruijin hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03355859"
690,"NCT03344367","Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Non Hodgkin Lymphoma","Biological: JWCAR029","Treatment-related adverse events (AEs)|Dose-limiting toxicities of JWCAR029|Objective response rate (ORR)|Maximum concentration (Cmax) of JWCAR029 in the peripheral blood and bone marrow|Time to maximum concentration (Tmax) of JWCAR029 in the peripheral blood and bone marrow|Area-under the concentration-vs-time-curve (AUC) of JWCAR029 in the peripheral blood and bone marrow|Complete response (CR) rate|Duration of response|Progression-free survival (PFS) and PFS ratio|Overall survival|Health-related quality of life (HRQoL)","Peking University|MingJu Therapeutics (Shanghai) Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JWCAR029-001","November 2017","October 2019","March 2022","November 17, 2017","null","November 17, 2017","Beijing Cancer Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT03344367"
691,"NCT03533283","An Open-Label Phase lB Study of RO7082859 and Atezolizumab in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Non-Hodgkins Lymphoma","Drug: RO7082859|Drug: Atezolizumab|Drug: Obinutuzumab","Dose Limiting Toxicities (DLTs)|Percentage of Participants with Adverse Events (AEs)|Anti-Drug Antibody (ADA) Formation|Complete Response (CR) Rate, as Assessed by Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) Scan|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DOR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Elimination Half-Life (T1/2) of RO7082859 Administered in Combination with Atezolizumab|Area Under the Concentration-Time Curve (AUC) for RO7082859 Administered in Combination with Atezolizumab|Time to Maximum Observed Serum Concentration (Tmax) of RO7082859 Administered in Combination with Atezolizumab|Maximum Observed Serum Concentration (Cmax) of RO7082859 Administered in Combination with Atezolizumab|Minimum Serum Concentration (Cmin) of RO7082859 Administered in Combination with Atezolizumab|Clearance (CL) of RO7082859 Administered in Combination with Atezolizumab|Volume of Distribution at Steady-State (Vss) of RO7082859 Administered in Combination with Atezolizumab|CD8-Positive T Cell Proliferation|CD20-Positive B-Cell Reduction","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Not Applicable","140","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP39488","May 8, 2018","June 17, 2023","June 17, 2023","May 23, 2018","null","September 27, 2018","UZ Gent, Gent, Belgium|Rigshospitalet; Fase 1 Enhed - Hæmatologi, København Ø, Denmark|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Duran i Reynals; Servicio de Hematologia, Barcelona, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|The HOPE Clinical Trials Unit, Leicester, United Kingdom|University College London Hospitals NHS Foundation Trust; NIHR UCLH Clinical Research Facility, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03533283"
692,"NCT02703272","A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Ibrutinib|Drug: Rituximab|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide|Drug: Vincristine|Drug: Idarubicin|Drug: Dexamethasone","Part 1: Area Under The Plasma Concentration-Time Curve (AUC) of Ibrutinib|Part 1: Apparent (oral) Plasma Clearance (CL/F) of Ibrutinib|Part 1: Apparent (oral) Volume of Distribution (Vd/F) of Ibrutinib|Part 1: Maximum Observed Plasma Concentration (Cmax)|Part 1: Relationship Between Pharmacokinetic Parameters and Age or Measure of Body Size|Part 2: Event-free Survival [EFS]) of Ibrutinib|Part 1: Number of Participants with Adverse Events|Part 1: Percentage of Participants Who Achieve Complete Response (CR) and Partial Response (PR)|Part 1: Disease-specific Biomarkers Assessment|Part 1: Bruton's tyrosine kinase (BTK) Percent Occupancy|Part 1: Visual analog Scale Score for Palatability|Part 2: Number of Participants with Adverse Events|Part 2: Percentage of Participants Who Achieve Complete Response (CR) and Partial Response (PR)|Part 2: Tumor Volume Reduction|Part 2: Percentage of Participants who Proceed to Stem Cell Transplantation|Part 2: Time to Response|Part 2: Duration of Response|Part 2: Percentage of Participants with Long-term Survival|Part 2: Overall Survival|Part 2: Disease-specific Biomarkers Assessment|Part 2: Bruton's tyrosine kinase (BTK) Percent Occupancy|Part 2: Visual analog Scale Score for Palatability|Part 2: Area under the plasma concentration-time curve (AUC)","Janssen Research & Development, LLC|Pharmacyclics LLC.","All","1 Year to 30 Years   (Child, Adult)","Phase 3","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108134|54179060LYM3003|2016-000259-28","December 2016","June 2021","March 2024","March 9, 2016","null","September 24, 2018","Childrens Hospital Los Angeles, Los Angeles, California, United States|Childrens Hospital of Orange County, Orange, California, United States|Stanford University, Palo Alto, California, United States|UCSF Benioff Children's Hospital, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Medical School CS Mott Children's Hospital, Ann Arbor, Michigan, United States|Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|New York Medical Center - NYU, Valhalla, New York, United States|Carolinas Healthcare, Charlotte, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Cook Childrens Medical Center, Fort Worth, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|Queen Fabiola Children'S University Hospital Huderf, Brussel, Belgium|UZ Leuven, Leuven, Belgium|Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, Brazil|Sociedade Hospital Samaritano, São Paulo, Brazil|GRAACC, São Paulo, Brazil|Instituto da Criança - ICRHCFMUSP, São Paulo, Brazil|UMHAT 'Sv. Georgi', Plovdiv, Bulgaria|University Hospital 'Queen Joanna', Sofia, Bulgaria|Iwk Health Centre, Halifax, Nova Scotia, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital For Sick Children, Toronto, Ontario, Canada|Fakultní nemocnici Brno, Brno, Czechia|Fakultni nemocnice v Motole, Praha, Czechia|CHU de Bordeaux, Hopital des Enfants, Bordeaux, France|Hôpital Jeanne de Flandre, Lille, France|Institute Of Pediatric Hematology And Oncology, Lyon, France|Hopital La Timone, Marseille, France|Hôpital Mère Enfant CHU Nantes, Nantes, France|CHU Toulouse, Toulouse, France|Hôpital D'Enfants, Vandoeuvre Les Nancy, France|Gustave Roussy, Villejuif, France|Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany|Medical Center- University of Freiburg, Center for Pediatrics, Freiburg, Germany|University Children´s Hospital, Justus-Liebig-University, Gießen, Germany|Universitatsklinikum Schleswig-Holstein - Kiel, Kiel, Germany|Dr. von Haunersches Kinderspital, München, Germany|Universitätsklinikum Münster, Münster, Germany|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Ospedale Pediatrico Bambin Gesù, Roma, Italy|AOU Città Salute e Scienza di Torino, PO Infantile Regina Margherita, Torino, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Sophia Children's hospital, Rotterdam, Netherlands|Princess Maxima Center, Utrecht, Netherlands|Uniwersytecki Szpital Dzieciecy w Krakowie, Krakow, Poland|Samodzielny Publiczny Dzieciecy Szpital Kliniczny, Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wroclaw, Poland|Institut Clinic Fundeni, Bucuresti, Romania|Spitalul Clinic de Urgenta pentru Copii M.S. Curie, Bucuresti, Romania|Institutul Oncologic 'Prof Dr. Ion Chiricuta' Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Clinic Municipal Dr. Gavril Curteanu Oradea, Oradea, Romania|Spitalul Clinic de Urgenta pentru Copii 'Louis Turcanu' Timisoara, Timisoara, Romania|Regional Pediatric Clinical Hospital No.1, Ekaterinburg, Russian Federation|Pediatric Regional Clinical Hospital for Krasnodar Region, Krasnodar, Russian Federation|Pediatric Oncology and Hematology Research Institute FSBSI, Moscow, Russian Federation|FRCC of Pediatric Hematology, Oncology and Immunology n.a.D.Rogachev, Moscow, Russian Federation|City Clinical Hospital # 40, Moscow, Russian Federation|Rostov Research Oncology Institute, Rostov-On-Don, Russian Federation|City Clinical Hospital #31, St. Petersburg, Russian Federation|Saint-Petersburg Clinical Scientific And Practical Center For Special Types Of Medical Care, St.Petersburg, Russian Federation|Hosp. Materno Infantil Vall D'hebron, Barcelona, Spain|Hosp. Sant Joan de Deu, Esplugues De Llobregat, Spain|Hosp. Infantil Univ. Niño Jesus, Madrid, Spain|Hosp. Infantil Universitario La Paz, Madrid, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan|Gazi University Medical Faculty, Ankara, Turkey|Ankara University Medical Faculty, Ankara, Turkey|Ege Universitesi Tip Fakultesi, Izmir, Turkey|Kocaeli University Medical Faculty, Kocaeli, Turkey|Ukr.National Pediatric Hosp,Center pediatric onkohem.and BMT, BMT dept, Kiev, Ukraine|State Institution National Cancer Institute, Kiev, Ukraine|Birmingham Children's Hospital, Birmingham, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Leeds Children's Hospital, Leeds, United Kingdom|Alder Hey Hospital, Liverpool, United Kingdom|University College of London Hospitals, London, United Kingdom|Great Ormond Street Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Great North Children's Hospital, Newcastle, United Kingdom|Sheffield Children's Hospital, Sheffield, United Kingdom|Royal Marsden Hospital, Surrey, United Kingdom","","https://ClinicalTrials.gov/show/NCT02703272"
693,"NCT02072967","Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma, Non-Hodgkin","Other: Ribomustin|Other: rituximab","Overall response rate|Adverse drug reactions","Astellas Pharma Europe B.V.|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","","97","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RU-BEN-NI-001","May 2012","October 2015","October 2015","February 27, 2014","null","February 22, 2016","City Clinical Hospital #8, Barnaul, Russian Federation|Chelyabinsk Regional Oncology Dispensary/15, Chelyabinsk, Russian Federation|Vologda Regional Clinical Hospital #2, Cherepovets, Russian Federation|Regional Oncology Dispensary/35, Irkutsk, Russian Federation|Irkutsk Regional Сlinical Hospital/31, Irkutsk, Russian Federation|Kaluga Regional Clinical Hospital/02, Kaluga, Russian Federation|District Cancer center od Khanty -Mansiysk, Khanty-Mansiysk, Russian Federation|City Сlinical Hospital#7/25, Krasnoyarsk, Russian Federation|Regional Сlinical Hospital/12, Krasnoyarsk, Russian Federation|Adygei Regional Clinical Oncology Dispensary/11, Maykop, Russian Federation|Scientific Medical Surgical Center n.a.I.V.Pyrogov/17, Moscow, Russian Federation|European Medical Center, Moscow, Russian Federation|RONC n.a.N.N.Blokhin/18, Moscow, Russian Federation|Сentral Clinical Hospital n.a. Semashko N.A./30, Moscow, Russian Federation|Moscow Scientific Research Oncology Institution n.a.P.A. Gertzen/37, Moscow, Russian Federation|Central Clinical Hospital of Department of Presidential Affairs, Moscow, Russian Federation|Municipal Сlinical Hospital № 12/20, Nizhniy Novgorod, Russian Federation|Novosibirsk State Regional Clinical Hospital/23, Novosibirsk, Russian Federation|Medical Radiology Scientific Center/38, Obninsk, Russian Federation|Omsk Regional Clinical Hospital/40, Omsk, Russian Federation|City Сlinical Hospital#1 n.a.Kabanov A.N./13, Omsk, Russian Federation|Orenburg State Medical Academy/05, Orenburg, Russian Federation|Rostov Scientific Research Oncology Institution/01, Rostov-on-Don, Russian Federation|City Сlinical Oncological Dispensary/22, Saint-Petersburg, Russian Federation|City Сlinical Hospital#31/08, Saint-Petersburg, Russian Federation|Military-Medical Academy n.a. Kirova, Saint-Petersburg, Russian Federation|Scientific Research Oncological Institution n.a. Petrov N.N./29, Saint-Petersburg, Russian Federation|Samara State Medical University' Clinics/36, Samara, Russian Federation|Road Clinical Hospital on Rostov-Main Station OAO RZhD/06, Smolensk, Russian Federation|Surgut Regional Clinical Hospital, Surgut, Russian Federation|Tula Regional Clinical Hospital/21, Tula, Russian Federation|Volgograd Regional Clinical Oncology Dispensary#1/10, Volgograd, Russian Federation|Vologda Regional Clinical Hospital/39, Vologda, Russian Federation|Yekaterinburg Regional Clinical Hospital #1, Yekaterinburg, Russian Federation|Sakhalin Regional Oncology Dispensary/32, Yuzhno-Sakhalinsk, Russian Federation","","https://ClinicalTrials.gov/show/NCT02072967"
694,"NCT03575351","A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas","TRANSFORM","Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Standard of Care|Genetic: JCAR017","Event-free survival (EFS)|Complete response rate (CRR)|Progression-free survival (PFS)|Overall survival (OS)|Overall response rate (ORR)|Duration of response (DOR)|PFS on next line of treatment (PFS-2)|Adverse Events (AEs)|HRQoL parameters assessed by European Organisation for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC-QLQ-C30)|HRQoL parameters assessed by EQ-5D-5L|HRQoL parameters assessed by FACT-Lym ""Additional concerns"" subscale|Reasons for hospital resource utilization|Rate of hematopoietic stem cell transplant (HSCT)|Frequency of hospital resource utilization","Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JCAR017-BCM-003|U1111-1213-1944|2018-000929-32","October 16, 2018","October 14, 2022","January 13, 2023","July 2, 2018","null","October 2, 2018","Mayo Clinic Arizona, Scottsdale, Arizona, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Baylor University Medical Center, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|UZ Gent, Gent, Belgium|Hamilton Health Sciences McMaster University, Hamilton, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|CHRU-Hopital Claude Huriez, Lille, France|Institut Paoli Calmette Hematologie, Marseille cedex, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut Gustave Roussy, Villejuif Cedex, France|Robert-Rössle-Klinik im HELIOS Klinikum Berlin-Buch Klinik für Hämatologie, Onkologie u. Tumorimmuno, Berlin, Germany|Medizinische Kinik und Poliklinik I, Dresden, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Universitat zu Koln, Köln, Germany|LMU Klinikum der Universitat, München, Germany|La Sapienza, University of Rome, Rome, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|National Cancer Center Hospital, Chuo-ku, Japan|Toranomon Hospital, Minato-ku, Japan|Erasmus Medical Center-Daniel den Hoed, Rotterdam, Netherlands|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Karolinska Hospital, Stockholm, Sweden|Universitatsspital Bern, Bern, Switzerland|UCL Cancer Institute, London, United Kingdom|University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT03575351"
695,"NCT03601442","CTL019 Out of Specification MAP for ALL or DLBCL Patients",,"Available","No Results Available","Acute Lymphoblastic Leukemia (ALL)|Diffuse Large B-cell Lymphoma (DLBCL)","Biological: CTL019","","Novartis Pharmaceuticals|Novartis","All","Child, Adult, Older Adult","","null","Industry","Expanded Access":Treatment IND/Protocol","","CCTL019B2003I","null","null","null","July 26, 2018","null","August 22, 2018","","","https://ClinicalTrials.gov/show/NCT03601442"
696,"NCT01491841","IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma","BRP","Active, not recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: Bendamustine + Rituximab + Pixantrone","Maximum Tolerated Dose|Overall Response|Progression free survival|Toxicity (number of participants with adverse events)|Overall survival","Anne Beaven, MD|CTI BioPharma|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00030834","November 2011","November 2016","November 2021","December 14, 2011","null","October 3, 2016","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01491841"
697,"NCT00210340","A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis",,"Withdrawn","No Results Available","Lymphoma, B Cell","Drug: intrathecal rituximab","Safety profile of rituximab given intrathecally|preliminary evaluation of the antitumor activity of i.t. rituximab|collection of CSF samples devoted to ancillary biological studies|pharmacokinetics of different dose levels of intrathecal rituximab","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG24","null","null","null","September 21, 2005","null","March 30, 2015","","","https://ClinicalTrials.gov/show/NCT00210340"
698,"NCT02453087","A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: DCDS0780A|Drug: Rituximab|Drug: Obinutuzumab","Number of Participants with Adverse Events|Percentage of Participants with Dose-Limiting Toxicities|Maximum Tolerated Dose (MTD) of DCDS0780A|Recommended Phase 2 Dose (RP2D) of DCDS0780A|Area Under the Serum Concentration-Time Curve (AUC) for DCDS0780A Total Antibody|Maximum Observed Serum Concentration (Cmax) for DCDS0780A Total Antibody|Total Clearance (CL) of DCDS0780A Total Antibody|Half-life (t1/2) of DCDS0780A Total Antibody|Volume of Distribution Under Steady-State Conditions (Vss) of DCDS0780A Total Antibody|Area Under the Plasma Concentration-Time Curve (AUC) for DCDS0780A Conjugate (Antibody-Conjugated Monomethyl Auristatin E [acMMAE])|Maximum Observed Plasma Concentration (Cmax) for acMMAE|Total Clearance (CL) of acMMAE|Half-life (t1/2) of acMMAE|Volume of Distribution Under Steady-State Conditions (Vss) of acMMAE|Area Under the Plasma Concentration-Time Curve (AUC) for Unconjugated Monomethyl Auristatin E (MMAE)|Maximum Observed Plasma Concentration (Cmax) for Unconjugated MMAE|Total Clearance (CL) of Unconjugated MMAE|Half-life (t1/2) of Unconjugated MMAE|Volume of Distribution Under Steady-State Conditions (Vss) of Unconjugated MMAE|Obinutuzumab Serum Concentration|Rituximab Serum Concentration|Percentage of Participants with Anti-DCDS0780A Antibodies|Absolute Lymphocyte Count|Change from Baseline in Intra-Patient Absolute Lymphocyte Counts|Time to CD19+ B-Cell Count Recovery to Baseline Value|Percentage of Participants with Best Overall Response of Complete Response (CR) or Partial Response (PR) Assessed According to Lugano Classification|Duration of Response Assessed According to Lugano Classification|Progression-Free Survival (PFS) Assessed According to Lugano Classification|Relative Dose Intensity (DI) Calculated as Ratio of Amount of Drug Actually Administered to the Amount Planned","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO29687","August 4, 2015","September 4, 2019","September 4, 2019","May 25, 2015","null","September 14, 2018","City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Medical Center of Aurora; Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota, Florida, United States|New York University Cancer Cen, New York, New York, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States","","https://ClinicalTrials.gov/show/NCT02453087"
699,"NCT00863369","Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Biological: rituximab|Drug: bortezomib|Drug: gemcitabine hydrochloride|Other: questionnaire administration","Safety and feasibility|Maximum tolerated dose|Response","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04115|P30CA033572|CHNMC-04115|MILLENNIUM-CHNMC-04115|CDR0000637492|NCI-2010-00925","June 20, 2005","July 2019","July 2019","March 18, 2009","null","April 5, 2018","City of Hope Medical Center, Duarte, California, United States|South Pasadena Cancer Center, South Pasadena, California, United States","","https://ClinicalTrials.gov/show/NCT00863369"
700,"NCT02109224","Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection",,"Terminated","No Results Available","Adult B Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia|Cutaneous B-Cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|HIV Infection|Intraocular Lymphoma|Multicentric Angiofollicular Lymphoid Hyperplasia|Nodal Marginal Zone Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Plasma Cell Myeloma|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Incidence of toxicities assessed using National Cancer Institute (NCI) CTCAE version 4.0|MTD of ibrutinib defined as the dose level in which no more than 1 out of 6 patients experiences a dose limiting toxicity assessed using NCI CTCAE version 4.0|1-year OS|1-year PFS|6-month overall survival (OS)|6-month progression free survival (PFS)|Changes in EBV DNA copy numbers in plasma and in PBMCs in relation to ibrutinib therapy|Changes in HHV-8 DNA copy numbers in plasma and in PBMCs in relation to ibrutinib therapy|Changes in HIV viral load|Changes in immunologic parameters|Clinical benefit|Objective response rate|Pharmacokinetic (PK) parameters of ibrutinib in relation to ART-CYP3A4 interactions, including half-life (T1/2), oral clearance (CL/F), and area under the curve (AUC)|Plasma concentrations of ibrutinib and its main metabolite|Time to tumor progression|Time to tumor response","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2014-00707|AMC-091|U01CA121947","September 2014","July 2015","July 2015","April 9, 2014","null","August 20, 2015","UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02109224"
701,"NCT01760226","Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies","DA-EPOCH-R","Completed","No Results Available","Diffuse Large B Cell Lymphoma|Post Transplant Lymphoproliferative Disorder|Primary Mediastinal (Thymic) Large B-cell Lymphoma","Drug: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|Drug: Methotrexate|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Prednisone|Drug: G-CSF","Measure and assess adverse events|Measure and assess immune function","Baylor College of Medicine|National Cancer Institute (NCI)|Texas Children's Hospital","All","up to 21 Years   (Child, Adult)","Early Phase 1","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-30759, DA-EPOCH-R|DA-EPOCH-R|5K12CA090433-12","January 2013","August 26, 2016","December 2016","January 4, 2013","null","November 17, 2017","Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01760226"
702,"NCT02240316","An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice",,"Active, not recruiting","No Results Available","Lymphoma, B-Cell, Lymphoma, Follicular","","Proportion of patients in both indications (DLBCL and follicular NHL) who have reached a complete remission (CR), including unconfirmed complete remission (CRu)|Total response rate|Two-year progression-free survival rate for patients with follicular lymphoma under maintenance therapy|Safety profile: incidence, nature, severity, and outcomes of all adverse events and pregnancies (composite outcome measure)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","","1076","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28886","July 8, 2014","July 31, 2019","July 31, 2019","September 15, 2014","null","July 31, 2018","Universitätsklinikum Essen; Klinik für Hämatologie, Essen, Germany","","https://ClinicalTrials.gov/show/NCT02240316"
703,"NCT00809341","R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Terminated","Has Results","Non-Hodgkin's Lymphoma","Biological: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide|Drug: High-dose cyclophosphamide|Procedure: PET scan","Event-free Survival in Patient Receiving Early Treatment Intensification Based on a Positive Mid-treatment PET Scan|Overall Survival in Patients Whose Treatment is Determined on the Basis of a Mid-treatment [18F] FDG-PET Scan Result.","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J0802|NA_00013656","January 2009","April 2014","April 2014","December 17, 2008","September 25, 2018","September 25, 2018","The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00809341"
704,"NCT02568683","Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)",,"Completed","No Results Available","Non-Hodgkin Lymphoma","Drug: ENTO|Drug: VCR","For dose escalation stage, incidence of adverse events defined as dose limiting toxicities (DLTs) for ENTO in combination with VCR in participants with relapsed or refractory NHL|For dose escalation stage, incidence of laboratory abnormalities defined as dose-limiting toxicities (DLTs) for ENTO in combination with VCR in participants with relapsed or refractory NHL|For dose escalation stage, incidence of adverse events not defined as DLTs for ENTO with VCR in participants with relapsed or refractory B-cell NHL|For dose escalation stage, incidence of laboratory abnormalities not defined as DLTs for ENTO with VCR in participants with relapsed or refractory B-cell NHL|For dose expansion stage, incidence of adverse events for ENTO with VCR in participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)|For dose expansion stage, incidence of laboratory abnormalities for ENTO with VCR in participants with relapsed or refractory DLBCL|For dose expansion stage, incidence of adverse events for ENTO with VCR in participants with relapsed or refractory B-cell NHL (non-DLBCL)|In dose expansion stage, incidence of laboratory abnormalities for ENTO with VCR in participants with relapsed or refractory B-cell NHL (non-DLBCL)|Objective response rate (ORR)|Progression free survival (PFS)|Duration of response (DOR)|Time to response (TTR)|Study drug administration|Duration of exposure of ENTO","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-339-1562|2015-002731-17","February 11, 2016","October 3, 2016","June 22, 2017","October 6, 2015","null","August 8, 2017","Forrest General Hospital, Hattiesburg, Mississippi, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Groupe Hospitalier du Haut Leveque, Pessac, Aquitaine, France|Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille), Lille cedex, Nord Pas-de-calais, France|Institut Paoli Calmettes, Marseille, Provence Alpes Cote D'azur, France|Centre Hospitalier Universitaire de Dijon Hôpital du Bocage, Dijon Cedex, France|Centre Hospital Lyon Sud, Pierre Benite, France","","https://ClinicalTrials.gov/show/NCT02568683"
705,"NCT03598179","XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects",,"Recruiting","No Results Available","Lymphoma, B-Cell|Leukemia, B-cell","Biological: chimeric antigen receptor T cells","Overall response rate|Overall Survival|Progression-free Survival|Event-free Survival|Dose-limiting toxicity (DLT)|Number of CAR-T cells|Duration of CAR-T cells","The First Affiliated Hospital with Nanjing Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JSPH-CART001","June 1, 2018","June 30, 2019","July 1, 2020","July 25, 2018","null","July 25, 2018","Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT03598179"
706,"NCT00290498","Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger",,"Completed","No Results Available","Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Methotrexate|Drug: Cytarabine|Drug: Prednisone","Overall Response","M.D. Anderson Cancer Center|Genentech, Inc.","All","16 Years to 60 Years   (Child, Adult)","Phase 2","67","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0054|NCI-2012-01355","August 1, 2005","August 11, 2017","August 11, 2017","February 13, 2006","null","August 18, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00290498"
707,"NCT03075696","A Dose Escalation Study of RO7082859 as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: RO7082859|Drug: Obinutuzumab|Drug: Tocilizumab","Part I and II: Percentage of Participants With Dose Limiting Toxicities (DLTs)|Part I, II and III: Percentage of Participants With Adverse Events (AEs)|Part II: MTD or OBD of RO7082859|Part II: Recommended Phase II Dose (RP2D) of RO7082859|Part I, II and III: Area Under the Serum Concentration Versus Time Curve (AUC) of RO7082859|Part I, II and III: Maximum Serum Concentration (Cmax) of RO7082859|Part I, II and III: Minimum Serum Concentration (Cmin) of RO7082859|Part I, II and III: Clearance (CL) of RO7082859|Part I, II and III: Volume of Distribution at Steady-State (Vss) of RO7082859|Part I, II and III: Half-Life (t1/2) of RO7082859|Part I, II and III: Cmax of Obinutuzumab|Part I, II and III: Cmin of Obinutuzumab|Part I, II and III: Anti-Drug Antibodies (ADA) to RO7082859|Part I, II and III: Percentage of Participants With Overall Response (Partial Response [PR] or Complete Response [CR]) as Determined by the Modified Lugano Classification|Part I, II and III: Percentage of Participants With Stable disease (SD) as Determined by the Modified Lugano Classification|Part I, II and III: Percentage of Participants With PR, CR or SD (Disease Control Rate) as Determined by the Modified Lugano Classification|Part I, II and III: Duration of Response as Determined by the Modified Lugano Classification|Part I, II and III: Progression-Free Survival (PFS) as Determined by the Modified Lugano Classification","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","160","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP30179|2016-001185-28","February 21, 2017","March 6, 2020","March 6, 2020","March 9, 2017","null","September 27, 2018","Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia|UZ Gent, Gent, Belgium|Princess Margaret Hospital, Medical Oncology & Haematology, Toronto, Ontario, Canada|Rigshospitalet; Hæmatologisk Klinik, København Ø, Denmark|Hopital Claude Huriez; Hematologie, Lille, France|Ch Lyon Sud; Hemato Secteur Jules Courmont, Pierre Benite, France|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia, Torino, Piemonte, Italy|Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz, Warszawa, Poland|Hospital Duran i Reynals L'Hospitalet; Hematology Department, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT03075696"
708,"NCT01992653","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Non Hodgkin","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Prednisolone|Drug: Prednisone|Drug: Rituximab","Percentage of Participants with Adverse Events|Percentage of Participants with Dose Limiting Toxicities|Maximum Tolerated Dose (MTD) of Polatuzumab Vedotin|Percentage of Participants with Objective Response (CR or Partial Response [PR]), as Assessed by Investigator using Cheson Criteria|Percentage of Participants with Anti-Polatuzumab Vedotin Antibodies|Percentage of Participants with Anti-Obinutuzumab Antibodies|Area Under the Concentration-Time Curve of Polatuzumab Vedotin|Maximum concentration (Cmax) of Polatuzumab Vedotin|Clearance (CL) of Polatuzumab Vedotin|Terminal Half-Life (t1/2) of Polatuzumab Vedotin|Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin|Plasma Levels of Cyclophosphamide|Plasma Levels of Doxorubicin|Percentage of Participants with Complete Response (CR), as Assessed by Investigator using Cheson Criteria|Peripheral Neuropathy Symptom Severity: Therapy-Induced Neuropathy Assessment Scale (TINAS) Overall Neuropathy Severity Score|Peripheral Neuropathy Symptom Interference: TINAS Numbness/Tingling Item Score|Duration of Response, as Assessed by Investigator Using Cheson Criteria|Progression Free Survival, as Assessed by Investigator Using Cheson Criteria|Event Free Survival, as Assessed by Investigator Using Cheson Criteria|Relative Dose Intensity of Polatuzumab Vedotin (Ratio of the Amount of Drug Actually Administered to the Amount Planned)|Overall Survival","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO29044|2013-003541-42","November 29, 2013","January 25, 2019","January 25, 2019","November 25, 2013","null","July 6, 2018","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University; Pediatrics, Saint Louis, Missouri, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Willamette Valley Clinical Studies; Cancer Institute, Springfield, Oregon, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Northwest Medical Specialties, PLLC; Research Department, Tacoma, Washington, United States|Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France|Hopital Claude Huriez - CHU Lille; Service des maladies du sang, Lille, France|Hopital Haut-Leveque - Centre Francois Magendie; Service d'Hematologie Clinique, Pessac, France|Centre Hospitalier Lyon Sud; Hematolgie, Pierre Benite, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|Centre Henri Becquerel; Hematologie, Rouen, France","","https://ClinicalTrials.gov/show/NCT01992653"
709,"NCT01549886","Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Non-Hodgkin's Lymphoma","Drug: Zevalin Regimen|Drug: Moxtezafin Gadolinium","Complete Response Rate (CR)|Overall Response Rate|Safety","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPI-MGD-11-201","November 2011","June 2014","December 2015","March 9, 2012","null","June 4, 2015","Alta Bates Summit Medical Center-Herrick, Berkeley, California, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Halifax Health- Center for Oncology, Daytona Beach, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Oncology Specialists, Park Ridge, Illinois, United States|University of Massachusetts - Worcester, Worcester, Massachusetts, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|West Virginia University, WVU Healthcare, Morgantown, West Virginia, United States","","https://ClinicalTrials.gov/show/NCT01549886"
710,"NCT01691807","Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Cancer","Drug: ofatumumab|Drug: bendamustine","Pharmacokinetic measures of Cmax and Area Under the Curve by analysis of blood samples for the amount of each drug present at different timepoints.|Changes in vital signs and the number adverse events|Measure the extent of the disease by CT scan or flow cytometry analysis","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","113603","January 2013","December 2015","December 2015","September 25, 2012","null","February 28, 2018","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Southaven, Mississippi, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Morgantown, West Virginia, United States","","https://ClinicalTrials.gov/show/NCT01691807"
711,"NCT01294579","Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)",,"Completed","Has Results","Lymphoma, Non-Hodgkin","Biological: Ofatumumab|Drug: Bendamustine","Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS)|Overall Response Rate (ORR) During Induction Phase After Cycle 6 (FAS)|Conversion Rate of Partial Response in Induction Phase to Complete Response With Maintenance Ofatumumab (FAS)|Percentage of Participants With Progression Free Survival (PFS) up to 30 Months (FAS)|Kaplan-Meier Estimates of Progression Free Survival up to 30 Months (FAS)|Pharmacokinetic Profile Which Includes Measuring Blood Levels of Ofatumumab and Bendamustine in Combination and Ofatumumab Alone During Maintenance Treatment and Measuring Blood Levels of Circulating B Cell|All Deaths by Preferred Term (Safety Set) up to Approximately 30 Months","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","114612","May 17, 2011","December 20, 2016","December 20, 2016","February 11, 2011","August 9, 2018","August 9, 2018","Novartis Investigative Site, Chandler, Arizona, United States|Novartis Investigative Site, Burbank, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Oxnard, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Orange Park, Florida, United States|Novartis Investigative Site, Burlington, Massachusetts, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Cary, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Kettering, Ohio, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Sherman, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Waco, Texas, United States|Novartis Investigative Site, Vancouver, Washington, United States|Novartis Investigative Site, Yakima, Washington, United States","","https://ClinicalTrials.gov/show/NCT01294579"
712,"NCT01805375","A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies",,"Completed","No Results Available","Indolent B-cell Lymphoma|Chronic Lymphocytic Leukaemia|Waldenström Macroglobulinaemia","Drug: DI-B4","To recommend a dose for future trials with a new drug called DI-B4 by finding the highest safe dose which can be given to patients|Measuring of PK parameter values for DI-B4 including AUC, Cmax, Tmax, and half life T1/2.|To evaluate the effect of DI-B4 on the depletion of peripheral blood and bone marrow B-cells.|To look for signs of anti-tumour activity of DI-B4 in patients with relapsed or refractory indolent B-cell malignancies.|To assess immunogenicity of DI-B4 in patients with relapsed or refractory indolent B-cell malignancies|To measure the time to disease progression and eighteen month survival","Cancer Research UK","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Primary Purpose: Treatment","CRUKD/12/003","April 2013","December 14, 2017","December 14, 2017","March 6, 2013","null","February 2, 2018","Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|The Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01805375"
713,"NCT00607854","Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)","ZEVALLO","Completed","No Results Available","Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma","Drug: Ibritumomab Tiuxetan (Zevalin)","the treatment-related mortality rate (except if the death is related to the lymphoma exclusively).|The event-free-survival (EFS)(an event is defined as: death from any cause, relapse or progression, need to another treatment except for donor-lymphocytes injection (DLI), patient lost for follow-up)|The rate of hematologic recovery (defined as ANC above 500/mm3 and platelets count above 20.000/mm3 for three consecutive days without stimulating growth support neither platelet transfusion)|Biological post allogenic effects of Zevalin® on the incidence of GVHD and B-cell and T-cell reconstitution|Chimérism","University Hospital, Bordeaux|Bayer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUBX 2007/11","February 2008","February 2011","November 2011","February 6, 2008","null","October 5, 2016","Service d'hématologie - CHU de Besançon, Besançon, France|Service des maladies du sang - Hôpital Haut-Lévêque - avenue de magellan, Bordeaux - Pessac, France|Service d'hématologie - CHU Hôtel Dieu Clermont-Ferrand, Clermont-Ferrand, France|Service de médecine nucléaire - Centre de Lutte contre le Cancer de la Région Auvergne Jean Perrin, Clermont-Ferrand, France|Hôpital Edouard Herriot, Lyon, France|Service d'Oncologie Hématologie, Institut Paoli Calmettes - 232 Bd Ste Marguerite, Marseille, France|Hématologie et Oncologie médicale - CHU Lapeyronie, Montpellier, France|Service d'Hématologie, Hôpital Hôtel Dieu, CHU Nantes - 1 Place Alexis Ricordeau, Nantes, France|Service d'hématologie clinique - Hôpital l'Archet 1, Nice, France|Service d'Hématologie Adultes - Hôpital Necker-Enfants Malade, Paris, France|Pôle hématologie et immunologie clinique - Hôpital Saint-Louis, Paris, France|Département d'hématologie et d'Oncologie - CHRU Hautepierre, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT00607854"
714,"NCT02813837","Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies",,"Recruiting","No Results Available","Leukemia, B-Cell|Lymphoma, B-Cell","Biological: CD19CART","Occurrence of study related adverse events|Anti-leukemia or lymphoma responses to CD19CART cell infusions","Innovative Cellular Therapeutics Co., Ltd.","All","up to 60 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCT019-01","June 2015","January 2021","July 2021","June 27, 2016","null","June 28, 2016","Innovative Cellular Therapeutics CO., LTD., Shanghai, China","","https://ClinicalTrials.gov/show/NCT02813837"
715,"NCT01840566","High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Biological: Pegfilgrastim|Biological: 19-28z T CELLS|Procedure: Autologous Stem Cell Transplantation","maximum tolerated dose (MTD)|safety|2 year progression-free (PFS)|overall survival (os)","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-117","April 2013","April 2019","April 2019","April 25, 2013","null","April 18, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01840566"
716,"NCT00460109","Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma","Biological: denileukin diftitox|Biological: rituximab","Proportion of Confirmed Tumor Response (Complete Response [CR], Unconfirmed CR, and Partial Response)|Survival Time|Time to Disease Progression|Duration of Response|Time to Subsequent Therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCCTG-N0682|NCI-2009-00662|CDR0000539551","April 2008","October 2010","March 2011","April 13, 2007","April 18, 2017","April 18, 2017","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Aurora Presbyterian Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States|St. Anthony Central Hospital, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|CCOP - Colorado Cancer Research Program, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|St. Anthony's Memorial Hospital, Effingham, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, South Bend, Indiana, United States|Saint Joseph Regional Medical Center, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Southwest Medical Center, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, St. Joseph, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Fergus Falls Medical Group, PA, Fergus Falls, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Regions Hospital Cancer Care Center, St. Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Community Medical Center, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Mercy Medical Center, Springfield, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|Adventist Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Franciscan Skemp Healthcare - La Crosse Campus, La Crosse, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States","","https://ClinicalTrials.gov/show/NCT00460109"
717,"NCT01483664","Communication Skills Intervention to Promote Transition Into Survivorship",,"Active, not recruiting","No Results Available","Hodgkin's Lymphoma|Diffuse Large B-cell Lymphoma","","impact on patient outcomes of targeted physician communication skills training|impact of a targeted CST intervention on the physicians|describe communication during doctor-patient visits during the patients' first three years of survivorship","Memorial Sloan Kettering Cancer Center|M.D. Anderson Cancer Center|Maimonides Medical Center|H. Lee Moffitt Cancer Center and Research Institute|Rutgers University|Tampa General Hospital|University of California, Los Angeles|National Cancer Institute (NCI)|Monash University|Weill Cornell Medical College in Qatar|New York Methodist Hospital|San Francisco State University","All","18 Years and older   (Adult, Older Adult)","","314","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","11-180","November 2011","November 2019","November 2019","December 1, 2011","null","August 6, 2018","Tampa General Hospital, Tampa, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Maimonides Medical Center, Brooklyn, New York, United States|Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center at Mercy, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States|Md Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01483664"
718,"NCT00073957","Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma","Biological: rituximab|Drug: cytarabine|Drug: liposomal cytarabine|Radiation: yttrium Y 90 ibritumomab tiuxetan","Response Rate = Complete and Partial Response at 12 Weeks.|Best Response|Event Free Survival","Beth Israel Deaconess Medical Center","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2003P000182|CDR0000341437","December 2003","January 1, 2012","January 1, 2012","December 11, 2003","January 23, 2018","January 23, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Fletcher Allen Health Care - Medical Center Campus, Burlington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT00073957"
719,"NCT00389818","Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Biological: sargramostim|Drug: cyclophosphamide|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI .|Duration of Response|Median Survival Time|Rate of Bacterial, Fungal, and Opportunistic Infections|Relationship Between MDR-1 Expression and Response to Treatment|Relationship Between Response and Survival and BCL-2 Expression in Tumor Tissue|Relationship Between Development of Bacterial, Fungal, and/or Opportunistic Infections and Baseline CD4 Lymphocyte Count, HIV-1 RNA Level, and Quantitative Immunoglobin Level, or Changes in Quantitative Immunoglobin Levels Over Time|Mortality and Cause of Death|Event-free Survival at 1 Year","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","43","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC-047|U01CA070019|CDR0000507634","January 2007","September 2011","September 2011","October 19, 2006","June 29, 2012","June 5, 2018","Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States|University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Boston University Cancer Research Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Virginia Mason Medical Center, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT00389818/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00389818"
720,"NCT01108341","Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)",,"Completed","Has Results","Non-Hodgkin's Lymphoma (NHL)","Drug: Bendamustine hydrochloride|Drug: Ofatumumab","Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR), as Determined by the International Working Group (IWG) Criteria As Assessed by Investigators|Percentage of Participants With a Best Overall Response of Complete Response (CR), as Determined by the International Working Group (IWG) Criteria As Assessed by Investigators","Cephalon|Teva Pharmaceutical Industries","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C18083/2048|2009-016725-34","May 2010","July 2011","October 2011","April 22, 2010","August 28, 2012","August 28, 2012","Birmingham Hematology and Oncology Associates, LLC, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Hematology Oncology, P.C., Stamford, Connecticut, United States|University Cancer Institute, Boynton Beach, Florida, United States|Florida Cancer Institute - New Hope, New Port Richey, Florida, United States|Dublin Hematology Oncology Care P.C., Dublin, Georgia, United States|Northwest Georgia Oncology Center, Marietta, Georgia, United States|Georgia Cancer Specialists, Tucker, Georgia, United States|Cancer Care and Hematology Specialists of Chicagoland, Niles, Illinois, United States|Siouxland Hematology-Oncology Assoc. LLP, Sioux City, Iowa, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Carroll County Cancer Center, Westminster, Maryland, United States|Columbia Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Somerset Hematology Oncology Associates, Somerville, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pittsburgh Medical Center - Cancer Institute, Pittsburgh, Pennsylvania, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|The West Clinic, Memphis, Tennessee, United States|Texas Oncology, P.A., Bedford, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Longview Cancer Center, Longview, Texas, United States|Joe Arrington Cancer Research, Lubbock, Texas, United States|Texas Oncology, P.A., McAllen, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Texas Oncology, Waco, Texas, United States|Texas Oncology, P.A., Webster, Texas, United States|US Oncology Research - Texoma Cancer Center, Wichita Falls, Texas, United States|Fairfax/Northern Virginia Hematology/Oncology, Fairfax, Virginia, United States|Yakima Valley Memorial Hospital/North Start Lodge, Yakima, Washington, United States|Cephalon Investigational Site, Bruxelles, Belgium|Cephalon Investigational Site, Bruxelles, Belgium|Cephalon Investigational Site, Gent, Belgium|Cephalon Investigational Site, Haifa, Israel|Cephalon Investigational Site, Nahariya, Israel","","https://ClinicalTrials.gov/show/NCT01108341"
721,"NCT03042247","Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-cell-lymphoma|Classical Hodgkin Lymphoma","","Diagnostic accuracy in terms of sensitivity and specificity of FDG-PET/MRI in the staging and post-chemotherapy revaluation","Claudio Cerchione|Federico II University","All","18 Years to 90 Years   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FDGMR-LIN","January 24, 2017","July 31, 2018","February 1, 2019","February 3, 2017","null","February 7, 2018","Prof Marco Picardi, Naples, Italy|Prof Marco Picardi - Hematology - AOU FEDERICO II, Napoli, Italy","","https://ClinicalTrials.gov/show/NCT03042247"
722,"NCT01435720","Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)",,"Unknown status","No Results Available","Multiple Myeloma|Multiple Myeloma in Relapse|Mantle Cell Lymphoma in Relapse|Diffuse Large B Cell Lymphoma in Relapse|Other B Cell Lymphoma in Relapse|Plasma Cell Leukemia","Biological: SNS01-T","Safety and tolerability|Profile of pharmacokinetics|Explore tumor response","Senesco Technologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNS01-T-001","September 2011","October 2014","December 2014","September 19, 2011","null","September 11, 2014","The University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Mayo Clinic, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Fred Hutchinson Cancer Research Center/University of Washington Medical Center, Seattle, Washington, United States|West Virginia University Mary Babb Randolf Cancer Center, Morgantown, West Virginia, United States|Unversity of Cape Town - Groote Schuur Hospital, Cape Town, South Africa|Pretoria East Hospital, Pretoria, South Africa","","https://ClinicalTrials.gov/show/NCT01435720"
723,"NCT00303953","PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma","Drug: belinostat","Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR)|Overall Survival|Progression-free Survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-01096|CDR0000462614|S0520|U10CA032102","January 2006","January 2010","August 2010","March 17, 2006","September 19, 2012","May 12, 2014","Providence Hospital, Mobile, Alabama, United States|University of Arizona Health Sciences Center, Tucson, Arizona, United States|NEA Baptist Memorial Hospital, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|East Bay Radiation Oncology Center, Castro Valley, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California, United States|Valley Medical Oncology Consultants-Fremont, Fremont, California, United States|Marin General Hospital, Greenbrae, California, United States|Saint Rose Hospital, Hayward, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Highland General Hospital, Oakland, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Breast Surgeons Inc, Oakland, California, United States|Bay Area Tumor Institute CCOP, Oakland, California, United States|Larry G Strieff MD Medical Corporation, Oakland, California, United States|Tom K Lee Inc, Oakland, California, United States|Valley Care Health System - Pleasanton, Pleasanton, California, United States|Valley Medical Oncology Consultants, Pleasanton, California, United States|Doctors Medical Center- JC Robinson Regional Cancer Center, San Pablo, California, United States|Sutter Solano Medical Center, Vallejo, California, United States|Cancer Centers of Central Florida PA, Leesburg, Florida, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Advocate Sherman Hospital, Elgin, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Saint Francis Hospital and Health Centers, Beech Grove, Indiana, United States|Reid Hospital and Health Care Services, Richmond, Indiana, United States|Providence Medical Center, Kansas City, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Radiation Oncology Practice Corporation Southwest, Overland Park, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States|Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|DeSoto Regional Health System, Mansfield, Louisiana, United States|Louisiana State University Sciences Center- Monroe, Monroe, Louisiana, United States|Interim LSU Public Hospital, New Orleans, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Highland Clinic, Shreveport, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Radiation Oncology Practice Corporation South, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Radiation Oncology Practice Corporation - North, Kansas City, Missouri, United States|Liberty Hospital, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Montana Cancer Consortium CCOP, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies PC, Billings, Montana, United States|Billings Clinic, Billings, Montana, United States|Deaconess Medical Center, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Internal Medicine of Bozeman, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Highland Hospital, Rochester, New York, United States|Wayne Radiation Oncology, Goldsboro, North Carolina, United States|Wilson Medical Center, Wilson, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton CCOP, Dayton, Ohio, United States|Veteran Affairs Medical Center, Dayton, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Wilford Hall Medical Center, Lackland AFB, Texas, United States|Southwest Oncology Group, San Antonio, Texas, United States|American Fork Hospital, American Fork, Utah, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Logan Regional Hospital, Logan, Utah, United States|Cottonwood Hospital Medical Center, Murray, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Intermountain Health Care, Salt Lake City, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Columbia Basin Hematology and Oncology PLLC, Kennewick, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Group Health Cooperative-Seattle, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|The Polyclinic, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|United General Hospital, Sedro-Woolley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Welch Cancer Center, Sheridan, Wyoming, United States","","https://ClinicalTrials.gov/show/NCT00303953"
724,"NCT00549185","Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma|Non-Hodgkin","Drug: SAR3419","Incidence of Dose Limiting Toxicity(ies) at each tested dose level|Tumor response (complete response, partial response, stable disease) according to Cheson criteria and duration of response|Incidence of Adverse Events","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED6828","October 2007","January 2012","January 2012","October 25, 2007","null","February 14, 2012","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT00549185"
725,"NCT00400907","Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9",,"Unknown status","No Results Available","Long-term Effects Secondary to Cancer Therapy in Adults|Lymphoma","Other: clinical observation|Procedure: management of therapy complications","Time to treatment failure|Complete remission rate|Relapse rate|Overall survival|Tumor control|Disease-free survival|Time to progression|Time to relapse|Late toxicities, particularly organ function deficiencies (e.g., cardiomyopathies), infections, and secondary neoplasms","German High-Grade Non-Hodgkin's Lymphoma Study Group|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","","667","Other","Observational","","CDR0000514350|DSHNHL-MINT-FU|EU-20656|DSHNHL-M39045","January 2006","null","null","November 17, 2006","null","December 20, 2011","","","https://ClinicalTrials.gov/show/NCT00400907"
726,"NCT00911183","Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma",,"Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: liposome-encapsulated doxorubicin citrate|Drug: prednisone|Drug: vincristine sulfate","Complete remission rate at 6 months|Toxicity|Progression-free survival, event-free survival, and overall survival|Overall response rate|Duration of complete remission|Acute side effects as assessed by the International CTC scale|Geriatric condition as assessed by the following questionnaires: the Cumulative Illness Rating Scale-Geriatric, the Mini Nutritional Assessment, the Instrumental Activities of Daily Living, the QLQ-C30, the Mini Mental State Examination, and the Geri ...","Institut Bergonié|National Cancer Institute (NCI)","All","70 Years and older   (Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000636032|IB-FRAIL06|INCA-RECF0892|IB-2008-25|EUDRACT-2008-001506-16","October 2008","October 2010","null","June 1, 2009","null","July 22, 2009","Institut Bergonie, Bordeaux, France","","https://ClinicalTrials.gov/show/NCT00911183"
727,"NCT00193479","Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Non-Hodgkins Lymphoma","Drug: Cyclophosphamide|Drug: Mitoxantrone|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab","Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment","SCRI Development Innovations, LLC|Genentech, Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LYM 28","April 2003","July 2008","February 2010","September 19, 2005","February 21, 2014","February 21, 2014","Florida Cancer Specialists, Fort Myers, Florida, United States|Tennessee Oncology, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00193479"
728,"NCT00556699","A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: rituximab|Drug: SGN-40","Incidence and nature of dose-limiting toxicities in order to determine the maximum tolerated dose|Changes in vital signs, physical examination findings, and clinical laboratory results|Incidence, nature, and severity of adverse events|Pharmacokinetic parameters|Patient's best response as assessed by the investigator|Duration of response|Event-free survival","Genentech, Inc.|Seattle Genetics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACF4325g","December 2007","November 2010","November 2010","November 12, 2007","null","March 20, 2014","","","https://ClinicalTrials.gov/show/NCT00556699"
729,"NCT03261349","Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma",,"Not yet recruiting","No Results Available","Indolent Lymphoma","Drug: Ledipasvir and sofosbuvir","The complete remission rate|The durability of complete remission (disease-free interval)|The overall response rate|The association between HCV RNA load and response of lymphoma.|The toxicity of Harvoni®.|Potential biomarkers predicting the response of Harvoni®.","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201612066MIPB","September 1, 2017","December 31, 2020","August 15, 2021","August 25, 2017","null","August 25, 2017","","","https://ClinicalTrials.gov/show/NCT03261349"
730,"NCT03242902","To Decrease Fatigue With Light Therapy","SPARKLE","Recruiting","No Results Available","Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma","Device: Light therapy intensity 1|Device: Light therapy intensity 2","Cancer related fatigue|Subjective sleep quality|Objective sleep quality|Depression|Anxiety|Quality of life|Subjective cognitive complaints|Objective cognitive complaints - alertness and sustained attention|Objective cognitive complaints - long-term memory|Objective cognitive complaints - short-term memory|Cancer worries|Fatigue catastrophizing|Self-efficacy|Circadian rhythms of cortisol and melatonin|Biomarkers of inflammation and genotype","The Netherlands Cancer Institute|Dutch Cancer Society","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NL61017.031.17","September 20, 2017","August 2019","May 2020","August 8, 2017","null","August 2, 2018","Radboudumc, Nijmegen, Gelderland, Netherlands|Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands|VUmc, Amsterdam, Noord-Holland, Netherlands|Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands|Erasmus MC, Rotterdam, Zuid-Holland, Netherlands|Haga ziekenhuis, Den Haag, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Admiraal de Ruyter ziekenhuis, Goes, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands","","https://ClinicalTrials.gov/show/NCT03242902"
731,"NCT01829958","Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy",,"Recruiting","No Results Available","Non Hodgkin Lymphoma (NHL)|Diffuse Large B-cell Lymphoma (DLBCL)","Drug: rituximab|Drug: prednisone|Behavioral: Geriatric Assessment","Toxicity Assessment","Memorial Sloan Kettering Cancer Center","All","60 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-028","April 2013","April 2019","April 2019","April 11, 2013","null","September 14, 2018","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT01829958"
732,"NCT02180711","Study of Acalabrutinib Alone or in Combination With Rituximab in Indolent B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Follicular Lymphoma (FL)","Drug: acalabrutinib|Drug: rituximab (IV)","Number of Participants With Treatment Emergent Adverse Events (AEs)","Acerta Pharma BV|Acerta Pharma, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-LY-003","February 2015","April 2022","July 2022","July 3, 2014","null","March 5, 2018","City of Hope, Duarte, California, United States|Innovative Clinical Research, Whittier, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Norton Cancer Center, Louisville, Kentucky, United States|University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Clinical Research Alliance, Lake Success, New York, United States|Weill Cornell Medical College, New York, New York, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|MD Anderson, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02180711"
733,"NCT00741871","A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies",,"Completed","No Results Available","Lymphoma, Malignant|Hodgkin's Lymphoma|B Cell Lymphoma","Drug: SB1518","To establish the maximum tolerated dose of SB1518 as a single agent when administered orally daily in subjects with advanced lymphoid malignancies.|To assess the safety and tolerability of SB1518, administered orally once daily in subjects with advanced lymphoid malignancies.|To assess the pharmacokinetic and pharmacodynamic profile of SB1518.","S*BIO","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB1518-2007-002","July 2008","October 2011","October 2011","August 26, 2008","null","April 20, 2012","MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00741871"
734,"NCT01665768","Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma",,"Active, not recruiting","No Results Available","CD20+, B-cell Lymphomas|Mantle Cell Lymphoma|Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL)|Transformed Lymphoma/DLBCL/PMBCL|Hodgkin's Disease|Gray Zone Lymphoma","Drug: Everolimus and Rituximab","Number of patients with adverse events when given treatment with maintenance rituximab and prolonged mTOR inhibition with everolimus in CD20+, B cell lymphomas, Gray Zone Lymphoma, and Hodgkin's Lymphoma after high-dose consolidative therapy|1) Event free survival at three years based on histology|2) Reduction of the frequency of circulating cancer cells due to maintenance rituximab with everolimus treatment|3) Sensitivity, in-vivo, of relapsed disease to mTor kinase inhibition.","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1228|NA_00067315","August 2012","July 2020","July 2020","August 15, 2012","null","July 13, 2017","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01665768"
735,"NCT00001512","Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines",,"Completed","No Results Available","B Cell Lymphoma|Follicular Lymphoma|Lymphoma","Drug: Id-KLH Vaccine|Drug: GM-CSF","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","NIH","Interventional","Primary Purpose: Treatment","960133|96-C-0133","September 9, 1996","March 5, 2010","March 5, 2010","November 4, 1999","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001512"
736,"NCT00577278","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma","Biological: rituximab|Drug: fludarabine phosphate|Drug: melphalan|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: yttrium Y 90 ibritumomab tiuxetan|Other: laboratory biomarker analysis","Relapse/progression rate|Relapse-free survival|Progression-free survival|Toxicity and safety of treatment regimen|Overall survival|Duration of response|Time-to-progression (TTP)|Non-relapse mortality","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2","54","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05149|P01CA030206|CHNMC-05149|CDR0000579136|NCI-2010-01230","January 15, 2007","March 2019","March 2019","December 20, 2007","null","May 9, 2018","City of Hope Medical Center, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT00577278"
737,"NCT01120834","Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)",,"Completed","Has Results","Lymphoma","Drug: azacytidine|Drug: vorinostat","Overall Response Rate (ORR)","Weill Medical College of Cornell University|Celgene|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0912010795","September 2010","April 2013","October 20, 2016","May 11, 2010","April 10, 2017","April 10, 2017","Weill Cornell Medical College, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01120834"
738,"NCT00612183","Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma","Drug: bendamustine hydrochloride","Overall response rate based on [Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas]|CR rate of overall results based on [Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas]","SymBio Pharmaceuticals","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007002","December 2007","September 2009","September 2009","February 11, 2008","null","July 22, 2010","Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Sapporo, Hokkaido, Japan|Isehara, Kanagawa, Japan|Sendai, Miyagi, Japan|Moriguchi, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Utsunomiya, Tochigi, Japan|Chuo, Tokyo, Japan|Koto, Tokyo, Japan|Shibuya, Tokyo, Japan|Shinagawa, Tokyo, Japan|Fukuoka, Japan|Kagoshima, Japan|Kumamoto, Japan|Kyoto, Japan|Nagoya, Japan","","https://ClinicalTrials.gov/show/NCT00612183"
739,"NCT01955668","AZD6738 First Time in Patient Multiple Ascending Dose Study",,"Completed","No Results Available","11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),|Prolymphocytic Leukaemia (PLL)|B Cell Lymphomas","Drug: Administration of AZD6738","Parts A and B: Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures.|Part A only: Define either the Maximum tolerated dose (MTD), if possible, or maximum feasible dose (MFD)|Part B only: Preliminary assessment of the effect of food on the Pharmacokinetic (PK) parameters of AZD6738 via plasma analysis|Parts A&B: Establish pharmacokinetics characteristics of AZD6738 and its active metabolite from plasma analysis|Part A and B: Anti tumour activity by assessing tumour response via CT or MRI scans|Part A and B: Measuring 4 beta-hydroxy cholesterol concentration for assessment of CYP3A4 induction potential|Part B: Pharmacokinetic profile of AZD6738 and its active metabolite from urinalysis|Part B only: Preliminary assessment of the effect of food on the PK parameters of AZD6738 via urinalysis|Part A: Determine the extent of ATR target inhibition using pharmacodynamic biomarkers|Part A and B: Biomarker analysis using lymph node biopsies|Part A and B: Confirmation of tumour response assessment by analysing bone marrow / aspirate|Part A and B: Bone marrow biopsy or aspirate will be analysed for biomarkers|Part A and B: Determination of 11q del status to investigate any potential changes in FISH cytogenetic's post treatment|Parts A and B: Identify patients with ATM deficient status, determine ATM mutation load and correlate this with clinical efficacy in order to better understand patient population which will most likely benefit from AZD6738 treatment|Part B: The extent of ATR target inhibition identified using pharmacodynamic biomarkers","AstraZeneca|CLL Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5330C00001","November 2013","December 2013","December 2013","October 7, 2013","null","June 19, 2014","Research Site, La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT01955668"
740,"NCT02051257","Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma","Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Other: Laboratory Biomarker Analysis","Incidence of dose limiting toxicities (DLTs), defined as any grade 3 or higher toxicity, any grade 3 or greater autoimmune toxicity, or failure for a research participant with documented T cell persistence to engraft by day 21 post HSCT|Incidence of adverse events attributable to the cellular immunotherapy product|MTD of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells based on DLTs|MTD of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells based on DLTs|Engraftment of the transferred T cell product|Levels of CD19+ B-cell precursors in the bone marrow, used as a surrogate for the in vivo effector function of transferred CD19-specific T-cells","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","51","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13277|NCI-2014-00133|P50CA107399","May 2014","June 2021","June 2021","January 31, 2014","null","February 8, 2018","City of Hope Medical Center, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT02051257"
741,"NCT00101010","Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: Filgrastim|Biological: Pegfilgrastim|Biological: Rituximab|Drug: Cyclophosphamide|Drug: Pegylated liposomal doxorubicin hydrochloride|Drug: Prednisone|Drug: Vincristine Sulfate","Disease response (complete, complete unconfirmed, and partial responses) after courses 4 and 8|Cardiac toxicity as measured by LVEF on ECHO after courses 4 and 8|Survival Rate|Disease-free survival","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Ortho Biotech, Inc.","All","61 Years and older   (Adult, Older Adult)","Phase 2","80","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000407533|MDA-CCOP-2004-0305|NCI-6485|2004-0305|NCI-2009-00064|2U10CA045809","September 2005","September 2014","null","January 10, 2005","null","September 11, 2014","Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Cancer Research for the Ozarks, Springfield, Missouri, United States|Hematology Oncology Associates of Central New York, PC - Northeast Center, East Syracuse, New York, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|University of Texas M.D. Anderson CCOP Research Base, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00101010"
742,"NCT01077518","Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen","COMPLEMENT A+B","Active, not recruiting","No Results Available","Lymphoma, Follicular","Drug: Ofatumumab and Bendamustine infusions (Arm A)|Drug: Bendamustine infusion (Arm B)","Progression-free-survival following ofatumumab and bendamustine combination therapy|Clinical benefit, changes in patient reported outcome measures, and pharmacokinetics following ofatumumab and bendamustine combination therapy|Overall response rate, overall survival, time to and duration of response following ofatumumab and bendamustine combination therapy|Safety and tolerability of ofatumumab and bendamustine combination therapy","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110918","August 26, 2010","January 3, 2018","December 20, 2024","March 1, 2010","null","June 7, 2018","Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Palm Springs, California, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Coeur d'Alene, Idaho, United States|Novartis Investigative Site, Silver Spring, Maryland, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Danville, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Morgantown, West Virginia, United States|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Derqui, Pilar, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Steyr, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Jau, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Brasila/DF, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Sao Paulo - SP, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Avignon cedex 9, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, France|Novartis Investigative Site, Grenoble cedex 9, France|Novartis Investigative Site, La Roche sur Yon Cedex 9, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Marseille Cedex 9, France|Novartis Investigative Site, Nantes cedex 1, France|Novartis Investigative Site, Pessac cedex, France|Novartis Investigative Site, Saint Pierre cedex, France|Novartis Investigative Site, Saint-Denis cedex, France|Novartis Investigative Site, Saint-Herblain cedex, France|Novartis Investigative Site, Tours cedex 9, France|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Aschaffenburg, Bayern, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Weilheim, Bayern, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Giessen, Hessen, Germany|Novartis Investigative Site, Hanau, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Marburg, Hessen, Germany|Novartis Investigative Site, Bielefeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bottrop, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Goch, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Herford, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Leverkusen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Paderborn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Recklinghausen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Kaiserslautern, Rheinland-Pfalz, Germany|Novartis Investigative Site, Koblenz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Neunkirchen, Saarland, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Alexandroupolis, Greece|Novartis Investigative Site, Athens,, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Haidari, Athens, Greece|Novartis Investigative Site, Heraklion, Crete, Greece|Novartis Investigative Site, Ioannina, Greece|Novartis Investigative Site, Piraeus, Greece|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Reggio Calabria, Calabria, Italy|Novartis Investigative Site, Napoli, Campania, Italy|Novartis Investigative Site, Meldola (FC), Emilia-Romagna, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Novara, Piemonte, Italy|Novartis Investigative Site, San Giovanni Rotondo, Puglia, Italy|Novartis Investigative Site, Terni, Umbria, Italy|Novartis Investigative Site, Verona, Veneto, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Hiroshima, Japan|Novartis Investigative Site, Hyogo, Japan|Novartis Investigative Site, Ibaraki, Japan|Novartis Investigative Site, Kanagawa, Japan|Novartis Investigative Site, Miyagi, Japan|Novartis Investigative Site, Okayama, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Legnica, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Hato Rey, Puerto Rico|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Kaluga, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhniy Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Penza, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tula, Russian Federation|Novartis Investigative Site, Ufa,, Russian Federation|Novartis Investigative Site, Volgograd, Russian Federation|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Makiivka, Ukraine|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom|Novartis Investigative Site, Uxbridge, United Kingdom","","https://ClinicalTrials.gov/show/NCT01077518"
743,"NCT00278408","Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Time to treatment failure (TTF) measured from day 1 of course 1 of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy up to 3 years on study with life-long follow-up|Complete response (CR) rate until first relapse|Progression rate during treatment|Survival|Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored)|Disease-free survival measured from day 1 of course 1 of CHOP therapy|Relapse-free survival of patients with complete response (CR) or unconfirmed complete response (CRu) following complete immunochemotherapy|Safety (adverse events, serious adverse events) assessed at 3 months after completion of study treatment|Consolidating radiotherapy","German High-Grade Non-Hodgkin's Lymphoma Study Group","All","18 Years to 60 Years   (Adult)","Phase 3","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000459796|DSHNHL-2004-3|EUDRACT-2005-005218-19|EU-205111","November 2005","November 2015","November 2015","January 18, 2006","null","January 21, 2016","Klinikum St. Marien, Amberg, Germany|Klinikum Augsburg, Augsburg, Germany|Kreiskrankenhaus Aurich, Aurich, Germany|Klinikum Bayreuth, Bayreuth, Germany|Charite - Campus Charite Mitte, Berlin, Germany|Charite University Hospital - Campus Virchow Klinikum, Berlin, Germany|Franziskus Hospital, Bielefeld, Germany|Augusta-Kranken-Anstalt gGmbH, Bochum, Germany|Staedtisches Klinikum Braunschweig, Braunschweig, Germany|Klinikum Bremen-Mitte, Bremen, Germany|Onkologische Schwerpunktpraxis Celle, Celle, Germany|Hospital Kuchwald Chemnitz, Chemnitz, Germany|Praxis Fuer Haematologie Internistische Onkologie, Cologne, Germany|Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany|Carl - Thiem - Klinkum Cottbus, Cottbus, Germany|Klinikum Dortmund, Dortmund, Germany|Virngrund-Klinik Ellwangen, Ellwangen, Germany|Hans - Susemihl - Krankenhaus, Emden, Germany|St. Antonius Hospital, Eschweiler, Germany|Universitaetsklinikum Essen, Essen, Germany|Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany|Krankenhaus Nordwest, Frankfurt, Germany|Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Klinikum Garmisch - Partenkirchen GmbH, Garmisch-Partenkirchen, Germany|Saint Josef Hospital, Gelsenkirchen, Germany|Wilhelm-Anton-Hospital gGmbH, Goch, Goch, Germany|Universitaetsklinikum Goettingen, Goettingen, Germany|Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Germany|St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH, Hagen, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|University Medical Center Hamburg - Eppendorf, Hamburg, Germany|Klinikum Stadt Hanau, Hanau, Germany|Krankenhaus Siloah - Medizinische Klinik II, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Medizinische Universitaetsklinik und Poliklinik, Heidelberg, Germany|Privatklinik Dr. R. Schindlbeck GmbH & Co. KG, Herrsching, Germany|St. Bernward Krankenhaus, Hildesheim, Germany|Haematologie und Internistische Onkologie Praxis, Homberg, Germany|Universitaetsklinikum des Saarlandes, Homburg, Germany|Clinic for Bone Marrow Transplantation and Hematology and Oncology, Idar-Oberstein, Germany|Staedtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany|Internistische Gemeinschaftspraxis - Kassel, Kassel, Germany|Klinikum Kempten Oberallgaeu, Kempten, Germany|Staedtisches Krankenhaus Kiel, Kiel, Germany|University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany|Internistische Praxis - Landshut, Landshut, Germany|Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen am Rhein, Germany|Kreiskrankenhaus Luedenscheid, Luedenscheid, Germany|Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg, Germany|III Medizinische Klinik Mannheim, Mannheim, Germany|Klinikum Minden, Minden, Germany|Krankenhaus Maria Hilf GmbH, Moenchengladbach, Germany|Haematologisch - Onkologische Gemeinschaftspraxis - Muenster, Muenster, Germany|Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster, Muenster, Germany|Klinikum der Universitaet Muenchen - Grosshadern Campus, Munich, Germany|Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany|Onkologische Schwerwpunktpraxis Dr. Ladda, Neumarkt, Germany|Klinikum Oldenburg, Oldenburg, Germany|Bruederkrankenhaus St. Josef Paderborn, Paderborn, Germany|Klinikum der Universitaet Regensburg, Regensburg, Germany|Klinikum Suedstadt Rostock, Rostock, Germany|Leopoldina - Krankenhaus, Schwienfurt, Germany|St. Marien - Krankenhaus Siegen GMBH, Siegen, Germany|Onkologische Schwerpunktpraxis - Straubing, Straubing, Germany|Klinik fuer Onkologie - Katharinenhospital Stuttgart, Stuttgart, Germany|Diakonie Klinikum Stuttgart, Stuttgart, Germany|Krankenanstalt Mutterhaus der Borromaerinnen, Trier, Germany|Krankenhaus Der Barmherzigen Brueder, Trier, Germany|Praxis Fuer Internistische Haematologie / Onkologie, Troisdorf, Germany|Praxis fuer Haematologie und Onkologie, Twistringen, Germany|Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm, Ulm, Germany|St. Marienhospital - Vechta, Vechta, Germany|Regional Hospital Waldbrol, Waldbrol, Germany|Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany|Kliniken St. Antonius, Wuppertal 2, Germany|Heinrich-Braun-Krankenhaus Zwickau, Zwickau, Germany|Rabin Medical Center - Beilinson Campus, Petah-Tikva, Israel","","https://ClinicalTrials.gov/show/NCT00278408"
744,"NCT00062296","Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Leukemia|Lymphoma","Biological: rituximab|Drug: epirubicin hydrochloride","","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","FCCC-02025|CDR0000304711","March 2003","August 2005","August 2005","June 6, 2003","null","July 11, 2013","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00062296"
745,"NCT00974792","Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma",,"Unknown status","No Results Available","Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate","Complete response rate|Toxicity|Progression-free survival","Cancer Research UK|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","150","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000644893|CRUK-UCL-R-CODOX-M/IVAC|EUDRACT-2005-003479-19|EU-20956","January 2006","May 2011","null","September 10, 2009","null","August 26, 2013","Nottingham City Hospital, Nottingham, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT00974792"
746,"NCT00001572","Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype",,"Completed","No Results Available","B Cell Lymphoma|Follicular Lymphoma|Neoplasm","Drug: Id-KLH Vaccine|Drug: QS-21 (Stimulation-QS-21) Drug","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","NIH","Interventional","Primary Purpose: Treatment","970077|97-C-0077","January 30, 1997","July 31, 1999","November 2, 2010","November 4, 1999","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001572"
747,"NCT03233854","CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","B Acute Lymphoblastic Leukemia|CD19 Positive|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly|Minimal Residual Disease|Philadelphia Chromosome Positive|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration","Incidence and severity of dose limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD19/CD22 chimeric antigen receptor (CAR) T cells|Maximum tolerated dose of CD19/CD22 chimeric antigen receptor (CAR) T cells defined as the dose level immediately below the level at which the enrollment is stopped due to a dose limiting toxicity|Rate of successful manufacture and expansion of the CD19/CD22 chimeric antigen receptor (CAR) T cells to satisfy the targeted dose level and meet the required release specifications outlined in the Certificate of Analysis|Overall survival|Progression free survival|The ability to achieve a clinical response after administration of CD19/CD22 chimeric antigen receptor (CAR) T cells","Crystal Mackall, MD|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1","57","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCT5001|41382","September 1, 2017","September 1, 2025","September 1, 2035","July 31, 2017","null","January 29, 2018","Stanford University, School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03233854"
748,"NCT00695409","Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma",,"Completed","Has Results","Lymphoma","Biological: rituximab|Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: ASCT|Radiation: yttrium Y 90 ibritumomab tiuxetan","2-Year Progression-Free Survival|2-Year Overall Survival|2-Year Cumulative Incidence of Progression|Number of Patients With Active Disease at ASCT Achieving CR/PR by Day 100 After ASCT|Number of Patients With Grade 3-4 Bearman Toxicities.|100-Day Treatment-Related Mortality|Time to Neutrophil Recovery|Time to Platelet Recovery|Number of Patients With RIT/ZBEAM Developing Therapy Induced MDS and AML","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","122","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07076|P01CA030206|P30CA033572|CHNMC-07076|CDR0000597569|NCI-2010-01231","March 18, 2008","March 27, 2017","March 27, 2017","June 11, 2008","July 6, 2018","July 6, 2018","City of Hope Medical Center, Duarte, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT00695409/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00695409"
749,"NCT03114865","A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|B-cell Non Hodgkin Lymphoma|Pre B-Cell Acute Lymphoblastic Leukaemia","Drug: Blinatumomab|Drug: Dexamethasone","Overall survival at two years post first treatment cycle|Non-Relapse Mortality|Progression-free survival|Disease-free Survival|Overall Survival|Minimal Residual Disease","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1713|IRB00125679","September 5, 2017","May 2020","May 2020","April 14, 2017","null","October 18, 2017","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03114865"
750,"NCT00765245","Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma",,"Completed","Has Results","Lymphoma","Drug: Lenalidomide|Drug: Rituximab","Disease-free Survival at 1 Year|Disease-free Survival at 2 Years|Number of Patients With Each Worst‐Grade Toxicity","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC HEM 0835|P30CA068485","October 2008","November 2014","November 2014","October 2, 2008","April 11, 2016","April 11, 2016","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00765245"
751,"NCT00989664","Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma, Non-Hodgkin","Biological: Tositumomab and Iodine I 131 Tositumomab","Number of Participants (Par.) Receiving TST and I 131 TST With a Response >=30 Days Versus Par. With a Response >=30 Days After Their Last Qualifying Chemotherapy Regimen (LQCR), Masked Independent Randomized Radiology and Oncology Review (MIRROR) Panel|Duration of Response for Par. Receiving TST and I 131 TST With a Response >=30 Days Versus the Number of Par. With a Response >=30 Days After Their LQCR, as Assessed by the MIRROR Panel|Number of Participants With Any Uncofirmed Response (CR, Clinical Complete Response [CCR], or PR), CR, CCR, CR+CCR, and PR), as Assessed by the Investigator|Number of Participants With Any Confirmed Response (CR, CCR, or PR), Confirmed CR, Confirmed CCR, Confirmed CR+CCR, and Confirmed PR, as Assessed by Investigator|Time to Progression of Disease or Death, as Assessed by the Investigator|Time to Treatment Failure, as Assessed by the Investigator|Overall Survival|Number of Participants With Responses of CR, CCR, CR+CCR, and PR Following TST and I 131 TST and Following the LQCR, as Assessed by the Investigator|Number of Participants With the Indicated Adverse Events (AE) Related to Study Drug Experienced by at Least 5% of Participants|Number of Participants With the Indicated Grade 3 or Grade 4 AEs Experienced by at Least 5% of Participants|Number of Participants With the Indicated Grade 3 or Grade 4 AEs Related to Study Drug and Experienced by at Least 5% of Participants|Number of Participants With the Indicated Primary Cause of Death|Number of Participants With the Indicated Time to Death From the Last Dose of Study Drug|Number of Participants With the Indicated Fatal Serious Adverse Events (SAE) Unrelated to Study Drug|Number of Participants With the Indicated Fatal SAEs Related to Study Drug|Number of Participants With the Indicated SAEs Related to Study Drug|Number of Participants With the Indicated Type of Infection|Number of Participants With an Infection for Which Anti-infectives Were Administered|Number of Participants Who Were Negative for Human Anti-murine Antibodies (HAMA) at Baseline (Before Receiving the Dosimetric Dose) But Positive or Negative After Receiving the Dosimetric Dose|Time to HAMA Positivity From the First Dosimetric Dose|Number of Participants With the Indicated Grade 3 or Grade 4 Hematologic Toxicities|Number of Participants With Hypothyroidism Prior to Therapy and After the Therapeutic Dose","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","104504","November 1996","January 2004","September 2008","October 5, 2009","April 10, 2012","December 13, 2016","","","https://ClinicalTrials.gov/show/NCT00989664"
752,"NCT00867529","Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma",,"Completed","Has Results","B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Biological: rituximab|Procedure: peripheral blood stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Other: pharmacological study|Other: laboratory biomarker analysis","Disease Relapse Rate|Incidence and Severity of Acute and Chronic GVHD Evaluated Per an Adapted Version of Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0|Overall Survival and Progression-free Survival|Rate of Graft Rejection and Graft Failure|Time to Engraftment","Fred Hutchinson Cancer Research Center|American Cancer Society, Inc.|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Phase 2","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2226.00|NCI-2010-00107|2226|P01CA078902|P30CA015704","February 2009","March 2015","March 26, 2015","March 23, 2009","May 22, 2017","January 2, 2018","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00867529"
753,"NCT03220022","Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas",,"Recruiting","No Results Available","AIDS-Related Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|CD20 Negative|CD20 Positive|Human Immunodeficiency Virus Positive","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Biological: Filgrastim|Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Biological: Pegfilgrastim|Other: Pharmacological Study|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","Maximum tolerated dose (MTD) of ibrutinib in combination with chemotherapy|Recommended phase II dose (RP2D) of ibrutinib in combination with chemotherapy|Incidence of adverse events graded using Common Terminology Criteria for Adverse Events version 4.0|Complete response rates|Progression free survival (PFS)|Overall survival (OS)|Lymphoma cell-of-origin (COO) assessment|Percentage of participants who receive two or more cycles of combination chemotherapy, and are able to continue on a minimum dose level of cyclophosphamide of -1 and above after dose adjustments|Average number of days per cycle participants are able to stay on planned dose of ibrutinib|Changes in the levels of human immunodeficiency virus (HIV)-1 viral reservoirs|Changes in Epstein-Barr virus (EBV) viral loads|Effect of treatment on HIV latency reservoirs|Effect of treatment on B-cell receptor signaling pathway including BTK activity|Effect of treatment on T-cell receptor signaling via ITK activity.|Soluble cytokine response to treatment|Pharmacokinetics (PK) parameters assessment for ibrutinib, doxorubicin hydrochloride, etoposide, and vincristine sulfate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2017-01240|AMC-101|UM1CA121947","November 3, 2017","September 18, 2020","September 18, 2020","July 18, 2017","null","August 23, 2018","UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|AIDS Malignancy Consortium, Rockville, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03220022"
754,"NCT00079443","FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Small Lymphocytic Lymphoma","Drug: romidepsin|Biological: rituximab|Drug: fludarabine phosphate|Other: laboratory biomarker analysis","Objective response rate (Phase II)|Survival (Phase II)|MTD, defined as the highest dose level at which 6 patients have been treated with not more than 1 DLT, graded according to NCI CTC version 2 (Phase I)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2013-00043|UMGCC #0307|MSGCC-0307|CDR0000355763|NCI-6015|U01CA069854","January 2004","September 2005","null","March 10, 2004","null","July 1, 2013","University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00079443"
755,"NCT00498043","A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma","LNH2007-3B","Completed","No Results Available","Lymphoma, B-Cell|Lymphoma, Large-Cell, Diffuse","Drug: R-CHOP14 induction regimen|Drug: R-ACVBP14 induction regimen","Complete response rate after 4 inductive cycles with R-ACVBP14 or R-CHOP14, in DLBCL CD 20 (+) patients, presenting with 2 or 3 adverse prognostic factors of the aa-IPI Test a Pet-driven strategy Complete response rate after the 4 inductive cycles|Response according to PET after 2 cycles, 4 cycles Induction toxicities Response duration Disease-, progression-, event-free and overall survival after autologous transplant Biological factors for prognosis Pharmacokinetic of rituximab","Hospices Civils de Lyon","All","18 Years to 59 Years   (Adult)","Phase 2","222","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007.462","July 2007","October 2013","October 2013","July 9, 2007","null","August 13, 2014","René Olivier Casasnovas, Dijon, France","","https://ClinicalTrials.gov/show/NCT00498043"
756,"NCT02017613","Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies","PI3K","Completed","No Results Available","Lymphoma, B-Cell|T-Cell Lymphoma","Drug: RP6530","Maximum tolerated dose (MTD) and pharmacokinetics (PK) of RP6530|Clinical response following administration of RP6530","Rhizen Pharmaceuticals SA","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RP6530-1301|2013-003769-32","November 2013","May 2016","May 2016","December 23, 2013","null","June 24, 2016","Rhizen Trial Site, Paris, France|Rhizen Trial Site 1, Milano, Italy|Rhizen Trial Site 2, Milano, Italy","","https://ClinicalTrials.gov/show/NCT02017613"
757,"NCT00875056","Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients (MK-0683-103)",,"Active, not recruiting","No Results Available","Lymphoma","Drug: vorinostat","Overall Response Rate|Time to event efficacy endpoints 2)Any clinical or laboratory adverse experiences","Merck Sharp & Dohme Corp.","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0683-103|2009_570|132248","April 15, 2009","February 25, 2011","January 31, 2019","April 3, 2009","null","February 9, 2018","","","https://ClinicalTrials.gov/show/NCT00875056"
758,"NCT02572453","Onalespib in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","ALK Positive|BCL6 Positive|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma","Other: Laboratory Biomarker Analysis|Drug: Onalespib","Objective response rate|Change in protein levels of ALK in ALK+ anaplastic large cell lymphoma via immunohistochemistry|Change in protein levels of cyclin D1 in mantle cell lymphoma via immunohistochemistry|Change in protein levels of BCL6 in diffuse large B cell lymphoma via immunohistochemistry|Incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Progression free survival|Overall survival|Duration of response","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2015-01681|15-XXX|16-712|9875|UM1CA186690|UM1CA186709","April 4, 2016","August 31, 2019","null","October 9, 2015","null","August 3, 2018","Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02572453"
759,"NCT01282424","Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma","DELTA","Completed","Has Results","Follicular Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Marginal Zone Lymphoma","Drug: Idelalisib","Overall Response Rate|Duration of Response|Lymph Node Response Rate|Time to Response|Progression-Free Survival|Overall Survival|Change in Health-related Quality of Life|Change in Karnofsky Performance Status|Safety and Tolerability of Idelalisib Assessed as the Number of Participants Experiencing Adverse Events (AEs) or Abnormalities in Vital Signs, Laboratory Tests, or Electrocardiograms|Study Drug Exposure|Idelalisib Plasma Concentration|Pharmacokinetic (PK) Parameter: Cmax|Pharmacokinetic (PK) Parameter: Tmax|Pharmacokinetic (PK) Parameter: AUClast","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","125","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101-09|2010-022155-33","March 4, 2011","June 25, 2013","May 16, 2018","January 25, 2011","September 4, 2014","June 21, 2018","St. Jude Medical Center, Fullerton, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|UCLA, Los Angeles, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|Stanford Cancer Center, Stanford, California, United States|Collaborative Research Group, LLC, Boynton Beach, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States|University of Medicine and Dentistry of NJ, New Brunswick, New Jersey, United States|Weill Cornell -New York Presbyterian Hospital, New York, New York, United States|Montefiore Medical Center, New York, New York, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Hem/Oncology Ass (SCRI), Chattanooga, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|CHU Morvan, Brest, France|Centre Hospitalier de Lyon Sud, Pierre Benite, France|Centre Henri Bequerel, Rouen, France|CHU Bretonneau - Centre Kaplan, Tours, France|Charité Campus Virchow Klinikum, Berlin, Germany|Universitätsklinikum Essen, Essen, Germany|Klinikum der Universität München-Großhadern, München, Germany|Universitatsklinikum Ulm, Ulm, Germany|Azienda Ospedaliera di Bologna - Policlinico S. Orsola Malpighi, Bologna, Italy|A.O.U. San Martino, Genova, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Università ""Sapienza"", Rome, Italy|Małopolskie Centrum Medyczne, Kraków, Poland|Centrum Onkologii w Warszawie, Warsaw, Poland|St James's Institute of Oncology, Leeds, United Kingdom|St Bartholemews Hospital, London, United Kingdom|Sarah Cannon Institute, London, United Kingdom|The Christie Hospital, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT01282424"
760,"NCT00944905","Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)",,"Completed","No Results Available","Renal Cell Carcinoma|Non-hodgkin's Lymphoma","Biological: MDX-1203","Safety profile of MDX-1203 and determine the maximum tolerated dose (MTD)|Biomarker: Incidence of CD70+ tumors in target population","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDX1203-01|CA211-001","July 2009","November 2012","November 2012","July 23, 2009","null","May 22, 2013","Yale University School of Medicine, New Haven, Connecticut, United States|Emory University Winship Cancer Center, Atlanta, Georgia, United States|The University of Chicago, Chicago, Illinois, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|The University of Michigan Health System, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00944905"
761,"NCT01980654","Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma",,"Completed","No Results Available","Follicular Lymphoma|B-cell Lymphoma|Non-Hodgkin's Lymphoma","Drug: Ibrutinib|Drug: rituximab","To evaluate the efficacy of ibrutinib when combined with rituximab (determined by the overall response rate [ORR]) in previously untreated subjects with FL.|To evaluate the efficacy of ibrutinib combined with rituximab in subjects with FL as assessed by the duration of response (DOR).|To evaluate the efficacy of ibrutinib combined with rituximab in subjects with FL as assessed by progression free survival (PFS).|To evaluate the efficacy of ibrutinib combined with rituximab in subjects with FL as assessed by overall survival (OS).|To evaluate the safety and tolerability of ibrutinib combined with rituximab in previously untreated subjects with FL","Pharmacyclics LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC-1125-CA","December 2013","November 2017","November 2017","November 11, 2013","null","November 21, 2017","Providence Saint Joseph Medical Center, Burbank, California, United States|City of Hope, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States|Stanford University, Stanford Care Center, Stanford, California, United States|Southeastern Regional Medical Center, Newnan, Georgia, United States|Community Health Network Community Regional Cancer Center North, Indianapolis, Indiana, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College New York-Presbyterian Hospital, New York, New York, United States|Mid-Ohio Oncology/ Hematology Inc, Columbus, Ohio, United States|Tennessee Oncology, PLLC The Sarah Cannon Research Institute, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01980654"
762,"NCT02254772","A Phase I/II Study of Intratumoral Injection of SD-101",,"Completed","Has Results","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma","Biological: Ipilimumab|Drug: SD-101|Radiation: Radiation therapy","Dose-limiting Toxicity (DLT) of Ipilimumab Plus a Fixed Dose of SD-101 (1 mg/Week)|Tumor Response|Median Time to Progression (TTP)","Robert Lowsky|National Cancer Institute (NCI)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-31133|NCI-2014-01978|LYMNHL0119|5R01CA188005-02","September 2014","November 10, 2016","January 26, 2017","October 2, 2014","September 29, 2017","September 29, 2017","Stanford University Hospitals and Clinics, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02254772"
763,"NCT02332980","Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","Recurrent Chronic Lymphocytic Leukemia|Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Nodal Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent Splenic Marginal Zone Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Nodal Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma|Refractory Splenic Marginal Zone Lymphoma|Richter Syndrome|Waldenstrom Macroglobulinemia","Drug: Ibrutinib|Drug: Idelalisib|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Proportion of patients who achieve a confirmed response|Complete response rate, defined as complete response or incomplete blood count recovery|Duration of response|Incidence of adverse events as measured per National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0|Overall response rate of patients treated with combination therapy|Progression-free survival of patients treated with combination therapy|Progression-free survival of patients treated with single pembrolizumab|Time to next treatment for patients on combination therapy|Time to next treatment for patients treated with single-agent pembrolizumab|Treatment-free survival of patients treated with combination therapy|Treatment-free survival of patients treated with single-agent pembrolizumab","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","68","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1485|NCI-2014-02561|P30CA015083","February 19, 2015","January 5, 2020","January 5, 2020","January 7, 2015","null","July 9, 2018","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02332980"
764,"NCT03543813","PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL",,"Recruiting","No Results Available","Solid Tumor, Adult|Head and Neck Cancer|Non Small Cell Lung Cancer|Pancreatic Cancer|Diffuse Large B Cell Lymphoma","Drug: CX-2029","The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapy|The percentage of subjects experiencing anti-cancer activity (ORR) at various dose levels when given CX-2029 as a monotherapy","CytomX Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTMX-M-2029-001","June 15, 2018","December 2020","December 2022","June 1, 2018","null","September 24, 2018","START Midwest, Grand Rapids, Michigan, United States|Providence Portland Medical Center, Portland, Oregon, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03543813"
765,"NCT01030536","Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)",,"Completed","Has Results","Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia","Drug: CAT-8015 20 mcg/kg|Drug: CAT-8015 30 mcg/kg|Drug: CAT-8015 40 mcg/kg|Drug: CAT-8015 50 mcg/kg|Drug: CAT-8015 60 mcg/kg","Maximum Tolerated Dose (MTD)|Number of Participants With Dose Limiting Toxicities (DLTs)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)|Number of Participants With Clinically Significant Laboratory Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Vital Signs Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Electrocardiogram (ECG) Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)|Percentage of Participants With Complete Response (CR)|Duration of Complete Response|Percentage of Participants With Partial Response (PR)|Percentage of Participants With Objective Response (OR)|Time to Response (TTR)|Duration of Objective Response (DOR)|Duration of Stable Disease (SD)|Maximum Plasma Concentration (Cmax) of Moxetumomab Pasudotox|Area Under Concentration-Time Curve From Dosing Extrapolated to Infinity (AUCinf) of Moxetumomab Pasudotox|Clearance (CL) of Moxetumomab Pasudotox|Elimination Half Life (t1/2) of Moxetumomab Pasudotox|Number of Participants With Positive Anti-Drug Antibody|Number of Participants With CD22 Expression Levels|Number of Capillary Leak Syndrome (CLS) Participants With Weight Changes, Albumin, Hypotension, Edema, Hypoxia, and Pulmonary Adverse Events (AEs)|Percentage of Participants With Stable Disease (SD)","MedImmune LLC","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MI-CP218","February 15, 2010","March 4, 2013","March 4, 2013","December 11, 2009","April 9, 2018","April 9, 2018","Research Site, Los Angeles, California, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Charleston, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Temple, Texas, United States|Research Site, Łódź, Poland","","https://ClinicalTrials.gov/show/NCT01030536"
766,"NCT02242045","Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Adults With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Chronic Lymphocytic Leukemia|Indolent Non-Hodgkin Lymphoma|Follicular Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)|Marginal Zone Lymphoma","Drug: Idelalisib","Type, frequency, severity, timing, and relationship to idelalisib of adverse events (AEs), abnormal laboratory tests, and drug discontinuations due to AEs and serious adverse events (SAEs)|PK profile of idelalisib and its major metabolite GS-563117|Idelalisib trough and peak plasma concentrations|Type, frequency, severity, timing, and relationship to idelalisib of AEs, abnormal laboratory tests, and drug discontinuations due to AEs and SAEs","Gilead Sciences","All","20 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-313-1380","October 1, 2014","December 25, 2014","October 17, 2017","September 16, 2014","null","October 25, 2017","Miyagi, Japan|Nagoya, Japan|Sendai, Japan|Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT02242045"
767,"NCT03605589","Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma",,"Recruiting","No Results Available","Leukemia, B-cell|Lymphoma, B-Cell","Drug: Blinatumomab|Drug: Pembrolizumab","Feasibility of combining pembrolizumab and blinatumomab (dose limiting toxicities)|Treatment related toxicities|Disease response","Children's Hospital Medical Center, Cincinnati","All","1 Year to 40 Years   (Child, Adult)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pembro-EB-1701","October 2018","August 2021","January 2022","July 30, 2018","null","October 2, 2018","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03605589"
768,"NCT00413959","VELCADE,Rituximab,Cyclophosphamide and Decadron","VRCD","Terminated","Has Results","Lymphoma, Non-Hodgkin|Lymphoma, B-Cell","Drug: VELCADE®|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Decadron","Overall Response Rate Using This Regimen in Patients With Low-grade B-Cell Non-Hodgkin's Lymphoma.|Overall Survival","Oncology Specialists, S.C.|Millennium Pharmaceuticals, Inc.","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0606","August 2006","January 2011","January 2011","December 20, 2006","September 27, 2013","September 19, 2018","Onocology Specialists, S.C, Niles, Illinois, United States|Oncology Specialists, S.C, Park Ridge, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00413959"
769,"NCT00087425","Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Leukemia|Lymphoma","Biological: rituximab|Drug: bryostatin 1","Feasability and safety|Antitumor response|Functional and molecular status of effector cells|Expression of CD20 and complement-inhibitory molecules on tumor cells before and after treatment|Effects on global gene expression pattern in chronic lymphocytic leukemia cells","National Institute on Aging (NIA)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000377250|NIA-CII0301|NCI-6216","July 2004","October 2007","null","July 12, 2004","null","April 30, 2015","NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00087425"
770,"NCT02659943","T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies",,"Active, not recruiting","No Results Available","Lymphoma, B-Cell|Lymphoma, Non-hodgkins","Biological: Anti-CD19-CAR T cells|Drug: Cyclophosphamide|Drug: Fludarabine","Determine the safety and feasibility of administering T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor (CAR)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 73 Years   (Adult, Older Adult)","Phase 1","27","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160054|16-C-0054","January 21, 2016","December 1, 2020","December 1, 2021","January 21, 2016","null","September 25, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02659943"
771,"NCT00968656","Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1","FISO PET/CT","Completed","No Results Available","Breast Cancer|Head and Neck Cancer|Diffuse Large B-cell Lymphoma","Radiation: PET/CT|Other: Laboratory Testing|Other: Safety Testing|Other: Immunohistochemistry staining|Drug: F-18-ISO","The primary out come is to assess the diagnostic quality of [18F]ISO-1-PET/CT images at the proposed 8 mCi dose.|Secondary outcome is to quantitatively determine the relationship between tumor [18F]ISO-1 uptake and Ki-67, S-phase, mitotic index and sigma-2 receptors content of the tumor.","Washington University School of Medicine|Isotrace Technologies","All","18 Years and older   (Adult, Older Adult)","Phase 1","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FISO 08-1010","January 2009","November 2011","November 2011","August 31, 2009","null","December 9, 2014","Washington University / Barnes Jewish Hospital, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00968656"
772,"NCT01311232","Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab",,"Completed","No Results Available","Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma|Patients Treated With Rituximab-CHOP or Rituximab-CVP","","Hepatitis B virus reactivation","Samsung Medical Center","All","15 Years to 90 Years   (Child, Adult, Older Adult)","","600","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","2010-11-035","November 1, 2010","December 1, 2012","December 1, 2013","March 9, 2011","null","October 27, 2017","Queen Mary Hospital, Hing Kong, China|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|National Cancer Center, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT01311232"
773,"NCT00543582","MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Hodgkin Lymphoma|Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)","Drug: MGCD0103 and Azacitidine","Primary efficacy is measured by: 1) PET, CT & physical exam, 2) overall response rate (complete response=disease is gone, partial response=disease has improved). Study treatment continues as long as the cancer is stable & side effects are tolerable.|Duration of response defined as: 1)the time of first documented objective response (either complete response or partial response) until the subject's disease gets worse, 2)how long his/her disease is stable.","Mirati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","103 PH US 2007 CL002","October 2007","March 2009","March 2009","October 15, 2007","null","July 1, 2015","St. Francis Cancer Research Foundation, Beech Grove, Indiana, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Weill Medical College of Cornell University, New York, New York, United States|University of Texas, MD Anderson, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00543582"
774,"NCT00210327","VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy",,"Completed","No Results Available","Lymphoma, Mucosa-Associated Lymphoid Tissue","Drug: Bortezomib (drug)","Antitumor activity, in terms of overall response rate (ORR) i.e. sum of complete and partial responses|Safety, as acute and long-term toxicity|Response duration (RD) (time to relapse or progression) in responders|Progression-free survival (PFS) (time to disease progression or death from lymphoma) in all patients","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG25A","July 2005","November 2008","April 2009","September 21, 2005","null","July 22, 2009","Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland","","https://ClinicalTrials.gov/show/NCT00210327"
775,"NCT01209130","A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia","Drug: DCDT2980S|Drug: rituximab","Incidence and nature of dose-limiting toxicities (DLTs)|Objective response, defined as a partial response (PR) or complete response (CR)","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","91","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCT4862g|GO01295","October 2010","March 2015","March 2015","September 27, 2010","null","November 2, 2016","Stanford, California, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Hackensack, New Jersey, United States|Portland, Oregon, United States|Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01209130"
776,"NCT01290549","A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma",,"Completed","No Results Available","Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia","Drug: Polatuzumab Vedotin|Drug: Rituximab","Percentage of Participants With Dose-Limiting Toxicities (DLTs)|Maximum Tolerated Dose|Proposed Phase II Dose of Polatuzumab Vedotin|Percentage of Participants With Adverse Events (AEs)|Percentage of Paticipants with Anti Therapeutic Antibodies (ATAs) Against Polatuzumab Vedotin|Progression Free Survival (PFS), as Assessed by Using Modified Response Criteria for Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)|Percentage of Participants With Objective Response [Complete Response (CR) or Partial Response (PR)], as Assessed by Using Modified Response Criteria for NHL or CLL|Duration of Response, as Assessed by Using Modified Response Criteria for NHL or CLL|Percentage of Participants with Best Overall Response (BOR), as Assessed by Using Modified Response Criteria for NHL or CLL|Area Under the Curve (AUC) from Time 0 to The Last Quantifiable Time Point (AUClast)-Polatuzumab Vedotin Monotherapy|AUC Extrapolating to Time of Infinity (AUCinf)-Polatuzumab Vedotin Monotherapy|Percentage of AUCinf (AUCextrap)-Polatuzumab Vedotin Monotherapy|Maximum Plasma Concentration (Cmax)-Polatuzumab Vedotin Monotherapy|Clearance-Polatuzumab Vedotin Monotherapy|Volume of Distribution at Steady State-Polatuzumab Vedotin Monotherapy|AUClast - Polatuzumab Vedotin Combined with Rituximab|AUCinf-Polatuzumab Vedotin Combined with Rituximab|AUCextrap-Polatuzumab Vedotin Combined with Rituximab|Cmax-Polatuzumab Vedotin Combined with Rituximab|Clearance-Polatuzumab Vedotin Combined with Rituximab|Volume of Distribution at Steady State-Polatuzumab Vedotin Combined with Rituximab|AUClast of Rituximab When Given in Combination With Polatuzumab Vedotin|AUCinf of Rituximab When Given in Combination With Polatuzumab Vedotin|AUCextrap of Rituximab When Given in Combination With Polatuzumab Vedotin|Cmax of Rituximab When Given in Combination With Polatuzumab Vedotin|Clearance of Rituximab When Given in Combination With Polatuzumab Vedotin|Volume of Distribution at Steady State-of Rituximab When Given in Combination With Polatuzumab Vedotin","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","95","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCS4968g|GO01294|2011-002330-39","March 22, 2011","June 29, 2012","November 18, 2014","February 7, 2011","null","June 16, 2017","Stanford Cancer Center, Stanford, California, United States|Stanford Cancer Institute Pharmacy, Stanford, California, United States|Florida Cancer Specialists; Sarasota, Sarasota, Florida, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, United States|M.D Anderson Cancer Center; Oncology, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|CHU Dijon - SCE Hemato, Dijon, France|Centre Hospitalier Regional Universitaire de Lille, Lille, France|CHU Lapeyronie, Hematologie, Montpellier, France|Centre Hospitalier Lyon Sud; Hematolgie, Pierre Benite, France|Centre Henri Becquerel; Hematologie, Rouen, France|Academisch Medisch Centrum; Hematologie, Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT01290549"
777,"NCT00210392","VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy",,"Terminated","No Results Available","Lymphoma, Mucosa-Associated Lymphoid Tissue","Drug: Bortezomib (drug)","Antitumor activity, in terms of overall response rate (ORR) i.e. sum of complete and partial responses|Safety, as acute and long-term toxicity|Response duration (RD) (time to relapse or progression) in responders|Progression-free survival (PFS) (time to disease progression or death from lymphoma) in all patients","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG25B","July 2005","November 2007","November 2007","September 21, 2005","null","March 30, 2015","Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland","","https://ClinicalTrials.gov/show/NCT00210392"
778,"NCT00210353","Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Mucosa-Associated Lymphoid Tissue","Drug: chlorambucil (drug)|Drug: rituximab+chlorambucil|Drug: rituximab","Event-free-survival (EFS) (failure or death from any cause) for all patients|Complete and partial remission rates for all patients|Response duration (time to relapse or progression) for responder patients|Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients|Overall survival for all patients|Acute and long-term toxicity","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG19","January 2003","April 2017","April 2020","September 21, 2005","null","July 27, 2016","ACZA Campus Stuivenberg, Antwerpen, Belgium|AZ StJan, Brugge, Belgium|St Luc, Bruxelles, Belgium|ULB Hopital Erasme, Bruxelles, Belgium|CHNDRF, Charleroi, Belgium|Hospital St Joseph, Gilly, Belgium|UCL de Mont Godinne, Yvoir, Belgium|Centre Hospitalier de Blois, Blois, France|Hopital Avicenne, Bobigny, France|CHU, Dijon, France|Centre Hospitalier, Lens, France|CHRU Lille, Lille, France|Centre Hospitalier Lyon Sud, Lyon, France|Centre Leon Berard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Hopital Arnold Villeneuve, Monpellier, France|CHU, Nancy, France|Centre R. Gauducheau, Nantes-St. Herblain, France|CHU Hotel Dieu, Nantes, France|Hopital Henri-Mondor, Paris, France|Hopital St Louis, Paris, France|Necker, Paris, France|Centre Henri Becquerel, Rouen, France|Spedali Civili, Brescia, Italy|Azienda ULSS 15 Alta Padovana, Cittadella, Italy|IST, Genova, Italy|IEO, Milano, Italy|INT, Milano, Italy|Humanitas, Milan, Italy|San Raffaele Hospital, Milan, Italy|Policlinico, Modena, Italy|Ospedale Civile, Piacenza, Italy|A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia, Reggio Calabria, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, Italy|S. Eugenio, Rome, Italy|Università Cattolica Sacro Cuore, Rome, Italy|Università La Sapienza, Rome, Italy|Sassuolo GISL, Sassuolo, Italy|AOU Senese, Siena, Italy|A.O.U. San Giovanni Battista-Molinette, S.C. Ematologia 2, Torino, Italy|Trani GISL, Trani, Italy|Ospedale di Circolo Fondazione Macchi, Varese, Italy|Policlinico GB Rossi, Verona, Italy|Clinic Hospital Universitari, Barcelona, Spain|Hopital Mataro', Barcelona, Spain|Hopital Santa Creu i Sant Pau, Barcelona, Spain|University Hospital, Salamanca, Spain|Joan XXIII, Tarragona, Spain|IOSI, Bellinzona, Switzerland|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Heartlands, Birmingham, United Kingdom|Victoria Hospital, Blackpool, United Kingdom|Royal Cornwall Hospital, Cornwall, United Kingdom|Darent Valley Hospital, Dartford, United Kingdom|Royal Devon &Exeter Healtcare NHS Trust, Devon, United Kingdom|Russels Hall Hospital, Dudley, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Medway Hospital, Gillingham, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Liverpool Royal Hospital, Liverpool, United Kingdom|University Hospital Aintree, Liverpool, United Kingdom|Barts & the London NHS Trust, London, United Kingdom|Royal Marsden NHS Foundation Trust, London, United Kingdom|St Georges, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Mount Vernon Hospital, Middlesex, United Kingdom|James Paget Hospital, Norfolk, United Kingdom|Queen Elisabeth, Norfolk, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|John Radcliffe, Oxford, United Kingdom|Weston Park, Sheffield, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Conquest Hospital, St Leonard on Sea, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom|Worchestershire Acute Hospital NHS Trust, Worcester, United Kingdom","","https://ClinicalTrials.gov/show/NCT00210353"
779,"NCT01851551","Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL",,"Completed","No Results Available","Non-Hodgkin's Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma","Drug: Vincristine Sulfate Liposome Injection plus rituximab","Objective response rate|Assessment of the number of events and number and percentage of patients with treatment-emergent AEs|Time to Progression|Overall survival","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA00005","September 2001","April 2004","April 2005","May 10, 2013","null","December 4, 2013","University of California, San Francisco, California, United States|Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT01851551"
780,"NCT00412321","A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease",,"Completed","No Results Available","Lymphoma, Non-Hodgkin|Multiple Myeloma|Giant Lymph Node Hyperplasia","Drug: CNTO 328","Number of Patients With Adverse Events as a Measure of Safety and Tolerability|Serum Concentration of CNTO 328|Pharmacodynamics of CNTO 328|Plasma antibodies to CNTO 328|Number of participants with Castleman's disease who achieved tumor response|Number of participants with multiple myeloma who achieved disease response|Number of participants with B-cell non-Hodgkin's lymphoma and multiple myeloma who achieved clinical benefit (CB)|Number of participants with Castleman's disease who achieved clinical benefit|Number of participants with B-cell non-Hodgkin's lymphoma who achieved disease response","Centocor, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","67","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR008566|C0328T03","May 2005","April 2011","April 2011","December 18, 2006","null","July 1, 2014","Little Rock, Arkansas, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Box 302, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00412321"
781,"NCT02257242","Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma","BRiM","Recruiting","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Mantle-Cell|Lymphoma, Small-Cell|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell, Marginal Zone","Drug: Rituximab|Drug: Bendamustine|Drug: Vincristine sulfate liposome injection","Maximum tolerated dose|Cumulative toxicity rate|Rate of treatment completion|Response rate|Complete response rate","Adam Olszewski|Spectrum Pharmaceuticals, Inc|Rhode Island Hospital|The Miriam Hospital|Brown University","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BrUOG 326","May 10, 2017","December 2018","December 2019","October 6, 2014","null","September 26, 2018","Kayla Rosati, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT02257242"
782,"NCT00082784","Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms",,"Completed","No Results Available","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Plasma Cell Myeloma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia","Drug: Bortezomib|Drug: Alvocidib Hydrochloride|Other: Pharmacological Study","Recommended phase II dose|Maximum tolerated dose, assessed according to NCI CTCAE v4.0|Response|Response duration|Time to progression|Survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","93","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00058|CDR0000360816|MCC 6413|MCC-6413|6413|R21CA110953|P30CA076292|N01CM00100","March 2004","October 2012","September 2014","May 19, 2004","null","December 23, 2014","Moffitt Cancer Center, Tampa, Florida, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00082784"
783,"NCT01088048","Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Indolent Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma","Drug: Idelalisib|Drug: Rituximab|Drug: Bendamustine|Drug: Ofatumumab|Drug: Fludarabine|Drug: Everolimus|Drug: Bortezomib|Drug: Chlorambucil|Drug: Lenalidomide","Extent of exposure to idelalisib and toxicity|Clinical Response Rate|Plasma concentrations of idelalisib|Plasma concentrations of chemotherapeutic agents in a select subset of participants|Plasma concentrations of everolimus|Plasma concentration of lenalidomide","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 1","241","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101-07","April 2010","April 2015","April 2015","March 17, 2010","null","May 13, 2015","Clearview Cancer Institute, Huntsville, Alabama, United States|UCLA, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Weill Medical College of Cornell, New York, New York, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer, Houston, Texas, United States|North Star Lodge Cancer Center, Yakima, Washington, United States","","https://ClinicalTrials.gov/show/NCT01088048"
784,"NCT03265158","Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0","BMPB","Recruiting","No Results Available","Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL)|Marginal Zone Lymphoma (MZL)","","Positive predictive value of PB flow cytometry compared to BM|Negative predictive value of PB flow cytometry compared to BM","Royal Marsden NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","","108","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CCR4595","July 19, 2017","April 1, 2020","April 1, 2020","August 29, 2017","null","August 29, 2017","The Royal Marsden NHS Foundation Trust, London, Surrey, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","","https://ClinicalTrials.gov/show/NCT03265158"
785,"NCT02885623","Role of CX3CR1-expressing Cells in Hematologic Malignancy",,"Recruiting","No Results Available","CX3CR1 Protein|Diffuse Large B Cell Lymphoma|Multiple Myeloma","","progression free survival|overall survival|Death","Saint Vincent's Hospital, Korea","All","18 Years and older   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","001","August 2016","August 2019","August 2021","August 31, 2016","null","October 11, 2017","The Catholic University of Korea, St.Vincent's hospital, Suwon-si, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02885623"
786,"NCT02914938","A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma (FL)|Marginal Zone B Cell Lymphoma|Diffuse Large B-cell Lymphoma (DLBCL)|High Grade Non-Hodgkin's Lymphoma","Drug: ME-401|Drug: Rituximab","Minimum Biologically Effective Dose (mBED) of ME-401 alone|Maximally Tolerated Dose (MTD) of ME-401 alone|Dose Limiting Toxicities (DLTs) of ME-401 alone|Evaluate the safety and tolerability of ME-401 plus Rituximab|Safety profile of ME-401 alone|Efficacy of ME-401 alone as assessed by (OR)|Evaluate the PK of ME-401 alone (AUC)|Evaluate the PK of ME-401 alone (Cmax)|Efficacy of ME-401 with Rituximab as assessed by (OR)|Evaluate the PK of ME-401 with Rituximab (AUC)|Evaluate the PK of ME-401 with Rituximab (Cmax)","MEI Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","133","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ME-401-002","October 2016","March 2020","July 2020","September 26, 2016","null","June 28, 2018","Compassionate Care, Corona, California, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Stony Brook, Stony Brook, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Vanderbilt, Nashville, Tennessee, United States|Swedish Cancer Center, Seattle, Washington, United States|Carbone Cancer Center, Madison, Wisconsin, United States|lstituto Oncologico della Svizzera ltaliana Ospedale Regionale Bellinzona e Valli CH, Bellinzona, Switzerland","","https://ClinicalTrials.gov/show/NCT02914938"
787,"NCT01479842","Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia","Drug: BTK inhibitor PCI-32765|Biological: rituximab|Drug: bendamustine hydrochloride|Other: pharmacogenomic studies|Other: pharmacological study|Other: laboratory biomarker analysis","Maximum tolerated dose (MTD) as determined by the incidence of dose limiting toxicities (DLT) of BTK inhibitor PCI-32765 when given in combination with rituximab and bendamustine hydrochloride|Frequency, severity, and relatedness of adverse events|Overall response rate|Duration of response|Identification of germinal center versus nongerminal center DLCL|Correlation of PGx with response and toxicity","Kami Maddocks|Pharmacyclics LLC.|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-10052|NCI-2011-03293","December 7, 2011","March 2014","December 31, 2018","November 28, 2011","null","November 9, 2017","Ohio State University Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01479842"
788,"NCT00985699","S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma",,"Completed","No Results Available","Lymphoma","Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: pharmacogenomic studies","Association of polymorphisms in oxidative stress-related genes with overall survival and/or progression-free survival|Association of polymorphisms in these genes with rate of grade 4-5 hematologic toxicity","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","","337","Other|NIH","Observational","Time Perspective: Retrospective","CDR0000643248|SWOG-S8516-S8736-S9125-S9240-S|U10CA032102","April 2009","June 2014","June 2014","September 28, 2009","null","July 24, 2014","","","https://ClinicalTrials.gov/show/NCT00985699"
789,"NCT00523939","DepoCyt for Active Lymphomatous or Leukemic Meningitis",,"Terminated","Has Results","Neoplastic Meningitis|Lymphoma, B Cell","Drug: cytarabine liposome injection","Response Rate|Time to Neurologic Progression","Duke University|Enzon Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00009742","June 2006","June 2009","June 2009","September 3, 2007","March 14, 2011","June 17, 2013","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00523939"
790,"NCT02498951","Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response",,"Recruiting","No Results Available","CD20 Positive|Central Nervous System B-Cell Non-Hodgkin Lymphoma","Procedure: Cognitive Assessment|Biological: Obinutuzumab|Other: Quality-of-Life Assessment","Complete response (CR) duration|Overall survival (OS) after CR|Neurocognitive function measured by the Wechsler Adult Intelligence Scale, Hopkins Verbal Learning Test-Revised, and Grooved Pegboard Test|Quality of life (QOL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 and Brain Cancer Module-20|Progression free survival (PFS)|Overall survival","OHSU Knight Cancer Institute|Genentech, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00011601|NCI-2015-01014|ML29496|P30CA069533|R01CA137488","July 12, 2016","April 18, 2021","April 18, 2022","July 15, 2015","null","September 20, 2018","University of Colorado, Denver, Colorado, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Rhode Island Hospital (Brown University), Providence, Rhode Island, United States|University of Texas Southwestern, Dallas, Texas, United States|University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02498951"
791,"NCT01791595","A Phase I Trial of AZD3965 in Patients With Advanced Cancer",,"Recruiting","No Results Available","Adult Solid Tumor|Diffuse Large B Cell Lymphoma|Burkitt Lymphoma","Drug: AZD3965","A recommended safe and biologically active dose of AZD3965 for evaluation in Phase II trials.|Pharmacokinetic profile of AZD3965 in plasma including area under the plasma concentration-time curve (AUC) maximum concentration (Cmax), time to maximum concentration (Tmax) and elimination half-life (T1/2)|Changes in the cell death markers M65,M30 and nuclear DNA (nDNA)|Objective tumour responses to AZD3965 according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measured after every 2 cycles","Cancer Research UK","All","18 Years and older   (Adult, Older Adult)","Phase 1","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRUKD/12/004","February 2013","August 2019","null","February 15, 2013","null","July 13, 2018","Royal Marsden Hospital, Sutton, London, United Kingdom|The Beatson West of Scotland, Glasgow, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|The Christie, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Derriford Hospital, Plymouth, United Kingdom","","https://ClinicalTrials.gov/show/NCT01791595"
792,"NCT03016000","Thalidomide Maintenance Treatment in DLBCL",,"Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Thalidomide|Other: Observation","Relapse-free survival|Overall survival|Incidence of treatment-emergent adverse events","Nanfang Hospital of Southern Medical University","All","18 Years to 60 Years   (Adult)","Phase 3","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFL2016-B2","July 26, 2017","December 2019","December 2023","January 10, 2017","null","July 28, 2017","Ru Feng, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03016000"
793,"NCT03559439","CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies",,"Recruiting","No Results Available","B-cell Malignancy|B-cell Lymphoma|B-Cell Acute Lymphoblastic Leukaemia","Biological: CD19 CAR T","Frequency and severity of toxicities and adverse events|overall response rate|overall survival","Shanghai Tong Ren Hospital|Gracell Biotechnology Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTA001","April 24, 2018","September 30, 2019","December 31, 2019","June 18, 2018","null","June 19, 2018","Shanghai Tong Ren hospital, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03559439"
794,"NCT03000738","The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas",,"Not yet recruiting","No Results Available","Lymphoma,Non-Hodgkin|Diffuse Large B Cell Lymphoma|Peripheral T-Cell Lymphoma","","overall survival|progression free survival","Peking Union Medical College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PUMCH-1163","December 2016","December 2019","December 2019","December 22, 2016","null","March 31, 2017","","","https://ClinicalTrials.gov/show/NCT03000738"
795,"NCT00337259","Gemcitabine for Marginal Zone Lymphoma",,"Terminated","No Results Available","Non-Hodgkin's Lymphoma|Marginal Zone Lymphoma","Drug: gemcitabine","response rate|safety and tolerability of the treatment","Asan Medical Center|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC 2006-60","June 2006","March 2009","March 2009","June 15, 2006","null","February 17, 2016","Asan Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT00337259"
796,"NCT02772198","T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia, B-precursor|Non-Hodgkin Lymphoma, B-cell","Biological: CD19 CAR T cells","Number of patients with treatment related adverse events as assessed by CTCAE v4.|Overall Response Rate|Feasibility of CD19 CAR T cell production as defined by number of products successfully meeting release criteria|CAR T cell persistence as measured by enumeration of CAR T cells in the blood and bone marrow of participants|T cell activity and exhaustion profile as measured by flow cytometry|Cytokine levels in the peripheral blood of the patients","Sheba Medical Center","All","1 Year to 50 Years   (Child, Adult)","Phase 1|Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-15-2076-AT-CTIL","November 2016","July 2019","November 2019","May 13, 2016","null","April 27, 2018","Chaim Sheba Medical Center, Ramat Gan, Israel","","https://ClinicalTrials.gov/show/NCT02772198"
797,"NCT01786135","A Safety Study of SGN-CD19A for B-Cell Lymphoma",,"Completed","No Results Available","Burkitt Lymphoma|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Mantle-Cell|Precursor B-cell Lymphoblastic Leukemia-Lymphoma","Drug: SGN-CD19A","Incidence of adverse events|Incidence of laboratory abnormalities|Objective response according to revised response criteria for malignant lymphoma (Cheson 2007)|Duration of response|Overall survival|Blood concentration of SGN-CD19A and metabolites|Incidence of antitherapeutic antibodies","Seattle Genetics, Inc.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1","64","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN19A-002","February 2013","August 2015","February 16, 2017","February 7, 2013","null","October 19, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01786135"
798,"NCT02646098","CD34+ Selected ASCT for Aggressive Lymphomas","SAAL","Recruiting","No Results Available","Malignant Non-Hodgkin Lymphomas","Procedure: CD34+ cell selection","Overall survival|Disease-free survival|Engraftment as the time needed until hematologic recovery after ASCT|Infectious complications|Response rate|Total time needed for the apheresis procedure|Number of apheresis days needed to ensure the collection of a sufficient number of autologous stem cells|Acute and late toxicity/adverse events as assessed according to the CTCAE 4.0|Need for the additional use of G-CSF (Neupogen)|Need for the stem cell releasing compound Plerixafor (Mozobil)","University Hospital Inselspital, Berne","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAAL-trial","November 2015","April 2019","April 2019","January 5, 2016","null","April 6, 2018","Department for Medical Oncology; University Hospital/Inselspital, Berne, Switzerland","","https://ClinicalTrials.gov/show/NCT02646098"
799,"NCT01562977","Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL","RGemOx","Completed","No Results Available","Aggressive Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma","Drug: Rituximab, Gemcitabine, Oxaliplatin, Dexametasone","The primary endpoint is to evaluate Overall response rate (ORR)|Safety of Gemcitabine in combination with Rituximab, Oxaliplatin and Dexametasone (R-GemOx) in DLBCL and Mantle cell lymphoma. (GELTAMO-RGemOx)|To identify clinical response predictive factors","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","All","18 Years and older   (Adult, Older Adult)","Phase 2","82","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEL-TAMO/R-GemOx-08-04/v2","April 2011","April 2015","April 2015","March 26, 2012","null","October 30, 2017","Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Duran i Reynals, Sabadell, Barcelona, Spain|Hospital SAS de Jerez, Jerez de la Frontera, Cádiz, Spain|Hospital Dr. Jose Molina Orosa, Arrecife, Lanzarote, Spain|Fundación Hospital de Alcorcón, Alcorcón, Madrid, Spain|Hospital Puerta de Hierro de Majadahonda, Majadahonda, Madrid, Spain|Hospital Virgen de Arrixaca, El Palmar, Murcia, Spain|Complejo Hospitalario de A Coruña, A Coruña, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital 12 Octubre, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Hospital Son Espasses, Palma de Mallorca, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Corporació Sanitari Parc Taulí, Sabadell, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain","","https://ClinicalTrials.gov/show/NCT01562977"
800,"NCT00054639","Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",,"Completed","Has Results","Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Biological: oblimersen sodium|Biological: rituximab|Other: laboratory biomarker analysis","Number of Patients With Objective Response","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2011-00617|ID02-148|N01CM17003|N01CM62202|N01CM17107|N01CM62203","January 2003","January 2010","January 2010","February 6, 2003","February 21, 2011","May 28, 2014","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00054639"
801,"NCT03417414","Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?",,"Not yet recruiting","No Results Available","B Cell Lymphocytic Leukemia|B Cell Non-Hodgkin's Lymphoma","","Is the presence of gNK cells associated with better clinical responses in rituxan treated lymphoma patients?|Are circulating gNK cells capable of killing CD20+ lymphoma cells through rituximab mediated ADCC mechanisms.","Ottawa Hospital Research Institute","All","Child, Adult, Older Adult","","160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GNK Cells in CLL and NHL","March 1, 2018","March 1, 2021","March 1, 2021","January 31, 2018","null","February 7, 2018","","","https://ClinicalTrials.gov/show/NCT03417414"
802,"NCT03666988","First Time in Humans (FTIH) Study of GSK3368715 in Subjects With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)",,"Not yet recruiting","No Results Available","Neoplasms","Drug: GSK3368715","Part 1: Number of subjects with dose limiting toxicity (DLT)|Part 1: Number of subjects with AEs and serious AEs (SAEs)|Part 1: Number of subjects with AEs by maximum grade|Part 2: Objective response rate (ORR)|Part 1: Best overall response|Part 1: Maximum observed plasma concentration (Cmax) following administration of GSK3368715|Part 1: Time to reach Cmax (Tmax) following administration of GSK3368715|Part 1: Area under the concentration time curve from time zero to last time of quantifiable concentration (AUC [0-t]) following administration of GSK3368715|Part 1: AUC from time zero extrapolated to infinite time (AUC [0-infinity]) following single dose administration of GSK3368715|Part 1: Area under the concentration-time curve over the dosing interval (AUC [0-tau]) following repeat dose administration of GSK3368715|Part 1: Trough concentration (Ctau) following repeat dose administration of GSK3368715|Part 1: Time invariance ratio following administration of GSK3368715|Part 1: Accumulation ratio following administration of GSK3368715|Part 2: Number of subjects with AEs and SAEs|Part 2: Number of subjects with AEs by maximum grade|Part 2: Progression-free survival (PFS)|Part 2: Cmax following administration of GSK3368715|Part 2: Tmax following administration of GSK3368715|Part 2: AUC (0-t) following administration of GSK3368715|Part 2: AUC (0-infinity) following single dose administration of GSK3368715|Part 2: AUC (0-tau) following repeat dose administration of GSK3368715|Part 2: Ctau following repeat dose administration of GSK3368715|Part 2: Time invariance ratio following administration of GSK3368715|Part 2: Accumulation ratio following administration of GSK3368715","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","215","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","207675","October 1, 2018","June 18, 2022","June 18, 2022","September 12, 2018","null","September 12, 2018","","","https://ClinicalTrials.gov/show/NCT03666988"
803,"NCT03106428","A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies",,"Recruiting","No Results Available","Acute Myeloid Leukemia|Multiple Myeloma|Diffuse Large B-cell Lymphoma","Drug: MEDI7247","Occurrence of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of dose-limiting toxicities (DLTs)|Number of patients with changes in laboratory parameters from baseline|Number of patients with changes in vital signs from baseline|Number of patients with changes in electrocardiogram (ECG) results from baseline|Percentage of patients with changes in laboratory parameters from baseline|MEDI7247 maximum observed concentration for PK|MEDI7247 area under the concentration-time curve for PK|MEDI7247 clearance for PK|MEDI7247 terminal half-life for PK|Number of subjects who develop anti-drug antibodies (ADAs)|Best overall response (BOR)|Objective response rate (ORR)|Time to response (TTR)|Duration of response (DoR)|Progression-free survival (PFS)|Overall survival (OS)","MedImmune LLC","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","228","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D8540C00001","March 29, 2017","July 20, 2021","July 20, 2021","April 10, 2017","null","September 24, 2018","Research Site, Little Rock, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, Denver, Colorado, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Greer, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Toronto, Ontario, Canada|Research Site, Pierre Benite, France|Research Site, Villejuif, France|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03106428"
804,"NCT02846935","p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies",,"Recruiting","No Results Available","T-cell Lymphoma|Aggressive B-cell Lymphoma|Non-Hodgkin's Lymphomas|Indolent B-cell Lymphoma","Drug: Decitabine|Drug: Tetrahydrouridine","Objective Response by Revised Response Criteria for Malignant Lymphoma|Complete Response|Partial Response|Stable Disease|Progressive Disease|Duration of response|Disease-free survival|Disease-specific survival|Progression-free survival|Time to progression|Time to treatment failure","Yogen Saunthararajah|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1416","April 25, 2017","August 2020","August 2021","July 27, 2016","null","May 4, 2018","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02846935"
805,"NCT00119392","Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","Has Results","B-cell Chronic Lymphocytic Leukemia|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Biological: rituximab|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Radiation: yttrium Y 90 ibritumomab tiuxetan|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Radiation: total-body irradiation","Treatment Related Mortality (TRM)|Overall and Progression-free Survival|Response Rates|Engraftment and Hematopoietic Toxicity|Incidence and Severity of Acute Graft-versus-host Disease (GVHD) and Chronic GVHD.","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1726.00|NCI-2010-01381","June 2004","July 2009","April 23, 2016","July 13, 2005","May 24, 2017","June 29, 2018","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00119392"
806,"NCT01352312","Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma",,"Terminated","No Results Available","Chronic Lymphocytic Leukemia|B-Cell Non-Hodgkin's Lymphoma","Drug: Bendamustine|Drug: Pentostatin|Drug: Ofatumumab","Maximum Tolerated Dose (MTD) of Bendamustine|Dose Limiting Toxicity (DLT)|Efficacy of Study Treatment Regimen","Sidney Kimmel Cancer Center at Thomas Jefferson University|GlaxoSmithKline|Novartis|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11P.166|2011-23|OFT114197","May 25, 2011","April 8, 2016","May 10, 2018","May 11, 2011","null","May 25, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01352312"
807,"NCT03593109","Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma",,"Recruiting","No Results Available","Lymphoma|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse","Drug: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy","Occurrence of treatment related adverse events|Objective response rate|Overall survival|Progression free survival","Second Affiliated Hospital of Xi'an Jiaotong University|Nanjing Legend Biotech Co.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XJTU-LCAR-L10D","September 18, 2018","May 1, 2023","May 1, 2023","July 19, 2018","null","September 14, 2018","Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China","","https://ClinicalTrials.gov/show/NCT03593109"
808,"NCT03133221","1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation",,"Recruiting","No Results Available","Non Hodgkin Lymphoma|Follicular Lymphoma|Indolent Lymphoma|B-cell Lymphoma|Transformed Lymphoma|Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma","Drug: Zydelig","Discontinuation rate due to Zydelig-related adverse events at 1 year|Progression-free survival at 1 and 2 years after autologous stem cell transplantation.","University of Maryland|Gilead Sciences|Washington University School of Medicine|Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00072715; 1630GCC","October 23, 2017","March 2021","March 2022","April 28, 2017","null","February 1, 2018","Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03133221"
809,"NCT00026182","Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma","Biological: rituximab|Biological: recombinant interleukin-12|Other: laboratory biomarker analysis|Other: questionnaire administration|Procedure: quality-of-life assessment","Objective response|Overall response rate for MCL patients|Overall survival|Time to treatment failure|Complete response rate|Quality of life assessed using FACT-BRM","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","99","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01865|NCCTG-N0087|CDR0000068994|N0087|U10CA025224","October 2001","February 2005","null","January 27, 2003","null","August 26, 2013","North Central Cancer Treatment Group, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00026182"
810,"NCT03564977","CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation",,"Recruiting","No Results Available","Lymphoma, B-Cell|Leukemia, B-Cell|Minimal Disease, Residual","Biological: CD19-targeted CAR-T cells","Objective response rate|Disease control rate|Overall survival|Progress-free survival","Qingdao Central Hospital|Yake Biotechnology Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QingdaoCH201805","July 15, 2018","June 15, 2020","June 15, 2020","June 21, 2018","null","July 2, 2018","Qingdao Central Hospital, Qingdao, Shandong, China","","https://ClinicalTrials.gov/show/NCT03564977"
811,"NCT01808599","Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma",,"Active, not recruiting","No Results Available","MALT Lymphoma","Drug: Chlorambucil|Drug: Rituximab i.v.|Drug: Rituximab s.c.","Complete remission rate|Response Rate|Event-free-survival (EFS)","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","Phase 2","112","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG38","December 2013","March 2016","September 2028","March 11, 2013","null","August 27, 2018","Créteil Hopital Henri Mondor, Créteil, France|Dijon CHU Hopital le Bocage, Dijon, France|Clermont Ferrand CHU Estaing, Estaing, France|Grenoble CHU Pontchaillou, Grenoble, France|Lille CHRU Hopital Claude Dieu, Lille, France|Lyon Centre Léon Bérard, Lyon, France|Pierre Bénite CHU Lyon Sud, Lyon, France|Marseille Paoli Calmettes, Marseille, France|Montpellier CHU Saint Eloi, Montpellier, France|Vandoeuvre lès Nancy CHU Brabois, Nancy, France|Nantes CHU Hotel Dieu, Nantes, France|Paris Hopital Saint Louis, Paris, France|Rennes CHU Pontchaillou, Rennes, France|Rouen Centre Henri Becquerel, Rouen, France|Tours CHU Bretonneau, Tours, France|AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Ancona, Ancona, Italy|Centro di Riferimento Oncologico di Aviano, Aviano, Italy|Biella Ospedale degli Infermi, Biella, Italy|Ematologia e CTMO Ospedale Bolzano, Bolzano, Italy|Ematologia Ospedale Businco (Cagliari), Cagliari, Italy|ARNAS Garibaldi Catania, Catania, Italy|Genova Ematologia I H San Martino, Genova, Italy|Azienda Sanitaria AUSL6 Livorno, Livorno, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Meldola, Italy|Istituto Nazionale dei Tumori, Milano, Milano, Italy|Milano Ospedale Policlinico, Milano, Italy|Nocera, Nocera Umbra, Italy|IOV Padova, Padova, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|UO Ematologia Ravenna, Ravenna, Italy|Arcispedale Santa Maria Nuova, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy|Ospedale Infermi Ematologia Rimini, Rimini, Italy|IRCCS/CROB Rionero in Vulture, Rionero in Vulture, Italy|Istituto Regina Elena, Roma, IFO, Roma, Italy|SC Oncoematologia Terni, Terni, Italy|SC Ematologia Torino-Molinette, Torino, Italy|Torino Università, Ematologia 1, AO Città della Salute e della Scienza, Torino, Italy|IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland","","https://ClinicalTrials.gov/show/NCT01808599"
812,"NCT01119794","Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab",,"Terminated","Has Results","Lymphoma, Non-Hodgkins","Drug: Ofatumumab and Bortezomib","Overall Response Rate (ORR) of the Combination of Ofatumumab and Bortezomib in Patients Receiving Study Treatment","Brown University|Rhode Island Hospital|The Miriam Hospital|Memorial Hospital of Rhode Island|Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BrUOG-NHL-227","July 2010","July 2015","July 2015","May 10, 2010","August 11, 2015","August 26, 2015","Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Miriam Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT01119794"
813,"NCT00089076","MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma",,"Terminated","Has Results","Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Biological: ipilimumab|Other: laboratory biomarker analysis","Number of Overall Confirmed Responses(Complete Response or Partial Response)|Time to Progression (Phase 2)|Overall Survival (Phase 2)|Duration of Response (Phase 2)|Mean Change in % of CD3+CD4+ for Marker HLA-DR+|Mean Change in % of CD3+CD4- for Marker HLA-DR+|Mean Change in % of CD3+CD4+ for Marker CD45RO+|Mean Change in % of CD3+CD4- for the Marker CD45RO+","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02784|MC0312|6359|P30CA015083|U01CA069912","June 2004","July 2008","October 2009","August 5, 2004","October 19, 2012","May 30, 2014","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00089076"
814,"NCT00051025","Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)",,"Completed","Has Results","Non-Hodgkin's Lymphoma|Lymphoma, B-cell|Lymphoma, Low-grade","Drug: ONTAK","Objective Clinical Response: Complete Response (CR) or Partial Response (PR) at Week 24, or, in the Event of Lengthened Cycle Intervals, at the End of Cycle 8.|Duration of Response|Time-to-Treatment Failure","Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","L4389-30","May 2000","January 2001","September 2006","January 3, 2003","August 3, 2011","July 13, 2012","Central Baptist Hospital, Lexington, Kentucky, United States|Hematology and Oncology Services, Metairie, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT00051025"
815,"NCT02650999","Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas",,"Recruiting","No Results Available","CD19+ Diffuse Large B-cell Lymphomas|Follicular Lymphomas|Mantle Cell Lymphomas","Drug: Pembrolizumab","Number of adverse events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 46415","January 2016","January 2019","null","January 8, 2016","null","December 20, 2016","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02650999"
816,"NCT00823719","Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)",,"Completed","Has Results","Lymphoma, Large-Cell, Diffuse","Drug: ofatumumab + ICE|Drug: ofatumumab + DHAP","Number of Participants With Overall Response (OR), as Assessed by the Investigator|Number of Participants With CR, as Assessed by the Investigator|Number of Participants With the Ability to Mobilize at Least 2 Million Cluster of Differentiation (CD)34+ Cells Per Kilogram (kg) From Peripheral Blood|Progression-free Survival (PFS)|Overall Survival|Area Under the Concentration-time Curve From Time Zero to Infinity, AUC(0-inf), of Ofatumumab at the First Infusion (Cycle 1, Day 1) and the Last Infusion (Cycle 3)|Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) of Ofatumumab at the Last Infusion (Cycle 3)|Clearance (CL) of Ofatumumab|Maximum Plasma Concentration (Cmax) of Ofatumumab at the First Infusion (Cycle 1 Day 1), Second Infusion (Cycle 1 Day 8), and Last Infusion (Cycle 3)|Trough Plasma Concentration (Ctrough) of Ofatumumab Prior to Second Infusion (Cycle 1 Day 8), Third Infusion (Cycle 2), and Last Infusion (Cycle 3)|Terminal Phase Half-life (t1/2) of Ofatumumab|Volume of Distribution at Steady State (Vss) of Ofatumumab|Number of Participants Who Were Positive and Negative for Human Anti-human Antibodies (HAHA) at the Indicated Time Points|Number of Participants With the Indicated Adverse Events (AEs) Associated With Neutropenia|Number of Participants With the Indicated AEs Associated With Decreased Hemoglobin Counts|Number of Participants With the Indicated AEs Associated With Decreased Platelet Counts","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110927","May 2009","July 2011","September 2011","January 16, 2009","September 5, 2012","March 12, 2013","","","https://ClinicalTrials.gov/show/NCT00823719"
817,"NCT03610724","Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients","BIANCA","Not yet recruiting","No Results Available","Non-Hodgkin Lymphoma","Biological: Tisagenlecleucel","Overall response rate (ORR)|Duration of response (DOR)|Event free survival (EFS)|Relapse free survival (RFS)|Progression free survival (PFS)|Overall survival (OS)|Cmax|Tmax|AUCs|Clast|Tlast|Levels of pre-existing and treatment induced humoral immunogenicity and cellular immunogenicity against tisagenlecleucel safety and efficacy|Subjects that proceed to stem cell transplant (SCT) after tisagenlecleucel infusion until end of study (EOS)|Levels of cytokines for early prediction of cytokine release syndrome (CRS) utilizing clinical and biomarker data","Novartis Pharmaceuticals|Novartis","All","up to 18 Years   (Child, Adult)","Phase 2","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCTL019C2202","September 28, 2018","March 31, 2021","October 31, 2022","August 1, 2018","null","August 7, 2018","","","https://ClinicalTrials.gov/show/NCT03610724"
818,"NCT02226965","PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)",,"Active, not recruiting","No Results Available","Lymphoma, Diffuse Large B-Cell","Drug: PNT2258","Overall response rate|Disease control rate|Time to response|Progression-free survival|Safety|Overall survival|Duration of overall response","Sierra Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PNT2258-03-DLBCL","December 2014","September 2016","July 2018","August 27, 2014","null","March 15, 2017","Long Beach Memorial Medical Center, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|Colorado Blood and Cancer Institute, Denver, Colorado, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Bond Clinic, P.A., Winter Haven, Florida, United States|Georgia Regents University, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|UHC Oncology, Lafayette, Louisiana, United States|Western Maryland Health System, Cumberland, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Michigan State University, Lansing, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University, Durham, North Carolina, United States|Bon Secours Saint Francis Cancer Center, Greenville, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Baylor Research Institute, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Tyler Hematology Oncology, Tyler, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|Fundacion de Investigacion, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT02226965"
819,"NCT03241017","Durvalumab in DLBCL After Autologous Transplant","IDA-D","Withdrawn","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Durvalumab","Progression-free survival|Response Rate|Adverse Events|Hematologic engraftment|The quality of life|Overall Survival","University Hospital Inselspital, Berne|Celgene","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDA-D Trial","October 2017","October 2021","December 2021","August 7, 2017","null","April 9, 2018","","","https://ClinicalTrials.gov/show/NCT03241017"
820,"NCT02499003","GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Obinutuzumab and Pixantrone","Objective overall response rate (ORR) after six treatment cycles or the individual end of treatment|Safety of the combination treatment as measured by the rate of adverse events, which reflects tolerability of the treatment.|Percentage of patients completing the entire trial treatment|Evaluation of best response to trial treatment as measured as best response either during or post the entire treatment|Progression free survival|Overall survival|Overall response rate (ORR) in separate germinal-center B-cell-like (GCB)- vs. non GCB-analysis (gene expression profiling (GEP))","Johannes Gutenberg University Mainz|Roche Pharma AG|CTI BioPharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ETN-1 GOAL|2014-004780-21|ML29498","August 2015","October 2018","October 2021","July 15, 2015","null","September 11, 2017","Department of Hematology, Oncology and Pneumology; University Medical Center of the Johannes Gutenberg-University, Mainz, RLP, Germany","","https://ClinicalTrials.gov/show/NCT02499003"
821,"NCT02652910","Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma","MeCAR","Recruiting","No Results Available","Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Follicular Lymphoma|Stage IV Mantle Cell Lymphoma","Drug: CD19.CAR-T cells","Phase 1: Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0|Phase 2: Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm|Phase 2: Comparison of overall complete remission rate for the two arms|Duration of remission|Minimum residual disease negative remission rate|Duration of CAR-positive T cells in circulation|Total number of CAR-positive T cells infiltrated into lymphoma tissue|Overall survival","Xinqiao Hospital of Chongqing|Xuzhou Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20151117","December 2015","December 2017","December 2019","January 12, 2016","null","April 27, 2016","Department of Oncology, ChongQing, Chongqing, China","","https://ClinicalTrials.gov/show/NCT02652910"
822,"NCT00110071","Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation|Radiation: iodine I 131 tositumomab|Other: laboratory biomarker analysis|Other: flow cytometry|Genetic: polymerase chain reaction","Maximum tolerated dose/dose limiting toxicity|Overall and progression-free survival rate|Response rate|Toxicity/tolerability of study regimen|Feasibility of concurrent high-dose radioimmunotherapy and chemotherapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","60 Years and older   (Adult, Older Adult)","Phase 1","38","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1943.00|NCI-2009-01470|P01CA044991","January 2005","June 2011","null","May 4, 2005","null","August 6, 2014","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00110071"
823,"NCT03156101","A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects",,"Recruiting","No Results Available","Relapsed B-cell Acute Lymphoblastic Leukemia|Refractory B-cell Acute Lymphoblastic Leukemia|Relapsed／Refractory B-cell Lymphoma","Biological: BinD19","Number of Participants With Adverse Events [Safety and Feasibility]|Overall Response [Efficacy]","Shenzhen BinDeBio Ltd.|The First Affiliated Hospital of Zhengzhou University","All","4 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","24","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017ZDYFY-BinD19","March 2, 2017","June 30, 2020","December 30, 2020","May 17, 2017","null","August 15, 2018","The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China","","https://ClinicalTrials.gov/show/NCT03156101"
824,"NCT02987400","Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL",,"Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Venetoclax|Drug: Obinutuzumab","Clinical activity and tolerability|Safety: Incidence of dose-limiting toxicities|Response duration|Progression-free survival|Overall survival|Ability to proceed to further stem cell transplantation|Genetically/biomarker defined subgroups","Arbeitsgemeinschaft medikamentoese Tumortherapie|Roche Pharma AG","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGMT_NHL-15B|2016-001760-10","January 2017","December 2020","December 2020","December 9, 2016","null","May 17, 2017","Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V Hämatologie und Onkologie, Innsbruck, Austria|AKH Meduni Wien Universitätsklinik für Innere Medizin I Klinische Abteilung für Hämatologie und Hämostaseologie, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT02987400"
825,"NCT01431209","Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",,"Active, not recruiting","No Results Available","Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Other: Laboratory Biomarker Analysis|Drug: Ruxolitinib Phosphate","Number of patients achieving overall response rate|Duration of response|Incidence of treatment-emergent adverse events (new or worsening from baseline)|Overall survival (OS)|Progression-free survival","University of Nebraska|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","71","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","283-11|NCI-2011-02733|12-C-0196|12C0196|P30CA036727","August 2011","December 2018","December 2019","September 9, 2011","null","August 6, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT01431209"
826,"NCT03664635","MB-CART20.1 Lymphoma",,"Not yet recruiting","No Results Available","Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Refractory/Relapsed CD20+ B-NHL","Biological: MB-CART20.1","Phase I - Determination of the maximum tolerated dose (MTD)|Phase II - Best overall response rate|Phase I - Related safety and toxicity of MB-CART20.1|Phase I - Best overall response rate over 4 weeks and 3 months|Phase I - Best overall response rate over 1 year|Phase I - Occurrence of B-cell aplasia|Phase I - Phenotype and Persistence of MB-CART20.1|Phase II - Best overall response rate over 1 year|Phase II - Overall response rate over 4 weeks and 3 months|Phase II - Overall response rate over 1 year|Phase II - Number of patients with CR, PR, SD and PD|Phase II -Percentage of patients with CR, PR, SD and PD|Phase II - Safety and toxicity assessment of MB-CART20.1|Phase II - Occurrence of B-cell aplasia|Phase II - Phenotype and Persistence of MB-CART20.1","Miltenyi Biotec GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M-2016-312","September 10, 2018","February 10, 2022","November 10, 2022","September 10, 2018","null","September 10, 2018","University Hospital of Cologne - Clinic for Internal Medicine I, Cologne, Germany","","https://ClinicalTrials.gov/show/NCT03664635"
827,"NCT00001582","Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer",,"Recruiting","No Results Available","T-cell Lymphoma|B-Cell Lymphoma|ATL|Myeloma","","Create Biobank","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 99 Years   (Child, Adult, Older Adult)","","1000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","970143|97-C-0143","July 10, 1997","null","null","November 4, 1999","null","August 9, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001582"
828,"NCT02417285","A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.",,"Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin","Drug: Obinutuzumab|Drug: CC-122","Adverse Events (AEs)|Tumor Response|Response Duration|Progression-free Survival (PFS)|Pharmacokinetics - Cmax|Pharmacokinetics AUC|Pharmacokinetics Tmax|Pharmacokinetics T1/2|Pharmacokinetics - CL/F|Pharmacokinetics ‐ Vz/f","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","79","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-122-NHL-001","May 22, 2015","April 16, 2019","September 27, 2019","April 15, 2015","null","August 8, 2018","Institut Bergonie, Borddeaux Cedex, France|Institut Paoli Calmettes, Marseille cedex, France|Centre hospitalier Lyon Sud Hematologie, Pierre-Bénite cedex, France|Institut Gustave Roussy, Villejuif Cedex, France|Institute of Hematology and Medical Oncology L. and A. Seragnoli, Bologna, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Academisch Medisch Centrum, Amsterdam, Netherlands|Erasmus Medical Center - Daniel den Hoed, Rotterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT02417285"
829,"NCT03265106","A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects",,"Recruiting","No Results Available","Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood|Refractory B-cell Acute Lymphoblastic Leukemia, Childhood|Relapsed/Refractory B-cell Lymphoma, Childhood","Biological: BinD19","Number of Participants With Adverse Events [Safety and Feasibility]|Overall Response [Efficacy]","Shenzhen BinDeBio Ltd.|Children's Hospital of Fudan University","All","1 Year to 18 Years   (Child, Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017FDEK-BinD19","November 1, 2016","June 30, 2020","December 30, 2020","August 29, 2017","null","August 29, 2017","Children's Hospital of Fudan University, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03265106"
830,"NCT01032681","EMD 521873 in Advanced Solid Tumors, MTD Finding",,"Completed","No Results Available","Non-Hodgkin Lymphoma","Biological: EMD 521873","Assess the safety and tolerability of EMD 521873|To determine whether the MTD is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose CPA in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma|Characterize the PK profile of EMD 521873 alone or in combination with fixed lowdose CPA|Evaluate the immunogenicity of EMD 521873 alone or in combination with CPA measured by the induction of o Specific antibodies against the genetically modified IL-2 o Fc-IL2-specific antibodies o Anti-idiotype antibodies|Collect evidence of best overall response, changes in serum tumor marker levels and best clinical response after treatment with EMD 521873 alone or in combination with CPA|Evaluate survival|Evaluate biological responses to EMD 521873 alone or in combination with CPA as measured by o Absolute cell numbers and ratios of lymphocyte subsets in defined combinations o Change in serum level of sIL2R and neopterin","Merck KGaA","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMR62235_001","December 2006","February 2011","January 2012","December 15, 2009","null","July 31, 2014","Universitäts-Klinikum Mainz III.Medizinische Klinik, Mainz, Germany|Medizinische Klinik Universitätsklinikum Mannheim Medizinische Fakultät Mannheim, Mannheim, Germany|Istituto Oncologico della Svizzera Italiana Ospedale Regionale Bellinzona e Valli (IOSI), Bellinzona, Switzerland|University of Lausanne Hospitals (CHUV) and Hospitals of Riveria-Chablais, Lausanne, Switzerland|Kantonsspital St. Gallen, St.Gallen, Switzerland","","https://ClinicalTrials.gov/show/NCT01032681"
831,"NCT00121199","Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Biological: rituximab|Biological: bevacizumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis","Progression-free Survival at 1 Year|Progression-free Survival at 2 Year|Objective Response (Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR))|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","73","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-03062|S0515|U10CA032102","June 2005","December 2010","December 2010","July 21, 2005","December 19, 2012","May 21, 2014","SWOG, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00121199"
832,"NCT01165112","Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma","TREC","Active, not recruiting","Has Results","Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma","Drug: Bendamustine Hydrochloride|Drug: Carboplatin|Biological: Rituximab|Drug: Etoposide|Other: Laboratory Biomarker Analysis","Maximally Tolerated Dose of Bendamustine Hydrochloride That Can be Combined With Rituximab, Carboplatin, and Etoposide Chemotherapy in Patients With Relapsed or Refractory Lymphoid Malignancies|Safety and Toxicity of This Regimen|Preliminary Assessment of the Efficacy of This Regimen|Ability to Proceed to Peripheral Blood Stem Cell (PBSC) Collection Following Treatment (Impact of This Regimen on Stem Cell Reserve)","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSOC 2502|NCI-2010-00907|P30CA015704","September 2010","June 2015","null","July 19, 2010","May 25, 2017","May 25, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01165112"
833,"NCT00854568","Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL",,"Completed","No Results Available","Lymphoma","Drug: CEOP regimen|Drug: CHOP regimen","Cardiotoxicity (Class III or IV cardiotoxicity according to New York Heart Association (NYHA) Classification or LVEF abnormality [< 50% or a decrease in absolute LVEF ≥ 10%) by post-treatment RNA])|Objective response rate","Fudan University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","398","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LMTG 09-01","March 2009","December 2012","February 2013","March 3, 2009","null","August 20, 2014","Fudan University Cancer Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT00854568"
834,"NCT02924402","Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies",,"Recruiting","No Results Available","B-cell Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Biological: XmAb13676","Safety as determined by the number of participants with treatment-related adverse events|Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb13676 dosing","Xencor, Inc.|Chiltern International Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XmAb13676-01","October 2016","August 2020","September 2020","October 5, 2016","null","September 28, 2018","Moores UC San Diego Cancer Center, La Jolla, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|MD Anderson Cancer Center, Houston, Texas, United States|UVA Health System, Division of Hematology & Oncology, Charlottesville, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Hopital Henri Mondor, Creteil, France|Institut Paoli Calmette Dpt of Oncology/Hematology, Marseille Cedex 9, France|Chu Montpellier, Hematologie Clinique St. Eloi, Montpellier Cedex 5, France|Centre Antoine Lacassagne, Nice Cedex, France|CHU Haut-Leveque, Service d'Hematologie Clinique et Therapie Cellulaire, Pessac, France|Centre Hospitalier Lyon-Sud, Service d'Hematologie, Pierre-Benite Cedex, France|Centre Henri Becquerel, Rouen, France|CLCC Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT02924402"
835,"NCT00937183","Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma",,"Unknown status","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|Biological: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|Biological: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine","Immune response|Progression-free survival|Adverse events","Maria Sklodowska-Curie Institute - Oncology Center","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","MSCMI-40-2003|CDR0000636859|EU-20913","September 2003","June 2010","null","July 10, 2009","null","December 7, 2016","Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw, Warsaw, Poland","","https://ClinicalTrials.gov/show/NCT00937183"
836,"NCT03598608","Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)",,"Not yet recruiting","No Results Available","Hodgkin Disease|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell","Biological: pembrolizumab|Biological: MK-4280","Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT)|Percentage of Participants Experiencing an Adverse Event (AE)|Percentage of Participants with Treatment Discontinuations Due to an AE|Objective Response Rate (ORR)|Serum Concentration of MK-4280|Serum Concentration of Pembrolizumab","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","134","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4280-003|MK-4280-003|2018-001461-16","October 17, 2018","July 18, 2025","December 18, 2025","July 25, 2018","null","August 31, 2018","","","https://ClinicalTrials.gov/show/NCT03598608"
837,"NCT03018626","R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL",,"Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Rituximab|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Vindesine|Drug: Bleomycin","Progression-free survival|Overall survival|Complete remission rate","Nanfang Hospital of Southern Medical University","All","18 Years to 60 Years   (Adult)","Phase 3","402","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFL2016-B1","July 27, 2017","January 2020","January 2021","January 12, 2017","null","July 28, 2017","Ru Feng, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03018626"
838,"NCT01567709","Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma",,"Completed","No Results Available","Adult B Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenstrom Macroglobulinemia","Drug: Alisertib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Vorinostat","MTD of alisertib defined as the highest dose tested in which less than 33% of patients experienced dose-limiting toxicity (DLT) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.)4.0|Incidence of toxicities produced by alisertib in combination with vorinostat assessed by the NCI CTCAE version 4.0|Clinical response rate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-00715|NCI#9091|PHI-67|CDR0000729769|CHNMC-PHI-67|9091|P30CA033572|U01CA062505|UM1CA186717","April 16, 2012","March 29, 2018","March 29, 2018","March 30, 2012","null","April 11, 2018","City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01567709"
839,"NCT01660776","BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology","BMS_PD-L1","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma|Hodgkin Lymphoma|Metastatic Breastcancer|Non-small Cell Lung Cancer","","Description of one or several blood cell types producing soluble PD-L1 in DLBCL, metastatic breast cancer, Hodgkin's lymphoma and non-small cell lung cancer|Analysis of PD-L1 membrane protein expression on circulating tumor cells by multiparameter flow cytometry and Veridex® in DLBCL and metastatic breast cancer, and bone marrow tumor cells by flow cytometry in DLBCL|Analysis of PD-L1 membrane protein expression on circulating endothelial cells with the Veridex® technology in DLBCL, Hodgkin's lymphoma and metastatic breast cancer (subpart ended in late 2012)|Analysis of PD-L1 membrane protein expression on monocytes, B and T lymphocytes in all cohorts|Development of an ELISPOT technique to detect soluble PD-L1 in the supernatants of sorted primary cells (subpart ended mid 2013)|Evaluation of the techniques (by immunomagnetic or cell-sorting) used to separate circulating tumor cells expressing PD-L1|Correlation between the PD-L1 expression *) in the plasma, **) in the tumor and ***) in the bronchoalveolar liquid in non-small cell lung cancer|Evaluation of the response to treatment according to soluble PD-L1 expression in non-small cell lung cancer|Evaluation of the susceptibility to develop a disease according to PD-L1 gene SNP in DLBCL and non-small cell lung cancer","Rennes University Hospital|Roche Pharma AG|National Research Agency, France","All","18 Years to 75 Years   (Adult, Older Adult)","","105","Other|Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","2011-A01163-38|B111181-40|11/32-821","June 2012","October 2, 2017","October 2, 2018","August 9, 2012","null","April 9, 2018","Rennes EFS, Rennes, Brittanny, France|Rennes University Hospital, Rennes, Brittanny, France|Institut Paoli Calmette, Marseille, France|Montpellier University Hospital, Montpellier, France","","https://ClinicalTrials.gov/show/NCT01660776"
840,"NCT03271515","Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL",,"Not yet recruiting","No Results Available","Leukemia|Lymphoma","Biological: anti-CD19 anti-CD20 Bispecific CAR-T","Antitumor Effects|Survival time of Anti-CD19 Anti-CD20 CAR T cells in vivo.|Adverse events of each patient.","Beijing Doing Biomedical Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Doing-006","October 1, 2017","April 1, 2019","April 1, 2020","September 5, 2017","null","September 5, 2017","","","https://ClinicalTrials.gov/show/NCT03271515"
841,"NCT02546739","Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL",,"Not yet recruiting","No Results Available","Leukemia|Lymphoma","Biological: Anti-CD19-CAR","Adverse events of each patient.|Survival time of Anti-CD19 CAR T cells in vivo.|Antitumor Effects|Maximum tolerated dose (MTD) of CD19 targeted CAR T cells.","Beijing Doing Biomedical Co., Ltd.|First Hospital of Jilin University|Tianjin People's Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","100","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Doing-002","March 1, 2018","September 2019","September 2020","September 11, 2015","null","February 6, 2018","Beijing Cancer Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Huai'An First People'S Hospital, Huaian, Jiangsu, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|First Hospital of Jilin University, Changchun, Jilin, China|Shanxi Dayi Hospital, Taiyuan, Shanxi, China|Tianjin people's hospital, Tianjin, Tianjin, China|Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China|Beijing DOING Biomedical Co., Ltd, Beijing, China","","https://ClinicalTrials.gov/show/NCT02546739"
842,"NCT03293173","Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis","Bio-CHIC","Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Combination Product: R-CHOEP|Combination Product: DA-EPOCH-R","Time to treatment failure (TTF) of the patients with biological risk factors|Time to treatment failure (TTF) at 3 years from date of registration of all patients and the patients in the low risk group|Incidence of treatment-emergent adverse events (Safety and tolerability)|Clinical response rate of all patients and the patients with biological risk factors|CNS relapse rate|Progression free survival rate (PFS) of all patients and the patients with biological risk factors|Overall survival rate (OS) of all patients and the patients with biological risk factors|Molecular correlates for survival","Nordic Lymphoma Group|Helsinki University Central Hospital|Aarhus University Hospital","All","18 Years to 64 Years   (Adult)","Phase 2","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG-LBC-06","August 4, 2017","June 2019","June 2022","September 26, 2017","null","September 26, 2017","Aarhus University Hospital, Aarhus, Denmark|Helsinki University Hospital Cancer Centre, Helsinki, Finland|Oslo University Hospital, Oslo, Norway|Skåne University Hospital, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT03293173"
843,"NCT02656147","Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL",,"Not yet recruiting","No Results Available","Leukemia|Lymphoma","Biological: Anti-CD19-CAR γδT","Adverse events of each patient.|Survival time of Anti-CD19 CAR γδT cells in vivo.|Antitumor Effects|Maximum tolerated dose (MTD) of CD19 targeted CAR γδT cells.","Beijing Doing Biomedical Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Doing-004","October 2017","April 2019","April 2020","January 14, 2016","null","September 5, 2017","Beijing DOING Biomedical Co., Ltd, Beijing, China","","https://ClinicalTrials.gov/show/NCT02656147"
844,"NCT01695941","Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma","Drug: Alisertib|Drug: Bortezomib|Other: Laboratory Biomarker Analysis|Biological: Rituximab","Recommended phase II dose of alisertib when combined with bortezomib and rituximab, defined as the highest dose level at which < 33% of the dose cohort experience a dose limiting toxicity (DLT)|Recommended phase II dose of bortezomib when combined with alisertib and rituximab, defined as the highest dose level at which < 33% of the dose cohort experience a dose limiting toxicity (DLT)|Overall response rate (ORR) (complete response and partial response)|Progression free survival (PFS)|Duration of response (DOR)|Overall survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01712|CDR0000740877|P9086|S12-02028|9086|P30CA013330","August 31, 2012","March 31, 2019","null","September 28, 2012","null","August 23, 2018","Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01695941"
845,"NCT02364050","Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM",,"Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","","OS|PFS|FFS|Response to initial therapy|Early mortality rate|% of patients who performed pre-phase therapy","Fondazione Italiana Linfomi ONLUS","All","65 Years and older   (Older Adult)","","1300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","FIL_Elderly Project","September 2013","December 2017","December 2019","February 16, 2015","null","August 2, 2018","Azienda Ospedaliera Caravaggio, Treviglio, Bergamo, Italy|A.O.Cardinale Panico Ematologia e centro trapianti, Tricase, LE, Italy|IRCCS Humanitas, Rozzano, Milano, Italy|CRO-Centro di Riferimento Oncologico, Aviano, Pordenone, Italy|CROB, Rionero in Vulture, Potenza, Italy|Polo Pontino, Latina, Roma, Italy|ASL TO-4, Ivrea, Torino, Italy|Ospedale S. Giacomo di Castelfranco Veneto, Castelfranco Veneto, Treviso, Italy|AO SS.Antonio e Biagio, Alessandria, Italy|AOU Ospedali Riuniti, Ancona, Italy|A.O. Universitaria Ospedale Consorziale Policlinico Di Bari, Bari, Italy|IRCC Istituto tumori Ematologia, Bari, Italy|AO Barletta, Barletta, Italy|SOS Ematologia Divisione Medicina Interna Ospedale degli Infermi, Biella, Italy|Spedali Civili di Brescia, Brescia, Italy|Ospedale Businco, Cagliari, Italy|Arnas Garibaldi, Catania, Italy|AO di Cosenza, Cosenza, Italy|AO Santa Croce e Carle, Cuneo, Italy|AOU Careggi, Firenze, Italy|Ematologia Ospedale Vito Fazzi, Lecce, Italy|USL 6 Livorno Centro Aziendale Ematologia, Livorno, Italy|Ospedale di Matera, Matera, Italy|Area Vasta Romagna e IRST, Meldola (FC), Italy|Ospedali Riuniti Papardo, Messina, Italy|Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico, Milano, Italy|Ospedale S. Raffaele, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|AO Niguarda, Milano, Italy|Osp. San Carlo Borromeo Divisione di Oncologia Medica, Milano, Italy|AOU Policlinico di Modena, Modena, Italy|Ospedale San Gerardo, Monza, Italy|AUO Maggiore della Carità, Novara, Italy|Istituto Oncologico Veneto, Padova, Italy|AOU Padova, Padova, Italy|A.O. Universitaria Policlinico Giaccone Di Palermo, Palermo, Italy|A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy|AO di Perugia S. Maria della misericordia, Perugia, Italy|Ospedale di Pescara, Pescara, Italy|Ospedale Civile di Piacenza, Piacenza, Italy|Ospedale S. Maria delle Croci, Ravenna, Italy|A.O. Bianchi Melacrino Morelli, Reggio Calabria, Italy|AO Santa Maria Nuova, Reggio Emilia, Italy|Ospedale degli Infermi, Rimini, Italy|AOU La Sapienza, Roma, Italy|Policlinico Universitario A.Gemelli, Roma, Italy|Azienda OSpedaliera S. Andrea, Roma, Italy|AOU Senese, Siena, Italy|AO Santa Maria di Terni, Terni, Italy|AO Città della Salute e della Scienza Ematologia Universitaria, Torino, Italy|AO Città della Salute e della Scienza SC Ematologia, Torino, Italy|Ospedale di Circolo, Varese, Italy|Presidio Ospedaliero S. Andrea, Vercelli, Italy","","https://ClinicalTrials.gov/show/NCT02364050"
846,"NCT02374424","Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients","GIOTTO","Terminated","No Results Available","Diffuse, Large B-Cell, Lymphoma","Drug: GA101_DHAP","Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.|Overall Response Rate (ORR) prior to consolidation with BEAM and ASCT|Progression free survival (PFS) at 6 month after the end of treatment (EOT)|Overall Survival (OS) at 2 years after the EOT|Toxicity: Severe, life-threatening, fatal (grade 3, 4 and 5) and/or serious adverse events|The hematopoietic cell mobilization|Feasibility: the rate of patients actually proceeding to ASCT","Fondazione Italiana Linfomi ONLUS","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_GA101_DHAP","June 2014","February 2018","June 2020","February 27, 2015","null","August 1, 2018","Azienda Ospedaliera S. Gerardo Di Monza, Monza, Monza Brianza, Italy|Onco-Ematologia I.R.C.C., Candiolo, TO, Italy|Ospedale Mauriziano, Torino, TO, Italy|Ospedale San Bortolo, Vicenza, VI, Italy|Ospedale ""C. e G. Mazzoni"", UOC Ematologia, Ascoli Piceno, Italy|Ospedale di Bolzano, Reparto di Ematologia & CTMO, Bolzano, Italy|A.O. Universitaria Careggi Di Firenze, Firenze, Italy|USL 6 Livorno Centro Aziendale Ematologia, Livorno, Italy|SC Ematologia AO Riuniti Papardo Piemonte, Messina, Italy|Ospedale dell'Angelo, U.O. Ematologia, Mestre, Italy|A.O. Universitaria Policlinico Di Modena, Modena, Italy|AUO Padova-Ematologia e Immunologia Clinica, Padova, Italy|A.O. Ospedali Riuniti Villa Sofia-Cervello, U.O. Ematologia I, Palermo, Italy|Ematologia Policlinico San Matteo, Pavia, Italy|AO di Perugia S. Maria della misericordia, Perugia, Italy|A.O. Universitaria Pisana, Pisa, Italy|Ematologia Ospedale S.Camillo Forlanini, Roma, Italy|Ematologia e Trapianto Istituto Regina Elena IFO, Roma, Italy|Policlinico Universitario Campus biomedico, Roma, Italy","","https://ClinicalTrials.gov/show/NCT02374424"
847,"NCT02081937","CART-19 Immunotherapy in Mantle Cell Lymphoma",,"Recruiting","No Results Available","Hematopoietic/Lymphoid Cancer|Non-hodgkin Lymphoma,B Cell|Mantle Cell Lymphoma","Biological: anti-CD19-CAR vector-transduced T cells","Occurrence of study related adverse events|Clinical responses to CART-19 cell therapy","Chinese PLA General Hospital","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN301-XYK-CAR001","March 2014","December 2018","December 2019","March 7, 2014","null","March 11, 2014","Department of Hematology of Chinese PLA General Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02081937"
848,"NCT03685786","CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT",,"Recruiting","No Results Available","Leukemia, Lymphocytic, Acute, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, B-Cell","Biological: CART19 cell and auto-HSCT","CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT","Shenzhen Second People's Hospital","All","14 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Weihong Chen06062018","June 1, 2018","June 2, 2021","September 2, 2021","September 26, 2018","null","September 26, 2018","Weihong Chen, Shenzhen, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03685786"
849,"NCT01593696","Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma",,"Completed","No Results Available","ALL|B Cell Lymphoma|Leukemia|Large Cell Lymphoma|Non-Hodgkin Lymphoma","Biological: Anti-CD19- CAR","Safety|Feasibility|Persistence of Anti-CD19-CAR Tcells|Antitumor Effects|Ability to reduce grade 4 CRS to less than or equal to 10%","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 30 Years   (Child, Adult)","Phase 1","53","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120112|12-C-0112","April 12, 2012","November 11, 2016","October 2, 2017","May 8, 2012","null","September 27, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01593696"
850,"NCT01141712","Autologous Transplant in HIV Patients (BMT CTN 0803)",,"Completed","Has Results","Lymphoma|HIV","Procedure: Autologous transplant|Drug: BCNU|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan","Overall Survival (OS)|Relapse/Progression|Progression-Free Survival (PFS)|Complete Remission (CR) and/or Partial Response (PR)|Time to Progression After CR|Lymphoma Disease-free Survival|Cumulative Incidence of Neutrophil Recovery|Cumulative Incidence of Platelet Recovery|Hematologic Function|Number of Participants Experiencing Toxicity|Number of Participants Experiencing Infections|Treatment-Related Mortality (TRM)|Immunologic Reconstitution|HIV Single-Copy Polymerase Chain Reaction (PCR)|Microbial Translocation Markers|Ig and Epstein-Barr Virus (EBV) DNA in Blood","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2","43","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMTCTN0803|U01HL069294|U01HL069294-06|U01CA121947","April 2010","May 2015","June 2016","June 10, 2010","March 28, 2017","October 27, 2017","City of Hope National Medical Center, Duarte, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|UCLA, Los Angeles, California, United States|University of CA, SF, San Francisco, California, United States|University of Florida College of Medicine, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|BMT Program at Northside Hospital, Atlanta, Georgia, United States|University of Maryland Medical Systems, Greenebaum Cancer Center, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Texas/MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01141712"
851,"NCT01686321","Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma","B-R-ENDA","Unknown status","No Results Available","Aggressive Lymphoma","Drug: Bendamustine and subcutaneous rituximab","Progression-free survival|adverse events (AE)'s|serious adverse events (SAE)'s|rate of therapy-associated deaths|protocol adherence|CR rate|PR rate|rate of primary progression|relapse rate|event-free survival|overall survival|Quality of life|Comprehensive Geriatric Assessment","University of Göttingen|Roche Pharma AG|Mundipharma Research GmbH & Co KG","All","60 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSHNHL-2010-1|2010-024004-98","May 2012","October 2017","October 2017","September 18, 2012","null","February 22, 2013","Prof. Trümper, Göttingen, Germany","","https://ClinicalTrials.gov/show/NCT01686321"
852,"NCT02624492","To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL",,"Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: BI 836826|Drug: GemOx|Drug: Rituximab","Number of patients with DLT|The MTD of BI 836826 with GemOx|Overall response (OR)|AUC 0-t of BI 836826|Cmax of BI 836826|Complete Response (CR)|Overall response based on investigator's assessment","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1270.11|2014-004794-16","January 28, 2016","March 16, 2018","March 16, 2018","December 8, 2015","null","May 9, 2018","UNIV UZ Gent, Gent, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Belgium|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|A. O. S. Maria della Misericordia, Udine, Italy|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital La Paz, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT02624492"
853,"NCT00655837","Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL",,"Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin","Drug: SGN-40|Drug: rituximab|Drug: gemcitabine","Determine the safety and adverse-event profile for combination therapy of SGN-40 with gemcitabine and rituximab.|Estimate progression free survival, clinical response rates to treatment, and overall survival to determine efficacy.","Seattle Genetics, Inc.|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SG040-0008","April 2008","February 2010","February 2010","April 10, 2008","null","December 18, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|University of Colorado, Aurora, Colorado, United States|Oncology Specialists, Park Ridge, Illinois, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00655837"
854,"NCT03276468","Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas",,"Recruiting","No Results Available","Follicular Lymphoma|Diffuse Large B Cell Lymphoma|Marginal Zone Lymphoma|Mucosa Associated Lymphoid Tissue","Drug: Atezolizumab|Drug: Obinutuzumab|Drug: Venetoclax","FL and DLBCL cohorts : Overall Metabolic Response Rate (OMRR) at the end of induction|for iNHL cohort : Overall Response Rate (ORR) at the end of induction|Progression Free Survival (PFS)|Overall Survival (OS)|Duration of Response (DR)|for FL and DLBCL cohorts : OMRR|for iNHL cohort : ORR|Best response","The Lymphoma Academic Research Organisation","All","18 Years and older   (Adult, Older Adult)","Phase 2","138","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GATA","February 12, 2018","November 2019","November 2021","September 8, 2017","null","March 7, 2018","CHU d'Angers, Angers, France|CHU de Caen, Caen, France|CHU de Clermont Ferrand - Estaing, Clermont-Ferrand, France|Hopital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CH Annecy Gennevois, Epagny, France|CHD de Vendée, La Roche-sur-Yon, France|CHU de Grenoble, La Tronche, France|CHRU de Lille, Lille, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy - Brabois, Nancy, France|CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|Hôpital Saint Louis, Paris, France|Hôpital Necker, Paris, France|CHU Lyon Sud, Pierre Bénite, France|CHU de Poitiers, Poitiers, France|CHU de Rennes - Hôpital de Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|Institut Curie - Hôpital René Huguenin, Saint-Cloud, France|CHRU de Strasbourg, Strasbourg, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France|CHRU de Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT03276468"
855,"NCT01397591","Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma",,"Terminated","Has Results","Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma","Biological: Ofatumumab|Drug: Bortezomib","Response Rate of Ofatumumab in Combination With Bortezomib in Patients With Relapsed CD20+ (Cluster of DIfferentiation Antigen 20) Diffuse Large B Cell Lymphoma, Follicular Lymphoma, or Mantle Cell Lymphoma|Overall Survival|Progression Free Survival|Disease Free Survival|Number of Participants With Adverse Events (Toxicity)","OHSU Knight Cancer Institute|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00007042|NCI-2011-01032|OFT113735","October 2011","May 2013","July 2013","July 19, 2011","July 30, 2014","July 30, 2014","OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT01397591"
856,"NCT00529503","A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL",,"Terminated","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin","Drug: SGN-40|Drug: placebo|Drug: rituximab|Drug: etoposide|Drug: carboplatin|Drug: ifosfamide","Complete response as assessed by CT and PET scans and revised response criteria for malignant lymphoma.|Adverse events, laboratory values, and anti-drug antibody immune responses.|Partial response, failure free survival, overall survival, and response for one and two years following treatment.","Seattle Genetics, Inc.|Genentech, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SG040-0005","September 2007","December 2009","May 2011","September 14, 2007","null","February 25, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California at Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|Christiana Care Health Systems, Newark, Delaware, United States|Georgetown University, Washington, District of Columbia, United States|MD Anderson Cancer Center, Orlando, Orlando, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Louisville - James Graham Brown Cancer Center, Louisville, Kentucky, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Park Nicollet Institute, St. Louis Park, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|St. Luke's Roosevelt Hospital Center, New York, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|MultiCare Health System, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|St. Vincent's Hospital - Sydney, Darlinghurst, New South Wales, Australia|Gosford & Wyong Hospital, Gosford, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|St. Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Universite de Gent, Gent, Belgium|AZ Sint-Augustinus, Wilrijk, Belgium|Cliniques Universitaires UCL de Mont-Goddine, Yvoir, Belgium|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic|Vseobecna fakultni nemocnice v Praze, Praha 2, Czech Republic|Fakultni nemocnice v Motole, Praha 5, Czech Republic|Centre Hospitalier Andre Mignot, Le Chesnay, France|Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes, Lyon, France|Hopital Hotel Dieu, Nantes, France|Groupe Hospitalier Necker - Enfants Malades, Paris, France|Hopitaux du Haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Henri Becquerel, Rouen, France|Hematologie CHU Purpan, Toulouse, France|Institut Gustave-Roussy, Villejuif, France|Johannes-Gutenberg Universitat Mainz, Mainz, Germany|KH Maria Hilf-Franziskushaus, Monchengladbach, Germany|Universitatsklinikum Ulm, Ulm, Germany|Debreceni Egyetem Orvos - es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Petz Aladar Megyei Oktato Korhaz, IInd Department of Internal Medicine, Gyor, Hungary|Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikat Kozpont, Szeged, Hungary|Azienda Ospedaliera Universitaria Careggi, Florence, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Szpital Akademii Medycznej w Gdansku, Gdansk, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Centrum Onkologii Institut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1, Wroclaw, Poland|Hospital Clinic i Provincial, Barcelona, Spain|Hospital de la Santa Creu i Sant Paul, Barcelona, Spain|H. Duran y Reynals Institue Catala D'Oncologia, Barcelona, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT00529503"
857,"NCT03527147","Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)",,"Recruiting","No Results Available","NHL|DLBCL|Non-hodgkin's Lymphoma|Diffuse Large B Cell Lymphoma","Drug: AZD9150|Drug: Acalabrutinib|Drug: AZD6738","Safety of the study treatments when given in combination [Incidence of adverse events]|Assessment of the efficacy of each treatment by evaluation of overall response rate using RECIL 2017 response criteria|Duration of response (DOR) using RECIL 2017 response criteria for the anti-tumour activity of each therapy.|Progression free survival (PFS) using RECIL 2017 response criteria for the anti-tumour activity of each therapy.|Overall Survival (OS)|Peak plasma concentration (Cmax) of Study Drug A (Arm 1)|Peak plasma concentration (Cmax) of Study Drug B (Arm 2)|Area under the plasma concentration versus time curve (AUC) of Study Drug A (Arm 1)|Area under the plasma concentration versus time curve (AUC) of Study Drug B (Arm 2)|Presence of Anti-Drug Antibody (ADA) titres in subjects treated with Study Drug A|Peak plasma concentration (Cmax) of acalabrutinib (Arm 1)|Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 1)|Peak plasma concentration (Cmax) of acalabrutinib (Arm 2)|Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 2)","Acerta Pharma BV|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-LY-111|2017-004191-63|D9820C00001|LYM 138","June 2018","January 2021","January 2021","May 17, 2018","null","June 14, 2018","Florida Cancer Specialists, Sarasota, Florida, United States|Tennessee Oncology, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03527147"
858,"NCT00003356","Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: aldesleukin|Biological: rituximab","","University of Rochester|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","58","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066338|P30CA011198|URCC-U4497|NCI-G98-1442","November 1997","May 2002","May 2002","March 22, 2004","null","October 16, 2013","University of Rochester Cancer Center, Rochester, New York, United States","","https://ClinicalTrials.gov/show/NCT00003356"
859,"NCT00001337","Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma (DLBCL)|Primary Mediastinal Large B-cell Lymphoma|Burkitt Lymphoma|Anaplastic Large-Cell Lymphoma|Gray Zone Lymphoma","Drug: EPOCH|Biological: Rituximab","Overall response and PFS","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","12 Years to 100 Years   (Child, Adult, Older Adult)","Phase 2","348","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","930133|93-C-0133","May 3, 1993","March 31, 2019","March 31, 2022","November 4, 1999","null","October 2, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001337"
860,"NCT00591630","Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation",,"Active, not recruiting","No Results Available","Diffuse Large Cell Lymphoma|Lymphoma","Drug: Zevalin|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Drug: Rituximab|Procedure: Stem Cell Transplant","2-Year Progression-Free Survival (PFS) Rates","M.D. Anderson Cancer Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-1018|NCI-2012-01753","November 2007","November 2019","November 2019","January 11, 2008","null","November 8, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00591630"
861,"NCT00436280","Chemotherapy for Patients With Lymphoma",,"Completed","No Results Available","Lymphoma, Large Cell, Diffuse","Drug: enzastaurin|Drug: gemcitabine|Drug: rituximab|Drug: oxaliplatin","Progression Free Survival after 1 year treatment|Response|Progression Free Survival after 2 and 4 years of treatment|Overall Survival after 1, 2 and 4 years|Event Free Survival after 1, 2 and 4 years|Assessment of biomarkers relevant for Enzastaurin|Characterization of pharmacokinetics of enzastaurin and it's metabolites","Eli Lilly and Company","All","60 Years and older   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9819|H6Q-MC-S013","February 2007","November 2009","November 2012","February 19, 2007","null","November 30, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Creteil, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nimes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pessac, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pierre Benite, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rouen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bremen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kassel, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kiel, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation","","https://ClinicalTrials.gov/show/NCT00436280"
862,"NCT00242996","Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Biological: sargramostim|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: adjuvant therapy|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","2-year event free survival|Overall survival","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","44","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","J0376 CDR0000447158|P30CA006973|JHOC-J0376|WIRB-20040009","March 2004","April 2007","April 2007","October 21, 2005","null","September 28, 2017","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00242996"
863,"NCT00568815","Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)",,"Completed","No Results Available","Lymphoma","Drug: Rituximab combined with ESHAP","Response rate|Toxicities","Fudan University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ESHAP-DLBCL","April 2007","December 2010","December 2010","December 6, 2007","null","February 20, 2012","Fudan University Cancer Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT00568815"
864,"NCT00093769","Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: bortezomib + rituximab","Response rate (complete response [CR], CR-unconfirmed [CRu], and partial response [PR])|Response rate (CR, CRu, and PR) at the first disease response evaluation|Overall CR rate (CR and CRu)|Safety and tolerability","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000390235|UCLA-0401054-01|MILLENNIUM-M34103-061","August 2004","August 2005","null","October 8, 2004","null","October 4, 2012","Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00093769"
865,"NCT01138579","Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation","STP-LYM-01","Terminated","No Results Available","Leukemia|Stem Cell Transplantation","Drug: FBTA05","Phase I: Determination of the maximum tolerated dose (MTD)|Phase II: Evaluation of preliminary efficacy of FBTA05 in combination with DLI","Technische Universität München","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STP-LYM-01-V01","August 2010","May 2016","June 2016","June 7, 2010","null","April 26, 2016","3. Medizinische Klinik, Klinikum rechts der Isar der TU München, Munich, Bavaria, Germany","","https://ClinicalTrials.gov/show/NCT01138579"
866,"NCT00690560","Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: yttrium Y 90 ibritumomab tiuxetan","Event-free survival|Overall survival|Relapse-free survival in responding patients|Rate of disease progression|Response rate|Toxicities","Centre Antoine Lacassagne","All","65 Years to 80 Years   (Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000589530|CALACASS-3RCHOPZ|INCA-RECF0624|EUDRACT-2006-006179-19|CALACASS-2006/27","May 2007","March 2010","October 2010","June 4, 2008","null","February 10, 2015","Centre Antoine Lacassagne, Nice, France","","https://ClinicalTrials.gov/show/NCT00690560"
867,"NCT00007839","Beta Alethine in Treating Patients With Low-Grade Lymphoma",,"Unknown status","No Results Available","Lymphoma","Drug: beta alethine","","LifeTime Pharmaceuticals|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000068279|LIFETIME-LTP-99-02|LIFETIME-IRB-0300202|NCI-V00-1628","August 2000","null","null","October 8, 2003","null","December 18, 2013","Victory Over Cancer, Rockville, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00007839"
868,"NCT00963274","Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",,"Completed","No Results Available","Leukemia|Lymphoma","Drug: Bortezomib|Drug: Romidepsin","Maximum tolerated dose|Pharmacodynamic responses","Virginia Commonwealth University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-12215|P30CA016059|R21CA137823|CDR0000652509","April 26, 2010","July 17, 2014","April 13, 2018","August 21, 2009","null","April 23, 2018","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00963274"
869,"NCT03588598","Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|B-Cell Non-Hodgkin Lymphomas(NHL)","Drug: SHC014748M","Dose Limiting Toxicity (DLT)|Time to Peak Plasma Concentration（Tmax）|Peak Plasma Concentration (Cmax)|Half-life Time(t1/2)|Area Under the Plasma Concentration Versus Time Curve (AUC)|Objective Response Rate (ORR)|Lymph Node Response (LNR)|Time to Response (TTR)|Progression-Free Survival (PFS)|Duration of Response (DOR)","Nanjing Sanhome Pharmaceutical, Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHC014-I-01","September 7, 2018","July 2019","December 2019","July 17, 2018","null","September 10, 2018","The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03588598"
870,"NCT00244985","Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma","Biological: rituximab|Drug: pegylated liposomal doxorubicin hydrochloride","Complete Response Rate at 20 Weeks|Partial Response Rate at 20 Weeks|Overall Response Rate (Complete and Partial Responses) at 20 Weeks|Progression Free Survival (PFS) Rate at 2 Years|Overall Survival (OS) Rate at 2 Years","Roswell Park Cancer Institute|Ortho Biotech, Inc.","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1|Phase 2","42","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000447130|RPC 02-04","September 2005","August 2008","December 2012","October 27, 2005","July 14, 2017","August 17, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT00244985"
871,"NCT00301301","A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)",,"Completed","No Results Available","Non-Hodgkins Lymphoma","Drug: Gemcitabine|Drug: Cisplatinum|Drug: Rituximab","","Royal Marsden NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","","39","Other","Observational","Time Perspective: Retrospective","2656","null","null","null","March 10, 2006","null","January 12, 2010","Royal Marsden NHS trust, Sutton, Surrey, United Kingdom","","https://ClinicalTrials.gov/show/NCT00301301"
872,"NCT02339922","Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia","Drug: Ixazomib Citrate|Other: Laboratory Biomarker Analysis|Biological: Rituximab","Overall response rate (ORR) (complete response [CR] + partial response [PR]) in patients with chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)|ORR (CR + very good PR + PR + minor response) in patients with Waldenstrom macroglobulinemia (WM)/ lymphoplasmacytic lymphoma (LPL)|Duration of response (DOR)|Progression-free survival (PFS)|Overall survival|CR rate|Time to next therapy (TNT)|Incidence of adverse events (AEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9571|NCI-2016-00401|9224|P30CA015704","May 18, 2016","December 30, 2021","null","January 16, 2015","null","June 18, 2018","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02339922"
873,"NCT00322218","Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R",,"Unknown status","No Results Available","Lymphoma, Large Cell, Diffuse","Drug: Zevalin Therapeutic Regimen|Other: Observation","Overall survival|Disease-free survival|Health-related quality of life","CTI BioPharma|Bayer","All","60 Years and older   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","307940/106-20","May 2006","December 2009","December 2009","May 5, 2006","null","October 23, 2008","Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, Berkeley, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Vallejo, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Morris,, Illinois, United States|Research Site, Overland Park, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, St Louis Park, Minnesota, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Commack, New York, United States|Research Site, East Setauket, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Aberdeen, South Dakota, United States|Research Site, Dallas, Texas, United States|Research Site, Houston,, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Brugge, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Helsinki, Finland|Research Site, Oulu, Finland|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, Lille Cedex, France|Research Site, Limoges, France|Research Site, Lyon Cedex, France|Research Site, Paris Cedex, France|Research Site, Toulouse Cedex, France|Research Site, Chemnitz, Germany|Research Site, Jena, Germany|Research Site, Karlsruhe, Germany|Research Site, Mainz, Germany|Research Site, Rostock, Germany|Research Site, Wurzburg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Bologna, Italy|Research Site, Milan, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Torino, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Yonsei, Korea, Republic of|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Poznan, Poland|Research Site, Warsaw, Poland|Research Site, Coimbra, Portugal|Research Site, Lisbon, Portugal|Research Site, Porto, Portugal|Research Site, Singapore, Singapore|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Malmo, Sweden|Research Site, Uddevalla, Sweden|Research Site, Umea, Sweden|Research Site, Bern, Switzerland|Research Site, St Gallen, Switzerland|Research Site, Bangkok, Thailand|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00322218"
874,"NCT00278421","Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Time to treatment failure (TTF) measured from day 1 of course 1 of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) therapy up to 3 years on study with life-long follow-up|Complete response (CR) rate duration until first relapse|Progression rate during treatment|Survival|Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored)|Disease-free survival measured from day 1 of course 1 of CHOP therapy|Safety (adverse events, serious adverse events) assessed at 3 months after treatment","German High-Grade Non-Hodgkin's Lymphoma Study Group","All","18 Years to 60 Years   (Adult)","Phase 3","592","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000459685|DSHNHL-2004-2|EU-205110|EUDRACT-2005-00521738|DSHNHL-FLYER-6664","November 2005","October 2016","October 2016","January 18, 2006","null","October 26, 2016","Haematologisch Onkologische Praxis, Aachen, Germany|Klinikum Augsburg, Augsburg, Germany|Klinikum Bayreuth, Bayreuth, Germany|Haematologisch-Onkologische Schwerpunktpraxis - Weilheim, Berlin, Germany|Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Franziskus Hospital, Bielefeld, Germany|Augusta-Kranken-Anstalt gGmbH, Bochum, Germany|Staedtisches Klinikum Braunschweig, Braunschweig, Germany|DIAKO Ev. Diakonie Krankenhaus gGmbH, Bremen, Germany|Hospital Kuchwald Chemnitz, Chemnitz, Germany|Praxis Fuer Haematologie Internistische Onkologie, Cologne, Germany|Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany|Carl - Thiem - Klinkum Cottbus, Cottbus, Germany|Praxis Dr. Rheinhold Siegmund - Dr. Matthias Penke, Damme, Germany|Klinikum Dortmund, Dortmund, Germany|Hans - Susemihl - Krankenhaus, Emden, Germany|St. Antonius Hospital, Eschweiler, Germany|Universitaetsklinikum Essen, Essen, Germany|Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Klinikum Fulda, Fulda, Germany|Saint Josef Hospital, Gelsenkirchen, Germany|Universitaetsklinikum Goettingen, Goettingen, Germany|Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Germany|Kreiskrankenhaus Gummersbach GMBH, Gummersbach, Germany|St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH, Hagen, Germany|St. Sixtus Hospital, Haltern, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|University Medical Center Hamburg - Eppendorf, Hamburg, Germany|Haematologisch-Onkologische Praxis Altona, Hamburg, Germany|St. Marien-Hospital Hamm - Klinik Knappenstrasse, Hamm, Germany|Evangelische Krankenhaus Hamm, Hamm, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Ruprecht - Karls - Universitaet Heidelberg, Heidelberg, Germany|St. Bernward Krankenhaus, Hildesheim, Germany|Universitaetsklinikum des Saarlandes, Homburg, Germany|Clinic for Bone Marrow Transplantation and Hematology and Oncology, Idar-Oberstein, Germany|Staedtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany|St. Vincentius - Kliniken, Karlsruhe, Germany|Klinikum Kempten Oberallgaeu, Kempten, Germany|University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany|Caritas - Krakenhaus Lebach, Lebach, Germany|Klinikum Lippe - Lemgo, Lemgo, Germany|St. Vincenz Hospital Limburg, Limburg, Germany|Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen am Rhein, Germany|Kreiskrankenhaus Luedenscheid, Luedenscheid, Germany|Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg, Germany|III Medizinische Klinik Mannheim, Mannheim, Germany|Universitaetsklinikum Giessen und Marburg GmbH - Marburg, Marburg, Germany|Krankenhaus Ludmillenstift, Meppen, Germany|Krankenhaus Maria Hilf GmbH, Moenchengladbach, Germany|Haematologisch - Onkologische Gemeinschaftspraxis - Muenster, Muenster, Germany|Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster, Muenster, Germany|Klinikum der Universitaet Muenchen - Grosshadern Campus, Munich, Germany|Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany|Klinikum Schwaebisch Gmuend Stauferklinik, Mutlangen, Germany|Onkologische Schwerwpunktpraxis Dr. Ladda, Neumarkt, Germany|Lukaskrankenhaus Neuss, Neuss, Germany|Schlossbergkliniken Oberstaufen, Oberstaufen, Germany|Klinikum Oldenburg, Oldenburg, Germany|Pforzheim, Germany|Klinikum Ernst Von Bergmann, Potsdam, Germany|Prosper-Hospital Recklinghausen, Recklinghausen, Germany|Rostock, Germany|St. Marien - Krankenhaus Siegen GMBH, Siegen, Germany|Diakonie Klinikum Stuttgart, Stuttgart, Germany|Krankenanstalt Mutterhaus der Borromaerinnen, Trier, Germany|Southwest German Cancer Center at Eberhard-Karls-University, Tuebingen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm, Ulm, Germany|St. Marienhospital - Vechta, Vechta, Germany|Onkologische Schwerpunktpraxis, Wendlingen, Germany|Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany|Helios Kliniken Wuppertal University Hospital, Wuppertal, Germany|Rabin Medical Center - Beilinson Campus, Petah-Tikva, Israel|Ospedale Civile - Piacenza, Piacenza, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Cellulari ed Ematologia Sapienza, Roma, Italy","","https://ClinicalTrials.gov/show/NCT00278421"
875,"NCT00504751","Phase II Study of ""VIPER"" Chemotherapy in Rel/Ref DLBCL",,"Completed","Has Results","Non-Hodgkin's Lymphoma","Drug: bortezomib, dexamethasone, ifosfamide|Drug: mesna, cisplatin, etoposide, rituximab","Complete Response","Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0701008963","May 2007","December 2010","February 17, 2012","July 20, 2007","April 7, 2017","April 7, 2017","Weill Cornell Medical College, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00504751"
876,"NCT01671813","Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly",,"Withdrawn","No Results Available","Lymphoma","Drug: brentuximab vedotin","Objective Response Rate (ORR)|Time to Response (TTR)|Duration of Response (DOR)|Time to Disease Progression|Progression Free Survival (PFS) Rate|Overall Survival (OS) Rate","H. Lee Moffitt Cancer Center and Research Institute|Seattle Genetics, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-17024|SGN 35-IST-006","March 2013","July 2013","July 2013","August 24, 2012","null","July 25, 2013","","","https://ClinicalTrials.gov/show/NCT01671813"
877,"NCT01101581","Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",,"Unknown status","No Results Available","Non Hodgkin's Lymphoma|NHL|Aggressive NHL|Diffuse Large B-cell Lymphoma","Drug: Veltuzumab and 90Y-Epratuzumab Tetraxetan|Drug: 90Y-epratuzumab tetraxetan|Drug: veltuzumab","Safety/dose limiting toxicity|Efficacy","Immunomedics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IM-T-hA20/90Y-hLL2-01","May 2010","December 2016","March 2017","April 12, 2010","null","March 3, 2015","Helen F. Graham Cancer Center, Newark, Delaware, United States|MDACC Orlando, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Med College of Cornell Univ/NYH, New York, New York, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01101581"
878,"NCT01393756","Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma","R2-CHOP2","Completed","No Results Available","Follicular Lymphoma","Drug: Lenalidomide and R-CHOP","Complete Response Rate (CR+CRu)|Overall survival|Duration of response","The Lymphoma Academic Research Organisation|Centre Henri Becquerel","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","(R2-CHOP2)","December 2010","July 2013","November 2015","July 13, 2011","null","February 17, 2016","Institut Bergonié, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|CHU Estaing, Clermont ferrand, France|Hôpital Henri Mondor, Creteil, France|CHU de DIJON, Dijon, France|Chru Lille, Lille, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Hôpital Notre Dame de Bon Secours, Metz, France|Hôpital Saint Eloi, Montpellier, France|CHU de NANTES, Nantes, France|Hôpital Saint Antoine, Paris, France|Hôpital de la Pitié Salpétrière, Paris, France|Hôpital Necker, Paris, France|Institut Curie, Paris, France|Hôpital St Louis, Paris, France|Chu Lyon Sud, Pierre-benite, France|CHU de Poitiers, Poitiers, France|Hôpital Robert Debré, Reims, France|Hôpital Pontchaillou, Rennes, France|Centre Henri BECQUEREL, Rouen, France|Hôpital René Huguenin, Saint-Cloud, France|Chu Brabois, Vandoeuvre-les-nancy, France|Institut Gustave Roussy, Villejuif, France","","https://ClinicalTrials.gov/show/NCT01393756"
879,"NCT01276717","Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: Drug: Carfilzomib|Drug: Vorinostat","Number of Participants who experience Adverse Events as a Measure of Safety and Tolerability|Number of Participants who Respond to Treatment","University of Rochester|Massey Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","32833","January 2011","July 2013","January 2015","January 13, 2011","null","December 3, 2015","University of Rochester, Rochester, New York, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01276717"
880,"NCT00361621","Ph II CHOP+Velcade in Mediastinal LBCL",,"Terminated","No Results Available","Non-Hodgkin's Lymphoma","Drug: bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Radiation: Radiation therapy","To evaluate the rate of complete response to therapy defined as resolution of PET avidity in all previously documented sites at the completion of chemotherapy.|Assess toxicity|evaluate event-free survival at 2 years|evaluate overall survival at 2 years|assess early PET restaging after 3 cycles of chemotherapy.","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-012|X05194","July 2006","November 2007","May 2008","August 8, 2006","null","December 3, 2012","Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00361621"
881,"NCT02339805","Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS","LymphoSeq","Completed","No Results Available","Non Hodgkin Lymphoma","Other: next generation sequencing|Device: Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)","Determine the clonal evolution during and after treatment by Next Generation Sequencing|Progression free survival|Overall survival|Assess the clonal architecture in tumor DNA and bone marrow|Compare the Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) procedure and the kinetic and pattern of somatic mutations identified in cfDNA","Centre Henri Becquerel|U918 ( Inserm unit)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHB13.03","November 1, 2014","July 2015","July 2016","January 15, 2015","null","July 7, 2017","Centre Henri Becquerel, Rouen, France","","https://ClinicalTrials.gov/show/NCT02339805"
882,"NCT01421667","A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma",,"Completed","Has Results","Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell","Drug: brentuximab vedotin|Drug: rituximab","Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy|Adverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Plus Rituximab|Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Plus Rituximab|Complete Remission (CR) Rate by Investigator|Duration of Objective Response With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis|Duration of Complete Remission With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis|Progression-Free Survival With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis|Correlation Between Antitumor Activity of Brentuximab Vedotin Monotherapy and CD30 Expression|Adverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Monotherapy|Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi) (Cycle 1)|Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough) (Cycle 1)|Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) (Cycle 1)|Time to Maximum Concentration (Tmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE)|Baseline Soluble CD30 Expression","Seattle Genetics, Inc.","All","6 Years and older   (Child, Adult, Older Adult)","Phase 2","176","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN35-012","August 2011","June 2015","June 2015","August 23, 2011","October 13, 2016","November 28, 2016","University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Stanford Cancer Center, Stanford, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Cancer Specialists of North Florida - St. Augustine, St. Augustine, Florida, United States|Emory Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, The, Cleveland, Ohio, United States|Willamette Valley Cancer and Research / USOR, Eugene, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|St. Francis Hospital, Greenville, South Carolina, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-Southwest Fort Worth, Fort Worth, Texas, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|Texas Oncology - Seton Williamson, Round Rock, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Swedish Cancer Institute Medical Oncology, Edmonds, Washington, United States|Seattle Cancer Care Alliance / University of Washington Medical Center, Seattle, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT01421667"
883,"NCT03366272","Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients","NIVEAU","Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Nivolumab|Drug: Rituximab|Drug: Gemcitabine|Device: Oxaliplatin","PFS|CR rate|PR rate|ORR rate|Duration of response|Primary Progression rate|Treatment related deaths rate|Relapse rate|EFS|OS|Toxicities: rates and grades of adverse events|Protocol adherence according to number of given chemotherapy cycles|Protocol adherence according to duration of given chemotherapy cycles|Protocol adherence according to cumulative dose of immunochemotherapy given|Protocol adherence according to relative dose of immunochemotherapy given|QoL|Biological Parameters according to PD-L1 expression alterations|Biological Parameters according to PD-1 expression|Biological Parameters according to cell of origin|Biological Parameters according to 9p24.1 alterations","University Hospital, Saarland|Bristol-Myers Squibb|Lymphoma Study Association|University of Leipzig","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","388","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSHNHL 2015-1","December 5, 2017","November 2022","November 2024","December 8, 2017","null","July 27, 2018","INSTITUT JULES BORDET -Hematology, Brüssel, Belgium|UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Hematology, Brüssel, Belgium|UNIVERSITAIR ZIEKENHUIS GENT - Hematology, Gent, Belgium|CHU DE LIEGE - Hematology, Liège, Belgium|UNIVERSITE CATHOLIQUE DE LOUVAIN MONT GODINNE - Hematology, Yvoir, Belgium|CHU Côte de Nacre - Service Hématologie Clinique, Caen, France|Hôpital Henri Mondor - Unité ""Hémopathies Lymphoïdes"" - HDJ 11è, Créteil Cedex, France|CHU Dijon - Hôpital d'Enfants - Hématologie Clinique, Dijon, France|CHU de Grenoble - Hôpital Albert Michallon - Hématologie Clinique, Grenoble, France|CH Départemental Vendée - Onco-Hématologie, La Roche-sur-Yon, France|CHRU de Lille - Hôpital Claude Hurriez, Lille, France|Institut Paoli Calmettes - Hématologie, Marseille, France|CHU de Montpellier - Hématologie Clinique, Montpellier, France|CHU de Nantes - Hôtel Dieu - Hématologie, Nantes, France|Hôpital Saint Louis - Onco-Hématologie, Paris cedex 20, France|Hôpital Necker - Hématologie Clinique, Paris, France|CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie, Pessac, France|CHU Lyon Sud - Hématologie, Pierre-Bénite, France|Hôpital Pontchaillou - Hématologie, Rennes, France|Centre Henri Becquerel - Hématologie, Rouen, France|Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre, Strasbourg, France|IUCT Oncopole - Hématologie, Toulouse, France|CHU Nancy - Hôpital de Brabois - Service d'Hématologie et Médecine Interne, Vandoeuvre-les-Nancy, France|Charité - Universitätsklinikum Berlin, Med. Klinik m. S. Hämatologie, Berlin, Germany|Vivantes Klinikum am Urban, Klinik für Innere, Hämatologie und Onkologie, Berlin, Germany|Klinikum Chemnitz, Innere Medizin III, Chemnitz, Germany|BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Germany|Gemeinschaftspraxis Dres. Mohm, Prange-Krex, Dresden, Germany|St. Antonius-Hospital Eschweiler, Klinik für Hämatologie, Eschweiler, Germany|Universitätsklinikum Essen, Klinik für Hämatologie, Essen, Germany|Universitätsmedizin Göttingen, Klinik für Hämatologie, Göttingen, Germany|Universitätsklinikum Haale (Saale), Klinik für Innere Medizin IV, Haale, Germany|Med. Hochschule Hannover, Klinik für Hämatologie, Hannover, Germany|Medizinische Hochschule Hannover, Klinik für Hämatologie, Hannover, Germany|Universitätsklinikum des Saarlandes, Innere Med. I, Homburg, Germany|Westpfalz-Klinikum, Klinik für Innere Medizin I, Kaiserslautern, Germany|St. Vincentius Kliniken Karlsruhe, Med. Klinik Abt. 2, Karlsruhe, Germany|Klinikum der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany|Uni Gießen und Marburg, Klinik für Hämatologie, Marburg, Germany|Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin, Mutlangen, Germany|Klinikum der Universität München, Med. Klinik und Poliklinik III, München, Germany|Universitätsklinikum Münster, Münster, Germany|Universitätsklinikum Regensburg, Klinik für Innere Medizin III, Regensburg, Germany|Universitätsmedizin Rostock, Klinik für Hämatologie, Rostock, Germany|Klinikum Stuttgart, Klinik für Hämatologie, Stuttgart, Germany|Klinikum Mutterhaus der Borromäerinnen, Med. Abteilung I, Trier, Germany|Krankenhaus der Barmherzigen Brüder, I. Med. Abteilung, Trier, Germany|Universitätsklinikum Tübingen, Innere Medizin II, Tübingen, Germany|Uniklinikum Ulm, Klinik für Innere Medizin III, Ulm, Germany|Schwarzwald-Baar Klinikum, Innere Medizin II, Villingen-Schwenningen, Germany|The Chaim Sheba Medical Center - Division of Hematology and Bone-Marrow Transplantation, Ramat Gan, Israel|Instituto Português Oncologia - Hematology, Lisboa, Portugal","","https://ClinicalTrials.gov/show/NCT03366272"
884,"NCT01210287","Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP","IHBVRL","Unknown status","No Results Available","Lymphoma","Drug: nucleoside analog reverse transcriptase inhibitor","incidence of HBV reactivation|the outcome of antiviral therapy in HBV-DNA abnormal patients","Fudan University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","110","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","201010HBV","October 2010","August 2014","August 2014","September 28, 2010","null","January 8, 2014","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Fudan University Cancer Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT01210287"
885,"NCT03483103","Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006)",,"Recruiting","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma, Nonhodgkin|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse","Biological: lisocabtagene maraleucel","Antitumor activity|Adverse events|Laboratory abnormalities|Maximum concentration (Cmax) of lisocabtagene maraleucel in blood|Time of the maximum concentration (Tmax) of lisocabtagene maraleucel in blood|Area under the curve of (AUC) lisocabtagene maraleucel concentration in blood|Progression-free survival|Event-free survival|Overall survival|Health-related quality of life and health economics and outcomes research","Juno Therapeutics, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","017006","July 26, 2018","May 2, 2021","May 2, 2021","March 30, 2018","null","August 1, 2018","University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03483103"
886,"NCT00028613","Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma",,"Completed","No Results Available","Lymphoma","Radiation: iodine I 131 monoclonal antibody Lym-1","","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRLX1400|CWRU-BRLX-1400|BRLX-303680|CWRU-090036|NCI-G01-2038","March 2001","October 2001","October 2001","June 30, 2003","null","January 9, 2014","Ireland Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00028613"
887,"NCT00007956","Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: monoclonal antibody mono-dgA-RFB4","","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000068356|NCI-01-C-0021|UTSMC-99-02-07","November 2000","null","null","January 27, 2003","null","April 30, 2015","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|Center for Cancer Research, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00007956"
888,"NCT00258336","Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Lymphoma","Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine|Biological: rituximab|Biological: sargramostim","Event-free survival by Kaplan-Meier|Overall response rate (partial and complete response) at month 6 and any time|Time-to-progression by Kaplan-Meier|Duration of response|Immune response by cellular or humoral anti-idiotype response positive|Safety","Favrille|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000449719|FAV-ID-70|FAV-ID-LYM-31","August 2004","November 2009","null","November 24, 2005","null","January 10, 2014","Sarah Cannon Cancer Center at Centennial Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00258336"
889,"NCT00450385","Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)","R-CHOP","Terminated","Has Results","Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine","Determination of a List of Genes and Construction of Survival Prediction Models That Will Predict Overall Survival at 30 Months in DLBCL Patients Receiving R-CHOP Therapy.|Usefulness of Biomarkers Associated With Anti-Tumor Effects of Rituximab in Predicting Overall Survival in DLBCL Patients Receiving R-CHOP Therapy|Comparison of the Ability of Constructed Survival Models to Predict Overall Survival in DLBCL Patients Receiving R-CHOP Therapy|Determination of the Ability of Models and/or Biomarkers Associated With Anti-Tumor Effects of Rituximab to Predict 24-month Time to Treatment Failure in DLBCL Patients Receiving R-CHOP Therapy|Overall Response Rate of Study Participants at the End of Protocol Therapy|Number of Participants From Whom Fixed Tissue Samples Were Collected for Future Studies.","University of Miami","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","57","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20061138|SCCC-2006069|WIRB-20070073","April 24, 2007","May 2016","May 2016","March 22, 2007","June 23, 2017","June 23, 2017","Stanford University, Stanford, California, United States|University of Miami, Miami, Florida, United States|University of Rochester Medical Center - Wilmot Cancer Institute, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00450385"
890,"NCT01403636","A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia",,"Completed","No Results Available","Lymphoma","Drug: SAR245409","Objective response rate (ORR) as defined as the proportion of patients who experience complete response/remission (CR) or partial response/remission (PR)|Progression free survival (PFS) at 6 months","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","167","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD12130|2011-001616-57|U1111-1118-6417","October 2011","September 2014","September 2014","July 27, 2011","null","March 17, 2016","Investigational Site Number 840012, Los Angeles, California, United States|Investigational Site Number 840104, Fort Meyers, Florida, United States|Investigational Site Number 840006, Augusta, Georgia, United States|Investigational Site Number 840011, Maywood, Illinois, United States|Investigational Site Number 840010, Kansas City, Kansas, United States|Investigational Site Number 840013, Lexington, Kentucky, United States|Investigational Site Number 840007, Paducah, Kentucky, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840015, St Louis, Missouri, United States|Investigational Site Number 840014, Canton, Ohio, United States|Investigational Site Number 840001, Philadelphia, Pennsylvania, United States|Investigational Site Number 840002, Morgantown, West Virginia, United States|Investigational Site Number 036002, Clayton, Australia|Investigational Site Number 036001, Hobart, Australia|Investigational Site Number 036005, Kingswood, Australia|Investigational Site Number 036003, Perth, Australia|Investigational Site Number 056003, Bruxelles, Belgium|Investigational Site Number 056002, Gent, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 250002, Montpellier, France|Investigational Site Number 250001, Pierre Benite Cedex, France|Investigational Site Number 250004, Rennes, France|Investigational Site Number 250005, Rouen Cedex, France|Investigational Site Number 250003, Villejuif Cedex, France|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276002, Jena, Germany|Investigational Site Number 276001, Ulm, Germany|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528003, Groningen, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT01403636"
891,"NCT03463057","The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL","HO151DLBCL","Recruiting","No Results Available","NHL|DLBCL","Drug: Atezolizumab","Disease free survival (DFS) measured from the date of registration to relapse or death from any cause whichever comes first.|(Severe) Adverse Events and the relation of adverse events in time to the recovery of the T-cell repertoire.|Overall survival (OS), calculated from registration until death from any cause. Patients still alive or lost to follow up are censored at the last date known to be alive.|The relationship between MRD status at the end-of-induction and end-of-consolidation therapy.|The relation between MRD conversion and 2-years DFS and OS.|The relation between the T-cell and NK cell repertoire and adverse events.","Stichting Hemato-Oncologie voor Volwassenen Nederland","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","114","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HO151|2017-002605-35","August 30, 2018","April 2022","April 2025","March 13, 2018","null","September 18, 2018","UZ Antwerpen, Antwerpen, Belgium|ZNA, Antwerpen, Belgium|AZ St Jan Brugge, Brugge, Belgium|UZ Leuven, Leuven, Belgium|AZ Delta, Roeselare, Belgium|Meander Medisch Centrum, Amersfoort, Netherlands|OLVG Oost, Amsterdam, Netherlands|VUmc, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Haga hospital, Den Haag, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|UMCG, Groningen, Netherlands|Tergooi Ziekenhuizen, Hilversum, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|LUMC, Leiden, Netherlands|MUMC, Maastricht, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud Umc, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|Zuyderland Medisch Centrum, Sittard, Netherlands|Elisabeth/Tweesteden Ziekenhuis, Tilburg, Netherlands|UMCU, Utrecht, Netherlands|Isala Klinieken, Zwolle, Netherlands","","https://ClinicalTrials.gov/show/NCT03463057"
892,"NCT01987505","MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma",,"Completed","Has Results","Lymphoma, Non Hodgkin","Drug: Rituximab","Percentage of Participants With Administration-Associated Reactions (AARs)|Percentage of Participants With At Least One Grade >/= 3 Adverse Events (AEs)|Percentage of Participants With At Least One Grade >/= 3 Infusion/ Injection Related Reactions (IIRRs)|Percentage of Participants With At Least One Serious Adverse Event (SAE)|Event-Free Survival (EFS)|Progression-Free Survival (PFS)|Overall Survival (OS)|Disease-Free Survival (DFS)|Treatment Response Rate","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","140","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML28943|2013-001118-14","November 11, 2013","April 11, 2017","April 11, 2017","November 19, 2013","July 4, 2018","July 4, 2018","Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital General de Elda; Servicio de Hematologia, Elda, Alicante, Spain|Hospital de Granollers, Servicio de Hematología, Granollers, Barcelona, Spain|Hospital Mutua de Terrassa; Servicio de Hematologia, Terrassa, Barcelona, Spain|Hospital Son Llatzer; Servicio de Hematologia, Palma de Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Hematologia, La Coruna, LA Coruña, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Hematologia, Santiago de Compostela, LA Coruña, Spain|Complejo Hospitalario San Millan - San Pedro; Servicio Hematologia, Logroño, LA Rioja, Spain|Complejo Asistencial de León, Servicio de Hematología, León, Leon, Spain|Hospital Universitario de Fuenlabrada; Servicio de Hematologia, Fuenlabrada, Madrid, Spain|Hospital Severo Ochoa; Servicio de Hematologia, Leganes, Madrid, Spain|Hosital Universitario de Mostoles;Servicio de Hematologia, Mostoles, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Hematologia, Pamplona, Navarra, Spain|Hospital de Navarra, Servicio de Hematología, Pamplona, Navarra, Spain|Complejo Hospitalario Universitario de Vigo; Servicio de Hematologia, Vigo, Pontevedra, Spain|Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia, Santa Cruz de Tenerife, Tenerife, Spain|Hospital de Basurto; Servicio de Hematologia, Bilbao, Vizcaya, Spain|Hospital de Galdakano; Servicio de Hematologia, Galdakao, Vizcaya, Spain|Complejo Hospitalario Torrecardenas; Servicio de Hematologia, Almeria, Spain|Hospital Universitario de Burgos, Servicio de Hematología, Burgos, Spain|Hospital General de Castellon; Servicio de Hematologia, Castellon, Spain|Hospital Universitario Reina Sofia; Servicio de Hematologia, Cordoba, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Hematologia, Granada, Spain|Hospital Universitario de Gaudalajara; Hematología, Guadalajara, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Hematologia, Lerida, Spain|Hospital Infanta Leonor; Servicio de Hematologia, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Hematología, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio Hematologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Principe de Asturias; Servicio de Hematología, Madrid, Spain|Hospital Univ. Virgen de la Victoria, Malaga, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Hematologia, Murcia, Spain|Complejo Hospitalario de Pontevedra; Servicio de Hematologia, Pontevedra, Spain|Complejo Asistencial de Segovia, Segovia, Spain|Hospital Universitario Virgen Macarena; Servicio de Hematologia, Sevilla, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Hematologia, Sevilla, Spain|Hospital de Rio Hortega; Servicio de Hematologia, Valladolid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT01987505/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT01987505/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01987505"
893,"NCT00002757","TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Leukemia|Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methotrexate|Drug: prednisolone|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate","Event Free Survival|Conditional Survival|Failure Free Survival","Children's Oncology Group|National Cancer Institute (NCI)|Societe Francaise Oncologie Pediatrique|Children's Cancer and Leukaemia Group","All","up to 20 Years   (Child, Adult)","Phase 3","1148","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","5961|COG-C5961|CCG-5961|SFOP-LMB-96|CCLG-NHL-9600|EU-96048|CDR0000064702","June 2001","October 2003","October 2009","January 27, 2003","null","July 24, 2014","Institut Gustave Roussy, Villejuif, France|Children's Hospital - Sheffield, Sheffield, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT00002757"
894,"NCT00039195","Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma",,"Completed","Has Results","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Progression Free Survival","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb|Genentech, Inc.","All","18 Years to 64 Years   (Adult)","Phase 2","98","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-142|MSKCC-01142|NCI-G02-2069","November 2006","January 2010","January 2010","January 27, 2003","August 10, 2016","August 10, 2016","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00039195"
895,"NCT00054171","Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Leukemia|Lymphoma","Drug: aminolevulinic acid hydrochloride","Pain grade and epidermal toxic response (ETR)|Feasibility of maintaining a pain grade of 1 or less and an approximate ETR of 2|Maximal irradiance and corresponding exposure|Cumulative response achieved at the completion of treatment|Number of sessions required to complete treatment|Correlation of ETR with incremental treatment response","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Phase 2","1","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","DS 97-32|RPCI-DS-9732","February 1999","July 2005","null","February 6, 2003","null","January 31, 2013","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT00054171"
896,"NCT00451178","An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only",,"Completed","No Results Available","Lymphoma","Drug: enzastaurin|Drug: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Progression Free Survival time|Compare R-CHOP plus enzastaurin versus R-CHOP in terms of CR and/or CRu rate and ORR|Compare R-CHOP plus enzastaurin versus R-CHOP in terms of 2-year Progression Free Survival rate|To evaluate PET-negative rate for each treatment arm|To investigate concordance between CT scan/MRI and PET scan|Event Free Survival|Overall Survival|Duration of complete response|Assess biomarkers and their correlation to clinical outcomes|Evaluate toxicity and tolerability of R-CHOP plus enzastaurin","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9824|H6Q-MC-S028","May 2007","February 2012","January 2013","March 23, 2007","null","April 2, 2013","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huntsville, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beverly Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenbrae, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palm Springs, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., South Bend, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Mathews, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Willow Grove, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Everett, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lacrosse, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00451178"
897,"NCT00472056","Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies",,"Completed","Has Results","Lymphoma","Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Drug: Rituximab","Disease-free Survival (DFS)","M.D. Anderson Cancer Center","All","up to 80 Years   (Child, Adult, Older Adult)","Phase 2","93","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0271","March 2005","June 2012","June 2012","May 11, 2007","February 13, 2012","March 15, 2016","UT MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00472056"
898,"NCT00387959","Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Leukemia|Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Survival at 1 Year After Transplantation","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-066|MSKCC-06066","July 2006","April 2014","April 2014","October 13, 2006","February 1, 2016","February 1, 2016","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00387959"
899,"NCT00004198","Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: keyhole limpet hemocyanin|Biological: sargramostim|Biological: tumor cell-based vaccine therapy","","University of Nebraska|National Cancer Institute (NCI)|Genitope Corporation","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","null","Other|NIH|Industry","Interventional","Primary Purpose: Treatment","196-99|P30CA036727|UNMC-196-99|GENITOPE-9901","June 1999","January 2002","November 2003","May 21, 2004","null","January 17, 2018","University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00004198"
900,"NCT00902018","Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)",,"Completed","No Results Available","Idiopathic Thrombocytopenic Purpura","Drug: Promacta (eltrombopag)","To determine how eltrombopag affects platelet counts.|To determine effect of eltrombopag on platelet apoptosis.|To determine how eltrombopag affects platelet function and platelet survival.|To continue to assess the safety and efficacy of eltrombopag.","Weill Medical College of Cornell University|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0809009980","January 2009","September 7, 2015","September 7, 2015","May 14, 2009","null","February 2, 2017","Weill Cornell Medical College, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00902018"
901,"NCT00425802","Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","Has Results","Leukemia|Lymphoma","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Radiation: total-body irradiation","Overall Survival at 1 Year|Time to Neutrophil Engraftment|Time to Platelet Engraftment|Incidence of Moderate to Severe Grades II to IV Graft Versus Host Disease (GVHD) at 100 Days|Incidence of Chronic GVHD at 1 Year|Immune Reconstruction/CD4+ Count at 3 Months|Response to Treatment|Immune Reconstruction/CD4+ Count at 6 Months|Immune Reconstruction/CD4+ Count at 1 Year","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","61","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-150|MSKCC-06150","November 28, 2006","October 28, 2016","October 28, 2016","January 23, 2007","October 31, 2017","October 31, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00425802"
902,"NCT00004197","Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: keyhole limpet hemocyanin|Biological: sargramostim|Biological: tumor cell-based vaccine therapy|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: vincristine sulfate","","University of Nebraska|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","197-99|P30CA036727|UNMC-197-99|GENITOPE-9902|SUMC-9902","June 1999","January 2002","November 2003","June 25, 2004","null","January 17, 2018","Stanford University Medical Center, Stanford, California, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00004197"
903,"NCT03418038","Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma",,"Recruiting","No Results Available","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Lymphoma","Dietary Supplement: Ascorbic Acid|Drug: Carboplatin|Drug: Cisplatin|Drug: Cytarabine|Drug: Dexamethasone|Drug: Etoposide|Drug: Gemcitabine Hydrochloride|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Oxaliplatin|Other: Placebo|Other: Questionnaire Administration|Biological: Rituximab","ORR (Arm C) defined as an objective status of CR or PR evaluated by RECIL criteria after 2 cycles of treatment|Overall response rate (ORR) (Arms A and B) defined as an objective status of complete response (CR) or partial response (PR) evaluated by Response Evaluation Criteria in Lymphoma (RECIL) criteria after 2 courses of treatment in all arms|Clinical benefit rate|Continued salvage therapy beyond cycle 2|Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events|Incidence of adverse events assessed using Patient Reported Outcomes (PRO)-CTCAE (Arms A and B)|Overall survival|Percent of transplant eligible patients proceeding to transplant|Progression-free survival","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","151","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LS1781|NCI-2018-00057|P30CA015083","March 23, 2018","March 15, 2024","March 15, 2024","February 1, 2018","null","March 27, 2018","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03418038"
904,"NCT00493454","Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas",,"Terminated","Has Results","Lymphoma","Drug: Zevalin|Drug: Rituximab|Drug: ^111 In Ibritumomab Tiuxetan","Objective Response Rate","M.D. Anderson Cancer Center|Biogen","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-0571","April 2006","March 2011","March 2011","June 28, 2007","May 31, 2013","May 31, 2013","UT MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00493454"
905,"NCT00041730","Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Non-Hodgkin's Lymphoma","Biological: Id-KLH","","Favrille","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FavId-04","July 2002","null","null","July 17, 2002","null","September 30, 2009","University of California, San Diego, La Jolla, California, United States|Tower Hematology Oncology Medical Group, Los Angeles, California, United States|Oncology Associates of San Diego, San Diego, California, United States|University California, San Francisco, San Francisco, California, United States|University of Florida, Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Ochsner Clinical Foundation, New Orleans, Louisiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|New York Medical College - Our Lady of Mercy Medical Center, Comprehensive Cancer Center, Bronx, New York, United States|Oncology/Hematology Care Clinical Cancer Institute, Cincinnati, Ohio, United States|University Hospitals of Cleveland Case Western, Ireland Cancer Center, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|The Sarah Cannon Cancer Center, Nashville, Tennessee, United States|University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00041730"
906,"NCT02597387","Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs",,"Recruiting","No Results Available","Relapsed DLBCL and PT/NKCLs","Drug: Mitoxantrone HCL Liposome Injection","Objective response rate (ORR; complete response + partial response [CR + PR])|Duration of Response (DOR)|Time to Response (TTR)|Progression-free survival (PFS)","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSPC-HE153/PRO/Ⅱ","August 2015","September 2018","October 2018","November 5, 2015","null","August 17, 2018","Beijing Cancer Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT02597387"
907,"NCT00265928","Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Lymphoma","Drug: bortezomib|Drug: rituximab|Procedure: antibody therapy|Procedure: biological therapy|Procedure: enzyme inhibitor therapy|Procedure: monoclonal antibody therapy","","University of Virginia|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000459747|UVACC-HIC-12077|UVACC-PRC-36805|MILLENNIUM-X05181|MILLENNIUM-LYMPHOMA2","null","null","null","December 15, 2005","null","January 28, 2008","University of Virginia Cancer Center at UV Health System, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00265928"
908,"NCT00644371","Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)","Z-RIC-Allo","Completed","No Results Available","Non-Hodgkin Lymphoma","Drug: Ibritumomab Tiuxetan (Zevalin)","progression-free survival|safety (toxicity, transplantation- and graft-related mortality)|response to treatment according to the Cheson's criteria (Cheson B, et al. JCO 25, 570, 2007).|overall survival|relapse rate|acute and chronic Graft-versus-Host Disease|haematological and immunological reconstitution, and chimerism.|the impact of Complete Clinical Response, determined by flow cytometry and PET, on progression-free survival","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GELTAMO-Z-RIC-Allo|EuDRACT nº:2007-003302-10","November 2007","February 21, 2011","February 4, 2013","March 26, 2008","null","March 27, 2017","H. Santa Creu i Sant Pau., Barcelona, Barcelona., Spain|Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|H.U. 12 de Octubre, Madrid, Spain|H.U. Gregorio Marañón, Madrid, Spain|H.U. La Princesa, Madrid, Spain|H.U. Ramón y Cajal., Madrid, Spain|H. Morales Meseguer., Murcia, Spain|H. Virgen de la Arrixaca, Murcia, Spain|H. Central de Asturias, Oviedo, Spain|H. Clinico de Salamanca, Salamanca, Spain|H. U. Marqués de Valdecilla., Santander, Spain|H. Clínico Valencia, Valencia, Spain|H. La Fe, Valencia, Spain|H.U. Miguel Servet, Zaragoza., Spain","","https://ClinicalTrials.gov/show/NCT00644371"
909,"NCT03225924","Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy",,"Recruiting","No Results Available","DLBCL","Drug: Entospletinib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Phase I: recommended phase 2 dose|Phase II: Complete Metabolic Response (CMR) rate at the end of treatment","The Lymphoma Academic Research Organisation","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","131","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENTO-R-CHOP","July 26, 2017","April 2020","September 2023","July 21, 2017","null","August 29, 2018","UCL Namur, Yvoir, Belgium|CHU Côte de Nacre, Caen, France|CHU Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CHU Lyon Sud, Lyon, France|CHU Montpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT03225924"
910,"NCT00036426","Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Lymphoma, Low-Grade","Biological: FavId (Id-KLH) active immunotherapy","","Favrille","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FavId-01","March 2001","null","null","May 10, 2002","null","June 24, 2005","Scripps Stevens Cancer Center, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|Tower Hematology Oncology Medical Group, Los Angeles, California, United States|Oncology Associates of San Diego, San Diego, California, United States|Medical Group of North County, Vista, California, United States|University of Florida, Jacksonville, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Henry Ford Hospital, Detroit, Michigan, United States|New York Medical College - Our Lady of Mercy Medical Center, Comprehensive Cancer Center, Bronx, New York, United States|New York Hospital - Cornell Medical Center, New York, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00036426"
911,"NCT00003963","Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: vinorelbine ditartrate","Tolerability and toxicity|Response rate","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000067163|P30CA016042|UCLA-9903029|NCI-G99-1545","May 1999","September 2003","February 2005","January 27, 2003","null","October 2, 2015","Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00003963"
912,"NCT00307710","Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: Trivalent Baculovirus-expressed Influenza HA vaccine","Immunogenic response across patients administered either licensed trivalent inactivated influenza vaccine (TIV) or one of three doses (15, 45 or 135 μg) of trivalent recombinant baculovirus expressed hemagglutinin vaccines.","M.D. Anderson Cancer Center|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2004-0340|DMID 04-036","August 2004","February 2007","February 2007","March 28, 2006","null","July 31, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00307710"
913,"NCT01325194","CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis","CHIC","Active, not recruiting","No Results Available","Primary Disease","Drug: liposomal cytarabine","Time to treatment failure|Maximal hematological, gastrointestinal, neuronal and other toxicities|Clinical response rate|Incidence of central nervous system(CNS) relapse in cerebrospinal fluid (CSF )cytology neg/flow cytometry positive cases|Incidence of CNS relapse in a subgroup of patients with more than one extranodal site and elevated lactate dehydrogenase (LDH)|Progression free survival|Overall survival|Molecular predictors|CNS relapse rate","Nordic Lymphoma Group|Mundipharma Pte Ltd.|Amgen","All","18 Years to 64 Years   (Adult)","Phase 2","143","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG-LBC-05","March 2011","December 2014","December 2017","March 29, 2011","null","September 7, 2017","Department of Hematology, Århus University Hospital, Århus, Denmark|Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland|Department of Oncology, Oslo University Hospital, Oslo, Norway|Department of Oncology, Lund University Hospital, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT01325194"
914,"NCT03123718","High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL",,"Not yet recruiting","No Results Available","DLBCL","Drug: Intrathecal methotrexate|Drug: High-dose intravenous methotrexate","Cumulative incidence of CNS relapse|Toxicity|Progression-free survival (PFS)","Chonnam National University Hospital|Consortium for Improving Survival of Lymphoma","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","205","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HDMTX","July 1, 2017","June 30, 2021","June 30, 2021","April 21, 2017","null","April 24, 2017","Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03123718"
915,"NCT00004039","Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma",,"Withdrawn","No Results Available","Lymphoma","Biological: recombinant interferon alfa|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","","Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group","All","Child, Adult, Older Adult","Phase 2","0","Other","Interventional","Primary Purpose: Treatment","CDR0000066762|CBRG-9807|NCI-V98-1494","June 1998","January 2000","January 2000","August 5, 2004","null","August 19, 2015","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States","","https://ClinicalTrials.gov/show/NCT00004039"
916,"NCT03144674","A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)",,"Recruiting","No Results Available","Lymphoma","Drug: INCB050465","Objective response rate based on Lugano Classification criteria|Duration of response|Complete response rate based on Lugano Classification criteria.|Progression-free survival|Overall survival|Best percentage change from baseline in target lesion size|Safety of INCB050465 as measured by adverse events (AEs)","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 50465-204 (CITADEL-204)","June 27, 2017","March 2020","March 2022","May 9, 2017","null","August 15, 2018","University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Arizona Oncology Associates - Biltmore Cancer Center, Phoenix, Arizona, United States|St. Joseph Heritage Healthcare, Petaluma, California, United States|Torrance Health Association, Redondo Beach, California, United States|Sansum Clinical, Santa Barbara, California, United States|St. Mary's Medical Center, Santa Barbara, California, United States|Mission Hope Cancer Center, Santa Maria, California, United States|UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Valley View Hospital, Glenwood Springs, Colorado, United States|University of Miami, SCCC, Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Boca Raton Clinical Research Associates, Inc, Plantation, Florida, United States|Asclepes Research Centers, Spring Hill, Florida, United States|Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Clinical Trials of SWLA, LLC, Lake Charles, Louisiana, United States|University of Michigan Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|St. Luke's Hospital, Kansas City, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Clinical Research Alliance, Lake Success, New York, United States|New York University Langone Medical Center - Perlmutter Cancer Center, New York, New York, United States|Hematology Oncology Associates of Rockland, Nyack, New York, United States|White Plains Hospital, White Plains, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Gabrail Cancer Research Center, Canton, Ohio, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Charleston Hematology Oncology Associates, Charleston, South Carolina, United States|Renovatio Clinical, Houston, Texas, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|Icon Cancer Care, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, Australia|Calvary North Adelaide Hospital, North Adelaide, Australia|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium|Aalborg University Hospital, Aalborg, Denmark|Zealand University Hospital, Roskilde, Denmark|Universitätsklinikum Essen, Essen, Germany|Klinikum der Stadt Ludwigshafen gGmbH, Ludwigshafen am Rhein, Germany|Universitätsklinikum Ulm, Ulm, Germany|Rambam Medical Center, Haifa, Israel|Hadassah Ein Karem Hospital, Jerusalem, Israel|Rabin Medical Center - Beilinson Hospital, Petah tikva, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|University Of Bologna, Institute Of Haematology, Bologna, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCS, Meldola, Italy|Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy|Fondazione Centro San Raffaele - Milano, Milan, Italy|Azienda Ospedaliero Universitaria Maggiore della Carità di Novara, Novara, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello, Palermo, Italy|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Institut Catala d'Oncologia Hospitalet, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|HM Universitario Sanchinarro, Madrid, Spain|Hospital Quirón Madrid, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hosp Universitario Salamanca, Salamanca, Spain|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Kent Oncology Centre, Maidstone, United Kingdom|NNUH NHS Foundation Trust - Norfolk and Norwich University Hospital, Norwich, United Kingdom|University Of Southampton, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT03144674"
917,"NCT00003397","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Biological: sargramostim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: gemcitabine hydrochloride|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","","University of Maryland|University of Maryland Greenebaum Cancer Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Primary Purpose: Treatment","CDR0000066399|MSGCC-9740|NCI-V98-1432","September 1998","December 2002","December 2002","April 30, 2004","null","September 24, 2009","Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00003397"
918,"NCT02481310","Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Adult Burkitt Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|MYC Gene Mutation|Plasmablastic Lymphoma","Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Ixazomib Citrate|Other: Laboratory Biomarker Analysis|Drug: Methotrexate|Drug: Prednisone|Biological: Rituximab|Drug: Therapeutic Hydrocortisone|Drug: Vincristine Sulfate","For phase I of the study, the dose-limiting toxicity of ixazomib given with DA-EPOCH-R will be evaluated|For phase II of the study, 12-month PFS (Progression Free Survival) of ixazomib given with DA-EPOCH-R will be measured|Frequency of toxicity|Severity of toxicity|Response rate and OS (Overall Survival)|Assess the predictive value of FDG-PET/CT scans on PFS","Northwestern University|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","55","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 14H09|NCI-2015-00400|X16042|STU00200596|P30CA060553","September 2015","July 2019","July 2020","June 25, 2015","null","August 29, 2018","Northwestern University, Chicago, Illinois, United States|Tufts University, Medford, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02481310"
919,"NCT00080847","S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Biological: oblimersen sodium|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis","1 year PFS|Overall survival|Response|1-year PFS in patients who are bcl2+|Overall survival in patients who are bcl2+|Response in patients who are bcl2+","National Cancer Institute (NCI)","All","19 Years to 59 Years   (Adult)","Phase 2","160","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-03031|S0349|U10CA032102|CDR0000356049","March 2004","June 2007","null","April 8, 2004","null","January 7, 2013","Southwest Oncology Group, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT00080847"
920,"NCT01318317","Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma","Procedure: peripheral blood stem cell transplantation (PBSCT)|Biological: filgrastim|Genetic: polymerase chain reaction|Biological: rituximab|Biological: genetically engineered lymphocyte therapy|Other: laboratory biomarker analysis|Drug: plerixafor|Procedure: autologous hematopoietic stem cell transplantation","MTD based on DLTs and defining the full toxicity profile (Phase I)|Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) detection above background (Phase II)|Rates of engraftment and persistence|Failure to engraft|Progression-free survival|Overall survival","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","57","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09174|NCI-2011-00344|P50CA107399","September 19, 2011","August 2022","August 2022","March 18, 2011","null","August 9, 2018","City of Hope Medical Center, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT01318317"
921,"NCT00080886","Rituximab and Carmustine, Cytarabine, Etoposide, and Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","evaluation of the relationship between levels of sCD20 in the blood of patients with non-Hodgkin's lymphoma pre and post rituximab/BEAM/autologous peripheral blood progenitor cell transplantation (PBPCT) as they relate to clinical outcomes.","University of Nebraska|National Cancer Institute (NCI)","All","19 Years to 120 Years   (Adult, Older Adult)","Phase 2","68","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","063-02|CDR0000357306","May 2002","November 2005","March 2015","April 8, 2004","null","January 24, 2018","UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00080886"
922,"NCT01713582","A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies (MK-8628-001)",,"Completed","Has Results","Acute Myeloid Leukemia|Diffuse Large B-cell Lymphoma|Acute Lymphoblastic Leukemia|Multiple Myeloma","Drug: OTX015/MK-8628","Number of Participants With Dose Limiting Toxicities (DLTs)|Number of Participants Who Experienced at Least One Adverse Event (AE)|Number of Participants Who Discontinued Study Therapy Due to AEs|Number of Participants Whose Best Response Was Partial Response (PR) or Complete Response (CR)|Maximum Concentration (Cmax) of MK-8628/OTX015|Time to Maximum Concentration (Tmax) of MK-8628/OTX015|Apparent Terminal Half-Life (t1/2) of MK-8628/OTX015|Area Under the Concentration Time Curve of MK-8628/OTX015 From Time 0 to Infinity (AUC 0-first)|Apparent Total Body Clearance (CL/F) of MK-8628/OTX015|Volume of Distribution at Steady State (Vz/F) of MK-8628/OTX015","Oncoethix GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1","141","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8628-001|OTX015_104|2012-003380-22|MK-8628-001","December 14, 2012","January 20, 2017","January 20, 2017","October 24, 2012","October 1, 2018","October 1, 2018","","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT01713582/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT01713582/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01713582"
923,"NCT01796470","Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies",,"Completed","No Results Available","Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Diffuse Large B-cell Lymphoma|Indolent Non-Hodgkin's Lymphoma","Drug: Entospletinib|Drug: Idelalisib","Objective response rate|Safety and tolerability|Maximum tolerated dose level|Progression-free survival|Duration of response|Time to response","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-339-0103","June 2013","April 2014","December 2016","February 21, 2013","null","January 23, 2017","Marin Cancer Care, Greenbrae, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Cancer Center of Santa Barbara, Santa Barbara, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Collaborative Research Group LLC, Boynton Beach, Florida, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|New York University School of Medicine, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|Hollings Cancer Center, Charleston, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Northwest Medical Specialties, Tacoma, Washington, United States","","https://ClinicalTrials.gov/show/NCT01796470"
924,"NCT00324779","Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia",,"Completed","No Results Available","Leukemia|Lymphoma","Biological: rituximab","Response rate|Effect of rituximab on different histological subtypes|Rituximab response|Toxicity|Pharmacokinetics and pharmacodynamics","University Hospital Erlangen|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 2","79","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000466643|B-NHL-BFM-Rituximab|EU-205119|NHL-BFM-RITUXIMAB","March 2004","April 2011","null","May 11, 2006","null","September 25, 2015","Kinderklinik - Universitaetsklinikum Aachen, Aachen, Germany|Klinikum Augsburg, Augsburg, Germany|Charite - Campus Charite Mitte, Berlin, Germany|Helios Klinikum Berlin, Berlin, Germany|Evangelisches Krankenhauus Bielfeld, Biefeld, Germany|Klinikum Bremen-Mitte, Bremen, Germany|Children's Hospital, Cologne, Germany|Vestische Kinderklinik, Datteln, Germany|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Universitaets - Kinderklinik, Erlangen, Germany|Universitaetsklinikum Essen, Essen, Germany|Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany|Universitaetskinderklinik - Universitaetsklinikum Freiburg, Freiburg, Germany|Kinderklinik, Giessen, Germany|Klinik und Poliklinik Fuer Kinder-und Jugendmedizin - Universitaetsklinikum Greifswald, Greifswald, Germany|University Medical Center Hamburg - Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaets-Kinderklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum des Saarlandes, Homburg, Germany|Universitaets - Kinderklinik, Jena, Germany|Staedtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany|Kinderkrankenhaus Park Schoenfeld, Kassel, Germany|University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany|Universitaets - Kinderklinik, Leipzig, Germany|Universitaets - Kinderklinik - Luebeck, Luebeck, Germany|Universitatsklinikum der MA, Magdeburg, Germany|Universitaets - Kinderklinik, Marburg, Germany|Klinik und Poliklinik fuer Kinder und Jugendmedizin - Universitaetsklinikum Muenster, Muenster, Germany|Krankenhaus Muenchen Schwabing, Munich, Germany|Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Germany|Cnopf'sche Kinderklinik, Nuremberg, Germany|Klinik St. Hedwig-Kinderklinik, Regensburg, Germany|Olgahospital, Stuttgart, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm, Ulm, Germany|Universitaets - Kinderklinik Wuerzburg, Wuerzburg, Germany|University Children's Hospital, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT00324779"
925,"NCT00004031","SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: CHOP regimen|Drug: carmustine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Survival|Progression-free survival","Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","397","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000065658|S9704|U10CA032102","July 1997","July 2010","null","January 27, 2003","null","May 23, 2013","Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada|Cross Cancer Institute at University of Alberta, Edmonton, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Moncton Hospital, Moncton, New Brunswick, Canada|Doctor H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada|Odette Cancer Centre at Sunnybrook, Toronto, Ontario, Canada|Hopital Notre-Dame du CHUM, Montreal, Quebec, Canada|Hopital Du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada|Hopital du Saint-Sacrement - Quebec, Quebec City, Quebec, Canada|Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon, Saskatchewan, Canada","","https://ClinicalTrials.gov/show/NCT00004031"
926,"NCT00429065","Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.",,"Unknown status","No Results Available","Non-Hodgkin Lymphoma","Drug: Rituximab","","Instituto Nacional de Cancerologia de Mexico","All","15 Years to 60 Years   (Child, Adult)","","30","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","Hemato INCAN 01/2007","January 2007","null","January 2007","January 31, 2007","null","January 31, 2007","Instituto Nacional de Cancerologia, Mexico City, D.f., Mexico","","https://ClinicalTrials.gov/show/NCT00429065"
927,"NCT03460977","PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",,"Recruiting","No Results Available","Small Cell Lung Cancer (SCLC)|Follicular Lymphoma (FL)|Castration Resistant Prostate Cancer (CRPC)|Diffuse Large B-Cell Lymphoma (DLBCL)","Drug: PF-06821497","Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)|Overall safety profile including adverse events|Preliminary efficacy determination as evaluated by disease specific response criteria|Overall safety profile including laboratory abnormalities|Overall safety profile including vital signs|Evaluate time to event anti-tumor activity of PF-06821497 including progression-free survival (PFS), and metastatic free survival (MFS)|Evaluate overall survival|Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)|Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)|Pharmacokinetic Parameters: Area Under the Curve (AUC)|Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)|Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)|Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","172","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C2321001","April 19, 2018","February 9, 2023","February 9, 2023","March 9, 2018","null","September 11, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center (IP Shipment Address), Hackensack, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|OU Medical Center Presbyterian Tower, Oklahoma City, Oklahoma, United States|Stephenson Cancer Center (chemo location), Oklahoma City, Oklahoma, United States|Stephenson Cancer Center (drug shipment), Oklahoma City, Oklahoma, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tennessee Oncolgy, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|NEXT Oncology, San Antonio, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03460977"
928,"NCT02981914","Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation",,"Recruiting","No Results Available","Classical Hodgkin Lymphoma|B-cell Non-Hodgkin Lymphoma|Acute Myeloid Leukemia|Myelodysplastic Syndromes","Drug: Pembrolizumab","Number of patients with adverse events|Time between initial response and subsequent disease progression or relapse|Time between first documentation of complete remission (CR) or partial remission (PR) (by IRC) to the first documentation of disease progression or death by any cause|Time between the start of therapy to death from any cause.","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB16-1195","March 7, 2017","February 2020","February 2020","December 5, 2016","null","April 18, 2018","University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02981914"
929,"NCT03498612","Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases",,"Recruiting","No Results Available","B-Cell Non-Hodgkin Lymphoma|Follicular Lymphoma|Indolent Non-Hodgkin Lymphoma|Marginal Zone Lymphoma","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Overall response rate (complete response [CR] + partial response [PR] for follicular lymphoma and marginal zone lymphoma)|Duration of response|Progression-free survival|Time to next therapy|Incidence of adverse events (AEs)","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9647|NCI-2018-00432|P30CA015704","October 9, 2018","March 14, 2020","March 14, 2022","April 13, 2018","null","July 19, 2018","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03498612"
930,"NCT00002682","Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach",,"Completed","No Results Available","Lymphoma","Drug: Amoxicillin|Drug: Bismuth Subsalicylate|Drug: Clarithromycin|Drug: Metronidazole Hydrochloride|Drug: Omeprazole|Drug: Tetracycline Hydrochloride","Number of Patients with Response to Antibiotic Treatment of Gastric Malt Lymphoma","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","5","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPPDM95-084|P30CA016672|MDA-CPPDM-95084|NCI-T95-0003D|CDR0000064361","August 1995","October 2001","October 2001","June 10, 2004","null","July 31, 2012","MD Anderson Cancer Center Orlando, Orlando, Florida, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00002682"
931,"NCT02732275","A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas",,"Recruiting","No Results Available","Lymphoma|Lymphoma, B-cell|Lymphoma, Follicular|Adult T-Cell Leukemia Lymphoma (ATLL)","Drug: DS-3201b","number of dose limiting toxicities|maximum concentration Cmax|time of maximum concentration Tmax|area under the plasma concentration time curve up to the last quantifiable time AUClast|area under the plasma concentration time curve during dosing interval AUCtau|response rate based on international consensus criteria|disease control rate based on international consensus criteria|the change of tri-methylated histone H3 lysine 27 (H3K27Me3) status by Immunohistochemistry","Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc.","All","20 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DS3201-A-J101","March 2016","March 2019","April 2019","April 8, 2016","null","January 23, 2018","National Cancer Center Hospital, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT02732275"
932,"NCT02791217","Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool",,"Not yet recruiting","No Results Available","Lymphoma, B-Cell|Follicular Lymphoma|Hodgkin Lymphoma|Multiple Myeloma","","Molecular characteristics (by GEP, miRNA)|Event free survival (EFS)|Overall survival (OS)","Assuta Medical Center|Laniado Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2015097","June 2016","June 2017","June 2019","June 6, 2016","null","June 6, 2016","","","https://ClinicalTrials.gov/show/NCT02791217"
933,"NCT01087294","Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation",,"Recruiting","No Results Available","Leukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-Cell","Procedure: Allogeneic stem cell transplant|Biological: Anti-CD19-chimeric-antigen-receptor- transduced T cell","To assess the safety of allogeneic anti-CD19-CAR|To determine if administering anti-CD19-CAR-transduced T cells from the original transplant donor can cause regression of B-cell malignancies that are relapsed or persistent after alloHSCT|To measure the persistence of anti-CD 19-CAR-transduced T cells in the blood of patients after infusion","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","150","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100054|10-C-0054","February 5, 2010","March 1, 2023","March 1, 2024","March 16, 2010","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01087294"
934,"NCT02983097","Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP","R²-DHAP","Terminated","No Results Available","Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma Grade III (FL III°)|Mantle Cell Lymphoma (MCL), Blastoid Variant|Burkitt Lymphoma (BL)|Aggressive Marginal Zone Lymphoma (MZL)","Drug: Rituximab|Drug: Cisplatin|Drug: Carboplatin|Drug: Dexamethasone|Drug: Cytarabine|Drug: Lenalidomide|Drug: PegFilgrastim|Procedure: peripheral stem cell collection","Overall Response Rate (ORR)|Maximum tolerated dose (MTD)|Rate of complete remission|Rate of primary progression|Rate of treatment related deaths|Relapse Rate|Overall Survival|Progression free survival|tumour control|feasibility of stem cell mobilization|incidence of non-hematological toxicities > grade 2 CTC|incidence and duration of neutropenia and thrombopenia grade 4","Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Celgene|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSHNHL 2008 R6|2009-010824-25","November 2010","January 2014","April 28, 2015","December 6, 2016","null","January 19, 2018","Diakonie Krankenhaus Bremen, Bremen, Germany|Klinikum Chemnitz, Chemnitz, Germany|Universitätsklinikum Essen, Essen, Germany|Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany|Universitätsklinikum Göttingen, Göttingen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Westpfalz Klinikum, Kaiserslautern, Germany|Städtisches Klinikum Karlsruhe, Karlsruhe, Germany|LMU Klinikum München-Großhadern, München, Germany","","https://ClinicalTrials.gov/show/NCT02983097"
935,"NCT00498667","The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma",,"Withdrawn","No Results Available","Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse","","progression free survival","Rambam Health Care Campus","All","18 Years to 70 Years   (Adult, Older Adult)","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","cc-NHL2615_CTIL","December 2006","December 2009","December 2014","July 10, 2007","null","May 6, 2015","RAMBAM health care Campus, Haifa, Israel","","https://ClinicalTrials.gov/show/NCT00498667"
936,"NCT00031642","Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Radiation: yttrium Y 90 ibritumomab tiuxetan","Maximum tolerated dose|Safety and efficacy","University of Nebraska|Biogen","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","535-00|CDR0000069211|NCI-V02-1691","January 2002","November 2005","March 2008","January 27, 2003","null","December 17, 2013","UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00031642"
937,"NCT00022555","Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma",,"Completed","No Results Available","AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma","Drug: bryostatin 1|Drug: vincristine sulfate","MTD of bryostatin-1 defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity|Dose-limiting toxicities|Immunomodulatory effects of this combination","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02398|AMC-029|U01CA070019|CDR0000068830","November 2001","July 2003","null","January 27, 2003","null","January 25, 2013","AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00022555"
938,"NCT00086944","Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma","Biological: oblimersen sodium|Biological: rituximab|Drug: ifosfamide|Drug: carboplatin|Drug: etoposide|Biological: filgrastim|Biological: pegfilgrastim|Other: laboratory biomarker analysis","Toxicity graded using the NCI CTCAE version 3.0|Complete and partial response rate according to the International Workshop Criteria|Duration of response|Overall survival|Time to progression","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02600|12975A|N01CM62201|CDR0000371904","May 2004","July 2006","null","July 12, 2004","null","January 24, 2013","University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00086944"
939,"NCT00491491","Zevalin-beam for Aggressive Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: ibritumomab tiuxetan|Procedure: BEAM chemotherapy and autologous stem-cell transplantation","overall survival|progression-free survival|clinical response|hematopoietic recovery|toxicity|secondary malignancies","Sheba Medical Center|City of Hope Medical Center|VU University Medical Center|University of Göttingen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-07-4466-AN-CTIL","June 2007","February 2015","February 2015","June 26, 2007","null","December 2, 2015","Mayo Clinic Arizona, Scottsdale, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Georg-August Universität, Göttingen, Germany|Chaim Sheba Medical Center, Tel Hashomer, Israel|VU Medical Center, Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT00491491"
940,"NCT00005601","Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cisplatin|Drug: cytarabine|Drug: dexamethasone|Drug: sargramostim","response|percentage of patients able to proceed to transplant after two courses of this treatment regimen|duration of response|overall survival","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","58","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCCTG-N9981|NCI-2012-02326|CDR0000067714","October 2000","July 2003","February 2008","January 27, 2003","null","December 7, 2016","CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Ochsner, New Orleans, Louisiana, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|CCOP - Duluth, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Health Plaza, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Medcenter One Health System, Bismarck, North Dakota, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada","","https://ClinicalTrials.gov/show/NCT00005601"
941,"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)","SAGAN","Recruiting","No Results Available","Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia","Biological: CD19 CAR T Cells|Drug: Fludarabine|Drug: Cyclophosphamide","Number of patients with dose limiting toxicity (DLT)|Survival of CD19.CAR-ATLs|Frequency of the two distinct T cell products post infusion|Number of patients with tumor response|Percentage of circulating modified T cells after additional doses|Function of CD19.CAR-ATLs","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 1","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-31970 SAGAN|SAGAN","February 2014","December 2018","February 2033","May 15, 2013","null","January 23, 2018","Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01853631"
942,"NCT01775631","Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma",,"Completed","No Results Available","B-Cell Malignancies","Biological: Urelumab|Biological: Rituximab","Safety and tolerability of Urelumab in combination with Rituximab as measured by incidence of adverse events (AEs), serious AEs, death, vital sign changes, electrocardiograms (ECGs), physical examination results, and laboratory test abnormalities|Efficacy-Antitumor Activity of Urelumab in combination with Rituximab as measured by best overall response, progression-free survival, time to response, and duration of response|Maximum observed serum concentration (Cmax) of Urelumab and Rituximab|Time of maximum observed serum concentration (Tmax) of Urelumab|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Urelumab|Trough observed serum concentration (Cmin) of Urelumab and Rituximab|Area under the concentration-time curve (AUC) in one dosing interval (AUC(TAU)) of Urelumab|Immunogenicity of Urelumab in combination with Rituximab as determined by blood sample measurements of anti-drug antibodies (ADA)","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA186-017","March 2013","August 2016","August 2016","January 25, 2013","null","March 31, 2017","Ucla Department Of Medicine, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Providence Cancer Center Oncology And Hematology Care- Eastside, Portland, Oregon, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|University Of Virginia School Of Medicine, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01775631"
943,"NCT00005592","Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: 90-Y-ibritumomab tiuxetan|Biological: rituximab|Radiation: indium In 111 ibritumomab tiuxetan","To provide treatment to those patients with low-grade follicular or transformed B-cell non-Hodgkin's lymphoma who are not eligible for other IDEC-Y2B8 protocols.|To add to the overall efficacy and safety experience in this indication.","University of Alabama at Birmingham|National Cancer Institute (NCI)|Biogen","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000067697|UAB-9930|IDEC-106-98","November 1999","March 2002","November 2005","December 16, 2003","null","October 21, 2015","University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Lombardi Cancer Center, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00005592"
944,"NCT00058292","Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: Carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: yttrium Y 90 ibritumomab tiuxetan","Determine the maximum tolerated dose of absorbed radiation to critical organs delivered with this combination of study treatments","Northwestern University|National Cancer Institute (NCI)","All","17 Years and older   (Child, Adult, Older Adult)","Phase 1","44","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 99H11|NU-99H11|IDEC-NU99H11","April 2000","June 2006","March 2009","April 9, 2003","null","June 1, 2012","Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00058292"
945,"NCT00496873","Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan",,"Completed","Has Results","Lymphoma","Drug: Cytoxan|Drug: Nipent|Drug: Rituxan","Participant Response Rate According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999|Number of Participants With Complete Response (CR)/Complete Response Unconfirmed (CRu) With Low-grade Lymphoma (N=83) After 6-9 Cycles of PCR Therapy|3-Year Progression-Free Survival","M.D. Anderson Cancer Center|Astex Pharmaceuticals|Pharmatech","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0818|NCI-2010-00635","June 2005","December 2014","December 2014","July 4, 2007","August 23, 2016","August 23, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00496873"
946,"NCT00040950","Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: agatolimod sodium","","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069423|UCLA-0112032|CPGI-C004-CPG7909|NCI-G02-2086","March 2002","null","October 2007","January 27, 2003","null","December 19, 2013","Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00040950"
947,"NCT03309878","Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas",,"Not yet recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma","Other: Laboratory Biomarker Analysis|Biological: Mogamulizumab|Biological: Pembrolizumab","Maximum tolerated dose (MTD) of mogamulizumab in combination with pembrolizumab (Phase I)|Progression-free survival (PFS) (Phase II)|Overall response rate (ORR)|Complete response (CR) rate|Partial response (PR) rate|Duration of response","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","76","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2017-01865|10106|UM1CA186691","June 29, 2018","February 1, 2022","February 1, 2022","October 16, 2017","null","May 31, 2018","","","https://ClinicalTrials.gov/show/NCT03309878"
948,"NCT00389051","A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: bendamustine hydrochloride","Hematological toxicity; > grade four (CTCAE v.3.0), during the treatment cycle (twenty one days)|Non-Hematological toxicity; > grade three(CTCAE v.3.0), during the treatment cycle (twenty one days)|All adverse events or adverse reactions, during the treatment cycle (twenty one days)|Pharmacokinetics profile","SymBio Pharmaceuticals","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006001","October 2006","null","September 2007","October 17, 2006","null","August 21, 2007","Kanagawa, Japan|Kyoto, Japan|Nagoya, Japan|Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT00389051"
949,"NCT00049036","Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",,"Completed","Has Results","AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma","Biological: rituximab|Drug: etoposide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: cyclophosphamide|Other: laboratory biomarker analysis","Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","106","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02926|ECOG-AMC34|CDR0000257660|AMC-034|U01CA070019","March 2003","May 2009","May 2009","January 27, 2003","June 22, 2011","May 14, 2014","AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00049036"
950,"NCT00726700","Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Side effects|Adherence to therapy regimens|Antitumor effectivity","German High-Grade Non-Hodgkin's Lymphoma Study Group|National Cancer Institute (NCI)","All","61 Years to 80 Years   (Adult, Older Adult)","Phase 2","109","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","DSHNHL-2003-2|CDR0000454473|EU-20534","May 2004","null","February 2012","August 1, 2008","null","August 2, 2013","","","https://ClinicalTrials.gov/show/NCT00726700"
951,"NCT00006241","Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: chemotherapy|Procedure: in vitro-treated peripheral blood stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1488.00|FHCRC-1488.00|ELIGIX-C99-105|NCI-G00-1846|CDR0000068166","March 2000","null","October 2000","June 22, 2004","null","November 30, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00006241"
952,"NCT00274924","Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","Has Results","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: prednisone|Drug: vincristine","2-year Progression-Free Survival (PFS)|5-year Overall Survival","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","100","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000455012|U10CA021115|E3404","April 2006","June 2013","March 2019","January 11, 2006","February 24, 2014","November 21, 2017","Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Evanston Northwestern Healthcare - Evanston Hospital, Evanston, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States|Hopedale Medical Complex, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|St. Margaret's Hospital, Spring Valley, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Bettendorf, Iowa, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|NYU Cancer Institute at New York University Medical Center, New York, New York, United States|Aultman Cancer Center at Aultman Hospital, Canton, Ohio, United States|Christ Hospital Cancer Center, Cincinnati, Ohio, United States|MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Cancer Center of Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|CCOP - Main Line Health, Wynnewood, Pennsylvania, United States|Lankenau Cancer Center at Lankenau Hospital, Wynnewood, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Center for Cancer Treatment & Prevention at Sacred Heart Hospital, Eau Claire, Wisconsin, United States|Marshfield Clinic Cancer Care at Regional Cancer Center, Eau Claire, Wisconsin, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States|Dean Medical Center - Madison, Madison, Wisconsin, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Saint Joseph's Hospital, Marshfield, Wisconsin, United States|Froedtert Hospital and Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States|Marshfield Clinic - Lakeland Center, Minocqua, Wisconsin, United States|Ministry Medical Group at Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Marshfield Clinic - Indianhead Center, Rice Lake, Wisconsin, United States|Saint Michael's Hospital Cancer Center, Stevens Point, Wisconsin, United States|Marshfield Clinic - Wausau Center, Wausau, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00274924"
953,"NCT00026351","Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Leukemia|Lymphoma","Biological: rituximab|Drug: pentostatin","","Pharmatech Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","null","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000069021|PHARMATECH-N007|PHARMATECH-20001631|SUPERGEN-PHARMATECH-N007","December 2000","null","June 2003","June 25, 2003","null","February 4, 2013","Cancer and Blood Institute of the Desert, Rancho Mirage, California, United States|Redding Medical Center, Redding, California, United States|Oncology-Hematology Associates, P.A., Clinton, Maryland, United States|North Shore Hematology/Oncology Associates, P.C., East Setauket, New York, United States|Hematology Oncology Associates of Central New York, P.C., Syracuse, New York, United States","","https://ClinicalTrials.gov/show/NCT00026351"
954,"NCT00014664","Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Lymphoma","Biological: apolizumab","","PDL BioPharma, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","null","Industry","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068585|PDL-1D10-901|CUMC-0101-552","October 2000","null","null","June 10, 2003","null","December 18, 2013","Protein Design Labs, Inc., Freemont, California, United States","","https://ClinicalTrials.gov/show/NCT00014664"
955,"NCT01541072","Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation","PALM2","Terminated","No Results Available","Non Hodgkin Lymphoma","Drug: Pegfilgrastim|Drug: Filgrastim","3 months kinetics of lymphocyte reconstitution, in the two arms|6 months kinetics of lymphocyte reconstitution, in the two arms|6 months kinetics of lymphocyte subsets reconstitution by phenotyping, in the 2 arms|Average duration of neutropenia and thrombopenia, in the 2 arms|Number of days with temperature ≥38°, in the 2 arms|Number of bacterial and/or viral and/or fungal infection longer than 7 days, average duration of anti-viral, anti-fungal and antibiotic treatments, in the 2 arms|Number of red blood cell units and platelets concentrates transfused to patient, in the 2 arms|Evaluation of duration of Filgrastim treatment, in arm ""Filgrastim""|Overall survival|Progression free survival|Average duration of febrile neutropenia (with neutrophils<0.5 G/L and temperature ≥38°), in the 2 arms","Centre Leon Berard|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET2011-010|2011-A00662-39","February 2012","June 2014","September 2014","February 29, 2012","null","November 1, 2016","CHU Clermont-Ferrand, Hôpital d'Estaing, Clermont-Ferrand, France|Centre Leon Berard, Lyon, France","","https://ClinicalTrials.gov/show/NCT01541072"
956,"NCT01205737","A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects",,"Completed","No Results Available","DLBCL","Biological: TL011|Biological: Rituximab","AUC during a dosing interval for Rituximab|PK and PD parameters","Teva Pharmaceutical Industries","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","186","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NHL-TL011-102","September 2010","July 2013","September 2013","September 20, 2010","null","October 22, 2013","Teva Investigational Site 59005, Pleven, Bulgaria|Teva Investigational Site 59003, Plovdiv, Bulgaria|Teva Investigational Site 59001, Sofia, Bulgaria|Teva Investigational Site 59002, Sofia, Bulgaria|Teva Investigational Site 59004, Varna, Bulgaria|Teva Investigational Site 55001, Tallinn, Estonia|Teva Investigational Site 55002, Tartu, Estonia|Teva Investigational Site 35066, Paris Cedex 13, France|Teva Investigational Site 51026, Debrecen, Hungary|Teva Investigational Site 30001, Firenze, Italy|Teva Investigational Site 30002, Napoli, Italy|Teva Investigational Site 56002, Daugavpils, Latvia|Teva Investigational Site 56001, Riga, Latvia|Teva Investigational Site 56003, Riga, Latvia|Teva Investigational Site 53010, Warsaw, Poland|Teva Investigational Site 50011, Arkhangelsk, Russian Federation|Teva Investigational Site 50001, Chelyabinsk, Russian Federation|Teva Investigational Site 50004, Ekaterinburg, Russian Federation|Teva Investigational Site 50006, Kazan, Russian Federation|Teva Investigational Site 50014, Kursk, Russian Federation|Teva Investigational Site 50005, Moscow, Russian Federation|Teva Investigational Site 50009, Moscow, Russian Federation|Teva Investigational Site 50010, Moscow, Russian Federation|Teva Investigational Site 50003, Novosibirsk, Russian Federation|Teva Investigational Site 50017, Pyatigorsk, Russian Federation|Teva Investigational Site 50012, St. Petersburg, Russian Federation|Teva Investigational Site 50015, Tomsk, Russian Federation|Teva Investigational Site 31005, Elche-Alicante, Spain|Teva Investigational Site 31006, Las Palmas de Gran Canaria, Spain|Teva Investigational Site 31002, Madrid, Spain|Teva Investigational Site 31001, Majadahonda-Madrid, Spain|Teva Investigational Site 31003, Valencia, Spain|Teva Investigational Site 31004, Valencia, Spain|Teva Investigational Site 58011, Cherkasy, Ukraine|Teva Investigational Site 58013, Dnipropetrovsk, Ukraine|Teva Investigational Site 58014, Donetsk, Ukraine|Teva Investigational Site 58017, Khmelnytskyi, Ukraine|Teva Investigational Site 58010, Kyiv, Ukraine|Teva Investigational Site 58012, Kyiv, Ukraine|Teva Investigational Site 58015, Kyiv, Ukraine|Teva Investigational Site 58016, Simferopol, Ukraine","","https://ClinicalTrials.gov/show/NCT01205737"
957,"NCT00026429","Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Leukemia|Lymphoma","Biological: denileukin diftitox","","Pharmatech Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000069029|PHARMATECH-LP-ONT-BL|LIGAND-PHARMATECH-LP-ONT-BL|PHARMATECH-20002024","January 2001","null","null","February 27, 2004","null","December 18, 2013","ION/Pharmatech Network, Pomona, California, United States|Cancer and Blood Institute of the Desert, Rancho Mirage, California, United States|Missouri Cancer Care, P.C., St. Charles, Missouri, United States|Nassau Hematology/Oncology PC, Lake Success, New York, United States|Coastal Cancer Center, Myrtle Beach, South Carolina, United States|Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00026429"
958,"NCT01804686","A Long-term Extension Study of PCI-32765 (Ibrutinib)",,"Enrolling by invitation","No Results Available","Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B-cell Lymphoma","Drug: PCI-32765 (Ibrutinib)","Number of participants affected by an adverse event|Number of participants with change in disease status","Janssen Research & Development, LLC|Pharmacyclics LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100955|2012-004225-24|PCI-32765CAN3001","September 9, 2013","December 29, 2021","December 29, 2026","March 5, 2013","null","September 24, 2018","City of Hope Cancer Center, Duarte, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|University of California Los Angeles, Los Angeles, California, United States|Sanford, Stanford, California, United States|Stanford University Medical Center, Stanford, California, United States|Norwalk Medical Group, Norwalk, Connecticut, United States|Northwestern University Hospital, Chicago, Illinois, United States|Indiana University, Goshen, Indiana, United States|Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky, United States|Dana Farber Cancer Center, Boston, Massachusetts, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Medical College of Cornell University, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|The Ohio State University- James Cancer Hospital, Columbus, Ohio, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center - University of Texas, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|University of Washington, Seattle, Washington, United States|University of Wisconsin Carbone Cancer Center - Wisconsin Institute for Medical Research, Madison, Wisconsin, United States|Fundaleu, Ciudad De Buenos Aires, Argentina|Royal Adelaide Hospital, Adelaide, Australia|John Fawkner Cancer Trial Centre, Coburg, Australia|Concord Hospital, Concord, Australia|Austin Health, Heidelberg, Australia|Peter MacCallum Cancer Institute, Melbourne, Australia|Royal Perth Hospital, Perth, Australia|Alfred Hospital, Prahran, Australia|UZA, Antwerp, Belgium|A.Z. Sint Jan, Brugge, Belgium|UCL - Saint Luc, Brussels, Belgium|UZ Gent - departement oncologie, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|UCL Mont-Godinne, Yvoir, Belgium|INCA - Instituto Nacional Do Cancer, Rio De Janeiro, Brazil|Instituto de Ensino E Pesquisa Sao Lucas, Sao Paulo, Brazil|Jewish General Hospital, Montreal, Quebec, Canada|Peking University People's Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peking University First Hospital, Beijing, China|West China Hospital Sichuan University, Chengdu, China|Fujian Medical University, Fuzhou, China|Sun Yat-sen University Cancer Hospital, Guangzhou, China|Zhejiang University First Hospital, Hangzhou, China|Jiangsu Province Hospital, Nanjing, China|Ruijin Hospital, Shanghai, China|Tangdu hospital the Fourth Military Medical, Shanxi, China|The First Affliated Hospital of Soochow University, Suzhou, Jaiangsu, China|The Institute of Hematological disease, Tianjin, China|Wuhan Union Hospital, Wuhan, China|Xijing Hospital of the Fourth Military Medical University, Xi'An, China|Fundacion Santa Fe, Bogota, Colombia|Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Brno, Czechia|Fakultni nemocnice Kralovske Vinohrady - Interni hematologicka klinika, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Czechia|Hôpital E. Muller, Mulhouse, France|Hôpital Necker Enfants Malades, Paris Cedex 15, France|HOPITAL SAINT LOUIS - Hematology / Oncology, Paris, France|CH LYON SUD - Hematology, Pierre Benite, France|Vivantes Klinikum Spandau-Klinik f. Innere Medizin Hämatologie/Onkologie/Gastroenterologie - Germany, Berlin, Germany|Universitätsklinikum Carl Gustav Carus; Med. Klinik und Poliklinik I - Hämatologische Ambulanz, Hau, Dresden, Germany|Universitätsklinikum Essen; Klinik f. Hämatologie- Germany, Essen, Germany|Universitätsklinikum Heidelberg Med. Klinik IV, Heidelberg, Germany|Universitätsklinikum des Saarlanden - Klinik für innere Medizin I - Germany, Homburg, Germany|Gemeinschaftspraxis Dres. Uhle/Müller/Kröning/Jentsch-Ullrich - Germany, Magdeburg, Germany|Internistische Praxis Dr. med. Balser - Germany, Marburg, Germany|Universitätsklinikum für Innere Med. III_Hämatologie, Onkologie...- Germany, Ulm, Germany|Semmelweis Egyetem, I. Belgyogyaszati Klinika, Budapest N/A, Hungary|Szegedi Tudomanyegyetem II. Belgyogyaszati Klinika, Szeged, Hungary|St James's Hospital, Dublin, Ireland|Haemek Medical Center, Afula, Israel|Hillel Yaffe Medical Center - Oncology, Hadera, Israel|Rambam Health Care Campus, Haifa, Israel|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ""LA SAPIENZA"", Roma, Italy|A.O.Citta della Salute e della Scienza di Torino, Torino, Italy|National Cancer Center, Goyang-Si, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Oaxaca Site Management Organization S.C., Oaxaca, Mexico|VU medisch centrum - Afd.Interne - INT, Amsterdam, Netherlands|Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza, Brzozow, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzów, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Malopolskie Centrum Medyczne, Krakow, Poland|Oddzial Hematologii, Opole, Poland|Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka, Slupsk, Poland|Katedra i Klinika Hematologii , Nowotworów Krwi i Transplantacji Szpiku, Wroclaw, Poland|Instituto Portugues de Oncologia, Lisboa, Portugal|Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Russian Federation|Chelyabinsk Regiona Onc. Center, Chelyabinsk, Russian Federation|Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Russian Federation|Cancer Research Center, Moscow N/A, Russian Federation|S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation|Regional Clinical Hospital n.a.Semashko, Nizhni Novgorod, Russian Federation|Medical Scientific Radiology - Center, Obninsk, Russian Federation|Perm Medical Sanitary Unit#1, Perm, Russian Federation|Republican Hospital named by V.A.Baranova, Petrozavodsk, Russian Federation|Rostov Research Institute of Oncology, Rostov-Na-Donu, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|Leningrad region clinical hospital, Saint, Russian Federation|Samara Region Clinical Hospital, Samara, Russian Federation|Oncological dispensary #2, Sochi, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Clinical Research Institute of Hematology and Transfusiology, St.-Petersburg, Russian Federation|Federal Center of Heart, Blood and Endocrinology, St.-Petersburg, Russian Federation|Oncology Dispensary of Komi Republic, Syktyvkar, Russian Federation|Hospital Vall d´Hebrón, Barcelona N/A, Spain|Inst. Cat. Doncologia-H Duran I Reynals, L'Hospitalet De Llobregat, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain|Hosp. Univ. Infanta Leonor, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona N/A, Spain|Hospital Clinico Universitario Salamanca, Salamanca, Spain|Sahlgrenska University hospital, Hematology Dept, Göteborg, Sweden|Skånes universitetssjukhus, Lund, Sweden|Karolinska Universitetssjukhuset Solna, Centrum för Hematologi, Stockholm, Stockholm, Sweden|Changhua Cristian Hospital, Changhua County, Taiwan|Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Turkey|Cherkassy Regional Oncology Dispensary, Department of Hematology, Cherkassy, Ukraine|Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Ukraine|SI Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine, Kharkiv, Ukraine|Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitskiy, Ukraine|State Institution Scientific Center for Radiation Medicine Academy of Medical Sciences of Ukraine, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine of AMS of Ukraine, Lviv, Ukraine|Vinnytsya Regional Clinical Hospital named after M.I.Pirogov, Vinnitsa, Ukraine|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Beatson West Of Scotland Cancer Centre, Glasgow, United Kingdom|St James's Institute of Oncology, Leeds, United Kingdom|Leicester Royal Infirmary - Haematology, Leicester, United Kingdom|University College London Hospitals NHSFT, London, United Kingdom|King's College Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom","","https://ClinicalTrials.gov/show/NCT01804686"
959,"NCT02793583","Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","UNITY-NHL","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Mantle Cell Lymphoma","Drug: TGR-1202 + Ublituximab|Drug: TGR-1202|Drug: TGR-1202 + Ublituximab + Bendamustine","Overall Response Rate|Progression-Free Survival","TG Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UTX-TGR-205","June 2016","May 2019","July 2019","June 8, 2016","null","September 6, 2018","TG Therapeutics Investigational Trial Site, Birmingham, Alabama, United States|TG Therapeutics Investigational Trial Site, Huntsville, Alabama, United States|TG Therapeutics Investigational Trial Site, Chandler, Arizona, United States|TG Therapeutics Investigational Trial Site, Tucson, Arizona, United States|TG Therapeutics Investigational Trial Site, Tucson, Arizona, United States|TG Therapeutics Investigational Trial Site, Costa Mesa, California, United States|TG Therapeutics Investigational Trial Site, Los Angeles, California, United States|TG Therapeutics Investigational Trial Site, Orange, California, United States|TG Therapeutics Investigational Trial Site, San Diego, California, United States|TG Therapeutics Investigational Trial Site, Whittier, California, United States|TG Therapeutics Investigational Trial Site, Boulder, Colorado, United States|TG Therapeutics Investigational Trial Site, Denver, Colorado, United States|TG Therapeutics Investigational Trial Site, Fort Collins, Colorado, United States|TG Therapeutics Investigational Trial Site, Newark, Delaware, United States|TG Therapeutics Investigational Trial Site, Washington, District of Columbia, United States|TG Therapeutics Investigational Trial Site, Boca Raton, Florida, United States|TG Therapeutics Investigational Trial Site, Fort Myers, Florida, United States|TG Therapeutics Investigational Trial Site, Jacksonville, Florida, United States|TG Therapeutics Investigational Trial Site, Jacksonville, Florida, United States|TG Therapeutics Investigational Trial Site, Jacksonville, Florida, United States|TG Therapeutics Investigational Trial Site, Miami, Florida, United States|TG Therapeutics Investigational Trial Site, Saint Petersburg, Florida, United States|TG Therapeutics Investigational Trial Site, Tallahassee, Florida, United States|TG Therapeutics Investigational Trial Site, Tampa, Florida, United States|TG Therapeutics Investigational Trial Site, West Palm Beach, Florida, United States|TG Therapeutics Investigational Trial Site, Macon, Georgia, United States|TG Therapeutics Investigational Trial Site, Marietta, Georgia, United States|TG Therapeutics Investigational Trial Site, Chicago, Illinois, United States|TG Therapeutics Investigational Trial Site, Chicago, Illinois, United States|TG Therapeutics Investigational Trial Site, Decatur, Illinois, United States|TG Therapeutics Investigational Trial Site, Evanston, Illinois, United States|TG Therapeutics Investigational Trial Site, Harvey, Illinois, United States|TG Therapeutics Investigational Trial Site, Maywood, Illinois, United States|TG Therapeutics Investigational Trial Site, Niles, Illinois, United States|TG Therapeutics Investigational Trial Site, Peoria, Illinois, United States|TG Therapeutics Investigational Trial Site, Swansea, Illinois, United States|TG Therapeutics Investigational Trial Site, Fort Wayne, Indiana, United States|TG Therapeutics Investigational Trial Site, Indianapolis, Indiana, United States|TG Therapeutics Investigational Trial Site, Fairway, Kansas, United States|TG Therapeutics Investigational Trial Site, Kansas City, Kansas, United States|TG Therapeutics Investigational Trial Site, Louisville, Kentucky, United States|TG Therapeutics Investigational Trial Site, Covington, Louisiana, United States|TG Therapeutics Investigational Trial Site, Hammond, Louisiana, United States|TG Therapeutics Investigational Trial Site, Brewer, Maine, United States|TG Therapeutics Investigational Trial Site, Baltimore, Maryland, United States|TG Therapeutics Investigational Trial Site, Bethesda, Maryland, United States|TG Therapeutics Investigational Trial Site, Columbia, Maryland, United States|TG Therapeutics Investigational Trial Site, Towson, Maryland, United States|TG Therapeutics Investigational Trial Site, Ann Arbor, Michigan, United States|TG Therapeutics Investigational Trial Site, Duluth, Minnesota, United States|TG Therapeutics Investigational Trial Site, Saint Louis Park, Minnesota, United States|TG Therapeutics Investigational Trial Site, Columbia, Missouri, United States|TG Therapeutics Investigational Trial Site, Saint Louis, Missouri, United States|TG Therapeutics Investigational Trial Site, Billings, Montana, United States|TG Therapeutics Investigational Trial Site, Lincoln, Nebraska, United States|TG Therapeutics Investigational Trial Site, Omaha, Nebraska, United States|TG Therapeutics Investigational Trial Site, Lebanon, New Hampshire, United States|TG Therapeutics Investigational Trial Site, Hackensack, New Jersey, United States|TG Therapeutics Investigational Trial Site, Morristown, New Jersey, United States|TG Therapeutics Investigational Trial Site, Mount Holly, New Jersey, United States|TG Therapeutics Investigational Trial Site, Farmington, New Mexico, United States|TG Therapeutics Investigational Trial Site, Bronx, New York, United States|TG Therapeutics Investigational Trial Site, Buffalo, New York, United States|TG Therapeutics Investigational Trial Site, New York, New York, United States|TG Therapeutics Investigational Trial Site, Syracuse, New York, United States|TG Therapeutics Investigational Trial Site, Cary, North Carolina, United States|TG Therapeutics Investigational Trial Site, Charlotte, North Carolina, United States|TG Therapeutics Investigational Trial Site, Durham, North Carolina, United States|TG Therapeutics Investigational Trial Site, Hickory, North Carolina, United States|TG Therapeutics Investigational Trial Site, Kinston, North Carolina, United States|TG Therapeutics Investigational Trial Site, Raleigh, North Carolina, United States|TG Therapeutics Investigational Trial Site, Raleigh, North Carolina, United States|TG Therapeutics Investigational Trial Site, Washington, North Carolina, United States|TG Therapeutics Investigational Trial Site, Canton, Ohio, United States|TG Therapeutics Investigational Trial Site, Cincinnati, Ohio, United States|TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States|TG Therapeutics Investigational Trial Site, Columbus, Ohio, United States|TG Therapeutics Investigational Trial Site, Elyria, Ohio, United States|TG Therapeutics Investigational Trial Site, Mentor, Ohio, United States|TG Therapeutics Investigational Trial Site, Middleburg Heights, Ohio, United States|TG Therapeutics Investigational Trial Site, Sandusky, Ohio, United States|TG Therapeutics Investigational Trial Site, Toledo, Ohio, United States|TG Therapeutics Investigational Trial Site, Portland, Oregon, United States|TG Therapeutics Investigational Trial Site, Portland, Oregon, United States|TG Therapeutics Investigational Trial Site, Springfield, Oregon, United States|TG Therapeutics Investigational Trial Site, Camp Hill, Pennsylvania, United States|TG Therapeutics Investigational Trial Site, Providence, Rhode Island, United States|TG Therapeutics Investigational Trial Site, Greenville, South Carolina, United States|TG Therapeutics Investigational Trial Site, Sioux Falls, South Dakota, United States|TG Therapeutics Investigational Trial Site, Watertown, South Dakota, United States|TG Therapeutics Investigational Trial Site, Chattanooga, Tennessee, United States|TG Therapeutics Investigational Trial Site, Kingsport, Tennessee, United States|TG Therapeutics Investigational Trial Site, Knoxville, Tennessee, United States|TG Therapeutics Investigational Trial Site, Memphis, Tennessee, United States|TG Therapeutics Investigational Trial Site, Austin, Texas, United States|TG Therapeutics Investigational Trial Site, Dallas, Texas, United States|TG Therapeutics Investigational Trial Site, Houston, Texas, United States|TG Therapeutics Investigational Trial Site, New Braunfels, Texas, United States|TG Therapeutics Investigational Trial Site, San Antonio, Texas, United States|TG Therapeutics Investigational Trial Site, Tyler, Texas, United States|TG Therapeutics Investigational Trial Site, Ogden, Utah, United States|TG Therapeutics Investigational Trial Site, Newport News, Virginia, United States|TG Therapeutics Investigational Trial Site, Roanoke, Virginia, United States|TG Therapeutics Investigational Trial Site, Edmonds, Washington, United States|TG Therapeutics Investigational Trial Site, Seattle, Washington, United States|TG Therapeutics Investigational Trial Site, Seattle, Washington, United States|TG Therapeutics Investigational Trial Site, Seattle, Washington, United States|TG Therapeutics Investigational Trial Site, Spokane, Washington, United States|TG Therapeutics Investigational Trial Site, Vancouver, Washington, United States|TG Therapeutics Investigational Trial Site, Green Bay, Wisconsin, United States|TG Therapeutics Investigational Trial Site, Madison, Wisconsin, United States|TG Therapeutics Investigational Trial Site, Wauwatosa, Wisconsin, United States|TG Therapeutics Investigational Trial Site, Benowa, Australia|TG Therapeutics Investigational Trial Site, Nedlands, Australia|TG Therapeutics Investigational Trial Site, Ashkelon, Israel|TG Therapeutics Investigational Trial Site, Haifa, Israel|TG Therapeutics Investigational Trial Site, Jerusalem, Israel|TG Therapeutics Investigational Trial Site, Nahariya, Israel|TG Therapeutics Investigational Trial Site, Tel Aviv, Israel|TG Therapeutics Investigational Trial Site, Bologna, Italy|TG Therapeutics Investigational Trial Site, Cona, Italy|TG Therapeutics Investigational Trial Site, Milan, Italy|TG Therapeutics Investigational Trial Site, Torino, Italy|TG Therapeutics Investigational Trial Site, Busan, Korea, Republic of|TG Therapeutics Investigational Trial Site, Incheon, Korea, Republic of|TG Therapeutics Investigational Trial Site, Seoul, Korea, Republic of|TG Therapeutics Investigational Trial Site, Chorzów, Poland|TG Therapeutics Investigational Trial Site, Gdynia, Poland|TG Therapeutics Investigational Trial Site, Kraków, Poland|TG Therapeutics Investigational Trial Site, Lublin, Poland|TG Therapeutics Investigational Trial Site, Słupsk, Poland|TG Therapeutics Investigational Trial Site, Warszawa, Poland|TG Therapeutics Investigational Trial Site, Wrocław, Poland|TG Therapeutics Investigational Trial Site, Łódź, Poland|TG Therapeutics Investigational Trial Site, Bratislava, Slovakia|TG Therapeutics Investigational Trial Site, Košice, Slovakia|TG Therapeutics Investigational Trial Site, Poprad, Slovakia|TG Therapeutics Investigational Trial Site, Barcelona, Spain|TG Therapeutics Investigational Trial Site, Madrid, Spain|TG Therapeutics Investigational Trial Site, Salamanca, Spain|TG Therapeutics Investigational Trial Site, Valencia, Spain|TG Therapeutics Investigational Trial Site, Cambridge, United Kingdom|TG Therapeutics Investigational Trial Site, Leeds, United Kingdom|TG Therapeutics Investigational Trial Site, Liverpool, United Kingdom|TG Therapeutics Investigational Trial Site, London, United Kingdom|TG Therapeutics Investigational Trial Site, Oxford, United Kingdom|TG Therapeutics Investigational Trial Site, Plymouth, United Kingdom","","https://ClinicalTrials.gov/show/NCT02793583"
960,"NCT01682044","Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma",,"Completed","Has Results","Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Other: flow cytometry|Procedure: biopsy|Other: immunohistochemistry staining method|Genetic: western blotting","Number of Participants With Adverse Events|Overall Response Rate|Percent Change in Functional and Phenotypic Characteristics of Host Neutrophils From Baseline|Percent Change in CD20 Antigen Expression and Density of Expression|Percent Change in Serum Levels of Tumor Necrosis Factor (TNF) From Baseline|Percent Change in Serum Levels of Interferon Alpha (INF) From Baseline|Percent Change in Serum Levels of Free Radical Levels (MFI) From Baseline","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Older Adult)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 83106|NCI-2011-00134","April 17, 2007","November 22, 2013","December 22, 2016","September 10, 2012","October 9, 2017","October 9, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT01682044/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01682044"
961,"NCT02580552","Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL",,"Recruiting","No Results Available","Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides (MF)|Chronic Lymphocytic Leukemia (CLL)|Diffuse Large B-Cell Lymphoma (DLBCL)|Adult T-Cell Leukemia/Lymphoma (ATLL)","Drug: MRG-106","Safety and tolerability of MRG-106 based on vital signs, physical examination, clinical laboratory tests, ECG, and incidence and severity of adverse events|Area under the plasma concentration vs. time curve (AUC) of MRG-106 following single and repeat doses administered intratumorally, subcutaneously or intravenously|Peak plasma concentration (Cmax) of MRG-106 following single and repeat doses administered intratumorally, subcutaneously or intravenously|Trough plasma concentration (Ctrough) of MRG-106 following each 4-week cycle of dosing|Skin disease severity (index lesions) - MF only|Skin disease severity (whole body) - MF only|Overall Response Rate - MF|Overall Response Rate - CLL|Minimal Residual Disease (MRD) - CLL only|Overall Response Rate - DLBCL|Overall Response Rate - ATLL|Duration of Response|Time to Progression|Progression Free Survival (PFS)|Overall Survival (OS)","miRagen Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRG106-11-101","February 2016","December 2018","December 2018","October 20, 2015","null","August 10, 2018","City of Hope, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|UCLA Department of Medicine, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center at University of California, Irvine, Orange, California, United States|Stanford University Hospital and Clinics, Stanford, California, United States|University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Northwestern University; Department of Dermatology, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Inova Melanoma and Skin Cancer Center / Inova Schar Cancer Institute, Fairfax, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02580552"
962,"NCT03448393","CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies",,"Recruiting","No Results Available","Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|Lymphoma, Non-Hodgkin","Biological: CD19/CD22 CAR T-Cells|Drug: Fludarabine|Drug: Cyclophosphamide","Safety|Feasability|Overall survival|Progression-free survival","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","3 Years to 30 Years   (Child, Adult)","Phase 1","87","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180059|18-C-0059","March 26, 2018","December 1, 2021","December 1, 2032","February 28, 2018","null","September 3, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03448393"
963,"NCT01722305","Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma",,"Active, not recruiting","No Results Available","B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Central Nervous System Lymphoma|Intraocular Lymphoma|Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System|Recurrent Adult Diffuse Large Cell Lymphoma|Retinal Lymphoma","Drug: Dexamethasone|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Pomalidomide","MTD of pomalidomide when given in combination with dexamethasone determined by dose-limiting toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Incidence of adverse events, graded according to CTCAE 4.0|Overall response rate defined as number of patients with an objective status of complete response (CR), complete response/unconfirmed (Cru), or partial response (PR) divided by total number of evaluable patients|Overall survival time|Progression-free survival","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","29","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1281|NCI-2012-01948|P30CA015083","April 8, 2013","June 3, 2016","June 2019","November 6, 2012","null","September 19, 2018","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01722305"
964,"NCT02348216","A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)","ZUMA-1","Recruiting","No Results Available","Refractory Diffuse Large B Cell Lymphoma|Refractory Primary Mediastinal B Cell Lymphoma|Refractory Transformed Follicular Lymphoma|Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma|Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma|Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma|Relapsed/Refractory Large B Cell Lymphoma Including DLBCL, PMBCL, TFL and HGBCL After Two Systemic Lines of Therapy"" in Phase 2 Expanded Cohorts","Biological: axicabtagene ciloleucel","Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT)|Phase 2: Overall Response Rate|Phase 2 Expanded Cohorts: Safety|Duration of Response|Progression Free Survival|Overall Survival|Safety|Phase 2 Expanded Cohorts","Kite, A Gilead Company","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KTE-C19-101","January 2015","August 2018","March 2032","January 28, 2015","null","July 24, 2018","Banner MD Anderson, Gilbert, Arizona, United States|City of Hope, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Sarah Cannon, Denver, Colorado, United States|University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center, Miami, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Loyola University, Maywood, Illinois, United States|Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Methodist Hospital, San Antonio, Texas, United States|Vancouver General Hospital, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre Hospitalier Universitaire (CHU), Bordeaux, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Universitaire De Rennes, Rennes, France|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Essen University Hospital, Essen, Germany|University Wuerzburg, Würzburg, Germany|Sourasky Medical Center, Tel Aviv, Israel|Academisch Medisch Centrum, Amsterdam, Netherlands|Erasmus Medical Center, CE Rotterdam, Netherlands|University Medical Center Groningen, GZ Groningen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands","","https://ClinicalTrials.gov/show/NCT02348216"
965,"NCT02342665","Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL",,"Active, not recruiting","No Results Available","Lymphoma Non-Hodgkin","Drug: Copanlisib (BAY80-6946)","Number of participants with Adverse Events|Intensity of AE|Objective Tumor Response (OR)|Recommended dose determined in the dose escalation/safety evaluation","Bayer","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17792","April 21, 2015","October 31, 2018","October 31, 2021","January 21, 2015","null","September 24, 2018","Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Maebashi, Gunma, Japan|Kobe, Hyogo, Japan|Sendai, Miyagi, Japan|Chuo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Kyoto, Japan","","https://ClinicalTrials.gov/show/NCT02342665"
966,"NCT01939327","Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma","R2","Recruiting","No Results Available","Non-Hodgkin Lymphoma","Drug: Lenalidomide/Rituximab","Response Rate|Progression|safety","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2/IPC-2012-004","September 2013","September 2016","September 2020","September 11, 2013","null","October 26, 2017","Institut Paoli-Calmettes, Marseille, France","","https://ClinicalTrials.gov/show/NCT01939327"
967,"NCT01281917","Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma",,"Completed","Has Results","Non-Hodgkins Lymphoma","Drug: Velcade|Drug: Temsirolimus","Overall Response Rate|Progression Free Survival|Safety of This Regimen|Complete Response Rate|Tolerability of the Regimen|Duration of Response|Overall Survival","University of Wisconsin, Madison|Millennium Pharmaceuticals, Inc.|Pfizer|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HO10407|H-2010-0393","February 2011","October 2013","June 2014","January 24, 2011","August 21, 2017","August 21, 2017","Rapid City Regional Hospital John T. Vucurevich Cancer Care Institute, Rapid City, South Dakota, United States|Aurora Baycare Medical Center-GreenBay, Green Bay, Wisconsin, United States|St Vincent Regional Cancer Center CCOP, Green Bay, Wisconsin, United States|Bellin Memorial Hospital, Inc, Green Bay, Wisconsin, United States|Gunderson Lutheran Health System, La Crosse, Wisconsin, United States|UW Health Oncology- 1 S Park, Madison, Wisconsin, United States|University Of Wisconsin Cancer Center, Madison, Wisconsin, United States|Aurora BayCare Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Columbia St Mary's, Inc, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sheboygan Memorial Medical Center, Sheboygan, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Aurora Medical Center in Two Rivers, Two Rivers, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Aspirus Wausau Hospital, Wausau, Wisconsin, United States|Aurora Health Care Metro, Inc., Wauwatosa, Wisconsin, United States|UW Cancer Center-Riverview, Wisconsin Rapids, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01281917"
968,"NCT00994643","Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma",,"Completed","Has Results","High Risk Non-Hodgkin's Lymphoma","Biological: Rituximab|Biological: Interleukin-2","Assess the Efficacy of Combination Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08S.461|2008-40","February 5, 2009","June 25, 2014","June 25, 2015","October 14, 2009","October 6, 2017","May 4, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00994643"
969,"NCT00077961","Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL",,"Terminated","No Results Available","Non-Hodgkin's Lymphoma","Drug: CAMPATH (alemtuzumab)","","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","49","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAM.NHL233","December 2003","February 2006","null","February 18, 2004","null","March 26, 2015","Colorado Springs, Colorado, United States|Ocala, Florida, United States|Park Ridge, Illinois, United States|Lafayette, Louisiana, United States|New Orleans, Louisiana, United States|Columbia, Missouri, United States|Manhasset, New York, United States|Cary, North Carolina, United States|Canton, Ohio, United States|Greenville, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT00077961"
970,"NCT01729104","Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Rituximab","Maximum Tolerated Dose (MTD) of Carfilzomib and Lenalidomide in Combination With Rituximab|Objective Response Rate (ORR)","M.D. Anderson Cancer Center|Celgene|Onyx Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0188|NCI-2013-00117","April 25, 2013","April 2019","April 2019","November 20, 2012","null","September 14, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01729104"
971,"NCT00709033","T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL","ATECRAB","Active, not recruiting","No Results Available","Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia","Biological: autologous or syngeneic PBTLs and EBV-CTLs","Number of patients with dose limiting toxicity|Survival and function of CD19CAR PBTLs and EBV-CTLs|Number of patients with tumor response","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System","All","Child, Adult, Older Adult","Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22899-ATECRAB|ATECRAB","July 2009","May 2012","April 2027","July 3, 2008","null","August 25, 2017","Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00709033"
972,"NCT01962636","Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases",,"Recruiting","No Results Available","Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL)|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelofibrosis|Myelodysplasia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Lymphoblastic Lymphoma|Burkitt's Lymphoma|Non-Hodgkin Lymphoma|Multiple Myeloma","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Drug: Cyclosporine A|Drug: Mycophenylate mofetil|Biological: Umbilical cord blood","Survival at 1 year post-transplant|Incidence of neutrophil engraftment at day 42.|Platelet engraftment at 1 year.|Pattern of chimerism after transplant.|Incidence of graft failure.|Incidence of acute graft versus host disease at 100 days.|Incidence of chronic graft versus host disease at 1 year.|Incidence of transplant related mortality at 6 months.|Incidence of disease free survival|Incidence of overall survival.","Masonic Cancer Center, University of Minnesota","All","up to 55 Years   (Child, Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013OC013","December 2016","October 2023","October 2023","October 14, 2013","null","September 25, 2018","University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01962636"
973,"NCT00055640","Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Genetic: microarray analysis","Molecular risk assessment to see how well it works in predicting response to therapy in patients who are receiving treatment for non-Hodgkin's lymphoma.","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CWRU1402|P30CA043703|CWRU-060244|CWRU-1402","October 2002","April 2005","March 2006","March 7, 2003","null","June 10, 2010","Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00055640"
974,"NCT02747043","Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab","JASMINE","Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: ABP 798|Drug: Rituximab","Risk difference (RD) of objective response rate (ORR)|Risk difference (RD) of overall response rate (ORR)|Risk difference of ORR|Percent of subjects with complete depletion of CD19 cell count and total Immunoglobin G (IgG) and IgM antibody levels|Subject incidence of treatment-emergent AEs and serious adverse events|Incidence of anti-drug antibodies|On study progression-free survival|On study overall survival|Geometric mean ratio (GMR) of test (ABP 798)-to-reference (rituximab)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20130109","May 25, 2016","April 16, 2019","April 16, 2019","April 21, 2016","null","September 14, 2018","Research Site, Encinitas, California, United States|Research Site, Vallejo, California, United States|Research Site, Mount Sterling, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Billings, Montana, United States|Research Site, Zanesville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Roanoke, Virginia, United States|Research Site, Gosford, New South Wales, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Sofia, Sofiya, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Windsor, Ontario, Canada|Research Site, Medellin, Antioquia, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Praha 5, Praha, Czechia|Research Site, Ostrava - Poruba, Severomoravsky KRAJ, Czechia|Research Site, Bordeaux Cedex, Aquitaine, France|Research Site, Clermont Ferrand, Auvergne, France|Research Site, Brest Cedex, Bretagne, France|Research Site, Cesson-Sevigne, Bretagne, France|Research Site, Corbeil Essonnes, Ile-de-france, France|Research Site, Boulogne sur Mer, NORD Pas-de-calais, France|Research Site, La Rochelle, Poitou-charentes, France|Research Site, Poitiers Cedex, Poitou-charentes, France|Research Site, Batumi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Freiburg, Baden-wuerttemberg, Germany|Research Site, Aschaffenburg, Bayern, Germany|Research Site, Augsburg, Bayern, Germany|Research Site, Würzburg, Bayern, Germany|Research Site, Kassel, Hessen, Germany|Research Site, Rostock, Mecklenburg-vorpommern, Germany|Research Site, Essen, Nordrhein-westfalen, Germany|Research Site, Münster, Nordrhein-westfalen, Germany|Research Site, Leipzig, Sachsen, Germany|Research Site, Flensburg, Schleswig-holstein, Germany|Research Site, Athens, Attica, Greece|Research Site, Athens, Attica, Greece|Research Site, Athens, Attica, Greece|Research Site, Ioannina, Epirus, Greece|Research Site, Patra, Peloponnese, Greece|Research Site, Vijayawada, Andhra Pradesh, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Surat, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Bikaner, Rajasthan, India|Research Site, Madurai, Tamil NADU, India|Research Site, Be'er Ya'akov, Rehoboth, Israel|Research Site, Haifa, Israel|Research Site, Nahariya, Israel|Research Site, San Fermo della Battaglia, Como, Italy|Research Site, San Giovanni Rotondo, Foggia, Italy|Research Site, Bergamo, Lombardia, Italy|Research Site, Pesaro, Pesaro E Urbino, Italy|Research Site, Aviano, Pordenone, Italy|Research Site, Candiolo, Torino, Italy|Research Site, Brescia, Italy|Research Site, Lecce, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Piacenza, Italy|Research Site, Potenza, Italy|Research Site, Ravenna, Italy|Research Site, Rimini, Italy|Research Site, Terni, Italy|Research Site, Verona, Italy|Research Site, Vimercate, Italy|Research Site, Chiba-city, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Maebashi-city, Gunma, Japan|Research Site, Kobe-city, Hyogo, Japan|Research Site, Tsu, MIE, Japan|Research Site, Utsunomiya City, Tochigi, Japan|Research Site, Tachikawa-city, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Seoul, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Gyeongsangnam-do, Korea, Republic of|Research Site, Jinju-si, Gyeongsangnam-do, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Monterrey, Nuevo LEON, Mexico|Research Site, Monterrey, Nuevo LEON, Mexico|Research Site, Boca del Rio, Veracruz, Mexico|Research Site, Chihuahua, Mexico|Research Site, Veracruz, Mexico|Research Site, Legnica, Dolnoslaskie, Poland|Research Site, Toruń, Kujawsko-pomorskie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Gdańsk, Pomorskie, Poland|Research Site, Targu-Mures, Mures, Romania|Research Site, Targu-Mures, Mures, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Sabadell, Barcelona, Spain|Research Site, Córdoba, Cordoba, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, La Laguna Tenerife, Santa CRUZ DE Tenerife, Spain|Research Site, Caceres, Spain|Research Site, Cadiz, Spain|Research Site, Madrid, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Kyiv, Kiev, Ukraine|Research Site, Kyiv, Kiev, Ukraine|Research Site, Uzhgorod, Transcarpathia, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine","","https://ClinicalTrials.gov/show/NCT02747043"
975,"NCT01868035","Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP",,"Completed","Has Results","Lymphoma, Non-Hodgkin","Drug: tositumomab and iodine I-131 tositumomab","Number of Participants With the Indicated Grade 4 Hematology Toxicities Following Iodine-131 Anti-B1 Antibody|Number of Participants (Par.) With Confirmed (Con.) Complete Response (CR) Confirmed, Confirmed Complete Response Unconfirmed (CRu), Confirmed Partial Response (PR), Relapse Disease (RD), and Progressive Disease (PD)|Duration of Response and Duration of Confirmed Complete Response|Progression-free Survival (PFS)|Time to Treatment Failure (TTF)|Total Body Residence Time (TBRT)|Number of Participants With an Adverse Experience, Including Adverse Events (AEs) and Serious Adverse Events (SAEs)|Time to Recovery From the Indicated Hematology Toxicities|Nadir for the Indicated Hematology Toxicities|Time to Nadir for the Indicated Hematology Toxicities|Number of Participants Needing Supportive Care at Week 7 and Week 13|Number of Participants Converting to Human Anti-Murine (Mouse) Antibody (HAMA) Positivity at Any Follow-up Visit From HAMA Negativity at Baseline|Overall Survival","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","393229/007","May 2000","October 2012","October 2012","June 4, 2013","September 12, 2013","January 9, 2017","","","https://ClinicalTrials.gov/show/NCT01868035"
976,"NCT03154775","Study of Safety and Efficacy of C-CAR011 in B-NHL Patients",,"Recruiting","No Results Available","Refractory or Relapsed Non-Hodgkin Lymphoma","Biological: C-CAR011","Safety(Incidence of adverse events)|Objective response rate (ORR)|Duration of remission(DOR)|Progression free survival(PFS)|Overall survival(OS)","Cellular Biomedicine Group Ltd.|Shanghai Tongji Hospital, Tongji University School of Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","15","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBMG-C2017003","May 3, 2017","April 30, 2018","December 31, 2018","May 16, 2017","null","May 16, 2017","Department of Hematology,Shanghai Tongji Hospital, Tongji University School of Medicin, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03154775"
977,"NCT03501576","Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Biological: Inactivated Influenza Vaccine","Percentage of subjects achieving seroprotection defined as the percentage of subjects with a post-vaccination hemagglutination inhibition (HI) titer > 1:40|Percentage of subjects achieving seroconversion|Measurement of influenza-specific serum antibody levels after influenza vaccination|Measurement of influenza-specific plasmablasts (PBs) after influenza vaccination|Measurement of influenza-specific memory B-cells (MBCs) after influenza vaccination|Maximum fold rise in antibody titer","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00101067|NCI-2017-02313|Winship4236-17","April 6, 2018","April 30, 2021","April 30, 2021","April 18, 2018","null","April 18, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03501576"
978,"NCT02594384","A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL)","LAM-002A/NHL","Recruiting","No Results Available","Lymphoma, Non-Hodgkin; Leukemai, Chronic Lymphocytic","Drug: LAM-002A|Drug: Rituximab|Drug: Atezolizumab","Determination of the MTD of oral LAM-002A|Peak Plasma Concentration (Cmax) of LAM-002A|Area under the plasma concentration versus time curve (AUC) of LAM-002A|Type and frequency of adverse events and serious adverse events as assessed by CTCAE v4.0|Anti-tumor response as assessed by investigator according to modified Hallek or Lugano Response Criteria","Lam Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAM-002A-NHL-CLN01","October 2015","May 2019","December 2019","November 3, 2015","null","June 8, 2018","Clearview Cancer Institute, Huntsville, Alabama, United States|Mayo Clinic, Jacksonville, Florida, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|New York University School of Medicine, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02594384"
979,"NCT00024115","BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Withdrawn","No Results Available","Leukemia|Lymphoma","Drug: BL22 immunotoxin|Procedure: antibody therapy|Procedure: biological response modifier therapy|Procedure: immunotoxin therapy","","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","NIH","Interventional","Primary Purpose: Treatment","CDR0000068892|NCI-01-C-0213|NCI-5336","null","null","null","January 27, 2003","null","April 28, 2015","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00024115"
980,"NCT00546377","Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer",,"Completed","Has Results","Leukemia|Lymphoma","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Biological: sargramostim|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Drug: pentostatin|Genetic: fluorescence in situ hybridization|Genetic: gene rearrangement analysis|Genetic: polymerase chain reaction|Genetic: protein expression analysis|Other: flow cytometry|Procedure: biopsy","Overall Response|Maximum Tolerated Dose (MTD) of Mitoxantrone","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-077|MSKCC-05077","July 2005","May 2014","May 2014","October 18, 2007","May 12, 2016","May 12, 2016","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00546377"
981,"NCT02500407","A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",,"Recruiting","No Results Available","Lymphocytic Leukemia, Chronic|Lymphoma, Non Hodgkin","Drug: BTCT4465A (Mosunetuzumab) IV|Drug: Atezolizumab|Drug: BTCT4465A (Mosunetuzumab) SC","Maximum Tolerated Dose (MTD) of BTCT4465A (Mosunetuzumab)|Percentage of Participants With Adverse Events|BTCT4465A (Mosunetuzumab) Serum Concentration|Atezolizumab Serum Concentration|Percentage of Participants with Complete Response as Assessed Using Standard Criteria for NHL|Duration of Response as Assessed Using Standard Criteria for NHL|Progression-Free Survival (PFS) as Assessed Using Standard Criteria for NHL|Overall Survival|European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Scores to Assess Health-Related Quality of Life (HRQoL)|Objective Response Rate (ORR)","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","665","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO29781","September 30, 2015","October 31, 2020","October 31, 2020","July 16, 2015","null","September 11, 2018","City of Hope National Medical Center, Duarte, California, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan-Kettering Cancer Center, Commack, New York, United States|New York Uni Medical Center, New York, New York, United States|University of Pennsylvania; School of Medicine, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Wollongong Hospital; Cancer Care Centre, Wollongong, New South Wales, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Monash Health Clinical Trial Pharmacy department, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia|The Alfred, Melbourne, Victoria, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|The Perth Blood Institute, Nedlands, Western Australia, Australia|BC Cancer Agency Vancouver Centre - PARENT, Vancouver, British Columbia, Canada|Princess Margaret Hospital; Department of Med Oncology, Toronto, Ontario, Canada|Jewish General Hospital; Research Unit, Montréal, Quebec, Canada|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hosp Universitario Salamanca, Salamanca, Spain","","https://ClinicalTrials.gov/show/NCT02500407"
982,"NCT00003650","Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: mercaptopurine|Drug: methotrexate|Drug: methylprednisolone|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","","UNICANCER|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 3","200","Other","Interventional","Primary Purpose: Treatment","CDR0000066742|FNCLCC-SFOP-96006-LMT-96|EU-98049","June 1998","null","null","January 27, 2003","null","January 21, 2011","Centre Leon Berard, Lyon, France","","https://ClinicalTrials.gov/show/NCT00003650"
983,"NCT01897012","Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas",,"Active, not recruiting","No Results Available","MYC Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Drug: Alisertib|Other: Laboratory Biomarker Analysis|Drug: Romidepsin","Incidence of adverse events as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (utilized for adverse event reporting beginning April 1, 2018)|Maximum tolerated dose graded according to NCI CTCAE version 5.0|Overall response rate|Complete response","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2013-01272|TX035|2012-0602|9342|P30CA016672|U01CA062461|UM1CA186688","July 17, 2013","October 1, 2018","null","July 11, 2013","null","September 26, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01897012"
984,"NCT00481871","Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies",,"Completed","Has Results","Relapsed or Refractory Lymphoproliferative Malignancies|Hodgkin's Lymphoma|Peripheral T-cell Lymphoma|B-cell Lymphoma|Waldenstrom's Macroglobulinemia","Drug: Pralatrexate Injection|Drug: Gemcitabine Hydrochloride|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid","Objective Responses Assessed by International Workshop Criteria (IWC)|Duration of Response|Progression-free Survival (PFS) Time","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","119","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDX-009","May 2007","May 2011","August 2011","June 4, 2007","September 18, 2012","May 10, 2013","University of California at Los Angeles, Los Angeles, California, United States|Stanford University School of Medicine, Stanford, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|University of Chicago Hospital, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|New York University Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00481871"
985,"NCT00138164","Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: denileukin diftitox","Objective clinical response (complete or partial response)|Time to progression|Overall survival at 1 year|Safety","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","LIGAND-PIND-123|UCLA-0412087-01|CDR0000439451","December 2004","February 2006","November 2008","August 30, 2005","null","May 30, 2013","Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00138164"
986,"NCT03207256","Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials",,"Enrolling by invitation","No Results Available","Chronic Lymphocytic Leukemia|Non Hodgkin Lymphoma","Drug: TGR-1202|Drug: TGR-1202 + Ublituximab","Adverse Events of TGR-1202 and/or TGR-1202 + ublituximab treatment, including delayed toxicities|Progression-free survival of TGR-1202 and/or TGR-1202 + ublituximab treatment","TG Therapeutics, Inc.","All","Child, Adult, Older Adult","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UTX-TGR-501","June 28, 2017","November 2024","December 2024","July 2, 2017","null","September 13, 2018","TG Therapeutics Investigational Trial Site, Huntsville, Alabama, United States|TG Therapeutics Investigational Trial Site, Durham, North Carolina, United States|TG Therapeutics Investigational Trial Site, Germantown, Tennessee, United States|TG Therapeutics Investigational Trial Site, Nashville, Tennessee, United States|TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03207256"
987,"NCT00166439","Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)","The proportion of successes will be estimated by the number of successes divided by the total number.|Survival time is defined as the time from registration to death due to any cause|The distribution of survival time will be estimated using the method of Kaplan-Meier.","Mayo Clinic","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC0485|2328-04","March 2005","September 2015","September 2015","September 14, 2005","null","March 22, 2017","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00166439"
988,"NCT01848652","Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.","MYLY","Terminated","No Results Available","Cerebral Lymphoma B Cell Refractory","Drug: infusion of MYOCET","Answer at treatment|Tolerance at treatment","University Hospital, Brest|Teva Pharmaceuticals USA","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RB 12.032 - MYLY","October 2013","May 2015","May 2015","May 7, 2013","null","July 14, 2015","CHRU de Brest, Brest, France|Hôpital Pitié Salpêtrière, Paris, France|CHU de Rennes Hôpital Pontchaillou, Rennes, France","","https://ClinicalTrials.gov/show/NCT01848652"
989,"NCT02950220","Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Mediastinal Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Incidence of adverse events assessed using NCI CTCAE version 4|MTD defined as the dose level at which no more than one of 6 patients experiences a dose-limiting toxicity assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4|Complete response rates|ORR|Overall survival|Progressive-free survival","Kami Maddocks|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","58","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-16070|NCI-2016-01560|P30CA016058","January 12, 2017","December 16, 2019","December 16, 2019","November 1, 2016","null","January 29, 2018","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02950220"
990,"NCT00006669","Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Lymphoma","Biological: rituximab|Biological: sargramostim|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate","","Washington Hospital Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068283|WHC-99365|NCI-V00-1630","September 1999","null","null","May 4, 2004","null","February 9, 2009","Washington Cancer Institute, Washington, District of Columbia, United States|Franklin Square Hospital Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00006669"
991,"NCT03680586","Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma",,"Not yet recruiting","No Results Available","Gastric Mucosa-Associated Lymphoid Tissue Lymphoma","Radiation: Radiation Therapy","Complete gastric response|Distant recurrence defined as disease progression outside of the stomach that was not present initially|Incidence of acute gastrointestinal toxicity graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03|Incidence of chronic gastrointestinal toxicity graded according to CTCAE v. 4.03|Time to local gastric event|Time to distant event|Tumor response","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0392|NCI-2018-01948|P30CA016672","January 31, 2019","May 8, 2021","May 8, 2021","September 21, 2018","null","September 21, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03680586"
992,"NCT03474744","Copanlisib and Rituximab in Marginal Zone Lymphoma Patients",,"Not yet recruiting","No Results Available","Marginal Zone Lymphoma","Drug: Copanlisib","Complete Response|Response rate|Best response|Time to best response|Time to first response|Progressioin free survival (PFS)|Time to Treatment failure (TTF)|Duration of Response (DR)|Cause specific survival (CSS)|Overall survival (OS)|Quality of life during induction and maintenance therapy","Christian Buske|University of Ulm","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COUP-1","June 1, 2018","June 1, 2018","December 1, 2026","March 23, 2018","null","March 23, 2018","","","https://ClinicalTrials.gov/show/NCT03474744"
993,"NCT00807495","Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma",,"Completed","Has Results","Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Burkitt's Lymphoma|T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma|Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component","Drug: Alisertib","Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria)|Time to Progression (TTP)|Progression Free Survival (PFS)|Duration of Response (DOR)|Number of Participants With Treatment-Emergent Adverse Events|Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events|Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C14004|U1111-1187-1268","February 10, 2009","January 4, 2011","February 13, 2013","December 12, 2008","March 27, 2018","March 27, 2018","Hematology Oncology Associates, Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT00807495"
994,"NCT02055820","A Safety and Pharmacokinetics (PK) Study of Venetoclax in Participants With Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Venetoclax|Drug: Cyclophosphamide|Drug: Obinutuzumab|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Safety: Percentage of Participants With Dose-Limiting Toxicities|Safety: MTD of Venetoclax|Percentage of Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET-CT) Scan Using the Modified Lugano Classification|Percentage of Participants With CR Defined by PET-CT Scan in Double Positive Diffuse Large B-Cell Lymphoma (DP-DLBCL) Participants|Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)|Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)|Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)|Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) within the Dosing Interval|Prednisone Plasma PK: AUC|Prednisone Plasma PK: Tmax|Prednisone Plasma PK: Cmax|Prednisone Plasma PK: Cmin within the Dosing Interval|Rituximab PK: Cmax|Rituximab PK: Cmin within the Dosing Interval|Obinutuzumab PK: Cmax|Obinutuzumab PK: Cmin within the Dosing Interval|Cyclophosphamide PK: Cmax|Cyclophosphamide PK: Cmin within the Dosing Interval|Doxorubicin PK: Cmax|Doxorubicin PK: Cmin within the Dosing Interval|Vincristine PK: Cmax|Vincristine PK: Cmin within the Dosing Interval|Percentage of Participants With Objective Response Defined as Partial or Complete Response Using the Modified Lugano Classification|Duration of Response Using the Modified Lugano Classification|Progression-Free Survival Using the Modified Lugano Classification|Percentage of Participants who are Alive and Without Disease Progression at Month 12|Overall Survival (OS)|Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification|Safety: Percentage of Participants With Adverse Events|Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy|Venetoclax Metabolite Plasma PK: AUC|Venetoclax Metabolite Plasma PK: Tmax|Venetoclax Metabolite Plasma PK: Cmax|Venetoclax Metabolite Plasma PK: Cmin|Relative Dose Intensity of CHOP Chemotherapy","Hoffmann-La Roche|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO27878|2013-003749-40","November 17, 2013","August 31, 2017","February 27, 2020","February 5, 2014","null","March 27, 2018","St. Jude Heritage Healthcare, Fullerton, California, United States|Marin Cancer Care Inc, Greenbrae, California, United States|UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|Memorial Cancer Institute, Hollywood, Florida, United States|The West Clinici, Saint Louis, Missouri, United States|Hackensack University Medical Center; WFAN - Imus Pediatric Center, Hackensack, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Uni of Rochester Medical Center; Wilmot Cancer Center, Pharmacy Department, Rochester, New York, United States|Mid Ohio Oncology Hematology;ZangMeister Center (West), Columbus, Ohio, United States|Oncology Hematology Care, Inc., Hamilton, Ohio, United States|University of Pennsylvania; School of Medicine, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Nashville, Tennessee, United States|Rocky Mountain Cancer Centers, LLP, Irving, Texas, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria|Medizinische Universität Wien, Wien, Austria|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency, CSI, Kelowna, British Columbia, Canada|BC Cancer Agency Vancouver Centre - PARENT; BC Cancer Agency, Vancouver, British Columbia, Canada|Jewish General Hospital; Research Unit, Montréal, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia|Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK, Praha 2, Czechia|Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, France|Clinique Victor Hugo; Pharmacie, Le Mans, France|Hopital Claude Huriez - CHU Lille, Lille, France|Hopital Saint Eloi, Montpellier, France|CHU Nantes - Hôtel Dieu; Service Assistance Medicale à la Procreation, Nantes, France|Hôpital Saint-Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Benite, France|CHU Rennes - Hopital Pontchaillou, Rennes cedex 09, France|Centre Henri Becquerel; Hematologie, Rouen, France|CHU Tours - Hôpital Bretonneau, Tours, France|Hôpital de Brabois Adultes, Vandoeuvre-les-nancy, France|Semmelweis Egyetem, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Debreceni Egyetem; Belgyogyaszati Klinika Hematologiai Tanszek, Debrecen, Hungary|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Lazio, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Liguria, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Azienda Ospedaliera Vincenzo Cervello, Palermo, Sicilia, Italy|Azienda Ospedaliero Universitaria Pisana; U.O. Farmaceutica, Pisa, Toscana, Italy|VU Medisch Centrum, Amsterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|ICO l´Hospitalet - Hospital Duran i Reynals; Hematology, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain","","https://ClinicalTrials.gov/show/NCT02055820"
995,"NCT02568553","Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","CD19 Positive|Mediastinal Lymphoma|Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mediastinal Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Mediastinal Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma","Biological: Blinatumomab|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide","Incidence of toxicity as coded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (version 5.0 beginning April 1, 2018)|Clinical anti-tumor response (complete response and partial response as per International workshop lymphoma response criteria)|Changes in the frequency of CD4+ T cells|Changes in the production of interferon (INF)-gamma from CD4+ T cells","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2015-01640|PHI-79|9924|UM1CA186644|UM1CA186717","June 14, 2016","December 31, 2018","null","October 6, 2015","null","August 3, 2018","City of Hope Comprehensive Cancer Center, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02568553"
996,"NCT03322865","Obinutuzumab in Marginal Zone Lymphoma",,"Not yet recruiting","No Results Available","Marginal Zone Lymphoma","Drug: Obinutuzumab","Complete Remission/Response (CR) rate|Progression free survival|Overall survival|Time to first response|Time to best response under treatment (induction and maintenance)Time|Response rate|Best response|Time to Treatment failure|Remission duration|Cause specific survival","Christian Buske|University of Ulm","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OLYMP-1|2017-003149-56","May 2, 2018","May 2, 2019","May 2, 2024","October 26, 2017","null","October 26, 2017","","","https://ClinicalTrials.gov/show/NCT03322865"
997,"NCT00028665","Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Total CD34 cells|T and B lymphocyte counts|Disease response|Engraftment","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CWRU1499|P30CA043703|CWRU-030040|NCI-G01-2040","June 2000","March 2005","null","January 27, 2003","null","June 10, 2010","Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00028665"
998,"NCT01007292","A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: YM155|Biological: Rituximab","Objective response rate (Confirmed Complete Remission +Confirmed Partial Remission)|Confirmed Complete remission rate|Confirmed Partial remission rate|Time to response|Duration of response|Clinical benefit rate|Progression-free survival|Overall survival|Safety assessed by recording of adverse events, physical examinations, vital signs, laboratory assessments and electrocardiograms (ECGs)","Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","155-CL-031","November 2009","March 2013","June 2015","November 4, 2009","null","October 19, 2015","Site US2778 John B. Amos Cancer Center, Columbus, Georgia, United States|Site US55 Loyola University Hospital - Maywood, Maywood, Illinois, United States|Site US9 Mount Sinai School of Medicine, New York, New York, United States|Site US2802 Mecklenburg Medical Group, Charlotte, North Carolina, United States|Site US2149 Gabrail Cancer Center Research, Canton, Ohio, United States|Site US402 University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States|Site FR1926 Institut Bergonie, Bordeaux-cedex, France|Site FR2700 Centre Antoine Lacassagne, Nice, France|Site FR476 Hopital Saint Louis, Paris, France|Site FR1889 Centre de Lutte Contre le Cancer - Centre Henri Becquerel, Rouen, France|Site FR1897 Hopital Bretonneau, Tours, France|Site ES1349 Hospital del Mar, Barcelona, Spain|Site ES1339 Hospital Universitario Ramon y Cajal, Madrid, Spain|Site ES2967 Hosptial Universitario Madrid Sanchinarro, Madrid, Spain|Site ES1346 Hospital Universitario de Salamanca, Salamanca, Spain|Site GB2702 Addenbrookes Hospital, Cambridge, United Kingdom|Site GB1928 St. Georges Hospital, London, United Kingdom|Site GB2624 The Christie NHS Foundation Trust, Manchester, United Kingdom|Site GB1903 Oxford Radcliffe Hospital, Oxford, United Kingdom","","https://ClinicalTrials.gov/show/NCT01007292"
999,"NCT02142530","Carfilzomib Plus Belinostat in Relapsed/Refractory NHL",,"Completed","No Results Available","Non-Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Peripheral T-cell Lymphoma","Drug: Carfilzomib|Drug: Belinostat","Maximum tolerated doses of carfilzomib and belinostat in combination|Number of Participants with Serious Adverse Events|Plasma Concentration Time Profiles|Objective response rate","Massachusetts General Hospital|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Older Adult)","Phase 1","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-096","October 2014","March 2017","January 2018","May 20, 2014","null","January 25, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02142530"
1000,"NCT00006695","Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: tositumomab and iodine I 131 tositumomab","event free survival rate|time to treatment failure|over all survival","University of Nebraska","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","051-00|UNMC-051-00|COULTER-IND-3323","April 2000","September 2005","December 2014","January 27, 2003","null","May 28, 2015","UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00006695"
